<SEC-DOCUMENT>0001493152-25-023940.txt : 20251118
<SEC-HEADER>0001493152-25-023940.hdr.sgml : 20251118
<ACCEPTANCE-DATETIME>20251117174023
ACCESSION NUMBER:		0001493152-25-023940
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20251118
DATE AS OF CHANGE:		20251117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Basel Medical Group Ltd
		CENTRAL INDEX KEY:			0002004489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42527
		FILM NUMBER:		251492234

	BUSINESS ADDRESS:	
		STREET 1:		600 NORTH BRIDGE ROAD, #12-02/03
		STREET 2:		PARKVIEW SQUARE
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			188778
		BUSINESS PHONE:		65 6291 9188

	MAIL ADDRESS:	
		STREET 1:		600 NORTH BRIDGE ROAD, #12-02/03
		STREET 2:		PARKVIEW SQUARE
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			188778
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>form20-f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:BMGL="http://baselmedical.com/20250630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_IFRS%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_BMGL_baselmedical.com_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240701_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0002004489 -->
<!-- Field: Set; Name: xdx; ID: xdx_077_XDX_Z%2D%2D\2025 OPERATIONS\EDGAR\11 NOVEMBER\Basel Medical Group Ltd\11%2D13%2D2025\Form 20%2DF\Draft\Production\form20%2Df.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_074_SO_Z%2D%2D\2025 OPERATIONS\EDGAR\11 NOVEMBER\Basel Medical Group Ltd\11%2D13%2D2025\Form 20%2DF\Draft\Production\form20%2Df.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_065_USD_0_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_SGD_1_iso4217%2D%2DSGD -->
<!-- Field: Set; Name: xdx; ID: xdx_06A_SGDPShares_0_iso4217%2D%2DSGD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000005" name="dei:EntityCentralIndexKey">0002004489</ix:nonNumeric>
  <ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0099" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0137" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2024-06-30" id="xdx2ixbrl0192" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_RelatedPartiesMember" id="xdx2ixbrl0219" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_RelatedPartiesMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2025-06-30" id="xdx2ixbrl0267" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2025-06-30" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0277" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2024-06-30" id="xdx2ixbrl0311" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2024-06-30" id="xdx2ixbrl0316" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0384" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0387" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0391" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0392" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0393" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0395" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0398" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0399" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0403" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0406" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0407" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0411" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0414" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0415" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0418" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0422" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0423" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="xdx2ixbrl0424" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0427" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0439" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0444" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0449" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0450" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve" contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0453" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve" contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0455" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0458" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0459" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0463" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember" id="xdx2ixbrl0464" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0490" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:CreditLossExpenseReversal" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0494" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:CreditLossExpenseReversal" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0515" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0520" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0581" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfInvestmentProperty" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0586" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:DecreaseInAmountDueFromDirector" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0603" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:DecreaseInAmountDueFromDirector" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseInBankOverdraft" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0619" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0624" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0644" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0649" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0669" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0973" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:ServiceIncome" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0978" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RentalIncome" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0983" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:ReversalOfExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0992" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:ReversalOfExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:BadDebtsWrittenOff" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl1056" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1125" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1130" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:UnderprovisionInRespectOfPriorYears" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl1136" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1171" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:UtilisationOfDeferredTaxAssets" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1186" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:UtilisationOfDeferredTaxAssets" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:DeferredIncomeTax" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1196" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:DeferredIncomeTax" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:UnderprovisionInRespectOfPriorYears" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl1202" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember" id="xdx2ixbrl1226" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember" id="xdx2ixbrl1234" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:WrittenOffRightofuseAssets" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember" id="xdx2ixbrl1239" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets" contextRef="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember" id="xdx2ixbrl1254" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:WrittenOffRightofuseAssets" contextRef="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember" id="xdx2ixbrl1264" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="xdx2ixbrl1293" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="xdx2ixbrl1296" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="xdx2ixbrl1297" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="xdx2ixbrl1298" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="xdx2ixbrl1299" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="xdx2ixbrl1300" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="xdx2ixbrl1302" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="xdx2ixbrl1311" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="xdx2ixbrl1314" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="xdx2ixbrl1318" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="xdx2ixbrl1323" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="xdx2ixbrl1324" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="xdx2ixbrl1327" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="xdx2ixbrl1329" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="xdx2ixbrl1332" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="xdx2ixbrl1336" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="xdx2ixbrl1365" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="xdx2ixbrl1368" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="xdx2ixbrl1372" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="xdx2ixbrl1374" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="xdx2ixbrl1383" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="xdx2ixbrl1386" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="xdx2ixbrl1390" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="xdx2ixbrl1395" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="xdx2ixbrl1399" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="xdx2ixbrl1404" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="xdx2ixbrl1408" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_MachineryMember" id="xdx2ixbrl1422" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_custom_AirConditionerMember" id="xdx2ixbrl1426" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_custom_SoftwareMember" id="xdx2ixbrl1428" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_MachineryMember" id="xdx2ixbrl1431" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_AirConditionerMember" id="xdx2ixbrl1435" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_MachineryMember" id="xdx2ixbrl1440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_AirConditionerMember" id="xdx2ixbrl1444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" contextRef="AsOf2024-06-30" id="xdx2ixbrl1611" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2025-06-30" id="xdx2ixbrl1620" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2025-06-30" id="xdx2ixbrl1623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2024-06-30" id="xdx2ixbrl1634" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2025-06-30" id="xdx2ixbrl1638" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2025-06-30" id="xdx2ixbrl1641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanOneMember" id="xdx2ixbrl1655" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanOneMember" id="xdx2ixbrl1658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanTwoMember" id="xdx2ixbrl1660" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanTwoMember" id="xdx2ixbrl1663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanThreeMember" id="xdx2ixbrl1665" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanThreeMember" id="xdx2ixbrl1668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanFourMember" id="xdx2ixbrl1670" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanFourMember" id="xdx2ixbrl1673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanSixMember" id="xdx2ixbrl1675" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanSixMember" id="xdx2ixbrl1678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanSevenMember" id="xdx2ixbrl1680" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanSevenMember" id="xdx2ixbrl1683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanNineMember" id="xdx2ixbrl1685" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanNineMember" id="xdx2ixbrl1688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanTenMember" id="xdx2ixbrl1690" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanTenMember" id="xdx2ixbrl1693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanElevenMember" id="xdx2ixbrl1695" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanElevenMember" id="xdx2ixbrl1698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember" id="xdx2ixbrl1700" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanTwelveMember" id="xdx2ixbrl1701" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember" id="xdx2ixbrl1703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanMember" id="xdx2ixbrl1705" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2025-06-30_custom_TermLoanMember" id="xdx2ixbrl1708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1818" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1822" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1824" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1826" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AdditionBankBorrowingsCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AdditionBankBorrowingsNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1852" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1854" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1856" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1878" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1888" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1890" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1892" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1894" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1896" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AdditionBankBorrowingsCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1908" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1912" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1914" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1920" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AdditionBankBorrowingsNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1922" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1924" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1926" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1928" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1948" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1950" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1954" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1960" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1962" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1964" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1966" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember" id="xdx2ixbrl1970" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1976" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AdditionBankBorrowingsCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1978" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1988" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromNoncurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1990" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AdditionBankBorrowingsNonCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1992" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="xdx2ixbrl1994" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="xdx2ixbrl2004" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="xdx2ixbrl2006" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="xdx2ixbrl2010" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl2087" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl2090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:InterestIncomeOnLoansAndReceivable" contextRef="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember" id="xdx2ixbrl2108" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:ManagementFee" contextRef="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember" id="xdx2ixbrl2113" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="xdx2ixbrl2211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="xdx2ixbrl2223" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="xdx2ixbrl2237" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="xdx2ixbrl2243" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember" id="xdx2ixbrl2256" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember" id="xdx2ixbrl2279" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2394" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2399" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2404" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2409" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2429" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2434" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2439" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2444" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2449" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2454" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="xdx2ixbrl2459" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="xdx2ixbrl2490" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="xdx2ixbrl2503" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="xdx2ixbrl2506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="xdx2ixbrl2508" unitRef="SGD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="xdx2ixbrl2511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bmgl-20250630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-07-01to2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_MergerReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_MergerReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_MergerReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_MergerReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_MergerReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-10_custom_OrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:OrdinaryShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-102023-08-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-10</xbrli:startDate>
        <xbrli:endDate>2023-08-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_OrdinaryShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:OrdinaryShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedicalGroupPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedicalGroupPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SSOCPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SSOCPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SSOSPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOSPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SSOSPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOSPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:PharmaAvenuePteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:PharmaAvenuePteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedflowPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedflowPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BethesdaMedicalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BethesdaMedicalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:OasisMedicalClinicPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:OasisMedicalClinicPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_OtherPropertyPlantAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_MedicalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">BMGL:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_MedicalServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">BMGL:MedicalServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AccumulatedDepreciationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AccumulatedDepreciationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_AccumulatedDepreciationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_MachineryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_MedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_RenovationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_AirConditionerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ThridPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:ThridPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ThridPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:ThridPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CustodianServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:CustodianServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-27</xbrli:startDate>
        <xbrli:endDate>2023-06-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-302023-06-30_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-30</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-01_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-01_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipAndSingmedInvestmentPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_DrKevinYipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DrKevinYipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipAndSingmedInvestmentPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-27_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-22_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-15_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-16_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-20_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-23_custom_RainforestCapitalVCCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_OthersRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:OthersRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TermLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTenTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTenTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTenThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTenThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanTenFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTenFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TermLoanElevenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanElevenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TermLoanTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_LeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_ShorttermBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-28_custom_InitialPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:InitialPublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_OverAllotmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:OverAllotmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-302025-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-30</xbrli:startDate>
        <xbrli:endDate>2025-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CategoryOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CategoryTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CategoryThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CategoryFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:NotPastDueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:LaterThanTwoMonthsAndNotLaterThanFourMonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanFourMonthsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:NotPastDueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:LaterThanTwoMonthsAndNotLaterThanFourMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanFourMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CreditRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_CarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_ContractualCashFlowsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">BMGL:ContractualCashFlowsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_CarryingAmountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_ContractualCashFlowsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">BMGL:ContractualCashFlowsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-31_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCNovenaPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-31_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCOrchardPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-31_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCFarrerParkPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCNovenaPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCOrchardPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCFarrerParkPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_custom_PharmaAvenuePteLtdMember_ifrs-full_TopOfRangeMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:PharmaAvenuePteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_custom_EyetrustMedicalPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:EyetrustMedicalPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_custom_CharteredImagingPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:CharteredImagingPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_NonadjustingEventsAfterReportingPeriodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0002004489</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SGD">
      <xbrli:measure>iso4217:SGD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SGDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:SGD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20240701__20250630_zyWNzSy47BCk"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000014" name="dei:DocumentType">20-F</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentRegistrationStatement_c20240701__20250630_zLFTqYTuhTD6"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000015" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric></span>
<b>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_907_edei--DocumentAnnualReport_c20240701__20250630_zoytchGUAzje"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_900_edei--DocumentPeriodEndDate_c20240701__20250630_zWqG0nsdeH52"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_905_edei--CurrentFiscalYearEndDate_c20240701__20250630_zFW3mMSNBxj8"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">June 30</ix:nonNumeric></span>, <span id="xdx_903_edei--DocumentFiscalYearFocus_c20240701__20250630_zv9HqVptCjA9"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000019" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentTransitionReport_c20240701__20250630_zN0Iju8luaFa"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from _______ to _______</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentShellCompanyReport_c20240701__20250630_znO6MDipTAKe"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000021" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric></span>
<b>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of event requiring this shell company report</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <b><span id="xdx_90E_edei--EntityFileNumber_c20240701__20250630_zyHRcz7sVUcc"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000022" name="dei:EntityFileNumber">001-42527</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_908_edei--EntityRegistrantName_c20240701__20250630_zHC5eW4WhSV3"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000023" name="dei:EntityRegistrantName">Basel
Medical Group Ltd</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not
Applicable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of Registrant&#8217;s name into English)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British
Virgin Islands <span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240701__20250630_zHzj1Pv7vGLk" style="display: none"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000024" name="dei:EntityIncorporationStateCountryCode">D8</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction
of incorporation or organization)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20240701__20250630_zO3Jts9CnWJl"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000025" name="dei:EntityAddressAddressLine1">6
Napier Road</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine2_c20240701__20250630_zYynPQ7dM8Qc"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000026" name="dei:EntityAddressAddressLine2">Unit
#02-10/11 Gleneagles Medical Centre</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20240701__20250630_zuOEDWXlhgOe"><span id="xdx_908_edei--EntityAddressCountry_c20240701__20250630_zjKR3V9IByZj"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000027" name="dei:EntityAddressCityOrTown"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt-sec:countrynameen" id="Fact000028" name="dei:EntityAddressCountry">Singapore</ix:nonNumeric></ix:nonNumeric></span></span>
<span id="xdx_903_edei--EntityAddressPostalZipCode_c20240701__20250630_zg2VVOGNVUI5"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000029" name="dei:EntityAddressPostalZipCode">258499</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--ContactPersonnelName_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z0XzYMP4yiCf"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" id="Fact000030" name="dei:ContactPersonnelName">Dr.
Darren Yen Feng Chhoa</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--ContactPersonnelEmailAddress_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zJdusILLLxC5"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" id="Fact000031" name="dei:ContactPersonnelEmailAddress">contact@baselmedical.com</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zQnxw59znpWf"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" id="Fact000032" name="dei:EntityAddressAddressLine1">6
Napier Road</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine2_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zTZlFRzxwknc"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" id="Fact000033" name="dei:EntityAddressAddressLine2">Unit
#02-10/11 Gleneagles Medical Centre</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zkGRlANijkp1"><span id="xdx_904_edei--EntityAddressCountry_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zI6LKB1y0wNi"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" id="Fact000034" name="dei:EntityAddressCityOrTown"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" format="ixt-sec:countrynameen" id="Fact000035" name="dei:EntityAddressCountry">Singapore</ix:nonNumeric></ix:nonNumeric></span></span>
<span id="xdx_900_edei--EntityAddressPostalZipCode_c20240701__20250630__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zAyOdE8ozxYc"><ix:nonNumeric contextRef="From2024-07-012025-06-30_dei_BusinessContactMember" id="Fact000036" name="dei:EntityAddressPostalZipCode">258499</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered, pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
                                                                                                              Symbol(s)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--Security12bTitle_c20240701__20250630_zZZTmHvXzEIj"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000037" name="dei:Security12bTitle">Ordinary
    shares with no par value</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--TradingSymbol_c20240701__20250630_ztEJT7Dyogtd"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000038" name="dei:TradingSymbol">BMGL</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_90B_edei--SecurityExchangeName_c20240701__20250630_zzmEhLK9tjNh"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt-sec:exchnameen" id="Fact000039" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of business covered
by the annual report: <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_c20250630_z6YItkkiUXOc"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,785,750</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary shares as of June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90B_edei--EntityWellKnownSeasonedIssuer_c20240701__20250630_ztdUL1spYDRe"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000041" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934. Yes &#9744; <span id="xdx_906_edei--EntityVoluntaryFilers_c20240701__20250630_za0rvDXtqJsa"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000042" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20240701__20250630_zU3xkegoIse"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000043" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20240701__20250630_zgmt2h1qt2ee"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000044" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
                                            accelerated filer &#9744;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
                                            filer &#9744;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityFilerCategory_c20240701__20250630_zmBX4qw7tle"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000045" name="dei:EntityFilerCategory">Non-accelerated
                                            filer</ix:nonNumeric></span> &#9746;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; border-left-width: 0in; border-left-color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
                                            growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20240701__20250630_zWBWkMq5PF0h"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000046" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;&#8224;
provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_90F_edei--EntityExTransitionPeriod_c20240701__20250630_zMxkZQ3AtSs1"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000047" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;
The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_900_edei--IcfrAuditorAttestationFlag_c20240701__20250630_zV0cXGelYUEj"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000048" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span id="xdx_909_edei--DocumentFinStmtErrorCorrectionFlag_c20240701__20250630_zKrEQrTHv6Ql"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000049" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    GAAP &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentAccountingStandard_c20240701__20250630_zwg0NgbKlIPd"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000050" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric></span> as issued by</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    International Accounting Standards Board &#9746;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    &#9744;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant
has elected to follow. Item 17 &#9744; Item 18 &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes &#9744; No <span id="xdx_90A_edei--EntityShellCompany_dbF_c20240701__20250630_zLGyo8M7hK9h"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000051" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(APPLICABLE
ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes &#9744; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="toc"></span>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONVENTIONS AND FREQUENTLY USED TERMS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><a href="#sd_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#sd_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">22</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">UNRESOLVED STAFF COMMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">35</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">40</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">47</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">FINANCIAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">49</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">THE OFFER AND LISTING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">50</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">ADDITIONAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">50</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">PART II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">CONTROLS AND PROCEDURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">57</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">[RESERVED]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">AUDIT COMMITTEE AND FINANCIAL EXPERT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">CODE OF ETHICS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16G.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">CORPORATE GOVERNANCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16H.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">MINE SAFETY DISCLOSURE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16I.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16J.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">INSIDER TRADING POLICIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16K.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">CYBERSECURITY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">60</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    17.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    18.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    19.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_029">EXHIBITS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_030">EXHIBIT INDEX</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_031">SIGNATURE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-weight: bold">Table
                                            of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_001"></span>CONVENTIONS
AND FREQUENTLY USED TERMS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report, unless the context otherwise requires, the &#8220;Company,&#8221; &#8220;Basel Medical&#8221; and references to &#8220;we,&#8221;
&#8220;us,&#8221; or similar references should be understood to be references to Basel Medical Group Ltd, a BVI business company incorporated
in the BVI and its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
amounts and percentages that appear in this annual report may not sum due to rounding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated or unless the context otherwise requires, in this annual report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Companies
and Personnel within our Group</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Basel
Medical&#8221; refers to Basel Medical Group Ltd, a BVI business company incorporated in the BVI;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FY&#8221;
refers to financial year, and &#8220;FY2023&#8221;, &#8220;FY2024&#8221; and &#8220;FY2025&#8221; refer to the financial years ended
June 30, 2023, 2024 and 2025 respectively;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Rainforest
Capital VCC&#8221; refers to Rainforest Capital VCC, a variable capital company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Basel
Medical Singapore&#8221; or &#8220;Singmed Specialists&#8221; refers to Singmed Specialists Pte. Ltd., a company incorporated in Singapore,
which changed its corporate name to Basel Medical Group Pte. Ltd. in October 2024;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SKC&#8221;
refers to Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SKS&#8221;
refers to Singapore Knee, Sports and Orthopaedic Services Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SSO
Clinic&#8221; refers to Singapore Sports &amp; Orthopaedic Clinic Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SSO
Services&#8221; refers to Singapore Sports &amp; Orthopaedic Services Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SSOC&#8221;
refers to SSOC Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SSOS&#8221;
refers to SSOS Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SSPC&#8221;
refers to Singapore Sports and Physiotherapy Centre Pte. Ltd., a company incorporated in Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technical
Terms</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;CT&#8221;
refers to computed tomography;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;endoscope&#8221;
refers to an illuminated optical, typically slender and tubular instrument used to look deep into the body and used in procedures called
an endoscopy;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;MediSave&#8221;
refers to Singapore&#8217;s national medical savings scheme;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;MOH&#8221;
refers to the Ministry of Health of Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;MRI&#8221;
refers to magnetic resonance imaging;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;orthopedic&#8221;
refers to a branch of medicine that focuses on the diagnosis, correction, prevention, and treatment of patients with disorders of the
musculoskeletal system comprising the bones, joints, muscles, ligaments, tendons, nerves and skin;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SMC&#8221;
refers to Singapore Medical Council;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
conventions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;BVI&#8221;
refers to the British Virgin Islands;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;BVI
Act&#8221; refers to the BVI Business Companies Act (As Revised) as the same may be amended from time to time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;IFRS&#8221;
refers to the International Financial Reporting Standards;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Ordinary
Shares&#8221; or &#8220;Shares&#8221; refer to Basel Medical&#8217;s ordinary shares;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;post-offering
amended and restated memorandum and articles of association&#8221; refers to our memorandum and articles of association to be in effect
upon completion of our initial public offering;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;S$&#8221;
or Singapore dollars refers to the legal currency of Singapore;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;SEC&#8221;
refers to the Securities and Exchange Commission; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;US$,&#8221;
&#8220;$&#8221; and &#8220;U.S. dollars&#8221; refer to the legal currency of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_002"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding
future events or future results of operations or financial condition and therefore are, or may be deemed to be, &#8220;forward-looking
statements.&#8221; These forward-looking statements are made under the &#8220;safe harbor&#8221; provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of forward-looking terminology,
including the terms &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;seek,&#8221;
&#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will&#8221; or &#8220;should&#8221; or, in
each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are
not historical facts. They appear in a number of places throughout this annual report and include statements regarding our intentions,
beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects,
growth, strategies, future market conditions or economic performance and developments in the capital markets, expected future financial
performance, the markets in which we operate, and the macroeconomic, political and regulatory environment. Such forward-looking statements
are based on currently available information and management&#8217;s current expectations, beliefs and forecasts concerning future events
impacting us. Factors that may impact such forward-looking statements include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            expected growth of demand for orthopedic treatment;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            expectations regarding the size and growth rate of our patients and customer base;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            regulatory environment and changes in laws, regulations or policies in the jurisdictions
                                            in which we operate;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to successfully compete in highly competitive industries and markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaches
                                            of laws or regulations in the operation and management of our current and future businesses
                                            and assets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            overall economic environment and general market and economic conditions in the jurisdictions
                                            in which we operate and the global economic condition;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to execute our strategies, manage growth and maintain our corporate culture as we
                                            grow;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            anticipated investments in new products and offerings, and the effect of these investments
                                            on our results of operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in the need for capital and the availability of financing and capital to fund these needs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated
                                            technology trends and developments and our ability to address those trends and developments
                                            with our services and offerings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in interest rates or rates of inflation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
                                            rate fluctuations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Man-made
                                            or natural disasters, including war, acts of international or domestic terrorism, civil disturbances,
                                            occurrences of catastrophic events and acts of God such as floods, earthquakes, wildfires,
                                            typhoons and health epidemics, pandemics or disease outbreaks that may directly or indirectly
                                            affect our business or assets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            loss of key personnel and the inability to replace such personnel on a timely basis or on
                                            acceptable terms;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal,
                                            regulatory and other proceedings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            ability to maintain the listing of our securities on NASDAQ; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            results of any future financing efforts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this annual report are based on our current expectations and beliefs concerning future developments
and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated.
These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions
that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, those factors described under &#8220;Item 3. Key Information&#8212;D.
Risk Factors.&#8221; Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect,
actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may
be required under applicable securities laws. In light of these risks and uncertainties, you should keep in mind that any event described
in a forward-looking statement made in this annual report or elsewhere might not occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_003"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_004"></span>ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_005"></span>ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_006"></span>ITEM
3. KEY INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
[Reserved]</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Capitalization and Indebtedness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Reasons for the Offer and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our Ordinary Shares involves significant risks. Below is a summary of material risks we face, organized under relevant
headings. These risks are discussed more fully after this summary. You should carefully consider the risks below and after this summary
before making an investment decision. Additional risks not presently known to us or that we currently deem immaterial may also impair
our business operations. Our business, financial condition, results of operations or prospects could be materially and adversely affected
by any of these risks. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent on our key medical practitioners.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    occasionally depend on external medical practitioners and vendors, and at times, we may enlist locum doctors to support our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    experience competition from other similar healthcare service providers in private and government-owned hospitals, medical
    centers and clinics.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business relies to some extent on the recognition of our brand names and trademarks, as well as the reputation of our specialist
    doctors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent on the continuing operations of the private hospital and medical center where we conduct our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend on a number of key relationships with corporations for patient volume.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in operating costs, namely lease rental rates and risk of relocation, may cause disruption to our business operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are exposed to the credit risks of customers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    control over suppliers and the quality of the products they provide is limited. If these products are not manufactured in accordance
    with the relevant quality standards, it could have a significant adverse impact on our business and reputation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be affected by technological disruptions in the healthcare sector.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technological
    advancements, failures, and other challenges associated with our medical equipment and information technology systems have the potential
    to negatively impact our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face potential risks associated with cybersecurity and the handling of personal information and medical data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    failure to safeguard our intellectual property rights or any infringement of third-party rights could have detrimental effects on
    our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    failure to comply with the restrictions in our bank loans could result in an event of default that could materially adversely affect
    our business, financial condition, and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    significant product liability lawsuit may affect our financial performance and reputation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to the Medical Healthcare Industry</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    healthcare services may decline due to a number of factors affecting the Company&#8217;s revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be affected by the spread or outbreak of any contagious or virulent diseases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business is subject to risks related to medical and legal claims, regulatory actions, and professional liability arising from our
    clinical and specialist services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not have adequate insurance coverage in place despite having mandatory professional malpractice insurance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    must comply with regulations and licensing conditions governing the healthcare sector, and compliance may involve significant costs.
    There is a risk that we may not retain, renew, or obtain the necessary licenses and permits for our business operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    regulation of healthcare fees and the potential rise in the number of medical practitioners could have adverse effects on our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Challenges
    faced by the healthcare industry may also have an effect on the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to political, economic and social developments as well as the laws, regulations and licensing requirements in Singapore.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Ownership of Our Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    incur additional costs as a result of becoming a public company, which could negatively impact our net income and liquidity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    obligation to disclose information publicly may put us at a disadvantage to competitors that are private companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &#8220;foreign private issuer&#8221; within the meaning of the rules under the Exchange Act, and as such we are exempt from
    certain provisions applicable to U.S. domestic public companies and subject to reporting obligations that, to some extent, are more
    lenient and less frequent than those of a U.S. issuer. As a result, we may not provide you the same information as U.S. domestic
    public companies or we may provide information at different times, which may make it more difficult for you to evaluate our performance
    and prospects.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &#8220;controlled company&#8221; under the Nasdaq corporate governance rules and, as a result, will be eligible to rely on
    exemptions from certain corporate governance requirements that provide protection to shareholders of companies that are not controlled
    companies.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging
    growth companies will make our ordinary shares less attractive to investors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our ordinary shares may be volatile or may decline regardless of our operating performance, and you may not be able
    to resell your shares at or above the initial public offering price.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    resale of our ordinary shares in the public market may cause the market price of our ordinary shares to decline.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    issuances or sales, or perceived issuances or sales, of substantial amounts of ordinary shares in the public market could materially
    and adversely affect the prevailing market price of the ordinary shares and our ability to raise capital in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    financing may cause a dilution in your shareholding or place restrictions on our operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    controlling shareholder holds control over our Group and this may limit your ability to influence the outcome of decisions requiring
    the approval of shareholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    may not be an active, liquid trading market for our ordinary shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you purchase ordinary shares sold in this offering, you will experience immediate and substantial dilution.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be
    able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a BVI company and, because judicial precedent regarding the rights of members is more limited under BVI law than that under U.S.
    law, you may have less protection for your member rights than you would under U.S. law.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    we do not expect to pay dividends in the near future after this offering, you must rely on price appreciation of the ordinary shares
    for return on your investment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased
    both our costs and the risk of non-compliance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may incur additional costs and procedural obstacles in effecting service of legal process, enforcing foreign judgments or bringing
    actions in the British Virgin Islands or Singapore based on U.S. or other foreign laws against us, our management or the experts
    named in this report.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our ordinary shares could be subject to rapid and substantial volatility. Such volatility, including any stock run-ups,
    may be due to factors unrelated to our actual or forecasted operating performance and financial condition or prospects, making it
    difficult for prospective investors to assess the underlying value of our ordinary shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    and certain of our current and directors or officers may be subject to securities litigation, which is expensive and could divert
    management attention.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research reports about us or our business, or if such analysts issue adverse recommendations
    regarding our ordinary shares, the market price for our ordinary shares or trading volume could decline.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we cannot satisfy, or continue to satisfy, the listing requirements and other rules of the Nasdaq Capital Market, our ordinary shares
    may be delisted, which could negatively impact the price of our securities and your ability to sell them.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-takeover
    provisions in our post-offering amended and restated memorandum and articles of association may discourage, delay, or prevent a change
    in control.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may be unable to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on our key medical practitioners.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Group&#8217;s specialist orthopedic, trauma, sports medicine and neurosurgical business, health screening and general practice is spearheaded
by our key medical practitioners who are all surgeons with extensive experience in their respective subspecialties. They each play an
instrumental role in our Group. If our Group should lose any of their services, it is expected that our Group&#8217;s specialist orthopedic,
trauma, sports medicine, neurosurgical, health screening and general practice services business would be adversely affected.
There is no assurance that our medical practitioners will continue or renew their employment with us. Competition for medical practitioners
may require us to enhance our various remuneration packages in order to remain competitive in recruiting or retaining our employees,
which may significantly increase our employee benefits expense. The loss of the services of any of our key medical practitioners without
suitable and timely replacements or an inability to attract and recruit qualified medical specialists may have a material adverse effect
on our Group&#8217;s business, financial position, results of operations and prospects. In addition, certain of the licenses upon which
we rely are issued to certain of our medical practitioners, and if we were to lose the employment of such persons, we may face temporary
disruptions to the operation of our business while we reapply for such licenses in the name of other of our medical practitioners, which
may have a detrimental effect on our Group&#8217;s business, financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
continued expansion may also be hampered if we are unable to employ sufficiently skilled and qualified medical practitioners to support
our operations. It is crucial for our Group to recruit and retain sufficiently skilled and qualified medical practitioners to join us
as we rely on their professional judgement in providing consistent and standardized experience and services to our patients. In the event
of any erroneous clinical decision and any misjudgment or action on the part of our medical practitioners, we may need to divert a significant
amount of resources and incur extra expenses to handle such incidents. In addition, if our reputation or brand image is damaged and/or
our medical practitioners are required to suspend his/her medical practice as a result of such medical incidents, it could materially
and adversely affect our business and financial conditions, operating results and business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
occasionally depend on external medical practitioners and vendors, and at times, we may enlist locum doctors to support our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
occasionally depend on external medical practitioners, and at times, we may enlist locum doctors to support our operations. If our key
medical specialists were to leave our Group, we may require substantial time to find replacements and we may have to rely on external
medical practitioners for extended periods of time. We also rely on external vendors and service providers who second radiologists to
us for our patients. Although we typically engage experienced locum doctors or external service providers with whom we are familiar,
there is no guarantee that the quality of service they provide will surpass or match the level offered by our regular medical practitioners.
In addition, certain of the licenses upon which we rely are issued to external professionals, and if we were to end our business relationship
with such persons, we may face temporary disruptions to the operation of our business while we engage the services of other service providers,
which may have a detrimental effect on our Group&#8217;s business, financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there has not been any prior material instance of poor service quality from locum doctors or external service providers causing a material
adverse impact on our Group, if our clinics need to be managed by locum doctors or external service providers for extended or frequent
periods, this could negatively affect our Group&#8217;s business, results of operations, financial condition, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
experience competition from other similar healthcare service providers in private and government-owned hospitals, medical centers
and clinics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
experience competition from other similar healthcare service providers in private and government-owned hospitals, medical centers
and clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare business is highly competitive, and competition among healthcare providers for patients has intensified in recent years. Other
healthcare providers in the areas we operate may provide services similar to those offered by us. This may have an impact on our competitive
position and patient volumes. If any of our clinics do not deliver quality medical services or medical services superior to that of other
healthcare providers or if our standard charges are higher than our competitors, our patient volumes could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete with other government-owned hospitals, private hospitals, medical centers and clinics. We will also have to compete with any
future healthcare business operators. Moreover, some of these competitors may have longer operating histories, be more established and
have greater financial, personnel and other resources than us. Competitors may price their services lower than ours and exert pricing
pressures on us. Some of our competitors may also have plans to expand their facilities, which may exert further pricing and recruitment
pressure on us. Increased competition may result in lower profit margins and a loss of market share. In particular, our competitors include
medical facilities owned or managed by government agencies and trusts, which may have access to wider financing options or may be in
a better commercial position to negotiate for the purchase of inventory on more favorable terms than private healthcare providers owned
and managed by for-profit interests, such as ourselves. New or existing competitors may price their services at a significant discount
to ours or offer greater convenience or better services or amenities than what we provide. Smaller hospitals and other medical facilities
may exert pricing pressures on some or all of our services and also compete with us for doctors and other medical professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to compete effectively against our competitors. If we are forced to reduce the price of our services or
are unable to attract patients to our Group, our business, financial position, results of operations and prospects may be materially
and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business relies to some extent on the recognition of our brand names and trademarks, as well as the reputation of our specialist doctors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our business operations, specific brand names, reputation and trademarks play a crucial role. Failure to adequately protect and enhance
our brand identities, inability to successfully register trademarks, or insufficient supervision of third-party medical services or facility
providers using our brands may lead to a deterioration in market recognition. Unauthorized or improper use of our name, logo, and brand
names by external parties may result in brand dilution or reputation damage. Claims and legal actions initiated by our patients or customers
can also negatively impact our brand image, potentially hindering the optimal operation of our clinical and specialist services. Consequently,
our business, financial condition, results of operations, and prospects may be materially and adversely affected. Given the scale of
our operations, which currently only cover Singapore, we have currently registered one trademark in Singapore, but we may create and
register other trademarks in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
given the nature of our clinical and specialist services business, the reputation of our Group and its subsidiaries is inherently tied
to the reputation of our specialist doctors. Any negative publicity against our specialist doctors may tarnish their standing in the
medical industry, potentially causing a decline in the number of patients visiting our clinics and adversely affecting our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on the continuing operations of the private hospital and medical center where we conduct our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our clinics are located in private hospitals, medical centers, offices and malls in Singapore. We do not have any lease or other direct agreements with Gleneagles Medical Centre, but our lease agreements
are entered into with certain landlords who own property units within Gleneagles Medical Centre. Nonetheless, we utilize the facilities
of Gleneagles Medical Centre, such as X-Ray facilities or operating suites, as and when the need arises. For instance, if we utilize
the surgical theater of the medical center, the fees for the use of such facility will be billed to the patient directly. If there are
any disruptions in the operations of such hospital or medical center, for instance, due to a major fire, a change in public reputation
of this hospital or medical center or an outbreak of certain diseases resulting in closure of the hospitals or medical centers for quarantine
purposes, our business may be adversely affected owing to our dependence on the facilities in such private hospital and medical center.
Additionally, our business in these clinics may also decrease due to a reduction in our patient base. We frequently utilize Gleneagles&#8217;
facilities due to their proximity to our clinics, but we are free to utilize other hospitals and medical centers in Singapore, and hence
we believe that our relationship with Gleneagles is unlikely to constitute a material risk to our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on a number of key relationships with corporations for patient volume.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on a number of key relationships with corporations with whom we have entered into arrangements for a significant portion
of our patient volume. We anticipate that a number of our key relationships with these corporations will continue to account for a significant
portion of our patient volume for the foreseeable future. Our dependence on such corporations increases their bargaining power and the
need for us to maintain good relationships with them. The loss of one or more of these key relationships, or reduced demand for our managed
healthcare solutions from any of our key relationships could have a material adverse effect on our patient volume and accordingly, our
business, results of operations, financial condition, cash flows and prospects. There is no guarantee that we will be able to retain
our key relationships with all of these corporations or be able to derive a consistent volume of patients from such companies. There
is also no assurance that our arrangements with these corporations will not be terminated or be renewed on terms no less favorable to
us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increase
in operating costs, namely lease rental rates and risk of relocation, may cause disruption to our business operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease the premises of our existing clinics. Our present lease terms for most of our clinics are for a period of three years or less.
Upon the expiry of the leased tenure, the landlords have the right to review and revise the terms and conditions of the lease agreements.
We face the possibility of an increase in rent by the landlords or not being able to renew the leases on terms and conditions favorable
to us. Any increase in rent would inevitably increase our operating costs, thereby affecting our profits. We will also incur additional
costs if we have to relocate our clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are exposed to the credit risks of customers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the credit risks associated with our customers, especially our corporate clients which tend to incur larger transaction
volumes compared to our individual patients. While past experiences have not seen significant delays in payment adversely affecting our
Group&#8217;s financials and operations, there is no guarantee that we will consistently collect our trade receivables in full or within
a reasonable timeframe, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any failure to collect trade receivables fully or promptly, we may need to allocate full or partial allowances for impairment
or write off bad debts, potentially causing a material and adverse impact on our Group&#8217;s business, financial condition, results
of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevertheless,
up to the latest practicable date prior to the date of this annual report, we are not aware of any existing conditions likely to result
in a significant impairment or write-off of trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
control over suppliers and the quality of the products they provide is limited. If these products are not manufactured in accordance
with the relevant quality standards, it could have a significant adverse impact on our business and reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
substantial portion of the devices, equipment, and medication used in delivering our services is procured from external suppliers. We
lack oversight over the operations of these third-party suppliers and the quality of the products they furnish to us. The assurance that
these products will be free from defects and comply with the necessary quality standards cannot be guaranteed. Failure to identify quality
defects in the supplied products may lead to various repercussions such as injuries, fatalities, product recalls or withdrawals, license
revocation, fines, or other complications that could materially and adversely affect our business, financial results, condition, and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be affected by technological disruptions in the healthcare sector.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advancement of disruptive technology (which has resulted in, among others, the proliferation of telemedicine and e-prescription platforms)
has led to alternative means for patients to access medical services and medicine. The popularity of such technological creations has
also been driven by factors such as increasing healthcare costs and government initiatives. Telemedicine offers greater convenience and
improved accessibility to medical support and medication through digital self-help options. Telemedicine and other disruptive technologies
could reduce demand and patient visits to our clinics and may also lead to competitive pricing pressures on our services, which could
reduce our profit margins and result in a material adverse effect on our business, results of operations, financial condition and prospects.
Further, we may be unable to respond on a timely basis to the changing needs of the corporations and insurance companies with whom we
have entered into arrangements, and the new technologies we adopt may prove to be ineffective. Our failure to develop and introduce or
enhance services able to compete with such new technologies in a timely manner could have a material adverse effect on our business,
results of operations, financial conditions and prospects. The convenience and cost efficiency afforded by such technological creations,
coupled with the factors propelling them, could negatively impact and materially and adversely affect our business, results of operations,
financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Technological
advancements, failures, and other challenges associated with our medical equipment and information technology systems have the potential
to negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
services heavily rely to some extent on medical equipment, such as X-ray machines. The rental, replacement, upgrading, or maintenance
of such equipment can incur substantial costs for our organization. Consequently, any damage or breakdown of this equipment could impair
our ability to deliver essential services to our patients. Falling behind in technological advancements may lead our patients to seek
services from other clinics with more advanced equipment, diminishing our competitive edge and potentially having a significant adverse
effect on our business, financial position, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology systems play a crucial role in our business, internal control, and management systems. They assist in managing
clinical systems, medical records, and inventory. Technical failures in our information technology systems, stemming from issues like
power failures, computer viruses, or unauthorized tampering, may disrupt our ability to provide services to patients. Failure to upgrade
our information technology systems as necessary could impede our ability to adequately manage clinical systems, medical records, and
inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the theft or misuse of personal information stored in our system could expose us to liability. In Singapore, regulations governing private
hospitals and medical clinics mandate licensees to maintain accurate, complete, and up-to-date medical records. Licensees must implement
necessary processes and safeguards, whether administrative, technical, or physical, to protect medical records against loss, modification,
destruction, or unauthorized access. Violation of these regulations could result in fines or imprisonment upon conviction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face potential risks associated with cybersecurity and the handling of personal information and medical data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
and other applicable laws and regulations mandate medical establishments to safeguard customer privacy, prohibiting the unauthorized
disclosure of personal information and patient medical records in our clinical and specialist services segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations
in our operating jurisdiction may require licensees of medical establishments to maintain accurate and secure medical records, imposing
obligations to implement processes ensuring accuracy, completeness, and up-to-date records. The rising concerns about data privacy globally,
with the enactment of laws and regulations, add an additional layer of responsibility. In Singapore, the Personal Data Protection Act
(PDPA) imposes obligations on our Group regarding the collection, use, or disclosure of personal data. Additionally, under applicable
regulations, we are required to ensure the accuracy, completeness, and security of patient medical records. However, despite our efforts
to protect customer data privacy, the implemented controls may not be foolproof in preventing unauthorized disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the financial years ended June 30, 2024, and 2025, and for the period from July 1, 2025 up to the latest practicable date prior to this
report, we have not encountered any breaches, human errors, or similar events that have created an adverse cybersecurity event. In order
to mitigate the risks of such events, we utilize physical servers and cybersecurity software, and we may implement more robust cybersecurity
measures in the future, such as intrusion detection systems to detect and respond to potential security breaches in real-time and to
encrypt sensitive patient information in our system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant failure in security measures could erode customer and patient confidence, potentially leading to misuse of information, litigious
actions, and regulatory fines. Our current practices involve the maintenance of both digital and paper medical records, exposing us to
liability from accidental or unlawful loss, unauthorized access, modification, disclosure, copying, hacking (in the case of digital records),
theft, or misuse of personal and medical information. Any such incidents could result in breaches of data privacy laws and regulations,
potentially leading to fines or imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
work with third party service providers from time to time for the provision of our services. Any theft or misuse of personal and medical
information stored on our third-party service providers&#8217; system, may result in us being in breach of applicable data privacy laws
and regulations, which may materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with evolving data protection, privacy, and security laws may increase operating costs and necessitate adjustments to our business model,
impacting our business, financial condition, results of operations, and prospects. Failure in security mechanisms could prompt regulatory
measures, leading to significant additional resources being used to modify protective measures or address vulnerabilities, with potential
adverse effects on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, failure to make reasonable assessments of the risks related to handling personal information and medical data may lead to enforcement
actions by competent authorities, resulting in financial penalties, reputational damage, and material adverse effects on our business,
financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure to safeguard our intellectual property rights or any infringement of third-party rights could have detrimental effects on our
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
regard our brands and intellectual property as among our most valuable assets, which includes our registered trademark and web domains.
There is a risk that third parties may adopt trade service names resembling our registered trademark, potentially creating confusion
for customers and patients or obstacles to new market entry. In addition, third parties might register trademarks identical or similar
to ours in Singapore or overseas. In case of trademark infringement, challenges to our trademark applications, or unsuccessful enforcement
of our intellectual property rights in legal proceedings, our business, financial condition, and operational results may be significantly
and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we strive to comply with others&#8217; intellectual property rights, there may be certainty regarding potential infringements. This uncertainty
may require us to make adjustments to our service offerings and marketing strategy. Furthermore, we may face claims from third parties
asserting infringement, leading to costly litigation, diversion of management attention and resources, incurrence of liabilities, and
the need for expensive royalty or licensing agreements, or even discontinuation of certain branding. Any of these outcomes could negatively
impact our business, financial condition, operational results, cash flows, and future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to comply with the restrictions in our bank loans could result in an event of default that could materially adversely affect
our business, financial condition, and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Group has entered into certain loan agreements with certain banks to fund our working capital requirements. We have in the past defaulted
on certain terms stipulated under such loan agreements. If there were further events of default under such loans in the future, the lender
under such loans could cause all amounts outstanding with respect to that debt to be due and payable immediately. Our assets or cash
flow may not be sufficient to fully repay borrowing under such loans if accelerated upon an event of default. Furthermore, if we are
unable to repay, refinance, or restructure such loans, the lenders under such loans may commence legal proceedings against us to enforce
the terms of such loans, which could force us into bankruptcy or liquidation. As a result, any default by us on our debt could have a
materially adverse effect on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
significant product liability lawsuit may affect our financial performance and reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the products that we prescribe for our patients, such as orthopedic devices, fail to perform as expected and such failure
results in, or is alleged to result in, bodily injury and/or property damage or other losses, we may be subject to product liability
lawsuits and other claims. Such customers may seek contribution or indemnification from our Group for all or a portion of the costs associated
with product liability and warranty claims, recalls or other corrective actions involving such products. These types of claims could
significantly harm our profitability, or may even harm our reputation amongst our target demographics, which could detrimentally affect
our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Medical Healthcare Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Private
healthcare services may decline due to a number of factors affecting the Company&#8217;s revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
slowdown in the Singapore economy in which we operate or regionally may lead to a decrease in demand for private healthcare services
as spending power decreases and more patients may opt for subsidized public healthcare services instead or opt for treatment from other
private healthcare providers that are more price competitive. Our revenue would be adversely affected if individual patients, corporate
clients and government clients are more cautious about their medical expenses and less keen to pay for private healthcare services. A
decrease in the demand for our private orthopedic and physiotherapy services, from individual patients, corporate clients and government
clients, will have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be affected by the spread or outbreak of any contagious or virulent diseases.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinics may be affected by outbreaks of infectious diseases. An outbreak of COVID-19 or resurgence of the outbreak of Severe Acute Respiratory
Syndrome (SARS), Middle East, Respiratory Syndrome (MERS) or any other contagious or virulent diseases like influenza (H5N1 and H7N9)
or bird flu in the region could have a material adverse impact on our operations. In the event such outbreaks occur at any of our clinics,
greater infection control measures will have to be implemented with the possibility of a temporary closure of the affected facility and
quarantine of all affected medical practitioners. There is no assurance that the outbreak of COVID-19 and the impact thereof will not
continue. If such an outbreak is not effectively controlled, we may be required to take necessary additional measures to minimize its
potential impacts on our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
patients from overseas may also decide to seek medical treatment from clinics in other countries. In addition, occurrences of epidemics
and pandemics could also result in negative public opinion of medical institutions, which could have a material adverse effect on the
business, financial condition, results of operations and prospects of our Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is subject to risks related to medical and legal claims, regulatory actions, and professional liability arising from our clinical
and specialist services and our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inherent nature of providing clinical and specialist services exposes our Group to various liabilities. Our business activities, service
performance, and the actions of our employees could result in complaints, legal actions, or regulatory scrutiny. Allegations may be made
against us or our medical specialists concerning our products and services, marketing activities, negligence, or medical malpractice.
Regardless of the validity of these complaints or legal actions, they have the potential to generate negative publicity, impacting the
reputation of our medical specialists, public perception of our service quality, and the engagement of patients in our medical clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Group&#8217;s business, financial condition, results of operations, and prospects could be significantly and adversely affected if substantial
damages and legal costs are assessed in connection with any legal action, or if judgments are made against us that harm our professional
standing and market reputation. Medical malpractice litigation or disciplinary actions against our medical specialists could result in
restrictions on their practice or other adverse outcomes, further impacting our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is also uncertainty regarding the sufficiency of coverage provided by insurance policies maintained by our specialist doctors and/or
by us for potential medical and legal claims, and the comprehensive nature of such coverage for various claim types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we may encounter material disputes with various parties, potentially leading to legal or other proceedings.
Such disputes could result in damage to our reputation, substantial costs, and the diversion of resources and management attention. While
we have not experienced disputes or legal proceedings that materially and adversely affected our business, operations, financial performance,
financial condition, results, and prospects, we cannot provide assurance about future occurrences and their potential impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not have adequate insurance coverage in place despite having mandatory professional malpractice insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to potential liability risks inherent in providing medical services may not be adequately covered by insurance. Liabilities
could surpass available insurance coverage, or claims might arise outside the scope of our insurance protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have secured mandatory insurance coverage, including professional medical malpractice insurance, we cannot guarantee that such coverage
will be sufficient to address all potential liabilities and risks. Although our medical specialists individually maintain insurance coverage
for medical malpractice indemnity, there is no assurance that liability claims will not exceed existing coverage or that the insurance
is comprehensive enough. The solvency of our insurers and their ability to meet contractual obligations when needed also remains uncertain.
In instances where our insurance or indemnification arrangements are insufficient to cover claims, especially those exceeding policy
limitations or the resources of the indemnifying party, substantial payments may be required, leading to a material adverse impact on
our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
unforeseen events like natural disasters or other events beyond our control may not have adequate insurance coverage, potentially causing
a material and adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will successfully renew all policies or secure new ones on similar terms. Any significant alterations in
the terms of our medical specialists&#8217; professional indemnities could disproportionately and adversely affect our business, financial
condition, results of operations, and prospects. Material changes, such as a shift to claims-based insurance, may result in incidents
for which we may not be compensated by insurance proceeds or contractual indemnities. Exposure to uninsured claims due to such changes
could lead to additional liabilities, having a material adverse effect on our business, financial condition, results of operations, and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
must comply with regulations and licensing conditions governing the healthcare sector, and compliance may involve significant costs.
There is a risk that we may not retain, renew, or obtain the necessary licenses and permits for our business operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current operations involve providing specialist orthopedic, trauma, and sports services through our clinics, and these are subject to
various laws and regulations from Singapore governmental agencies like the Ministry of Health (MOH), Health Sciences Authority, Ministry
of Manpower, and the Singapore Medical Council (SMC). These regulations encompass aspects such as the pricing of medical services, procurement
of medical equipment, licensing and operation of medical establishments, and licensing of medical staff. Singapore&#8217;s stringent
safety, health, and environmental laws could become stricter in the future. Violations of these regulatory requirements may lead to fines,
operational modifications, suspensions, or discontinuation, incurring additional operating costs, and potential criminal charges against
our employees, all of which could materially impact our business, financial position, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in government regulations or the introduction of new laws may increase compliance costs, and authorities like the MOH and SMC could suspend
or deny the renewal of our existing licenses if we fail to meet applicable standards. Although we presently satisfy licensing requirements,
there is no guarantee of maintaining or obtaining licenses for future operations. Failure to maintain or renew licenses, permits, qualifications,
and approvals could adversely affect our operations, leading to negative impacts on our business, financial position, results of operations,
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we currently hold regulatory licenses, approvals, and permits for our business operations, these are subject to specified conditions.
Non-compliance with these conditions could result in the revocation of licenses and permits by relevant authorities. Although we have
not encountered such issues in the past, any such occurrence could significantly affect our business, financial position, and results
of operations. The renewal of licenses, approvals, or permits, especially if new laws are enacted, is uncertain, and there is no assurance
that we will successfully renew them in a timely manner, on favorable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulation of healthcare fees and the potential rise in the number of medical practitioners could have adverse effects on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Singapore Ministry of Health (MOH) published Fee Benchmarks for private sector professional fees related to common
surgical procedures. These benchmarks establish a fee range for each procedure, considering factors such as the complexity of medical
procedures and the time, effort, and expertise involved. Less complex cases may be charged at the lower end of the fee benchmarks range,
while more complex cases could be at the higher end of the range. Fees may exceed the fee benchmarks in cases of exceptional complexity,
due to the additional risk, time and effort required for the procedure. In such rare circumstances, fees charged above the fee benchmarks
may not be unreasonable. While the Fee Benchmarks serve as a recommendation and guideline, medical practitioners are not obligated to
price their services accordingly. Presently, all our services are priced within the Fee Benchmarks. However, there is no guarantee that
these benchmarks will not be revised in the future. If the Fee Benchmarks are lowered, we may need to adjust our fees accordingly, potentially
reducing our revenues and profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there is a trend towards increasing the number of medical practitioners in Singapore. The heightened competition within the private healthcare
sector is likely to put pressure on service rates, leading to a potential reduction in the fees we can charge for our services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Challenges
faced by the healthcare industry may also have an effect on the Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, financial condition, results of operations and prospects may be affected by the challenges currently faced by the healthcare
industry, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    and business climate at local, regional, national and international levels;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    in the threat of terrorism and occurrence of natural and man-made disasters that affect travel security or the global economy may
    reduce the number of medical travelers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improvements
    in the quality of healthcare services in other countries that may affect the number of medical travelers coming to the Company&#8217;s
    clinics and facilities for the orthopedic and physiotherapy services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rising
    costs of medicines and pharmaceutical drugs, overheads and other costs incurred for the provision of the Group&#8217;s services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stricter
    laws and regulations relating to the protection of patient information from unauthorized disclosure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stricter
    laws and regulations governing the purchase and dispensation of medicines and pharmaceutical drugs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diagnostic
    services, overheads and other costs incurred for the provision of the Group&#8217;s services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, the SMC issued the 2016 edition of the SMC&#8217;s Ethical Code and Ethical Guidelines (&#8220;ECEG&#8221;) which came into force
on January 1, 2017. Guideline H3(7) prohibits doctors from paying managed care companies, third party administrators, insurance entities
or patient referral services (for the purposes of this risk factor, &#8220;Third Parties&#8221;): (a) fees that are based primarily on
the services the doctors provide or the fees doctors collect; (b) fees that are so high as to constitute &#8220;fee splitting&#8221;
or &#8220;fee sharing&#8221;; or (c) fees which render medical practitioners unable to provide the required standard of care. Guideline
H3(7) came into effect on July 1, 2017 and places the onus of complying with the same solely on doctors and not Third Parties. If our
Group enters into or maintains arrangements with Third Parties in breach of the ECEG and the SMC receives a complaint or information
pertaining to the same, the SMC will refer such complaint or information to the chairman of the Complaint Panel, and a Complaints Committee
will enquire into the complaint or information. This may result in disciplinary actions being taken against our specialists or our Group.
While we have been complying with the ECEG, there is no guarantee that we will not be subjected to a complaint in the future arising
from future or previous arrangements with Third Parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to political, economic and social developments as well as the laws, regulations and licensing requirements in Singapore.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, prospects, financial condition and results of operations may be adversely affected by political, economic, social and legal
developments that are beyond our control in the countries in which we operate in. Such political and economic uncertainties may include
risks of war, terrorism, nationalism, expropriation or nullification of contracts, changes in interest rates, economic growth, national
fiscal and monetary policies, inflation, deflation, methods of taxation and tax policy. Negative developments in the socio-political
climate of Singapore and the region may also adversely affect the Company&#8217;s business, financial condition, results of operations
and prospects. The regional countries are in a state of rapid political, economic and social changes, which will entail risks to our
business and operations if we are to expand in the region in the future. As such, we are unable to assure you that we will be able to
adapt to the local conditions, regulations and business practices and customs in the future. Any changes implemented by the governments
of the countries in which we operate resulting, inter alia, in currency and interest rate fluctuations, capital restrictions, and changes
in duties and taxes detrimental to our business could materially and adversely affect our operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we have in place a number of existing regulatory licenses, approvals and permits for the purposes of its business operations. We will
continue to seek the appropriate licenses, approvals and permits in the event that the Company expands its operations to other countries
in which it does not currently operate in. The licenses and permits we have obtained are subject to conditions stipulated in the licenses
and permits and/or in the relevant laws, rules and regulations under which they have been issued. These conditions must be complied with
for the duration of the licenses and permits. Where there is a failure to comply fully, the relevant authorities have the power to revoke
the licenses and permits. In the event this happens, our business, operations and financial position will be adversely affected. If our
licenses are revoked or renewal of such licenses and permits cannot be obtained, or the terms imposed for renewal are not acceptable
or favorable to us, our operations and business may be adversely affected. Consequently, our financial condition, results and prospects
will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that upon the expiration of the licenses, approval or permits under which the Company carries on its business operations,
the Company will be able to successfully renew them in a timely manner or at all, or that the renewal of these licenses will be granted
on terms acceptable to us, or that if the relevant authorities enact new laws and regulations, the Company will be able to successfully
comply with these requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may also expand to other cities where we do not possess the same level of familiarity with the regulations and business climate
in those cities. We cannot assure investors that we will be able to obtain the requisite licenses, approvals and permits in those cities.
Any failure by the Company to obtain the requisite licenses, approvals and permits in a timely manner and any unforeseen difficulties
arising from the new and unfamiliar territories may have a material adverse effect on the Company&#8217;s business, financial condition,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to this Offering and Ownership of our Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur additional costs as a result of becoming a public company, which could negatively impact our net income and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition,
Sarbanes-Oxley and rules and regulations implemented by the Securities and Exchange Commission and Nasdaq require significantly heightened
corporate governance practices for public companies. As a result, these rules and regulations have increased our legal, accounting and
financial compliance costs and make many corporate activities more time-consuming and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to incur materially greater costs as a result of becoming a public company than those incurred by similarly sized U.S.
public companies. If we fail to comply with these rules and regulations, we could become the subject of a governmental enforcement action,
investors may lose confidence in us and the market price of our ordinary shares could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002 and rules subsequently implemented by the Securities and Exchange Commission and Nasdaq impose various requirements on the
corporate governance practices of public companies. As a company with less than US$1.235 billion in net revenues for our last financial
year, we qualify as an &#8220;emerging growth company&#8221; pursuant to the JOBS Act. An emerging growth company may take advantage
of specified reduced reporting and other generally applicable requirements that are otherwise applicable generally to public companies.
These provisions include exemption from the auditor attestation requirement under Section 404 of the Sarbanes-Oxley Act of 2002 in the
assessment of the emerging growth company&#8217;s internal control over financial reporting and permission to delay adopting new or revised
accounting standards until such time as those standards apply to private companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect these rules and regulations to increase our legal and financial compliance costs and to make some corporate activities more time-consuming
and costly. After we are no longer an &#8220;emerging growth company,&#8221; we expect to incur significant expenses and devote substantial
management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and the other rules
and regulations of the Securities and Exchange Commission. We also expect that operating as a public company will make it more difficult
and expensive for us to obtain director and officer liability insurance. We may be required to accept reduced policy limits and coverage
or incur substantially higher costs to obtain the same or similar coverage. In addition, we incur additional costs associated with our
public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors
or as executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we
cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, shareholders of a public company often brought securities class action suits against the company following periods of instability
in the market price of that company&#8217;s securities. If we were involved in a class action suit, it could divert a significant amount
of our management&#8217;s attention and other resources from our business and operations, which could harm our results of operations
and require us to incur significant expenses to defend the suit. Any such class action suit, whether or not successful, could harm our
reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be
required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
obligation to disclose information publicly may put us at a disadvantage to competitors that are private companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a publicly listed company in the United States. As a publicly listed company, we will be required to file periodic reports with the
Securities and Exchange Commission upon the occurrence of matters that are material to our company and shareholders. In some cases, we
will need to disclose material agreements or results of financial operations that we would not be required to disclose if we were a private
company. Our competitors may have access to this information, which would otherwise be confidential. This may give them advantages in
competing with our company. Similarly, as a U.S.-listed public company, we will be governed by U.S. laws that our competitors, mostly
Singapore-based companies, are not required to follow. To the extent compliance with U.S. laws increases our expenses or decreases our
competitiveness against such companies, our public listing could affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;foreign private issuer&#8221; within the meaning of the rules under the Exchange Act, and as such we are exempt from certain
provisions applicable to U.S. domestic public companies and subject to reporting obligations that, to some extent, are more lenient and
less frequent than those of a U.S. issuer. As a result, we may not provide you the same information as U.S. domestic public companies
or we may provide information at different times, which may make it more difficult for you to evaluate our performance and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a foreign private issuer and, as a result, we are not subject to the same requirements as U.S. domestic issuers. Under the Exchange
Act, we will be subject to reporting obligations that, to some extent, are more lenient and less frequent than those of U.S. domestic
reporting companies. For example, we will not be required to issue quarterly reports or proxy statements. In addition, we will not be
required to disclose detailed individual executive compensation information. Furthermore, our directors and executive officers will not
be required to report equity holdings under Section 16 of the Exchange Act and will not be subject to the insider short swing profit
disclosure and recovery regime.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, we will also be exempt from the requirements of Regulation FD (Fair Disclosure) which, generally, are meant
to ensure that select groups of investors are not privy to specific information about an issuer before other investors. However, we will
still be subject to the anti-fraud and anti-manipulation rules of the SEC, such as Rule 10b-5 under the Exchange Act. Since many of the
disclosure obligations imposed on us as a foreign private issuer differ from those imposed on U.S. domestic reporting companies, you
should not expect to receive the same information about us and at the same time as the information provided by U.S. domestic reporting
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information we are required to file with or furnish to the SEC will be less extensive and less timely as compared to that required to
be filed with the SEC by U.S. domestic issuers. As a BVI business company listed on the Nasdaq Capital Market, we will be subject to
the Nasdaq Capital Market corporate governance listing standards. However, Nasdaq Capital Market rules permit a foreign private issuer
like us to follow the corporate governance practices of its home country. Certain corporate governance practices in BVI, which is deemed
our home country, may differ significantly from the Nasdaq Capital Market corporate governance listing standards. We utilize the home
country exemption for corporate governance matters, and as a result, our shareholders may be afforded less protection than they otherwise
would under the Nasdaq Capital Market corporate governance listing standards applicable to U.S. domestic issuers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to follow certain BVI corporate governance practices in lieu of certain requirements of the listing rules of Nasdaq, including
rules that require each Listed Company must have a board of directors comprised of a majority of independent directors; that each Listed
Company shall hold an annual meeting of shareholders no later than one year after the end of the company&#8217;s fiscal year-end; that
shareholder approval is required prior to an issuance of securities in connection with: (i) the acquisition of the stock or assets of
another company; (ii) equity-based compensation of officers, directors, employees or consultants; (iii) a change of control; and (iv)
transactions other than public offerings; that each Listed Company is required to distribute annual and interim reports to shareholders,
among others. As a result, you may not be afforded the same protections or information, which would be made available to you, were you
investing in a U.S. domestic issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;controlled company&#8221; under the Nasdaq corporate governance rules and, as a result, will be eligible to rely on exemptions
from certain corporate governance requirements that provide protection to shareholders of companies that are not controlled companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
based on available information, Rainforest Capital VCC owns a majority of the total voting power of our ordinary shares. We are thus
a &#8220;controlled company&#8221; under the Nasdaq corporate governance standards. Because we will qualify to be treated as a controlled
company, we will have the option not to comply with certain requirements to which companies that are not controlled companies are subject,
including the requirement that a majority of our board of directors consists of independent directors, the requirement that a majority
of the independent directors select or recommend its director nominees, the requirement that the remuneration committee be responsible
for determining or recommending the compensation of executive officers other than our chief executive officer and the requirement that
its remuneration committee be composed entirely of independent directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to use the exemptions available to foreign private issuers, which exempt us from such requirements as well. As a result,
we do not have to directly rely on the exemptions available to controlled companies. The effect is that our shareholders will not have
the same protections afforded to shareholders of companies that are not &#8220;controlled companies&#8221; and that are subject to the
above mentioned corporate governance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth
companies will make our ordinary shares less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company,
we will take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments
not previously approved. We could be an emerging growth company for up to five years, although we could lose that status sooner if our
revenues exceed US$1.235 billion, if we issue more than US$1 billion in non-convertible debt in a three-year period, or if the market
value of our shares held by non-affiliates exceeds US$700 million as of any June 30 before that time, in which case we would no longer
be an emerging growth company as of the following June 30. We cannot predict if investors will find our ordinary shares less attractive
because we may rely on these exemptions. If some investors find our shares less attractive as a result, there may be a less active trading
market for our shares and our stock price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have elected to avail our Company of this exemption from new or revised accounting standards. Therefore,
we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our ordinary shares may be volatile or may decline regardless of our operating performance, and you may not be able to
resell your shares at or above the initial public offering price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our ordinary shares may fluctuate significantly in response to numerous factors, many of which are beyond our control,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our revenue and other operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow
    our company, or our failure to meet these estimates or the expectations of investors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant products or features, technical innovations, acquisitions, strategic partnerships, joint
    ventures, or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
    and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lawsuits
    threatened or filed against us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, including those resulting from war or incidents of terrorism, or responses to these events.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the trading price of our ordinary shares is likely to be volatile and could fluctuate widely due to factors beyond our control,
regardless of our actual operating performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
resale of our ordinary shares in the public market may cause the market price of our ordinary shares to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
of our ordinary shares in the public market by investors that have participated in our initial public offering or our pre-IPO investors,
or the perception that these sales could occur, could cause the market price of our ordinary shares to decline. All ordinary shares sold
pursuant to our Public Offering Prospectus and the Resale Prospectus both dated February 24, 2025 will be freely transferable without
restriction or additional registration under the Securities Act of 1933.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
issuances or sales, or perceived issuances or sales, of substantial amounts of ordinary shares in the public market could materially
and adversely affect the prevailing market price of the ordinary shares and our ability to raise capital in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our ordinary shares could decline as a result of future sales of substantial amounts of shares or other securities relating
to the shares in the public market, including by the Company&#8217;s substantial shareholders, or the issuance of new shares by the Company,
or the perception that such sales or issuances may occur. We may issue additional securities without shareholder approval, which would
dilute existing ownership interests and may depress the market price of our shares. Future sales, or perceived sales, of substantial
amounts of the shares could also materially and adversely affect our ability to raise capital in the future at a time and at a price
favorable to us, and our shareholders will experience dilution in their holdings upon our issuance or sale of additional securities in
the future. In addition, these factors could make it more difficult for us to raise funds through future offerings of our ordinary shares.
A few shareholders hold a significant portion of our ordinary shares and these are &#8220;restricted securities&#8221; as defined in
Rule 144. These ordinary shares may be sold in the future without registration under the Securities Act to the extent permitted by Rule
144 or other exemptions under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
financing may cause a dilution in your shareholding or place restrictions on our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to raise additional funds in the future to finance further expansion of our capacity and business relating to our existing operations,
acquisitions or strategic partnerships. If additional funds are raised through the issuance of new equity or equity-linked securities
of the Company other than on a pro rata basis to existing shareholders, the percentage ownership of such shareholders in the Company
may be reduced, and such new securities may confer rights and privileges that take priority over those conferred by the shares. Alternatively,
if we meet such funding requirements by way of additional debt financing, we may have restrictions placed on us through such debt financing
arrangements which may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    limit our ability to pay dividends or require us to seek consents for the payment of dividends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our vulnerability to general adverse economic and industry conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to dedicate a substantial portion of our cash flows from operations to service our debt, thereby reducing the availability of
    our cash flow to fund capital expenditure, working capital requirements and other general corporate needs; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    our flexibility in planning for, or reacting to, changes in our business and our industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
controlling shareholder holds control over our Group and this may limit your ability to influence the outcome of decisions requiring
the approval of shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
controlling shareholder, namely Rainforest Capital VCC, owns a majority of our shares and will be able to significantly influence all
matters requiring approval by our shareholders, including the appointment of directors and the approval of significant corporate transactions.
This concentration of ownership may have the effect of delaying, preventing or deterring a change in control of our Company or otherwise
discourage a potential acquirer from attempting to obtain control of us through corporate actions such as merger or take-over attempts,
which could conflict with the interests of other shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may not be an active, liquid trading market for our ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
active trading market for our ordinary shares may not develop or be sustained. You may not be able to sell your ordinary shares at the
market price, if at all, if trading in our ordinary shares is not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be able
to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to our initial public offering, we were a private company with limited accounting personnel and other resources to address our internal
controls and procedures. Accordingly, we will be in a continuing process of developing, establishing, and maintaining internal controls
and procedures that will allow our management to report on, and our independent registered public accounting firm to attest to, our internal
controls over financial reporting if and when required to do so under Section 404 of the Sarbanes-Oxley Act of 2002. Although our independent
registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting pursuant
to Section 404(b) of the Sarbanes-Oxley Act until the date we are no longer an emerging growth company, our management will be required
to report on our internal controls over financial reporting under Section 404.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to address and resolve the foregoing material weakness, we will implement measures designed to improve our internal control over
financial reporting to remediate this material weakness, including hiring outside financial personnel with requisite training and experience
in the preparation of financial statements in compliance with applicable Securities and Exchange Commission requirements within six months
from the completion of our offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a BVI company and, because judicial precedent regarding the rights of members is more limited under BVI law than that under U.S.
law, you may have less protection for your member rights than you would under U.S. law.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate affairs are governed by our post-offering amended and restated memorandum and articles of association, as amended and restated
from time to time, the BVI Act and the common law of the BVI. The right of members to take action against the directors, actions by minority
members and the fiduciary responsibilities of our directors to us under BVI law are to a large extent governed by the common law of the
BVI. The common law of the BVI is derived in part from comparatively limited judicial precedent in the BVI as well as that from English
common law, which has persuasive, but not binding, authority on a court in the BVI. The rights of our members and the fiduciary responsibilities
of our directors under BVI law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions
in the U.S. In particular, the BVI has a less exhaustive body of securities laws than the U.S. In addition, some U.S. states, such as
Delaware, have more fully developed and judicially interpreted bodies of corporate law than the BVI. There is no statutory recognition
in the BVI of judgments obtained in the U.S., although the courts of the BVI will in certain circumstances recognize and enforce a non-penal
judgment of a foreign court of competent jurisdiction without retrial on the merits. As a result of all of the above, public members
may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors
or controlling members than they would as members of a U.S. public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we do not expect to pay dividends in the near future after this offering, you must rely on price appreciation of the ordinary shares
for return on your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to retain most, if not all, of our available funds and any future earnings after this offering to fund the development
and growth of our business. As a result, we do not expect to pay any cash dividends in the near future. Therefore, you should not rely
on an investment in the ordinary shares as a source for any future dividend income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has complete discretion as to whether to distribute dividends. All dividends are subject to certain restrictions under
BVI law and provided that in no circumstances may a dividend be paid unless the value of the Company&#8217;s assets exceeds its liabilities
and the Company is able to pay its debts as they fall due. Even if we decide to declare and pay dividends, the timing, amount and form
of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, the amount of distributions,
if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by
our board of directors. Accordingly, the return on your investment in the ordinary shares will likely depend entirely upon any future
price appreciation of the ordinary shares. There is no guarantee that the ordinary shares will appreciate in value after this offering
or even maintain the price at which you purchased the ordinary shares. You may not realize a return on your investment in the ordinary
shares and you may even lose your entire investment in the ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased
both our costs and the risk of non-compliance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to rules and regulations by various governing bodies, including, for example, the Securities and Exchange Commission, which
are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving
regulatory measures under applicable law, including the laws of the BVI. Our efforts to comply with new and changing laws and regulations
have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management
time and attention from revenue-generating activities to compliance activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time
as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs
necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations
and any subsequent changes, we may be subject to penalties and our business may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may incur additional costs and procedural obstacles in effecting service of legal process, enforcing foreign judgments or bringing actions
in the British Virgin Islands or Singapore based on U.S. or other foreign laws against us, our management or the experts named in this
report.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
Medical is a BVI business company and substantially all of our assets are located outside of the United States. All of our current operations
are conducted in Singapore. In addition, all of our current directors and officers are nationals and residents of countries other than
the United States. As a result, it may be difficult for you to effect service of process within the U.S. or elsewhere upon these persons.
It may also be difficult for you to enforce in Singapore or British Virgin Islands courts judgments obtained in U.S. courts based on
the civil liability provisions of the U.S. federal securities laws against us and our officers and directors, and the substantial majority
of whose assets are located outside of the U.S. It may be difficult or impossible for you to bring an action against us in the British
Virgin Islands if you believe your rights under the U.S. securities laws have been infringed. In addition, there is uncertainty as to
whether the courts of the British Virgin Islands or Singapore would recognize or enforce judgments of U.S. courts against us or such
persons predicated upon the civil liability provisions of the securities laws of the U.S. or any state and it is uncertain whether such
British Virgin Islands or Singapore courts would hear original actions brought in the British Virgin Islands or Singapore against us
or such persons predicated upon the securities laws of the U.S. or any state.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our ordinary shares could be subject to rapid and substantial volatility. Such volatility, including any stock run-ups, may
be due to factors unrelated to our actual or forecasted operating performance and financial condition or prospects, making it difficult
for prospective investors to assess the underlying value of our ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with recent initial
public offerings, especially among those with relatively smaller public floats. As a relatively small-capitalization company with a relatively
small public float, we may experience greater share price volatility, extreme price run-ups, lower trading volume, and less liquidity
than large-capitalization companies. In particular, as there was no prior market for our shares, our ordinary shares may be subject to
rapid and substantial price volatility, low volumes of trading, and large spreads in bid and ask prices. Such volatility, including any
stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult
for prospective investors to assess the rapidly changing value of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the trading volume of our ordinary shares is low, investors buying or selling in relatively small quantities may easily
influence the price of our ordinary shares. This low volume of trades could also cause the price of our ordinary shares to fluctuate
greatly, with large percentage changes in price occurring in any trading day session. Holders of our ordinary shares may also not be
able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations
and general economic and political conditions may also adversely affect the market price of our ordinary shares. As a result of this
volatility, investors may experience losses on their investment in our ordinary shares. A decline in the market price of our ordinary
shares also could adversely affect our ability to issue additional ordinary shares or other securities and our ability to obtain additional
financing in the future. No assurance can be given that an active market in our ordinary shares will develop or be sustained. If an active
market does not develop, holders of our ordinary shares may be unable to readily sell the shares they hold or may not be able to sell
their shares at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
and certain of our current and directors or officers may be subject to securities litigation, which is expensive and could divert management
attention.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Ordinary Shares may be volatile and, in the past, companies that have experienced volatility in the market price
of their stock have been subject to securities class action litigation and regulatory investigations. Involvement in securities litigation
against us could result in substantial costs and divert management&#8217;s attention from other business concerns, which could seriously
harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research reports about us or our business, or if such analysts issue adverse recommendations
regarding our ordinary shares, the market price for our ordinary shares or trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our ordinary shares will be influenced by research reports that industry or securities analysts publish about our
business and financial results, or the lack thereof. The lack of analyst coverage may adversely affect our share price, trading volume,
and general investor interest. If analysts who cover us downgrade their recommendation of our ordinary shares, the market price for our
ordinary shares would likely decline. If one or more of these analysts cease to cover us or fail to regularly publish reports on us,
we could lose visibility in the financial markets, which in turn could cause the market price or trading volume for our ordinary shares
to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we cannot satisfy, or continue to satisfy, the listing requirements and other rules of the Nasdaq Capital Market, our ordinary shares
may be delisted, which could negatively impact the price of our securities and your ability to sell them.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares are listed and traded on the Nasdaq Capital Market under the symbol &#8220;BMGL.&#8221; We cannot assure you that our
ordinary shares will continue to be listed on the Nasdaq Capital Market. In order to maintain our listing on the Nasdaq Capital Market,
we will be required to comply with certain rules of the Nasdaq Capital Market, including those regarding minimum stockholders&#8217;
equity, minimum share price, minimum market value of publicly held shares, and various additional requirements. Even if we initially
meet the listing requirements and other applicable rules of the Nasdaq Capital Market, we may not be able to continue to satisfy these
requirements and applicable rules. If we are unable to satisfy the Nasdaq Capital Market criteria for maintaining our listing, our securities
could be subject to delisting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Nasdaq Capital Market subsequently delists our securities from trading, we could face significant consequences, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability for market quotations for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity with respect to our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our ordinary share is a &#8220;penny stock,&#8221; which will require brokers trading in our ordinary share to
    adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our
    ordinary share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    amount of news and analyst coverage; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions in our post-offering amended and restated memorandum and articles of association may discourage, delay, or prevent a change
in control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
provisions of our post-offering amended and restated memorandum and articles of association may discourage, delay or prevent a change
in control of the Company or management that shareholders may consider favorable, including, among other things, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    that authorize our board of directors to issue shares with preferred, deferred or other rights or restrictions, whether in regard
    to dividend, voting, return of capital or otherwise, without any further vote or action by our shareholders; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
    that limit the ability of our shareholders to call meetings and to propose special matters for consideration at shareholder meetings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may be unable to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">British
Virgin Islands law provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders
with any right to put any proposal before a general meeting. These rights, however, may be provided in a company&#8217;s memorandum and
articles of association. Our post-offering amended and restated memorandum and articles of association allow our shareholders holding
shares representing in aggregate not less than 10% by number of issued shares which as at that date carry the right to vote, to requisition
a general meeting of our shareholders, in which case our directors are obliged to call such meeting. Advance notice of at least seven
clear days is required for the convening of our annual general shareholders&#8217; meeting and at least seven clear days&#8217; notice
any other general meeting of our shareholders. A quorum required for a meeting of shareholders consists of the holders of one-third of
the shares being individuals present in person or by proxy. For these purposes, &#8220;clear days&#8221; means that period excluding
the day when the notice is received or deemed to be received and the day for which it is given or on which it is to take effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sd_007"></span>ITEM
4. INFORMATION ON THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
History and Development of the Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
Medical Group Ltd is a business company incorporated in the BVI on August 10, 2023 under the BVI Business Companies Act (As Revised),
with operations conducted by our subsidiaries based in Singapore. Our first orthopedic-focused clinic was set up in Singapore in 2001,
and our first subsidiary, SSO Clinic, was incorporated in 2004. From 2004 to the 2020s, we expanded our orthopedic specialty operations
as the group, Singmed Specialists, operating two clinics in Singapore &#8211; namely, Spine &amp; Orthopaedics Centre (Singapore) and
Singapore Sports &amp; Orthopaedics Clinic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, AIP Investment Partners Pte. Ltd., an asset management company based in Singapore, through its sub-fund Basel Medical Fund
from the private equity umbrella fund, Rainforest Capital VCC, fully acquired Singmed Specialists, and changed its name to Basel Medical
Group. In February 2025, Basel Medical Group Ltd listed successfully on NASDAQ with the goal to grow into a more international medical
group, transcending the role of a conventional healthcare provider with a vision for innovation, growth and far-reaching impact. We aim
to keep expanding in Singapore to general practices, other specialized practices, and also into other South-east Asian countries. Our
goal is to become the premier healthcare provider, offering seamless, one-stop solutions with unparalleled customer experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                                                           April 11, 2025, Basel Medical Group Pte. Ltd., a subsidiary of Basel Medical Group Ltd, entered into a sale and purchase agreement
                                                                           with Silkroute Biomed Healthcare Pte. Ltd. for the acquisition of all of the ordinary shares of Bethesda Medical Pte. Ltd., a
                                                                           company incorporated in Singapore, for a total consideration of US$8 million in tranches. The acquisition of Bethesda Medical was
                                                                           completed on April 30, 2025. Following such completion, Bethesda Medical became a wholly owned indirect subsidiary of Basel Medical
                                                                           Group Ltd. Our Group through Bethesda Medical operates six general practice clinics in Singapore.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is at 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore 258499 and our telephone number is
+65 62919188. Our website is https:// https://baselmedical.com/. The information contained in, or accessible through, our website does
not constitute a part of this annual report. The SEC maintains a website that contains reports, proxy and information statements, and
other information regarding issuers that file electronically with the SEC. Our electronic filings with the SEC are available for viewing
on this website, at <i>www.sec.gov</i>. Our agent for service of process in the United States is Puglisi &amp; Associates, 850 Library
Avenue, Suite 204, Newark, Delaware 19711.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Business Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>OVERVIEW</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
Medical Group Ltd, or &#8220;Basel Medical&#8221;, is a BVI business company incorporated in the BVI. Basel Medical serves as the holding
company of our Group and we conduct our operations through our operating subsidiaries based in Singapore.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide a wide spectrum of general and subspecialized orthopedic including but not limited to trauma and sports medicine services such
as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as
well as neurosurgical treatments. Also, we have health screening services, mental health, woman&#8217;s health and general practice services
as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are based in Singapore, with our specialist clinics being at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles
Medical Centre, a convenient and central location in Singapore accessible by public transportation. Our general practices in the
group are at locations across Singapore, including Suntec City, Grantral Mall, Toa Payoh Hub, Margaret Drive, Tampines and Gateway
East. We currently have 14 medical practitioners in our Group, comprising four specialists and 10 general practitioners<span style="background-color: yellow"></span>.
The services provided by our clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical
treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women&#8217;s health and
neurosurgical conditions and our clinics are equipped with the facilities needed to perform a variety of procedures on site and
minor surgical services. Major surgeries will be carried out at Gleneagles Hospital, Mount Elizabeth Hospital, Mount Elizabeth
Novena Hospital, Parkway East Hospital, Mount Alvernia Hospital, Farrer Park Hospital and other day surgery centers in Singapore
where our medical practitioners are accredited to practice. Our clinics have been selected by several insurance providers as
preferred medical care providers and our medical doctors are MediSave accredited, and therefore patients can submit their MediSave
or Integrated Shield Plan claims through our clinics. MediSave is a national medical savings scheme in Singapore that helps
individuals set aside part of their income to pay for their personal or approved dependents&#8217; hospitalization, day surgery and
certain outpatient expenses, as well as their healthcare needs in old age. MediShield Life (&#8220;MSHL&#8221;) is a basic national
health insurance scheme in Singapore that provides lifelong coverage for Singapore citizens and permanent residents. Certain aspects
of MediShield Life are paid for using MediSave funds. Integrated Shield Plans are optional health coverage in Singapore provided by
private insurers that complements MSHL with higher coverage benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patients who visit our clinics are either walk-in patients, employees of corporations, or policyholders of insurance companies with whom
we have entered into arrangements. We believe that such arrangements with corporations and insurance companies to offer our medical services
at preferred rates allow for the convenient, reliable and cost-effective inpatient and outpatient medical treatments at private hospitals,
provide our Group&#8217;s clinics with patient volume and enables these corporations and insurance companies to meet their budgetary
constraints in relation to the medical treatment of their employees or, as the case may be, policyholders. For the past five years, we
served more than 20 insurance companies and over 300 corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>OUR
BUSINESS MODEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
specialize in providing a range of medical and therapeutic treatments in the fields of orthopedics and neurosurgery. As of the date of
this report, we employ 14 medical practitioners in our Group, comprising 10 general practitioners
and four specialists who specialize in orthopedic, trauma, sports medicine and neurosurgical
treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patient
Types, Fees and Payments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model can be broadly divided into two segments, comprising the (i) individual patient segment, which is made up of individual
walk-ins and recurring individual patients, and (ii) our corporate client segment, which mainly includes patients referred to us by their
employers which are our corporate clients. Our fees are paid for either by the patient, or by the patient&#8217;s employer or insurer
in the case of a qualifying claim which qualification depends on the terms of employment or insurance coverage of such patient. As is
the case with other clinical groups in Singapore, our fees and charges are determined based on the types of services rendered and medication
prescribed. We maintain an internal itemized fee scale which sets out the prices of our services for patients. The Singapore Ministry
of Health has published a set of fee benchmarks which constitute recommended charges for doctors and hospital fees in the private sector,
for routine and typical cases. These benchmarks inform what is a reasonable range of fees that patients and insurers could expect to
pay, and serve as a reference for doctors and hospitals in setting their fees. Our fee scale is determined and periodically revised with
reference to such benchmarks. We also prescribe orthopedic devices as part of the treatment of our patients where necessary, with such
orthopedic devices being wholly-sourced from and supplied by wholesale suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patient
Demographics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2025, approximately 17% of our patients were aged 25 years old and below, approximately 35% aged 26 to 40 years
old, approximately 36% were aged 41 to 60 years old and approximately 12% were 61 years old and above. For the same year, approximately
44% were male and 56% were female.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2025, based on our historical estimation, approximately 1.0% of our patients are employees of corporate clients
who receive treatment of work related injuries, such as manual laborers from the construction, marine, and oil and gas industries, approximately
0.2% are individual clients who are treated for spinal surgery and other neurological conditions, while approximately 0.8% are individual
clients treated for other sub-specialties, including trauma, sports medicine, joint replacement, knee replacement, physiotherapy, arthroscopy,
knee/hip replacements, sports medicine/surgery, foot/ankle surgery and others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Medical Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Group operates 8 medical clinics that are located at the following locations in Singapore:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical
    Clinic</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Location</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spine
    &amp; Orthopaedic Centre (Singapore)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    Napier Road, #03-07 Gleneagles Medical Centre</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
    Sports &amp; Orthopaedic Clinic</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    Napier Road, #02-10/11 Gleneagles Medical Centre</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Clinic (Suntec)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    Temasek Boulevard #03-330 Suntec City Mall </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Clinic (Grantral Mall-Macpherson)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">601
    Macpherson Road #01-04 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Clinic (Toa Payoh)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500
    Lorong 6 Toa Payoh #04-33 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Clinic (Margaret Drive)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38
    Margaret Drive #02-03</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Clinic (Tampines)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">406
    Tampines Street 41 #01-31 </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Clinic (Beach Road)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152
    Beach Road, #03-08 Gateway East</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Types
of Treatments and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Group is a healthcare group primarily involved in the provision of a comprehensive range of health services including but not limited
to orthopedic treatments and surgeries, trauma and sports medicine services (both surgical and non-surgical), physiotherapy services,
general practices, health screening, mental health, woman&#8217;s health and neurological treatments. As at the latest practicable date,
we have four medical practitioners serving patients at our two clinics in Gleneagles Medical Centre in Singapore and eight others in all
other locations mentioned above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orthopedic
Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, our orthopedic services can be categorized as surgical and non-surgical treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Surgical</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
medical professional team provides surgical services to treat a wide range of orthopedic conditions and adopt advanced techniques such
as minimally invasive surgery and keyhole surgery which enhances surgical precisions, reduces complications, and encourages fast recovery
for our patients. We also employ the use of advanced technology such as robots which enable us to perform our surgeries with precision.
Our medical practitioners are all trained and experienced surgeons who have many years of clinical and surgical experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Surgical</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also provide a wide range of non-surgical services, ranging from general consultations to diagnostic and therapeutic orthopedic procedures
such as medications, injections, splinting and physiotherapy in the outpatient setting. Our medical practitioners also provide, inter
alia, second opinions and being on-call in the hospitals associated with our clinics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Treatment
Process</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a patient first visits one of our clinics, he or she will go through a consultation with one of our medical practitioners for an accurate
diagnosis of their medical condition. Depending on the medical condition, tests such as MRI scans, CT scans or X-rays may be arranged
for the patient. Our medical practitioners will then review the results of such tests and determine the best form of treatment for the
patient and advise them accordingly. We may prescribe orthopedic devices to our patients where necessary, such as joint implants, bone
fixation devices, orthopedic braces and supports and other related devices, with such orthopedic devices being supplied by wholesale
suppliers. Generally, surgical procedures are carried out in the hospitals and medical centers in which our clinics are located. We also
provide post-surgical services to our patients which include arranging inpatient support as well as follow-up consultations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Physiotherapy
services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physiotherapy
is the use of evidence-based proven techniques to help restore, maintain and maximize movement, function and overall-well-being. It includes
rehabilitation as well as injury prevention and promotion of health and fitness. Physiotherapy services are ideal for patients of all
ages affected by injury or orthopedic conditions, for pain management, improved sports performance and for general health and wellbeing.
Generally, patients seeking a non-invasive treatment option that would improve their mobility would consider physiotherapy. During the
initial session, our medical practitioners will perform a physical examination to assess the patient&#8217;s musculoskeletal condition,
identify its cause or contributing factors and work with the physiotherapists develop a holistic management plan that will optimize the
treatment outcome. The focus is on resolving functional issues such as difficulties in the movement and performance of daily activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neurology
and Neurosurgical Treatments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
neurosurgeon, Dr. Matthew Tung, possesses substantial experience in the field of neuroscience and is able to provide comprehensive services
for the treatment of brain and spine conditions across all age groups. Our Group is able to address a wide range of issues, from headaches
and brain tumors to aneurysms and strokes. Additionally, our team of medical practitioners collaborate to offer comprehensive care for
patients facing various orthopedic and neurological diseases and disorders. This encompasses conditions such as epilepsy, brain and spine
tumors, concussions, craniofacial deformities, scoliosis, movement disorders, and more. The seamless coordination between our orthopedic
doctors and neurosurgeon facilitates smooth transitions in patient care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate Clients</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
portion of the patients who visit our clinics are employees of corporations, such as construction, marine, and oil &amp; gas companies,
or policyholders of insurance companies. We have entered into arrangements with such corporations and insurers, a common practice in
the Singapore medical services industry, where such counterparties may refer their employees to us for treatment, or include us in a
panel of recognized medical clinics eligible for coverage under the relevant insurance plan. The material terms in our typical agreements
with such corporations are set out below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scope</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Group contracts with corporations to provide medical services for their employees. If and when an employee utilizes the services
    of our Group, we will bill and seek payment from the employer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusivity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may have exclusivity arrangements with certain corporations to enjoy our preferential rates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    of cooperation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Typically,
    our agreements with such corporations are perpetual but are terminable subject to periodic renewal or provision of the required notice
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    terms</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    typically provide preferential rates for our consultancy, treatment, and medication charges, which may be subject to adjustment.
    We may provide credit terms to the corporations to settle our fees on a periodic basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    obligations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are typically contractually obligated to maintain the required licenses, permits and insurance to provide our medical services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms in our typical agreements with third-party insurers are set out below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scope</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Group contracts with insurers which provide insurance or health programs to their covered participants. Such insurers may list our
    clinics on their panel lists and provide information about our Group and our services to their covered participants. When a participant
    utilizes the services of our Group, we will bill and seek payment from the insurer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusivity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    are generally no exclusivity arrangements and such insurers are free to enter into similar arrangements with other clinic and medical
    service providers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
                                            of cooperation</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Typically,
    our agreements with such insurers are perpetual but are terminable subject to periodic renewal or provision of the required notice
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
                                            terms</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    typically provide a schedule of our consultancy, treatment, and medication charges, which may be subject to adjustment. Certain agreed
    discounts may be available to the insurer based on the usual and customary charges for our services. Certain corporate insurers may
    charge administration fees from us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    obligations</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are typically contractually obligated to maintain the required licenses, permits and insurance to provide our medical services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Specialist Doctors:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Group&#8217;s reputation and image was built painstakingly through the professionalism of our specialist doctors whose credentials, experience
and expertise are set out below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Kevin Yip</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MBBS
(U of London, United Kingdom), FRCS (Orth Surg) (RCS, Edinburgh, United Kingdom), FHKCOS (Hong Kong College of Orthopaedic Surgeons,
Hong Kong, China), FAMS (Orth Surg) (Academy of Medicine, Singapore)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kevin Yip is the founder of our Group. Before Dr. Kevin Man Hing Yip became an orthopedic surgeon in Singapore, he obtained his medical
degree from St. Thomas&#8217; Hospital London, England. He completed his post-graduate training in London, obtained his Fellowship of
the Royal College of Surgeons in 1990, and worked in several hospital units in England before moving to Hong Kong. Dr. Kevin Yip became
an Associate Professor at the Chinese University of Hong Kong Prince of Wales Hospital and participated in extensive research in various
fields, especially the knee and shoulder. After leaving Hong Kong in 1998, he joined Gleneagles Hospital in Singapore as an Orthopedic
Surgeon. Apart from general orthopedics, his main areas of expertise are back pain, neck pain, knee surgery and shoulder surgery. Dr.
Yip is also a founding member of Asian Association for Dynamic Osteosynthesis, an honorary faculty member of The Interdisciplinary Research
Centre for Musculoskeletal Bioengineering and Rehabilitation Technology &amp; The Hong Kong Medical Association. Over the course of his
career, Dr. Yip has published close to 80 research articles. Dr. Yip is currently a locum doctor with our Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Matthew Tung</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MBBS
(NUS, Singapore), FRCS (Neurosurgery) (RCPS, Glasgow, United Kingdom)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Matthew Tung joined our Group in November 2017 and specializes in treating disorders of the brain and spine with special interest in
back pain and neck pain, nerve pain and headache. He believes that neurosurgery should always consider the non-invasive options before
open surgery to attain minimum morbidity and a fast return to optimum function. In spinal disorders, Dr. Tung aims for motion preservation,
reversible treatments that can be repeated in preference to fusion. In the last 15 years he has performed operations using non-invasive
techniques like stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) for brain tumors, minimally invasive techniques with
endoscope-assisted method to access the pituitary adenoma, treat hydrocephalus and ventricular tumors, spinal laminectomy for spinal
tumors, facet joint injections, cervical and lumbar disc replacements, spinal decompression and fusion, and endoscopic thoracic sympathectomy
for sweaty palms. Dr. Tung pursues continued medical education eagerly and keeps abreast of latest techniques by attending courses and
attachments in Europe (SRS, SRT, spinal surgery and disc replacement), America (skull base approaches to acoustic neuroma) and China
(endovascular techniques for vascular disorders).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Palanisamy Arul Murugan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MBBS
in Orthopaedic Surgery (IN), MRCS (Member of the Royal College of Surgeons of Edinburgh) Edin, Mmed (Master of Medicine, Ortho), FRCS
(Ortho)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Palanisamy Arul Murugan is a practicing doctor with our Singapore Sports and Orthopaedic Clinic and joined our Group in December 2020.
He completed his MBBS from Madras Medical College, India. He has been working in Singapore since November 2010. In his 10 years in Singapore,
he has been posted to KK Women&#8217;s &amp; Children&#8217;s Hospital, Singapore General Hospital, Tan Tock Seng Hospital, Khoo Teck
Puat Hospital and Thye Hua Kwan Hospital in the departments of Orthopaedic Surgery, Accident and Emergency, General Surgery, Anaesthesia,
Hand Surgery, Rehabilitation Medicine and Neurosurgery. He passed the MRCS (Edin) in 2012. He was awarded SingHealth best medical officer
award in 2013. He was given National Health Group Orthopaedic Residency in 2014. He received his MMed (Ortho) in 2019. He completed his
orthopedic residency on July 30, 2020 and passed the FRCS ortho exam held in November, 2020. He has presented research papers in many
international conferences and has journal publications in the fields of orthopedic trauma and hand surgery. In his orthopedic career,
he has worked in various sub-specialities such as trauma, joint replacement, sports injuries, foot and ankle problems and hand surgery.
Dr. Arul Murugan is fluent in Tamil, English and Hindi.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Kelvin Tan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MBBS
(Singapore), MRCS (Edinburg), M.Med (Orthopedics), FRCS (Edinburg) (Orthopedics)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kelvin Guoping Tan is a consultant orthopedic surgeon at Singapore Sports and Orthopaedic Clinic and joined our Group in August 2024.
After completing his postgraduate specialist training in orthopedic surgery, he became a Fellow of the Royal College of Surgeons of Edinburgh
in 2015 and is also registered with the Singapore Specialist Accreditation Board. Dr. Kelvin Tan is highly proficient in robotic-assisted
primary and revision hip and knee joint replacement surgeries, complex hip reconstruction, including impaction bone grafting for failed
hip replacements/hip dysplasia, Direct Anterior Approach (DAA) to hip replacement, and trauma surgeries including peri-prosthetic fracture
fixation and sports surgeries. He is an avid proponent of the use of cutting-edge technology such as robotics and computer navigation
to perform hip and knee replacement, including unicompartmental (partial) knee replacement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kelvin Tan was the previous head of Adult Reconstruction/Joint Replacement unit and a senior consultant at Tan Tock Seng Hospital in
Singapore and he has been practicing medicine for more than 15 years. Dr. Kelvin Tan is a key opinion leader in Singapore and regionally
in the field of robotic-assisted joint replacements as well as enhanced recovery after surgery (ERAS), sitting on various national committees
prior to private practice. He has extensive experience in robotic joint replacements having performed more than 500 Mako Robotic-assisted
joint replacements (MAKOplasty). He is also a certified Mako Robotic trainer in partial knee, total knee as well total hip replacement.
Dr. Kelvin Tan is an Adjunct Assistant Professor at National University of Singapore (NUS) and was a core clinical faculty member and
clinical competencies committee member of Singapore&#8217;s NHG&#8217;s orthopedic residency programme. He is an examiner for NUS and
Lee Kong Chian School of Medicine undergraduates as well as an Orthopaedic Master of Medicine. He has published extensively in international
peer-reviewed medical journals and presented widely locally and in international conferences. He is currently the chairman of the Singapore
Arthroplasty Society, representing Singapore at various international conferences. He is also the Young Surgeon Nominate for Singapore
at the Asia Pacific Orthopaedic Association.]</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>COMPETITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
orthopedic treatment market in Singapore is highly fragmented, with low barriers to entry and low consolidation. We generally face competition
from both medical practitioners and non-medical practitioners. The medical practitioners are doctors and surgeons in specialties such
as orthopedics, neurosurgeons, neurologists, and rheumatologists who offer similar medical procedures to treat pain or alternative medical
treatments. There are certain other corporate groups in Singapore offering orthopedic treatments, including listed companies, as well
as small and medium enterprises, some of which have been offering similar private orthopedic and physiotherapy
services for twenty or more years in the Singapore market. The non-medical practitioners who provide comparable pain management treatments
include traditional Chinese medicine physicians, physiotherapists, and chiropractors, who provide alternative services to our pain care
services designed to alleviate pain conditions suffered by patients. As for the general services under Bethesda Medical Clinics the competition
can come from general practices with rich experience clinicians. Singapore is a densely populated country and most neighbourhoods have
some form of general practice clinic(s). These clinics may range from solo practitioners to group practices and the clinicians&#8217;
experience can be highly variable. Regardless, sometimes the pool of targeted patients can have potential overlap. Ultimately the moat
lies in how integrated the services can be within its micro ecosystem i.e. musculoskeletal related diseases, integration into payors&#8217;
ecosystem such as insurers or national programs, quality and continuity of care of the practice itself.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR
PATIENTS AND CLIENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Customer
Base</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
customers primarily include (i) first time or recurring individual patients and (ii) corporate employers, a substantial portion of which
are construction, marine and oil &amp; gas companies, walk in customers, referral from our general practitioners. Our revenue for the
periods indicated below categorized according to inpatient treatment (which involves ward admission), outpatient treatment (which do
not require hospitalization), corporate patients (being patients referred to us by our corporate customers) and individual patients (who
are our direct customers and are not referred to us by corporate customers) is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Years ended June 30</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$&#8217;000</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">S$&#8217;000</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; font-style: italic; text-align: center">%</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; font-style: italic">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">S$&#8217;000</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; font-style: italic">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; font-style: italic; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Specialist clinics</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Corporate patients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Inpatients</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,139</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,448</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outpatients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,878</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Corporate patients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,837</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,372</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Individual patients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Inpatients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outpatients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,548</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Total individual patients</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,588</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">58</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,679</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">General practice clinics</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate patients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Individual patients</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total Group revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,900</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,051</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2025, we had approximately 964 patients referred by our corporate clients and 13,161 individual patients and
the revenues generated from our ten largest customers represented approximately 4.0% of our revenues for the same period, while such
ten largest customers include three corporate clients who refer their employees to us for treatment. During the year ended June 30, 2024,
we had approximately 989 patients referred by our corporate clients and 4,433 individual patients and the revenues generated from our
ten largest customers represented approximately 4.0% of our revenues for the same period, while such ten largest customers include seven
corporate clients who refer their employees to us for treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketing and business development activities are spearheaded by our management and senior medical practitioner leaders who plan and
formulate our overall objectives and business strategies within the ambits of the applicable guidelines issued by the MOH and the relevant
laws and regulations in Singapore. We have a dedicated corporate marketing team comprising of a marketing supervisor and several marketing
staff who implement and monitor our marketing and business development initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market our services and develop our business through the following methods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Personal
    referrals</b>. Personal referrals by &#8220;word of mouth&#8221; have proven to be a particularly effective method. This is our Group&#8217;s
    most important asset and strong point. Through this &#8220;soft&#8221; marketing approach, we attract quality patients who are confident
    in our healthcare services. We will continue to cultivate brand loyalty and goodwill amongst our existing patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advertising
    and social media</b>. In order to create awareness of our Group, we make use of traditional newspaper advertisements, Google advertisements
    as well as social media in compliance with all relevant laws, rules, and regulations, including but not limited to the SMC&#8217;s
    Ethical Code and Ethical Guidelines, as well as the advertising guidelines and publicity regulations published under the Singapore
    Private Hospitals and Medical Clinics Act. Our digital media presence through our website and social media, and search engine optimization
    has enabled us to increase our brand awareness and customer reach and drive business volumes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Panels
    of insurance companies. </b>Our clinics have been selected by several insurance providers as preferred medical care providers. The
    inclusion of our clinics on these panels provides another avenue through which we are able to reach new customers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    marketing.</b> We recognize that corporate clients are an important source of income, and we actively pursue corporate client accounts
    through conducting presentations at potential corporate client&#8217;s premises. Our marketing team is constantly engaging current
    and new corporate clients to understand their needs and requirements. Prospective corporate clients are also presented with highly
    competitive preferential rates for the specialist healthcare services offered by our Group that are tailored to the needs of their
    employees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Participation
    in medical conferences, seminars and workshops</b>. Our medical practitioners attend health conferences in Singapore and overseas.
    These events provide opportunities, either as guest speakers or participants, to network with other medical practitioners and the
    public to increase our presence in the medical industry. Such events are also opportunities for us to identify promising medical
    specialists that we may recruit to join our Group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    website</b>. Our corporate website highlights the profiles of our specialist medical practitioners, the range of services that we
    provide and the location of our medical clinics. This allows us to raise the potential customers&#8217; awareness of our Group and
    the services we provide in addition to traditional marketing methods. It is also an avenue for us to update the public on our Group&#8217;s
    latest activities and to educate the public on health issues. Direct online bookings continues to grow, in part because of effective
    search engine optimization. We have also been utilizing search engine optimization to improve our website traffic and widen our reach
    to our targeted audience in order to drive our business volumes. Information contained on our website does not constitute part of
    this report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continually obtain market updates and keep abreast of the latest relevant technology in the healthcare industry, and we formulate growth
strategies to increase our profile in the industry. This also enables us to devise growth strategies locally and overseas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quality
Control and Training</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
place a great emphasis on delivering quality personalized care for our patients. Our clinical decisions are made based on patients&#8217;
interests and contemporary evidence-based medicine. Our clinic operations team conducts regular training sessions for our medical professionals
and support staff, regular surveillance and performance audits and provides professional support to ensure our medical professionals
and support staff are in compliance with our operating procedures and business rules. As a condition of their employment, medical professionals
are required to provide background information, certificates and evidence that they have complied with the applicable regulatory requirements
and have a valid professional indemnity insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that service quality is vital to any industry and even more so in the medical and healthcare sectors. We comply with all MOH
and SMC guidelines with regards to quality standards. We continually seek feedback from our patients via direct dialogue. The results
are relayed to our medical professionals and management. Such feedback is taken seriously and is designed to contribute positively to
the overall experience of the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that the industry that we operate in is competitive, and it is vital to provide quality services and maintain high standards
in our operations. We believe that staff training is important for our Group, capability and morale of our staff is of high importance,
and that continual staff training and development is crucial to supporting the strategic vision of our Group and the future growth of
our business and operations. In order to ensure that our employees are competent in their roles and responsibilities, staff training
plays an important role in our operations, and comprises largely on-the-job training and in-house training.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>OUR
SUPPLIERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patients typically obtain their required drugs and medication from our clinics. The drugs and medications that we prescribed include
painkillers, antibiotics, and nerve repair medication. Generally such drugs are widely available, and we do not anticipate any substantive
difficulties in procuring such drugs and medications. We have also not experienced significant fluctuations in the prices of such drugs
and medications. We obtain such supplies primarily from wholesalers based in Singapore, with which we do not usually have long term contracts
as we anticipate being able to have access to alternative suppliers at comparable prices. Other suppliers include laboratory tests service
providers, and radiology service providers. For the year ended June 30, 2025, we had approximately 301 suppliers and expenses incurred
in relation to our five largest suppliers represented approximately 12% of our total expenses for the same period. For the year ended
June 30, 2024, we had approximately 85 suppliers and expenses incurred in relation to our five largest suppliers represented approximately
16% of our total expenses for the same period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>SEASONALITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the nature of our medical services, we have not observed any significant seasonal trends affecting our business operations and financial
performance and results. We believe that there is no apparent seasonality affecting the business of providing orthopedics and other related
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTELLECTUAL
PROPERTY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary intellectual property rights comprise website domain names (including &#8220;www.orthopaedicclinic.com.sg&#8221;, &#8220;www.baselorthopaedics.com&#8221;,
www.baselneurosurgery.com and www.baselmedical.com<span style="text-decoration: underline">,</span>) and our registered trademark. Given the scale of our operations, which currently
only covers Singapore, we currently have registered only one trademark. We may create and register other trademarks in the future as our business grows.
We intend to protect our intellectual properties vigorously, but there can be no assurance that our efforts will be successful. Even
if our efforts are successful, we may incur significant costs in defending our rights. From time to time, third parties may initiate
litigation against us alleging infringement of their proprietary rights or declaring their non-infringement of our intellectual property
rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had 36 full-time employees as of January 31, 2025, and 77 full-time employees as of September 30, 2025. The following table sets forth
the number of our full-time employees categorized by function as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Function</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of employees</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical practitioner</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical staff</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting, human resource
    and others</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Organizational Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
Medical is a BVI business company incorporated on August 10, 2023 with operations conducted by our subsidiaries based in Singapore. From
2004 to the 2020s, we expanded our operations and incorporated further operating entities in Singapore. The following entities were incorporated
on the following dates primarily to serve different segments of our clientele, including dormant entities indicated below which do not
have any operations to date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 4%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Group
    entity</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    of incorporation</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel Medical Group Pte. Ltd. (formerly Singmed Specialists
    Pte. Ltd., which changed its corporate name in October 2024)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 20, 2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intermediate holding company</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSO Clinic (Singapore Sports &amp; Orthopaedic Clinic
    Pte. Ltd.)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 30, 2004</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orthopaedic specialist clinics
    at Gleneagles</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC (SSOC Pte. Ltd.)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 3, 2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSO Services (Singapore Sports &amp; Orthopaedic Services
    Pte. Ltd.)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 30, 2004</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOS (SSSOS Pte. Ltd.)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 3, 2013</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharma Avenue Pte. Ltd. (formerly Singapore Sports
    and Physiotherapy Centre Pte. Ltd. which changed its corporate name in June 2025)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 12, 2017</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SKC (Singapore Knee, Sports and Orthopaedic Clinic
    Pte. Ltd.)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 8, 2014</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SKS (Singapore Knee, Sports and Orthopaedic Services
    Pte. Ltd.)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 8, 2014</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel Medflow Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 16, 2025</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant &#8211;
    to be used for medical supplies business</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">10.</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda Medical Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 13, 1995</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General practitioner clinic</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">11.</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oasis Medical Clinic Pte. Ltd</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 26, 2021</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General practitioner clinic</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC Farrer Park Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 18, 2025</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant &#8211;
    to be used for new orthopaedic specialist clinic at Farrer Park</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">13.</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC Novena Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 18, 2025</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently dormant &#8211;
    to be used for new orthopaedic specialist clinic at Novena</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">14.</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC Orchard Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 18, 2025</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><p style="font: 12pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
dormant &#8211; to be used for new orthopaedic specialist clinic at Orchard</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">15.</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyetrust Medical Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 11, 2025</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><p style="font: 12pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
dormant &#8211; to be used for new eye specialist clinic</span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">16.</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chartered Imaging Pte. Ltd.</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 15, 2025</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><p style="font: 12pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
dormant &#8211; to be used for New imaging centre</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Property, Plants and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are headquartered in Singapore. Our corporate headquarters in Singapore is located at 6 Napier Road, Unit #02-10/11 Gleneagles Medical
Centre, Singapore 258499.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also lease our clinics at 6 Napier Road, Units #02-10/11 and #03-07, Gleneagles Medical Centre, Singapore, 406 Tampines Street 41 #01-31,
152 Beach Road #03-08 &amp; #03-08A Gateway East, 38 Margaret Drive #02-03, 500 Lorong 6 Toa Payoh #04-33, 3 Temasek Boulevard #03-330
Suntec City Mall and 601 Macpherson Road #01-04. We believe our properties are sufficient for our current needs and that, should it be
needed, suitable additional space will be available on commercially reasonable terms to accommodate any such expansion of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>ITEM
4A. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our financial condition and results of operations for the year ended June 30, 2024 and 2025 should
be read in conjunction with our audited consolidated financial statements and related notes for the fiscal years ended June 30, 2024
and 2025. This discussion and analysis and other parts of this document contain forward-looking statements based upon current beliefs,
plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could
differ materially from those anticipated in these forward-looking statements as a result of several factors. Factors that might cause
future results to differ significantly from those projected in the forward-looking statements include, but are not limited to, those
discussed below and elsewhere in this document. Under no circumstances should the inclusion of such forward-looking statements herein
be regarded as a representation, warranty or prediction with respect to the accuracy of the underlying assumptions by our Company or
any other person. These forward-looking statements that speak only as of the date hereof.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVIEW
OF RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
increased by S$1,269,021, approximately 12.6%, from S$10,050,923 in year ended June 30, 2024 to S$11,319,944 (US$8,900,027) in year ended
June 30, 2025. This increase in revenue was mainly attributable to the revenue generated by the newly acquired general practitioners
clinic group of S$895,362.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our orthopedic specialist clinic at Gleneagles, revenue increased by S$373,659, approximately 3.7%, from S$10,050,923 in year ended
June 30, 2024 to S$10,424,582 (US$8,196,071) in year ended June 30, 2025. This increase in revenue was mainly attributable to higher
patient count recorded for the clinics from the corporate patients in which revenue increased by S$464,885 in year ended June 30,
2025 as compared to year ended June 30, 2024. This is attributed to the rebound from the COVID pandemic, as construction workers
constitute a large segment of our patients. As the construction sector continues to rebound post-COVID, there is an increase in
injury-related cases. This increase in revenue is partially offset by the decrease in revenue from individual walk-in patients in
which revenue decreased by S$91,225, in year ended June 30, 2025 as compared to year ended June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income increased by S$641,174, approximately 139.1% from S$461,029 in the year ended June 30, 2024 to S$1,102,203 (US$866,580) in year
ended June 30, 2025. This increase was mainly due to contribution from Bethesda group by S$220,133. In addition, interest income from
fixed deposits and waiver of long outstanding balance in other creditors contributed partially to the increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consumables,
medical supplies and other related expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consumables,
medical supplies and other related expenses increased by S$278,113, approximately 12.4% from S$2,248,136 in the year ended June 30, 2024
to S$2,526,250 (US$1,986,201) in year ended June 30, 2025. The increase was in line with the increase in revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
benefit expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
benefit expense increased by S$2,758,991, approximately 75.8% from S$3,638,942 in the year ended June 30, 2024 to S$6,397,933 (US$5,030,217)
in the year ended June 30, 2025. This increase was mainly due to an increase in headcount and bonus payments. With the acquisition of
the Bethesda group, the additional staff from Bethesda group also contributed to the increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Depreciation
expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense increased by S$652,401 or 123.4%, from S$528,727 in the year ended June 30, 2024 to S$1,181,128 (US$928,633) in the year ended
June 30, 2025. This was mainly contributed by the Bethesda group as a result of depreciation from right of use assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rent
expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense increased by S$137,895 or 4,336.3%, from S$3,180 in the year ended June 30, 2024, to S$ 141,075 (US$110,917) in the year ended
June 30, 2025 due to a short term lease of office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
operating expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
operating expenses increased by S$1,819,450 or 120.3% from S$1,512,168 in the year ended June 30, 2024 to S$3,331,619 (US$2,619,403)
in the year ended June 30, 2024. Other operating expenses from the newly acquired Bethesda group contributed to S$349,043 of the increase
in other operating expenses. Furthermore, exchange loss resulting from the strengthening of the USD against SGD and professional fees
incurred further contributed to the increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Finance
costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
costs increased by S$27,710 or 15.7% from S$176,238 in the year ended June 30, 2024 to S$ 203,948 (US$160,349) in year ended June 30,
2025, mainly due to increase in interest expense for term loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
loss on goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$11,145,691 (US$8,763,025) impairment loss on goodwill was recognized for year ended June 30, 2025 from the acquisition of the Bethesda group. As
the group was newly acquired and its operations and performance has yet to be turned around, on prudent basis, the full amount of goodwill
has been impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Profit
before tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
before tax decreased by S$14,910,058 from a profit of S$2,404,561 in the year ended June 30, 2024 to a loss of S$12,505,497 (US$9,832,138)
in the year ended June 30, 2025, mainly arising from impairment loss on goodwill of S$10,327,724.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
tax expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense decreased by S$749,154 from S$331,761 in the year ended June 30, 2024 to a tax benefit of S$417,393 (US$328,165) in the year
ended June 30, 2025, due to reversal of over-provision of tax for prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVIEW
OF FINANCIAL POSITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
at June 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets amounted to S$13,118,561 (US$10,314,145) or 77.8% of the total assets as at June 30, 2025, and mainly comprised inventories, trade
and other receivables, cash and cash equivalents and deferred offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
amounted to S$376,291 (US$295,850) and accounted for 2.9% of the current assets, and comprised of drugs and medical supplies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other receivables amounted to S$9,731,390 (US$7,651,065) and accounted for 74.2% of the current assets, which are mainly trade receivables
due from corporate clients, deposits, and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents amounted to S$2,979,083 (US$2,342,230), and accounted for 22.7% of the current assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs amounted to S$31,798 (US$25,000), and accounted for 0.2% of the current assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Current
Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2025, non-current assets amounted to S$3,736,060 (US$2,937,386) or 22.2% of our Group&#8217;s total assets. Non-current
assets mainly consist of right of use assets from lease properties of S$3,176,522 (US$2,497,462), deferred tax assets of S$281,982 (US$221,702),
investment in associate of S$49 (US$39), and property and equipment of S$277,507 (US$218,183).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities amounted to S$10,691,724 (US$8,406,105) and accounted for 89.2% of our total liabilities, and comprised of trade and other
payables, borrowings, amount due to related parties, and asset retirement obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other payables amounted to S$6,913,006 (US$5,435,180) and accounted for 64.7% of our current liabilities. Trade and other payables
mainly comprised trade payables to suppliers in relation to the purchases of consumables and medical supplies, accrued bonus for employees
and goods and services tax payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings,
which amounted to S$2,121,119 (US$1,667,677) and accounted for 19.8% of our current liabilities, mainly related to lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
due to related parties of S$1,642,599 (US$1,291,453), or 15.4% of our Group&#8217;s total current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset
retirement obligation of S$15,000 (US$11,795), or 0.1% of our Group&#8217;s total current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-current
liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities amounted to S$1,298,357 (US$1,020,801) and accounted for 10.8% of our total liabilities, and comprised of lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Total
Equity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
equity amounted to S$4,864,541 (US$3,824,625), mainly comprising S$34,208,562 (US$25,609,109) of share capital, S$24,455,170 (US$18,362,500)
of merger reserve arising from group restructuring, S$4,396,611 (US$3,836,948) of retained earnings, translation reserve of S$495,739
(US$412,213) and non-controlling interest of S$3,499 (US$2,751).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIQUIDITY
AND CAPITAL RESOURCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
financed our growth and operations through a combination of shareholders&#8217; equity (including retained profits), net cash generated
from operating activities, and borrowings from financial institutions. Our principal uses of cash have been for operational expenses,
working capital purposes and payment of taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2025, we had cash and cash equivalents of S$2,979,083 (US$2,342,230) and equity attributable to owners of our Company amounted
to S$4,861,042 (US$3,821,874).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Directors are of the reasonable opinion that, after taking into consideration the cash flows generated from our operations, our external
borrowings and our existing cash and cash equivalents, and without considering any subsequent drawdowns thereof, the working capital
available to our Group is sufficient to meet our present requirements and for at least 12 months after the period end.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
set out below a summary of our consolidated statements of cash flows for the year under review. The following net cash flow summary
should be read in conjunction with the full text of this document, including consolidated financial statements for the year ended June
30, 2025 and 2024, as set out in this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended June 30</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$&#8217;
    000</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$&#8217;
    000</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$&#8217;
    000</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash (used
    in)/ generated from operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,415</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,344</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,509</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash generated from/ (used
    in) investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,681</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,041</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash
    generated from/ (used in) financing activities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,294</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,909</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,767</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net increase /(decrease) in
    cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,198</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,524</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">734</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents
    at beginning of financial year</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,534</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,951</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,217</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects
    of currency translation on cash and cash <br/> equivalents</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(390</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(496</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents at end of financial year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,342</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,979</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,951</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
ended June 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2025, we used operating cash flows before working capital changes of S$240,357 (US$188,973). Net changes in working
capital amounted to -S$3,251,528 (-US$2,556,434). This was due mainly to an increase in trade and other receivables of S$7,284,324 (US$5,727,121),
an increase in trade and other payables of S$4,337,057 (US$3,409,904) and an increase in inventories of S$304,261 (US$239,218). We paid
interest of S$203,948 (US$160,349) and income tax of S$648,292 (US$509,704) in the year ended June 30, 2025. As a result, the net cash
used in operating activities amounted to S$4,344,125 (US$3,415,460).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
generated used in investing activity amounted to S$11,040,944 (US$8,680,671), mainly due to acquisition of new subsidiary of S$10,986,135
(US$8,637,578) and acquisition of property and equipment of S$ 54,760 (US$43,054).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash generated from financing activities of S$16,908,838 (US$13,294,157) was mainly due to proceed of share issuance of S$9,753,384 (US$7,668,358),
decrease in amount due from related parties of S$10,557,240 (US$8,300,370), proceeds from borrowings of S$4,000,000 (US$3,144,901), decrease
in deferred offering costs of S$1,556,226 (US$1,223,544). This increase was partially offset by repayment of borrowings of S$8,261,290
(US$6,495,235) and payment of principal portion of lease liabilities of S$981,342 (US$771,556).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, our Group&#8217;s cash and cash equivalents increased by S$1,523,769 from S$1,951,053 as at June 30, 2024 to
S$2,979,083 (US$2,342,230) as at June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAPITAL
EXPENDITURES AND CONTINGENT LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no material capital expenditures other than routine purchases of medical, computer and office equipment. The Group has no known
contingent liabilities as at June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNIFICANT
ACCOUNTING POLICIES CHANGES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies have been consistently applied by the Group during the years under review, except for the changes in accounting policies
as discussed in the consolidated financial statements appended to this document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Directors and Senior Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information relating to our executive officers and directors as of the date of this annual report.
Unless otherwise stated, the business address for our directors and executive officers is that of our principal executive offices at
6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore 258499.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
    and Executive Officers</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darren
    Yen Feng Chhoa</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jianing
    Lu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chief Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tan
    Boon Chye (Darren) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keng
    Leong Fung (Raymond)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Freudenthaler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony
    Chen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwek
    Yoon Soong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Darren Chhoa,</i></b> (MD GDHM MACHE), Group Chief Executive Officer. Dr. Darren joined our Group in June 2024. He leads our Group&#8217;s health value proposition strategy and also focuses on expansion and introduction of latest clinical solutions into the Group&#8217;s practices. Dr. Darren also oversees and develop partnerships and collaborations with other healthcare organizations and stakeholders
to enhance Basel&#8217;s service delivery and patient care. Additionally, Dr. Darren&#8217;s role includes leading enterprise clinical
business development opportunities focusing on care delivery models, technologies, and products. Dr. Darren has led many initiatives
over the past 12 years and has been directly involved in building a health unicorn in Asia-Pacific in his previous appointments. He also
is accountable for Basel&#8217;s environmental stewardship work, corporate social responsibility projects, to which the Basel group
offers clinical services and pharmaceutical support to the under-served and financially challenged communities around the world. From
November 2016 to March 2022, Dr. Darren served as the medical director and vice president with the Fullerton Healthcare Group. From March
2022 to April 2024, Dr. Darren served as a senior director (Health Services) with MHC Health (HMI Group).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jianing
Lu</i></b><i>, </i>Director and Chief Financial Officer. Ms. Lu joined our group in January 2024 and leads our group&#8217;s accounting,
finance, reporting and budgetary functions. From June 2018 to December 2021, Ms. Lu served in a leadership role with BaselCorp Pte Ltd,
a Singapore-based professional services firm in accounting, tax, and payroll, where she managed a portfolio of clients and led and oversaw
the execution of the accounting team. From January 2022 to December 2023, Ms. Lu was the finance manager for The Farrer Park Company
Pte Ltd, a hospital and hotel holding company, where she oversaw financial and statutory reporting, assisted with the treasury function,
as well as budget planning and forecasting. Ms. Lu graduated from Nanyang Technological University in Singapore with a bachelor&#8217;s degree in accountancy and is a Chartered Accountant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tan
Boon Chye (Darren)</i></b>, Group Chief Commercial Officer. Mr. Tan joined us as our Chief Commercial Officer in August 2025. Mr. Darren
Tan began his entrepreneurial journey in 2007 with a marketing venture. With extensive experience in business consulting, marketing,
financing, and corporate development, he has a proven track record in business. A graduate of the University of London (BSc Accounting
&amp; Finance), Mr. Tan has also co-founded multiple companies across diverse industries. His achievements have been recognized with
the 2010 Successful Entrepreneur Award (Platinum Category) and the 2011 SME1 Asia Emerging Award, and he has been featured by Global
Business Magazine, Channel News Asia, and Phoenix Satellite TV.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Keng
Leong Fung (Raymond)</i></b>, Director and Chairman of the Board. Mr. Fung is the founder of Basel Medical Group Ltd prior to our listing
on Nasdaq and serves as our adviser. He has extensive experience in Family Offices, Merger and Acquisition, Capital Market Advisory,
Risk &amp; Compliance and Fund Operations. Prior to founding the Basel Medical Group, he started BaselCorp in 2012 as a corporate and
financial services firm which was later merged with Incorp Asia. Being a shareholder of the enlarged group, he was in charge of its family
offices and financial services. With a portfolio of 15,000 corporate clients across eight countries, Incorp Asia was eventually sold
to Hillhouse Capital in 2023. Before establishing BaselCorp, Mr. Fung was a team manager in Citibank in charge of institutional investment
funds compliance and trustee operations. He was also a finance lead in the Singapore Ministry of Defence handling defence budget. He
started his career as an auditor in a Singapore audit firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Fung served as a non-executive director for various private companies. He was also the advisor and director to various international
non-profit organization set up by the Oil and Gas Safety Council and other medical associations. He was also the honorary chairman for
Global Chinese Societies Exchange Association. Mr. Fung holds a Master of Business Administration from Nanyang Business School, Nanyang
Technological University of Singapore, and is a member of the Institute of Singapore Chartered Accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Paul
Freudenthaler,</i></b> Independent Director. Mr. Freudenthaler is an independent director on our board. He is the former chief financial
officer and current board member and board secretary for Freight Technologies Inc. (Nasdaq: FRGT). Prior thereto, Mr. Freudenthaler served
as the chief financial officer for several leading companies in both the U.S. and Mexico. From August 2015 to April 2016, he was the
chief financial officer for EZ Corp., the Mexico division of Crediamigo, a payroll discount lender. From November 2016 to August 2020,
Mr. Freudenthaler was the chief financial officer of Ascentium Capital, an independent small business lender in the U.S. Mr. Freudenthaler
drove the growth and successful sale of Ascentium Capital from private equity investors to one of the largest banks in the United States.
Mr. Freudenthaler was the chief financial officer for Old Mutual in Latin America from June 2012 to July 2015, Macquarie in Mexico City
from June 2009 to May 2012 and Irwin Union Bank in the United States from August 2005 to August 2008. Mr. Freudenthaler&#8217;s experience
includes successful public offerings and a number of acquisitions totaling well over US$1 billion in both Mexico and the United States.
Mr. Freudenthaler was born in Canada and grew up in Mexico City, before spending the following 30 years splitting his time among Mexico,
the U.S. and Canada. Mr. Freudenthaler earned his MBA in Finance from The Wharton School of Business, a CPA License from Texas State
Board of Public Accounting, and a Bachelor of Commerce in Accounting and Economics from the University of Calgary, Canada. We believe
Mr. Freudenthaler&#8217;s extensive experience and knowledge in financials and management will help the Group effectively manage corporate
risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tony
Chen,</i></b> Independent Director. Mr. Chen is an independent director on our board. He is the CEO of Zirauti Global Ventures, a services
company in global commodities trading. He also serves as an advisor to AeroGreens Indonesia, a fast-growing agribusiness company which
he cofounded in August 2020. From May 2017 to December 2022, Mr. Chen was the group managing director for Platindo Group, Indonesia,
where he oversaw the group&#8217;s overall business development and strategy. From March 2002 to September 2009, Mr. Chen served as
the CEO for Microsoft Indonesia, in which Microsoft Indonesia won the world&#8217;s best subsidiary for two consecutive years (2007
and 2008). From August 1996 to February 2002, Mr. Chen was the country sales director for Oracle Indonesia. Prior to Oracle, Mr. Chen
also served with Andersen Consulting, Dun &amp; Bradstreet and Stratus Computer. Mr. Chen graduated from UNINUS, Bandung, Indonesia with
a bachelor&#8217;s degree in computer science, and obtained various trainings in business, management and leadership from many institutions,
including the Harvard Business School in Boston. We believe that Mr. Chen is well qualified to serve on our board due to his wealth of
professional experiences and qualifications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kwek
Yoon Soong,</i></b> Independent Director. Mr. Soong is an independent director on our board. Mr. Soong possesses extensive experience
in the insurance industry in Singapore. From October 2018 to December 2022, he was the Chief Agency Officer of Prudential Insurance Company
Singapore. In this role, he oversaw the agency channel and managed a 5,000-strong agency force. He began his career as an insurance agent
in 1989. Mr. Soong brings with him many years of experience in training, recruitment and business development which includes leading
and driving agency sales, manpower and productivity targets. Prior to joining Prudential, Mr. Soong was a consultant with Zurich Insurance
Plc from October 2013 to September 2017 and engaged in projects to transform the agency channel, improve agent productivity and drive
revenue growth for Zurich&#8217;s subsidiary insurers in ASEAN including Zurich Topas Life (Indonesia) and Zurich Global Life (Singapore).
At Allianz Asia Pacific, Mr. Soong was Senior Regional Manager from September 1999 to June 2008 and from November 2011 to September 2013.
During his tenure he was seconded as the Chief Agency Officer of Pioneer Life (Philippines) (January 2006 &#8212; December 2008), Ayudhya
Allianz (Thailand) (October 2004 &#8212; June 2005), Allianz Dazhong (China) (February 2003 &#8212; September 2004) and Pioneer-Allianz
(Philippines) (February 2002 &#8212; February 2003). A Singaporean, Mr. Soong graduated from National University of Singapore Law School.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationship between any of the persons named above. To the best of our knowledge, there are no arrangement or understanding
with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or
member of senior management, other than Mr. Keng Leong Fung (Raymond) and Mr. Tan Boon Chye (Darren), who were nominated to the abovementioned
positions by Rainforest Capital VCC, which is the majority and controlling shareholder of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the years ended June 30, 2024 and 2025, we paid an aggregate of US$148,597 and US$584,165 respectively in cash compensation to our directors
and executive officers as a group. None of our directors or executive officers receives pension, retirement or other similar benefits
from us, and we have not set aside or accrued any amount to provide such benefits to our directors or executive officers. Our subsidiaries
in Singapore are required by the applicable laws and regulations of Singapore to make contributions, as employers, to the Central Provident
Fund for all employees (including our executive officers) who are employed under a contract of service by our Singapore subsidiaries
as prescribed under the Central Provident Fund Act 1953. The contribution rates vary, depending on the age of the employee, and whether
such employee is a Singapore citizen or permanent resident (contributions are not required or permitted in respect of a foreigner on
a work pass). Our directors&#8217; service contracts with the Company do not provide for material benefits upon termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify
our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made
by reason of their being a director or executive officer of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Board Practices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors currently consists of five directors, including two executive directors and three independent directors. The powers
and duties of our directors include convening general meetings and reporting our board&#8217;s work at our shareholders&#8217; meetings,
declaring dividends and distributions, determining our business and investment plans, appointing officers and determining the term of
office of the officers, preparing our annual financial budgets and financial reports, formulating proposals for the increase or reduction
of our authorized shares as well as exercising other powers, functions and duties as conferred by our post-offering amended and restated
memorandum and articles of association. A director may exercise all the powers of our company to borrow money and to mortgage or charge
its undertaking, property and assets (present and future) and to issue debentures, debenture stock, mortgages, bonds and other such securities
whether outright or as security for any debt, liability or obligation of our company or of any third party. A director may vote in respect
of any contract or proposed contract or arrangement notwithstanding that he may be interested therein and if he does so his vote shall
be counted and he may be counted in the quorum at any meeting of the directors at which any such contract or proposed contract or arrangement
is considered. A director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with us is
required to declare the nature of his interest at a meeting of our directors. A general notice given to the directors by any director
to the effect that he is a member, shareholder, director, partner, officer or employee of any specified company or firm and is to be
regarded as interested in any contract or transaction with that company or firm shall be deemed a sufficient declaration of interest
for the purposes of voting on a resolution in respect to a contract or transaction in which he has an interest, and after such general
notice it shall not be necessary to give special notice relating to any particular transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Duties
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
British Virgin Islands law, the directors owe fiduciary duties at both common law and under statute, including a statutory duty to act
honestly, in good faith and with a view to our best interests. When exercising powers or performing duties as a director, the director
is required to exercise the care, diligence and skill that a reasonable director would exercise in the circumstances taking into account,
without limitation, the nature of the company, the nature of the decision and the position of the director and the nature of the responsibilities
undertaken by him. In exercising the powers of a director, the directors must exercise their powers for a proper purpose and shall not
act or agree to the company acting in a manner that contravenes the post-offering amended and restated memorandum and articles of association
or the BVI Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
British Virgin Islands law, the directors owe fiduciary duties at both common law and under statute, including a statutory duty to act
honestly, in good faith and with a view to our best interests. When exercising powers or performing duties as a director, the director
is required to exercise the care, diligence and skill that a reasonable director would exercise in the circumstances taking into account,
without limitation, the nature of the company, the nature of the decision and the position of the director and the nature of the responsibilities
undertaken by him. In exercising the powers of a director, the directors must exercise their powers for a proper purpose and shall not
act or agree to the company acting in a manner that contravenes our post-offering amended and restated memorandum and articles of association
or the BVI Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement
to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person
carrying out the same functions as are carried out by that director in relation to the company and the general knowledge skill and experience
which that director has.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">British
Virgin Islands law does not regulate transactions between a company and its significant members, however it does provide that such transactions
must be entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority members.
We have adopted a code of business conduct and ethics which requires employees to fully disclose any situations that could reasonably
be expected to give rise to a conflict of interest, and sets forth relevant restrictions and procedures when a conflict of interest arises
to ensure the best interest of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing,
or to otherwise benefit as a result of their position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of Directors and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our amended and restated memorandum and articles of association, directors are appointed and removed by a resolution
of members. Our board of directors has the power from time to time and at any time to appoint any person as a director to fill a vacancy
on the board or as an additional director provided that the appointment does not cause the number of directors to exceed any number fixed
by or in accordance with the post-offering amended and restated memorandum and articles of association as the maximum number of directors.
Our directors shall be appointed for such term as may be determined by the members and will hold their offices until expiration of their
respective terms of office and until their successors shall have been appointed and qualified. In addition, the office of any of our
directors shall be vacated if the director (i) gives notice in writing to the Company that he resigns the office of director; or (ii)
absents himself (for the avoidance of doubt, without being represented by proxy) from three consecutive meetings of the board of directors
without special leave of absence from the directors, and the directors pass a resolution of directors confirming that he has by reason
of such absence vacated office; or (iii) dies, becomes bankrupt or makes any arrangement or composition with his creditors generally;
or (iv) the director is found to be or becomes of unsound mind; or (v) the other directors (being not less than two in number) determine
that he should be removed as a director, either by resolution of directors passed by a majority of the other directors at a meeting of
the directors duly convened and held in accordance with the post-offering amended memorandum and articles of association or by resolution
of directors in writing signed by a majority of the other directors; or (vi) the director becomes disqualified to act as a director under
section 111 of the BVI Act. An appointment of a director may be on terms that the director shall automatically retire from office (unless
he or she has sooner vacated office) at the next or a subsequent annual general meeting or upon any specified event or after any specified
period in a written agreement between the director and us, if any; but no such term shall be implied in the absence of express provision.
Our officers are elected by and serve at the discretion of the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has an audit committee, a compensation committee and a nominating committee. Each committee&#8217;s members and functions
are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee consists of Paul Freudenthaler, Tony Chen and Kwek Yoon Soong, and is chaired by Paul Freudenthaler. Each member satisfies
the &#8220;independence&#8221; requirements of Rule 5605(c)(2) of the Listing Rules of Nasdaq and meet the independence standards under
Rule 10A-3 under the Securities Exchange Act of 1934, as amended. We have determined that Paul Freudenthaler qualifies as an &#8220;audit committee financial expert.&#8221; The audit committee oversees our accounting and financial reporting processes and the audits
of the financial statements of our company. The audit committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    the independent registered public accounting firm and pre-approving all auditing and non-auditing services permitted to be performed
    by the independent registered public accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with the independent registered public accounting firm any audit problems or difficulties and management&#8217;s response;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the Securities Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the annual audited financial statements with management and the independent registered public accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    major issues as to the adequacy of our internal controls and any special audit steps adopted in light of material control deficiencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually
    reviewing and reassessing the adequacy of our audit committee charter;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
    separately and periodically with management and the independent registered public accounting firm; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
    regularly to the board of directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee consists of Tony Chen, Paul Freudenthaler and Kwek Yoon Soong, and is chaired by Tony Chen. Each member satisfies
the &#8220;independence&#8221; requirements of Rule 5605(a)(2) of the Listing Rules of Nasdaq. The compensation committee assists the
board of directors in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors
and executive officers. Our executive officers may not be present at any committee meeting during which their compensation is deliberated
upon. The compensation committee is responsible for, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the total compensation package for our executive officers and making recommendations to the board of directors with respect to it;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    and overseeing the total compensation package for our executives other than the three most senior executives;</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the compensation of our directors and making recommendations to the board of directors with respect to it; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
    reviewing and approving any long-term incentive compensation or equity plans, programs or similar arrangements, annual bonuses, and
    employee pension and welfare benefit plans.</span></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nominating and corporate governance committee consists of Kwek Yoon Soong, Tony Chen and Paul Freudenthaler, and is chaired by Kwek Yoon
Soong. Each member satisfies the &#8220;independence&#8221; requirements of Rule 5605(a)(2) of the Listing Rules of Nasdaq. The nominating
and corporate governance committee assists the board of directors in selecting individuals qualified to become our directors and in determining
the composition of the board of directors and its committees. The nominating and corporate governance committee is responsible for, among
other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    nominees to the board of directors for election or re-election to the board of directors, or for appointment to fill any vacancy
    on the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    annually with the board of directors the current composition of the board of directors with regards to characteristics such as independence,
    age, skills, experience and availability of service to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting
    and recommending to the board of directors the names of directors to serve as members of the audit committee and the compensation
    committee, as well as of the nominating and corporate governance committee itself; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to
    ensure proper compliance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
Private Issuer Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Listing Rule 5615(a)(3)(A) provides (with certain exceptions not relevant to the conclusions expressed herein) that a Foreign Private
Issuer may follow its home country practice in lieu of the requirements of the Rule 5600 Series, the requirement to disclose third party
director and nominee compensation set forth in Rule 5250(b)(3), and the requirement to distribute annual and interim reports set forth
in Rule 5250(d), provided, however, that such a Company shall: comply with the Notification of Noncompliance requirement (Rule 5625),
the Voting Rights requirement (Rule 5640), have an audit committee that satisfies Rule 5605(c)(3), and ensure that such audit committee&#8217;s members meet the independence requirement in Rule 5605(c)(2)(A)(ii) and that Nasdaq Information Memorandum IM-5615-3 provides that
a Foreign Private Issuer that elects to follow country practice in lieu of a requirement of Rules 5600, 5250(b)(3) or 5250(d) shall submit
to Nasdaq a written statement from an independent counsel in such company&#8217;s home country certifying that the company&#8217;s
practices are not prohibited by the home country&#8217;s laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted by the Nasdaq listing rules, we have elected to follow certain BVI corporate governance practices in lieu of certain requirements
of the listing rules of Nasdaq below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5605(b)(1) provides that each Listed Company must have a board of directors
                                            comprised of a majority of independent directors as required by Rule 5605(b)(1).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5605(b)(2) provides that each Listed Company must have regularly scheduled
                                            meetings at which only independent directors present (&#8220;executive sessions&#8221;),
                                            as required by Rule 5605(b)(2).</span></td></tr></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5620 provides that (with certain exceptions) each Listed Company shall hold an annual meeting of shareholders no later
                                            than one year after the end of the company&#8217;s fiscal year-end.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5620(b) provides that each Listed Company is required to solicit proxies
                                            and provide proxy statements for all shareholder meetings. It must also provide copies of
                                            its proxy solicitation to Nasdaq.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5635 sets forth the circumstances under which shareholder approval is required
                                            prior to an issuance of securities in connection with: (i) the acquisition of the stock or
                                            assets of another company; (ii) equity-based compensation of officers, directors, employees
                                            or consultants; (iii) a change of control; and (iv) transactions other than public offerings.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5250(b)(3) provides that each Listed Company must disclose all agreements
                                            and arrangements in accordance with this rule by no later than the date on which the company
                                            files or furnishes a proxy or information statement subject to Regulation 14A or 14C under
                                            the Securities Exchange Act of 1934 in connection with the company&#8217;s next shareholders&#8217;
                                            meeting at which directors are elected.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                            Marketplace Rule 5250(d) provides that each Listed Company is required to distribute annual
                                            and interim reports to shareholders.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s practices with regard to these exemptions are not prohibited by the BVI Business Companies Act (Revised Edition) 2020
or the amended and restated memorandum and articles of association of the Company as currently in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Conduct and Ethics. We seek to conduct business ethically, honestly, and in compliance with applicable
laws and regulations. Our Code of Business Conduct and Ethics sets out the principles designed to guide our business practices-compliance,
integrity, respect and dedication. The code applies to all directors, officers, employees and extended workforce. We expect our suppliers,
contractors, consultants, and other business partners to follow the principles set forth in our code when providing goods and services
to us or acting on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at June 30, 2023, 2024 and 2025, the Group employed a total of 23, 28 and 82 full-time employees respectively in Singapore.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Share Ownership</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership
of the Company&#8217;s shares by its directors and executive officers is set forth in &#8220; Item 7. Major Shareholders and Related
Party Transactions &#8212;A. Major Shareholders&#8221; of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Major Shareholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of Ordinary Shares as of November 17, 2025 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: right"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person known by us to be the beneficial owner of more than 5% of Ordinary Shares;</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors and executive officers; and</span></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            our directors and executive officers as a group.</span></td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-indent: -63pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to, or the power
to receive the economic benefit of ownership of, the securities. In computing the number of shares beneficially owned by a person and
the percentage ownership of that person, shares that the person has the right to acquire within 60 days are included, including through
the exercise of any option or other right or the conversion of any other security. The percentage of our Ordinary Shares beneficially
owned is computed on the basis of 18,785,750 Ordinary Shares issued and outstanding as of November 17, 2025. Unless otherwise noted,
the business address for each of our directors and executive officers is 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore
258499.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
                                            shares beneficially owned </b></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p>
                                                                                                                                                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ordinary</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            </b></span></p></td><td style="padding-bottom: 1pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of beneficial ownership </b></span></td><td style="padding-bottom: 1pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Executive Officers</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darren Yen Feng Chhoa</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jianing Lu</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tan Boon Chye
    (Darren) <sup>(1)</sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,205,229</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.3</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keng Leong Fung (Raymond)<sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,205,229</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Freudenthaler</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tony Chen</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kwek Yoon Soong</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Directors
    and Executive Officers as a Group</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Shareholders:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rainforest Capital VCC, acting
    on behalf of its sub-funds, Basel Medical Fund, Fan Mingchun, Wei Hua and Baselcorp Capital <sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,205,229</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rainforest
    Capital VCC is a variable capital company incorporated in Singapore and holds 9,997,910 ordinary shares, 23,256 ordinary shares,
    46,512 ordinary shares, and 106,901 ordinary shares of the Company on behalf of Rainforest Capital VCC&#8217;s four subfunds, Basel
    Medical Fund, Fan Mingchun, Wei Hua and Baselcorp Capital respectively. Tan Boon Chye (Darren) and Keng Leong Fung (Raymond) are the major beneficial owners of Rainforest Capital VCC. AIP Investment Partners Pte. Ltd., as the manager of Rainforest Capital VCC,
    controls Rainforest Capital VCC. Mengli Chen, as the director of Rainforest Capital VCC, controls Rainforest Capital VCC and,
    accordingly, may be deemed to beneficially own the shares that Rainforest Capital VCC beneficially owns in Basel Medical. Mengli
    Chen, Mi Suk Han and Hyoung Kyun Kim, as the directors of AIP Investment Partners Pte. Ltd., control AIP Investment Partners Pte.
    Ltd. and indirectly control Rainforest Capital VCC. The business address of AIP Investment Partners Pte. Ltd, Mi Suk Han and Hyoung
    Kyun Kim is 65 Chulia Street, #49-05/06, OCBC Centre, Singapore 049513. The business address of Rainforest Capital VCC and Mengli
    Chen is 600 North Bridge Road, #12-02, Parkview Square, Singapore 188778.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, as of the date of this annual report, none of our Ordinary Shares were held by record holders in the United States. Because
many of our Ordinary Shares are held by brokers or other nominees, we cannot ascertain the exact number of Ordinary Shares ultimately
held by holders in the United States. We are not aware of any arrangement that may, at a subsequent date, result in a change of control
of our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the related party information disclosed elsewhere in this report, the following transactions with related parties took
place at terms agreed between the parties during the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    to related party</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">354,372</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,000</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income on loan to related party</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,507</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,917</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    made on behalf of related party</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,862</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Management fee</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3,852,504</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">4,900,000</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan to related party, interest income on loan to related party and payment
made on behalf of related party are incurred between the group and the newly acquired Bethesda group. Management fee is incurred between the Singapore holding company and its
subsidiary within the group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
                                            30, 2024</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    due from related parties</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,557,240</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    due to related parties</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,291,453</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,642,599</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,422,849</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Amount
due from related parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2023, Rainforest Capital VCC (the &#8220;Purchaser&#8221;) entered into a sale and purchase agreement with Dr. Kevin Yip (the
&#8220;Seller&#8221;) for the transfer of the entire share capital of Basel Medical Group Pte. Ltd. According to the sales and purchase
agreement, the Provisional Consideration shall be an aggregate amount equivalent to the sum of S$24,000,000 (US$18,191,465) and the Agreed
Amount. The Agreed Amount is computed based on the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net
amount due from a former director (Dr. Kevin Yip) to the Group less the net assets of the Group as at June 30, 2023. The Agreed Amount
will be a negative figure if the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net amount due from
a director to the Group is more than the net assets of the Group as of June 30, 2023. The Agreed Amount was initially estimated to be
negative S$5,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;
On July 1, 2023, S$11,800,000 (US$8,944,137) was paid from the Purchaser to the Seller. This was computed based on 70% of S$24,000,000
and Estimated Agreed Amount of negative S$5,000,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the agreement on the purchase consideration between Rainforest Capital VCC as the buyer and Dr. Kevin Yip as the seller for the
purchase of the shares of Basel Medical Group Pte. Ltd. under the sale and purchase agreement dated June 27, 2023, the outstanding receivables
due from director, Dr. Kevin Yip, and related party, Singmed Investment Pte Ltd, have been assigned to and are borne by Rainforest Capital
VCC. On August 23, 2024, Rainforest Capital VCC entered into a deed of undertaking (the &#8220;Repayment Deed&#8221;) with the Group,
undertaking to fully transfer and pay to the Group, any and all outstanding receivables that is owed by Singmed Investment Pte Ltd and
Dr. Kevin Yip to the Group, being S$11,877,624 (the &#8220;Loan Amount&#8221;), to the Group by September 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out the amounts owed to the Group by Rainforest Capital VCC, which has assumed the obligations of Dr. Kevin Yip
and Singmed Investment Pte Ltd pursuant to the Repayment Deed as of the date indicated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
    30, 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
    30, <br/>2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S$</b></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount due from
    a director</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">976,453</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,320,457</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    due from related parties</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,806,823</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,557,167</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,783,276</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,877,624</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the financial year ended June 30, 2024, the Group incurred an aggregate sum of S$900,000 (US$682,180) for professional medical practitioner
salaries owed to Dr. Kevin Yip for his services from July 1, 2023 to June 30, 2024. Such sum of US$682,180 was set-off by the Group
against the amounts owed to the Group by Dr. Kevin Yip and Singmed Investment Pte Ltd. Thus, following such set-off, as of June 30, 2024,
total amounts due from Dr. Kevin Yip and Singmed Investment Pte Ltd is estimated to amount to US$8,101,096.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Rainforest Capital VCC has paid an aggregate sum of US$599,730 for the period from July 1, 2023 to June 30, 2024 on behalf
of the Group for professional fees incurred in connection with the group&#8217;s initial public offering. On February 27, 2024, July
22, 2024 and July 31, 2024, Rainforest Capital VCC also repaid a sum of US$20,000, US$630,000 and US$4,048,000 respectively to the Group
to partially settle the amounts due from a director and related parties. Finally, Rainforest Capital VCC has paid US$750,000 on August
15, 2024, US$750,000 on August 16, 2024, US$651,000 on September 20, 2024 and a final US$652,366 on September 23, 2024 pursuant to the
Repayment Deed as final settlement of such amounts owed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
such repayment, the full amount due from a former director and Singmed Investment Pte Ltd, that has been assigned to Rainforest Capital
VCC, has been fully paid off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Amount
due to related parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
due to related parties consist of amount due to shareholders and directors. The amounts are non-trade in nature, unsecured, interest-bearing,
repayable on demand and is to be settled in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
due to a related parties represents advances provided to cover various business expenses and other expenditures incurred by the Group
in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Interests of Experts and Counsel</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
8. FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Consolidated Statements and Other Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
financial statements have been filed as part of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be involved from time to time in private actions, collective actions, class actions, investigations and various other legal proceedings
by patients, consumers, employees, commercial partners, competitors and government agencies, among others, relating to, for example,
personal injury cases, employment or labor-related disputes such as wrongful termination of employment, consumer complaints, contractual
disputes with suppliers or commercial partners, disputes with third parties and regulatory inquiries and proceedings relating to compliance
with privacy or other applicable regulations. We may also initiate various legal proceedings such as against former employees, suppliers
or other third parties to enforce our rights. There are inherent uncertainties in these matters, some of which are beyond our management&#8217;s control, making the ultimate outcomes difficult to predict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we are not a party to, nor are we aware of, any legal proceeding, investigation or claim which, in
the opinion of our management, is likely to have a material adverse effect on our business, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Policy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividend on our Ordinary Shares. We currently intend to retain any future earnings and do not expect
to pay any dividends in the foreseeable future. Any further determination to pay dividends on our ordinary shares would be at the discretion
of our board of directors, subject to applicable laws, and would depend on our financial condition, results of operations, capital requirements,
general business conditions, and other factors that our board of directors may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Significant Changes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed elsewhere in this annual report, we have not experienced any significant changes since the date of our audited consolidated
financial statements included in this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
9. THE OFFER AND LISTING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Offer and Listing Details</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Ordinary Shares are listed on NASDAQ under the symbol &#8220;BMGL&#8221;. Holders of Ordinary Shares should obtain current market quotations
for their securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Plan of Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Markets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Ordinary Shares are listed on NASDAQ under the symbol &#8220;BMGL&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Selling Shareholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Dilution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Expenses of the Issue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
10. ADDITIONAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Share Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Memorandum and Articles of Association</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this annual report the description of our amended and restated memorandum and articles of association in
relation to our ordinary shares contained in our registration statement on Form F-1 as amended (File No.: 333-282096) filed with the
SEC. For our board of directors, see &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Board
of Directors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Material Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not entered into any material contracts other than in the ordinary course of business and other than those described in &#8220;Item 4. Information on the Company,&#8221; &#8220;Item 5. Operating and Financial Review and Prospects,&#8221; &#8220;Item 7. Major
Shareholders and Related Party Transactions&#8212;B. Related Party Transactions&#8221; or elsewhere in this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Exchange Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no governmental laws, decrees, regulations or other legislation in the British Virgin Islands that may affect the import or export
of capital, including the availability of cash and cash equivalents for use by the Company, or that may affect the remittance of dividends,
interest, or other payments by the Company to non-resident holders of its Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Taxation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not purport to be a legal opinion or to address all tax aspects that may be relevant to a holder of our ordinary shares.
Each prospective holder should consult its tax adviser as to the particular tax considerations to such holder of the ownership and disposition
of our ordinary shares, including the applicability and effect of any other tax laws or tax treaties, of pending or proposed changes
in applicable tax laws as of the date of this annual report, and of any actual changes in applicable tax laws after such date. It is
emphasized that neither the Company nor any other persons involved in this annual report accepts responsibility for any tax effects or
liabilities resulting from the holding or disposal of our Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MATERIAL
U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a discussion of the material U.S. federal income tax considerations relevant to the acquisition, ownership, and disposition
of our ordinary shares by U.S. Holders (as defined below) that will hold our ordinary shares as &#8220; capital assets&#8221; (generally,
property held for investment) under the U.S. Internal Revenue Code of 1986, as amended, or the  &#8220;Code&#8221;). This discussion
is based upon applicable provisions of the Code, U.S. Treasury regulations promulgated thereunder, pertinent judicial decisions, interpretive
rulings of the U.S. Internal Revenue Service, or the IRS, and such other authorities as we have considered relevant, all of which are
subject to change, possibly with retroactive effect. This discussion does not address all aspects of U.S. federal income taxation that
may be important to particular investors in light of their individual investment circumstances, including investors subject to special
tax and/or reporting rules (for example, certain financial institutions; insurance companies; broker-dealers; pension plans; regulated
investment companies; real estate investment trusts; tax-exempt organizations (including private foundations); holders who are not U.S.
Holders (as defined below); holders who own (directly, indirectly, or constructively) 10% or more of the voting power or value of our
stock; investors that will hold their ordinary shares as part of a straddle, hedge, conversion, constructive sale, or other integrated
transaction for U.S. federal income tax purposes; investors that are traders in securities that have elected the mark-to-market method
of accounting; investors that have a functional currency other than the U.S. dollar), or holders that acquire ordinary shares through
the exercise of options or other convertible instruments or in connection with the provision of services, all of whom may be subject
to tax rules that differ significantly from those discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, this discussion does not address tax considerations relevant to U.S. Holders under any non-U.S., state or local tax laws, the
Medicare tax on net investment income, the one-percent excise tax on stock repurchases, estate or gift tax, or the alternative minimum
tax. Each U.S. Holder is urged to consult its tax advisors regarding the U.S. federal, state, local, and non-U.S. income and other tax
considerations of an investment in ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion below of U.S. federal income tax consequences applies to you if you are a &#8220; U.S. Holder.&#8221; You are a U.S. Holder
if you are a beneficial owner of our ordinary shares and you are: (i) an individual who is a citizen or resident of the United States
for U.S. federal income tax purposes; (ii) a corporation, or other entity treated as a corporation for U.S. federal income tax purposes,
created in, or organized under the law of any state of the United States, or the District of Columbia; (iii) an estate the income of
which is includible in gross income for U.S. federal income tax purposes regardless of its source; or (iv) a trust (A) the administration
of which is subject to the primary supervision of a U.S. federal or state court and which has one or more U.S. persons who have the authority
to control all substantial decisions of the trust or (B) that has otherwise validly elected to be treated as a U.S. person under the
Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a partner in a partnership (including any entity or arrangement treated or elects to be treated as a partnership for U.S. federal
income tax purposes) that holds our ordinary shares, your tax treatment generally will depend on your status and the activities of the
partnership (or any such entity or arrangement treated as or elects to be treated as a partnership for U.S. federal income tax purposes).
Partners in a partnership (or any such entity or arrangement treated as or elects to be treated as a partnership for U.S. federal income
tax purposes) holding our ordinary shares should consult their tax advisors regarding the tax consequences of an investment in the ordinary
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the PFIC rules discussed below, any cash distributions paid on our ordinary shares out of our current or accumulated earnings and
profits, as determined under U.S. federal income tax principles, will generally be includible in your gross income as dividend income
on the day actually or constructively received by you. Because we do not intend to determine our earnings and profits under U.S. federal
income tax principles, any distribution paid will generally be treated as a dividend for U.S. federal income tax purposes by us. Dividends
received by corporations on our ordinary shares may be eligible for the dividends received deduction allowed to U.S. corporations under
the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-corporate U.S. Holder generally may be subject to tax at preferential tax rates applicable to &#8220; qualified dividend income,&#8221;
provided that certain conditions are satisfied, including that (1) our stock is readily tradable on an established securities market
in the United States, (2) we are neither a PFIC nor treated as such with respect to a U.S. Holder (as discussed below) for the taxable
year in which the dividend was paid and the preceding taxable year, and (3) certain holding period requirements are met. U.S. holders
are urged to consult their own tax advisors regarding the availability of the preferential rate for any dividends paid with respect to
our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
U.S. foreign tax credit purposes, dividends generally will be treated as income from foreign sources and generally will constitute &#8220;passive&#8221; category income. Depending on your particular circumstances, you may be eligible, subject to a number of complex limitations,
to claim a foreign tax credit in respect of any foreign withholding taxes imposed on dividends received on our ordinary shares. If you
do not elect to claim a foreign tax credit for foreign tax withheld, you may instead claim a deduction, for U.S. federal income tax purposes,
for the foreign tax withheld, but only for a year in which you elect to do so for all creditable foreign income taxes. The rules governing
the foreign tax credit are complex. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under
your particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
or Other Disposition of Ordinary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the PFIC rules discussed below, you generally will recognize capital gain or loss upon the sale or other disposition of our ordinary
shares in an amount equal to the difference, if any, between the amount realized upon the disposition and your adjusted tax basis in
such ordinary shares. Any capital gain or loss will be long-term capital gain or loss if you have held the ordinary shares for more than
one year, and will generally be U.S.-source gain or loss for U.S. foreign tax credit purposes. If such income were treated as U.S.-source
income for foreign tax credit purposes, you might not be able to use the foreign tax credit arising from any tax imposed on the sale,
exchange, or other taxable disposition of our ordinary shares unless such credit could be applied (subject to applicable limitations)
against tax due on other income derived from foreign sources. The deductibility of a capital loss may be subject to limitations. You
are urged to consult your tax advisor regarding the tax consequences if a foreign tax is imposed on a disposition of our ordinary shares,
including the availability of the foreign tax credit under your particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PFIC
Rules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. corporation, such as our company, will be classified as a PFIC for U.S. federal income tax purposes for any taxable year, if
either (i) 75% or more of its gross income for such year consists of certain types of &#8220; passive&#8221; income or (ii) 50% or more
of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production of
passive income. Passive income generally includes dividends, interest, royalties, rents, annuities, net gains from the sale or exchange
of property producing such income and net foreign currency gains. For this purpose, cash is categorized as a passive asset and the company&#8217;s goodwill associated with active business activity is taken into account as an active asset. We will be treated as owning our proportionate
share of the assets and income of any other corporation in which we own, directly or indirectly, more than 25% (by value) of the stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the projected composition of our assets and income, we do not anticipate being classified as a PFIC for our taxable year ended June
30, 2025 or ending June 30, 2026. While we do not anticipate being classified as a PFIC, because the value of our assets for purposes
of the PFIC asset test will generally be determined by reference to the market price of our ordinary shares, fluctuations in the market
price of our ordinary shares may cause us to become a PFIC for the current or any subsequent taxable year. The determination of whether
we will become a PFIC will also depend, in part, on the composition of our income and assets, which will be affected by how, and how
quickly, we use our liquid assets and the cash raised in this offering. Whether we are a PFIC is a factual determination and we must
make a separate determination each taxable year as to whether we are a PFIC (after the close of each taxable year). Accordingly, we cannot
assure you that we will not be classified as a PFIC for our taxable year ended June 30, 2025 or any future taxable year. If we are classified
as a PFIC for any taxable year during which you hold our ordinary shares, we generally will continue to be treated as a PFIC, unless
you make certain elections, for all succeeding years during which you hold our ordinary shares even if we cease to qualify as a PFIC
under the rules set forth above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which you hold our ordinary shares, you will be subject to special tax rules with respect to
any &#8220; excess distribution&#8221; that you receive and any gain you realize from a sale or other disposition (including a pledge)
of our ordinary shares, unless you make a &#8220; mark-to-market&#8221; election as discussed below. Distributions you receive in a taxable
year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years
or your holding period for the ordinary shares will be treated as an excess distribution. Under these special tax rules:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    excess distribution or gain will be allocated ratably over your holding period for the ordinary shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts
    allocated to the current taxable year and any taxable years in your holding period prior to the first taxable year in which we are
    classified as a PFIC (a &#8220;pre-PFIC year&#8221;) will be taxable as ordinary income; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amounts
    allocated to each prior taxable year, other than the current taxable year or a pre-PFIC year, will be subject to tax at the highest
    tax rate in effect applicable to you for that year, and such amounts will be increased by an additional tax equal to interest on
    the resulting tax deemed deferred with respect to such years.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are classified as a PFIC for any taxable year during which you hold our ordinary shares and any of our non-U.S. subsidiaries is also
a PFIC, you will be treated as owning a proportionate amount (by value) of the shares of each such non-U.S. subsidiary classified as
a PFIC for purposes of the application of these rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alternatively,
a U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a mark-to-market election for such stock of a
PFIC to elect out of the tax treatment discussed in the two preceding paragraphs. If you make a valid mark-to-market election for the
ordinary shares, you will include in income each year an amount equal to the excess, if any, of the fair market value of the ordinary
shares as of the close of your taxable year over your adjusted basis in such ordinary shares. You will be allowed a deduction for the
excess, if any, of the adjusted basis of the ordinary shares over their fair market value as of the close of the taxable year. However,
deductions will be allowable only to the extent of any net mark-to-market gains on the ordinary shares included in your income for prior
taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition
of the ordinary shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any
mark-to-market loss on the ordinary shares, as well as to any loss realized on the actual sale or disposition of the ordinary shares,
to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such ordinary shares.
Your basis in the ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a mark-to-market election,
tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us (except that the preferential
rates for qualified dividend income would not apply).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 24.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mark-to-market election is available only for &#8220;marketable stock&#8221; which is stock that is traded in other than de minimis
quantities on at least 15 days during each calendar quarter (&#8220;regularly traded&#8221;) on a qualified exchange or other market,
as defined in applicable U.S. Treasury regulations. Our ordinary shares are listed on Nasdaq, which is a qualified exchange for these
purposes. If the ordinary shares are regularly traded, and the ordinary shares qualify as &#8220; marketable stock&#8221; for purposes
of the mark-to-market rules, then the mark-to-market election might be available to you if we were to become a PFIC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because,
as a technical matter, a mark-to-market election cannot be made for any lower-tier PFICs that we may own, you may continue to be subject
to the PFIC rules with respect to your indirect interest in any investments held by us that are treated as an equity interest in a PFIC
for U.S. federal income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently intend to provide information necessary for U.S. Holders to make qualified electing fund elections, which, if available,
would result in tax treatment different from the general tax treatment for PFICs described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you own our ordinary shares during any taxable year that we are a PFIC, you must file an annual report with the IRS, subject to certain
exceptions based on the value of the ordinary shares held. You are urged to consult your tax advisor concerning the U.S. federal income
tax consequences of purchasing, holding, and disposing of our ordinary shares if we are or become a PFIC, including the possibility of
making a mark-to-market election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
Reporting and Backup Withholding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may be required to submit to the IRS certain information with respect to your beneficial ownership of our ordinary shares, if such ordinary
shares are not held on your behalf by certain financial institutions. Penalties also may be imposed if you are required to submit such
information to the IRS and fail to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
payments with respect to ordinary shares and proceeds from the sale, exchange or redemption of ordinary shares may be subject to information
reporting to the IRS and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes
a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding.
U.S. Holders who are required to establish their exempt status generally must provide such certification on IRS Form W-9 or by otherwise
establishing an exemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. Federal income tax liability,
and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund
with the IRS and furnishing any required information. You are urged to consult your tax advisors regarding the application of the U.S.
information reporting and backup withholding rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal income tax discussion set forth above is included for general information only and may not be applicable depending upon
a holder&#8217;s particular situation. Holders are urged to consult their tax advisors with respect to the tax consequences to them
of the acquisition, ownership and disposition of our ordinary shares and warrants, including the tax consequences under state, local,
estate, foreign and other tax laws and tax treaties and the possible effects of changes in U.S. or other tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>British
Virgin Islands Tax Considerations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and all dividends, interest, rents, royalties, compensation and other amounts paid by the Company to persons who are not resident
in the BVI and any capital gains realized with respect to any shares, debt obligations, or other securities of the Company by persons
who are not resident in the BVI are exempt from all provisions of the Income Tax Ordinance in the BVI. No estate, inheritance, succession
or gift tax, rate, duty, levy or other charge is payable by persons who are not resident in the BVI with respect to any shares, debt
obligation or other securities of the Company. All instruments relating to transfers of property to or by the Company and all instruments
relating to transactions in respect of the shares, debt obligations or other securities of the Company and all instruments relating to
other transactions relating to the business of the Company are exempt from payment of stamp duty in the BVI. This assumes that the Company
does not hold an interest in real estate in the BVI. There are currently no withholding taxes or exchange control regulations in the
BVI applicable to the Company or its members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Dividends and Paying Agents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
Statement by Experts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
Documents on Display</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to certain of the informational filing requirements of the Exchange Act. Since we are a &#8220;foreign private issuer,&#8221;
we are exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and our
officers, directors and principal shareholders are exempt from the reporting and &#8220; short-swing&#8221; profit recovery provisions
contained in Section 16 of the Exchange Act, with respect to their purchase and sale of our shares. In addition, we are not required
to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered
under the Exchange Act. However, we are required to file with the SEC an Annual Report on Form 20-F containing financial statements audited
by an independent accounting firm. We may, but are not required, to furnish to the SEC, on Form 6-K, unaudited financial information
after each of our first three fiscal quarters. Reports and other information that we file with or furnish electronically with the SEC
are accessible via the SEC&#8217;s website at <i>www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
Subsidiary Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
Annual Report to Security Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. These risks primarily include credit risk, foreign currency risk,
translation exposure and interest rate risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to credit risk from our operating activities, which arises principally from trade and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to foreign exchange risk arising from sales or purchases that are denominated in a currency other than the functional currency
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Translation
Exposure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also exposed to foreign exchange rate fluctuations as we translate the financial statements of our subsidiaries and consolidated
affiliated entities into U.S. dollars in consolidation. If there is a change in foreign currency exchange rates, the translation adjustments
resulting from the conversion of the financial statements of our subsidiaries and consolidated affiliated entities into U.S. dollars
would result in a gain or loss recorded as a component of accumulated other comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
main interest rate risk arises from short term loans. These transactions and balances were not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>ITEM
12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Debt Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Warrants and Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Other Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
American Depositary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>ITEM
13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>ITEM
14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 10. Additional Information&#8221; for a description of the rights of shareholders, which remain unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&#8217;s initial public offering and listing on NASDAQ, the Company filed a registration statement on Form
F-1 (File No.: 333-282096) with the SEC, which was declared effective on February 18, 2025. On February 14, 2025, the Company entered
into an underwriting agreement with Cathay Securities, Inc. as representative of the underwriters and commenced its offering of 2,205,000
new Ordinary Shares at a public offering price of US$4.00 per share. In addition, the Company granted the underwriters a 45-day option
to purchase up to an additional 330,750 Ordinary Shares at the public offering price, less the underwriting discount. The Ordinary Shares
are approved for listing on The Nasdaq Capital Market and commenced trading under the ticker symbol &#8220;BMGL&#8221; on February 25,
2025. On March 17, 2025, the Representative exercised the overallotment option in full to purchase an additional 330,750 Ordinary Shares
at US$4.00 per share, less the underwriting discount. The issuance of the overallotment option shares closed on March 19, 2025. Following
such closing, the Company had a total of 18,785,750 ordinary shares issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently,
the Company&#8217;s registration statement on Form F-1, as amended (File No. 333-282096) also registered for resale up to 2,000,000
existing Ordinary Shares by certain selling shareholders. A final prospectus relating to such resale was filed with the SEC on February
25, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our initial public offering (including the over-allotment option), up to June 30, 2025, the amount of expenses incurred
for the Company&#8217;s account in connection with the issuance and distribution of the registered securities for underwriting discounts
and commissions, expenses paid to or for underwriters, and other expenses amounted to a total of approximately US$2,896,391. None of
such expenses were direct or indirect payments to directors, officers, general partners of the Company or their associates; to persons
owning 10% or more of any class of the Company&#8217;s equity securities; and to affiliates of the Company. The net offering proceeds
to the Company after deducting the total expenses was approximately US$7,246,609. As of the date of this annual report, all of such proceeds
have been used, mainly to acquire Bethesda Group and working capital for the current business. None of such usages were direct or indirect
payments to directors, officers, general partners of the Company or their associates; to persons owning 10% or more of any class of the
Company&#8217;s equity securities; and to affiliates of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>ITEM
15. CONTROLS AND PROCEDURES </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures Evaluation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we carried
out an evaluation of the effectiveness of our disclosure controls and procedures, which is defined in Rules 13a-15(e) of the Exchange
Act, as of June 30, 2025. Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure
controls and procedures as of June 30, 2025 were not effective as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s Annual Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate
internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with (&#8220;International Financial Reporting Standards&#8221;) IFRS. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions or because the degree of compliance with policies or procedures may deteriorate. Under the supervision and with the participation
of our management, including our chief executive officer and chief financial officer, we conducted an assessment of the effectiveness
of our internal control over financial reporting as of June 30, 2025. The assessment was based on criteria established in the framework
Internal Control&#8212;Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to the examination of our combined and consolidated financial statements presented in this Annual Report, we have identified
a significant weakness in our internal control over financial reporting. This identified material weakness is associated with a lack
of adequately skilled staff possessing IFRS knowledge for financial reporting purposes, thereby affecting the proper adherence to
IFRS and SEC requirements. A comprehensive assessment of our internal control, aimed at identifying and reporting material weaknesses
and other deficiencies, was not conducted by either us or our independent registered public accounting firm. Performing such an assessment
or having an audit of our internal control over financial reporting might have revealed additional deficiencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address the identified material weakness stemming from the audit of our combined and consolidated financial statements for the year ended
June 30, 2025, we intend to implement various measures, including the hiring of additional accounting personnel to enhance the financial
reporting function and the establishment of a financial and system control framework. We also intend to initiate regular IFRS and
SEC financial reporting training programs for our accounting and financial personnel. However, we cannot provide assurance that these
measures will be entirely effective in remediating the material weakness in a timely manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Being
a company with less than US$1.235 billion in revenue for the fiscal year ended September 30, 2022, we qualify as an &#8220;emerging
growth company&#8221; under the JOBS Act. An emerging growth company is entitled to certain reduced reporting and other requirements
that are typically applicable to public companies. These provisions include exemption from the auditor attestation requirement under
Section 404 of the Sarbanes-Oxley Act of 2002 concerning the assessment of the emerging growth company&#8217;s internal control over
financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attestation
Report of the Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 20-F does not include an attestation report of our registered public accounting firm because our company is an
emerging growth company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than those disclosed above, there were no changes in our internal controls over financial reporting that occurred during the period covered
by this annual report on Form 20-F that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>ITEM
16. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>ITEM
16A. AUDIT COMMITTEE AND FINANCIAL EXPERT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has determined that Paul Freudenthaler qualifies as an audit committee financial expert as defined in Item 16A of
Form 20-F. Each member of the Audit Committee is an independent director within the meaning of the NASDAQ listing rules and the criteria
for independence set forth in Rule 10A-3 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>ITEM
16B. CODE OF ETHICS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a code of business conduct and ethics that applies to all our directors, officers and employees, including
our principal executive officer, principal financial officer, principal accounting officer or controller and any other persons who perform
similar functions for us. A copy of our code of business conduct and ethics is appended to this report as exhibit 11.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>ITEM
16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered
by our principal accountants for the respective period including any associated or affiliated organizations or entities. We did not pay
any other fees to our auditors during the periods indicated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended June 30</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees
    <sup>(1)</sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">248,306</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;US$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">293,241</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related Fees <sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,750</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees <sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right">&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right">&#8212;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Fees <sup>(4)</sup></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">306,056</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;US$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">356,241</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Audit Fees&#8221; represents the aggregate fees billed or to be billed for each of the fiscal years listed for professional services
    rendered by our auditors for the audit of our annual financial statements, as well as assistance with and review of documents filed
    with the SEC and other statutory and regulatory filings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Audit-related Fees&#8221; represents the aggregate fees billed in each of the fiscal years listed for the assurance and related services
    rendered by our auditors that are reasonably related to the performance of the audit or review of our financial statements and not
    reported under &#8220;Audit Fees.&#8221; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Tax Fees&#8221; represents the aggregate fees billed in each of the fiscal years listed for the professional tax services rendered
    by our auditors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;All Other Fees&#8221; represents the aggregate fees billed in each of the fiscal years listed for services rendered by our auditors
    other than services reported under &#8220;Audit Fees,&#8221; &#8220;Audit-related Fees&#8221; and &#8220;Tax Fees.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policy of our audit committee is to pre-approve all audit and non-audit services provided by our principal accountant for the respective
period including any associated or affiliated organizations or entities, including audit services, audit-related services, tax services
and other services as described above, other than those for de minimis services that are approved by the audit committee prior to the
completion of the audit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>ITEM
16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>ITEM
16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2025, Rainforest Capital VCC, the controlling shareholder of the Company, purchased 30,650 Ordinary Shares for a total consideration
of US$99,613 in a privately negotiated transaction independent of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_020"></span>ITEM
16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company appointed NLA DFK Assurance PAC (&#8220;NLA DFK&#8221;) as its independent registered public accounting firm, effective on
June 30, 2025. The appointment of NLA DFK was made after a careful evaluation process by the Company and has been approved by the audit
committee and the board of directors of the Company. NLA DFK is engaged to audit and report on the consolidated financial statements
of the Company for the fiscal year ended June 30, 2025, and review the consolidated financial statements of the Company for the six months
ending December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Company&#8217;s fiscal years ended December 31, 2023 and 2024 and until the engagement of NLA DFK, neither the Company nor anyone
on its behalf has consulted with NLA DFK on either (a) the application of accounting principles to a specified transaction, either completed
or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s consolidated financial statements, and neither
a written report nor oral advice was provided to the Company by NLA DFK which NLA DFK concluded as an important factor considered by
the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was the subject
of a disagreement, as that term is defined in Item 16F(a)(1)(iv) of Form 20-F (and the related instructions thereto) or a reportable
event as set forth in Item 16F(a)(1)(v)(A) through (D) of Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee and the board of directors of the Company also approved the dismissal of Onestop Assurance PAC as the independent accountant
of the Company. The audit report of Onestop Assurance PAC on the consolidated financial statements of the Company dated November 4, 2024
did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting
principles. During the fiscal years ended June 30, 2023 and 2024, and the subsequent interim period through June 30, 2025, there were
no: (1) &#8220; disagreements&#8221; (as that term is defined in 16F (a)(1)(iv) of Form 20-F and the related instructions) between the
Company and Onestop Assurance PAC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope
or procedure, which disagreements, if not resolved to the satisfaction of Onestop Assurance PAC, would have caused Onestop Assurance
PAC to make reference in connection with their opinion to the subject matter of the disagreement, or (2) reportable events as set forth
in Item 16F(a)(1)(v)(A) through (D) of Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes abovementioned were reported in the current report on Form 6-K of the Company dated July 1, 2025, in accordance with instruction
2 to item 16F of Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_021"></span>ITEM
16G. CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a company incorporated in the British Virgin Islands and are listed on NASDAQ. NASDAQ market rules permit a foreign private issuer
like us to follow the corporate governance practices of our home country. Certain corporate governance practices in the British Virgin
Islands, which is our home country, may differ significantly from NASDAQ corporate governance listing standards applicable to domestic
U.S. companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
other things, we are not required to have: (i) a majority-independent board of directors; (ii) a compensation committee consisting of
independent directors; (iii) a nominating committee consisting of independent directors; or (iv) regularly scheduled executive sessions
with only independent directors each year. In addition, we are not required to have our shareholders approve certain issuances of securities,
including those in connection with the establishment of or material amendments to equity compensation plans or arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
not required and as may be changed from time to time, we have a majority-independent board of directors, a majority-independent compensation
committee and a nominating committee. Subject to the foregoing, we rely on the exemptions listed above. As a result, you may not be provided
with the benefits of certain corporate governance requirements of NASDAQ applicable to U.S. domestic public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_022"></span>ITEM
16H. MINE SAFETY DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_023"></span>ITEM
16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_024"></span>ITEM
16J. INSIDER TRADING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established <span id="xdx_90A_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240701__20250630_zrrRUdvgGWDd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000052" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">insider trading policies</ix:nonNumeric></span> and procedures to provide guidelines on the purchases, sales, and other dispositions
of our securities by our directors, officers, employees, consultants and contractors, with the goal of promoting compliance with applicable
insider trading laws, rules and regulations, and the listing standards of NASDAQ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insider trading policy is filed as Exhibit 11.2 to this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_025"></span><b>ITEM
16K. CYBERSECURITY</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_982_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240701__20250630_gBFCRMPFAIAMT-LWRQH_z80MNATwQ9wa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" continuedAt="ConU000056-01" escape="true" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s executive officers oversee the strategic processes to safeguard data and comply with relevant regulations and has overall
responsibility for evaluating cybersecurity risks, as well as related policies and risks in connection with the Company&#8217;s patient
database, suppliers and other service providers. The Company does not currently engage any assessors, consultants, auditors, or other
third parties in connection with any such processes, given the size and scale of the Company, the resources available to it, the anticipated
expenditures, and the risks it faces in terms of cybersecurity. The Company&#8217;s executive officers are responsible for overseeing
and periodically reviewing and identifying risks from cybersecurity threats associated with its use of any third-party service provider.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C00_gBFCRMPFAIAMT-LWRQH_zinhLK0pGtuj"><ix:continuation continuedAt="ConU000056-02" id="ConU000056-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C02_gBFCRMPFAIAMT-LWRQH_zWA2rq3QZKsk"><ix:continuation continuedAt="ConU000056-03" id="ConU000056-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the start of its latest completed fiscal year and up to the date of this annual report, the Company is not aware of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially
affect the registrant, including its business strategy, results of operations, or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p id="xdx_986_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240701__20250630_zZH5ipsVNQRk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000057" name="cyd:CybersecurityRiskRoleOfManagementTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s board of directors is collectively responsible for oversight of risks from cybersecurity threats. <span id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zUQhdKM1RVea" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000058" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The Company&#8217;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#8217;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#8217;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#8217;s executive officers will promptly inform, update, and seek the instructions
of the board.</ix:nonNumeric></span></span></ix:nonNumeric></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C07_gBFCRMPFAIAMT-LWRQH_zX42ddlVdryk"><ix:continuation id="ConU000056-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_026"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_027"></span>ITEM
17. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to provide financial statements pursuant to Item 18.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_028"></span>ITEM
18. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited consolidated financial statements of the Company and its subsidiaries and consolidated affiliated entities are included at the
end of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_029"></span>ITEM
19. EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_030"></span>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224036168/ex3-1.htm" style="-sec-extract: exhibit">Amended and restated memorandum and articles of association of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of Form F-1 filed on September 13, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224036168/ex4-1.htm" style="-sec-extract: exhibit">Registrant&#8217;s Specimen Certificate for Ordinary Shares &#160;(incorporated by reference to Exhibit 4.1 of Form F-1 filed on September 13, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315225008598/ex4-2.htm" style="-sec-extract: exhibit">Representative&#8217;s Warrant dated February 26, 2025 granted to Cathay Securities, Inc. (incorporated by reference to Exhibit 4.2 of Form 6-K furnished on February 28, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315225010926/ex4-1.htm" style="-sec-extract: exhibit">Representative&#8217;s Warrant dated March 19, 2025 granted to Cathay Securities, Inc. (incorporated by reference to Exhibit 4.1 of Form 6-K furnished on March 19, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224036168/ex2-1.htm" style="-sec-extract: exhibit">Share Transfer Agreement dated August 22, 2023 between Basel Medical Group Ltd and Rainforest Capital VCC relating to the shares of Singmed Specialist Pte. Ltd. (incorporated by reference to Exhibit 2.1 of Form F-1 filed on September 13, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315225008598/ex4-1.htm" style="-sec-extract: exhibit">Underwriting Agreement dated as of February 24, 2025, by and between Basel Medical Group Ltd and Cathay Securities, Inc. (incorporated by reference to Exhibit 4.1 of Form 6-K furnished on February 28, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224034242/filename5.htm" style="-sec-extract: exhibit">Form of Independent Director Agreement between the Registrant and each of its independent directors (incorporated by reference to Exhibit 10.3 of Form F-1/A filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224034242/filename6.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.4 of Form F-1/A filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224018231/filename3.htm" style="-sec-extract: exhibit">Letter of Appointment dated January 1, 2024 between the Registrant and Jianing Lu. (incorporated by reference to Exhibit 10.6 of Form F-1 filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224024643/filename3.htm" style="-sec-extract: exhibit">Letter of Appointment dated June 1, 2024 between the Registrant and Dr. Darren Yen Feng Chhoa. (incorporated by reference to Exhibit 10.8 of Form F-1 filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224034242/filename7.htm" style="-sec-extract: exhibit">Deed of Undertaking between Rainforest Capital VCC and the Registrant dated August 23, 2024 (incorporated by reference to Exhibit 10.9 of Form F-1 filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224034242/filename8.htm" style="-sec-extract: exhibit">Deed of Undertaking between certain Group entities and Singmed Investment Pte. Ltd. Dated August 26, 2024. (incorporated by reference to Exhibit 10.10 of Form F-1 filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000164117225003702/ex4-1.htm" style="-sec-extract: exhibit">Sale and Purchase Agreement dated April 11, 2025 between Basel Medical Group Pte. Ltd. and Silkroute Biomed Healthcare Pte. Ltd. (incorporated by reference to Exhibit 4.1 of Form 6-K furnished on April 11, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000164117225012095/ex99-2.htm" style="-sec-extract: exhibit">Master Supply Agreement dated May 20, 2025 (incorporated by reference to Exhibit 99.2 of Form 6-K furnished on May 22, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex8-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/2004489/000149315224034242/filename9.htm" style="-sec-extract: exhibit">Code of Business Conduct and Ethics <span style="text-decoration: underline"></span>(incorporated by reference to Exhibit 99.1 of Form F-1 filed on November 4, 2024 (File No.: 333-282096))</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex11-2.htm">Insider Trading Policy</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex12-1.htm">Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex12-2.htm">Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex13-1.htm">Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex13-2.htm">Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex97-1.htm">Compensation Recovery Policy</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith this annual report.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith this annual report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_031"></span>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this annual report on its behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
    Medical Group Ltd</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Darren Yen Feng Chhoa</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Darren Yen Feng Chhoa</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jianing Lu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jianing
    Lu</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November 17, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="toc_001"></span><b>Consolidated
Financial Statements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the financial year ended June 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#finc_001">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a> (PCAOB ID 6889)</span></td>
    <td style="border-top: black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#finc_002">CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#finc_003">CONSOLIDATED BALANCE SHEETS</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#finc_004">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">F-5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#finc_005">CONSOLIDATED STATEMENT OF CASH FLOWS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#finc_006">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">F-7</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="finc_001"></span></b></span><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>T<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o
the shareholders and the Board of Directors of Basel Medical Group Ltd.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclaimer
of Opinion on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were engaged to audit the accompanying consolidated balance sheets of Basel Medical Group Ltd. and its subsidiaries (collectively referred
to as the &#8220;Company&#8221;) as of June 30, 2025 and 2024, and the related consolidated statements of profit or loss and comprehensive
income, changes in shareholders&#8217; equity and cash flows for each of the years in the two-year period ended June 30, 2025, and
the related notes (collectively referred to as the &#8220;financial statements&#8221;). As described in the following paragraphs,
we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on the financial statements,
and we do not express, an opinion on these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insufficient Supporting Documentation and Reports pertaining to the Acquisition of Bethesda Medical Pte Ltd and its
subsidiary, Oasis Medical Clinic Pte Ltd (&#8220;subsidiaries&#8221;)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acquired a 100% stake in Bethesda Medical Pte Ltd on 30 April 2025 (the acquisition date).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the change in management for the newly acquired subsidiaries, we were unable to have access to the complete accounting records and source
documents. As a result, we were unable to carry out alternative audit procedures to satisfy ourselves regarding the occurrence, nature,
and whether there would be any adjustments on the current year&#8217;s financial statements as a result from the assets acquired, liabilities
assumed and the resulting goodwill recognised on the acquisition date. We are also unable to determine whether there would be any adjustments
on the current financial year&#8217;s financial statements as a result from the potential adjustments on the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Formal
Purchase Price Allocation to be completed</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Purchase Price Allocation (&#8220;PPA&#8221;) exercise is currently ongoing by an external expert and pending finalisation at the
reporting date. The PPA exercise is expected to be completed latest by 30 April 2026. This is in compliance with International Financial
Reporting Standard 3 Business Combinations (&#8220;IFRS 3&#8221;), which allows the Company to complete the assessment of the PPA within
a year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the formal PPA exercise, the Company has performed a provisional PPA exercise. The provisional PPA exercise has
resulted in an element of goodwill amounting to $11,145,691. A formal PPA exercise is likely to attribute fair values to the respective
assets acquired and liabilities assumed which could cause the residual goodwill value to change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
view of the above, we were unable to obtain sufficient appropriate audit evidence, subject to the completion of the formal PPA exercise,
with respect to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The fair value of assets acquired of $2,785,433;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
The fair value of the liabilities assumed of $3,623,124; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
The goodwill recognised of $11,145,691.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
Assessment of Goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed in Note 21 to the financial statements, the carrying amount of the Company&#8217;s goodwill were $0 (net of impairment
losses of $11,145,691) as at 30 June 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has recognised a full impairment on the goodwill recognised based on discounted cash flow projections (value-in-use) to assess the
recoverable amount of the goodwill. However, we were unable to obtain sufficient appropriate audit evidence to evaluate the reasonableness
of the key assumptions applied in the cash flow projections. In determining the recoverable amount, management also did not consider
the higher of fair value less costs of disposal and value in use, as required by IAS 36 Impairment of Assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we were unable to obtain sufficient appropriate audit evidence to determine the appropriateness of full impairment loss recognised on
the goodwill during the financial year, and whether any other adjustments that might be found necessary in respect of these financial
statements for the year ended 30 June 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Disclaimer of Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. We are a public accounting firm registered with the
Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
NLA DFK Assurance PAC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorName_c20240701__20250630_zARGiYm1YDl"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000059" name="dei:AuditorName">NLA
DFK Assurance PAC</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--AuditorLocation_c20240701__20250630_z1ByGul8a3Ai"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000060" name="dei:AuditorLocation">Singapore</ix:nonNumeric></span>,
November 17, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB
ID No.<span id="xdx_908_edei--AuditorFirmId_c20240701__20250630_zYyNeKJjGnd"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000061" name="dei:AuditorFirmId">6889</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="finc_002"></span><b>CONSOLIDATED
STATEMENT OF PROFIT OR LOSS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
COMPREHENSIVE INCOME </b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_zj1JWVyaMR0l" summary="xdx: Statement - Consolidated Statement of Profit or Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20240701__20250630_zofSPpGRjwyk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230701__20240630_znbo30DSJ6Xd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p>US$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p>S$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2024</b></p>S$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Revenue_uSGD_maPLBTzcCa_zKMMDVTxMiY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: center">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--Revenue_uUSD_maStOpSang_c20240701__20250630_zyzwZ34m4Use" title="Revenue" style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-01to2025-06-30" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,900,027</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-01to2025-06-30" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,319,944</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-07-012024-06-30" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,050,923</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--OtherGainsLosses_uSGD_maPLBTzcCa_zdlYv4Mxkfj3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--OtherGainsLosses_uUSD_maStOpSang_c20240701__20250630_zKZcPQKeJDHg" title="Other income" style="text-align: right"><ix:nonFraction name="ifrs-full:OtherGainsLosses" contextRef="From2024-07-01to2025-06-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,580</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherGainsLosses" contextRef="From2024-07-01to2025-06-30" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,102,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherGainsLosses" contextRef="From2023-07-012024-06-30" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">461,029</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ConsumablesMedicalSuppliesAndOtherRelatedExpenses_iN_di_uSGD_msPLBTzcCa_zvRnUsS6GANk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Consumables, medical supplies and other related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ConsumablesMedicalSuppliesAndOtherRelatedExpenses_iN_di_uUSD_msStOpSang_c20240701__20250630_zPOlypKJYlrc" title="Consumables, medical supplies and other related expenses" style="text-align: right">(<ix:nonFraction name="BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,986,201</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,526,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses" contextRef="From2023-07-012024-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,248,136</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--EmployeeBenefitsExpense_iN_di_uSGD_msPLBTzcCa_zERWrGORBji5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee benefit expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--EmployeeBenefitsExpense_iN_di_uUSD_msStOpSang_c20240701__20250630_zcWpKBVqxRwa" title="Employee benefit expenses" style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,030,217</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,397,933</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2023-07-012024-06-30" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,638,942</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DepreciationExpense_iN_di_uSGD_msPLBTzcCa_zrVnphuDzsG" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--DepreciationExpense_iN_di_uUSD_msStOpSang_c20240701__20250630_zzHt8pOxEk76" title="Depreciation expense" style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">928,633</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,181,128</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationExpense" contextRef="From2023-07-012024-06-30" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">528,727</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--RentalExpense_iN_di_uSGD_msPLBTzcCa_zT80gHcwgEuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rent expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RentalExpense_iN_di_uUSD_msStOpSang_c20240701__20250630_zDYubXlKOIRl" title="Rent expense" style="text-align: right">(<ix:nonFraction name="ifrs-full:RentalExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,917</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RentalExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">141,075</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RentalExpense" contextRef="From2023-07-012024-06-30" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,180</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherOperatingIncomeExpense_uSGD_maPLBTzcCa_zVDa36OXJjzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--OtherOperatingIncomeExpense_uUSD_maStOpSang_c20240701__20250630_zwQnP4ZpR5zg" title="Other operating expense" style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,619,403</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000093" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">3,331,619</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherOperatingIncomeExpense" contextRef="From2023-07-012024-06-30" id="Fact000094" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,512,168</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ImpairmentLoss_iN_di_uSGD_msPLBTzcCa_zw1ODId7lL0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment loss on goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--ImpairmentLoss_iN_di_uUSD_msStOpSang_c20240701__20250630_zx6FX4uckvLl" title="Impairment loss on goodwill" style="text-align: right">(<ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,763,025</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ImpairmentLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,145,691</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--FinanceCosts_iN_di_uSGD_msPLBTzcCa_zPX9hUrKnve1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Finance cost</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">6</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--FinanceCosts_iN_di_uUSD_msStOpSang_c20240701__20250630_zK2PGmacH23b" title="Finance cost" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2024-07-01to2025-06-30" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2024-07-01to2025-06-30" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">203,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2023-07-012024-06-30" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">176,238</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossBeforeTax_iT_uSGD_maPLz63W_mtPLBTzcCa_zJCzAzTrg7W1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">(Loss)/Profit before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--ProfitLossBeforeTax_iT_uUSD_maStOpNaveen_mtStOpSang_c20240701__20250630_zgMxEPOjrRB8" title="(Loss)/Profit before tax" style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000111" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,832,138</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000108" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,505,497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-07-012024-06-30" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,404,561</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_uSGD_msPLz63W_zDbJKTbfcWhl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax benefit/(expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_uUSD_msStOpNaveen_c20240701__20250630_zmcdqHszCtPd" title="Income tax expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-01to2025-06-30" id="Fact000116" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-01to2025-06-30" id="Fact000113" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">417,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2023-07-012024-06-30" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">331,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ProfitLoss_iT_uSGD_maPLz63W_maCIz75Y_zJ0L1Zep8dSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit after tax</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ProfitLoss_iT_uUSD_mtStOpNaveen_c20240701__20250630_zLlUcn6vjVof" title="(Loss)/Profit after tax" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000121" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000118" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,088,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ProfitLossAndNetComprehensiveIncome_i01T_uSGD_mtCIz75Y_zAE69zX2HDGe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><b>(Loss)/Profit for the year, representing total comprehensive
    income for the year</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td id="xdx_98D_ecustom--ProfitLossAndNetComprehensiveIncome_iT_uUSD_c20240701__20250630_zJgQb7fCbHyl" title="(Loss)/Profit for the year, representing total comprehensive income for the year" style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="BMGL:ProfitLossAndNetComprehensiveIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000126" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,974</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>)</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><b>(<ix:nonFraction name="BMGL:ProfitLossAndNetComprehensiveIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,088,104</ix:nonFraction></b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><b>)</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: right"><b><ix:nonFraction name="BMGL:ProfitLossAndNetComprehensiveIncome" contextRef="From2023-07-012024-06-30" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToAbstract_iB_zLFwHOIdROn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">(Loss)/Profit attributable to:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_uSGD_maPLzsz6_zagwOJU5grfh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Owners of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--ProfitLossAttributableToOwnersOfParent_uUSD_c20240701__20250630_zgBkawaGB1ll" title="Owners of the Company" style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-07-01to2025-06-30" id="Fact000134" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-07-01to2025-06-30" id="Fact000131" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,087,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2023-07-012024-06-30" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--ProfitLossAttributableToNoncontrollingInterests_i01_uSGD_maPLzsz6_zTpd4h3gExl4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Non-controlling interests</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ProfitLossAttributableToNoncontrollingInterests_uUSD_c20240701__20250630_zE8RtY7iKbzc" title="Non-controlling interests" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2024-07-01to2025-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">394</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2024-07-01to2025-06-30" id="Fact000136" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0137">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProfitLossIncludingMinorityInterest_iT_uSGD_mtPLzsz6_ze58bWCiRw83" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">(Loss)/Profit for the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ProfitLossIncludingMinorityInterest_iT_uUSD_c20240701__20250630_zmWUPFlqkHfd" title="(Loss)/Profit for the year" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:ProfitLossIncludingMinorityInterest" contextRef="From2024-07-01to2025-06-30" id="Fact000144" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:ProfitLossIncludingMinorityInterest" contextRef="From2024-07-01to2025-06-30" id="Fact000141" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,088,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:ProfitLossIncludingMinorityInterest" contextRef="From2023-07-012024-06-30" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Profit/Earnings per ordinary share &#8211; basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eifrs-full--BasicEarningsLossPerShare_uUSDPShares_c20240701__20250630_zxlY4yy5curg" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><span id="xdx_90B_eifrs-full--DilutedEarningsLossPerShare_uUSDPShares_c20240701__20250630_znuBZmoLpPT6" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-07-01to2025-06-30" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-07-01to2025-06-30" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.506</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eifrs-full--BasicEarningsLossPerShare_uSGDPShares_c20240701__20250630_z6IKWFlhsHsk" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><span id="xdx_905_eifrs-full--DilutedEarningsLossPerShare_uSGDPShares_c20240701__20250630_zFLFkfRHXOV2" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-07-01to2025-06-30" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-07-01to2025-06-30" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGDPShares">0.643</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eifrs-full--BasicEarningsLossPerShare_uSGDPShares_c20230701__20240630_z79kwqGp9Ugd" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><span id="xdx_90B_eifrs-full--DilutedEarningsLossPerShare_uSGDPShares_c20230701__20240630_zTUxLdsaZSDk" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2023-07-012024-06-30" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="SGDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2023-07-012024-06-30" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="SGDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            average number of shares &#8211; basic and diluted</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eifrs-full--WeightedAverageShares_c20240701__20250630_zAIsVd9T8HMc" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><span id="xdx_90D_eifrs-full--AdjustedWeightedAverageShares_c20240701__20250630_zUv7Wo2gg9yl" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-07-01to2025-06-30" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-07-01to2025-06-30" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,785,750</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eifrs-full--WeightedAverageShares_c20240701__20250630_zvT8FSB3Wejk" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><span id="xdx_908_eifrs-full--AdjustedWeightedAverageShares_c20240701__20250630_zBqMiuibIk1f" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-07-01to2025-06-30" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-07-01to2025-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,785,750</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eifrs-full--WeightedAverageShares_c20230701__20240630_zfrIvDMEuF47" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><span id="xdx_90D_eifrs-full--AdjustedWeightedAverageShares_c20230701__20240630_zZoC1xDKCCnf" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBvZiBQcm9maXQgb3IgTG9zcwA_"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2023-07-012024-06-30" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-07-012024-06-30" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,250,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes form an integral part of these consolidated financial statements.</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="finc_003"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of June 30, 2025 and 2024</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zFLwYIHhrES8" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zje5rt0JJSJj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20240630_zlHf277K8Bej" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AssetsAbstract_iB_zb0YftOf5ycl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--NoncurrentAssetsAbstract_i01B_z664e59dxoPe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--RightofuseAssets_i02I_uSGD_maCz4st_zg9iLxWkNJmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Right-of-use-assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: center">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_980_eifrs-full--RightofuseAssets_i02I_uUSD_c20250630_zUhkEKr2fv09" title="Right-of-use-assets" style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,497,462</ix:nonFraction></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,176,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">23,460</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--PropertyPlantAndEquipment_i02I_uSGD_maCz4st_z0F3VvInPZ1j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_982_eifrs-full--PropertyPlantAndEquipment_i02I_uUSD_c20250630_zqkXF2HfQ8w1" title="Property and equipment" style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,183</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">277,507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">34,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxAssets_i02I_uSGD_maCz4st_z9ufl7XqfW17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98C_eifrs-full--DeferredTaxAssets_i02I_uUSD_c20250630_zJSs5scUv8r" title="Deferred tax assets" style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2025-06-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,702</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2025-06-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">281,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2024-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">77,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_i02I_uSGD_maCz4st_z6tnJPEz8yl5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_98E_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_i02I_uUSD_c20250630_zCsxqDWwTaY9" title="Investment in associate" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2025-06-30" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2025-06-30" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0192">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--NoncurrentAssets_i02TI_pp0p0_uSGD_mtCz4st_maCzf5h_zGR6cFdcGZ0d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Non-current assets</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_98D_eifrs-full--NoncurrentAssets_i02TI_uUSD_c20250630_znlOpb3XDjT1" title="Total Non-current assets" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2025-06-30" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,937,386</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2025-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="SGD">3,736,060</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2024-06-30" id="Fact000197" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="SGD">134,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentAssetsAbstract_i01B_z19KjuAnyyu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--Inventories_i02I_uSGD_maCzq5o_z9lX5Nl3TS36" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Inventories_i02I_uUSD_c20250630_zEQMKM6Eeps8" title="Inventories" style="text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2025-06-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,850</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2025-06-30" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">376,291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2024-06-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">72,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--TradeAndOtherCurrentReceivables_i02I_uSGD_maCzq5o_zrcWI2ga1hm2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98C_eifrs-full--TradeAndOtherCurrentReceivables_i02I_uUSD_c20250630_zXN52oK65WVd" title="Trade and other receivables" style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,651,065</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,731,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,005,219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CashAndCashEquivalents_i02I_uSGD_maCzq5o_zovihXOtwS8d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_980_eifrs-full--CashAndCashEquivalents_i02I_uUSD_c20250630_z1cPstejZFc6" title="Cash and cash equivalents" style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherCurrentReceivables_i02I_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_maCzq5o_zd2xdUnPozU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_986_eifrs-full--OtherCurrentReceivables_i02I_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zZ9kONsGGmEa" title="Amount due from related parties" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">-</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2024-06-30_ifrs-full_RelatedPartiesMember" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredOfferingCost_i02I_uSGD_maCzq5o_z6FnTXk2us4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Deferred offering costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_98A_ecustom--DeferredOfferingCost_i02I_uUSD_c20250630_ziNBpJHZcfec" title="Deferred offering costs" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="BMGL:DeferredOfferingCost" contextRef="AsOf2025-06-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:DeferredOfferingCost" contextRef="AsOf2025-06-30" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">31,798</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:DeferredOfferingCost" contextRef="AsOf2024-06-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,588,024</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentAssets_i02TI_uSGD_mtCzq5o_maCzf5h_zyY6gg0LQEM6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Current assets</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_987_eifrs-full--CurrentAssets_i02TI_uUSD_c20250630_zNPjgOduTr08" title="Total Current assets" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2025-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,314,145</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2025-06-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">13,118,562</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2024-06-30" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">16,173,566</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--Assets_i01TI_uSGD_mtCzf5h_maNALz6xq_zNt9xPPwE1wl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_986_eifrs-full--Assets_i01TI_uUSD_c20250630_zpeBuMSJXaA7" title="Total assets" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2025-06-30" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,251,531</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2025-06-30" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">16,854,622</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2024-06-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">16,308,544</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LiabilitiesAbstract_iB_zPKFCzOYZOnk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--NoncurrentLiabilitiesAbstract_i01B_zAB1cIL8wYu3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LongtermBorrowings_i02I_uSGD_maLzyw7_z6GNun1Yig41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_982_eifrs-full--LongtermBorrowings_i02I_uUSD_c20250630_zbfNM0luLet3" title="Borrowings" style="text-align: right"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="AsOf2025-06-30" id="Fact000248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,801</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="AsOf2025-06-30" id="Fact000245" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="AsOf2024-06-30" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentLiabilitiesAbstract_i01B_zA31xivp7OE2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherCurrentPayables_i02I_uSGD_maLzyw7_zb5nzC7UnLeb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_989_eifrs-full--TradeAndOtherCurrentPayables_i02I_uUSD_c20250630_z6jcLariR8Y8" style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2025-06-30" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,435,180</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2025-06-30" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,913,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2024-06-30" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,575,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ShorttermBorrowings_i02I_uSGD_maLzyw7_zwyhSxd4twc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98D_eifrs-full--ShorttermBorrowings_i02I_uUSD_c20250630_zUWhxzD0EuQ6" title="Borrowings" style="text-align: right"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="AsOf2025-06-30" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,667,677</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="AsOf2025-06-30" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,121,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="AsOf2024-06-30" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,706,356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--OtherCurrentFinancialLiabilities_i02I_uSGD_maLzyw7_znjedNvecoAi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amount due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_987_eifrs-full--OtherCurrentFinancialLiabilities_i02I_uUSD_c20250630_z1qJAQyWXr2h" title="Amount due to related parties" style="text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialLiabilities" contextRef="AsOf2025-06-30" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,291,453</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialLiabilities" contextRef="AsOf2025-06-30" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,642,599</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentFinancialLiabilities" contextRef="AsOf2024-06-30" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AmountDueToFormerDirector_i02I_uSGD_maLzyw7_zgPVk0yFB1Qe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount due to a former director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_ecustom--AmountDueToFormerDirector_i02I_uUSD_c20250630_zlzJKUYn938d" title="Amount due to a former director" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2024-06-30" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">111,459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentProvisionsForEmployeeBenefits_i02I_uSGD_maLzyw7_zCSV4XghZSei" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Asset retirement obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_982_eifrs-full--CurrentProvisionsForEmployeeBenefits_i02I_uUSD_c20250630_zg2nv1CbGnOa" title="Asset retirement obligation" style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="AsOf2025-06-30" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,795</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="AsOf2025-06-30" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentProvisionsForEmployeeBenefits" contextRef="AsOf2024-06-30" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentTaxLiabilitiesCurrent_i02I_uSGD_maLzyw7_zsio9wkAsBi4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Provision for income tax</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_986_eifrs-full--CurrentTaxLiabilitiesCurrent_i02I_uUSD_c20250630_zIwZDKr2QkP6" title="Provision for income tax" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentTaxLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">443,315</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Liabilities_i01TI_uSGD_mtLzyw7_msNALz6xq_zmTa7IC6mvdb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_98E_eifrs-full--Liabilities_i01TI_uUSD_c20250630_z0LUj1Ag0nz9" title="Total liabilities" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2025-06-30" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,426,906</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2025-06-30" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,990,081</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2024-06-30" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">8,746,903</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--NetAssetsLiabilities_i01TI_uSGD_mtNALz6xq_zYW1InZ8Cym5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">NET ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_982_eifrs-full--NetAssetsLiabilities_i01TI_uUSD_c20250630_zpInJHPDPyCa" title="NET ASSETS" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="AsOf2025-06-30" id="Fact000290" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,625</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="AsOf2025-06-30" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,864,541</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NetAssetsLiabilities" contextRef="AsOf2024-06-30" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,641</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EQUITY</b></span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--EquityAbstract_i01B_z0n7l3X6qAbh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Capital attributable to equity holders of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--IssuedCapital_i02I_uSGD_maEzVDy_z1SpLx8ZqEpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_980_eifrs-full--IssuedCapital_i02I_uUSD_maBSCal_c20250630_zgNydY8tloG8" title="Share capital" style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2025-06-30" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,609,109</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2025-06-30" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">34,208,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2024-06-30" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,178</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--MergerReserveArisingFromGroupRestructuring_i02NI_di_uSGD_msEzVDy_zLocJSOcGhLg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Merger reserve arising from group restructuring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--MergerReserveArisingFromGroupRestructuring_i02NI_di_uUSD_msBSCal_c20250630_ztr4fVA6Canf" title="Merger reserve arising from group restructuring" style="text-align: right">(<ix:nonFraction name="BMGL:MergerReserveArisingFromGroupRestructuring" contextRef="AsOf2025-06-30" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,362,500</ix:nonFraction>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:MergerReserveArisingFromGroupRestructuring" contextRef="AsOf2025-06-30" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:MergerReserveArisingFromGroupRestructuring" contextRef="AsOf2024-06-30" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eifrs-full--RetainedEarnings_i02I_uSGD_maEzVDy_z183OIlPT48j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--RetainedEarnings_i02I_uUSD_maBSCal_c20250630_zriLfobSTsj7" title="Retained earnings" style="text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2025-06-30" id="Fact000308" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,836,948</ix:nonFraction>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2025-06-30" id="Fact000305" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">4,396,611</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2024-06-30" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--NoncontrollingInterests_i02I_pp0p0_uSGD_maEzVDy_zUJFiU7pBEw7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--NoncontrollingInterests_i02I_uUSD_maBSCal_c20250630_z6b7IH9KXzol" title="Non-controlling interest" style="text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2025-06-30" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,751</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2025-06-30" id="Fact000310" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="SGD">3,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--OtherReserves_i02I_pp0p0_uSGD_maEzVDy_ztP0wevwBd8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Translation reserve</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_98C_eifrs-full--OtherReserves_i02I_uUSD_maBSCal_c20250630_zgH2pX0UNiB9" title="Translation reserve" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2025-06-30" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,213</ix:nonFraction> </td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2025-06-30" id="Fact000315" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="SGD">495,739</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--Equity_i02TI_uSGD_mtEzVDy_z1ZRyyDUFWaa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td id="xdx_986_eifrs-full--Equity_i02TI_uUSD_mtBSCal_c20250630_z8nyfl2k1fZ5" title="Total equity" style="border-bottom: Black 1pt solid; text-align: right; padding-bottom: 1pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30" id="Fact000323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,625</ix:nonFraction></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,864,541</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,641</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes form an integral part of these consolidated financial statements.</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="finc_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENT OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zIeVSlqloWU3" summary="xdx: Statement - Consolidated Statement of Changes In Shareholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_zxIdAtLqrDo1" style="border-bottom: Black 1pt solid; display: none; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none">capital</b></span></p></td><td style="display: none; padding-bottom: 1pt">&#160;</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_ifrs-full--ComponentsOfEquityAxis_ifrs-full--MergerReserveMember_zLXccqAOdJk7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0">Merger</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">reserve</p></td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B5_ifrs-full--ComponentsOfEquityAxis_ifrs-full--ReserveOfExchangeDifferencesOnTranslationMember_zzrD2O1ZI4z" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0"><span id="xdx_913_eifrs-full--ReserveOfExchangeDifferencesOnTranslationMember_zSvPCZy4E1F3">Translation reserve [member]</span></p></td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_ze1yeKcJKzP8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0">Retained</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">earnings</p></td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BB_ifrs-full--ComponentsOfEquityAxis_ifrs-full--EquityAttributableToOwnersOfParentMember_zF8GDW5wPdj3" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0">Total</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">attributable</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">to owners of</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">Company</p></td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B4_ifrs-full--ComponentsOfEquityAxis_ifrs-full--NoncontrollingInterestsMember_zYq7SAcYshK9" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0">Non-</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">controlling</p>
                                                                  <p style="display: none; margin-top: 0; margin-bottom: 0">interest</p></td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_zBIw75VTrB5k" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>capital</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Merger</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">reserve</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Translation</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">reserve</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Retained</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">earnings</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">attributable</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">to owners of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Company</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Non-</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">controlling</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">interest</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_431_c20240701__20250630_eifrs-full--Equity_iS_uUSD_zyVsD8Sp2qwh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; font-weight: bold; text-align: left">As at July 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,362,506</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,362,500</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,686</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,588,403</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,579,723</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,579,723</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--IssueOfEquity_uUSD_zcraeb6Q8jUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,246,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,246,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-01to2025-06-30" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,246,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_uUSD_zhMiYPc9KRFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,899</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-01to2025-06-30" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_uUSD_zgtAugi9cGqk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,623</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,623</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-01to2025-06-30" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,623</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--MinorityInterestInSubsidiary_uUSD_zbo5Ywa5csO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-01to2025-06-30" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,751</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherComprehensiveIncomeBeforeTax_uUSD_zuCld0txVj68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Loss for the year, representing total comprehensive loss for the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000372" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,503,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240701__20250630_eifrs-full--Equity_iE_uUSD_zCSo5IsLndqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">As at June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_IssuedCapitalMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,609,109</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_MergerReserveMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,362,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,213</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,836,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,821,874</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,751</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,824,625</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>capital</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Merger</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">reserve</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Translation</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">reserve</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Retained</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">earnings</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">attributable</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">to owners of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Company</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Non-</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">controlling</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">interest</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43C_c20240701__20250630_eifrs-full--Equity_iS_z6NFnFDctAPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; font-weight: bold; text-align: left">As at July 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,178</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,633</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,641</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,641</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--IssueOfEquity_zOl53eVRKJJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,753,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,753,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2024-07-01to2025-06-30" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,753,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_zUaNcu4vN2bd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">495,739</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">29,860</ix:nonFraction></p></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">465,879</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2024-07-01to2025-06-30" id="Fact000404" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">465,879</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_z7DH96U3B65i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share based payment reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-07-01to2025-06-30" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--MinorityInterestInSubsidiary_zE59SPVfvFzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:MinorityInterestInSubsidiary" contextRef="From2024-07-01to2025-06-30" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherComprehensiveIncomeBeforeTax_zXMTFNHCfPH6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Loss for the year, representing total comprehensive income for the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,088,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,088,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000428" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,088,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240701__20250630_eifrs-full--Equity_iE_zTudWwLbcX2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">As at June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_IssuedCapitalMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">34,208,562</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_MergerReserveMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" id="Fact000432" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">495,739</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_RetainedEarningsMember" id="Fact000433" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">4,396,611</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,861,042</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,499</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2025-06-30" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,864,541</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_z3Na54o9RvSg" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>capital</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B9_ifrs-full--ComponentsOfEquityAxis_ifrs-full--MergerReserveMember_zQlUtdRVp0d6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Merger</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">reserve</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zNXMBDtxWg57" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Retained</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">earnings</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BE_zXTWb89uPQB8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_432_c20230701__20240630_eifrs-full--Equity_iS_z81WQraUiOZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">As at July 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_IssuedCapitalMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">8</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_RetainedEarningsMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,488,833</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,488,841</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20230701__20240630_eifrs-full--Equity_iS_zZvVD5oDqg2a" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; text-align: left">Balance</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_IssuedCapitalMember" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">8</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">-</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30_ifrs-full_RetainedEarningsMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,488,833</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2023-06-30" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,488,841</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--IssueOfEquity_zRq3LKfdHqv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IssueOfEquity" contextRef="From2023-07-012024-06-30" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--IncreaseDecreaseThroughTransferToStatutoryReserve_zuvTJdzYaBx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Merger reserve arising from group restructuring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve" contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve" contextRef="From2023-07-012024-06-30" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ProfitLoss_zqydSEGajQl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Profit for the year, representing total comprehensive income for the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--ProfitLoss_zMdSy6RMeKg5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-bottom: 1pt; text-align: left">Profit/(Loss)</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012024-06-30" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,072,800</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20230701__20240630_eifrs-full--Equity_iE_zonyYVfFmdzk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">As at June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,178</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,633</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,641</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20230701__20240630_eifrs-full--Equity_iE_zvlPJo881sv1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; text-align: justify; padding-bottom: 1pt">Balance</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,178</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">24,455,170</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">)</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,633</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-06-30" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,561,641</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes form an integral part of these consolidated financial statement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="finc_005"></span><b>CONSOLIDATED
STATEMENT OF CASH FLOWS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024 </b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<table cellpadding="0" cellspacing="0" id="xdx_305_112_z0uVUlUfvJs4" summary="xdx: Statement - Consolidated Statement of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240701__20250630_zsUwwxTT3ulk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zJJABYuRlAAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB_z2F3PNEGHFH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cash flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--ProfitLossBeforeTax_i01_maATRPLzsnX_zGN9zscYKVu9" style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: justify">(Loss)/Profit before tax</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ProfitLossBeforeTax_uUSD_c20240701__20250630_zmwDimD91UB8" title="(Loss)/Profit before tax" style="width: 11%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000484" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,832,138</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,505,497</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-07-012024-06-30" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,404,561</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForReconcileProfitLossAbstract_iB_zCJypJCzYsra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Adjustments for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--RecoveriesOnLoansPreviouslyWrittenOff_i01_maATRPLzsnX_zr6TpoKhpq17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bad debts written off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RecoveriesOnLoansPreviouslyWrittenOff_uUSD_c20240701__20250630_zAK5H66Hmgea" title="Bad debts written off" style="text-align: right"><ix:nonFraction name="ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff" contextRef="From2024-07-01to2025-06-30" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff" contextRef="From2024-07-01to2025-06-30" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">240,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CreditLossExpenseReversal_i01N_di_msATRPLzsnX_zglxBKzQgBG2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Reversal of estimated credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--CreditLossExpenseReversal_iN_di_uUSD_c20240701__20250630_zJi7aPUeRw0j" title="Reversal of estimated credit losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:CreditLossExpenseReversal" contextRef="From2023-07-012024-06-30" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">55,741</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--AdjustmentsForProvisions_i01_maATRPLzsnX_zZMOf1PBrMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Provision for estimated credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--AdjustmentsForProvisions_uUSD_c20240701__20250630_z0hKTQQ4prYd" title="Provision for estimated credit losses" style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="From2024-07-01to2025-06-30" id="Fact000502" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,404</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="From2024-07-01to2025-06-30" id="Fact000499" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">682,252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForProvisions" contextRef="From2023-07-012024-06-30" id="Fact000500" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">50,168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--AdjustmentsForDepreciationExpense_i01_maATRPLzsnX_zOqOz9yyBzHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--AdjustmentsForDepreciationExpense_uUSD_c20240701__20250630_zfTPfLWG26Fl" title="Depreciation of property and equipment" style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">107,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="From2023-07-012024-06-30" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">30,093</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AdjustmentsForAmortizationOfRightOfUseAsset_i01_maATRPLzsnX_zryOaggfrnT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortisation of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdjustmentsForAmortizationOfRightOfUseAsset_uUSD_c20240701__20250630_zUcCQztpbHSf" title="Amortisation of right-of-use assets" style="text-align: right"><ix:nonFraction name="BMGL:AdjustmentsForAmortizationOfRightOfUseAsset" contextRef="From2024-07-01to2025-06-30" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">843,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:AdjustmentsForAmortizationOfRightOfUseAsset" contextRef="From2024-07-01to2025-06-30" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,073,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:AdjustmentsForAmortizationOfRightOfUseAsset" contextRef="From2023-07-012024-06-30" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">498,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--RecoveriesOnLoansPreviouslyWrittenOffFixedAssets_i01_maATRPLzsnX_zgYexxuC9SA1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Loss on written off fixed asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--RecoveriesOnLoansPreviouslyWrittenOffFixedAssets_uUSD_c20240701__20250630_zWgO9c9xfHC9" title="Loss on written off fixed asset" style="text-align: right"><ix:nonFraction name="BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" contextRef="From2024-07-01to2025-06-30" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,549</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" contextRef="From2024-07-01to2025-06-30" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">176,220</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_i01_maATRPLzsnX_zscGP71JAxEl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Impairment loss on goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_uUSD_c20240701__20250630_zwV05bc0eeyj" title="Impairment loss on goodwill" style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2024-07-01to2025-06-30" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,763,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" contextRef="From2024-07-01to2025-06-30" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,145,691</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--AdjustmentsForInterestExpense_i01_maATRPLzsnX_zOrPGxRsKqG" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--AdjustmentsForInterestExpense_uUSD_c20240701__20250630_zvM55OI8RIcc" title="Interest expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForInterestExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForInterestExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">203,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForInterestExpense" contextRef="From2023-07-012024-06-30" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">176,238</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_i01T_mtATRPLzsnX_maAFDIIzzPN_zNWNBDHJxM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating cash flows before changes in working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_iT_uUSD_c20240701__20250630_z0zppI3IL7Sc" title="Operating cash flows before changes in working capital" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="From2024-07-01to2025-06-30" id="Fact000532" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">188,973</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="From2024-07-01to2025-06-30" id="Fact000529" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">240,357</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" contextRef="From2023-07-012024-06-30" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,103,954</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInNonCashWorkingCapitalAbstract_iB_ze3AqgCJjxU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in working capital:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--AdjustmentsForDecreaseIncreaseInInventories_i01_maAFDIIzzPN_zpB87lUN0yP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--AdjustmentsForDecreaseIncreaseInInventories_uUSD_c20240701__20250630_ztTkyJo37UC4" title="Inventories" style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="From2024-07-01to2025-06-30" id="Fact000540" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">239,218</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="From2024-07-01to2025-06-30" id="Fact000537" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">304,261</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" contextRef="From2023-07-012024-06-30" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">22,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_i01_maAFDIIzzPN_zZxe4GcVdD78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_uUSD_c20240701__20250630_zmLX1IHw8mci" title="Trade and other receivables" style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="From2024-07-01to2025-06-30" id="Fact000545" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,727,120</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="From2024-07-01to2025-06-30" id="Fact000542" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">7,284,324</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" contextRef="From2023-07-012024-06-30" id="Fact000543" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">415,080</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_i01N_di_msAFDIIzzPN_zK1xhSGWOJ1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Trade and other payables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_iN_di_uUSD_c20240701__20250630_zHnai9xr63n4" title="Trade and other payables" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2024-07-01to2025-06-30" id="Fact000550" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,409,904</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2024-07-01to2025-06-30" id="Fact000547" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">4,337,057</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2023-07-012024-06-30" id="Fact000548" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">387,690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CashFlowsFromUsedInOperations_i01T_maCzoZZ_mtAFDIIzzPN_zO8kxXIyoiOb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Cash (used in)/ generated from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashFlowsFromUsedInOperations_iT_uUSD_c20240701__20250630_zSebXtxJoPb9" title="Cash (used in)/ generated from operations" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="From2024-07-01to2025-06-30" id="Fact000555" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,745,407</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="From2024-07-01to2025-06-30" id="Fact000552" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">3,491,885</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperations" contextRef="From2023-07-012024-06-30" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,099,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--IncomeTaxesPaidRefundClassifiedAsOperatingActivities_i01N_di_msCzoZZ_zDT1KFX6C3Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Income tax paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--IncomeTaxesPaidRefundClassifiedAsOperatingActivities_iN_di_uUSD_c20240701__20250630_zBBPQ1aidGVd" title="Interest paid" style="text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,704</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">648,292</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" contextRef="From2023-07-012024-06-30" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">176,238</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--InterestPaidClassifiedAsOperatingActivities_i01N_di_msCzoZZ_zrtAqtVVJXx9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Interest paid</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--InterestPaidClassifiedAsOperatingActivities_iN_di_uUSD_c20240701__20250630_zjYFrJdR6lVc" title="Income tax paid" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">203,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" contextRef="From2023-07-012024-06-30" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">413,612</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--CashFlowsFromUsedInOperatingActivities_i01T_mtCzoZZ_maIDICAzxDX_zVoyucAUfplj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            cash (used in)/generated from operating activities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CashFlowsFromUsedInOperatingActivities_iT_uUSD_c20240701__20250630_z5N3xWu6Mbp4" title="Net cash (used in)/generated from operating activities" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000570" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,415,460</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000567" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">4,344,125</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2023-07-012024-06-30" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,509,285</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB_zrerOmN9tkd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_i01N_di_msCFFUIzlQ2_zgGrWrU236L6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_iN_di_uUSD_c20240701__20250630_z1rqFWSoHkGb" title="Acquisition of property and equipment" style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,054</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">54,760</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2023-07-012024-06-30" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,920</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_i01N_di_msCFFUIzlQ2_zovM5eMjbPr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acquisition of new subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_iN_di_uUSD_c20240701__20250630_zcuNPwdpL5q3" title="Acquisition of new subsidiary" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,637,578</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,986,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--PurchaseOfInvestmentProperty_i01N_di_msCFFUIzlQ2_zeo3aFVPLJC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">(Increase) in investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--PurchaseOfInvestmentProperty_iN_di_uUSD_c20240701__20250630_zFrBwAm2DUSh" title="(Increase) in investment in associate" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfInvestmentProperty" contextRef="From2024-07-01to2025-06-30" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfInvestmentProperty" contextRef="From2024-07-01to2025-06-30" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashFlowsFromUsedInInvestingActivities_i01T_mtCFFUIzlQ2_maIDICAzxDX_zpW6Q2vpEQUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash provided by/ (used in) investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--CashFlowsFromUsedInInvestingActivities_iT_uUSD_c20240701__20250630_ztRiIH6WNeha" title="Cash provided by/ (used in) investing activities" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000593" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,680,671</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000590" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">11,040,944</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2023-07-012024-06-30" id="Fact000591" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">7,920</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashFlowsFromUsedInFinancingActivitiesAbstract_iB_zoC5YaltXK71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ProceedsFromDeferredOfferingCosts_i01N_di_msCFFUIznS1_zph8Up9iU8f9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ProceedsFromDeferredOfferingCosts_iN_di_uUSD_c20240701__20250630_z5FcQcX0l1Il" title="Deferred offering costs" style="text-align: right"><ix:nonFraction name="BMGL:ProceedsFromDeferredOfferingCosts" contextRef="From2024-07-01to2025-06-30" id="Fact000601" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,223,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:ProceedsFromDeferredOfferingCosts" contextRef="From2024-07-01to2025-06-30" id="Fact000598" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,556,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:ProceedsFromDeferredOfferingCosts" contextRef="From2023-07-012024-06-30" id="Fact000599" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,588,024</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--DecreaseInAmountDueFromDirector_i01N_di_msCFFUIznS1_zPmdPoiFYwja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Decrease in amount due from a director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DecreaseInAmountDueFromDirector_iN_di_uUSD_c20240701__20250630_zsfVglrzo4b2" title="Decrease in amount due from a director" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DecreaseInAmountDueFromDirector" contextRef="From2023-07-012024-06-30" id="Fact000604" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,320,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncreaseInAmountDueToRelatedParties_i01N_di_msCFFUIznS1_zYSAc4qEth5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in amount due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IncreaseInAmountDueToRelatedParties_iN_di_uUSD_c20240701__20250630_zV9fGyBeQQd" title="Increase in amount due to related parties" style="text-align: right"><ix:nonFraction name="BMGL:IncreaseInAmountDueToRelatedParties" contextRef="From2024-07-01to2025-06-30" id="Fact000611" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">260,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:IncreaseInAmountDueToRelatedParties" contextRef="From2024-07-01to2025-06-30" id="Fact000608" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">331,209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:IncreaseInAmountDueToRelatedParties" contextRef="From2023-07-012024-06-30" id="Fact000609" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CashAdvancesAndLoansFromRelatedParties_i01_maCFFUIznS1_zlm9Qc2j2bai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Decrease/(Increase) in amount due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashAdvancesAndLoansFromRelatedParties_uUSD_c20240701__20250630_zMmX6jDuCxld" title="Decrease/(Increase) in amount due from related parties" style="text-align: right"><ix:nonFraction name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" contextRef="From2024-07-01to2025-06-30" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,300,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" contextRef="From2024-07-01to2025-06-30" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" contextRef="From2023-07-012024-06-30" id="Fact000614" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">73</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseInBankOverdraft_i01N_di_msCFFUIznS1_z9BPg9vYdxAi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in bank overdraft</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseInBankOverdraft_iN_di_uUSD_c20240701__20250630_zFe7BJQIkfM3" title="Increase in bank overdraft" style="text-align: right"><ix:nonFraction name="BMGL:IncreaseInBankOverdraft" contextRef="From2024-07-01to2025-06-30" id="Fact000621" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:IncreaseInBankOverdraft" contextRef="From2024-07-01to2025-06-30" id="Fact000618" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">61,371</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--ProceedsFromCurrentBorrowings_i01_maCFFUIznS1_zA4yME60pPv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630_zsi5CF5oLWu4" title="Proceeds from borrowings" style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2024-07-01to2025-06-30" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,144,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2024-07-01to2025-06-30" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_i01N_di_msCFFUIznS1_zJk6KxzEBQg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payment of principal portion of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_iN_di_uUSD_c20240701__20250630_zrOCNPF713P6" title="Payment of principal portion of lease liabilities" style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">771,556</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">981,342</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2023-07-012024-06-30" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">566,039</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--RepaymentsOfBorrowingsClassifiedAsFinancingActivities_i01N_di_msCFFUIznS1_z8sEtfV0fcKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Repayment of borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--RepaymentsOfBorrowingsClassifiedAsFinancingActivities_iN_di_uUSD_c20240701__20250630_zLH89vR6h5Kc" title="Repayment of borrowings" style="text-align: right">(<ix:nonFraction name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,495,235</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">8,261,290</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" contextRef="From2023-07-012024-06-30" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,356,930</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--DecreaseincreaseInAmountDueToFormerDirector_i01N_di_msCFFUIznS1_zTvx8EEf4IP5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Decrease)/Increase in amount due to former director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DecreaseincreaseInAmountDueToFormerDirector_iN_di_uUSD_c20240701__20250630_ziE8UA0AsiTh" title="(Decrease)/Increase in amount due to former director" style="text-align: right">(<ix:nonFraction name="BMGL:DecreaseincreaseInAmountDueToFormerDirector" contextRef="From2024-07-01to2025-06-30" id="Fact000641" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,632</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:DecreaseincreaseInAmountDueToFormerDirector" contextRef="From2024-07-01to2025-06-30" id="Fact000638" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">111,459</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DecreaseincreaseInAmountDueToFormerDirector" contextRef="From2023-07-012024-06-30" id="Fact000639" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">111,459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--ProceedsFromContributionsOfNoncontrollingInterests_i01_maCFFUIznS1_z2MBeE56cUg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-controlling interest contributions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProceedsFromContributionsOfNoncontrollingInterests_uUSD_c20240701__20250630_zCPRp6qpfGCh" title="Non-controlling interest contributions" style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" contextRef="From2024-07-01to2025-06-30" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests" contextRef="From2024-07-01to2025-06-30" id="Fact000643" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProceedsFromIssueOfOrdinaryShares_i01_maCFFUIznS1_znJfcVEVu2Nl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Share issuance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ProceedsFromIssueOfOrdinaryShares_uUSD_c20240701__20250630_zu7v5pJYY8si" title="Share issuance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="From2024-07-01to2025-06-30" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,668,358</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="From2024-07-01to2025-06-30" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,753,384</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashFlowsFromUsedInFinancingActivities_i01T_mtCFFUIznS1_maIDICAzxDX_zRA8S0xvB1pi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            cash generated from/(used in) financing activities</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--CashFlowsFromUsedInFinancingActivities_iT_uUSD_c20240701__20250630_zz9ImZwtq9f9" title="Net cash generated from/(used in) financing activities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,294,157</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">16,908,838</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2023-07-012024-06-30" id="Fact000654" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,767,760</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_iT_mtIDICAzxDX_zAlNV7VvYVal" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_iT_uUSD_c20240701__20250630_zyjwYvU7gkcl" title="Net increase/(decrease) in cash and cash equivalents" style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="From2024-07-01to2025-06-30" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,198,026</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="From2024-07-01to2025-06-30" id="Fact000658" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,523,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" contextRef="From2023-07-012024-06-30" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">733,605</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CashAndCashEquivalents_iS_zNIVCsIBZ6Ui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents at beginning of financial period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--CashAndCashEquivalents_iS_uUSD_c20240701__20250630_zAqyFMNBGKRb" title="Cash and cash equivalents at beginning of financial period" style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,533,967</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,217,448</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--EffectOfExchangeRateChangesOnCashAndCashEquivalents_zSeWYELXXj2l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effects of currency translation on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--EffectOfExchangeRateChangesOnCashAndCashEquivalents_uUSD_c20240701__20250630_zZaFV5dZwILg" title="Effects of currency translation on cash and cash equivalents" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2024-07-01to2025-06-30" id="Fact000671" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">389,763</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2024-07-01to2025-06-30" id="Fact000668" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">495,739</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CashAndCashEquivalents_iE_ztCzOkWVtaul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
                                            and cash equivalents at end of financial year</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--CashAndCashEquivalents_iE_uUSD_c20240701__20250630_zLtj07pe9kN4" title="Cash and cash equivalents at end of financial year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes form an integral part of these consolidated financial statements.</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="finc_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
year ended June 30, 2025 and 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
notes form an integral part of and should be read in conjunction with the accompanying consolidated financial statements.</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000678" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_zC65qhZxHiP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
                                                                                                                                                             <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zBL1s5KWVyBe">General</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
Medical Group Ltd. is incorporated and domiciled in British Virgin Islands (BVI) with operations conducted by its fully owned subsidiary,
Basel Medical Group Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.), based in Singapore at 6 Napier Road #03-07 Gleneagles Medical Centre,
Singapore 258499.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal activities of the Company pertain to investment holding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reorganization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, as part of an internal reorganization, all of the shares in our operating subsidiaries were transferred by our founder,
Dr. Kevin Yip, to Basel Medical Group Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.) Subsequently, in June 2023, Dr. Kevin Yip entered
into an agreement with Rainforest Capital VCC to transfer all the shares he held in Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists
Pte. Ltd.) to Rainforest Capital VCC. Upon completion, Rainforest Capital VCC became the sole shareholder of Basel Medical Group Pte.
Ltd. (F.K.A Singmed Specialists Pte. Ltd.), which holds the shares of all of our subsidiaries. Rainforest Capital VCC is a variable capital
company incorporated in Singapore and is an investment fund managed by AIP Investment Partners Pte. Ltd., a licensed fund manager in
Singapore.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 10, 2023, Basel Medical Group Ltd. was incorporated under the laws of the BVI as our holding Company to facilitate this offering
and the listing of Basel Medical Group Ltd.&#8217;s ordinary shares on Nasdaq, and in connection therewith, Rainforest VCC (an umbrella
fund with multiple sub-funds), through its sub-fund, Basel Medical Fund, subscribed for <span id="xdx_907_ecustom--NumberOfSharesSubscribed_iI_pid_c20230810__ifrs-full--ComponentsOfEquityAxis__custom--OrdinaryShareMember_zx4tpetcKF56" title="Number of shares subscribe"><ix:nonFraction name="BMGL:NumberOfSharesSubscribed" contextRef="AsOf2023-08-10_custom_OrdinaryShareMember" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,250,000</ix:nonFraction></span> ordinary shares in Basel Medical Group
Ltd. amounting to US$<span id="xdx_909_eifrs-full--ProceedsFromIssueOfOrdinaryShares_uUSD_c20230810__20230810_ziTgAO9h8r4e"><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="From2023-08-102023-08-10" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,362,500</ix:nonFraction></span> at a subscription price of US$<span id="xdx_90D_eifrs-full--ParValuePerShare_iI_pid_uUSDPShares_c20230810_zxKdq2jIRBce" title="Par value per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2023-08-10" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.13</ix:nonFraction></span> per share. In August 2023, all of the shares in Basel Medical Group
Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.) were transferred to Basel Medical Group Ltd. by Rainforest Capital VCC to prepare for
this listing and offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
between September 2023 and January and April 2024, Rainforest Capital VCC sold certain of the shares it held in Basel Medical Group Ltd.
to certain other investors, following which Rainforest Capital VCC held a total of <span id="xdx_90B_eifrs-full--SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_iI_pid_c20240430__ifrs-full--ComponentsOfEquityAxis__custom--OrdinaryShareMember_zPrG1W62lwVa" title="Number of shares held"><ix:nonFraction name="ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" contextRef="AsOf2024-04-30_custom_OrdinaryShareMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,387,982</ix:nonFraction> </span>ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group were prepared on the basis as if the reorganisation became effective as of the beginning
of the first period presented in the accompanying consolidated financial statements of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000687" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"><p id="xdx_895_eifrs-full--DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_zvthun1QaGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has following subsidiaries as at June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zeoAc06NJlze">Schedule
of activities of subsidiaries</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of entity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>activities</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
    of business and incorporation</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proportion
                                            of ordinary</b></span></p>
                                                                                                                                                                                                                                                          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            held by Group</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 23%; text-align: center"><span id="xdx_902_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zc1BBMfhEro4" title="Name of entity"><span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zNJgHh6AI4Dj" title="Name of entity"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000689" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000691" name="ifrs-full:NameOfSubsidiary">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; width: 2%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-style: normal; width: 25%; font-weight: normal; text-align: center"><span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zdBvBauCsVGg" title="Principal activities"><span id="xdx_90F_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zzFOcucgLfc3" title="Principal activities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000693" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000695" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Other holding companies</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 18%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zEwlzLQSSzs5" title="Country of business / incorporation"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_ztcvILYAElq" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000697" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000699" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zltgYElMqL7" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_z9bcMuVZrWab" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zOzOyDX03s03" title="Name of entity"><span id="xdx_90F_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zK1XjIDwwyg6" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000705" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000707" name="ifrs-full:NameOfSubsidiary">Singapore Sports &amp; Orthopaedic Clinic Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zggHx0CDuUkj" title="Principal activities"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zf7sDb0M7y2j" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000709" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000711" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zXLhuQWSQMki" title="Country of business / incorporation"><span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zWuypqel38i" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000713" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000715" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_906_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zuhnLnmr1jQ" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zGrdAldIgz43" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90A_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z0XyM9JssMuf" title="Name of entity"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z03jl5uXkGne" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000721" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000723" name="ifrs-full:NameOfSubsidiary">Singapore Sports &amp; Orthopaedic Services Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zs0LvmA9JQuk" title="Principal activities"><span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z6oqqv8mCxGg" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000725" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000727" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zY243244fo5i" title="Country of business / incorporation"><span id="xdx_90B_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zhinC50O2bg8" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000729" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000731" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zS5Ad7cehbb5" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zcwTCZrdaH6f" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zOsl4sc4J3u5" title="Name of entity"><span id="xdx_905_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_z6ILKpDLuAvf" title="Name of entity"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember" id="Fact000737" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SSOCPteLtdMember" id="Fact000739" name="ifrs-full:NameOfSubsidiary">SSOC Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zxeaQs8hI2C9" title="Principal activities"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zGpTnKyKVqF2" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SSOCPteLtdMember" id="Fact000741" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember" id="Fact000743" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zZVrAbsvd5Vb" title="Country of business / incorporation"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zor5f0wkcJki" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember" id="Fact000745" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember" id="Fact000747" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zXrspKKGida9" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_SSOCPteLtdMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zWTVjlOy8Km5" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_z12DAYMgkW5g" title="Name of entity"><span id="xdx_906_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zZDzQUcveG27" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember" id="Fact000753" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember" id="Fact000755" name="ifrs-full:NameOfSubsidiary">SSOS Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_ztKtziVMD4X" title="Principal activities"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zrIrvPAJmCp8" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember" id="Fact000757" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember" id="Fact000759" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90A_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zfmMhjqYiDv1" title="Country of business / incorporation"><span id="xdx_907_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zQcoWaVaenjg" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember" id="Fact000761" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember" id="Fact000763" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zpJ3A4fs3j6g" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zkPulwrJ1kPc" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of entity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>activities</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Country
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">business and</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">incorporation</p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proportion
                                            of ordinary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            held by Group</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_za0JX4vZW2ea" title="Name of entity"><span id="xdx_901_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7j4ELHbTVzg" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000769" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000771" name="ifrs-full:NameOfSubsidiary">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMLArotMAfg6" title="Principal activities"><span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zhGGsa64pb62" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000773" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000775" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7t1hwkMhr7a" title="Country of business / incorporation"><span id="xdx_909_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMUlWcLUNGaj" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000777" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000779" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zuozTzY5mMS4" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zBTjjjM4v6Aa" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zhL15wGo2FK5" title="Name of entity"><span id="xdx_909_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zF22JgZ1SDig" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000785" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000787" name="ifrs-full:NameOfSubsidiary">Singapore Knee, Sports &amp; Orthopaedic Services Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_900_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zqP7sDJR4V23" title="Principal activities"><span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zIbsDlM7ngif" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000789" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000791" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90C_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zUbL5K9sCini" title="Country of business / incorporation"><span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zxV2i7KQWzyl" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000793" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000795" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zY3JPgMM8cj7" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_z0hM1ejPszJ9" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zpFdI0TUDcx3" title="Name of entity"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_z4R9kaqAzQwi" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000801" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000803" name="ifrs-full:NameOfSubsidiary">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zTxs2Y2CvlX5" title="Principal activities"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zVhIy287sDRb" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000805" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000807" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zcIKhSJZ04Y7" title="Country of business / incorporation"><span id="xdx_906_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zxkKKhZPFVI8" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000809" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000811" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zz6nw51dbST4" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zQvojkoCY0kb" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZH2ea4faCDi" title="Name of entity"><span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zkI0fpZqUhr6" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember" id="Fact000817" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember" id="Fact000819" name="ifrs-full:NameOfSubsidiary">Basel Medflow Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZLgUn3Eh5lh" title="Principal activities"><span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_ziJb3AB8jt3g" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember" id="Fact000821" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember" id="Fact000823" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zCaVcEFMbzDi" title="Country of business / incorporation"><span id="xdx_90E_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zOaG7nCiOa9h" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember" id="Fact000825" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember" id="Fact000827" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zeT4trlE7MCh" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_z5XZTPxD0Xd5" title="Name of entity"><span id="xdx_90E_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zl8nZWrIS3z4" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000831" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000833" name="ifrs-full:NameOfSubsidiary">Bethesda Medical Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90B_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zdp2H7AmJKxa" title="Principal activities"><span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zcEJL1B7wt2l" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000835" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000837" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western)</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zm4ljxZvbRT6" title="Country of business / incorporation"><span id="xdx_90F_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zHgkJJy0PPIl" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000839" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000841" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zD7rakTxlHp4" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zPZ6CfUJUr97" title="Name of entity"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zhz8vKyYBJ2c" title="Name of entity"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000845" name="ifrs-full:NameOfSubsidiary"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000847" name="ifrs-full:NameOfSubsidiary">Oasis Medical Clinic Pte. Ltd.</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWJ33wEaTrg9" title="Principal activities"><span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zvRxu6diZxql" title="Principal activities"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000849" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000851" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">Clinics and other general medical services (western)</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_za40r1XsueIb" title="Country of business / incorporation"><span id="xdx_900_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zOC0OWSKwuIf" title="Country of business / incorporation"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000853" name="ifrs-full:CountryOfIncorporation"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000855" name="ifrs-full:CountryOfIncorporation">Singapore</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWHW0BmX0go8" title="Ownership percentage"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A0_z5ckeivur6rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2024, Singmed Specialists Pte. Ltd. changed its corporate name to Basel Medical Group Pte. Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2025, Singapore Sports and Physiotherapy Centre Pte. Ltd. changed its corporate name to Pharma Avenue Pte. Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000859" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory"><p id="xdx_805_eifrs-full--DisclosureOfChangesInAccountingPoliciesExplanatory_zzuAznr5QwX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><b><span id="xdx_828_znF30Q7r0Gva">Material accounting policy information</span></b></td></tr></table>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000861" name="BMGL:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory"><p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_zI4sF8qCbosk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><b>2.1</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><b><span id="xdx_86C_z0I5Q3qpuyua">Compliance
                                            with International Financial Reporting Standards (&#8220;IFRS&#8221;)</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;)
and interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS IC&#8221;) applicable to companies reporting under IFRS.
The financial statements comply with IFRS as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared on a going concern basis.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
ability of the Group to continue as going concern is dependent on: (Please refer to Note 26)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of its major shareholder to provide financial support</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of the Group to generate sufficient and sustainable operating profits and cash flows
                                            over the next 12 months from the date of these financial statements to meet its operating
                                            and financial obligations as and when they fall due; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of the Group to procure additional financing and to garner the continuous support
                                            of its existing financiers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000863" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations"><p id="xdx_845_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_z8tyN44gZzUj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zaapWlfTeQZ6">New
                                            and amended standards adopted by the Group</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has applied the following amendments for the first time for their annual reporting period commencing July 1, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
                                            of Liabilities as Current or Non-current and Non-current liabilities with covenants &#8211;
                                            Amendments to IAS 1;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
                                            Liability in Sale and Leaseback &#8211; Amendments to IFRS 16; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplier
                                            Finance Arrangements &#8211; Amendments to IAS 7 and IFRS 7.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000865" name="BMGL:DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory"><p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_zOSlo6Ziw3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.3</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zw46494mBlR4">New
                                            standards and interpretations not yet adopted</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Certain
new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for June
30, 2025 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected
to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"></p>

<ix:exclude><!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material accounting policy information (Continued)</span></td>
</tr></table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000867" name="BMGL:DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_z0MFTpCADvNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.4</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zN4EmdCwMtYc">Revenue
                                            from contracts with customers </span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is in the business of providing medical services to patients. Revenue from contracts with customers is recognized when control
of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be
entitled in exchange for those goods or services. Revenue is presented net of goods and services tax, rebates, and discounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the rendering of medical services is recognized at the point in time when the entity satisfies the performance obligation by transferring
a promised good or service to the customer, which is when the customer obtains control of the good or service. This is generally when
the significant acts have been completed, ie, upon the completion of consultations, clinical treatments, medical tests and operations.
The Group considers whether there are other promises in the contract that are separate performance obligations to which a portion of
the transaction price needs to be allocated. The amount of revenue recognized is the amount allocated to the satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
price is the amount of consideration in the contract to which the Group expects to be entitled in exchange for transferring the promised
goods or services. In determining the transaction price for the rendering of medical services the Group considers the effects of variable
consideration. Contracts with customers normally does not include any contractual adjustment such as right of return, volume discount
etc. In rare circumstances where consideration is variable, the Group estimates the amount of consideration to which it will be entitled
in exchange for rendering of service to the customer. The variable consideration is estimated at contract inception and constrained until
it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated
uncertainty with the variable consideration is subsequently resolved.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000869" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory"><p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zNlI4GOW3hB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.5</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zjjZCf7gH2k3">Segment
                                            reporting</span></b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the Group&#8217;s internal organizational structure as well as information about geographical
areas, business segments and major clients in the consolidated financial statements for detailing the Group&#8217;s business segments.
Based on the criteria established, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief
Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the
Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. As the Group&#8217;s long-lived assets are substantially located in Singapore, no geographical segments are presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material accounting policy
                                                                                                                                   information (Continued)</span></td>
</tr></table>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000871" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForGovernmentGrants_zAuRT15sMxta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.6</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zCgyw8r1jMv5">Government
                                            grants</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
from the government are recognized as a receivable at their fair value when there is reasonable assurance that the grant will be received
and the Group will comply with all the attached conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
grants receivable are recognized as income over the periods necessary to match them with the related costs which they are intended to
compensate, on a systematic basis. Government grants relating to expenses are shown separately as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
grants relating to assets are deducted against the carrying amount of the assets.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000873" name="BMGL:DescriptionOfAccountingPolicyForBasisOfConsolidation"><p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForBasisOfConsolidation_z38KFzsEqiE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold"><span id="xdx_86D_zk2dNQCWZlJf">Basis of consolidation</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The financial statements
of the subsidiaries used in the preparation of the consolidated financial statements are prepared as of the same reporting date as the
Company. Consistent accounting policies are applied to like transactions and events in similar circumstances.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consolidation
                                            </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed
to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power
over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated
from the date on that control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements, transactions, balances and unrealized gains on transactions between group entities are
eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment indicator of the transferred
asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.
Deferred tax relief on unrealized intra-Group profit is accounted for only to the extent that it is considered recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
interests comprise the portion of a subsidiaries&#8217; net results of operations and its net assets, which is attributable to the interests
that are not owned directly or indirectly by the equity holders of the Group. They are shown separately in the consolidated statement
of profit or loss and other comprehensive income, statement of changes in equity, and statement of financial position. Total comprehensive
income is attributed to the non-controlling interests based on their respective interests in a Subsidiaries, even if this results in
the non-controlling interests having a deficit balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold">Group accounting (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisitions</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition method of accounting is used to account for business combinations entered into by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration transferred for the acquisition of a subsidiary or business comprises the fair value of the assets transferred, the liabilities
incurred and the equity interests issued by the Group. The consideration transferred also includes any contingent consideration arrangement
and any pre-existing equity interest in the subsidiaries measured at their fair values at the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognized in the income statement.
Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. The
part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within
investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition
date is reported within operating cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the consideration transferred, together with the noncontrolling interest, exceeds the fair value of the net assets, liabilities and contingent
liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in
the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is capitalized as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and
associates. Goodwill is denominated in the currency of the operation acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the cost of acquisition is below the Group&#8217;s interest in the net assets acquired, the difference is recognized directly in the
income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold">Group accounting (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
                                            (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisitions
                                            </i>(Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
not all of the equity of a subsidiary is acquired the noncontrolling interest is recognized either at fair value or at the non-controlling
interest&#8217;s share of the net assets of the subsidiary, on a case-by-case basis. Changes in the Group&#8217;s ownership percentage
of subsidiaries are accounted for within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition-related
costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifiable
assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially
at their fair values at the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
an acquisition-by-acquisition basis, the Group recognizes any non-controlling interest in the acquiree at the date of acquisition either
at fair value or at the non-controlling interest&#8217;s proportionate share of the acquiree&#8217;s identifiable net assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
excess of (a) the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair
value of any previous equity interest in the acquiree over the (b) fair value of the identifiable net assets acquired is recorded as
goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disposal</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a change in the Group&#8217;s ownership interest in a subsidiary result in a loss of control over the subsidiary, the assets and liabilities
of the subsidiary including any goodwill are derecognized. Amounts previously recognized in other comprehensive income in respect of
that entity are also reclassified to profit or loss or transferred directly to retained earnings if required by a specific Standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
retained equity interest in the entity is remeasured at fair value. The difference between the carrying amount of the retained interest
at the date when control is lost and its fair value is recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
                                            with non-controlling interests</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in the Group&#8217;s ownership interest in a subsidiary that do not result in a loss of control over the subsidiaries are accounted for
as transactions with equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest
and the fair value of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000875" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_zCo3ehzwuvge" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.8</td>
    <td style="font-weight: bold"><span id="xdx_867_zwcwUjFPi41i">Property and equipment</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">All
items of property and equipment are initially recorded at cost. Subsequent to recognition, property and equipment are measured at cost
less accumulated depreciation and any accumulated impairment losses. The cost of property and equipment includes its purchase price and
any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the
manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property and equipment
if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the property and equipment.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000877" name="BMGL:DisclosureOfDepreciationRatesExplanatory"><p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zCtkh77xqXQ3">Schedule of expected useful lives for property, plant and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt">Useful lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Machinery</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1"><ix:nonNumeric contextRef="From2024-07-012025-06-30_ifrs-full_MachineryMember" format="ixt-sec:duryear" id="Fact000878" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and Fittings</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa"><ix:nonNumeric contextRef="From2024-07-012025-06-30_ifrs-full_FixturesAndFittingsMember" format="ixt-sec:duryear" id="Fact000879" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5"><ix:nonNumeric contextRef="From2024-07-012025-06-30_ifrs-full_OtherPropertyPlantAndEquipmentMember" format="ixt-sec:duryear" id="Fact000880" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Renovation</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_RenovationMember" format="ixt-sec:duryear" id="Fact000881" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">5</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Air conditioner</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_AirConditionerMember" format="ixt-sec:duryear" id="Fact000882" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives"><ix:nonNumeric contextRef="From2024-07-012025-06-30_ifrs-full_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000884" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Software</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_SoftwareMember" format="ixt-sec:duryear" id="Fact000886" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span> years</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zvVjLwhjcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
residual values, estimated useful lives and depreciation method of property and equipment are reviewed, and adjusted prospectively, if
appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
depreciated assets are retained in the consolidated financial statements until they are no longer in use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.
Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
expenditure relating to property and equipment that has already been recognized is added to the carrying amount of the asset only when
it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured
reliably. All other repair and maintenance expenses are recognized in profit or loss when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
disposal of an item of property and equipment, the difference between the disposal proceeds and its carrying amount is recognized in
profit or loss within &#8220;other losses&#8221;. Any amount in revaluation reserve relating to that item is transferred to retained
profits directly.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>

<ix:exclude><!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000888" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"><p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zDVTBkhz5Ob" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold"><span id="xdx_863_z4k9wJFUQg4l">Financial instruments</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Initial
recognition and measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets are recognized when, and only when the entity becomes party to the contractual provisions of the instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value
through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction
costs of financial assets carried at FVPL are expensed in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are measured at the amount of consideration to which the Group expects to be entitled in exchange for transferring promised
goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant
financing component at initial recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investments
in debt instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
measurement of debt instruments depends on the Group&#8217;s business model for managing the asset and the contractual cash flow characteristics
of the asset. The three measurement categories for classification of debt instruments are amortized cost, fair value through other comprehensive
income (FVOCI) and FVPL. The Group only has debt instruments at amortized cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest
are measured at amortized cost. Financial assets are measured at amortized cost using the effective interest method, less impairment.
Gains and losses are recognized in profit or loss when the assets are derecognized or impaired, and through the amortisation process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investments
in equity instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition of an investment in equity instrument that is not held for trading, the Group may irrevocably elect to present subsequent
changes in fair value in other comprehensive income which will not be reclassified subsequently to profit or loss. Dividends from such
investments are to be recognized in profit or loss when the Group&#8217;s right to receive payments is established. For investments in
equity instruments which the Group has not elected to present subsequent changes in fair value in other comprehensive income, changes
in fair value are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold">Financial instruments (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets (Continued)</span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derecognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset is derecognized where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial
asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or
loss that had been recognized in other comprehensive income for debt instruments is recognized in profit or loss.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Initial
recognition and measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
liabilities are recognized when, and only when, the Group becomes a party to the contractual provisions of the financial instrument.
The Group determines the classification of its financial liabilities at initial recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial liabilities are recognized initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable
transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortized cost using the effective
interest method. Gains and losses are recognized in profit or loss when the liabilities are derecognized, and through the amortisation
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Borrowings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
are presented as current liabilities unless the Group has an unconditional right to defer settlement for at least 12 months after the
balance sheet date, in which case they are presented as non-current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
are initially recognized at fair value (net of transaction costs) and subsequently carried at amortized cost. Any difference between
the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using
the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold">Financial instruments (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derecognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. On derecognition,
the difference between the carrying amounts and the consideration paid is recognized in profit or loss.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000890" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zTvtswurBuz4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.10</td>
    <td style="font-weight: bold"><span id="xdx_862_ztFFXn91QRf9">Impairment of financial assets</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes an allowance for expected credit losses (&#8220;ECLs&#8221;) for all debt instruments not held at FVPL. ECLs are based
on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects
to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from
the sale of collateral held or other credit enhancements that are integral to the contractual terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition,
ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For
those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is
recognized for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
trade receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit
risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix
that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic
environment which could affect debtors&#8217; ability to pay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers a financial asset in default when contractual payments are 30 days past due. However, in certain cases, the Group may
also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive
the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is
written off when there is no reasonable expectation of recovering the contractual cash flows.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000892" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_zEbBVId9vcLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.11</td>
    <td style="font-weight: bold"><span id="xdx_868_zrGwJwras9J7">Cash and cash equivalents</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand, deposits with
financial institutions which are subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are presented
as current borrowings on the balance sheet. For cash subjected to restriction, assessment is made on the economic substance of the restriction
and whether they meet the definition of cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000894" name="BMGL:DescriptionOfAccountingPolicyForInventoriesExplanatory"><p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForInventoriesExplanatory_zqEuxNn1sUUk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.12</td>
    <td style="font-weight: bold"><span id="xdx_86A_zq3Oz7xXvOa7">Inventories</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost and net realisable value, Cost is calculated using the weighted average basis and includes all costs
of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the
estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make
the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
necessary, allowance is provided for damaged, obsolete and slow-moving item to adjust the carrying value of inventories to the lower
of cost and net realisable value.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000896" name="ifrs-full:DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory"><p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_z4i3ikD7CKWa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.13</td>
    <td style="font-weight: bold"><span id="xdx_867_z0YCIUDfVGo">Offsetting of financial instruments</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset
and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000898" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory"><p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForProvisionsExplanatory_znYA0tqHSlMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.14</td>
    <td style="font-weight: bold"><span id="xdx_86C_zS9WURuRBCS6">Provisions</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow
of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated
reliably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that
an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value
of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to
the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Asset
Retirement Obligation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes a liability and capitalize an expense in property and equipment if the Group has a present legal or constructive obligation
to reinstate the leased premises to their original state upon expiry of the lease. The provision is made based on management&#8217;s
best estimate of the expected costs to be incurred to reinstate the leased premises to their original state. The capitalized provision
for reinstatement costs in property and equipment is amortized over the period of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000900" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"><p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_zR9ayGVXiuC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.15</td>
    <td style="font-weight: bold"><span id="xdx_862_zA0TdvBE7VEi">Impairment of non-financial assets</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, (or, where
applicable, when an annual impairment testing for an asset is required), the Group makes an estimate of the asset&#8217;s recoverable
amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of all non-current assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating
unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available
for use are tested for impairment annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairments
of goodwill are not reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
asset&#8217;s recoverable amount is the higher of an asset&#8217;s or cash-generating unit&#8217;s fair value less costs of disposal
and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent
of those from other assets or group of assets. Where the carrying amount of an asset or cash-generating unit exceeds its recoverable
amount, the asset is considered impaired and is written down to its recoverable amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset&#8217;s
recoverable amount since the last impairment loss was recognized. If that is the case, the carrying amount of the asset is increased
to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had
no impairment loss been recognized previously. Such reversal is recognized in profit or loss.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000902" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zUuYUw0kOTQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.16</td>
    <td style="font-weight: bold"><span id="xdx_86B_z895DwYRVzTd">Taxes</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            income tax</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid
to the taxation authority. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted
at the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income taxes are recognized in profit or loss except to the extent that the tax relates to items recognized outside profit or loss, either
in other comprehensive income or directly in equity. Management periodically evaluates positions taken in the tax returns with respect
to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: normal; width: 0.5in"><b>2.16</b></td>
    <td style="font-weight: normal"><b>Taxes (Continued)</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: right"/><td style="width: 0.5in">(b)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
                                            tax</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided using the liability method on temporary differences at the end of the reporting date between the tax bases of assets
and liabilities and their carrying amounts for financial reporting purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability
is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current income tax assets against
current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
                                            and Services Tax (&#8220;GST&#8221;)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues,
expenses and assets are recognized net of the amount of GST except:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the GST incurred on a purchase of assets or services is not recoverable from the taxation
                                            authority, in which case the GST is recognized as part of the cost of acquisition of the
                                            asset or as part of the expense item as applicable; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receivables
                                            and payables that are stated with the amount of GST included.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement
of financial position.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000904" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory"><p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zvhp9UbmErB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zXMQr25szXsj">Leases</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control
the use of an identified asset for a period of time in exchange for consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets.
The Group recognizes lease liabilities representing the obligations to make lease payments and right-of-use assets representing the right
to use the underlying leased assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
                                            (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Right-of-use
assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on
a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option,
depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. The
accounting policy for impairment is disclosed in Note 2.15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s right-of-use assets are presented in Note 9.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating the lease, if the lease term reflects the Group exercising the option to terminate. Variable lease payments that do not
depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the
event or condition that triggers the payment occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments
resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase
the underlying asset.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
                                            (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
liabilities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s lease liabilities are included in borrowings (Note 15).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Short-term
leases and leases of low-value assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of office premises (i.e. those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognized
as expense on a straight-line basis over the lease term. The Group has no lease of low-value assets for the year.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000906" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zLbnIfLbRzwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.18</td>
    <td style="font-weight: bold"><span id="xdx_869_zErVOWCP1J1h">Currency translation</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(a)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Functional
                                            and presentation currency </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment
in which the entity operates (&#8220;functional currency&#8221;). The consolidated financial statements are presented in Singapore Dollar,
which is the functional currency of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
                                            and balances </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in a currency other than the functional currency (&#8220;foreign currency&#8221;) are translated into the functional currency using the
exchange rates at the dates of the transactions. Currency exchange differences resulting from the settlement of such transactions and
from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the end of balance
sheet date are recognized in profit or loss. Monetary items include primarily financial assets (other than equity investments), contract
assets and financial liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a foreign operation is disposed of or any loan forming part of the net investment of the foreign operation is repaid, a proportionate
share of the accumulated currency translation differences is reclassified to profit or loss, as part of the gain or loss on disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange gains and losses that relate to borrowings are presented in the income statement within &#8220;finance expense&#8221;. All other
foreign exchange gains and losses impacting profit or loss are presented in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.18</td>
    <td style="font-weight: bold">Currency translation (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
                                            and balances </i>(Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-monetary
items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(c)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Translation
                                            of Group entities&#8217; financial statements </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a
functional currency different from the presentation currency are translated into the presentation currency as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets
                                            and liabilities are translated at the closing exchange rates at the reporting date;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income
                                            and expenses are translated at average exchange rates (unless the average is not a reasonable
                                            approximation of the cumulative effect of the rates prevailing on the transaction dates,
                                            in which case income and expenses are translated using the exchange rates at the dates of
                                            the transactions); and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            resulting currency translation differences are recognized in other comprehensive income and
                                            accumulated in the currency translation reserve. These currency translation differences are
                                            reclassified to profit or loss on disposal or partial disposal with loss of control of the
                                            foreign operation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Goodwill
and fair value adjustments arising on the acquisition of foreign operations are treated as assets and liabilities of the foreign operations
and translated at the closing rates at the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Translations
of the consolidated balance sheets, consolidated statement of profit or loss and comprehensive income, consolidated statement of changes
in shareholders&#8217; equity and consolidated statements of cash flows from S$ into US$ as of and for the year ended June 30, 2025 are
solely for the convenience of the reader and were calculated at the rate of S$1 = US$1.2719, as set forth in the statistical release
of the Federal Reserve System on June 30, 2025. No representation is made that the S$ amounts could have been, or could be, converted,
realized or settled into US$ at that rate on June 30, 2025, or at any other rate.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000908" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_z1DrsIFo15i3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.19</td>
    <td style="font-weight: bold"><span id="xdx_860_zakbKSZ3qNXj">Employee benefits</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined
                                            contribution plans</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify; text-indent: -32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to
defined contribution pension schemes are recognized as an expense in the period in which the related service is performed.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.19</td>
    <td style="font-weight: bold">Employee benefits (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
                                            employee benefits</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is
recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result
of past service provided by the employee, and the obligation can be estimated reliably.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000910" name="ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_z9f4subZNxTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.20</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zAaJgTtYdHae">Derivative
                                            financial instruments</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">A
derivative financial instrument for which no hedge accounting is applied is initially recognized at its fair value on the date the contract
is entered into and is subsequently carried at its fair value. Changes in its fair value are recognized in profit or loss. The Group
does not apply hedge accounting for its derivative financial instruments.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000912" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zFFrc5tiaJS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.21</td>
    <td style="font-weight: bold"><span id="xdx_866_zyfTi1CoYnAh">Earnings per share</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share is computed by dividing net income attributable to the holders of ordinary shares by the weighted average number of
ordinary shares outstanding during the period presented. Diluted income per share is calculated by dividing net income attributable to
the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number
of ordinary shares and dilutive ordinary share equivalents outstanding during the period. However, ordinary share equivalents are not
included in the denominator of the diluted earnings per share calculation when inclusion of such shares would be anti-dilutive, such
as in a period in which a net loss is recorded.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000914" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"><p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_z7O2XohbwfEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.22</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKVVItQqxjU3">Share
                                            capital</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from issuance of ordinary shares are recognized as share capital in equity. Incremental costs directly attributable to the issuance of
ordinary shares are deducted against share capital.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000916" name="BMGL:DescriptionOfAccountingPolicyForReservesExplanatory"><p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForReservesExplanatory_zzNfiz5l0SJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zdWg2h5Q17nl">Merger
    reserve</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a business combination under common control, any difference between the consideration paid and the carrying amounts of assets and liabilities
received is presented as a change within equity and recorded under merger reserves.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000918" name="BMGL:DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_zgQ4rvBzv7Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zM5sPpJ0twd4">Deferred
    Offering cost</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers specific incremental costs directly attributable to an equity securities offering. These costs will be charged against
the gross proceeds of the offering as a reduction of additional paid-in capital. If the Company does not complete the initial public
offering, the deferred costs of the aborted offering will be deferred and charged against the proceeds of a subsequent offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    offering cost (Continued)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
costs related to an aborted offering will be expensed in the period in which the Company elects to abort the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the initial public offering, deferred offering costs, which mainly consist of direct incremental legal, auditing,
accounting, consulting, and other fees relating to the initial public offering, are capitalized on the consolidated balance sheets.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000920" name="ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForDividendsExplanatory_zt3Xm83uISgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zci6cjHtuHwc">Dividend
    to Company&#8217;s shareholders</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to the Company&#8217;s shareholders are recognized when the dividends are approved for payment.</span></p>

</ix:nonNumeric><p id="xdx_854_zriQWrLNMCxf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000922" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zXCSDbolq7Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span id="xdx_821_zy876ojIElb1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
                                            accounting judgements and estimates</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Group&#8217;s financial statements requires management to make judgments, estimates and assumptions that affect the
reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting
period. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying
amount of the asset or liability affected in the future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.1</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Judgements
                                            made in applying accounting policies </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Management
is of the opinion that there are no significant judgements made in applying accounting estimates and policies that have a significant
risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
                                            sources of estimation uncertainty </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period are discussed
below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances
and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the
Group. Such changes are reflected in the assumptions when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">3.</td>
    <td style="font-weight: bold">Significant accounting judgements and estimates (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
                                            sources of estimation uncertainty (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
                                            useful lives of property and equipment (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the property and equipment over their estimated useful lives after taking into account of their estimated residual
values. The estimated useful life reflects management&#8217;s estimate of the period that the Group intends to derive future economic
benefits from the use of the Group&#8217;s property and equipment. The residual value reflects management&#8217;s estimated amount that
the Group would currently obtain from the disposal of the asset, after deducting the estimated costs of disposal, as if the asset were
already of the age and in the condition expected at the end of its useful life. Changes in the expected level of usage and technological
developments could affect the economics, useful lives and the residual values of these assets which could then consequentially impact
future depreciation charges. The carrying amounts of the Group&#8217;s property and equipment as at June 30, 2025 and June 30, 2024 were
disclosed in Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory
                                            valuation method</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-down is made based on the current market conditions, historical experience and selling goods of similar nature. It could change
significantly as a result of changes in market conditions. A review is made periodically on inventories for excess inventories, obsolescence
and declines in net realisable value and an allowance is recorded against the inventory balances for any such declines. The realisable
value represents the best estimate of the recoverable amount and is based on the most reliable evidence available and inherently involves
estimates regarding the future expected realisable value. The carrying amount of the Company&#8217;s inventories as at June 30, 2025
was S$<span id="xdx_90B_eifrs-full--Inventories_iI_c20250630_zpsOuY8yYGE1" title="Inventories"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2025-06-30" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">376,291</ix:nonFraction></span> (US$<span id="xdx_908_eifrs-full--Inventories_iI_uUSD_c20250630_zjvjJTZUX4Z8" title="Inventories"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2025-06-30" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,850</ix:nonFraction></span>) (June 30, 2024: S$<span id="xdx_909_eifrs-full--Inventories_iI_c20240630_zq2u45m2aax7" title="Inventories"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2024-06-30" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">72,030</ix:nonFraction></span>). If the future expected realisable value was lower by 10% of its carrying amount,
the carrying amount of the Company&#8217;s inventories would have been S$<span id="xdx_902_eifrs-full--InventoriesTotal_iI_c20250630_zUHeDEWTeNHh" title="Inventories total"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="AsOf2025-06-30" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">37,629</ix:nonFraction></span> (US$<span id="xdx_90F_eifrs-full--InventoriesTotal_iI_uUSD_c20250630_zHUl9GmwG5lj" title="Inventories total"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="AsOf2025-06-30" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,585</ix:nonFraction></span>) (June 30, 2024: S$<span id="xdx_906_eifrs-full--InventoriesTotal_iI_c20240630_zZUiyrpWwaL4" title="Inventories total"><ix:nonFraction name="ifrs-full:InventoriesTotal" contextRef="AsOf2024-06-30" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,203</ix:nonFraction></span>) lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allowance
                                            for expected credit losses of trade receivables</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of
various customer segments that have similar loss patterns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision matrix is initially based on the Company&#8217;s historical observed default rates. The Company will calibrate the matrix to
adjust historical credit loss experience with forward-looking information. At every reporting date, historical default rates are updated
and changes in the forward-looking estimates are analysed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate.
The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Company&#8217;s historical credit
loss experience and forecast of economic conditions may also not be representative of customer&#8217;s actual default in the future.
The information about the ECLs on the Company&#8217;s trade receivables is disclosed in Note 23 (a). The carrying amount of the Company&#8217;s
trade receivables as at the end of each reporting period were disclosed in Note 12.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">3.</td>
    <td style="font-weight: bold">Significant accounting judgements and estimates (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
                                            sources of estimation uncertainty (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allowance
                                            for expected credit losses of other receivables </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assessed the latest performance and financial position of the counterparties, adjusted for the outlook of the industry in which
the counterparties operate in, and concluded that there had been no significant increase in credit risk since initial recognition of
the financial assets. Accordingly, the Group measured the impairment loss allowance using 12-month ECL and determined that the ECL is
insignificant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Group&#8217;s other receivables as at June 30, 2025 were S$<span id="xdx_90C_ecustom--OthersReceivables_iI_c20250630_zNZeieUc2Gac"><ix:nonFraction name="BMGL:OthersReceivables" contextRef="AsOf2025-06-30" id="Fact000935" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">206,391</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(US$<span id="xdx_903_ecustom--OthersReceivables_iI_uUSD_c20250630_zrKhZoRBu6u8"><ix:nonFraction name="BMGL:OthersReceivables" contextRef="AsOf2025-06-30" id="Fact000936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,070</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
(June 30, 2024: S$<span id="xdx_906_ecustom--OthersReceivables_iI_c20240630_zcicjvmP7p72"><ix:nonFraction name="BMGL:OthersReceivables" contextRef="AsOf2024-06-30" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">213,644</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(e)</td>
    <td style="font-weight: bold">Leases &#8211; estimating the incremental borrowing rate</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate to measure
lease liabilities. The incremental borrowing rate is the rate of interest that the Group would have to pay to borrow over a similar term,
and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic
environment. The incremental borrowing rate therefore reflects what the Group &#8216;would have to pay&#8217;, which requires estimation
when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Group estimates
the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to make certain
entity-specific estimates.<br/></span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000939" name="ifrs-full:DisclosureOfRevenueExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfRevenueExplanatory_zzVe5du4kQEg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zt9fFz8JZyg9">Revenue</span></b></span></td></tr></table>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000941" name="BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zg589ArOBNR8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zgY8SssJj8Ig">Summary
of revenue from transfer of goods and services</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zJSMp0T9YV6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230701__20240630_zxDW9goPP9qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Type of service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Revenue_hifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zUrdzqUB9b12" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">Rendering of services &#8211; Medical services</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zYny4s4eHom6" title="Rendering of services - Medical services" style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-012025-06-30_custom_MedicalServicesMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,900,027</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-012025-06-30_custom_MedicalServicesMember" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,319,944</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-07-012024-06-30_custom_MedicalServicesMember" id="Fact000944" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,050,923</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_zwFhhuC4tmV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--Revenue_uUSD_c20240701__20250630_zqPXIcZVGZpl" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-01to2025-06-30" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,900,027</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-01to2025-06-30" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,319,944</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-07-012024-06-30" id="Fact000949" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,050,923</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Timing of transfer of service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_hifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_z0kWK0HRvYI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">At a point in time</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zCubJur4o6Si" title="Rendering of services - Medical services" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,900,027</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,319,944</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-07-012024-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,050,923</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_z9YYotkhmN3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Revenue_uUSD_c20240701__20250630_zYdCNdgWixj3" title="Rendering of services - Medical services" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-01to2025-06-30" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,900,027</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2024-07-01to2025-06-30" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,319,944</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Revenue" contextRef="From2023-07-012024-06-30" id="Fact000959" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,050,923</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z0fN8uP1JDLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000963" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory"><p id="xdx_806_eifrs-full--DisclosureOfOtherOperatingIncomeExplanatory_zSDob4D2DEI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zDNDgc47SXNa">Other
income</span></b></span></td></tr></table>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000965" name="BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory"><p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_z0EGt6Y88i3d" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zmEFHk4BxpAd" style="display: none">Schedule
of Other income</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zQcI36fMgvjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230701__20240630_zl8VqLXIeAnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--RevenueFromGovernmentGrants_maOGLzcHg_z6yPseML2Gs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Government grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--RevenueFromGovernmentGrants_uUSD_c20240701__20250630_zsA5obhFXjpj" title="Government grant" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromGovernmentGrants" contextRef="From2024-07-01to2025-06-30" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,003</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromGovernmentGrants" contextRef="From2024-07-01to2025-06-30" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">75,046</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromGovernmentGrants" contextRef="From2023-07-012024-06-30" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">19,600</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--RevenueFromInterest_maOGLzcHg_zqQgjS01vjrl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RevenueFromInterest_uUSD_c20240701__20250630_zx992W9DYSwh" title="Interest income" style="text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2024-07-01to2025-06-30" id="Fact000975" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2024-07-01to2025-06-30" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">83,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ServiceIncome_maOGLzcHg_zvK55TG9uJh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Service income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ServiceIncome_uUSD_c20240701__20250630_zIoypFFBAt42" title="Service income" style="text-align: right"><ix:nonFraction name="BMGL:ServiceIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:ServiceIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RentalIncome_maOGLzcHg_zxgglFPtjw4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eifrs-full--RentalIncome_uUSD_c20240701__20250630_zR3YwcLNx32j" title="Rental income" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:RentalIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,469</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:RentalIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000982" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">157,040</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eifrs-full--OtherIncome_maOGLzcHg_ztN1apPL8Wk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--OtherIncome_uUSD_c20240701__20250630_z5Pd0wSjebmg" title="Other income" style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">591,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2024-07-01to2025-06-30" id="Fact000987" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">751,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:OtherIncome" contextRef="From2023-07-012024-06-30" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">385,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ReversalOfExpectedCreditLosses_maOGLzcHg_zS8tDxfRHIaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Reversal of ECL</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ReversalOfExpectedCreditLosses_uUSD_c20240701__20250630_ziAFvIafIb3d" title="Reversal of ECL" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:ReversalOfExpectedCreditLosses" contextRef="From2023-07-012024-06-30" id="Fact000993" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">55,741</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherGainsLosses_iT_mtOGLzcHg_zbSfOr8b8zV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--OtherGainsLosses_iT_uUSD_c20240701__20250630_zEDsJGfzVwpe" title="Other income" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherGainsLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherGainsLosses" contextRef="From2024-07-01to2025-06-30" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,102,203</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherGainsLosses" contextRef="From2023-07-012024-06-30" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">461,029</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zRlA7XZO8Ka9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Other
income pertains to the reversal of long-outstanding payables which are no longer considered due. The reversal was made after confirming
that no obligation remains, as no claims or demands have been received from the creditors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001002" name="ifrs-full:DisclosureOfFinanceCostExplanatory"><p id="xdx_803_eifrs-full--DisclosureOfFinanceCostExplanatory_zxWbvWEIfUAe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zWoDLbfTk727">Finance
cost</span></b></span></td></tr></table>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001004" name="BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory"><p id="xdx_897_ecustom--DisclosureOfDetailedInformationAboutFinanceCostExplanatory_zqI950I3xYy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zFJdkm8yEad1" style="display: none">Schedule
of Finance cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240701__20250630_zotMZH6LvfGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230701__20240630_zg6OGOwTaZC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense on:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--InterestExpenseOnBorrowings_maFCzCYG_zZQBUxzFcZ27" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">- Bank borrowings</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zvn8O8rQdoyi" title="Interest expense on bank borrowings" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="From2024-07-01to2025-06-30" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,960</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="From2024-07-01to2025-06-30" id="Fact001006" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">88,982</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="From2023-07-012024-06-30" id="Fact001007" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">160,777</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--InterestExpenseOnBorrowings_zZhIxQtlxiuj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense on bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zLX1Qsmi04Y2" title="Interest expense on bank borrowings" style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="From2024-07-01to2025-06-30" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="From2024-07-01to2025-06-30" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">88,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnBorrowings" contextRef="From2023-07-012024-06-30" id="Fact001012" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">160,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eifrs-full--InterestExpenseOnLeaseLiabilities_maFCzCYG_z2K4eUN2YWag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">- Lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zfQIkmOnEqP7" title="Interest expenses on lease liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact001019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact001016" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">114,966</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2023-07-012024-06-30" id="Fact001017" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">15,461</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--InterestExpenseOnLeaseLiabilities_zlGBw0jgAxJh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense on lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zk5ryB9OmTj7" title="Interest expenses on lease liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact001021" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">114,966</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2023-07-012024-06-30" id="Fact001022" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">15,461</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eifrs-full--FinanceCosts_iT_mtFCzCYG_zgNgOQGrKinf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Finance costs</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinanceCosts_iT_uUSD_c20240701__20250630_zUmPJJUe9kOe" title="Finance costs" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2024-07-01to2025-06-30" id="Fact001029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2024-07-01to2025-06-30" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">203,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2023-07-012024-06-30" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">176,238</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zAgV9K51z6xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001031" name="BMGL:DisclosureOfProfitLossBeforeTaxExplanatory"><p id="xdx_809_ecustom--DisclosureOfProfitLossBeforeTaxExplanatory_zYF8sn4ILxRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zDDXbMHmOd9f">(Loss)/Profit before tax</span></b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001033" name="BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory"><p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_z2CvdijwpRu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
before tax has been arrived at after charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zV56QQ3MPSJ9" style="display: none">Schedule
of Profit before tax</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zfQRdLsNeQr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zMrtXK5Z5jl5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--SalesAndMarketingExpense_zm4fxnBkkNl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Marketing and advertisement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--SalesAndMarketingExpense_uUSD_c20240701__20250630_zXo0mueiFFY8" title="Marketing and advertisement" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:SalesAndMarketingExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,960</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:SalesAndMarketingExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001035" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">611,733</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:SalesAndMarketingExpense" contextRef="From2023-07-012024-06-30" id="Fact001036" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">698,336</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ProfessionalFeesExpense_zP0bwYtAUvi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProfessionalFeesExpense_uUSD_c20240701__20250630_ztynUwXJj6Q2" title="Legal and professional fees" style="text-align: right"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001040" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">243,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2023-07-012024-06-30" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">426,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--InsuranceExpense_zO1q2E0mtfTg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InsuranceExpense_uUSD_c20240701__20250630_zDSZI0xvCkbb" title="Insurance" style="text-align: right"><ix:nonFraction name="ifrs-full:InsuranceExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InsuranceExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001045" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">342,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InsuranceExpense" contextRef="From2023-07-012024-06-30" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">48,112</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TransportationExpense_zR68IiE1L9Nc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transportation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--TransportationExpense_uUSD_c20240701__20250630_zeqSo1EN0jRc" title="Transportation" style="text-align: right"><ix:nonFraction name="ifrs-full:TransportationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TransportationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001050" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">44,248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TransportationExpense" contextRef="From2023-07-012024-06-30" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">38,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BadDebtsWrittenOff_zGWzKyGGE3Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debts written off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--BadDebtsWrittenOff_uUSD_c20240701__20250630_z03E7GGYrOV7" title="Bad debts written off" style="text-align: right"><ix:nonFraction name="BMGL:BadDebtsWrittenOff" contextRef="From2024-07-01to2025-06-30" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:BadDebtsWrittenOff" contextRef="From2024-07-01to2025-06-30" id="Fact001055" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">240,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProvisionForExpectedCreditLosses_zEvrB05ZeEIj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for expected credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ProvisionForExpectedCreditLosses_uUSD_c20240701__20250630_zOYlbTczwA79" title="Provision for expected credit losses" style="text-align: right"><ix:nonFraction name="BMGL:ProvisionForExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">536,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:ProvisionForExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">682,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:ProvisionForExpectedCreditLosses" contextRef="From2023-07-012024-06-30" id="Fact001061" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">50,168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--DepreciationPropertyPlantAndEquipment_zwKE2H3odbXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--DepreciationOfPropertyAndEquipment_uUSD_c20240701__20250630_zG5S3Y8cTakf" title="Depreciation of property and equipment" style="text-align: right"><ix:nonFraction name="BMGL:DepreciationOfPropertyAndEquipment" contextRef="From2024-07-01to2025-06-30" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,174</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-01to2025-06-30" id="Fact001065" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">107,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30" id="Fact001066" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">30,093</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--AmortisationExpense_zW5o3xpAYzx1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortisation of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--AmortisationExpense_uUSD_c20240701__20250630_zJ3QwWOoYRkc" title="Amortisation of right-of-use assets" style="text-align: right"><ix:nonFraction name="ifrs-full:AmortisationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">843,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AmortisationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001070" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,073,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AmortisationExpense" contextRef="From2023-07-012024-06-30" id="Fact001071" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">498,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--RecruitmentExpenses_z2IYbQCtdvt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recruitment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--RecruitmentExpenses_uUSD_c20240701__20250630_zyvbvwS5XRIc" title="Recruitment" style="text-align: right"><ix:nonFraction name="BMGL:RecruitmentExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact001078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:RecruitmentExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact001075" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:RecruitmentExpenses" contextRef="From2023-07-012024-06-30" id="Fact001076" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">131,786</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--SubscriptionCirculationRevenue_zF79tmeO4j6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Membership and subscription</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--SubscriptionCirculationRevenue_uUSD_c20240701__20250630_zuJkoceV38bi" title="Membership and subscription" style="text-align: right"><ix:nonFraction name="ifrs-full:SubscriptionCirculationRevenue" contextRef="From2024-07-01to2025-06-30" id="Fact001083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,207</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:SubscriptionCirculationRevenue" contextRef="From2024-07-01to2025-06-30" id="Fact001080" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">20,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:SubscriptionCirculationRevenue" contextRef="From2023-07-012024-06-30" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">38,919</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TelephoneExpense_zgw0ybXBITj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Telephone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--TelephoneExpense_uUSD_c20240701__20250630_z3EWC2y2vs6j" title="Telephone" style="text-align: right"><ix:nonFraction name="BMGL:TelephoneExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,689</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:TelephoneExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001085" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">41,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:TelephoneExpense" contextRef="From2023-07-012024-06-30" id="Fact001086" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">32,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EmployeeBenefitsExpenses_zPLHIBxTBCua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefit expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DirectorsSalariesAndBonuses_z2F7ar6XH5C9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Director&#8217;s salaries and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--DirectorsSalariesAndBonuses_uUSD_c20240701__20250630_zJyZVBgcyzv5" title="Director's salaries and bonuses" style="text-align: right"><ix:nonFraction name="BMGL:DirectorsSalariesAndBonuses" contextRef="From2024-07-01to2025-06-30" id="Fact001096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DirectorsSalariesAndBonuses" contextRef="From2024-07-01to2025-06-30" id="Fact001093" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">333,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DirectorsSalariesAndBonuses" contextRef="From2023-07-012024-06-30" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">121,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DirectorsCentralProvidentFund_zrcNNKeVszLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Director&#8217;s CPF</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DirectorsCentralProvidentFund_uUSD_c20240701__20250630_zLRb1v9xpyNk" title="Director's CPF" style="text-align: right"><ix:nonFraction name="BMGL:DirectorsCentralProvidentFund" contextRef="From2024-07-01to2025-06-30" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DirectorsCentralProvidentFund" contextRef="From2024-07-01to2025-06-30" id="Fact001098" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">30,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DirectorsCentralProvidentFund" contextRef="From2023-07-012024-06-30" id="Fact001099" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--EmployeesSalariesAndBonus_zonympWtyKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Employees&#8217; salaries and bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--EmployeesSalariesAndBonus_uUSD_c20240701__20250630_z0jOwS3HTZP" title="Employees' salaries and bonus" style="text-align: right"><ix:nonFraction name="BMGL:EmployeesSalariesAndBonus" contextRef="From2024-07-01to2025-06-30" id="Fact001106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,773,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:EmployeesSalariesAndBonus" contextRef="From2024-07-01to2025-06-30" id="Fact001103" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,799,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:EmployeesSalariesAndBonus" contextRef="From2023-07-012024-06-30" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,218,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeesCentralProvidentFund_zY7HxnES0T58" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Employees&#8217; CPF</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EmployeesCentralProvidentFund_uUSD_c20240701__20250630_zWqqeuA7E587" title="Employees' CPF" style="text-align: right"><ix:nonFraction name="BMGL:EmployeesCentralProvidentFund" contextRef="From2024-07-01to2025-06-30" id="Fact001111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:EmployeesCentralProvidentFund" contextRef="From2024-07-01to2025-06-30" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">440,539</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:EmployeesCentralProvidentFund" contextRef="From2023-07-012024-06-30" id="Fact001109" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">177,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherStaffExpenses_zLJfRmX5698b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Other staff expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--OtherStaffExpenses_uUSD_c20240701__20250630_zWuFaLYtWFXk" title="Other staff expenses" style="text-align: right"><ix:nonFraction name="BMGL:OtherStaffExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact001116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:OtherStaffExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact001113" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">848,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:OtherStaffExpenses" contextRef="From2023-07-012024-06-30" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">121,576</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A7_zs4kmrQapNAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001118" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfIncomeTaxExplanatory_zmye4p91Mzl3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zegVTmqWCEWc">Income
tax (benefit)/expense</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001120" name="BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory"><p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_zKRKvpvLPn99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
major components of income tax expense recognized in profit or loss for the periods ended June 30, 2025 and 2024 were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B4_zOkcU8aJDK4g" style="display: none">Schedule
of component of income tax expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_z72t25CmNjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230701__20240630_zX7SCv2fJ87k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB_zP0ofMd8SLu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncome_maITECOzPgr_z05qB93wkJF1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- Current year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentTaxExpenseIncome_uUSD_c20240701__20250630_zO3fmtjagek9" title="- Current year" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2023-07-012024-06-30" id="Fact001126" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">383,453</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DeferredTaxExpenseIncome_maITECOzPgr_ztHkHoRmRErc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Deferred income tax</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DeferredTaxExpenseIncome_uUSD_c20240701__20250630_z9A8WG1h4nVb" title="- Deferred income tax" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="color: red; text-align: left">&#160;</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="color: red; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="From2023-07-012024-06-30" id="Fact001131" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">49,440</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzPgr_zQdnspfq28F6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    Underprovision in respect of prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zXgXqyvHf8mb" title="-Underprovision in respect of prior years" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="BMGL:UnderprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="BMGL:UnderprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001135" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">355</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OverprovisionInRespectOfPriorYears_maITECOzPgr_zgZj4BoOjNTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">- Overprovision in respect of prior years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zKFKwIK4YRt1" title="- Overprovision in respect of prior years" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OverprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001143" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OverprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001140" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">417,748</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OverprovisionInRespectOfPriorYears" contextRef="From2023-07-012024-06-30" id="Fact001141" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">2,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzPgr_zcGFYykKQDHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (benefit)/expense recognized in profit or loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zm5SOzgYM9vk" title="Income tax (benefit)/expense recognized in profit or loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-01to2025-06-30" id="Fact001148" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-01to2025-06-30" id="Fact001145" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">417,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2023-07-012024-06-30" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">331,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><p id="xdx_8AB_zqYqJuh9TNFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Relationship
between tax expense and accounting profit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001150" name="BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory"><p id="xdx_89A_ecustom--DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_zc1V0F7XMD5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation between tax expense and the product of accounting (loss)/profit multiplied by the applicable corporate tax rate for the financial
periods ended June 30, 2025 and 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8BE_zctMmdtSK9Sj" style="display: none">Schedule of reconciliation
between tax expense and corporate tax rate</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zyTwNGAOVeO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230701__20240630_ztlWz7Vx54xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_zd7CrxkW0Ep8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">(Loss)/Profit before tax</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProfitLossBeforeTax_uUSD_c20240701__20250630_zwiWeCGx3CBc" title="(Loss)/Profit before tax" style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact001155" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,832,138</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact001152" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">12,505,497</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-07-012024-06-30" id="Fact001153" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,404,561</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_maITECOzdOp_zaUAzDhHu467" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax using the statutory tax rate of <span id="xdx_90F_eifrs-full--ApplicableTaxRate_pid_dp_c20240701__20250630_zJjAnKz6suE1" title="Statutory tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2024-07-01to2025-06-30" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>% (2024: <span id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_c20230701__20240630_zoshOBeXpck6" title="Statutory tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2023-07-012024-06-30" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_uUSD_c20240701__20250630_zJXyOze5Zkke" title="Income tax using the statutory tax rate of 17% (2024: 17%)" style="text-align: right">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="From2024-07-01to2025-06-30" id="Fact001164" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,671,463</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="From2024-07-01to2025-06-30" id="Fact001157" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">2,125,934</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="From2023-07-012024-06-30" id="Fact001158" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">408,775</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effects of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NondeductibleExpenses_maITECOzdOp_zt9IEb2eZ20i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--NondeductibleExpenses_uUSD_c20240701__20250630_zRRkNWd47233" title="Non-deductible expenses" style="text-align: right"><ix:nonFraction name="BMGL:NondeductibleExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact001169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,661,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:NondeductibleExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,113,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:NondeductibleExpenses" contextRef="From2023-07-012024-06-30" id="Fact001167" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">16,416</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TaxEffectOfTaxLosses_maITECOzdOp_zUJpTY9br8C2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Income not subject to tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--TaxEffectOfTaxLosses_uUSD_c20240701__20250630_z8toyypwFmve" title="Income not subject to tax" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2023-07-012024-06-30" id="Fact001172" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">83,039</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxExemption_maITECOzdOp_z4Ao0HfzyZ85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Income tax exemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--IncomeTaxExemption_uUSD_c20240701__20250630_zndnrXr1Xlp2" title="Income tax exemption" style="text-align: right">(<ix:nonFraction name="BMGL:IncomeTaxExemption" contextRef="From2024-07-01to2025-06-30" id="Fact001179" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:IncomeTaxExemption" contextRef="From2024-07-01to2025-06-30" id="Fact001176" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">17,425</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:IncomeTaxExemption" contextRef="From2023-07-012024-06-30" id="Fact001177" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">75,350</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--UtilisationOfCapitalAllowance_iN_di_msITECOzdOp_zPlXDmzsos7h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Utilisation of capital allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UtilisationOfCapitalAllowance_iN_di_uUSD_c20240701__20250630_zFbhGVB59ool" title="(Loss)/Profit before tax" style="text-align: right">(<ix:nonFraction name="BMGL:UtilisationOfCapitalAllowance" contextRef="From2024-07-01to2025-06-30" id="Fact001184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:UtilisationOfCapitalAllowance" contextRef="From2024-07-01to2025-06-30" id="Fact001181" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">449</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:UtilisationOfCapitalAllowance" contextRef="From2023-07-012024-06-30" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,322</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--UtilisationOfDeferredTaxAssets_maITECOzdOp_zA18jw3pPKTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Utilisation of deferred tax assets not recognised in prior year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--UtilisationOfDeferredTaxAssets_uUSD_c20240701__20250630_z9s7XwgAYLPe" title="- Utilisation of deferred tax assets not recognised in prior year" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:UtilisationOfDeferredTaxAssets" contextRef="From2023-07-012024-06-30" id="Fact001187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">56,037</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_maITECOzdOp_zKr6icq0bUKc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Deferred tax asset not recognized during the financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_uUSD_c20240701__20250630_zj9zG7k3N1R9" title="Deferred tax asset not recognized during the financial year" style="text-align: right"><ix:nonFraction name="BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001191" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">30,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses" contextRef="From2023-07-012024-06-30" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,932</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredIncomeTax_iN_di_msITECOzdOp_zSAuB8w5MtCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Deferred income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DeferredIncomeTax_iN_di_uUSD_c20240701__20250630_ziuDHctyStcg" title="Deferred income tax" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:DeferredIncomeTax" contextRef="From2023-07-012024-06-30" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">49,440</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzdOp_zysRGi0csu04" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-Underprovision
    in respect of prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zwZekJQntUE2" title="Underprovision in respect of prior years" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="BMGL:UnderprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="BMGL:UnderprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">355</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--OverprovisionInRespectOfPriorYears_maITECOzdOp_zKEwAKwgm2T9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">-Overprovision in respect of prior years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zAS0PfjbLWgj" title="Overprovision in respect of prior years" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OverprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OverprovisionInRespectOfPriorYears" contextRef="From2024-07-01to2025-06-30" id="Fact001206" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">417,748</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OverprovisionInRespectOfPriorYears" contextRef="From2023-07-012024-06-30" id="Fact001207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">2,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzdOp_zodhLq0HOyjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (benefit)/expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zhUZeXA4zcZ1" title="Income tax (benefit)/expense" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-01to2025-06-30" id="Fact001214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-01to2025-06-30" id="Fact001211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">417,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2023-07-012024-06-30" id="Fact001212" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">331,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zTjUPeBSFAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001216" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_ziJAZW2Jaev9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">9.</td>
    <td style="font-weight: bold"><span id="xdx_821_zhD4feFeuw2k">Right of use assets</span></td></tr>
  </table>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001218" name="BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOfRightOfUseAssets_zcL0wtpCbpq7" style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B9_zyvUX4DjkF5b" style="display: none">Schedule of Right of use assets</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240701__20250630_zo6f1W5XaOWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230701__20240630_zDyKh9Q68n93" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zjygkYC3N1Ok" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">At beginning of financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zj5MhPtewhta" title="At beginning of financial year" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,164,551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001220" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,753,093</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,753,093</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zshkwbPYjof4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlkes6T5WX77" title="Additions" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,575,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001225" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,275,940</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z58CQbzBjFf7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Additions" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zqreUGnhhKWb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zJ7F3mhHJ3Nl" title="Acquisition" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,793,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001233" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,825,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zxxlgJhDChf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z8MmI9xatuU6" title="Written off" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffRightofuseAssets" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001241" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,118,402</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffRightofuseAssets" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001238" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,966,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zeomylu1puM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z2XJujeLn8Qh" title="At end of financial year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,415,473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001243" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,887,940</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001244" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,753,093</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_z7buZQ04Tbw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">At beginning of financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zepWJUzLP7Za" title="At beginning of financial year" style="text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30_custom_AccumulatedDepreciationMember" id="Fact001251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,146,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30_custom_AccumulatedDepreciationMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,729,633</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2023-06-30_custom_AccumulatedDepreciationMember" id="Fact001249" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,230,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zwpUEpQBLFs2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zTsadXuGUNk9" title="Acquisition" style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets" contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember" id="Fact001256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,902,285</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets" contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember" id="Fact001253" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,691,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zfijastsiDWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zVIs6xVq42Gk" title="Depreciation" style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember" id="Fact001261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">843,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember" id="Fact001258" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,073,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">498,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zi1KIc4mhLS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zYi5sbWCSxW8" title="Written off" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffRightofuseAssets" contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember" id="Fact001266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,974,369</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffRightofuseAssets" contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember" id="Fact001263" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,783,101</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zKF5m2yJUibl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zE4LvUsnRXf5" title="At end of financial year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30_custom_AccumulatedDepreciationMember" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,918,011</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30_custom_AccumulatedDepreciationMember" id="Fact001268" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,711,418</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30_custom_AccumulatedDepreciationMember" id="Fact001269" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,729,633</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--RightofuseAssets_iE_zmeDaEoioJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Carrying amount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zxwq0muk8QL9" title="At end of financial year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30" id="Fact001276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,497,462</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,176,522</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30" id="Fact001274" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">23,460</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--RightofuseAssets_iE_zRhvBajuORCf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zjNFvH4G7Eog" title="At end of financial year" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30" id="Fact001281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,497,462</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2025-06-30" id="Fact001278" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,176,522</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-06-30" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">23,460</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AB_zQ6GOtM1Symc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001283" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory"><p id="xdx_806_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zgtPu5hYnpsa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">10.</td>
    <td style="font-weight: bold"><span id="xdx_82C_zEInHxyAxPcg">Property and equipment</span></td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001285" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"><p id="xdx_89B_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zuLG4kYM29k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zZwBvvjCIXla" style="display: none">Schedule
of Property and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--MachineryMember_zeOKGw84jUB6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Machinery</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--FixturesAndFittingsMember_zu3TCMeEiIui" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Furniture</b></span></p>
                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&amp;
                                            Fittings</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--MedicalEquipmentMember_znlea5dKw731" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Medical</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">equipment</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RenovationMember_z5q4WpdegFRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Renovation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--AirConditionerMember_zpJcwKQZIC31" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Air</b></span></p>
                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>conditioner</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--ComputerAndOfficeEquipmentMember_zau2Ezgx4pfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Computer</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">&amp; office</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">equipment</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--SoftwareMember_zUtHsdyzLZM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Software</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_zr61neq8C6rk" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zCZ5v7VZxk91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; width: 20%">At July 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">47,226</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="Fact001289" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">86,724</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="Fact001290" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">405,349</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">43,727</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001292" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">350,248</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,034,126</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zDaOUZgqvRbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001301" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,920</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,920</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zanp3BM2OHT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="Fact001305" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">47,226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="Fact001306" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,852</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="Fact001307" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">86,724</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="Fact001308" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">405,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="Fact001309" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">43,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001310" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">358,168</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001312" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,042,046</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zm91ZHPlscU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">Acquisition</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">367,243</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,500,493</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="Fact001317" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,285,136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">378,669</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="Fact001320" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">86,978</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001321" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,618,519</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zw18jBJKfOPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="Fact001325" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">13,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="Fact001326" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">21,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001328" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">20,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001330" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">54,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zsRdT3QzTkZg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    off</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">313,691</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="Fact001334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">709,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="Fact001335" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">315,832</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001337" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">253,806</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="Fact001338" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">9,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,601,659</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlTKXLdOqJSe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iE_zquz533acuMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember" id="Fact001350" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">47,226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember" id="Fact001351" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">154,404</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember" id="Fact001352" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">890,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,396,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember" id="Fact001354" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">43,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">503,145</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember" id="Fact001356" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">77,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,113,666</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zvLDGdQ3vFN1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At July 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="Fact001359" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">47,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">75,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001362" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">363,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="Fact001363" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">43,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">346,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">977,440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zmKIBQalHaZf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001370" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,888</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001371" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">18,431</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1374">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001375" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">30,093</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zzLVbLoEvcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">47,226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001378" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">100,664</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">81,533</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001380" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">382,200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">43,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001382" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">352,183</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001384" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,007,533</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zFfyPNabMaLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001387" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">277,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001388" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,244,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001389" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,192,766</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001391" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">317,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="Fact001392" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">83,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,116,339</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zCHxEv3eKnQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001397" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">50,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001398" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001400" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">25,347</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="Fact001401" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DepreciationPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001402" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">107,659</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zUoBhUuwjYa6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001405" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">248,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001406" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">687,468</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001407" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">231,410</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">220,994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="Fact001410" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">7,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,395,372</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iE_zmfezmVF0xVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember" id="Fact001413" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">47,226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember" id="Fact001414" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">137,072</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">688,904</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember" id="Fact001416" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,368,084</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">43,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember" id="Fact001418" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">474,280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">76,866</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation" contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember" id="Fact001420" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,836,159</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net book values</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20230701__20240630_eifrs-full--PropertyPlantAndEquipment_iE_zTAn0Sf9Wfsf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1422">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_ifrs-full_FixturesAndFittingsMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">188</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_custom_MedicalEquipmentMember" id="Fact001424" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_custom_RenovationMember" id="Fact001425" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">23,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30_custom_ComputerAndOfficeEquipmentMember" id="Fact001427" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,985</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2024-06-30" id="Fact001429" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">34,513</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_zvQBYqEaqWX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember" id="Fact001432" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">17,332</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_MedicalEquipmentMember" id="Fact001433" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">202,084</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_RenovationMember" id="Fact001434" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,114</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_ComputerAndOfficeEquipmentMember" id="Fact001436" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,865</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_SoftwareMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,112</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact001438" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">277,507</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">US$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_uUSD_zNRoMjmXqZC6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_MedicalEquipmentMember" id="Fact001442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,884</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_RenovationMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,104</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_ComputerAndOfficeEquipmentMember" id="Fact001445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,694</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30_custom_SoftwareMember" id="Fact001446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">874</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,183</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




</ix:nonNumeric><p id="xdx_8AE_zJN5oUmqopW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001449" name="ifrs-full:DisclosureOfInventoriesExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfInventoriesExplanatory_zktgVVJjpAJ9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">11.</td>
    <td style="font-weight: bold"><span id="xdx_822_zS6cZbecu4sc">Inventories</span></td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001451" name="BMGL:DisclosureOfDetailedInformationAboutInventoriesExplanatory"><p id="xdx_894_ecustom--DisclosureOfDetailedInformationAboutInventoriesExplanatory_z7nkwaMszD7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8BC_zy27EmEnCk38" style="display: none">Schedule
of Inventories</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zjXZUJMhFMC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zjoFjHzeNLT6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Statement of financial position:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Inventories_iI_uSGD_zhGCMKEYdCgi" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">Medicine,drugs and medical devices</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--Inventories_iI_uUSD_c20250630_zUP6NJDGidO1" title="Medicine,drugs and medical devices" style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2025-06-30" id="Fact001456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,850</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2025-06-30" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">376,291</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:Inventories" contextRef="AsOf2024-06-30" id="Fact001454" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">72,030</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Statement of comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Inventories recognized as an expense in cost of sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uUSD_c20240701__20250630_zjPs8IGJFiue" title="Inventories recognized as an expense in cost of sales" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="From2024-07-01to2025-06-30" id="Fact001458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">517,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20240701__20250630_z7srhafeFRTf" title="Inventories recognized as an expense in cost of sales" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="From2024-07-01to2025-06-30" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">658,479</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20230701__20240630_zquxUcgjmjg8" title="Inventories recognized as an expense in cost of sales" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" contextRef="From2023-07-012024-06-30" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">637,037</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zCyvn2N2Km6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001464" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zwS8tszNcRN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">12.</td>
    <td style="font-weight: bold"><span id="xdx_827_zTbDVgTq3op1">Trade and other receivables</span></td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001466" name="BMGL:DisclosureOfTradeAndOtherReceivableExplanatory"><p id="xdx_896_ecustom--DisclosureOfTradeAndOtherReceivableExplanatory_zProBPpufZgc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zVkSvGDeOPR7" style="display: none">Schedule
of trade and other receivables</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zLxTTTndWmGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_z02274trgh3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade receivables:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentTradeReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zS5i1iY7nyT3" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- third parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentTradeReceivables_iS_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zeAT30Q6n6m8" title="Trade receivables - third parties" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="AsOf2025-06-30_custom_ThridPartiesMember" id="Fact001471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="AsOf2025-06-30_custom_ThridPartiesMember" id="Fact001468" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,281,902</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="AsOf2024-06-30_custom_ThridPartiesMember" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,133,573</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uSGD_z26AmgvKnYH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Allowance for expected credit loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uUSD_c20250630_zsAyMoFdVC33" title="Less: Allowance for expected credit loss" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2025-06-30" id="Fact001476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">781,133</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2025-06-30" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">993,524</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2024-06-30" id="Fact001474" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">460,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--TradeReceivables_iI_uSGD_zPY9oXipJrh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Receivables</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--TradeReceivables_iI_uUSD_c20250630_zdD1YLxBAWcg" title="Trade Receivables" style="text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30" id="Fact001481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,799,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30" id="Fact001478" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,288,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30" id="Fact001479" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,673,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LongtermDeposits_iI_uSGD_z9Yjqdoe3dB7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630_zInmKCnGFL1h" title="Deposits" style="text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30" id="Fact001486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,362,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30" id="Fact001483" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,820,731</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2024-06-30" id="Fact001484" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">90,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--Prepayments_iI_uSGD_zUR4bP5ubSvj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--Prepayments_iI_uUSD_c20250630_z4Vbs8my1Yma" title="Prepayments" style="text-align: right"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="AsOf2025-06-30" id="Fact001491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="AsOf2025-06-30" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">415,890</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="AsOf2024-06-30" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherCurrentReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zLMVm3xS6ZJ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--OtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_z7Iu2zWVZEo6" title="Other receivables - third parties" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2025-06-30_custom_ThridPartiesMember" id="Fact001496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,070</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2025-06-30_custom_ThridPartiesMember" id="Fact001493" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">206,391</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2024-06-30_custom_ThridPartiesMember" id="Fact001494" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">213,644</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentReceivables_iI_uSGD_zYE5waP2kkl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other receivables</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"/><td id="xdx_98C_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630_z2plWLQfMay8" title="Trade and other receivables" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30" id="Fact001501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,651,065</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30" id="Fact001498" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,731,390</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30" id="Fact001499" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,005,219</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zuYuNN2ctVzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Trade
receivables are unsecured, non-interest bearing and are generally on 60 days terms (June 30, 2024: 60 days).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">There
is no other class of financial assets that is past due and/or impaired except for trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Trade
and other receivables are denominated in Singapore Dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
deposits include payments made for custodian services amounting to S$<span id="xdx_90D_eifrs-full--LongtermDeposits_iI_uSGD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CustodianServicesMember_zfOGA0XGYu72" title="Deposits"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_custom_CustodianServicesMember" id="Fact001503" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,300,375</ix:nonFraction></span> (US$<span id="xdx_90D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CustodianServicesMember_zIyQs06tbUU" title="Deposits"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_custom_CustodianServicesMember" id="Fact001505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,683,776</ix:nonFraction></span>), which are classified as non-financial
assets and earmarked for use in upcoming mergers and acquisitions within the Singapore market.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"></p>

<ix:exclude><!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">12.</td>
    <td style="font-weight: bold">Trade and other receivables (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001507" name="ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory"><p id="xdx_89E_eifrs-full--DisclosureOfAllowanceForCreditLossesExplanatory_z6LgFI7dcwuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
movement in allowance for expected credit losses of trade receivables computed based on lifetime ECL was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zFOP7QBl50D6" style="display: none">Schedule
of movement in allowance for expected credit losses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630_zfCV8pkMULRf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20240630_zg9SJ7kNNHCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--AllowanceForExpectedCreditLoss_iS_uSGD_z77Y7vyaYfW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Beginning of financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iS_uUSD_c20240701__20250630_zs9ZH5cHIPNf" style="width: 14%; text-align: right"><ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2024-06-30" id="Fact001511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,988</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2024-06-30" id="Fact001509" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">460,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2023-06-30" id="Fact001510" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">465,986</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AdditionAllowanceForExpectedCreditLosses_uSGD_zbPPBjasV45a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for expected credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--AdditionAllowanceForExpectedCreditLosses_uUSD_c20240701__20250630_zYZyCn3xbuDh" style="text-align: right"><ix:nonFraction name="BMGL:AdditionAllowanceForExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">536,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:AdditionAllowanceForExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001513" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">682,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:AdditionAllowanceForExpectedCreditLosses" contextRef="From2023-07-012024-06-30" id="Fact001514" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">50,168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uSGD_zCTBSfgSGGGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Reversal of allowance for expected credit losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uUSD_c20240701__20250630_z2IQK6Qs4WWi" title="Less: Reversal of allowance for expected credit losses" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:ReversalOfAllowanceForExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:ReversalOfAllowanceForExpectedCreditLosses" contextRef="From2024-07-01to2025-06-30" id="Fact001517" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">149,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:ReversalOfAllowanceForExpectedCreditLosses" contextRef="From2023-07-012024-06-30" id="Fact001518" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">55,741</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--AllowanceForExpectedCreditLoss_iE_uSGD_zSUBdrh9wBva" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">End of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForExpectedCreditLoss_iE_uUSD_c20240701__20250630_zXdSXVDETDOl" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2025-06-30" id="Fact001524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">781,133</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2025-06-30" id="Fact001522" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">993,524</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:AllowanceForExpectedCreditLoss" contextRef="AsOf2024-06-30" id="Fact001523" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">460,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zT5V0tyIHCul" style="margin-top: 0; margin-bottom: 0">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001526" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory"><p id="xdx_802_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_z90t0Y05TjLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">13.</td>
    <td style="font-weight: bold"><span id="xdx_826_zzcIM0A7ZxYi">Cash and cash equivalents</span></td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001528" name="BMGL:DisclosureOfCashAndCashEquivalentExplanatory"><p id="xdx_896_ecustom--DisclosureOfCashAndCashEquivalentExplanatory_zHWzwlOymI9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zyEKgIEHqG6a" style="display: none">Schedule
of cash and cash equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zAPyEzVnff49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20240630_zR2w2f76WZ77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashOnHand_iI_zDzX0CsHdh7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Cash on hand</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashOnHand_iI_uUSD_c20250630_zY27CGCTsgIj" title="Cash on hand" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2025-06-30" id="Fact001533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">310</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2025-06-30" id="Fact001530" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">395</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2024-06-30" id="Fact001531" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--BalancesWithBanks_iI_zJHDCQxJfTT7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash at banks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--BalancesWithBanks_iI_uUSD_c20250630_zveTKI9tORR9" title="Cash at banks" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:BalancesWithBanks" contextRef="AsOf2025-06-30" id="Fact001538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,341,920</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:BalancesWithBanks" contextRef="AsOf2025-06-30" id="Fact001535" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,978,688</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:BalancesWithBanks" contextRef="AsOf2024-06-30" id="Fact001536" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,949,553</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CashAndCashEquivalents_i02I_zT8cFh5xiaK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630_zt2A4KpjDhbi" title="Cash and cash equivalents" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30" id="Fact001543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30" id="Fact001540" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30" id="Fact001541" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_znEVVkCNIcJ5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001545" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfRelatedPartyExplanatory_zWtzHhk5mmWc" style="font: bold 10pt Times New Roman, Times, Serif; display: none; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">14.</td>
    <td style="font-weight: bold"><span id="xdx_82E_zwTlFbkOmlBh">Amount due from/to related parties</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Amount
due from related parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2023, Rainforest Capital VCC (the &#8220;Purchaser&#8221;) entered into a sale and purchase agreement with Dr. Kevin Yip (the
&#8220;Seller&#8221;) for the transfer of the entire share capital of Basel Medical Group Pte. Ltd. According to the sales and purchase
agreement, the Provisional Consideration shall be an aggregate amount equivalent to the sum of S$<span id="xdx_90D_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zGqIez1SBZU6" title="Provisional consideration amount for transfer of share"><ix:nonFraction name="ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" contextRef="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember" id="Fact001547" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,000,000</ix:nonFraction></span> (US$<span id="xdx_904_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_uUSD_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zbfu8XIKOoNd" title="Provisional consideration amount"><ix:nonFraction name="ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" contextRef="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember" id="Fact001549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,191,465</ix:nonFraction></span>) and the Agreed
Amount. The Agreed Amount is computed based on the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net
amount due from a former director (Dr. Kevin Yip) to the Group less the net assets of the Group as at June 30, 2023. The Agreed Amount
will be a negative figure if the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net amount due from
a director to the Group is more than the net assets of the Group as of June 30, 2023. The Agreed Amount was initially estimated to be
negative S$<span id="xdx_907_eifrs-full--SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_c20230630__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z6blSUkAO8Lf" title="Estimated settlement liability"><ix:nonFraction name="ifrs-full:SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" contextRef="From2023-06-302023-06-30_custom_RainforestCapitalVCCMember" id="Fact001551" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#8239;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2023, S$<span id="xdx_90C_ecustom--CashPaidOnClosingInitialSettlement_c20230701__20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zIdQ0hvJdIq3" title="Cash paid on closing initial settlement"><ix:nonFraction name="BMGL:CashPaidOnClosingInitialSettlement" contextRef="From2023-07-012023-07-01_custom_RainforestCapitalVCCMember" id="Fact001553" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,800,000</ix:nonFraction></span> (US$<span id="xdx_909_ecustom--CashPaidOnClosingInitialSettlement_uUSD_c20230701__20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zGFg2Dj6NvT1" title="Cash paid on closing initial settlement"><ix:nonFraction name="BMGL:CashPaidOnClosingInitialSettlement" contextRef="From2023-07-012023-07-01_custom_RainforestCapitalVCCMember" id="Fact001555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,944,137</ix:nonFraction></span>) was paid from the Purchaser to the Seller. This was computed based on <span id="xdx_904_ecustom--PercentageOfProvisionalConsiderationAmountForTransferOfShare_iI_dp_c20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zOvv3D7iPKR5" title="Percentage of provisional consideration amount for transfer of share"><ix:nonFraction name="BMGL:PercentageOfProvisionalConsiderationAmountForTransferOfShare" contextRef="AsOf2023-07-01_custom_RainforestCapitalVCCMember" id="Fact001557" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of S$<span id="xdx_902_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zBgdhcl1glgg" title="Provisional consideration amount for transfer of share"><ix:nonFraction name="ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" contextRef="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember" id="Fact001559" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,000,000</ix:nonFraction></span> and
Estimated Agreed Amount of negative S$<span id="xdx_907_eifrs-full--SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_c20230630__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z90apEOgBox3" title="Estimated settlement liability"><ix:nonFraction name="ifrs-full:SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" contextRef="From2023-06-302023-06-30_custom_RainforestCapitalVCCMember" id="Fact001561" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">5,000,000</ix:nonFraction></span>.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">14.</td>
    <td style="font-weight: bold">Amount due from/to related parties (continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the agreement on the purchase consideration between Rainforest Capital VCC as the buyer and Dr. Kevin Yip as the seller for the
purchase of the shares of Basel Medical Group Pte. Ltd. under the sale and purchase agreement dated June 27, 2023, the outstanding receivables
due from director, Dr. Kevin Yip, and related party, Singmed Investment Pte Ltd, have been assigned to and are borne by Rainforest Capital
VCC. On August 23, 2024, Rainforest Capital VCC entered into a deed of undertaking (the &#8220;Repayment Deed&#8221;) with the Group,
undertaking to fully transfer and pay to the Group, any and all outstanding receivables that is owed by Singmed Investment Pte Ltd and
Dr. Kevin Yip to the Group, being S$<span id="xdx_907_eifrs-full--LoansAndAdvances_iI_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipAndSingmedInvestmentPteLtdMember_zPZ5t0DRBnv5" title="Loan amount"><ix:nonFraction name="ifrs-full:LoansAndAdvances" contextRef="AsOf2024-09-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember" id="Fact001563" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,877,624</ix:nonFraction></span> (the &#8220;Loan Amount&#8221;), to the Group by September 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out the amounts owed to the Group by Rainforest Capital VCC, which has assumed the obligations of Dr. Kevin Yip
and Singmed Investment Pte Ltd pursuant to the Repayment Deed as of the date indicated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001565" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"><p id="xdx_894_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zPtPEuMmPGsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zC2JEy5rSo2l">Schedule
of amount due from related party</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June 30,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230630_znLudtLnW56h" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June 30,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">US$</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">S$</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zFT09TOy3V76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">Amount due from a director</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzuSgYcTlDH" title="Amount due from a director" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2023-06-30_custom_DirectorsMember" id="Fact001569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,453</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2023-06-30_custom_DirectorsMember" id="Fact001567" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,320,457</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z6SSlYJZFT3d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z81emXwnUhV5" title="Amount due from related parties" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2023-06-30_custom_OthersRelatedPartiesMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,806,823</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2023-06-30_custom_OthersRelatedPartiesMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,167</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zAkXyPtHolqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630_zXCUsdqcUWKf" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2023-06-30" id="Fact001577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,783,276</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2023-06-30" id="Fact001575" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,877,624</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zXcBg8Jag026" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the financial year ended June 30, 2024, the Group incurred an aggregate sum of S$<span id="xdx_904_eifrs-full--WagesAndSalaries_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zdrR2Ds9PCf" title="Professional medical practitioner salary"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2023-07-012024-06-30_custom_DrKevinYipMember" id="Fact001579" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">900,000</ix:nonFraction></span> (US$<span id="xdx_902_eifrs-full--WagesAndSalaries_uUSD_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zN9jp70PYZpj" title="Professional medical practitioner salary"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2023-07-012024-06-30_custom_DrKevinYipMember" id="Fact001581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,180</ix:nonFraction></span>) for professional medical practitioner
salaries owed to Dr. Kevin Yip for his services from July 1, 2023 to June 30, 2024. Such sum of US$<span id="xdx_90C_eifrs-full--OtherPayables_iI_uUSD_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zDcVpgHjemdb" title="Salary payable"><ix:nonFraction name="ifrs-full:OtherPayables" contextRef="AsOf2024-06-30_custom_DrKevinYipMember" id="Fact001583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,180</ix:nonFraction></span> will be set-off by the Group
against the amounts owed to the Group by Dr. Kevin Yip and Singmed Investment Pte Ltd. Thus, following such set-off, as of June 30, 2024,
total amounts due from Dr. Kevin Yip and Singmed Investment Pte Ltd is estimated to amount to US$<span id="xdx_90D_eifrs-full--AmountsReceivableRelatedPartyTransactions_iI_uUSD_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipAndSingmedInvestmentPteLtdMember_zlybycqXgAne" title="Receivables from related parties"><ix:nonFraction name="ifrs-full:AmountsReceivableRelatedPartyTransactions" contextRef="AsOf2024-06-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,101,096</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Rainforest Capital VCC has paid an aggregate sum of US$<span id="xdx_90F_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z71kNQwuc7V6" title="Related party advance for IPO expenses paid"><ix:nonFraction name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" contextRef="From2023-07-012024-06-30_custom_RainforestCapitalVCCMember" id="Fact001587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,730</ix:nonFraction></span> for the period from July 1, 2023 to June 30, 2024 on behalf
of the Group for professional fees incurred in connection with the group&#8217;s initial public offering. On February 27, 2024, July
22, 2024 and July 31, 2024, Rainforest Capital VCC also repaid a sum of US$<span id="xdx_902_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240227__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zCu9XYqPzJo" title="Partial settlement of related party receivables"><ix:nonFraction name="ifrs-full:ReceivablesDueFromAssociates" contextRef="AsOf2024-02-27_custom_RainforestCapitalVCCMember" id="Fact001589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span>, US$<span id="xdx_901_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240722__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zFxwjeFUVA2a" title="Partial settlement of related party receivables"><ix:nonFraction name="ifrs-full:ReceivablesDueFromAssociates" contextRef="AsOf2024-07-22_custom_RainforestCapitalVCCMember" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,000</ix:nonFraction></span> and US$<span id="xdx_901_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240731__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zuyZMkF4bQB7" title="Partial settlement of related party receivables"><ix:nonFraction name="ifrs-full:ReceivablesDueFromAssociates" contextRef="AsOf2024-07-31_custom_RainforestCapitalVCCMember" id="Fact001593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,048,000</ix:nonFraction></span> respectively to the Group
to partially settle the amounts due from a director and related parties. Finally, Rainforest Capital VCC has paid US$<span id="xdx_907_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240815__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z6O0HzkJH0Nf" title="Final settlement under repayment deed"><ix:nonFraction name="BMGL:CashReceivedToFullySettleRelatedPartyReceivables" contextRef="AsOf2024-08-15_custom_RainforestCapitalVCCMember" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span> on August
15, 2024, US$<span id="xdx_90E_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240816__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_za5uQHDQPiy9" title="Final settlement under repayment deed"><ix:nonFraction name="BMGL:CashReceivedToFullySettleRelatedPartyReceivables" contextRef="AsOf2024-08-16_custom_RainforestCapitalVCCMember" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span> on August 16, 2024, US$<span id="xdx_90F_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240920__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zzrmPel3Injb" title="Final settlement under repayment deed"><ix:nonFraction name="BMGL:CashReceivedToFullySettleRelatedPartyReceivables" contextRef="AsOf2024-09-20_custom_RainforestCapitalVCCMember" id="Fact001599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">651,000</ix:nonFraction></span> on September 20, 2024 and a final US$<span id="xdx_907_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240923__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zgALa3JqZGe5" title="Final settlement under repayment deed"><ix:nonFraction name="BMGL:CashReceivedToFullySettleRelatedPartyReceivables" contextRef="AsOf2024-09-23_custom_RainforestCapitalVCCMember" id="Fact001601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">652,366</ix:nonFraction></span> on September 23, 2024 pursuant to the
Repayment Deed as final settlement of such amounts owed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
such repayment, the full amount due from a former director and Singmed Investment Pte Ltd, that has been assigned to Rainforest Capital
VCC, has been fully paid off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Amount
due to related parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount
due to related parties consist of amount due to shareholders and directors. The amounts are non-trade in nature, unsecured, interest-bearing,
repayable on demand and is to be settled in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount
due to a related parties represents advances provided to cover various business expenses and other expenditures incurred by the Group
in the ordinary course of business.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p>

<ix:exclude><!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: 003 -->
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001603" name="ifrs-full:DisclosureOfBorrowingsExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfBorrowingsExplanatory_zZcTqjS6HeTd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold"><span id="xdx_82E_zZ6TWi4fwlc3">Borrowings</span></td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001605" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory"><p id="xdx_89A_eifrs-full--DisclosureOfDetailedInformationAboutBorrowingsExplanatory_zmN8Qhr6RF51" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zdt7LE6MD55l" style="display: none">Schedule
of borrowings</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zwlNex0l6wPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zZKEthUKq2Cf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--CurrentPortionOfBorrowingsAbstract_iB_zQ729fu69Byb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_z9MC6pvOiik3" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- Bank overdraft</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_uUSD_c20250630_zHRARvdwfRui" title="- Bank overdraft" style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" contextRef="AsOf2025-06-30" id="Fact001613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" contextRef="AsOf2025-06-30" id="Fact001610" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">61,371</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentLeaseLiabilities_iI_zU5gGaaZhtb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--CurrentLeaseLiabilities_iI_uUSD_c20250630_zpuJBUb8KF36" title="- Lease liabilities" style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2025-06-30" id="Fact001618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2025-06-30" id="Fact001615" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,059,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-06-30" id="Fact001616" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--BankBorrowings_iI_zFSQaeP0Gxvl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- Bank borrowings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--BankBorrowings_iI_uUSD_c20250630_zvfOsocVggXl" title="- Bank borrowings" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1620">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2024-06-30" id="Fact001621" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,677,856</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--ShorttermBorrowings_iI_maCBACPzDNY_zA3J4qZPVtCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings Current</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ShorttermBorrowings_iI_uUSD_c20250630_zhZW43QmPIC3" title="Borrowings Current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="AsOf2025-06-30" id="Fact001628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,667,677</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="AsOf2025-06-30" id="Fact001625" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,121,119</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ShorttermBorrowings" contextRef="AsOf2024-06-30" id="Fact001626" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,706,356</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_iB_zB4QdRluA1O1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_zfmOzutEoqvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iI_uUSD_c20250630_ztiRF4DFLkPl" title="- Lease liabilities" style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2025-06-30" id="Fact001636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2025-06-30" id="Fact001633" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1634">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_zbiryHuikNkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">- Bank borrowings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_uUSD_c20250630_zSeXumxc9Os7" title="- Bank borrowings" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1638">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2024-06-30" id="Fact001639" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--LongtermBorrowings_iI_maCBACPzDNY_z5BJ7i2ZDasg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings Non-Current</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LongtermBorrowings_iI_uUSD_c20250630_zef1XgI4UvVa" title="Borrowings Non-Current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="AsOf2025-06-30" id="Fact001646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,801</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="AsOf2025-06-30" id="Fact001643" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,357</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LongtermBorrowings" contextRef="AsOf2024-06-30" id="Fact001644" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_mtCBACPzDNY_zQITjCNLUDph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_uUSD_c20250630_zNR5XqMpmVPe" title="Borrowings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="AsOf2025-06-30" id="Fact001651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,688,478</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="AsOf2025-06-30" id="Fact001648" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,419,476</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" contextRef="AsOf2024-06-30" id="Fact001649" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,289,790</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zmpOgHyCWPSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
breakdown of borrowings are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001653" name="BMGL:DisclosureOfDetailedInformationAboutBreakdownOfBorrowings"><p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_ziCBI0sPKCS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zWDdgdsTb0mh">Schedule
of breakdown borrowings</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zNdeaiaRKbB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zfwvnxKW8Slf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zxoPc4KMg4pd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Term loan #1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zY1xyzDrTAa1" title="Term loan #1" style="width: 14%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1658">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1655">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanOneMember" id="Fact001656" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">206,695</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zeBcMdLSjO1h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zqLwc4NbzFN5" title="Term loan #2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanTwoMember" id="Fact001661" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">280,233</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zkl0zIS7Oz7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_z5YP4TD0ZUD4" title="Term loan #3" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1665">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanThreeMember" id="Fact001666" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">178,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zxKTBFvAzdC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zvDBLiBftzX5" title="Term loan #4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1673">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanFourMember" id="Fact001671" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">195,299</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zIPzY2ktgdY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zetrWLakq162" title="Term loan #6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanSixMember" id="Fact001676" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">531,708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zoOhaJDdCZj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zCeq04oCt6Ie" title="Term loan #7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1683">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanSevenMember" id="Fact001681" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">280,239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zcDk25wLaR07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zwdcDI3cuEua" title="Term loan #9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1688">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanNineMember" id="Fact001686" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">322,818</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_z7aQ7Mv5s3C7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zrUrbxCAElk5" title="Term loan #10" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanTenMember" id="Fact001691" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,573,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zB8fnSzo1QW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zwI8CWYChySb" title="Term loan #11" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1695">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanElevenMember" id="Fact001696" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">691,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z5m3JcKwdPS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Term loan #12</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z371D7LxwDO2" title="Term loan #12" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1700">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1701">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zJQcXa01mFGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    loan</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zu6KKmPCkRq5" title="Term loan" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1708">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1705">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LoansReceived" contextRef="AsOf2024-06-30_custom_TermLoanMember" id="Fact001706" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,261,290</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>




</ix:nonNumeric><p id="xdx_8A8_zcOobwGxFTUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001710" name="BMGL:DisclosureOfDetailedInformationAboutBorrowings"><p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutBorrowings_z7Z3O9OHS2Jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of borrowings are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zqwfwL5RQPh5">Schedule
of details borrowings</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Term loan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Facility</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">amount</p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Effective</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">interest rate</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maturity date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%
                                            p.a.</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Term loan #1</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zmwe5qGEnbYi" title="Term loan facility amount" style="width: 20%; text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanOneMember" id="Fact001712" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">600,000</ix:nonFraction></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zXftvuI5Mfvc" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanOneMember" id="Fact001714" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: right"><span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_z96JMNsqrX5i" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanOneMember" id="Fact001716" name="ifrs-full:BorrowingsMaturity">October 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #2</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zo27zLqEwcfl" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTwoMember" id="Fact001718" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,000,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_z3zLZh8Q6KB7" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTwoMember" id="Fact001720" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.75</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zCEof4omSSu5" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTwoMember" id="Fact001722" name="ifrs-full:BorrowingsMaturity">October 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #3</td><td>&#160;</td>
    <td id="xdx_983_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zZScS99VHdce" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanThreeMember" id="Fact001724" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">600,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zEQDShG6OZE4" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanThreeMember" id="Fact001726" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.75</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zATvoJ4ZG6d" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanThreeMember" id="Fact001728" name="ifrs-full:BorrowingsMaturity">November 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #4</td><td>&#160;</td>
    <td id="xdx_989_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zJP4gzAywMp5" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanFourMember" id="Fact001730" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">700,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_z4GhlSEknfH4" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanFourMember" id="Fact001732" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.50</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zRa8gabc442g" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanFourMember" id="Fact001734" name="ifrs-full:BorrowingsMaturity">November 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #6</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zSWuZ6MrwTv7" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanSixMember" id="Fact001736" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,400,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zcKiNqHB0Io6" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanSixMember" id="Fact001738" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.25</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zOL0DfbOCMVj" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanSixMember" id="Fact001740" name="ifrs-full:BorrowingsMaturity">April 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #7</td><td>&#160;</td>
    <td id="xdx_980_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zjvSjDiIMNV" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanSevenMember" id="Fact001742" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,000,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zyyRWErTzY9j" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanSevenMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.75</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zVCjHKippPUk" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanSevenMember" id="Fact001746" name="ifrs-full:BorrowingsMaturity">October 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #9</td><td>&#160;</td>
    <td id="xdx_981_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_z8kNMs3jXSLd" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanNineMember" id="Fact001748" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">850,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zpW1oRi2kVWd" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanNineMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.25</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zsJvLxwgL8rb" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanNineMember" id="Fact001752" name="ifrs-full:BorrowingsMaturity">April 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #10</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zRLLPOyMADtc" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTenMember" id="Fact001754" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">600,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zqoQHJtVtV5l" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTenMember" id="Fact001756" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.75</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_za5oe8qgkVF" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTenMember" id="Fact001758" name="ifrs-full:BorrowingsMaturity">November 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zIBpnDvgdMni" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTenOneMember" id="Fact001760" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,000,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zvK0ob31ByUi" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTenOneMember" id="Fact001762" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zqiD5Y1yqA1h" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTenOneMember" id="Fact001764" name="ifrs-full:BorrowingsMaturity">November 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zjvXaaZgKAs1" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTenTwoMember" id="Fact001766" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">500,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_z9IZjshJeJtc" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTenTwoMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.50</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zsx6e8CUqMi5" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTenTwoMember" id="Fact001770" name="ifrs-full:BorrowingsMaturity">March 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_z3O9f7OqgR45" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTenThreeMember" id="Fact001772" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">529,890</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zXsBAnX0tHZ6" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTenThreeMember" id="Fact001774" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.53</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zSZRyAqhlFXb" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTenThreeMember" id="Fact001776" name="ifrs-full:BorrowingsMaturity">December 2035</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zDLFxKuDwkR7" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTenFourMember" id="Fact001778" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">501,670</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zn8aOp0JAuJh" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTenFourMember" id="Fact001780" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.53</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_z8ws7KhQnl6k" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTenFourMember" id="Fact001782" name="ifrs-full:BorrowingsMaturity">December 2035</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #11</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_z27O3M099r9a" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanElevenMember" id="Fact001784" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">400,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zCRg2dGta2K3" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanElevenMember" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.25</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zQ2J0zJXvgW8" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanElevenMember" id="Fact001788" name="ifrs-full:BorrowingsMaturity">January 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_z7nETdPtOQOd" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanElevenOneMember" id="Fact001790" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,500,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zKHmVImFfpe3" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanElevenOneMember" id="Fact001792" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.50</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zZGx25X3Jklc" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanElevenOneMember" id="Fact001794" name="ifrs-full:BorrowingsMaturity">December 2025</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #12</td><td>&#160;</td>
    <td id="xdx_985_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zUpZt2bPFomb" title="Term loan facility amount" style="text-align: right">S$<ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember" id="Fact001796" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,000,000</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zeo2FBScLV3" title="Borrowings interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember" id="Fact001798" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.30</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z1FRr2XA00V1" title="Borrowing maturity date"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_TermLoanTwelveMember" id="Fact001800" name="ifrs-full:BorrowingsMaturity">One-month term, upon maturity</ix:nonNumeric></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zsOZjll8XZX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
loan #1 to #12 was fully settled during the financial year, and as at June 30, 2025, there are no outstanding bank borrowings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001802" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"><p id="xdx_89F_eifrs-full--DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_zbFJuUGQizij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of liabilities arising from financing activities is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfiMpdyhrmdg">Schedule
of reconciliation of liabilities arising from financing activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Beginning of</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proceed from</b></span></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>Non-cash changes</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">End of</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">financial
                                            year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
    flows</b></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>
                                                                                                                                                                                                                              <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>bank</b></span></p>
                                                                                                                                                                                                                              <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>borrowings</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Addition</b></span></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Accretion
                                            of</p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">interests</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">financial</p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">period</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 10%">- Current</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zt3WYqOApUYi" title="Lease liabilities current, beginnings" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,407</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zULAica0qbTb" title="Repayment of lease liabilities cash flows" style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001806" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">861,945</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z4Dg6eG11iNa" title="Proceed from bank borrowings lease liabilities, current" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zumGlwPxqnyi" title="Addition lease liabilities current" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,557,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z9m5DJkhsgUe" title="Accretion of interests current" style="width: 10%; text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zh1GdGMnjdt9" title="Other non cash changes current" style="width: 10%; text-align: right">(<ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,188,472</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z5rjM5nVLmag" title="Lease liabilities current, ending" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,426</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zCCXuDOVsfz8" title="Lease liabilities non-current, beginnings" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeIUBS8onrIf" title="Repayment of lease liabilities non current cash flows" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z8GsKz6zc8pi" title="Proceed from bank borrowings lease liabilities, non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zl07H7xrRPMc" title="Addition lease liabilities non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1824">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjmqj9cSZSb3" title="Accretion of interests Non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1826">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zFhyROnbMh28" title="Other non cash changes non current" style="text-align: right"><ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zIWHiFuDIeF9" title="Lease liabilities non-current, ending" style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,801</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--BankBorrowings_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zQ03przyNmv" title="Bank borrowings, beginnings" style="text-align: right"><ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,105,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zgjyNKdFBFcb" title="Cash flows lease liabilities and bank borrowings current" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001834" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,259</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUDWSvmuBqW7" title="Proceed from bank borrowings, current" style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,144,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionBankBorrowingsCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zrOoTURCPyA6" title="Addition bank borrowings current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUYIJbWaaAYl" title="Accretion of interests bank borrowings current" style="text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zue9Q6PgASn2" title="Other non cash changes bank borrowings current" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--BankBorrowings_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zcs3uL1C2UCc" title="Bank borrowings, ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1844">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z44DTK1GAyWf" title="Bank borrowings non current, beginnings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,244,936</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zIzI3cBpoz22" title="Cash flows lease liabilities and bank borrowings noncurrent" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001848" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,244,936</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zFFvWz4hnZ4h" title="Proceed from bank borrowings, non current" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1850">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionBankBorrowingsNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zWdV86ZXOPIg" title="Addition bank borrowings non current" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1852">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsYQmTbr5FZ1" title="Accretion of interests bank borrowings non current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUHbvi6QWvH1" title="Other non cash changes bank borrowings non current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1856">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zMzTr4m7Mze4" title="Bank borrowings non current, ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zs1RvxrtUEc8" title="Reconciliation of liabilities financing activities current and non current, beginnings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,372,741</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zZCSZn4dJfob" title="Cash flows lease liabilities and bank borrowings" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001862" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,427,140</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z3nhdVOyuJ1a" title="Proceed from bank borrowings lease liabilities, current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,144,901</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zcTmyKWWRvvf" title="Addition bank lease liabilities current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,557,047</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zGdOLaZ5eRq2" title="Accretion of interests current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zFJbavN0oYCh" title="Other non cash changes current and non current" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001870" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">161,671</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zu66LVzQlkT2" title="Reconciliation of liabilities financing activities current and non current, ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="AsOf2025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,640,227</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>

<ix:exclude><!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Beginning of</p></td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Proceed
                                            from</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Non-cash changes</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">End
    of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">financial
                                            year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Cash flows</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">bank</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">borrowings</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Addition</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Accretion
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">interests</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
year</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 10%">- Current</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--CurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zZkCagR1EcP6" title="Lease liabilities current, beginnings" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001874" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbdVKp4xYHC8" title="Repayment of lease liabilities cash flows" style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001876" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,096,308</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zS9GRUWFcb4" title="Proceed from bank borrowings lease liabilities, current" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1878">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeo4YnIcGu9g" title="Addition lease liabilities current" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001880" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,524,209</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z6YbZ6hH5uBh" title="Accretion of interests current" style="width: 10%; text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001882" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">114,966</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zouRKEM8rSE" title="Other non cash changes current" style="width: 10%; text-align: right">(<ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001884" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,511,619</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--CurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zSqlGB2becgi" title="Lease liabilities current, ending" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001886" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,059,748</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NoncurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJZH4bRh0yR9" title="Lease liabilities non-current, beginnings" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zny0HBAasPxi" title="Repayment of lease liabilities non current cash flows" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zfqmOtgZKqBj" title="Proceed from bank borrowings lease liabilities, non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbUZvdy7iVyg" title="Addition lease liabilities non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z3NFbRxnAbLj" title="Accretion of interests Non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1896">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_ziFc4frHhLQe" title="Other non cash changes non current" style="text-align: right"><ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001898" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NoncurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJVjOxYKgQlf" title="Lease liabilities non-current, ending" style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001900" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--BankBorrowings_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zd4RJQm3TgO9" title="Bank borrowings, beginnings" style="text-align: right"><ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001902" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,677,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuTsUG1V7vCd" title="Bank borrowings current cash flows" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001904" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">6,766,838</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5OjWXPNfgOe" title="Proceed from bank borrowings, current" style="text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001906" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AdditionBankBorrowingsCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zhyTlkOGjvIi" title="Addition bank borrowings current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1908">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z1Nibn0iDCo1" title="Accretion of interests bank borrowings current" style="text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001910" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">88,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsgrdK3gkz03" title="Other non cash changes bank borrowings current" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1912">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--BankBorrowings_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zTGx3TRaq7n6" title="Bank borrowings, ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1914">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8wHAK9WGSy5" title="Bank borrowings non current, beginnings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001916" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zN6tU9fiYlHd" title="Bank borrowings non current cash flows" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001918" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zV6SjydDYlTd" title="Proceed from bank borrowings, non current" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1920">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zpAp65clDFN2" title="Addition bank borrowings non current" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1922">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5uIHhwvKCQ2" title="Accretion of interests bank borrowings non current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1924">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEVJi6rswpba" title="Other non cash changes bank borrowings non current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1926">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z0gDTthVuxd4" title="Bank borrowings non current, ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1928">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z7z9f1IDrXx1" title="Reconciliation of liabilities financing activities current and non current, beginnings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001930" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,289,790</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zsY8H7j33HD1" title="Repayment of lease and bank liabilities cash flows" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001932" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">9,446,580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zMqxQZUOx8Yk" title="Proceed from bank borrowings lease liabilities, current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001934" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zD75IkMb2AWj" title="Addition bank lease liabilities current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001936" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,524,209</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z99G6ECJKoNl" title="Accretion of interests current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001938" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">203,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zEuO6YN4I9Ue" title="Other non cash changes current and non current" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001940" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">213,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zBp1vkK8bi2c" title="Reconciliation of liabilities financing activities current and non current, ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="AsOf2025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact001942" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,358,105</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--CurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zP372ZNlPoXd" title="Lease liabilities current, beginnings" style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2023-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">566,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zERGdLLo45K1" title="Repayment of lease liabilities cash flows" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001946" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">553,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_znqo69272iEe" title="Proceed from bank borrowings and lease liabilities, current" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1948">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm5A180JBrke" title="Addition lease liabilities current" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1950">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm31aQcXiosa" title="Accretion of interests current" style="text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001952" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">15,461</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zRAessjprRXe" title="Other non cash changes current" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1954">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjGwJ26L4kX5" title="Lease liabilities current, ending" style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001956" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NoncurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zBAk8eJkwj5b" title="Lease liabilities non-current, beginnings" style="text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2023-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001958" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">28,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zc1p5vsFZ4Ik" title="Repayment of lease liabilities non current cash flows" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zdsbCwzQf6cj" title="Proceed from bank borrowings and lease liabilities, noncurrent" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1962">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOBAqgc2SVQi" title="Addition lease liabilities non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zUih1hJ51mS1" title="Accretion of interests Non current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1966">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOao7WUyTys8" title="Other non cash changes non current" style="text-align: right">(<ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember" id="Fact001968" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">28,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zMb6CDB6D4hf" title="Lease liabilities non-current, ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--BankBorrowings_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEtuzHIWPoK" title="Bank borrowings, beginnings" style="text-align: right"><ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2023-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001972" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,223,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPeo5LD0MS4c" title="Cash flows lease liabilities and bank borrowings current" style="text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001974" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">2,517,707</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zvbuW1upupy1" title="Proceed from bank borrowings and lease liabilities, current" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionBankBorrowingsCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPAvYTRS1XVa" title="Addition bank borrowings current" style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1978">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuf9MMclmfQi" title="Accretion of interests current" style="text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001980" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">160,777</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zfBjlNMJHAxh" title="Other non cash changes current" style="text-align: right"><ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001982" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,811,636</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--BankBorrowings_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zJeXZUJvbral" title="Bank borrowings, ending" style="text-align: right"><ix:nonFraction name="BMGL:BankBorrowings" contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001984" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,677,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zmqSRO5hu3xf" title="Bank borrowings non current, beginnings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2023-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001986" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,395,070</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zdzCUTrf0gYb" title="Cash flows lease liabilities and bank borrowings noncurrent" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zLUypYBpj3N5" title="Proceed from bank borrowings and lease liabilities, noncurrent" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1990">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8Tzxwk0Qalb" title="Addition bank borrowings non current" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z45tYKiRywPe" title="Accretion of interests noncurrent" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1994">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_ztaPrbh1zlF6" title="Other non cash changes non current" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001996" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,811,636</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zSgZjzQPcqV1" title="Bank borrowings non current, ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember" id="Fact001998" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z8KcFElCssf7" title="Reconciliation of liabilities financing activities current and non current, beginnings" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="AsOf2023-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact002000" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,212,759</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zOqXe0pjd2Ri" title="Cash flows lease liabilities and bank borrowings" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact002002" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">3,070,707</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zpsjjnUBMeG5" title="Proceed from bank borrowings and lease liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2004">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zLto3361fobj" title="Addition bank lease liabilities current and non current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2006">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zuuNTzX4WiXf" title="Accretion of interests current and non current" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact002008" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">176,238</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zIJpZq6y9ihh" title="Other non cash changes current and non current" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2010">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zF7NmYHGg4K5" title="Reconciliation of liabilities financing activities current and non current, ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LiabilitiesArisingFromFinancingActivities" contextRef="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" id="Fact002012" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,289,790</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zjUGRqdZzZqa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>

<ix:exclude><!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002014" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zdpindPSPCMc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">16.</td>
    <td style="font-weight: bold"><span id="xdx_82E_zQ9gVc9pFpKc">Trade and other payables</span></td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002016" name="BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory"><p id="xdx_89B_ecustom--DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_zKxJ7xXfueWl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z6Nk7R5z831k" style="display: none">Schedule
of trade and other payables</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20250630_zLTYgA4E3Ym9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_zYyqsXkpafxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_maTAOPzVdB_zi02tmFckYoa" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: left">- third parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_uUSD_c20250630_zVy5PUMftfL8" title="Trade payable- third parties" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="AsOf2025-06-30" id="Fact002021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="AsOf2025-06-30" id="Fact002018" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,097,415</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" contextRef="AsOf2024-06-30" id="Fact002019" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">829,324</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Accruals_iI_maTAOPzVdB_zbLoTrZPRdcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--Accruals_iI_uUSD_c20250630_zVtkIXLjXUeb" title="Accruals" style="text-align: right"><ix:nonFraction name="ifrs-full:Accruals" contextRef="AsOf2025-06-30" id="Fact002026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,222,998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Accruals" contextRef="AsOf2025-06-30" id="Fact002023" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,555,531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Accruals" contextRef="AsOf2024-06-30" id="Fact002024" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,074,868</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ValueAddedTaxPayables_iI_maTAOPzVdB_zhilMtwv2CYk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">GST payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ValueAddedTaxPayables_iI_uUSD_c20250630_zgh4jgwuoOui" title="GST payables" style="text-align: right"><ix:nonFraction name="ifrs-full:ValueAddedTaxPayables" contextRef="AsOf2025-06-30" id="Fact002031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ValueAddedTaxPayables" contextRef="AsOf2025-06-30" id="Fact002028" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">279,638</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:ValueAddedTaxPayables" contextRef="AsOf2024-06-30" id="Fact002029" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">391,330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--OtherPayables_iI_maTAOPzVdB_zNPe2CehumO4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--OtherPayables_iI_uUSD_c20250630_zLHXbmlFvPd5" title="Other payables third parties" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherPayables" contextRef="AsOf2025-06-30" id="Fact002036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,343,283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherPayables" contextRef="AsOf2025-06-30" id="Fact002033" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,980,422</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:OtherPayables" contextRef="AsOf2024-06-30" id="Fact002034" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">280,427</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherPayables_iTI_mtTAOPzVdB_zuyH3ZABFMDe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TradeAndOtherPayables_iTI_uUSD_c20250630_zodGfcyXNFAi" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30" id="Fact002041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,435,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30" id="Fact002038" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,913,006</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2024-06-30" id="Fact002039" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,575,949</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zPkVeAP2qu8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
payables are non-interest bearing and are normally settled on <span id="xdx_908_ecustom--TradePayablesMaturity_c20240701__20250630_zwvGO3jKESWh" title="Trade payable, maturity"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact002043" name="BMGL:TradePayablesMaturity">30 to 90 days terms</ix:nonNumeric></span> (June 30, 2024: <span id="xdx_90C_ecustom--TradePayablesMaturity_c20230701__20240630_zwtSdzmqiGE7" title="Trade payable, maturity"><ix:nonNumeric contextRef="From2023-07-012024-06-30" id="Fact002045" name="BMGL:TradePayablesMaturity">30 to 90 days</ix:nonNumeric></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
payables are non-trade related, unsecured, non-interest bearing, repayable on demand and are to be settled in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other payables are denominated in Singapore Dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002047" name="BMGL:DisclosureOfAmountDueToAFormerDirectorExplanatory"><p id="xdx_807_ecustom--DisclosureOfAmountDueToAFormerDirectorExplanatory_zhgZNHaNFPv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">17.</td>
    <td style="font-weight: bold"><span id="xdx_820_zFQmBjqwhKjf">Amount due to a former director</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount
due to a former director is denominated in Singapore Dollar. Please refer to Note 14 for the terms of the sale and purchase agreement
between Rainforest Capital VCC and Dr. Kevin Yip, a former director. </span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002049" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory"><p id="xdx_802_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zW1VXfZQBfy9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">18.</td>
    <td style="font-weight: bold"><span id="xdx_82F_z8qKF0k7Ysd7">Share capital</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company was established under the laws of BVI on August 10, 2023 with authorized share of <span id="xdx_907_eifrs-full--NumberOfSharesAuthorised_iI_c20230810_zpUDIhfvuD7e" title="Ordinary shares, authorized"><ix:nonFraction name="ifrs-full:NumberOfSharesAuthorised" contextRef="AsOf2023-08-10" id="Fact002051" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,250,000</ix:nonFraction></span> ordinary shares amounting to S$<span id="xdx_902_ecustom--ValueOfSharesAuthorised_iI_c20230810_zTfIUUysnkxb" title="Ordinary shares, amount"><ix:nonFraction name="BMGL:ValueOfSharesAuthorised" contextRef="AsOf2023-08-10" id="Fact002053" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">24,455,178</ix:nonFraction></span>
(US$<span id="xdx_908_ecustom--ValueOfSharesAuthorised_iI_uUSD_c20230810_zGJS85MeZv5h" title="Ordinary shares, amount"><ix:nonFraction name="BMGL:ValueOfSharesAuthorised" contextRef="AsOf2023-08-10" id="Fact002055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,362,500</ix:nonFraction></span>) at a subscription price of US$<span id="xdx_90E_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20230810_zbGJnWe72Qdh" title="Share subscription price"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2023-08-10" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.13</ix:nonFraction></span> per share at the time of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 96pt; text-align: justify; text-indent: -0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is authorized to issue one class of ordinary share.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
holders of ordinary shares are entitled to receive dividends as and when declared by the Group. All ordinary shares carry one vote per
share without restrictions. The ordinary shares have no par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
February 2025, following the Company&#8217;s initial public offering on Nasdaq, <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_c20250228__ifrs-full--ComponentsOfEquityAxis__custom--InitialPublicOfferingMember_zoovN8LMXNTf" title="Share issue on capital market"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-02-28_custom_InitialPublicOfferingMember" id="Fact002059" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,205,000</ix:nonFraction></span> ordinary shares at a subscription price of
US$<span id="xdx_90B_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20250228__ifrs-full--ComponentsOfEquityAxis__custom--InitialPublicOfferingMember_zB7kD3RbJtx3" title="Share subscription price"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2025-02-28_custom_InitialPublicOfferingMember" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share were issued. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
March 2025, following the exercise of the overallotment option by the underwriter, <span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--ComponentsOfEquityAxis__custom--OverAllotmentOptionsMember_zNvzOvn22j29" title="Share issue on capital market"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-03-31_custom_OverAllotmentOptionsMember" id="Fact002063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">330,750</ix:nonFraction></span> ordinary shares at a subscription price of
US$<span id="xdx_908_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20250331__ifrs-full--ComponentsOfEquityAxis__custom--OverAllotmentOptionsMember_zTRP35jlTVw7" title="Share subscription price"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2025-03-31_custom_OverAllotmentOptionsMember" id="Fact002065" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">As
of June 30, 2025, <span id="xdx_90A_eifrs-full--NumberOfSharesIssued_iI_c20250630_zzXGYbeBvZl8" title="Number of share issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-06-30" id="Fact002067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,785,750</ix:nonFraction></span> ordinary shares of the Company were issued in total.</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002069" name="ifrs-full:DisclosureOfLeasesExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfLeasesExplanatory_zNrnzAX0gSI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">19.</td>
    <td style="font-weight: bold"><span id="xdx_825_zNNwkJ1JBg1k">Leases</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Company
as a lessee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company has lease contracts for clinics. The Company&#8217;s obligations under these leases are secured by the lessor&#8217;s title to
the leased assets. The Company is restricted from assigning and subleasing the leased assets. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company also has certain leases of machinery with lease terms of <span id="xdx_905_ecustom--LeaseTermOfContract_dtM_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zkZGmHGA9lRa" title="Lease term"><ix:nonNumeric contextRef="From2024-07-012025-06-30_ifrs-full_MachineryMember" format="ixt-sec:durmonth" id="Fact002071" name="BMGL:LeaseTermOfContract">12</ix:nonNumeric></span> months or less and leases of office equipment with low value. The
Company applies the &#8216;short-term lease&#8217; and &#8216;lease of low-value assets&#8217; recognition exemptions for these leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(a)</td>
    <td style="font-weight: bold">Carrying amounts of right-of-use assets under leasing arrangements</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
carrying amounts of right-of-use assets under leasing arrangements are disclosed in Note 9.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(b)</td>
    <td style="font-weight: bold">Lease liabilities</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of lease liabilities (included under borrowings) and the movements during the year are disclosed in Note 15 and the maturity
analysis of lease liabilities is disclosed in Note 22 under liquidity risk. The Company adopt <span id="xdx_904_eifrs-full--WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_iI_dp_uPure_c20250630_zAEK63GqtCC9" title="Weighted average borrowing rate"><ix:nonFraction name="ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" contextRef="AsOf2025-06-30" id="Fact002073" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% as weighted average borrowings rate
to determine the present value of the lease payments. The weighted average remaining life of the lease was 1 year.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">19.</td>
    <td style="font-weight: bold">Leases (Continued)</td></tr>
  </table>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002075" name="BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock"><p id="xdx_892_ecustom--DisclosureOfLeaseRelatedExpensesTableTextBlock_zEdUSPhrJEv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zzvUbXrLCC2g">Schedule
of amounts recognized in profit or loss</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(c)</td>
    <td style="font-weight: bold">Amounts recognized in profit or loss</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630_zMIG3aDMmcqd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230701__20240630_zoA8EUzu3Dxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--DepreciationRightofuseAssets_zr0aogHlwPNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: justify">Depreciation of right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630_zjHtOc7VspNl" title="Depreciation of right-of-use assets" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="From2024-07-01to2025-06-30" id="Fact002080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">843,989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="From2024-07-01to2025-06-30" id="Fact002077" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,073,469</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:DepreciationRightofuseAssets" contextRef="From2023-07-012024-06-30" id="Fact002078" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">498,635</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InterestExpenseOnLeaseLiabilities_zajyIKN3s6Vh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zQRGWEPLldXg" title="Interest expense on lease liabilities" style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact002085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact002082" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">114,966</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2023-07-012024-06-30" id="Fact002083" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">15,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease expense not capitalized in lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_zuzdLirjcTX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">- Expense relating to short-term leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_uUSD_c20240701__20250630_zTg9aLWWruhc" title="Expense relating to short-term leases" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2090">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2087">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" contextRef="From2023-07-012024-06-30" id="Fact002088" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_zuOZvYvg1lE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total amount recognized in profit or loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_uUSD_c20240701__20250630_zeeVw7pGL8G9" title="Total amount recognized in profit or loss" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" contextRef="From2024-07-01to2025-06-30" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">934,378</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" contextRef="From2024-07-01to2025-06-30" id="Fact002092" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,188,435</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" contextRef="From2023-07-012024-06-30" id="Fact002093" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">517,276</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zjXndZ1SG6S5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(d)</td>
    <td style="font-weight: bold">Total cash outflow</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had total cash outflows for leases of S$<span id="xdx_900_eifrs-full--CashOutflowForLeases_c20240701__20250630_zPA3DTp2Cvu2" title="Cash outflow for leases"><ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="From2024-07-01to2025-06-30" id="Fact002097" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,096,308</ix:nonFraction></span> (US$<span id="xdx_90F_eifrs-full--CashOutflowForLeases_uUSD_c20240701__20250630_zOclcdB87uci" title="Cash outflow for leases"><ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="From2024-07-01to2025-06-30" id="Fact002099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">861,945</ix:nonFraction></span>) (June 30, 2024: S$<span id="xdx_90B_eifrs-full--CashOutflowForLeases_c20230701__20240630_zggItRhNyzTk" title="Cash outflow for leases"><ix:nonFraction name="ifrs-full:CashOutflowForLeases" contextRef="From2023-07-012024-06-30" id="Fact002101" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">566,039</ix:nonFraction></span>).</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(e)</td>
    <td style="font-weight: bold">Extension options</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has several lease contracts that include extension options. These options are negotiated by management to provide flexibility
in managing the leased-asset portfolio and align with the Company&#8217;s business needs. Management exercises significant judgement
in determining whether these extension options are reasonably certain to be exercised.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002103" name="BMGL:DisclosureOfSignificantRelatedPartyExplanatory"><p id="xdx_805_ecustom--DisclosureOfSignificantRelatedPartyExplanatory_zVXmrBJcPg7e" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">20.</td>
    <td style="font-weight: bold"><span id="xdx_822_zcjNc75MDGRb">Significant related party transactions</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002105" name="BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory"><p id="xdx_896_ecustom--ScheduleOfTransactionsWithRelatedPartyExplanatory_zGuasCrT7mLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
addition to the related party information disclosed elsewhere in the consolidated financial statements, the following transactions with
related parties took place at terms agreed between the parties during the financial period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span id="xdx_8BC_zb9wgXRCFjXl" style="display: none">Schedule of transactions with
related parties</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zgyvd0rOAcl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zZmR0Df9i1y6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--InterestIncomeOnLoansAndReceivable_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_z57jlsdK27Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Interest income on loan to related party</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_ecustom--InterestIncomeOnLoansAndReceivable_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zghxAXZ9dL0h" title="Interest income on loan to related party"><ix:nonFraction name="BMGL:InterestIncomeOnLoansAndReceivable" contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember" id="Fact002110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,507</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="BMGL:InterestIncomeOnLoansAndReceivable" contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember" id="Fact002107" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ManagementFee_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zCp1F2zFTJmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ManagementFee_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zojJerwhMhXa" title="Management fee"><ix:nonFraction name="BMGL:ManagementFee" contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember" id="Fact002115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852,504</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="BMGL:ManagementFee" contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember" id="Fact002112" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,900,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2113">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zfpY8fj25SHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Payment made on behalf to related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zBpXczlu1ZRe" title="Payment made on behalf to related parties"><ix:nonFraction name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,715</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember" id="Fact002117" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,725</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" contextRef="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zVZr7J9zHg6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Compensation
of key management personnel</i></span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002122" name="BMGL:ScheduleOfCompensationOfKeyManagementPersonnelExplanatory"><p id="xdx_899_ecustom--ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_z4XNVvVbHTid" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span id="xdx_8B7_zC8yZ2n2EV39" style="display: none">Schedule of
compensation of key management personnel</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zctqUncmGv89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20240630_z2iqErxQlKz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--WagesAndSalaries_maKMPCzbwJ_zGlLrYwfMeUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left">Salaries and bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">544,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2024-07-01to2025-06-30" id="Fact002124" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">693,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2023-07-012024-06-30" id="Fact002125" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">121,200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CentralProvidentFund_maKMPCzbwJ_zq33XkIqskpb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">CPF</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">46,540</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="BMGL:CentralProvidentFund" contextRef="From2024-07-01to2025-06-30" id="Fact002127" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">59,194</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="BMGL:CentralProvidentFund" contextRef="From2023-07-012024-06-30" id="Fact002128" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">137</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--KeyManagementPersonnelCompensation_iT_mtKMPCzbwJ_zecM9P1e6kK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">591,394</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2024-07-01to2025-06-30" id="Fact002130" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">752,194</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2023-07-012024-06-30" id="Fact002131" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">121,337</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zXzeaS786D76" style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002133" name="ifrs-full:DisclosureOfGoodwillExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfGoodwillExplanatory_zJn8lmsAotUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">21.</td>
    <td style="font-weight: bold"> <span id="xdx_82F_zo5HLuKJIash">Impairment loss on goodwill</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of Bethesda Medical Pte Ltd and its subsidiary, Oasis Medical Clinic Pte Ltd (&#8220;Bethesda Group Acquisition&#8221;)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">On April 30, 2025, the Company completed its acquisition on all of the ordinary shares in the issued and paid-up share capital of Bethesda
Medical Pte Ltd, a company incorporated in Singapore. Pursuant to the Sale and Purchase Agreement, the aggregate consideration is S$<span id="xdx_90E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_c20250430_zAb6XuybgHpl" title="Consideration transferred"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2025-04-30" id="Fact002135" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,308,000</ix:nonFraction></span>
(US$<span id="xdx_907_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_uUSD_c20250430_zR4ylFwOhXAf" title="Consideration transferred"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2025-04-30" id="Fact002137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000,000</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the completion of the acquisition, Bethesda Medical Pte Ltd became a wholly owned indirect subsidiary of Basel Medical Group
Ltd.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002139" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"><p id="xdx_89D_eifrs-full--DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_zvMglfu9Iu7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
fair value of identifiable assets and liabilities of Bethesda Group as at the acquisition date were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; display: none">&#160;<span id="xdx_8BA_z7nji0UumfN2">Schedule
of fair value of identifiable assets and liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250430_zIGEZzMVyiPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_znTdXUgmookc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-bottom: 1pt">Purchase Consideration</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2025-04-30" id="Fact002141" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,308,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Assets and liabilities recognised as a result of the acquisition:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_iI_zFFMwjARNYb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002143" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">502,180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_z427Po6Vqe38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002145" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,133,786</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DeferredTaxAssetsRecognisedAsOfAcquisitionDate_iI_zBDHMaHsycg8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002147" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">34,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--InvestmentRecognisedAsOfAcquisitionDate_iI_zFOsNFqmAT69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="BMGL:InvestmentRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002149" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InventoryRecognisedAsOfAcquisitionDate_iI_zyfjupa7QVKk" style="vertical-align: bottom; background-color: White">
    <td>Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002151" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">276,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--FairValueOfAcquiredReceivables_iI_zBwWrZZfQNlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:FairValueOfAcquiredReceivables" contextRef="AsOf2025-04-30" id="Fact002153" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">669,746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_iI_zUM2ni11yyYf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002155" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">168,895</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LeaseLiabilitiesRecognisedAsOfAcquisitionDate_iI_zVzLSQOUwhCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="BMGL:LeaseLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002157" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">431,744</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--BorrowingsRecognisedAsOfAcquisitionDate_iNI_di_zzsyeNLArTV9" style="vertical-align: bottom; background-color: White">
    <td>Borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002159" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">453,250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_iNI_di_zjngBgwWr8Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002161" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,544,185</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--AmountDueRecognisedAsOfAcquisitionDate_iI_zbEBiQ0upnh7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amount due to director</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="BMGL:AmountDueRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002163" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">193,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_zhyQkKtUZaQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net identifiable liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002165" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">837,691</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_zbPR2aYXYPj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Add: Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" contextRef="AsOf2025-04-30" id="Fact002167" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">11,145,691</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Purchase consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zW29lKC3N9k4" title="Purchase consideration"><ix:nonFraction name="ifrs-full:ProfitLossOfCombinedEntity" contextRef="From2025-04-302025-04-30" id="Fact002169" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,308,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_ziYlOJwKHpF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">As
the new subsidiary&#8217;s operation has yet to be turned around, an impairment loss on the goodwill from this investment has been fully
recognised in year ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase consideration of S$<span id="xdx_909_eifrs-full--CashTransferred_iI_c20250430_zNXplRcECIug" title="Consideration transferred cash"><ix:nonFraction name="ifrs-full:CashTransferred" contextRef="AsOf2025-04-30" id="Fact002171" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,308,000</ix:nonFraction></span> was settled by cash hence, there is a S$<span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zUHBbXapDN5d" title="Purchase consideration"><ix:nonFraction name="ifrs-full:ProfitLossOfCombinedEntity" contextRef="From2025-04-302025-04-30" id="Fact002173" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,308,000</ix:nonFraction></span> of net cash outflow impact on the acquisition.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goodwill is attributable to Basel Medical Group&#8217;s expansion strategy in Singapore and the broader Southeast Asian healthcare market.
By broadening its service offerings and integrating advanced medical solutions, Basel Medical Group is positioning itself as a key player
in the region&#8217;s evolving healthcare ecosystem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquired business contributed revenue of S$<span id="xdx_90B_eifrs-full--RevenueOfAcquiree_c20250501__20250630_zAJB3wOWwUu" title="Revenue"><ix:nonFraction name="ifrs-full:RevenueOfAcquiree" contextRef="From2025-05-012025-06-30" id="Fact002175" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">895,362</ix:nonFraction></span> and net loss of S$<span id="xdx_903_eifrs-full--ProfitLossOfAcquiree_c20250501__20250630_zgDA3nQrh578" title="Net loss"><ix:nonFraction name="ifrs-full:ProfitLossOfAcquiree" contextRef="From2025-05-012025-06-30" id="Fact002177" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">448,857</ix:nonFraction></span> to the Group for the period from 1 May 2025 to 30 June 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

</ix:nonNumeric><p id="xdx_815_zDeuZ4YVr4Z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002179" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zpQPBL6iYbS6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">22.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span><span id="xdx_82C_zbIWqI0kpMOa">Fair value of assets and liabilities</span></span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assets
and liabilities not measured at fair value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and cash equivalents, other receivables, amount due from/(to) related parties, other payables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of these balances approximate their fair values due to the short-term nature of these balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
receivables and trade payables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of these receivables and payables approximate their fair values as they are subject to normal trade credit terms.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Borrowings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of borrowings approximate their fair values as they are subject to interest rates close to market rate of interests
for similar arrangements with financial institutions.</span></p>
<!-- Field: Split-Segment; Name: 004 -->
</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002181" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory"><p id="xdx_802_eifrs-full--DisclosureOfFinancialRiskManagementExplanatory_zutlzvfpcVk6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">23.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"> <span id="xdx_824_zoH2nrhmmYM1">Financial risk management</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s activities expose it to a variety of financial risks from its operations. The key financial risks include credit risk,
market risk (including foreign currency risk, interest rate risk) and liquidity risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors review and agree policies and procedures for the management of these risks, which are executed by the management team. It is,
and has been throughout the current and previous financial year, the Group&#8217;s policy that no trading in derivatives for speculative
purposes shall be undertaken.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sections provide details regarding the Group&#8217;s exposure to the abovementioned financial risks and the objectives, policies
and processes for the management of these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been no change to the Group&#8217;s exposure to these financial risks or the manner in which it manages and measures the risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk refers to the risk that the counterparty will default on its contractual obligations resulting in a loss to the Group. The Group&#8217;s
exposure to credit risk arises primarily from trade and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has adopted a policy of only dealing with creditworthy counterparties. The Group performs ongoing credit evaluation of its counterparties&#8217;
financial condition and generally do not require a collateral.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit
risk on an ongoing basis throughout each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has determined the default event on a financial asset to be when internal and/or external information indicates that the financial
asset is unlikely to be received, which could include default of contractual payments due for more than 60 days, default of interest
due for more than 30 days or there is significant difficulty of the counterparty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
minimise credit risk, the Group has developed and maintained the Group&#8217;s credit risk gradings to categorise exposures according
to their degree of risk of default. The credit rating information is supplied by publicly available financial information and the Group&#8217;s
own trading records to rate its major customers and other debtors. The Group considers available reasonable and supportive forward-looking
information which includes the following indicators:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
                                            or expected significant adverse changes in business, financial or economic conditions that
                                            are expected to cause a significant change to the debtor&#8217;s ability to meet its obligations</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
                                            or expected significant changes in the operating results of the debtor</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            increases in credit risk on other financial instruments of the same debtor</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            changes in the expected performance and behaviour of the debtor, including changes in the
                                            payment status of debtors in the Group and changes in the operating results of the debtor.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.9pt; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the analysis above, a significant increase in credit risk is presumed if a debtor is more than 30 days past due in making contractual
payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group determined that its financial assets are credit-impaired when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is significant difficulty of the debtor</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            breach of contract, such as a default or past due event</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is becoming probable that the debtor will enter bankruptcy or other financial reorganisation</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is a disappearance of an active market for that financial asset because of financial difficulty</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group categorises a receivable for potential write-off when a debtor fails to make contractual payments more than 120 days past due.
Financial assets are written off when there is evidence indicating that the debtor is in severe financial difficulty and the debtor has
no realistic prospect of recovery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002183" name="BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock"><p id="xdx_89E_ecustom--DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_zog6lTZLQyq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s current credit risk grading framework comprises the following categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8B2_zYzUwT9fUvRi" style="display: none">Schedule of group&#8217;s current
credit risk grading framework</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definition
    of category</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
                                            for recognising</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expected
    credit loss</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ECL)</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zVczdX1ZFn16" title="Definition of category"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryOneMember" id="Fact002185" name="BMGL:DescriptionOfCreditRisk">Counterparty
    has a low risk of default and does not have any past-due amounts.</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zNyyOW8P7z1j" title="Basis for recognizing ECL"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryOneMember" id="Fact002187" name="BMGL:BasisForRecognizingExpectedCreditLoss">12-month
    ECL</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zRLruJZXQntb" title="Definition of category"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryTwoMember" id="Fact002189" name="BMGL:DescriptionOfCreditRisk">Amount
    is &gt;30 days past due or there has been a significant increase in credit risk since initial recognition.</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zkukHFujJcZ" title="Basis for recognizing ECL"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryTwoMember" id="Fact002191" name="BMGL:BasisForRecognizingExpectedCreditLoss">Lifetime
    ECL - not credit-impaired</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z9U7FpNFObC9" title="Definition of category"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryThreeMember" id="Fact002193" name="BMGL:DescriptionOfCreditRisk">Amount
    is &gt;60 days past due or there is evidence indicating the asset is credit-impaired (in default).</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z4YRgcfhBHXh" title="Basis for recognizing ECL"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryThreeMember" id="Fact002195" name="BMGL:BasisForRecognizingExpectedCreditLoss">Lifetime
    ECL - credit impaired</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zt9RtvWDB877" title="Definition of category"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryFourMember" id="Fact002197" name="BMGL:DescriptionOfCreditRisk">There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zYzuI04ZA2wj" title="Basis for recognizing ECL"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CategoryFourMember" id="Fact002199" name="BMGL:BasisForRecognizingExpectedCreditLoss">Amount
    is written off</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><p id="xdx_8AC_zqYNOEEcEJq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002201" name="BMGL:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory"><p id="xdx_89F_ecustom--ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_zKm570U498u4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the credit quality of the Group&#8217;s financial assets, as well as maximum exposure to credit risk by credit risk
rating categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span id="xdx_8B8_zrG1GeTypH5h" style="display: none">Schedule of financial assets,
minimum exposure to credit risk</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>12-month
                                            or</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lifetime</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ECL</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>allowance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.85pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_ziTubbL19H18" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580,313</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zlUyH4k8RT1a" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002205" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">781,133</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_z7fiYqAVot4" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,799,180</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z3LbbXTeA2P4" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,362,632</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUWmScCAw49k" title="Deposits" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2211">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zME7G9b0uaXh" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,362,632</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td title="Deposits" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Deposits" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(781,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td title="Deposits" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>12-month
                                            or</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lifetime
                                            </b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ECL</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>allowance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.65pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zI5oyuT6Qu42" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002215" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,281,902</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zsLG2ZF2P4Sd" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002217" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">993,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zr47nPmnEtz8" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002219" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,288,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.65pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zqKJeUcVd6Gd" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002221" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,820,731</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWCpyLh8alNh" title="Deposits" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2223">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zIbc0ZOVrFui" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002225" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,820,731</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--ExpectedCreditLosses_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zKUfOFKE1Taf" title="Expected credit losses" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember" id="Fact002227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">993,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zq5uK3F5IJVi" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002229" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,133,573</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zwDyLLeajhh9" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">460,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zPcX0KAr0NH6" title="Trade receivables" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember" id="Fact002233" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,673,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z7EHk61iRdth" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002235" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">90,252</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zJzifXoOaLn8" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zBxg9HJHStW4" title="Deposits" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:LongtermDeposits" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002239" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">90,252</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">Amount due from&#160;&#160;related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUPrVPwObpD" title="Amount due from related parties" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002241" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWrqjJ0jJc96" title="Amount due from related parties" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2243">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zhC9d4R2trJ8" title="Amount due from related parties" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember" id="Fact002245" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zGTw3eF0G8f3" title="Expected credit losses" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember" id="Fact002247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">460,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zp9uUKXq0Ri8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Trade
receivables</span></b> (Note 1)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all
trade receivables. The Group determines the ECL by using a provision matrix, estimated based on historical credit loss experience based
on the past due status of the debtors, adjusted as appropriate to reflect current conditions and estimates of future economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002249" name="BMGL:ScheduleOfExpectedCreditRiskExplanatory"><p id="xdx_89B_ecustom--ScheduleOfExpectedCreditRiskExplanatory_z7GFIIDMZome" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span id="xdx_8B8_z0PTqeAx9RTg" style="display: none">Schedule of credit risk</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zSWj97CBRD38" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_z8VWMWkzkBS5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zxdsx6dfxx67" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zrhImKX3LN81" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zbYszB9rMicc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20250630_zDHftNBWLb35" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Days past due</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not past</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>due</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">1 &#8211; 60</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">61 &#8211; 120</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 120 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 365 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zOQLD6ESaT5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember" id="Fact002251" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember" id="Fact002252" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002253" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002254" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">41</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember" id="Fact002255" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2256">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TradeReceivables_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zB4qKU2FXWRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember" id="Fact002258" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">703,914</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember" id="Fact002259" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">843,949</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002260" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">133,126</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002261" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">644,290</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember" id="Fact002262" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">255,034</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember" id="Fact002263" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">2,580,315</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExpectedCreditLosses_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zyrjjlngKzb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember" id="Fact002265" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">130,816</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember" id="Fact002266" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">97,778</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002267" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">34,150</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002268" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">263,355</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember" id="Fact002269" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">255,034</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember" id="Fact002270" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USD">781,133</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630_z7aXZHiS2tO" title="Trade receivables" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30" id="Fact002272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,799,182</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zhq2ibgnSIne" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zoN70IEmx7P4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_z4hJs9mERKW3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49A_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zKpbcz8XHpYi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zi6k2QOgYn5c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20250630_zDcRTUyZPDdi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Days past due</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not past</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>due</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">1 &#8211; 60</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">61 &#8211; 120</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 120 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 365 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFtwuIwycojf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember" id="Fact002274" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember" id="Fact002275" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002276" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002277" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">41</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember" id="Fact002278" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2279">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeReceivables_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zb1J5GV3pMq2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember" id="Fact002281" format="ixt:numdotdecimal" decimals="INF" unitRef="SGD">895,308</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember" id="Fact002282" format="ixt:numdotdecimal" decimals="INF" unitRef="SGD">1,073,420</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002283" format="ixt:numdotdecimal" decimals="INF" unitRef="SGD">169,323</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002284" format="ixt:numdotdecimal" decimals="INF" unitRef="SGD">819,473</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember" id="Fact002285" format="ixt:numdotdecimal" decimals="INF" unitRef="SGD">324,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember" id="Fact002286" format="ixt:numdotdecimal" decimals="INF" unitRef="SGD">3,281,902</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ExpectedCreditLosses_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFqaNuN7FvK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember" id="Fact002288" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGD">166,385</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember" id="Fact002289" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGD">124,365</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002290" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGD">43,436</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember" id="Fact002291" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGD">334,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember" id="Fact002292" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGD">324,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember" id="Fact002293" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="SGD">993,524</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--CreditRiskTradeReceivables_iI_c20250630_zJ6JINQ8o1d1" title="Trade receivables" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2025-06-30" id="Fact002295" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,288,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zcJwzkYlvbrf" title="ECL rate"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember" id="Fact002297" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.95</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zQsdCAPyt6Hh" title="ECL rate"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" id="Fact002299" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zUJ39UpmVr8a" title="ECL rate"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" id="Fact002301" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.61</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zy7ZnMYaXuI6" title="ECL rate"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember" id="Fact002303" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.54</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zUhfYuAVsWdf" title="ECL rate"><ix:nonFraction name="ifrs-full:ExpectedCreditLossRate" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember" id="Fact002305" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89.08</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zge5wyrSroV9" title="Estimated total gross carrying amount at"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember" id="Fact002307" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">814,544</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zPtCBonBXbLg" title="Estimated total gross carrying amount at"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" id="Fact002309" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">321,783</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zE32rCuLq1L2" title="Estimated total gross carrying amount at"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" id="Fact002311" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">227,123</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zCkKjpLhdN08" title="Estimated total gross carrying amount at"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember" id="Fact002313" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">323,323</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zd8w0DKwHK1h" title="Estimated total gross carrying amount at"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember" id="Fact002315" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">446,800</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zMh3HipymTd3" title="Estimated total gross carrying amount at"><ix:nonFraction name="ifrs-full:TradeReceivables" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember" id="Fact002317" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,133,573</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zpBBQn7jbiyj" title="ECL">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember" id="Fact002319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">15,880</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_908_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zt9l4iR1bBlk" title="ECL">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" id="Fact002321" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">6,494</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_90E_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zRTtaH1tSFkk" title="ECL">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" id="Fact002323" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">5,939</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zJxe2eSSgzUd" title="ECL">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember" id="Fact002325" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">34,093</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_90A_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_znOSSRDaQy3" title="ECL">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember" id="Fact002327" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">398,007</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zPSKFY2iDg8h" title="ECL">(<ix:nonFraction name="BMGL:ExpectedCreditLosses" contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember" id="Fact002329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">460,413</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20240630_zwIIwwVh3NK9" title="Trade receivables" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:CreditRiskTradeReceivables" contextRef="AsOf2024-06-30" id="Fact002331" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,673,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table><div style="clear: both"></div>

</ix:nonNumeric><p id="xdx_8A4_zdoHYasj5Hte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding movement of loss of allowance of trade receivables is disclosed in Note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Excessive
risk concentration</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentrations
arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have
economic features that would cause their ability to meet contractual obligations to be similarly affected by changes in economic, political
or other conditions. Concentrations indicate the relative sensitivity of the Group&#8217;s performance to developments affecting a particular
industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exposure
to credit risk</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group have no significant concentration of credit risk other than those balances with related company comprising <span id="xdx_907_ecustom--PercentageOfTradeReceivables_dp_c20240701__20250630_zFBePr3Vba25" title="Percentage of trade receivables"><ix:nonFraction name="BMGL:PercentageOfTradeReceivables" contextRef="From2024-07-01to2025-06-30" id="Fact002333" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% (June 30, 2024: <span id="xdx_908_ecustom--PercentageOfTradeReceivables_dp_c20230701__20240630__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zDomN74dqWdb" title="Percentage of trade receivables"><ix:nonFraction name="BMGL:PercentageOfTradeReceivables" contextRef="From2023-07-012024-06-30_ifrs-full_TopOfRangeMember" id="Fact002335" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>%
and <span id="xdx_904_ecustom--PercentageOfTradeReceivables_dp_c20230701__20240630__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zffazXWcOzwd" title="Percentage of trade receivables"><ix:nonFraction name="BMGL:PercentageOfTradeReceivables" contextRef="From2023-07-012024-06-30_ifrs-full_BottomOfRangeMember" id="Fact002337" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>%) of trade receivables. The Group has credit policies and procedures in place to minimise and mitigate its credit risk exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Other
receivables, amount due from related parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assessed the latest performance and financial position of the counterparties, adjusted for the future outlook of the industry in
which the counterparties operate in, and concluded that there has been no significant increase in the credit risk since the initial recognition
of the financial assets. Accordingly, the Group measured the impairment loss allowance using 12-month ECL and determined that the ECL
is insignificant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">b)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Market risk</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
risk is the risk that changes in market prices, such as interest rates and foreign exchange rates will affect the Group&#8217;s income.
The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing
the return on risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Foreign
currency risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s foreign exchange risk results mainly from cash flows from transactions denominated in foreign currencies. At present, the
Group does not have any formal policy for hedging against currency risk. The Group ensures that the net exposure is kept to an acceptable
level by buying or selling foreign currencies at spot rates, where necessary, to address short term imbalances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has transactional currency exposures arising from sales or purchases that are denominated in a currency other than the functional
currency of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group determined that sensitivity to the exchange rate changes does not impose significant impact on the results and operations of the
Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">b)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Market risk (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Interest
rate risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
rate risk is the risk that the fair value or future cash flows of the Group&#8217;s financial instruments will fluctuate because of changes
in market interest rates. The Group&#8217;s exposure to interest rate risk arises primarily from fixed deposits. These transactions and
balances were not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not expect any significant effect on the Group&#8217;s profit or loss arising from the effects of reasonably possible changes
to interest rates on interest bearing financial instruments at the end of the financial year due to those interest-bearing assets and
liabilities are insignificant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">c)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Liquidity risk</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
risk refers to the risk that the Group will encounter difficulties in meeting its short-term obligations due to shortage of funds. The
Group&#8217;s exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. It is
managed by matching the payment and receipt cycles. The Group&#8217;s objective is to maintain a balance between continuity of funding
and flexibility through the use of standby credit facilities. The Group finances its working capital requirements through funds generated
from operations of the Group. Management is satisfied that funds are available to finance the operation of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002339" name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities"><p id="xdx_893_eifrs-full--MaturityAnalysisForNonderivativeFinancialLiabilities_zHuwj19Xz6Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarises the maturity profile of the Group&#8217;s financial assets and liabilities at the reporting date based on contractual
undiscounted repayment obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span id="xdx_8B8_zTqCxxh6D5Qg" style="display: none">Schedule of remaining contractual
undiscounted repayment obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zDDiv7Uyiqie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zfr36bvkRSbc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zLkTVD1YOtD2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zvbVnaM9Of34" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_zvJDoZzrgjHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,882</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,882</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,323,882</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_uUSD_zmW9cWmnPnXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zs51y2g0Ooci" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_ziLkbRfhBvgb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,666,112</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,666,112</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,666,112</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2359">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Financial
                                            risk management</span> (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">c)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Liquidity risk (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="display: none"></span></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znO760aU70nh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zurfTvoC7Yye" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zb5RlKmYKbZb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhWJyUO6pjGd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025 (Continued)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_uUSD_zsHKTzy7TL71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,215,322</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,215,322</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,215,322</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2364">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_zrIw9nuG007f" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AmountDueToFormerDirector_iI_zcxyvuJAgCp9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Borrowings_iI_uUSD_zqkAZygjtpY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,688,478</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,688,478</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,667,677</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,802</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_z2zpiHjOhMxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,903,800</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,903,800</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,882,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,802</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_uUSD_zvvGDwrZUDEl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total net undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,762,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,762,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,783,113</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002389" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,020,802</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zhdhZnAY4t68" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zW4tLDXGLexd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zNgEeiziSPd8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhhxnr1PC8wj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years to</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_zMSKFELmFdhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002391" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,315,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002392" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,315,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002393" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,315,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2394">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zgJePvqtm8xi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002396" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002397" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002398" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2399">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_zJXtpSinTMGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002401" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">12,294,583</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002402" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">12,294,583</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002403" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">12,294,583</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2404">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zspTpalBKRai" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002406" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,633,368</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002407" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,633,368</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002408" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,633,368</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2409">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Borrowings_iI_zkkKL6iOu2D8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002411" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,419,476</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002412" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,419,476</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002413" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,121,119</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002414" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,358</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_zjnCSjWNQJw3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002416" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,052,844</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002417" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,052,844</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002418" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">8,754,487</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002419" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,298,358</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_z5LgE80ohDmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total net undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember" id="Fact002421" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,241,739</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember" id="Fact002422" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,241,739</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002423" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,540,096</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,298,358</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znN8DpCkgdq6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zY9OSMmQ8S63" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zlWNv2tbOdO" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zqIuGgJuqj83" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_z9OLBq9OEQF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002426" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,763,412</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002427" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,763,412</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002428" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,763,412</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2429">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zNPISg6gTXh4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002431" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002432" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002433" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2434">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_z3wIzxMYjFO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002436" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002437" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002438" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2439">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_ztvSrpCVRiw9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002441" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">14,271,705</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002442" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">14,271,705</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002443" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">14,271,705</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2444">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zodiNqYuKph3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002446" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,184,619</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002447" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,184,619</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002448" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,184,619</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2449">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z8RYXNGOL424" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002451" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002452" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002453" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2454">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AmountDueToFormerDirector_iI_zWRDy7mbp5w5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002456" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">111,459</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002457" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">111,459</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002458" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">111,459</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2459">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--Borrowings_iI_zDMi5kh8vIKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002461" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,289,790</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002462" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,289,790</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002463" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,706,356</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002464" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z8tOCrqCxNie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002466" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,897,258</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002467" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,897,258</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002468" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,313,824</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002469" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_zEskyGVecE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total net undiscounted financial assets/(liabilities)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember" id="Fact002471" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,374,447</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember" id="Fact002472" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,374,447</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember" id="Fact002473" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,957,881</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="BMGL:TotalNetUndiscountedFinancialAssetsliabilities" contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember" id="Fact002474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="SGD">1,583,434</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z6PafSkHHsDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002476" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory"><p id="xdx_803_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zFzaAV8cAUle" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">24.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span id="xdx_82A_zIFdHuv9GwKb">Financial instruments by category</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the reporting date, the aggregate carrying amounts of financial assets, at FVPL, financial assets measured at amortized cost and financial
liabilities at amortized cost were as follows:</span></p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002478" name="BMGL:ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory"><p id="xdx_89E_ecustom--ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_zmCC3cVS4V3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zZnnlwFhzcd8" style="display: none">Schedule
of financial assets measured at amortized cost and financial
liabilities at amortized cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zVEFq3dl8azk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zmZEV0hdg5X9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financial assets measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--TradeAndOtherCurrentReceivables_iI_z0LKC611wQmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zC2ElVRk1an3" title="Trade and other receivables" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,324,082</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002480" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">9,315,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002481" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,763,412</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iI_zxW5T2z5Aw84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zTqqPBT1zTHe" title="Cash and cash equivalents" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,342,230</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002485" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,979,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002486" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,951,053</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zwvylzcMY9hh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2490">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002491" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">10,557,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TotalUndiscountedFinancialAssets_iI_zGe8bkeB0v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total financial assets measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zZgeX7zugoW8" title="Total financial assets measured at amortized cost" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,666,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002493" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">12,294,583</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:TotalUndiscountedFinancialAssets" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002494" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">14,271,705</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financial liabilities measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeAndOtherPayables_iI_zt9Vfjrdue9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--TradeAndOtherPayables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zATLIUf99y0j" title="Trade and other payables" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,215,322</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002498" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,633,369</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002499" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">2,184,619</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z2yV5YWknT0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zpqOqmykWp4" title="Amount due to related parties" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2506">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2503">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002504" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">1,311,390</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AmountDueToFormerDirector_iI_zgR4cCpHnL2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--AmountDueToFormerDirector_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zNcRi8uGR6ai" title="Amount due to a former director" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2511">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2508">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="BMGL:AmountDueToFormerDirector" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002509" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">111,459</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Borrowings_iI_zy6Wr8d5EP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--Borrowings_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zYAiDlnSzWja" title="Borrowings" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002513" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">61,371</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002514" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">4,261,290</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z2g9QyNok5Ie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total financial liabilities measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zLxzGpFYvJzg" title="Total financial liabilities measured at amortized cost" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,263,573</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002518" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">6,694,739</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" id="Fact002519" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">7,868,758</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zkAu9wq9lKU4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002523" name="BMGL:CapitalManagementExplanatory"><p id="xdx_807_ecustom--CapitalManagementExplanatory_zKWYOklXuIm4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; display: none; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">25.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"> <span id="xdx_829_zDrs2MakOlxk">Capital management</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of the Group&#8217;s capital management is to safeguard the entity&#8217;s ability to continue as a going concern.
The related parties have undertaken not to recall the amounts due to them until such time the Company is in the position to repay these
amounts without impairing its liquidity position and to provide continuing financial support and adequate funds to enable the Company
to meet its liabilities as and when they fall due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
changes were made in the objectives, policies or processes during the financial year ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is not subjected to either internal or external imposed capital requirement. The Group&#8217;s overall strategy remains unchanged
from 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_001" style="font-weight: bold">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact002525" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_zrE0f8up98E8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">26.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span id="xdx_824_zQoD25TCaUnc">Events occurring after the reporting period</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no significant events that occurred after the financial year ended June 30, 2025, which require adjustment to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
the following non-adjusting events occurred subsequent to the reporting period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, the Company has appointed NLA DFK Assurance PAC as its new auditor, in place of
                                            Onestop Assurance PAC.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, the Company has put on hold the plan for the acquisition of Bitcoin in exchange
                                            for the issue of ordinary shares in the Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, Basel Medical Group Pte Ltd has made <span id="xdx_905_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zHz1BQ46TLka" title="Investments percentage"><span id="xdx_905_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zyzkgV3yp9zh" title="Investments percentage"><span id="xdx_909_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zzgm5LhtVKJa" title="Investments percentage"><ix:nonFraction name="BMGL:InvestmentsPercentage" contextRef="From2025-07-012025-07-31_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002527" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="BMGL:InvestmentsPercentage" contextRef="From2025-07-012025-07-31_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002529" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="BMGL:InvestmentsPercentage" contextRef="From2025-07-012025-07-31_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002531" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% investments in SSOC Novena Pte. Ltd.,
                                            SSOC Orchard Pte. Ltd. and SSOC Farrer Park Pte. Ltd. In September 2025, <span id="xdx_90E_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zrPqT0yIUyXa" title="Investments sale percentage"><span id="xdx_90F_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1lqMQe4h8zd" title="Investments sale percentage"><span id="xdx_905_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zYRCPWbpxRdg" title="Investments sale percentage"><ix:nonFraction name="BMGL:InvestmentsSalePercentage" contextRef="From2025-09-012025-09-30_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002533" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="BMGL:InvestmentsSalePercentage" contextRef="From2025-09-012025-09-30_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002535" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="BMGL:InvestmentsSalePercentage" contextRef="From2025-09-012025-09-30_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002537" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% of these investments
                                            in each of the 3 companies has been sold to external party, such that the company holds <span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zifyCwlFvWJe" title="Investments hold percentage"><span id="xdx_90D_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zti3fExn0fBl" title="Investments hold percentage"><span id="xdx_908_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zcLO6L8LAk1j" title="Investments hold percentage"><ix:nonFraction name="BMGL:InvestmentsHoldPercentage" contextRef="From2025-09-012025-09-30_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002539" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="BMGL:InvestmentsHoldPercentage" contextRef="From2025-09-012025-09-30_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002541" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="BMGL:InvestmentsHoldPercentage" contextRef="From2025-09-012025-09-30_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002543" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>%
                                            of the share capital in each of the 3 companies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, the Company&#8217;s subsidiary, Pharma Avenue Pte Ltd, increased its share capital
                                            to <span id="xdx_90D_eifrs-full--NumberOfSharesIssued_iI_c20250731__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zdYrgspkxlX2" title="Number of shares issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2025-07-31_custom_PharmaAvenuePteLtdMember_ifrs-full_TopOfRangeMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002545" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            August 2025, Mr Tan Boon Chye (Darren) was appointed as the Chief Commercial Officer of the
                                            Company. In the same month, Mr Vincent Teo resigned as Chief Partnership Officer from the
                                            Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2025, Eyetrust Medical Pte Ltd was incorporated with Basel Medical Group Pte Ltd
                                            holding <span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--EyetrustMedicalPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_znrYhAnyo6z8" title="Investments hold percentage"><ix:nonFraction name="BMGL:InvestmentsHoldPercentage" contextRef="From2025-09-012025-09-30_custom_EyetrustMedicalPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002547" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span>% of the ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2025, the Company&#8217;s subsidiary, Bethesda Medical Pte Ltd, has fully disposed
                                            its investment in associate company, Cereza Bethesda Medical Pte Ltd.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            October 2025, Chartered Imaging Pte Ltd was incorporated with Basel Medical Group Pte Ltd
                                            holding <span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20251001__20251031__ifrs-full--CounterpartiesAxis__custom--CharteredImagingPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_ziYrHvnXvOD4" title="Investments hold percentage"><ix:nonFraction name="BMGL:InvestmentsHoldPercentage" contextRef="From2025-10-012025-10-31_custom_CharteredImagingPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002549" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            October 2025, Basel Medical Group Pte Ltd has obtained a S$<span id="xdx_901_eifrs-full--NetDebt_iI_c20251031__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1Hr2BKEC9t2" title="Loan"><ix:nonFraction name="ifrs-full:NetDebt" contextRef="AsOf2025-10-31_custom_NonadjustingEventsAfterReportingPeriodMember" id="Fact002551" format="ixt:numdotdecimal" decimals="0" unitRef="SGD">3,000,000</ix:nonFraction></span> term loan facility for
                                            a 3 year tenor.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                                            <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">j)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The major shareholder, Rainforest Capital VCC has agreed to provide financial support for at least 12 months from the date of the auditor&#8217;s
report.</td></tr>
                                                                            </table>

</ix:nonNumeric><p id="xdx_81A_zSBMjKwgrYzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 115; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>ex8-1.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
8.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>List
of Subsidiaries of the Registrant</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 73%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction
    of Incorporation</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
    Medical Group Pte. Ltd. (previously known as Singmed Specialists Pte. Ltd.)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
    Knee, Sports and Orthopaedic Clinic Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
    Knee, Sports and Orthopaedic Services Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
    Sports &amp; Orthopaedic Clinic Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore
    Sports &amp; Orthopaedic Services Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC
    Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOS
    Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharma
    Avenue Pte. Ltd. (previously known as Singapore Sports and Physiotherapy Centre Pte. Ltd.)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
    Medflow Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bethesda
    Medical Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oasis
    Medical Clinic Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC
    Farrer Park Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC
    Novena Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSOC
    Orchard Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyetrust
    Medical Pte. Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chartered
    Imaging Pte. Ltd</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.2
<SEQUENCE>3
<FILENAME>ex11-2.htm
<DESCRIPTION>EX-11.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
11.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BASEL
MEDICAL GROUP LTD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>STATEMENT
OF POLICIES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>GOVERNING
MATERIAL NON-PUBLIC INFORMATION AND</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>THE
PREVENTION OF INSIDER TRADING</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OBJECTIVE</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly-traded company, Basel Medical Group Ltd (the &ldquo;Company&rdquo; or &ldquo;we&rdquo;), directors, officers and employees
of the Company, its subsidiaries and consolidated affiliated entities, and others who may have access to information regarding the Company
are subject to securities laws relating to the treatment of undisclosed material information that prohibit trading in the Company&rsquo;s
securities while in possession of material non-public information about the Company. These laws also prohibit trading in the securities
of other public companies to the extent that you come into possession of material non-public information of those companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidelines set out in this Trading Policy (the &ldquo;Policy&rdquo;) have been developed to protect the Company and those to whom this
Policy applies by preventing improper trading, and the appearance of improper trading, in the Company&rsquo;s securities. These guidelines
are in addition to, and do not replace, securities laws in the United States and other applicable jurisdictions governing the trading
of the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is essential that all persons to whom this Policy applies are aware of the laws relating to insider trading. It is your personal responsibility
to ensure that when you propose to trade in the Company&rsquo;s securities or the securities of other public companies with which we
do business, that you comply with this Policy and all applicable insider trading laws. If you are ever unsure of whether or not you are
permitted to trade in the Company&rsquo;s securities or the securities of another public company, contact the Chief Executive Officer
or Chief Financial Officer (the &ldquo;Compliance Officers&rdquo;) at ______ before you act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCOPE</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all directors, officers and employees of the Company and its subsidiaries and consolidated affiliated entities and
to consultants and contractors of the Company and its subsidiaries and consolidated affiliated entities, wherever located.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should be particularly sensitive to ensuring that your spouse, partner or other family members who live with you do not, intentionally
or unintentionally, gain access to undisclosed material information about the Company. The trading restrictions in this Policy and under
securities laws, as well as the potential consequences for violation, will apply to your spouse, partner or other family members if they
gain access to undisclosed material information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all trading in any securities of the Company, including any of the Company&rsquo;s shares, securities convertible or
exchangeable into shares or other securities of the Company, debt instruments, puts, calls, options and any other rights or obligations
to purchase or sell securities of the Company. It also applies to derivative securities relating to the Company&rsquo;s securities, whether
or not issued by the Company. &ldquo;Trading&rdquo; for the purposes of this Policy includes purchases, sales and gifts, unless otherwise
stated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is important to understand that this Policy applies to all securities that you beneficially own and/or over which you have direct or
indirect control or direction, which includes securities owned by other persons (including family members, trusts or corporations) where
you direct or influence their investment decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
information</U>&rdquo; means any fact or change (or a decision by the Board of Directors or senior management to implement a change)
in the business, operations, financial situation or capital of the Company that would reasonably be expected to have a significant effect
on the market price or value of the Company&rsquo;s securities. Material information also includes information that a reasonable investor
would consider to be important in reaching an investment decision. Any information that could be expected to affect a company&rsquo;s
stock price, whether positive or negative, or whether the change is large or small, may be considered material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to define all categories of information that is or may be considered material, as the ultimate determination of materiality
by enforcement authorities will be based on an assessment of all of the facts and circumstances. Information that is material at one
point in time may cease to be material at another point in time, and vice versa. While the following is not intended to be an exhaustive
list or a substitute for the exercise of judgment in making materiality determinations, some examples of information that could be considered
to be material include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                            and financial results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
                                            projections;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proposed
                                            mergers, acquisitions or joint ventures involving the Company or divestitures of significant
                                            assets or a subsidiary or consolidated affiliated entity by the Company;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in control or management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
                                            of Directors changes;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in officers or other senior management of the Company;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
                                            or private sales of the Company&rsquo;s securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">proposed
                                            or pending material financings;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">events
                                            of default under financing or other agreements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">material
                                            transactions involving directors, officers or principal shareholders of the Company;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labor
                                            disputes or disputes with key customers;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
                                            disasters or any other significant event related to environment, health and safety;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the Company&rsquo;s auditors, or a notification from its auditors that the Company may
                                            no longer rely on the auditors&rsquo; audit report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending
                                            or threatened litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">internal
                                            investigations and compliance-related matters;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">material
                                            impairments, write-offs or restructurings;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creation
                                            of a material direct or contingent financial obligation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impending
                                            bankruptcy or financial liquidity problems;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">material
                                            agreements not in the ordinary course of business (or termination thereof);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            risks or incidents relating to cybersecurity, data protection or privacy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decisions
                                            or recommendations regarding dividend payments or policies or other modifications to the
                                            rights of the Company&rsquo;s securityholders;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in capital or corporate structure; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            matters which could affect the market for Company securities, such as a forthcoming research
                                            recommendation by a major brokerage firm or the intention by any party to buy or sell a large
                                            amount of Company securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Undisclosed
material information</U>&rdquo; means material information that has not yet been generally disclosed to the public. Material information
about the Company should be considered non-public or undisclosed unless there is a certainty that it is publicly available. As a general
rule, material information is only considered &ldquo;generally disclosed&rdquo; once it has been accurately published and widely disseminated,
making it generally available to investors, and sufficient time has elapsed in order for investors to react to the information. The circulation
of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. Given the requirement that
sufficient time has elapsed for investors to react to the information, even after public disclosure of material information about the
Company, you must wait one (1) full trading day before you can treat the information as public, unless otherwise advised by the Compliance
Officers that the sufficient time period is longer or shorter in light of prevailing circumstances. The term &ldquo;trading day&rdquo;
means a day on which the stock exchange(s) on which the Company&rsquo;s securities are traded (currently Nasdaq) are open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GUIDELINES</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Insider trading and tipping restrictions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
trading and tipping prohibitions are designed to ensure that anyone who has access to undisclosed material information does not trade
or assist others in trading to the disadvantage of investors generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <I>Persons
in a &ldquo;special relationship&rdquo; with the Company</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may come into possession of material information about the Company or other companies in the normal course of your work (such as news
about financial results prior to public disclosure, material corporate transactions, significant management changes, etc.). Under applicable
United States securities laws, directors, officers, employees, contractors and consultants of the Company, among others, are considered
to be in a &ldquo;special relationship&rdquo; with the Company and, as a result, are caught by the prohibitions against insider trading
and tipping described below. The concept of a special relationship with a public company is defined very broadly and extends to any person
or company who falls within one of the categories summarized in Appendix A. Importantly, it also captures a potentially infinite chain
of persons who receive undisclosed material information about the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <I>No
trading on undisclosed material information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is illegal and strictly prohibited by this Policy to directly or indirectly engage in any transaction involving a purchase or sale of
the Company&rsquo;s securities, or otherwise engage in any transactions (including gifting), directly or indirectly, in any of the Company&rsquo;s
securities, at any time when you have knowledge of undisclosed material information. To do so would be &ldquo;insider trading&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may, from time to time, have to forego a proposed transaction in the Company&rsquo;s securities even if you planned to complete the transaction
before learning of the undisclosed material information. Questions about whether information is material, whether material information
is now public or has been &ldquo;generally disclosed&rdquo;, or has ceased to be material, should be directed to the Compliance Officers
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
that may be necessary or justifiable for independent reasons (such as the need to raise money to settle a tax payment or for an emergency
expenditure) are not exempted from these restrictions or the restrictions on tipping. The securities laws do not recognize mitigating
circumstances and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company&rsquo;s reputation
for adhering to the highest standards of conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <I>No
&ldquo;tipping&rdquo; or &ldquo;recommending&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also illegal and strictly prohibited by this Policy to disclose, other than in the necessary course of business, undisclosed material
information relating to the Company to any other person (such as, but not limited to, family members, neighbors, friends, acquaintances,
investment professionals, financial planners, family companies or family trusts), or to make recommendations or encourage the purchase,
sale or gifting of the Company&rsquo;s securities on the basis of material non-public information. To do so would be &ldquo;tipping&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
question of whether a particular disclosure is being made in the &ldquo;necessary course of business&rdquo; is a mixed question of law
and fact that must be determined on a case-by-case basis. While communications between employees, officers and board members, legal counsel,
auditors and other professional advisors is generally acceptable, disclosure to analysts, institutional investors, other market professionals
and members of the press and other media is a form of &ldquo;tipping&rdquo; and will not be considered to be in the necessary course
of business. Questions about whether certain proposed disclosure is in the &ldquo;necessary course of business&rdquo; should be directed
to the Compliance Officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
Restrictions on short selling and other speculative trading</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
to whom this Policy applies must refrain from active or speculative trading involving the Company&rsquo;s securities based on short-term
fluctuations in the price of the Company&rsquo;s securities or other market conditions. This includes, but is not limited to, short sales,
trading in puts, calls or options or similar rights or obligations to buy or sell the Company&rsquo;s securities or derivative securities
relating to the Company&rsquo;s securities, and the purchase of the Company&rsquo;s securities with the intention of quickly reselling
them. You may, of course, exercise stock options granted to you by the Company and, subject to the restrictions discussed in this Policy,
sell shares acquired through the exercise of those options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
put is an option to sell a security at a specific price before a set date, and a call is an option or right to buy a security at a specific
price before a set date. Generally, put options are purchased when a person believes the value of a security will fall, and call options
are purchased when a person believes the value of a security will rise. A transaction in options is, in effect, a bet on the short-term
movement of the Company&rsquo;s securities, and therefore creates the appearance of trading on the basis of material non-public information.
Transactions in options may also focus your attention on short-term performance at the expense of the Company&rsquo;s long-term objectives.
Accordingly, you may not engage in a put, call or other derivative security transaction relating to the Company&rsquo;s securities on
an exchange or in any other organized market without prior approval from the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
Hedging transactions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
to whom this Policy applies are also prohibited from purchasing financial instruments (such as prepaid variable forward contracts, equity
swaps or collars) designed to hedge or offset a decrease in the market value of the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
forms of hedging or monetization transactions, including zero-cost collars, equity swaps, exchange funds and forward sale contracts,
allow a stockholder to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for
upside appreciation in the stock. These transactions allow the stockholder to continue to own the covered securities, but without the
full risks and rewards of ownership. Because participating in these transactions may cause you to no longer have the same objectives
as the Company&rsquo;s other stockholders, you may not engage in such transactions without prior approval from the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
Margin accounts and pledges</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
held in margin accounts for collateral as a margined loan may be sold by the broker without the customer&rsquo;s consent if the customer
fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the
borrower defaults on the loan. A margin sale or foreclosure sale that occurs at a time when the pledgor is aware of material non-public
information or otherwise is not permitted to trade in the Company&rsquo;s securities would fall under the restrictions in this Policy
on trading during such times. Therefore, no person to whom the Policy is applicable may hold the Company&rsquo;s securities in a margin
account or pledge the Company&rsquo;s securities as collateral for a loan without prior approval from the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
Trading blackouts</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established certain periods (&ldquo;Blackout Periods&rdquo;) during which all directors, officers and employees of the Company
shall refrain from conducting any transactions in the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise advised by the Compliance Officers, a Blackout Period will begin 15 days prior to the end of a fiscal half year (December 31)
or fiscal year (June 30) and will end one (1) full trading day after the public release of the Company&rsquo;s financial results for
such fiscal half year or year-end, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time the Compliance Officers, in consultation with other departments within the Company, may impose special Blackout Periods,
during which you and other affected persons will be prohibited from engaging in transactions in the Company&rsquo;s securities. In the
event of a special Blackout Period, the General Counsel will notify you and other affected persons, who will be prohibited from engaging
in any transaction involving the Company&rsquo;s securities until further written notice. The imposition of a special Blackout Period
is itself confidential information, and the fact that it has been imposed may not be disclosed to others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compliance Officers may shorten, suspend, terminate or extend any Blackout Period at such time and for such duration as deemed appropriate
given the relevant circumstances. Any persons affected by such a modification will be appropriately notified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
in the absence of a Blackout Period, any person possessing undisclosed material information about the Company should not engage in any
transactions in its securities until such information has been disclosed publicly for one (1) full trading day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
Certain exceptions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock
Option Exercises</U>: This Policy does not apply to the exercise of any employee stock options, whereby you pay out-of-pocket to exercise
and hold the stock, or to the &ldquo;net exercise&rdquo; of a tax withholding right pursuant to which you elect to have the Company withhold
shares subject to an option to satisfy tax-withholding requirements. This Policy does apply, however, to any sale of shares as part of
a broker-assisted cashless exercise of an option or any other market sale for the purpose of generating the cash needed to pay the exercise
price of an option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employee
Stock Purchase Plan</U>: This Policy does not apply to purchases of Company stock resulting from your periodic contribution of money
to any employee stock purchase plan adopted by the Company from time to time pursuant to the election made by you at the time of enrollment.
This Policy does apply, however, to (1) an election to participate in the plan for any enrollment period, (2) sales of Company stock
purchased pursuant to the plan and (3) an election to increase or decrease the amount of automatic periodic contributions by payroll
deduction to the plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restricted
Stock and Restricted Stock Unit Awards</U>: This Policy does not apply to the vesting and settlement of restricted stock and restricted
stock units, or the withholding or sale of stock back to the Company to satisfy tax withholding obligations upon the vesting of any restricted
stock or restricted stock units. The Policy does apply, however, to any market sale of stock after vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
whose Permitted Entities or Permitted Transferees are involved in such transfer has certified to the Company that such Permitted Entity
or Permitted Transferee has access to all information available to such Key Executive at the time of decision-making with respect to
such transfer; provided further that any such transfer occurring other than during a Blackout Period or absent such certification shall
otherwise be subject to the terms of this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
Retention of Incentive Securities on Company&rsquo;s platform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enhance the Company&rsquo;s ability to enforce this insider trading policy, directors, officers and employees of the Company, subsidiaries
and consolidated affiliated entities must keep the Company&rsquo;s securities acquired under the Company&rsquo;s share incentive plans
(including, for the avoidance of doubt, any equity stock purchase plan) (the &ldquo;Incentive Securities&rdquo;) in the Company&rsquo;s
equity management platform unless otherwise agreed by the Compliance Officers. However, directors and Section 16 Officers (as defined
in Appendix B hereto) may transfer their Incentive Securities to their personal brokerage accounts for limited purposes, such as to establish
a &ldquo;10b5-1 trading plan&rdquo;, subject to prior approval by the Compliance Officers. In addition, Incentive Securities may be transferred
outside of the Company&rsquo;s equity management platform upon termination of employment and/or services with the Company, provided that
(i) directors and Section 16 Officers may not do so until three (3) months after their termination of employment and/or services with
the Company unless otherwise agreed by the Compliance Officers; and (ii) the Compliance Officers may postpone the dates of such transfers
made by those to whom this Policy applies in order to promote compliance with applicable insider trading laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
Pre-clearance of trades by directors and Section 16 Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
trading the Company&rsquo;s securities, directors and Section 16 Officers of the Company must obtain written pre-clearance from the Chairman
of the Board of Directors (whereas for any trading by the Chairman of the Board of Directors, the pre-clearance shall be obtained from
the General Counsel). Each proposed trade will be evaluated to determine if it raises potential insider trading or other concerns under
securities laws. Notwithstanding receipt of pre-clearance, (i) if the director or Section 16 Officer proposing to trade the Company&rsquo;s
securities becomes aware of material nonpublic information or becomes subject to a Blackout Period before the trade is effected, they
shall not proceed with the trade; and (ii) it remains the responsibility of such director or Section 16 Officer to make an independent
determination as to whether they possess material nonpublic information when the trade is made and that the trade is not in violation
of insider trading and other applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
10b5-1 trading plans</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Those
to whom this Policy applies must follow the guidelines set forth in Appendix B hereto if they wish to adopt a 10b5-1 trading plan for
the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
Trading in securities of other companies</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is not restricted to information affecting the Company&rsquo;s securities. You may obtain material information about other companies
in the course of your work for the Company. As such, this Policy and the guidelines set out herein also apply to undisclosed material
information about other companies or entities with which we do business, including but not limited to joint venture partners or service
providers, customers, partners, vendors and suppliers of the Company, as well as potential take-over bid, merger or acquisition candidates
(collectively, &ldquo;business counterparties&rdquo;), when that information is obtained in the course of employment with or providing
services to or on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
and civil penalties, and termination of your relationship with the Company may result from trading in the securities of, or tipping or
recommending trades in relation to, any business counterparty when in possession of undisclosed material information about that business
counterparty. Undisclosed material information about the Company&rsquo;s business counterparties should be treated in the same way and
with the same care as information related directly to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
Confidentiality</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
must maintain the confidentiality of the Company&rsquo;s non-public information. In the event you receive any inquiry or request for
information (particularly financial results and/or projections, and including any inquiry or request to affirm or deny information about
the Company), from any person or entity outside the Company, such as a stock analyst, and it is not part of your regular corporate duties
to respond to such inquiry or request, the inquiry should be referred to Investor Relations, which will determine whether such inquiry
should also be forwarded to the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
Policy awareness and consequences for violation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of this Policy will be made available to directors, officers, employees, consultants and contractors, either directly or by posting the
Policy on the Company&rsquo;s website, and such individuals will be informed whenever significant changes are made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
trading and tipping are serious offences and the consequences can be severe. Company directors, officers, employees, contractors or consultants
who violate this Policy will be subject to disciplinary action by the Company, including possible termination of their relationship with
the Company. This is in addition to facing significant fines and penalties and/or imprisonment. You should carefully consider how your
trading activities may be construed by enforcement authorities who have the benefit of hindsight. Remedies available to the United States
government or private plaintiffs under the securities laws in the United States include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative
                                            sanctions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
                                            injunctions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
                                            awards to private plaintiffs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disgorgement
                                            of all profits;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
                                            fines for the violator of up to three times the amount of profit gained or loss</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoided;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
                                            fines for the employer or other controlling person of a violator (i.e., where the violator
                                            is an employee or other controlled person) of up to the greater of US$1,000,000 or three
                                            times the amount of profit gained or loss avoided by the violator;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
                                            fines for individual violators of up to US$5,000,000 (US$25,000,000 for an entity); and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prison
                                            sentences of up to 20 years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insiders
may also be liable for improper transactions by any person (commonly referred to as a &ldquo;tippee&rdquo;) to whom they have disclosed
undisclosed material information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of
such information. Large penalties have been imposed even when the disclosing person did not profit from the trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
any such activities (or even an accusation of securities law violations) may not only result in significant consequences for you, but
could also be very damaging to the Company&rsquo;s reputation and its relationships with its business counterparties, and may expose
it to liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compliance Officers may, from time to time, permit departures from this Policy and no provision contained herein is intended to give
rise to civil liability to securityholders of the Company or other liability whatsoever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
Post-Termination Transactions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions set out in this Policy continue to apply even after termination of employment or service with the Company. If you are in
possession of material non-public information when your employment or service terminates, you may not trade in the Company&rsquo;s securities
(or another company&rsquo;s securities, as described in this Policy) until such information has become public for one (1) full trading
day or is no longer material. If your employment or service terminates during a quarterly Blackout Period or a special Blackout Period,
you will continue to be subject to the Blackout Period until its end date, unless otherwise determined by the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
Review of the Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy will be reviewed periodically by the Company in order to ensure that it continues to comply with applicable laws and good corporate
governance practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy may be amended at any time at the discretion of the Company&rsquo;s Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
Questions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have questions about general insider trading matters, any part of this Policy or your responsibilities under this Policy, please
contact the Compliance Officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
Acknowledgment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
must confirm your understanding of, and intent to comply with, this Policy by completing, executing and returning to the Compliance Officers
of the Company the form provided in Appendix C hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APPENDIX
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PERSONS
AND COMPANIES IN A SPECIAL RELATIONSHIP WITH THE COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable securities laws, persons considered to be in a &ldquo;special relationship&rdquo; with the Company include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all directors, officers and employees of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
all directors, officers and employees of any subsidiary or consolidated affiliated entity of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
any person or company who beneficially owns, controls or directs more than 10% of the ordinary shares of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
every director or officer of a company referred to in (c);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
a person or company that is: (i) considering or evaluating whether or proposing to make a takeover bid for the shares of the Company;
or (ii) considering or evaluating whether or proposing to become a party to a reorganization, amalgamation, merger, arrangement, or other
business combination with the Company; or (iii) considering or evaluating whether or proposing to acquire a substantial portion of the
Company&rsquo;s property; (each of (i), (ii), or (iii) is herein referred to as a &ldquo;Merger Partner&rdquo;), and every director,
officer or employee of a Merger Partner and any person who beneficially owns, controls or directs more than 10% of the voting shares
of the Merger Partner;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
a person or company (such as lawyers, accountants, engineers, and other advisers or consultants) that is engaging in or considering or
evaluating whether or proposing to engage in any business or professional activity with or on behalf of the Company or a Merger Partner,
and every director, officer or employee thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
a person or company that learns of undisclosed material information while the person or company was any of the persons or companies described
in (a) through (f) above; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
a person or company that learns of undisclosed material information with respect to the Company (a &ldquo;tippee&rdquo;) from any other
person or company in a special relationship with the Company (a &ldquo;tipper&rdquo;) where the tippee knows or ought reasonably to have
known that the tipper is in a special relationship with the Company. This includes a &ldquo;tippee&rdquo; who is tipped by a previous
&ldquo;tippee&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APPENDIX
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULE
10B5-1 TRADING PLAN GUIDELINES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are guidelines for any Rule 10b5-1 trading plan covering the Company&rsquo;s securities proposed to be adopted by persons
to whom the Company&rsquo;s Insider Trading Policy (the &ldquo;Policy&rdquo;) applies. In addition to the Policy and these guidelines,
all 10b5-1 trading plans, as well as amendments, modifications or terminations of those plans, must comply with Rule 10b5-1 promulgated
under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). For the purposes of these guidelines, &ldquo;Section
16 Officers&rdquo; refers to personnel that would be deemed to be an &ldquo;officer&rdquo; in accordance with Rule 16a-1(f) promulgated
under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
<B>Participants. </B>The Company&rsquo;s directors and Section 16 Officers are encouraged to adopt a 10b5-1 trading plan to govern all
trades they make involving the Company&rsquo;s securities. Other employees are not expected to set up 10b5-1 trading plans but if they
wish to do so they should arrange with their own brokers, and seek prior written approval from the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
<B>Plan Adoption and Approval</B>. The 10b5-1 trading plan must be in writing and signed by the person establishing the plan. The Company
will keep a copy of each 10b5-1 trading plan. The Compliance Officers must pre-approve, in writing, each 10b5-1 trading plan, including
any amendment, modification or termination. Participants must enter into a plan in good faith and not as part of a plan or scheme to
evade the prohibitions of Section 10(b) of the Exchange Act or Rules 10b-5 or 10b5-1 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
<B>Representations</B>. Each 10b5-1 trading plan, including any Material Modification (as defined below) of a 10b5-1 trading plan, must
include a representation by the participant certifying that he or she (A) at the time of adoption, (i) is not aware of any material non-public
information about the Company or its securities; and (ii) is adopting the 10b5-1 trading plan or Material Modification of such plan in
good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Exchange Act or Rules 10b-5 or 10b5-1
thereunder; and (B) will at all times act in good faith with respect to the 10b5-1 trading plan, including any amendments, modifications
or terminations thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<B>Timing and Term of a Plan</B>. A participant can only set up a 10b5-1 trading plan when the participant does not possess material
non-public information about the Company. In addition, participants may only adopt a trading plan during an open trading window (as prescribed
under the Policy) and at a time when the participant is not otherwise subject to any trading restrictions imposed by the Company. At
the time of adoption, each 10b5-1 trading plan must have an expected term of at least 12 months but no longer than 24 months, unless
otherwise approved by the General Counsel or an individual designated by the General Counsel. That said, 10b5-1 trading plans may provide
for early termination at any time after 90 days following the day on which the participant is no longer a director, officer or employee
of the Company, provided that the participant no longer possesses any material non-public information about the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
<B>Timing of a Plan Amendment or Modification</B>. All amendments or modifications of a 10b5-1 trading plan must be pre-approved by the
General Counsel or an individual designated by the General Counsel. Each 10b5-1 trading plan may be amended or modified by a participant
to change the amount, price or timing of the purchase, sale or gifting of the securities underlying the 10b5-1 trading plan, including
to amend or change a written formula or algorithm, or computer program that affects the amount, price, or timing of the purchase, sale
or gifting of such securities (a &ldquo;Material Modification&rdquo;), only when the participant does not possess material non-public
information about the Company. In addition, participants may only enter into a Material Modification during an open trading window (as
prescribed under the Policy) and at a time when the participant is not otherwise subject to any trading restrictions imposed by the Company.
All Material Modifications will be considered a termination of the original plan and an adoption of a new 10b5-1 plan, triggering a new
Cooling-Off Period, as described below in Section 7 under &ldquo;Delayed Effectiveness of First Trade&rdquo;. A 10b5-1 Plan may not be
amended or modified more than once in any 12-month period. Administrative changes to a 10b5-1 plan that do not affect the price, number
or timing of a purchase, sale or gifting (or any written formula or algorithm, or computer program that affects the amount, price, or
timing of a purchase, sale or gifting), such as adjustments for a stock split, will not be deemed a termination that triggers a new cooling-off
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
<B>Termination</B>. Each 10b5-1 trading plan may be terminated prior to expiration in accordance with its terms at any time, provided
that such termination must be pre-approved by the General Counsel or an individual designated by the General Counsel. Participants are
discouraged from terminating a 10b5-1 trading plan while in possession of material non-public information. In addition, participants
are discouraged from terminating a 10b5-1 trading plan during a trading blackout period (as prescribed under the Policy) or when such
participants are subject to other trading restrictions imposed by the Company. If a participant terminates his or her 10b5-1 trading
plan early after obtaining such approval, he or she may not trade in the Company&rsquo;s securities until 30 days after the date of termination
or, if the day immediately following this 30-day period falls during a blackout period, after the end of that blackout period. This 30-day
restriction does not apply to 10b5-1 trading plans that expire by their own terms (e.g., pursuant to the expiration date or where all
shares included in the plan have been sold).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
<B>Delayed Effectiveness of First Trade</B>. The first trade under a 10b5-1 trading plan cannot occur until the expiration of the applicable
waiting period (the &ldquo;Cooling-Off Period&rdquo;) as follows: (i) if the participant is a director or Section 16 Officer of the Company,
the later of (A) 90 days following the adoption of the Rule 10b5-1 trading plan or (B) two business days following the disclosure of
the Company&rsquo;s financial results in a Form 6-K or Form 20-F covering the fiscal quarter in which the plan was adopted (subject to
a maximum of 120 days after adoption of the plan), and (ii) for all other participants, at least 30 days. Following a Material Modification
of a 10b5-1 trading plan, trades under the plan must not take place until the expiration of the applicable Cooling-Off Period measured
from the date of the Material Modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
<B>Relationships with Plan Broker; No Subsequent Influence</B>. If the 10b5-1 trading plan allows a broker discretion regarding the details
of trading (e.g., timing, share amounts), the participant cannot communicate any material non-public information about the Company to
the broker, or attempt to influence how, when and whether the broker exercises its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
<B>Plan Specifications; Single-Trade Plans</B>. The 10b5-1 trading plan must specify the amount of stock to be purchased, sold or gifted,
or specify or set an objective formula for determining the amount of stock to be traded. Transaction types such as market, limit and
VWAP orders are allowed. Each 10b5-1 trading plan should specify the timing of trading or allow for the broker to exercise its discretion
regarding the timing of trading. Other than 10b5-1 trading plans providing for nondiscretionary sell-to-cover transactions to satisfy
tax withholding obligations arising exclusively from the vesting of a compensatory award, such as restricted stock or restricted stock
unit awards (&ldquo;Eligible Sell-to-Cover Plans&rdquo;), 10b5-1 trading plans that are designed to effect the open-market purchase or
sale or gifting of Company securities as a single trade may only be entered into once every 12-month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
<B>Other Trades</B>. Except as may be pre-approved by the General Counsel or an individual designated by the General Counsel, no participant
entering into a 10b5-1 trading plan may make open-market purchases or sales or gifting of the Company&rsquo;s securities while a 10b5-1
trading plan is in effect other than in connection with sell-to-cover transactions to satisfy tax withholding obligations arising exclusively
from the vesting of a compensatory award, such as restricted stock or restricted stock unit awards, which shall be sold in compliance
with applicable U.S. securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)
<B>Only One Plan in Effect at Any Time</B>. A participant may have only one 10b5-1 trading plan in effect at any time. A series of separate
contracts with different broker-dealers to execute trades pursuant to a single 10b5-1 trading plan will be treated as a single plan.
However, a participant may adopt an additional 10b5-1 trading plan if trading under the later-commencing plan is not authorized to begin
until after all trades under the earlier-commencing plan are completed or expire without execution. However, if the first plan is terminated
early, the first trade under the later-commencing plan must not be scheduled to occur until expiration of the applicable Cooling-Off
Period measured from the date of termination of the first plan. This restriction on overlapping plans does not apply to Eligible Sell-to-Cover
Plans, provided that the participant is not permitted to exercise control over the timing of the sales under such plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)
<B>No Hedging</B>. Participants subject to the Policy are prohibited from engaging in any hedging or similar transactions designed to
decrease the risks associated with holding the Company&rsquo;s securities. Likewise, before adopting a 10b5-1 trading plan, the participant
must not have entered into a transaction or position that has yet to settle with respect to the securities subject to the 10b5-1 trading
plan. The participant must also agree not to enter into any such transaction while the 10b5-1 trading plan is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)
<B>Mandatory Suspension or Termination</B>. Each 10b5-1 trading plan must suspend trades or terminate if legal, regulatory or contractual
restrictions are imposed on the participant, or other events occur that would prohibit trades under such a plan. For example, trading
would need to be suspended or the plan terminated if these guidelines were amended to preclude the particular sort of trade contemplated
by the plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)
<B>Compliance with Rule 144</B>. Each 10b5-1 trading plan must provide for specific procedures to comply with Rule 144 under the Securities
Act, including the filing of Forms 144, when and if applicable, including the disclosure of the adoption date of a Rule 10b5-1 plan that
is applicable to the planned sale reported on the Form 144. If you need additional information on Rule 144 and Form 144, please contact
the Compliance Officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)
<B>Company Not Party to the Plan</B>. The 10b5-1 trading plan must not have the Company as party to the plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)
<B>Exceptions; Waivers</B>. Any exception to or waiver of these guidelines must be pre-approved by the General Counsel or an individual
designated by the General Counsel, or in the event that the General Counsel is seeking such exception to or waiver of these guidelines,
such request must be pre-approved by the Company&rsquo;s Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
C</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF COMPLIANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:
Compliance Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FROM:
___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RE:
STATEMENT OF POLICIES OF BASEL MEDICAL GROUP LTD GOVERNING MATERIAL NON-PUBLIC INFORMATION AND THE PREVENTION OF INSIDER TRADING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have received, reviewed, and understand the policies set forth in the above-referenced Statement of Policies (such policies, as from
time to time amended, the &ldquo;Policy&rdquo;) and hereby undertake, as a condition to my present and continued employment at or association
with Basel Medical Group Ltd or any of its subsidiaries or affiliated entities, to comply fully with the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby certify that I have adhered to the Policy during the time period that I have been employed by or associated with Basel Medical
Group Ltd or any of its subsidiaries or affiliated entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
agree to adhere to the Policies in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ID
Card Number :</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title:
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>ex12-1.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
by the Principal Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Darren Yen Feng Chhoa, Chief Executive Officer of Basel Medical Group Ltd (the &ldquo;Company&rdquo;), certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 20-F of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rule 13a-15(f) and 15d-15(f)) for the Company and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 17, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Darren Yen Feng Chhoa</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dr. Darren Yen Feng Chhoa</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>ex12-2.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
by the Principal Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Jianing Lu, Chief Financial Officer of Basel Medical Group Ltd (the &ldquo;Company&rdquo;), certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 20-F of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rule 13a-15(f) and 15d-15(f)) for the Company and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 17, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jianing Lu</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Jianing Lu</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ex13-1.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
by the Principal Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Darren Yen Feng Chhoa, Chief Executive Officer of Basel Medical Group Ltd (the &ldquo;Company&rdquo;), hereby certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
the Company&rsquo;s annual report on Form 20-F for the fiscal year ended June 30, 2025 (the &ldquo;Report&rdquo;) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 64.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company for the periods presented therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 17, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Darren Yen Feng Chhoa</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">DZr. Darren Yen Feng Chhoa</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>ex13-2.htm
<DESCRIPTION>EX-13.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
by the Principal Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Jianing Lu, Chief Financial Officer of Basel Medical Group Ltd (the &ldquo;Company&rdquo;), hereby certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
the Company&rsquo;s annual report on Form 20-F for the fiscal year ended June 30, 2025 (the &ldquo;Report&rdquo;) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 64.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company for the periods presented therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 17, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jianing Lu</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Jianing Lu</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>ex97-1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BASEL
MEDICAL GROUP LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLAWBACK
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee (the &ldquo;<U>Committee</U>&rdquo;) of the Board of Directors (the &ldquo;<U>Board</U>&rdquo;) of Basel Medical
Group Ltd (the &ldquo;<U>Company</U>&rdquo;) believes that it is appropriate for the Company to adopt this Clawback Policy (the &ldquo;<U>Policy</U>&rdquo;)
to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, the following definitions shall apply:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
    Group</U>&rdquo; means the Company and each of its subsidiaries or consolidated affiliated entities, as applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Covered
    Compensation</U>&rdquo; means any Incentive-Based Compensation granted, vested or paid to a person who served as an Executive Officer
    at any time during the performance period for the Incentive-Based Compensation and that was Received (i) on or after Effective Date
    (the effective date of the Nasdaq listing standards), (ii) after the person became an Executive Officer, and (iii) at a time that
    the Company had a class of securities listed on a national securities exchange or a national securities association such as Nasdaq.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
    Date</U>&rdquo; means the date of listing of the Company&rsquo;s ordinary shares on Nasdaq.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Erroneously
    Awarded Compensation</U>&rdquo; means the amount of Covered Compensation granted, vested or paid to a person during the fiscal period
    when the applicable Financial Reporting Measure relating to such Covered Compensation was attained that exceeds the amount of Covered
    Compensation that otherwise would have been granted, vested or paid to the person had such amount been determined based on the applicable
    Restatement, computed without regard to any taxes paid (i.e., on a pre-tax basis). For Covered Compensation based on stock price
    or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly
    from the information in a Restatement, the Committee will determine the amount of such Covered Compensation that constitutes Erroneously
    Awarded Compensation, if any, based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder
    return upon which the Covered Compensation was granted, vested or paid and the Committee shall maintain documentation of such determination
    and provide such documentation to Nasdaq.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
    Act</U>&rdquo; means the U.S. Securities Exchange Act of 1934.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Executive
    Officer</U>&rdquo; means the Company&rsquo;s president, principal financial officer, principal accounting officer (or if there is
    no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division,
    or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person
    (whether or not an officer or employee of the Company) who performs similar policy-making functions for the Company. &ldquo;Policy-making
    function&rdquo; does not include policy-making functions that are not significant. Both current and former Executive Officers are
    subject to the Policy in accordance with its terms.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Financial
    Reporting Measure</U>&rdquo; means (i) any measure that is determined and presented in accordance with the accounting principles
    used in preparing the Company&rsquo;s financial statements, and any measures derived wholly or in part from such measures and may
    consist of IFRS/U.S. GAAP or non-IFRS/non-U.S. GAAP financial measures (as defined under Regulation G of the Exchange Act and Item
    10 of Regulation S-K under the Exchange Act), (ii) stock price or (iii) total shareholder return. Financial Reporting Measures need
    not be presented within the Company&rsquo;s financial statements or included in a filing with the SEC.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Home
    Country</U>&rdquo; means the Company&rsquo;s jurisdiction of incorporation, i.e., the British Virgin Islands.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Incentive-Based
    Compensation</U>&rdquo; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a
    Financial Reporting Measure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lookback
    Period</U>&rdquo; means the three completed fiscal years (plus any transition period of less than nine months that is within or immediately
    following the three completed fiscal years and that results from a change in the Company&rsquo;s fiscal year) immediately preceding
    the date on which the Company is required to prepare a Restatement for a given reporting period, with such date being the earlier
    of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if
    Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement,
    or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Restatement. Recovery of any
    Erroneously Awarded Compensation under the Policy is not dependent on whether or when the Restatement is actually filed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Nasdaq</U>&rdquo;
    means the Nasdaq Stock Market.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Received</U>&rdquo;:
    Incentive-Based Compensation is deemed &ldquo;Received&rdquo; in the Company&rsquo;s fiscal period during which the Financial Reporting
    Measure specified in or otherwise relating to the Incentive-Based Compensation award is attained, even if the grant, vesting or payment
    of the Incentive-Based Compensation occurs after the end of that period.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Restatement</U>&rdquo;
    means a required accounting restatement of any Company financial statement due to the material noncompliance of the Company with
    any financial reporting requirement under the securities laws, including (i) to correct an error in previously issued financial statements
    that is material to the previously issued financial statements (commonly referred to as a &ldquo;Big R&rdquo; restatement) or (ii)
    to correct an error in previously issued financial statements that is not material to the previously issued financial statements
    but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current
    period (commonly referred to as a &ldquo;little r&rdquo; restatement). Changes to the Company&rsquo;s financial statements that do
    not represent error corrections under the then-current relevant accounting standards will not constitute Restatements. Recovery of
    any Erroneously Awarded Compensation under the Policy is not dependent on fraud or misconduct by any person in connection with the
    Restatement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC</U>&rdquo;
    means the U.S. Securities and Exchange Commission.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recovery
    of Erroneously Awarded Compensation</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a Restatement, any Erroneously Awarded Compensation Received during the Lookback Period prior to the Restatement (a) that
is then-outstanding but has not yet been paid shall be automatically and immediately forfeited and (b) that has been paid to any person
shall be subject to reasonably prompt repayment to the Company Group in accordance with Section 3 of this Policy. The Committee must
pursue (and shall not have the discretion to waive) the forfeiture and/or repayment of such Erroneously Awarded Compensation in accordance
with Section 3 of this Policy, except as provided below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the Committee (or, if the Committee is not a committee of the Board responsible for the Company&rsquo;s executive compensation
decisions and composed entirely of independent directors, a majority of the independent directors serving on the Board) may determine
not to pursue the forfeiture and/or recovery of Erroneously Awarded Compensation from any person if the Committee determines that such
forfeiture and/or recovery would be impracticable due to any of the following circumstances: (i) the direct expense paid to a third party
(for example, reasonable legal expenses and consulting fees) to assist in enforcing the Policy would exceed the amount to be recovered,
including the costs that could be incurred if pursuing such recovery would violate local laws other than the Company&rsquo;s Home Country
laws (following reasonable attempts by the Company Group to recover such Erroneously Awarded Compensation, the documentation of such
attempts, and the provision of such documentation to Nasdaq), (ii) pursuing such recovery would violate the Company&rsquo;s Home Country
laws adopted prior to the Effective Date (provided that the Company obtains an opinion of Home Country counsel acceptable to Nasdaq that
recovery would result in such a violation and provides such opinion to Nasdaq), or (iii) recovery would likely cause any otherwise tax-qualified
retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26
U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Means
    of Repayment</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Committee determines that any person shall repay any Erroneously Awarded Compensation, the Committee shall provide
written notice to such person by email or certified mail to the physical address on file with the Company Group for such person, and
the person shall satisfy such repayment in a manner and on such terms as required by the Committee, and the Company Group shall be entitled
to set off the repayment amount against any amount owed to the person by the Company Group, to require the forfeiture of any award granted
by the Company Group to the person, or to take any and all necessary actions to reasonably promptly recover the repayment amount from
the person, in each case, to the fullest extent permitted under applicable law, including without limitation, Section 409A of the U.S.
Internal Revenue Code and the regulations and guidance thereunder. If the Committee does not specify a repayment timing in the written
notice described above, the applicable person shall be required to repay the Erroneously Awarded Compensation to the Company Group by
wire, cash, cashier&rsquo;s check or other means as agreed by the Committee no later than thirty (30) days after receipt of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
    Indemnification</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person shall be indemnified, insured or reimbursed by the Company Group in respect of any loss of compensation by such person in accordance
with this Policy, nor shall any person receive any advancement of expenses for disputes related to any loss of compensation by such person
in accordance with this Policy, and no person shall be paid or reimbursed by the Company Group for any premiums paid by such person for
any third-party insurance policy covering potential recovery obligations under this Policy. For this purpose, &ldquo;indemnification&rdquo;
includes any modification to current compensation arrangements or other means that would amount to <I>de facto</I> indemnification (for
example, providing the person a new cash award which would be cancelled to effect the recovery of any Erroneously Awarded Compensation).
In no event shall the Company Group be required to award any person an additional payment if any Restatement would result in a higher
incentive compensation payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Miscellaneous</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy generally will be administered and interpreted by the Committee, provided that the Board may, from time to time, exercise discretion
to administer and interpret this Policy, in which case, all references herein to &ldquo;Committee&rdquo; shall be deemed to refer to
the Board. Any determination by the Committee with respect to this Policy shall be final, conclusive and binding on all interested parties.
Any discretionary determinations of the Committee under this Policy, if any, need not be uniform with respect to all persons, and may
be made selectively amongst persons, whether or not such persons are similarly situated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is intended to satisfy the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act, as it
may be amended from time to time, and any related rules or regulations promulgated by the SEC or the Nasdaq, including any additional
or new requirements that become effective after the Effective Date which upon effectiveness shall be deemed to automatically amend this
Policy to the extent necessary to comply with such additional or new requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy
is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted and
shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to applicable law.
The invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability of any other provision
of this Policy. Recovery of Erroneously Awarded Compensation under this Policy is not dependent upon the Company Group satisfying any
conditions in this Policy, including any requirements to provide applicable documentation to the Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights of the Company Group under this Policy to seek forfeiture or reimbursement are in addition to, and not in lieu of, any rights
of recovery, or remedies or rights other than recovery, that may be available to the Company Group pursuant to the terms of any law,
government regulation or stock exchange listing requirement or any other policy, code of conduct, employee handbook, employment agreement,
equity award agreement, or other plan or agreement of the Company Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
    and Termination</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted by, and in a manner consistent with applicable law, including SEC and Nasdaq rules, the Committee may terminate,
suspend or amend this Policy at any time in its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Successors</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all persons and their respective beneficiaries, heirs, executors, administrators or other
legal representatives with respect to any Covered Compensation granted, vested or paid to or administered by such persons or entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bmgl-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaMKbP9z5Z8OekhvWB/bbmq3y0jYX5/ZicOyJmGMdYL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:BMGL="http://baselmedical.com/20250630" elementFormDefault="qualified" targetNamespace="http://baselmedical.com/20250630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://baselmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/StatementOfProfitOrLoss" id="StatementOfProfitOrLoss">
          <link:definition>00000002 - Statement - Consolidated Statement of Profit or Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" id="StatementOfChangesInShareholdersEquityParenthetical">
          <link:definition>00000004 - Statement - Consolidated Statement of Changes In Shareholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" id="StatementOfChangesInShareholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statement of Changes In Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/StatementOfCashFlows" id="StatementOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statement of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/General" id="General">
          <link:definition>999014 - Disclosure - General</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformation" id="MaterialAccountingPolicyInformation">
          <link:definition>999015 - Disclosure - Material accounting policy information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" id="SignificantAccountingJudgementsAndEstimates">
          <link:definition>999016 - Disclosure - Significant accounting judgements and estimates</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/Revenue" id="Revenue">
          <link:definition>999017 - Disclosure - Revenue</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/OtherIncome" id="OtherIncome">
          <link:definition>999018 - Disclosure - Other income</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinanceCost" id="FinanceCost">
          <link:definition>999019 - Disclosure - Finance cost</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/LossprofitBeforeTax" id="LossprofitBeforeTax">
          <link:definition>999020 - Disclosure - (Loss)/Profit before tax</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpense" id="IncomeTaxBenefitexpense">
          <link:definition>999021 - Disclosure - Income tax (benefit)/expense</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/RightOfUseAssets" id="RightOfUseAssets">
          <link:definition>999022 - Disclosure - Right of use assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999023 - Disclosure - Property and equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/Inventories" id="Inventories">
          <link:definition>999024 - Disclosure - Inventories</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/TradeAndOtherReceivables" id="TradeAndOtherReceivables">
          <link:definition>999025 - Disclosure - Trade and other receivables</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
          <link:definition>999026 - Disclosure - Cash and cash equivalents</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedParties" id="AmountDueFromtoRelatedParties">
          <link:definition>999027 - Disclosure - Amount due from/to related parties</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/Borrowings" id="Borrowings">
          <link:definition>999028 - Disclosure - Borrowings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
          <link:definition>999029 - Disclosure - Trade and other payables</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/AmountDueToFormerDirector" id="AmountDueToFormerDirector">
          <link:definition>999030 - Disclosure - Amount due to a former director</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ShareCapital" id="ShareCapital">
          <link:definition>999031 - Disclosure - Share capital</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/Leases" id="Leases">
          <link:definition>999032 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactions" id="SignificantRelatedPartyTransactions">
          <link:definition>999033 - Disclosure - Significant related party transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwill" id="ImpairmentLossOnGoodwill">
          <link:definition>999034 - Disclosure - Impairment loss on goodwill</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" id="FairValueOfAssetsAndLiabilities">
          <link:definition>999035 - Disclosure - Fair value of assets and liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinancialRiskManagement" id="FinancialRiskManagement">
          <link:definition>999036 - Disclosure - Financial risk management</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategory" id="FinancialInstrumentsByCategory">
          <link:definition>999037 - Disclosure - Financial instruments by category</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/CapitalManagement" id="CapitalManagement">
          <link:definition>999038 - Disclosure - Capital management</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" id="EventsOccurringAfterReportingPeriod">
          <link:definition>999039 - Disclosure - Events occurring after the reporting period</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" id="MaterialAccountingPolicyInformationPolicies">
          <link:definition>999040 - Disclosure - Material accounting policy information (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/GeneralTables" id="GeneralTables">
          <link:definition>999041 - Disclosure - General (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" id="MaterialAccountingPolicyInformationTables">
          <link:definition>999042 - Disclosure - Material accounting policy information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/RevenueTables" id="RevenueTables">
          <link:definition>999043 - Disclosure - Revenue (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/OtherIncomeTables" id="OtherIncomeTables">
          <link:definition>999044 - Disclosure - Other income (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinanceCostTables" id="FinanceCostTables">
          <link:definition>999045 - Disclosure - Finance cost (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/LossprofitBeforeTaxTables" id="LossprofitBeforeTaxTables">
          <link:definition>999046 - Disclosure - (Loss)/Profit before tax (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" id="IncomeTaxBenefitexpenseTables">
          <link:definition>999047 - Disclosure - Income tax (benefit)/expense (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/RightOfUseAssetsTables" id="RightOfUseAssetsTables">
          <link:definition>999048 - Disclosure - Right of use assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999049 - Disclosure - Property and equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/InventoriesTables" id="InventoriesTables">
          <link:definition>999050 - Disclosure - Inventories (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesTables" id="TradeAndOtherReceivablesTables">
          <link:definition>999051 - Disclosure - Trade and other receivables (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
          <link:definition>999052 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" id="AmountDueFromtoRelatedPartiesTables">
          <link:definition>999053 - Disclosure - Amount due from/to related parties (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/BorrowingsTables" id="BorrowingsTables">
          <link:definition>999054 - Disclosure - Borrowings (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
          <link:definition>999055 - Disclosure - Trade and other payables (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999056 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" id="SignificantRelatedPartyTransactionsTables">
          <link:definition>999057 - Disclosure - Significant related party transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" id="ImpairmentLossOnGoodwillTables">
          <link:definition>999058 - Disclosure - Impairment loss on goodwill (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinancialRiskManagementTables" id="FinancialRiskManagementTables">
          <link:definition>999059 - Disclosure - Financial risk management (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" id="FinancialInstrumentsByCategoryTables">
          <link:definition>999060 - Disclosure - Financial instruments by category (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" id="ScheduleOfActivitiesOfSubsidiariesDetails">
          <link:definition>999061 - Disclosure - Schedule of activities of subsidiaries (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
          <link:definition>999062 - Disclosure - General (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" id="ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails">
          <link:definition>999063 - Disclosure - Schedule of expected useful lives for property, plant and equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" id="SignificantAccountingJudgementsAndEstimatesDetailsNarrative">
          <link:definition>999064 - Disclosure - Significant accounting judgements and estimates (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" id="SummaryOfRevenueFromTransferOfGoodsAndServicesDetails">
          <link:definition>999065 - Disclosure - Summary of revenue from transfer of goods and services (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" id="ScheduleOfOtherIncomeDetails">
          <link:definition>999066 - Disclosure - Schedule of Other income (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" id="ScheduleOfFinanceCostDetails">
          <link:definition>999067 - Disclosure - Schedule of Finance cost (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" id="ScheduleOfProfitBeforeTaxDetails">
          <link:definition>999068 - Disclosure - Schedule of Profit before tax (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" id="ScheduleOfComponentOfIncomeTaxExpenseDetails">
          <link:definition>999069 - Disclosure - Schedule of component of income tax expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" id="ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails">
          <link:definition>999070 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" id="ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical">
          <link:definition>999071 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" id="ScheduleOfRightOfUseAssetsDetails">
          <link:definition>999072 - Disclosure - Schedule of Right of use assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999073 - Disclosure - Schedule of Property and equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfInventoriesDetails" id="ScheduleOfInventoriesDetails">
          <link:definition>999074 - Disclosure - Schedule of Inventories (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" id="ScheduleOfTradeAndOtherReceivablesDetails">
          <link:definition>999075 - Disclosure - Schedule of trade and other receivables (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" id="ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails">
          <link:definition>999076 - Disclosure - Schedule of movement in allowance for expected credit losses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" id="TradeAndOtherReceivablesDetailsNarrative">
          <link:definition>999077 - Disclosure - Trade and other receivables (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" id="ScheduleOfCashAndCashEquivalentsDetails">
          <link:definition>999078 - Disclosure - Schedule of cash and cash equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" id="ScheduleOfAmountDueFromRelatedPartyDetails">
          <link:definition>999079 - Disclosure - Schedule of amount due from related party (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" id="AmountDueFromtoRelatedPartiesDetailsNarrative">
          <link:definition>999080 - Disclosure - Amount due from/to related parties (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" id="ScheduleOfBorrowingsDetails">
          <link:definition>999081 - Disclosure - Schedule of borrowings (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" id="ScheduleOfBreakdownBorrowingsDetails">
          <link:definition>999082 - Disclosure - Schedule of breakdown borrowings (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" id="ScheduleOfDetailsBorrowingsDetails">
          <link:definition>999083 - Disclosure - Schedule of details borrowings (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" id="ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails">
          <link:definition>999084 - Disclosure - Schedule of reconciliation of liabilities arising from financing activities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" id="ScheduleOfTradeAndOtherPayablesDetails">
          <link:definition>999085 - Disclosure - Schedule of trade and other payables (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" id="TradeAndOtherPayablesDetailsNarrative">
          <link:definition>999086 - Disclosure - Trade and other payables (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ShareCapitalDetailsNarrative" id="ShareCapitalDetailsNarrative">
          <link:definition>999087 - Disclosure - Share capital (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" id="ScheduleOfAmountsRecognizedInProfitOrLossDetails">
          <link:definition>999088 - Disclosure - Schedule of amounts recognized in profit or loss (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999089 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" id="ScheduleOfTransactionsWithRelatedPartiesDetails">
          <link:definition>999090 - Disclosure - Schedule of transactions with related parties (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" id="ScheduleOfCompensationOfKeyManagementPersonnelDetails">
          <link:definition>999091 - Disclosure - Schedule of compensation of key management personnel (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" id="ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails">
          <link:definition>999092 - Disclosure - Schedule of fair value of identifiable assets and liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" id="ImpairmentLossOnGoodwillDetailsNarrative">
          <link:definition>999093 - Disclosure - Impairment loss on goodwill (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" id="ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails">
          <link:definition>999094 - Disclosure - Schedule of group&#8217;s current credit risk grading framework (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" id="ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails">
          <link:definition>999095 - Disclosure - Schedule of financial assets, minimum exposure to credit risk (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" id="ScheduleOfCreditRiskDetails">
          <link:definition>999096 - Disclosure - Schedule of credit risk (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" id="ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails">
          <link:definition>999097 - Disclosure - Schedule of remaining contractual undiscounted repayment obligations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" id="FinancialRiskManagementDetailsNarrative">
          <link:definition>999098 - Disclosure - Financial risk management (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" id="ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails">
          <link:definition>999099 - Disclosure - Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" id="EventsOccurringAfterReportingPeriodDetailsNarrative">
          <link:definition>999100 - Disclosure - Events occurring after the reporting period (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="bmgl-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmgl-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmgl-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmgl-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <element id="BMGL_OrdinaryShareMember" name="OrdinaryShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_BaselMedicalGroupPteLtdMember" name="BaselMedicalGroupPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" name="SingaporeSportsOrthopaedicClinicPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" name="SingaporeSportsOrthopaedicServicesPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SSOCPteLtdMember" name="SSOCPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SSOSPteLtdMember" name="SSOSPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" name="SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" name="SingaporeKneeSportsOrthopaedicServicesPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_PharmaAvenuePteLtdMember" name="PharmaAvenuePteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_BaselMedflowPteLtdMember" name="BaselMedflowPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_BethesdaMedicalPteLtdMember" name="BethesdaMedicalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OasisMedicalClinicPteLtdMember" name="OasisMedicalClinicPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_RenovationMember" name="RenovationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AirConditionerMember" name="AirConditionerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SoftwareMember" name="SoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_MedicalServicesMember" name="MedicalServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AccumulatedDepreciationMember" name="AccumulatedDepreciationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_MedicalEquipmentMember" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ThridPartiesMember" name="ThridPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CustodianServicesMember" name="CustodianServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_RainforestCapitalVCCMember" name="RainforestCapitalVCCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" name="DrKevinYipAndSingmedInvestmentPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DrKevinYipMember" name="DrKevinYipMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DirectorsMember" name="DirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OthersRelatedPartiesMember" name="OthersRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanOneMember" name="TermLoanOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTwoMember" name="TermLoanTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanThreeMember" name="TermLoanThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanFourMember" name="TermLoanFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanSixMember" name="TermLoanSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanSevenMember" name="TermLoanSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanNineMember" name="TermLoanNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTenMember" name="TermLoanTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanElevenMember" name="TermLoanElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTwelveMember" name="TermLoanTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanMember" name="TermLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTenOneMember" name="TermLoanTenOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTenTwoMember" name="TermLoanTenTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTenThreeMember" name="TermLoanTenThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanTenFourMember" name="TermLoanTenFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TermLoanElevenOneMember" name="TermLoanElevenOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_InitialPublicOfferingMember" name="InitialPublicOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OverAllotmentOptionsMember" name="OverAllotmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CategoryOneMember" name="CategoryOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CategoryTwoMember" name="CategoryTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CategoryThreeMember" name="CategoryThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CategoryFourMember" name="CategoryFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_LifeTimeExpectedCreditLossMember" name="LifeTimeExpectedCreditLossMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TwelveExpectedCreditLossMember" name="TwelveExpectedCreditLossMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_NotPastDueMember" name="NotPastDueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" name="LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ContractualCashFlowsMember" name="ContractualCashFlowsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SSOCNovenaPteLtdMember" name="SSOCNovenaPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_NonadjustingEventsAfterReportingPeriodMember" name="NonadjustingEventsAfterReportingPeriodMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SSOCOrchardPteLtdMember" name="SSOCOrchardPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SSOCFarrerParkPteLtdMember" name="SSOCFarrerParkPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_EyetrustMedicalPteLtdMember" name="EyetrustMedicalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CharteredImagingPteLtdMember" name="CharteredImagingPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" name="ConsumablesMedicalSuppliesAndOtherRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ProfitLossAndNetComprehensiveIncome" name="ProfitLossAndNetComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ProfitLossIncludingMinorityInterest" name="ProfitLossIncludingMinorityInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IfrsStatementLineItems" name="IfrsStatementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DeferredOfferingCost" name="DeferredOfferingCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AmountDueToFormerDirector" name="AmountDueToFormerDirector" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_MergerReserveArisingFromGroupRestructuring" name="MergerReserveArisingFromGroupRestructuring" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_MinorityInterestInSubsidiary" name="MinorityInterestInSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CreditLossExpenseReversal" name="CreditLossExpenseReversal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" name="AdjustmentsForAmortizationOfRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" name="RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract" name="IncreaseDecreaseInNonCashWorkingCapitalAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ProceedsFromDeferredOfferingCosts" name="ProceedsFromDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DecreaseInAmountDueFromDirector" name="DecreaseInAmountDueFromDirector" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseInAmountDueToRelatedParties" name="IncreaseInAmountDueToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseInBankOverdraft" name="IncreaseInBankOverdraft" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DecreaseincreaseInAmountDueToFormerDirector" name="DecreaseincreaseInAmountDueToFormerDirector" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" name="DisclosureOfChangesInAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" name="DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureRevenueAbstract" name="DisclosureRevenueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfOtherIncomeAbstract" name="DisclosureOfOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureLossprofitBeforeTaxAbstract" name="DisclosureLossprofitBeforeTaxAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" name="DisclosureOfProfitLossBeforeTaxExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureRightofuseAssetAbstract" name="DisclosureRightofuseAssetAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosurePropertyPlantAndEquipmentAbstract" name="DisclosurePropertyPlantAndEquipmentAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfInventoriesAbstract" name="DisclosureOfInventoriesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureTradeAndOtherReceivablesAbstract" name="DisclosureTradeAndOtherReceivablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureCashAndCashEquivalentsAbstract" name="DisclosureCashAndCashEquivalentsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" name="DisclosureAmountsDueFromToRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureBorrowingsAbstract" name="DisclosureBorrowingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureTradeAndOtherPayablesAbstract" name="DisclosureTradeAndOtherPayablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureAmountDueToRelatedPartyAbstract" name="DisclosureAmountDueToRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" name="DisclosureOfAmountDueToAFormerDirectorExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureShareCapitalAbstract" name="DisclosureShareCapitalAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureRelatedPartyTransactionsAbstract" name="DisclosureRelatedPartyTransactionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfSignificantRelatedPartyExplanatory" name="DisclosureOfSignificantRelatedPartyExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureImpairmentLossOnGoodwillAbstract" name="DisclosureImpairmentLossOnGoodwillAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract" name="DisclosureFairValueOfAssetsAndLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureFinancialRiskManagementAbstract" name="DisclosureFinancialRiskManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureFinancialInstrumentsAbstract" name="DisclosureFinancialInstrumentsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureCapitalManagementAbstract" name="DisclosureCapitalManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CapitalManagementExplanatory" name="CapitalManagementExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" name="DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" name="DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" name="DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation" name="DescriptionOfAccountingPolicyForBasisOfConsolidation" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" name="DescriptionOfAccountingPolicyForInventoriesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory" name="DescriptionOfAccountingPolicyForReservesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" name="DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDepreciationRatesExplanatory" name="DisclosureOfDepreciationRatesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" name="DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" name="DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory" name="DisclosureOfDetailedInformationAboutFinanceCostExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" name="DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" name="DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" name="DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets" name="DisclosureOfDetailedInformationAboutOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory" name="DisclosureOfDetailedInformationAboutInventoriesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory" name="DisclosureOfTradeAndOtherReceivableExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfCashAndCashEquivalentExplanatory" name="DisclosureOfCashAndCashEquivalentExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" name="DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutBorrowings" name="DisclosureOfDetailedInformationAboutBorrowings" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock" name="DisclosureOfLeaseRelatedExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory" name="ScheduleOfTransactionsWithRelatedPartyExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" name="ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" name="DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" name="ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ScheduleOfExpectedCreditRiskExplanatory" name="ScheduleOfExpectedCreditRiskExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" name="ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_NumberOfSharesSubscribed" name="NumberOfSharesSubscribed" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OthersReceivables" name="OthersReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ServiceIncome" name="ServiceIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ReversalOfExpectedCreditLosses" name="ReversalOfExpectedCreditLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_BadDebtsWrittenOff" name="BadDebtsWrittenOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ProvisionForExpectedCreditLosses" name="ProvisionForExpectedCreditLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DepreciationOfPropertyAndEquipment" name="DepreciationOfPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_RecruitmentExpenses" name="RecruitmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TelephoneExpense" name="TelephoneExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_EmployeeBenefitsExpenses" name="EmployeeBenefitsExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DirectorsSalariesAndBonuses" name="DirectorsSalariesAndBonuses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DirectorsCentralProvidentFund" name="DirectorsCentralProvidentFund" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_EmployeesSalariesAndBonus" name="EmployeesSalariesAndBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_EmployeesCentralProvidentFund" name="EmployeesCentralProvidentFund" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OtherStaffExpenses" name="OtherStaffExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_UnderprovisionInRespectOfPriorYears" name="UnderprovisionInRespectOfPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OverprovisionInRespectOfPriorYears" name="OverprovisionInRespectOfPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_NondeductibleExpenses" name="NondeductibleExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncomeTaxExemption" name="IncomeTaxExemption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_UtilisationOfCapitalAllowance" name="UtilisationOfCapitalAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_UtilisationOfDeferredTaxAssets" name="UtilisationOfDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" name="DeferredTaxAssetsNotRecognizedOnTaxLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DeferredIncomeTax" name="DeferredIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_WrittenOffRightofuseAssets" name="WrittenOffRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" name="WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" name="PropertyPlantAndEquipmentAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AllowanceForExpectedCreditLoss" name="AllowanceForExpectedCreditLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AdditionAllowanceForExpectedCreditLosses" name="AdditionAllowanceForExpectedCreditLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ReversalOfAllowanceForExpectedCreditLosses" name="ReversalOfAllowanceForExpectedCreditLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CashPaidOnClosingInitialSettlement" name="CashPaidOnClosingInitialSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" name="PercentageOfProvisionalConsiderationAmountForTransferOfShare" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CashReceivedToFullySettleRelatedPartyReceivables" name="CashReceivedToFullySettleRelatedPartyReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CurrentPortionOfBorrowingsAbstract" name="CurrentPortionOfBorrowingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_BankBorrowings" name="BankBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" name="IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" name="OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" name="CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" name="IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" name="IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" name="OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AdditionBankBorrowingsCurrent" name="AdditionBankBorrowingsCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AdditionBankBorrowingsNonCurrent" name="AdditionBankBorrowingsNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" name="IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" name="IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TradePayablesMaturity" name="TradePayablesMaturity" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ValueOfSharesAuthorised" name="ValueOfSharesAuthorised" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_LeaseTermOfContract" name="LeaseTermOfContract" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_InterestIncomeOnLoansAndReceivable" name="InterestIncomeOnLoansAndReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ManagementFee" name="ManagementFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CentralProvidentFund" name="CentralProvidentFund" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_InvestmentRecognisedAsOfAcquisitionDate" name="InvestmentRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" name="LeaseLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_AmountDueRecognisedAsOfAcquisitionDate" name="AmountDueRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_IfrsStatementTable" name="IfrsStatementTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="BMGL_CategoryAxis" name="CategoryAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="BMGL_CategoryDomain" name="CategoryDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfCreditRisk" name="DescriptionOfCreditRisk" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_BasisForRecognizingExpectedCreditLoss" name="BasisForRecognizingExpectedCreditLoss" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_CreditRiskTradeReceivables" name="CreditRiskTradeReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_ExpectedCreditLosses" name="ExpectedCreditLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TotalUndiscountedFinancialAssets" name="TotalUndiscountedFinancialAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_TotalNetUndiscountedFinancialAssetsliabilities" name="TotalNetUndiscountedFinancialAssetsliabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_PercentageOfTradeReceivables" name="PercentageOfTradeReceivables" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_InvestmentsPercentage" name="InvestmentsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_InvestmentsSalePercentage" name="InvestmentsSalePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_InvestmentsHoldPercentage" name="InvestmentsHoldPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_DescriptionOfAccountingPolicyForGroupAccounting" name="DescriptionOfAccountingPolicyForGroupAccounting" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMGL_SaleAndPurchaseAgreementMember" name="SaleAndPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bmgl-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Cover" roleURI="http://baselmedical.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfProfitOrLoss" roleURI="http://baselmedical.com/role/StatementOfProfitOrLoss" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#BalanceSheets" roleURI="http://baselmedical.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfChangesInShareholdersEquityParenthetical" roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfChangesInShareholdersEquity" roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfCashFlows" roleURI="http://baselmedical.com/role/StatementOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#General" roleURI="http://baselmedical.com/role/General" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformation" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformation" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantAccountingJudgementsAndEstimates" roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Revenue" roleURI="http://baselmedical.com/role/Revenue" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#OtherIncome" roleURI="http://baselmedical.com/role/OtherIncome" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinanceCost" roleURI="http://baselmedical.com/role/FinanceCost" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LossprofitBeforeTax" roleURI="http://baselmedical.com/role/LossprofitBeforeTax" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#IncomeTaxBenefitexpense" roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpense" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RightOfUseAssets" roleURI="http://baselmedical.com/role/RightOfUseAssets" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#PropertyAndEquipment" roleURI="http://baselmedical.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Inventories" roleURI="http://baselmedical.com/role/Inventories" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivables" roleURI="http://baselmedical.com/role/TradeAndOtherReceivables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CashAndCashEquivalents" roleURI="http://baselmedical.com/role/CashAndCashEquivalents" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedParties" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedParties" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Borrowings" roleURI="http://baselmedical.com/role/Borrowings" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayables" roleURI="http://baselmedical.com/role/TradeAndOtherPayables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueToFormerDirector" roleURI="http://baselmedical.com/role/AmountDueToFormerDirector" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ShareCapital" roleURI="http://baselmedical.com/role/ShareCapital" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Leases" roleURI="http://baselmedical.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantRelatedPartyTransactions" roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwill" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FairValueOfAssetsAndLiabilities" roleURI="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagement" roleURI="http://baselmedical.com/role/FinancialRiskManagement" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialInstrumentsByCategory" roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategory" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CapitalManagement" roleURI="http://baselmedical.com/role/CapitalManagement" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#EventsOccurringAfterReportingPeriod" roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformationPolicies" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#GeneralTables" roleURI="http://baselmedical.com/role/GeneralTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformationTables" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RevenueTables" roleURI="http://baselmedical.com/role/RevenueTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#OtherIncomeTables" roleURI="http://baselmedical.com/role/OtherIncomeTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinanceCostTables" roleURI="http://baselmedical.com/role/FinanceCostTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LossprofitBeforeTaxTables" roleURI="http://baselmedical.com/role/LossprofitBeforeTaxTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#IncomeTaxBenefitexpenseTables" roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RightOfUseAssetsTables" roleURI="http://baselmedical.com/role/RightOfUseAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://baselmedical.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#InventoriesTables" roleURI="http://baselmedical.com/role/InventoriesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivablesTables" roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CashAndCashEquivalentsTables" roleURI="http://baselmedical.com/role/CashAndCashEquivalentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedPartiesTables" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#BorrowingsTables" roleURI="http://baselmedical.com/role/BorrowingsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayablesTables" roleURI="http://baselmedical.com/role/TradeAndOtherPayablesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LeasesTables" roleURI="http://baselmedical.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantRelatedPartyTransactionsTables" roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwillTables" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagementTables" roleURI="http://baselmedical.com/role/FinancialRiskManagementTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialInstrumentsByCategoryTables" roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfActivitiesOfSubsidiariesDetails" roleURI="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#GeneralDetailsNarrative" roleURI="http://baselmedical.com/role/GeneralDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" roleURI="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantAccountingJudgementsAndEstimatesDetailsNarrative" roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" roleURI="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfOtherIncomeDetails" roleURI="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinanceCostDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfProfitBeforeTaxDetails" roleURI="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfComponentOfIncomeTaxExpenseDetails" roleURI="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfRightOfUseAssetsDetails" roleURI="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfInventoriesDetails" roleURI="http://baselmedical.com/role/ScheduleOfInventoriesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTradeAndOtherReceivablesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" roleURI="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivablesDetailsNarrative" roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCashAndCashEquivalentsDetails" roleURI="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfAmountDueFromRelatedPartyDetails" roleURI="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedPartiesDetailsNarrative" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfBreakdownBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfDetailsBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTradeAndOtherPayablesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayablesDetailsNarrative" roleURI="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ShareCapitalDetailsNarrative" roleURI="http://baselmedical.com/role/ShareCapitalDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfAmountsRecognizedInProfitOrLossDetails" roleURI="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LeasesDetailsNarrative" roleURI="http://baselmedical.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTransactionsWithRelatedPartiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCompensationOfKeyManagementPersonnelDetails" roleURI="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwillDetailsNarrative" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" roleURI="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCreditRiskDetails" roleURI="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" roleURI="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagementDetailsNarrative" roleURI="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#EventsOccurringAfterReportingPeriodDetailsNarrative" roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfProfitOrLoss" xlink:title="00000002 - Statement - Consolidated Statement of Profit or Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses" xlink:label="loc_ifrs-fullOtherGainsLosses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullOtherGainsLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:label="loc_BMGLConsumablesMedicalSuppliesAndOtherRelatedExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_BMGLConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-fullEmployeeBenefitsExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullEmployeeBenefitsExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-fullDepreciationExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullDepreciationExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense" xlink:label="loc_ifrs-fullRentalExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullRentalExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-fullOtherOperatingIncomeExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullOtherOperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-fullImpairmentLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullImpairmentLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullFinanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProfitLossAndNetComprehensiveIncome" xlink:label="loc_BMGLProfitLossAndNetComprehensiveIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_BMGLProfitLossAndNetComprehensiveIncome" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProfitLossIncludingMinorityInterest" xlink:label="loc_BMGLProfitLossIncludingMinorityInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_BMGLProfitLossIncludingMinorityInterest" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_BMGLProfitLossIncludingMinorityInterest" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/BalanceSheets" xlink:title="00000003 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-fullDeferredTaxAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullDeferredTaxAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-fullInventories" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullInventories" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredOfferingCost" xlink:label="loc_BMGLDeferredOfferingCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_BMGLDeferredOfferingCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-fullLongtermBorrowings" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullLongtermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-fullShorttermBorrowings" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullShorttermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="loc_ifrs-fullOtherCurrentFinancialLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullOtherCurrentFinancialLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_BMGLAmountDueToFormerDirector" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-fullCurrentProvisionsForEmployeeBenefits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentProvisionsForEmployeeBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-fullCurrentTaxLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentTaxLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-fullNetAssetsLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetAssetsLiabilities" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetAssetsLiabilities" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MergerReserveArisingFromGroupRestructuring" xlink:label="loc_BMGLMergerReserveArisingFromGroupRestructuring" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_BMGLMergerReserveArisingFromGroupRestructuring" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" xlink:title="00000004 - Statement - Consolidated Statement of Changes In Shareholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes In Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statement of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff" xlink:label="loc_ifrs-fullRecoveriesOnLoansPreviouslyWrittenOff" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-fullRecoveriesOnLoansPreviouslyWrittenOff" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditLossExpenseReversal" xlink:label="loc_BMGLCreditLossExpenseReversal" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_BMGLCreditLossExpenseReversal" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-fullAdjustmentsForProvisions" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-fullAdjustmentsForProvisions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" xlink:label="loc_BMGLAdjustmentsForAmortizationOfRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_BMGLAdjustmentsForAmortizationOfRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:label="loc_BMGLRecoveriesOnLoansPreviouslyWrittenOffFixedAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_BMGLRecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-fullAdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-fullAdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="loc_ifrs-fullAdjustmentsForInterestExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="loc_ifrs-fullAdjustmentsForInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperations" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInInventories" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperations" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperations" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperations" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="loc_ifrs-fullIncomeTaxesPaidRefundClassifiedAsOperatingActivities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullIncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-fullInterestPaidClassifiedAsOperatingActivities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullInterestPaidClassifiedAsOperatingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentProperty" xlink:label="loc_ifrs-fullPurchaseOfInvestmentProperty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullPurchaseOfInvestmentProperty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProceedsFromDeferredOfferingCosts" xlink:label="loc_BMGLProceedsFromDeferredOfferingCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_BMGLProceedsFromDeferredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DecreaseInAmountDueFromDirector" xlink:label="loc_BMGLDecreaseInAmountDueFromDirector" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_BMGLDecreaseInAmountDueFromDirector" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseInAmountDueToRelatedParties" xlink:label="loc_BMGLIncreaseInAmountDueToRelatedParties" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_BMGLIncreaseInAmountDueToRelatedParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseInBankOverdraft" xlink:label="loc_BMGLIncreaseInBankOverdraft" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_BMGLIncreaseInBankOverdraft" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="loc_ifrs-fullProceedsFromCurrentBorrowings" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullProceedsFromCurrentBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullRepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DecreaseincreaseInAmountDueToFormerDirector" xlink:label="loc_BMGLDecreaseincreaseInAmountDueToFormerDirector" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_BMGLDecreaseincreaseInAmountDueToFormerDirector" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="loc_ifrs-fullProceedsFromContributionsOfNoncontrollingInterests" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullProceedsFromContributionsOfNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/General" xlink:title="999014 - Disclosure - General" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformation" xlink:title="999015 - Disclosure - Material accounting policy information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" xlink:title="999016 - Disclosure - Significant accounting judgements and estimates" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Revenue" xlink:title="999017 - Disclosure - Revenue" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/OtherIncome" xlink:title="999018 - Disclosure - Other income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinanceCost" xlink:title="999019 - Disclosure - Finance cost" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LossprofitBeforeTax" xlink:title="999020 - Disclosure - (Loss)/Profit before tax" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/IncomeTaxBenefitexpense" xlink:title="999021 - Disclosure - Income tax (benefit)/expense" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RightOfUseAssets" xlink:title="999022 - Disclosure - Right of use assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/PropertyAndEquipment" xlink:title="999023 - Disclosure - Property and equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Inventories" xlink:title="999024 - Disclosure - Inventories" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivables" xlink:title="999025 - Disclosure - Trade and other receivables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CashAndCashEquivalents" xlink:title="999026 - Disclosure - Cash and cash equivalents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedParties" xlink:title="999027 - Disclosure - Amount due from/to related parties" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Borrowings" xlink:title="999028 - Disclosure - Borrowings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayables" xlink:title="999029 - Disclosure - Trade and other payables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueToFormerDirector" xlink:title="999030 - Disclosure - Amount due to a former director" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ShareCapital" xlink:title="999031 - Disclosure - Share capital" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Leases" xlink:title="999032 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantRelatedPartyTransactions" xlink:title="999033 - Disclosure - Significant related party transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwill" xlink:title="999034 - Disclosure - Impairment loss on goodwill" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" xlink:title="999035 - Disclosure - Fair value of assets and liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagement" xlink:title="999036 - Disclosure - Financial risk management" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialInstrumentsByCategory" xlink:title="999037 - Disclosure - Financial instruments by category" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CapitalManagement" xlink:title="999038 - Disclosure - Capital management" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" xlink:title="999039 - Disclosure - Events occurring after the reporting period" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" xlink:title="999040 - Disclosure - Material accounting policy information (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/GeneralTables" xlink:title="999041 - Disclosure - General (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" xlink:title="999042 - Disclosure - Material accounting policy information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RevenueTables" xlink:title="999043 - Disclosure - Revenue (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/OtherIncomeTables" xlink:title="999044 - Disclosure - Other income (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinanceCostTables" xlink:title="999045 - Disclosure - Finance cost (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LossprofitBeforeTaxTables" xlink:title="999046 - Disclosure - (Loss)/Profit before tax (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" xlink:title="999047 - Disclosure - Income tax (benefit)/expense (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RightOfUseAssetsTables" xlink:title="999048 - Disclosure - Right of use assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/PropertyAndEquipmentTables" xlink:title="999049 - Disclosure - Property and equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/InventoriesTables" xlink:title="999050 - Disclosure - Inventories (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivablesTables" xlink:title="999051 - Disclosure - Trade and other receivables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CashAndCashEquivalentsTables" xlink:title="999052 - Disclosure - Cash and cash equivalents (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" xlink:title="999053 - Disclosure - Amount due from/to related parties (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/BorrowingsTables" xlink:title="999054 - Disclosure - Borrowings (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayablesTables" xlink:title="999055 - Disclosure - Trade and other payables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LeasesTables" xlink:title="999056 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" xlink:title="999057 - Disclosure - Significant related party transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" xlink:title="999058 - Disclosure - Impairment loss on goodwill (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagementTables" xlink:title="999059 - Disclosure - Financial risk management (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" xlink:title="999060 - Disclosure - Financial instruments by category (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" xlink:title="999061 - Disclosure - Schedule of activities of subsidiaries (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/GeneralDetailsNarrative" xlink:title="999062 - Disclosure - General (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" xlink:title="999063 - Disclosure - Schedule of expected useful lives for property, plant and equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" xlink:title="999064 - Disclosure - Significant accounting judgements and estimates (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" xlink:title="999065 - Disclosure - Summary of revenue from transfer of goods and services (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" xlink:title="999066 - Disclosure - Schedule of Other income (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses" xlink:label="loc_ifrs-fullOtherGainsLosses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="loc_ifrs-fullRevenueFromGovernmentGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherGainsLosses" xlink:to="loc_ifrs-fullRevenueFromGovernmentGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherGainsLosses" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ServiceIncome" xlink:label="loc_BMGLServiceIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherGainsLosses" xlink:to="loc_BMGLServiceIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalIncome" xlink:label="loc_ifrs-fullRentalIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherGainsLosses" xlink:to="loc_ifrs-fullRentalIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-fullOtherIncome" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherGainsLosses" xlink:to="loc_ifrs-fullOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ReversalOfExpectedCreditLosses" xlink:label="loc_BMGLReversalOfExpectedCreditLosses" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherGainsLosses" xlink:to="loc_BMGLReversalOfExpectedCreditLosses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" xlink:title="999067 - Disclosure - Schedule of Finance cost (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-fullInterestExpenseOnBorrowings" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullFinanceCosts" xlink:to="loc_ifrs-fullInterestExpenseOnBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullFinanceCosts" xlink:to="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" xlink:title="999068 - Disclosure - Schedule of Profit before tax (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" xlink:title="999069 - Disclosure - Schedule of component of income tax expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UnderprovisionInRespectOfPriorYears" xlink:label="loc_BMGLUnderprovisionInRespectOfPriorYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLUnderprovisionInRespectOfPriorYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverprovisionInRespectOfPriorYears" xlink:label="loc_BMGLOverprovisionInRespectOfPriorYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLOverprovisionInRespectOfPriorYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" xlink:title="999070 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-fullTaxExpenseIncomeAtApplicableTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-fullTaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NondeductibleExpenses" xlink:label="loc_BMGLNondeductibleExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLNondeductibleExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-fullTaxEffectOfTaxLosses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_ifrs-fullTaxEffectOfTaxLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncomeTaxExemption" xlink:label="loc_BMGLIncomeTaxExemption" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLIncomeTaxExemption" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UtilisationOfCapitalAllowance" xlink:label="loc_BMGLUtilisationOfCapitalAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLUtilisationOfCapitalAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UtilisationOfDeferredTaxAssets" xlink:label="loc_BMGLUtilisationOfDeferredTaxAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLUtilisationOfDeferredTaxAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:label="loc_BMGLDeferredTaxAssetsNotRecognizedOnTaxLosses" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLDeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredIncomeTax" xlink:label="loc_BMGLDeferredIncomeTax" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLDeferredIncomeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UnderprovisionInRespectOfPriorYears" xlink:label="loc_BMGLUnderprovisionInRespectOfPriorYears" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLUnderprovisionInRespectOfPriorYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverprovisionInRespectOfPriorYears" xlink:label="loc_BMGLOverprovisionInRespectOfPriorYears" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:to="loc_BMGLOverprovisionInRespectOfPriorYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" xlink:title="999071 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" xlink:title="999072 - Disclosure - Schedule of Right of use assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999073 - Disclosure - Schedule of Property and equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfInventoriesDetails" xlink:title="999074 - Disclosure - Schedule of Inventories (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" xlink:title="999075 - Disclosure - Schedule of trade and other receivables (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" xlink:title="999076 - Disclosure - Schedule of movement in allowance for expected credit losses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" xlink:title="999077 - Disclosure - Trade and other receivables (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999078 - Disclosure - Schedule of cash and cash equivalents (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" xlink:title="999079 - Disclosure - Schedule of amount due from related party (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" xlink:title="999080 - Disclosure - Amount due from/to related parties (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" xlink:title="999081 - Disclosure - Schedule of borrowings (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-fullCurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-fullShorttermBorrowings" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="loc_ifrs-fullShorttermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-fullLongtermBorrowings" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="loc_ifrs-fullLongtermBorrowings" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" xlink:title="999082 - Disclosure - Schedule of breakdown borrowings (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" xlink:title="999083 - Disclosure - Schedule of details borrowings (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" xlink:title="999084 - Disclosure - Schedule of reconciliation of liabilities arising from financing activities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:title="999085 - Disclosure - Schedule of trade and other payables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToTradeSuppliers" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullTradeAndOtherPayables" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToTradeSuppliers" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-fullAccruals" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullTradeAndOtherPayables" xlink:to="loc_ifrs-fullAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxPayables" xlink:label="loc_ifrs-fullValueAddedTaxPayables" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullTradeAndOtherPayables" xlink:to="loc_ifrs-fullValueAddedTaxPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-fullOtherPayables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullTradeAndOtherPayables" xlink:to="loc_ifrs-fullOtherPayables" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" xlink:title="999086 - Disclosure - Trade and other payables (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ShareCapitalDetailsNarrative" xlink:title="999087 - Disclosure - Share capital (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" xlink:title="999088 - Disclosure - Schedule of amounts recognized in profit or loss (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LeasesDetailsNarrative" xlink:title="999089 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" xlink:title="999090 - Disclosure - Schedule of transactions with related parties (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" xlink:title="999091 - Disclosure - Schedule of compensation of key management personnel (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensation" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-fullWagesAndSalaries" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullKeyManagementPersonnelCompensation" xlink:to="loc_ifrs-fullWagesAndSalaries" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CentralProvidentFund" xlink:label="loc_BMGLCentralProvidentFund" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullKeyManagementPersonnelCompensation" xlink:to="loc_BMGLCentralProvidentFund" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" xlink:title="999092 - Disclosure - Schedule of fair value of identifiable assets and liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" xlink:title="999093 - Disclosure - Impairment loss on goodwill (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" xlink:title="999094 - Disclosure - Schedule of group&#8217;s current credit risk grading framework (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" xlink:title="999095 - Disclosure - Schedule of financial assets, minimum exposure to credit risk (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" xlink:title="999096 - Disclosure - Schedule of credit risk (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" xlink:title="999097 - Disclosure - Schedule of remaining contractual undiscounted repayment obligations (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" xlink:title="999098 - Disclosure - Financial risk management (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" xlink:title="999099 - Disclosure - Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" xlink:title="999100 - Disclosure - Events occurring after the reporting period (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bmgl-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Cover" roleURI="http://baselmedical.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfProfitOrLoss" roleURI="http://baselmedical.com/role/StatementOfProfitOrLoss" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#BalanceSheets" roleURI="http://baselmedical.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfChangesInShareholdersEquityParenthetical" roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfChangesInShareholdersEquity" roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfCashFlows" roleURI="http://baselmedical.com/role/StatementOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#General" roleURI="http://baselmedical.com/role/General" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformation" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformation" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantAccountingJudgementsAndEstimates" roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Revenue" roleURI="http://baselmedical.com/role/Revenue" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#OtherIncome" roleURI="http://baselmedical.com/role/OtherIncome" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinanceCost" roleURI="http://baselmedical.com/role/FinanceCost" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LossprofitBeforeTax" roleURI="http://baselmedical.com/role/LossprofitBeforeTax" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#IncomeTaxBenefitexpense" roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpense" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RightOfUseAssets" roleURI="http://baselmedical.com/role/RightOfUseAssets" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#PropertyAndEquipment" roleURI="http://baselmedical.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Inventories" roleURI="http://baselmedical.com/role/Inventories" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivables" roleURI="http://baselmedical.com/role/TradeAndOtherReceivables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CashAndCashEquivalents" roleURI="http://baselmedical.com/role/CashAndCashEquivalents" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedParties" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedParties" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Borrowings" roleURI="http://baselmedical.com/role/Borrowings" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayables" roleURI="http://baselmedical.com/role/TradeAndOtherPayables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueToFormerDirector" roleURI="http://baselmedical.com/role/AmountDueToFormerDirector" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ShareCapital" roleURI="http://baselmedical.com/role/ShareCapital" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Leases" roleURI="http://baselmedical.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantRelatedPartyTransactions" roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwill" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FairValueOfAssetsAndLiabilities" roleURI="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagement" roleURI="http://baselmedical.com/role/FinancialRiskManagement" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialInstrumentsByCategory" roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategory" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CapitalManagement" roleURI="http://baselmedical.com/role/CapitalManagement" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#EventsOccurringAfterReportingPeriod" roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformationPolicies" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#GeneralTables" roleURI="http://baselmedical.com/role/GeneralTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformationTables" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RevenueTables" roleURI="http://baselmedical.com/role/RevenueTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#OtherIncomeTables" roleURI="http://baselmedical.com/role/OtherIncomeTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinanceCostTables" roleURI="http://baselmedical.com/role/FinanceCostTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LossprofitBeforeTaxTables" roleURI="http://baselmedical.com/role/LossprofitBeforeTaxTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#IncomeTaxBenefitexpenseTables" roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RightOfUseAssetsTables" roleURI="http://baselmedical.com/role/RightOfUseAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://baselmedical.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#InventoriesTables" roleURI="http://baselmedical.com/role/InventoriesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivablesTables" roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CashAndCashEquivalentsTables" roleURI="http://baselmedical.com/role/CashAndCashEquivalentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedPartiesTables" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#BorrowingsTables" roleURI="http://baselmedical.com/role/BorrowingsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayablesTables" roleURI="http://baselmedical.com/role/TradeAndOtherPayablesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LeasesTables" roleURI="http://baselmedical.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantRelatedPartyTransactionsTables" roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwillTables" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagementTables" roleURI="http://baselmedical.com/role/FinancialRiskManagementTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialInstrumentsByCategoryTables" roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfActivitiesOfSubsidiariesDetails" roleURI="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#GeneralDetailsNarrative" roleURI="http://baselmedical.com/role/GeneralDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" roleURI="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantAccountingJudgementsAndEstimatesDetailsNarrative" roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" roleURI="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfOtherIncomeDetails" roleURI="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinanceCostDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfProfitBeforeTaxDetails" roleURI="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfComponentOfIncomeTaxExpenseDetails" roleURI="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfRightOfUseAssetsDetails" roleURI="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfInventoriesDetails" roleURI="http://baselmedical.com/role/ScheduleOfInventoriesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTradeAndOtherReceivablesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" roleURI="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivablesDetailsNarrative" roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCashAndCashEquivalentsDetails" roleURI="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfAmountDueFromRelatedPartyDetails" roleURI="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedPartiesDetailsNarrative" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfBreakdownBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfDetailsBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTradeAndOtherPayablesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayablesDetailsNarrative" roleURI="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ShareCapitalDetailsNarrative" roleURI="http://baselmedical.com/role/ShareCapitalDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfAmountsRecognizedInProfitOrLossDetails" roleURI="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LeasesDetailsNarrative" roleURI="http://baselmedical.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTransactionsWithRelatedPartiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCompensationOfKeyManagementPersonnelDetails" roleURI="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwillDetailsNarrative" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" roleURI="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCreditRiskDetails" roleURI="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" roleURI="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagementDetailsNarrative" roleURI="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#EventsOccurringAfterReportingPeriodDetailsNarrative" roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_40" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_deiContactPersonnelEmailAddress_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelEmailAddress_40" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_40" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_40" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName_40" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation_40" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId_40" xlink:type="arc" order="64" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfProfitOrLoss" xlink:title="00000002 - Statement - Consolidated Statement of Profit or Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/BalanceSheets" xlink:title="00000003 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartiesMember" xlink:label="loc_ifrs-fullRelatedPartiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ifrs-fullRelatedPartiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-fullNoncurrentAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAssetsAbstract_50" xlink:to="loc_ifrs-fullNoncurrentAssetsAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullRightofuseAssets_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-fullDeferredTaxAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullDeferredTaxAssets_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullNoncurrentAssets_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAssetsAbstract_50" xlink:to="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-fullInventories_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullInventories_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullCashAndCashEquivalents_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullOtherCurrentReceivables_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredOfferingCost" xlink:label="loc_BMGLDeferredOfferingCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:to="loc_BMGLDeferredOfferingCost_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentAssetsAbstract_50" xlink:to="loc_ifrs-fullCurrentAssets_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAssetsAbstract_50" xlink:to="loc_ifrs-fullAssets_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-fullLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLiabilitiesAbstract_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesAbstract_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-fullLongtermBorrowings_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullLongtermBorrowings_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-fullShorttermBorrowings_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullShorttermBorrowings_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="loc_ifrs-fullOtherCurrentFinancialLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullOtherCurrentFinancialLiabilities_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:to="loc_BMGLAmountDueToFormerDirector_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-fullCurrentProvisionsForEmployeeBenefits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullCurrentProvisionsForEmployeeBenefits_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-fullCurrentTaxLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullCurrentTaxLiabilitiesCurrent_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullLiabilities_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-fullNetAssetsLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullNetAssetsLiabilities_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullEquityAbstract_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityAbstract_50" xlink:to="loc_ifrs-fullIssuedCapital_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MergerReserveArisingFromGroupRestructuring" xlink:label="loc_BMGLMergerReserveArisingFromGroupRestructuring_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityAbstract_50" xlink:to="loc_BMGLMergerReserveArisingFromGroupRestructuring_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityAbstract_50" xlink:to="loc_ifrs-fullRetainedEarnings_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityAbstract_50" xlink:to="loc_ifrs-fullNoncontrollingInterests_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityAbstract_50" xlink:to="loc_ifrs-fullOtherReserves_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityAbstract_50" xlink:to="loc_ifrs-fullEquity_50" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" xlink:title="00000004 - Statement - Consolidated Statement of Changes In Shareholders&apos; Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes In Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MergerReserveMember" xlink:label="loc_ifrs-fullMergerReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullMergerReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="loc_ifrs-fullReserveOfExchangeDifferencesOnTranslationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullReserveOfExchangeDifferencesOnTranslationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-fullIssueOfEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIssueOfEquity_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MinorityInterestInSubsidiary" xlink:label="loc_BMGLMinorityInterestInSubsidiary_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLMinorityInterestInSubsidiary_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeBeforeTax_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeBeforeTax_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughTransferToStatutoryReserve_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughTransferToStatutoryReserve_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_80" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statement of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/General" xlink:title="999014 - Disclosure - General" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformation" xlink:title="999015 - Disclosure - Material accounting policy information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" xlink:title="999016 - Disclosure - Significant accounting judgements and estimates" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Revenue" xlink:title="999017 - Disclosure - Revenue" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/OtherIncome" xlink:title="999018 - Disclosure - Other income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinanceCost" xlink:title="999019 - Disclosure - Finance cost" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LossprofitBeforeTax" xlink:title="999020 - Disclosure - (Loss)/Profit before tax" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/IncomeTaxBenefitexpense" xlink:title="999021 - Disclosure - Income tax (benefit)/expense" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RightOfUseAssets" xlink:title="999022 - Disclosure - Right of use assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/PropertyAndEquipment" xlink:title="999023 - Disclosure - Property and equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Inventories" xlink:title="999024 - Disclosure - Inventories" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivables" xlink:title="999025 - Disclosure - Trade and other receivables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CashAndCashEquivalents" xlink:title="999026 - Disclosure - Cash and cash equivalents" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedParties" xlink:title="999027 - Disclosure - Amount due from/to related parties" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Borrowings" xlink:title="999028 - Disclosure - Borrowings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayables" xlink:title="999029 - Disclosure - Trade and other payables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueToFormerDirector" xlink:title="999030 - Disclosure - Amount due to a former director" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ShareCapital" xlink:title="999031 - Disclosure - Share capital" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Leases" xlink:title="999032 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantRelatedPartyTransactions" xlink:title="999033 - Disclosure - Significant related party transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwill" xlink:title="999034 - Disclosure - Impairment loss on goodwill" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" xlink:title="999035 - Disclosure - Fair value of assets and liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagement" xlink:title="999036 - Disclosure - Financial risk management" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialInstrumentsByCategory" xlink:title="999037 - Disclosure - Financial instruments by category" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CapitalManagement" xlink:title="999038 - Disclosure - Capital management" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" xlink:title="999039 - Disclosure - Events occurring after the reporting period" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" xlink:title="999040 - Disclosure - Material accounting policy information (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/GeneralTables" xlink:title="999041 - Disclosure - General (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" xlink:title="999042 - Disclosure - Material accounting policy information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RevenueTables" xlink:title="999043 - Disclosure - Revenue (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/OtherIncomeTables" xlink:title="999044 - Disclosure - Other income (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinanceCostTables" xlink:title="999045 - Disclosure - Finance cost (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LossprofitBeforeTaxTables" xlink:title="999046 - Disclosure - (Loss)/Profit before tax (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" xlink:title="999047 - Disclosure - Income tax (benefit)/expense (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RightOfUseAssetsTables" xlink:title="999048 - Disclosure - Right of use assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/PropertyAndEquipmentTables" xlink:title="999049 - Disclosure - Property and equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/InventoriesTables" xlink:title="999050 - Disclosure - Inventories (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivablesTables" xlink:title="999051 - Disclosure - Trade and other receivables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CashAndCashEquivalentsTables" xlink:title="999052 - Disclosure - Cash and cash equivalents (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" xlink:title="999053 - Disclosure - Amount due from/to related parties (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/BorrowingsTables" xlink:title="999054 - Disclosure - Borrowings (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayablesTables" xlink:title="999055 - Disclosure - Trade and other payables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LeasesTables" xlink:title="999056 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" xlink:title="999057 - Disclosure - Significant related party transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" xlink:title="999058 - Disclosure - Impairment loss on goodwill (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagementTables" xlink:title="999059 - Disclosure - Financial risk management (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" xlink:title="999060 - Disclosure - Financial instruments by category (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" xlink:title="999061 - Disclosure - Schedule of activities of subsidiaries (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BaselMedicalGroupPteLtdMember" xlink:label="loc_BMGLBaselMedicalGroupPteLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLBaselMedicalGroupPteLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" xlink:label="loc_BMGLSingaporeSportsOrthopaedicClinicPteLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeSportsOrthopaedicClinicPteLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" xlink:label="loc_BMGLSingaporeSportsOrthopaedicServicesPteLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeSportsOrthopaedicServicesPteLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCPteLtdMember" xlink:label="loc_BMGLSSOCPteLtdMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCPteLtdMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOSPteLtdMember" xlink:label="loc_BMGLSSOSPteLtdMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOSPteLtdMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" xlink:label="loc_BMGLSingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" xlink:label="loc_BMGLSingaporeKneeSportsOrthopaedicServicesPteLtdMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeKneeSportsOrthopaedicServicesPteLtdMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PharmaAvenuePteLtdMember" xlink:label="loc_BMGLPharmaAvenuePteLtdMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLPharmaAvenuePteLtdMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BaselMedflowPteLtdMember" xlink:label="loc_BMGLBaselMedflowPteLtdMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLBaselMedflowPteLtdMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BethesdaMedicalPteLtdMember" xlink:label="loc_BMGLBethesdaMedicalPteLtdMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLBethesdaMedicalPteLtdMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OasisMedicalClinicPteLtdMember" xlink:label="loc_BMGLOasisMedicalClinicPteLtdMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLOasisMedicalClinicPteLtdMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="loc_ifrs-fullNameOfSubsidiary_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNameOfSubsidiary_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:label="loc_ifrs-fullDescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporation" xlink:label="loc_ifrs-fullCountryOfIncorporation_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCountryOfIncorporation_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_230" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/GeneralDetailsNarrative" xlink:title="999062 - Disclosure - General (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OrdinaryShareMember" xlink:label="loc_BMGLOrdinaryShareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_BMGLOrdinaryShareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NumberOfSharesSubscribed" xlink:label="loc_BMGLNumberOfSharesSubscribed_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLNumberOfSharesSubscribed_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="loc_ifrs-fullSharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullSharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" xlink:title="999063 - Disclosure - Schedule of expected useful lives for property, plant and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="loc_ifrs-fullMachineryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullMachineryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-fullFixturesAndFittingsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullFixturesAndFittingsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullOtherPropertyPlantAndEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullOtherPropertyPlantAndEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RenovationMember" xlink:label="loc_BMGLRenovationMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLRenovationMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AirConditionerMember" xlink:label="loc_BMGLAirConditionerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLAirConditionerMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-fullComputerEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullComputerEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SoftwareMember" xlink:label="loc_BMGLSoftwareMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLSoftwareMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_80" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" xlink:title="999064 - Disclosure - Significant accounting judgements and estimates (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" xlink:title="999065 - Disclosure - Summary of revenue from transfer of goods and services (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-fullProductsAndServicesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_ifrs-fullProductsAndServicesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="loc_ifrs-fullProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullProductsAndServicesAxis" xlink:to="loc_ifrs-fullProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="loc_ifrs-fullProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullProductsAndServicesAxis" xlink:to="loc_ifrs-fullProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MedicalServicesMember" xlink:label="loc_BMGLMedicalServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullProductsAndServicesDomain" xlink:to="loc_BMGLMedicalServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" xlink:to="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" xlink:to="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="loc_ifrs-fullGoodsOrServicesTransferredAtPointInTimeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain" xlink:to="loc_ifrs-fullGoodsOrServicesTransferredAtPointInTimeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullRevenue_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" xlink:title="999066 - Disclosure - Schedule of Other income (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" xlink:title="999067 - Disclosure - Schedule of Finance cost (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" xlink:title="999068 - Disclosure - Schedule of Profit before tax (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" xlink:title="999069 - Disclosure - Schedule of component of income tax expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" xlink:title="999070 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" xlink:title="999071 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" xlink:title="999072 - Disclosure - Schedule of Right of use assets (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="loc_ifrs-fullCarryingAmountMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="loc_ifrs-fullCarryingAmountMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-fullGrossCarryingAmountMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_ifrs-fullGrossCarryingAmountMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AccumulatedDepreciationMember" xlink:label="loc_BMGLAccumulatedDepreciationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_BMGLAccumulatedDepreciationMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullRightofuseAssets_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" xlink:label="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-fullDepreciationRightofuseAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDepreciationRightofuseAssets_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsRightofuseAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsRightofuseAssets_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_WrittenOffRightofuseAssets" xlink:label="loc_BMGLWrittenOffRightofuseAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLWrittenOffRightofuseAssets_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999073 - Disclosure - Schedule of Property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="loc_ifrs-fullCarryingAmountMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="loc_ifrs-fullCarryingAmountMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-fullGrossCarryingAmountMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_ifrs-fullGrossCarryingAmountMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-fullAccumulatedDepreciationAndAmortisationMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_ifrs-fullAccumulatedDepreciationAndAmortisationMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="loc_ifrs-fullMachineryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullMachineryMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-fullFixturesAndFittingsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullFixturesAndFittingsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MedicalEquipmentMember" xlink:label="loc_BMGLMedicalEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLMedicalEquipmentMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RenovationMember" xlink:label="loc_BMGLRenovationMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLRenovationMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AirConditionerMember" xlink:label="loc_BMGLAirConditionerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLAirConditionerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ComputerAndOfficeEquipmentMember" xlink:label="loc_BMGLComputerAndOfficeEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLComputerAndOfficeEquipmentMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SoftwareMember" xlink:label="loc_BMGLSoftwareMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLSoftwareMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment_970" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_970" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_970" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_BMGLWrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLWrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_970" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDepreciationPropertyPlantAndEquipment_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDepreciationPropertyPlantAndEquipment_970" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_BMGLPropertyPlantAndEquipmentAccumulatedDepreciation_970" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPropertyPlantAndEquipmentAccumulatedDepreciation_970" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfInventoriesDetails" xlink:title="999074 - Disclosure - Schedule of Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" xlink:title="999075 - Disclosure - Schedule of trade and other receivables (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ThridPartiesMember" xlink:label="loc_BMGLThridPartiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLThridPartiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-fullCurrentTradeReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentTradeReceivables_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AllowanceForExpectedCreditLoss" xlink:label="loc_BMGLAllowanceForExpectedCreditLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAllowanceForExpectedCreditLoss_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-fullTradeReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeReceivables_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="loc_ifrs-fullLongtermDeposits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLongtermDeposits_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments" xlink:label="loc_ifrs-fullPrepayments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullPrepayments_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherCurrentReceivables_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" xlink:title="999076 - Disclosure - Schedule of movement in allowance for expected credit losses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" xlink:title="999077 - Disclosure - Trade and other receivables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CustodianServicesMember" xlink:label="loc_BMGLCustodianServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLCustodianServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="loc_ifrs-fullLongtermDeposits_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLongtermDeposits_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999078 - Disclosure - Schedule of cash and cash equivalents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" xlink:title="999079 - Disclosure - Schedule of amount due from related party (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsMember" xlink:label="loc_BMGLDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLDirectorsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OthersRelatedPartiesMember" xlink:label="loc_BMGLOthersRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLOthersRelatedPartiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" xlink:title="999080 - Disclosure - Amount due from/to related parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RainforestCapitalVCCMember" xlink:label="loc_BMGLRainforestCapitalVCCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLRainforestCapitalVCCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" xlink:label="loc_BMGLDrKevinYipAndSingmedInvestmentPteLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLDrKevinYipAndSingmedInvestmentPteLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DrKevinYipMember" xlink:label="loc_BMGLDrKevinYipMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLDrKevinYipMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" xlink:label="loc_ifrs-fullMeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullMeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" xlink:label="loc_ifrs-fullSettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullSettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashPaidOnClosingInitialSettlement" xlink:label="loc_BMGLCashPaidOnClosingInitialSettlement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCashPaidOnClosingInitialSettlement_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" xlink:label="loc_BMGLPercentageOfProvisionalConsiderationAmountForTransferOfShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPercentageOfProvisionalConsiderationAmountForTransferOfShare_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances" xlink:label="loc_ifrs-fullLoansAndAdvances_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansAndAdvances_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-fullWagesAndSalaries_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullWagesAndSalaries_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-fullOtherPayables_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherPayables_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:label="loc_ifrs-fullAmountsReceivableRelatedPartyTransactions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAmountsReceivableRelatedPartyTransactions_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="loc_ifrs-fullReceivablesDueFromAssociates_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullReceivablesDueFromAssociates_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashReceivedToFullySettleRelatedPartyReceivables" xlink:label="loc_BMGLCashReceivedToFullySettleRelatedPartyReceivables_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCashReceivedToFullySettleRelatedPartyReceivables_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" xlink:title="999081 - Disclosure - Schedule of borrowings (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" xlink:title="999082 - Disclosure - Schedule of breakdown borrowings (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanOneMember" xlink:label="loc_BMGLTermLoanOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwoMember" xlink:label="loc_BMGLTermLoanTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanThreeMember" xlink:label="loc_BMGLTermLoanThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanFourMember" xlink:label="loc_BMGLTermLoanFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSixMember" xlink:label="loc_BMGLTermLoanSixMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSixMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSevenMember" xlink:label="loc_BMGLTermLoanSevenMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSevenMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanNineMember" xlink:label="loc_BMGLTermLoanNineMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanNineMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenMember" xlink:label="loc_BMGLTermLoanTenMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenMember" xlink:label="loc_BMGLTermLoanElevenMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanElevenMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwelveMember" xlink:label="loc_BMGLTermLoanTwelveMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwelveMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanMember" xlink:label="loc_BMGLTermLoanMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived" xlink:label="loc_ifrs-fullLoansReceived_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansReceived_230" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" xlink:title="999083 - Disclosure - Schedule of details borrowings (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanOneMember" xlink:label="loc_BMGLTermLoanOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwoMember" xlink:label="loc_BMGLTermLoanTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanThreeMember" xlink:label="loc_BMGLTermLoanThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanFourMember" xlink:label="loc_BMGLTermLoanFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSixMember" xlink:label="loc_BMGLTermLoanSixMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSixMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSevenMember" xlink:label="loc_BMGLTermLoanSevenMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSevenMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanNineMember" xlink:label="loc_BMGLTermLoanNineMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanNineMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenMember" xlink:label="loc_BMGLTermLoanTenMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenOneMember" xlink:label="loc_BMGLTermLoanTenOneMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenOneMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenTwoMember" xlink:label="loc_BMGLTermLoanTenTwoMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenTwoMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenThreeMember" xlink:label="loc_BMGLTermLoanTenThreeMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenThreeMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenFourMember" xlink:label="loc_BMGLTermLoanTenFourMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenFourMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenMember" xlink:label="loc_BMGLTermLoanElevenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanElevenMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenOneMember" xlink:label="loc_BMGLTermLoanElevenOneMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanElevenOneMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwelveMember" xlink:label="loc_BMGLTermLoanTwelveMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwelveMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-fullBorrowingsMaturity_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsMaturity_310" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" xlink:title="999084 - Disclosure - Schedule of reconciliation of liabilities arising from financing activities (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-fullLeaseLiabilitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="loc_ifrs-fullLeaseLiabilitiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="loc_ifrs-fullShorttermBorrowingsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="loc_ifrs-fullShorttermBorrowingsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-fullAssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="loc_ifrs-fullAssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="loc_ifrs-fullCashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="loc_ifrs-fullProceedsFromCurrentBorrowings_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromCurrentBorrowings_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullIncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" xlink:label="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" xlink:label="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" xlink:label="loc_BMGLCashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-fullProceedsFromNoncurrentBorrowings_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromNoncurrentBorrowings_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" xlink:label="loc_BMGLIncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" xlink:label="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" xlink:label="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BankBorrowings" xlink:label="loc_BMGLBankBorrowings_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLBankBorrowings_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionBankBorrowingsCurrent" xlink:label="loc_BMGLAdditionBankBorrowingsCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAdditionBankBorrowingsCurrent_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:label="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived_160" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionBankBorrowingsNonCurrent" xlink:label="loc_BMGLAdditionBankBorrowingsNonCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAdditionBankBorrowingsNonCurrent_160" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivities_160" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_160" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullProceedsFromBorrowingsClassifiedAsFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromBorrowingsClassifiedAsFinancingActivities_160" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" xlink:label="loc_BMGLIncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_160" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" xlink:label="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_160" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_160" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:title="999085 - Disclosure - Schedule of trade and other payables (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" xlink:title="999086 - Disclosure - Trade and other payables (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ShareCapitalDetailsNarrative" xlink:title="999087 - Disclosure - Share capital (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InitialPublicOfferingMember" xlink:label="loc_BMGLInitialPublicOfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_BMGLInitialPublicOfferingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverAllotmentOptionsMember" xlink:label="loc_BMGLOverAllotmentOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_BMGLOverAllotmentOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-fullNumberOfSharesAuthorised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesAuthorised_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ValueOfSharesAuthorised" xlink:label="loc_BMGLValueOfSharesAuthorised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLValueOfSharesAuthorised_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" xlink:title="999088 - Disclosure - Schedule of amounts recognized in profit or loss (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LeasesDetailsNarrative" xlink:title="999089 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="loc_ifrs-fullMachineryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullMachineryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LeaseTermOfContract" xlink:label="loc_BMGLLeaseTermOfContract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLLeaseTermOfContract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-fullWeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-fullCashOutflowForLeases_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashOutflowForLeases_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" xlink:title="999090 - Disclosure - Schedule of transactions with related parties (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartiesMember" xlink:label="loc_ifrs-fullRelatedPartiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ifrs-fullRelatedPartiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InterestIncomeOnLoansAndReceivable" xlink:label="loc_BMGLInterestIncomeOnLoansAndReceivable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInterestIncomeOnLoansAndReceivable_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ManagementFee" xlink:label="loc_BMGLManagementFee_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLManagementFee_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" xlink:title="999091 - Disclosure - Schedule of compensation of key management personnel (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" xlink:title="999092 - Disclosure - Schedule of fair value of identifiable assets and liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" xlink:title="999093 - Disclosure - Impairment loss on goodwill (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" xlink:title="999094 - Disclosure - Schedule of group&#8217;s current credit risk grading framework (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementTable" xlink:label="loc_BMGLIfrsStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIfrsStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryAxis" xlink:label="loc_BMGLCategoryAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_BMGLIfrsStatementTable" xlink:to="loc_BMGLCategoryAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryDomain" xlink:label="loc_BMGLCategoryDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_BMGLCategoryAxis" xlink:to="loc_BMGLCategoryDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryDomain" xlink:label="loc_BMGLCategoryDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_BMGLCategoryAxis" xlink:to="loc_BMGLCategoryDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryOneMember" xlink:label="loc_BMGLCategoryOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryTwoMember" xlink:label="loc_BMGLCategoryTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryThreeMember" xlink:label="loc_BMGLCategoryThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryFourMember" xlink:label="loc_BMGLCategoryFourMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryFourMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfCreditRisk" xlink:label="loc_BMGLDescriptionOfCreditRisk_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLDescriptionOfCreditRisk_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BasisForRecognizingExpectedCreditLoss" xlink:label="loc_BMGLBasisForRecognizingExpectedCreditLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLBasisForRecognizingExpectedCreditLoss_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" xlink:title="999095 - Disclosure - Schedule of financial assets, minimum exposure to credit risk (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-fullBusinessCombinationsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullBusinessCombinationsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-fullBusinessCombinationsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullBusinessCombinationsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-fullBusinessCombinationsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullBusinessCombinationsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-fullGrossCarryingAmountMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullBusinessCombinationsDomain" xlink:to="loc_ifrs-fullGrossCarryingAmountMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember" xlink:label="loc_ifrs-fullAllowanceForCreditLossesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullBusinessCombinationsDomain" xlink:to="loc_ifrs-fullAllowanceForCreditLossesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullBusinessCombinationsDomain" xlink:to="loc_ifrs-fullCarryingAmountMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryAxis" xlink:label="loc_BMGLCategoryAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_BMGLCategoryAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryDomain" xlink:label="loc_BMGLCategoryDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_BMGLCategoryAxis" xlink:to="loc_BMGLCategoryDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryDomain" xlink:label="loc_BMGLCategoryDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_BMGLCategoryAxis" xlink:to="loc_BMGLCategoryDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryOneMember" xlink:label="loc_BMGLCategoryOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-fullTypesOfRisksAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullTypesOfRisksAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-fullTypesOfRisksDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfRisksAxis" xlink:to="loc_ifrs-fullTypesOfRisksDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-fullTypesOfRisksDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfRisksAxis" xlink:to="loc_ifrs-fullTypesOfRisksDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LifeTimeExpectedCreditLossMember" xlink:label="loc_BMGLLifeTimeExpectedCreditLossMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfRisksDomain" xlink:to="loc_BMGLLifeTimeExpectedCreditLossMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TwelveExpectedCreditLossMember" xlink:label="loc_BMGLTwelveExpectedCreditLossMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfRisksDomain" xlink:to="loc_BMGLTwelveExpectedCreditLossMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditRiskTradeReceivables" xlink:label="loc_BMGLCreditRiskTradeReceivables_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCreditRiskTradeReceivables_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="loc_ifrs-fullLongtermDeposits_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLongtermDeposits_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ExpectedCreditLosses" xlink:label="loc_BMGLExpectedCreditLosses_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLExpectedCreditLosses_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" xlink:title="999096 - Disclosure - Schedule of credit risk (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="loc_ifrs-fullDisclosureOfProvisionMatrixTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfProvisionMatrixTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="loc_ifrs-fullPastDueStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfProvisionMatrixTable" xlink:to="loc_ifrs-fullPastDueStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PastDueStatusDomain" xlink:label="loc_ifrs-fullPastDueStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullPastDueStatusAxis" xlink:to="loc_ifrs-fullPastDueStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PastDueStatusDomain" xlink:label="loc_ifrs-fullPastDueStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullPastDueStatusAxis" xlink:to="loc_ifrs-fullPastDueStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NotPastDueMember" xlink:label="loc_BMGLNotPastDueMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_BMGLNotPastDueMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:label="loc_ifrs-fullLaterThanOneMonthAndNotLaterThanTwoMonthsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_ifrs-fullLaterThanOneMonthAndNotLaterThanTwoMonthsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" xlink:label="loc_BMGLLaterThanTwoMonthsAndNotLaterThanFourMonthsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_BMGLLaterThanTwoMonthsAndNotLaterThanFourMonthsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFourMonthsMember" xlink:label="loc_ifrs-fullLaterThanFourMonthsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_ifrs-fullLaterThanFourMonthsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-fullLaterThanOneYearMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_ifrs-fullLaterThanOneYearMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-fullTypesOfRisksAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfProvisionMatrixTable" xlink:to="loc_ifrs-fullTypesOfRisksAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-fullTypesOfRisksDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfRisksAxis" xlink:to="loc_ifrs-fullTypesOfRisksDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-fullTypesOfRisksDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfRisksAxis" xlink:to="loc_ifrs-fullTypesOfRisksDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-fullCreditRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfRisksDomain" xlink:to="loc_ifrs-fullCreditRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedCreditLossRate" xlink:label="loc_ifrs-fullExpectedCreditLossRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedCreditLossRate_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-fullTradeReceivables_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeReceivables_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ExpectedCreditLosses" xlink:label="loc_BMGLExpectedCreditLosses_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLExpectedCreditLosses_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditRiskTradeReceivables" xlink:label="loc_BMGLCreditRiskTradeReceivables_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCreditRiskTradeReceivables_150" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" xlink:title="999097 - Disclosure - Schedule of remaining contractual undiscounted repayment obligations (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-fullMaturityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_ifrs-fullMaturityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-fullMaturityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullMaturityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-fullMaturityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullMaturityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_ifrs-fullCarryingAmountMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ContractualCashFlowsMember" xlink:label="loc_BMGLContractualCashFlowsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_BMGLContractualCashFlowsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-fullNotLaterThanOneYearMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_ifrs-fullNotLaterThanOneYearMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-fullLaterThanOneYearMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_ifrs-fullLaterThanOneYearMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalUndiscountedFinancialAssets" xlink:label="loc_BMGLTotalUndiscountedFinancialAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLTotalUndiscountedFinancialAssets_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayables_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAmountDueToFormerDirector_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalNetUndiscountedFinancialAssetsliabilities" xlink:label="loc_BMGLTotalNetUndiscountedFinancialAssetsliabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLTotalNetUndiscountedFinancialAssetsliabilities_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" xlink:title="999098 - Disclosure - Financial risk management (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullTopOfRangeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullBottomOfRangeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PercentageOfTradeReceivables" xlink:label="loc_BMGLPercentageOfTradeReceivables_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPercentageOfTradeReceivables_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" xlink:title="999099 - Disclosure - Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-fullFinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsDomain" xlink:to="loc_ifrs-fullFinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalUndiscountedFinancialAssets" xlink:label="loc_BMGLTotalUndiscountedFinancialAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLTotalUndiscountedFinancialAssets_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayables_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAmountDueToFormerDirector_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows_30" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" xlink:title="999100 - Disclosure - Events occurring after the reporting period (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCNovenaPteLtdMember" xlink:label="loc_BMGLSSOCNovenaPteLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCNovenaPteLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCOrchardPteLtdMember" xlink:label="loc_BMGLSSOCOrchardPteLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCOrchardPteLtdMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCFarrerParkPteLtdMember" xlink:label="loc_BMGLSSOCFarrerParkPteLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCFarrerParkPteLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PharmaAvenuePteLtdMember" xlink:label="loc_BMGLPharmaAvenuePteLtdMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLPharmaAvenuePteLtdMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EyetrustMedicalPteLtdMember" xlink:label="loc_BMGLEyetrustMedicalPteLtdMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLEyetrustMedicalPteLtdMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CharteredImagingPteLtdMember" xlink:label="loc_BMGLCharteredImagingPteLtdMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLCharteredImagingPteLtdMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NonadjustingEventsAfterReportingPeriodMember" xlink:label="loc_BMGLNonadjustingEventsAfterReportingPeriodMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain" xlink:to="loc_BMGLNonadjustingEventsAfterReportingPeriodMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullTopOfRangeMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsPercentage" xlink:label="loc_BMGLInvestmentsPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInvestmentsPercentage_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsSalePercentage" xlink:label="loc_BMGLInvestmentsSalePercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInvestmentsSalePercentage_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsHoldPercentage" xlink:label="loc_BMGLInvestmentsHoldPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInvestmentsHoldPercentage_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-fullNetDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNetDebt_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>bmgl-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartiesMember" xlink:label="ifrs-full_RelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartiesMember" xlink:to="ifrs-full_RelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartiesMember_lbl" xml:lang="en-US">Total for all related parties [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MergerReserveMember" xlink:label="ifrs-full_MergerReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MergerReserveMember" xlink:to="ifrs-full_MergerReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MergerReserveMember_lbl" xml:lang="en-US">Merger reserve [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US">Translation reserve [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OrdinaryShareMember" xlink:label="BMGL_OrdinaryShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OrdinaryShareMember" xlink:to="BMGL_OrdinaryShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OrdinaryShareMember_lbl" xml:lang="en-US">Ordinary Share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BaselMedicalGroupPteLtdMember" xlink:label="BMGL_BaselMedicalGroupPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BaselMedicalGroupPteLtdMember" xlink:to="BMGL_BaselMedicalGroupPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_BaselMedicalGroupPteLtdMember_lbl" xml:lang="en-US">Basel Medical Group Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" xlink:label="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" xlink:to="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember_lbl" xml:lang="en-US">Singapore Sports Orthopaedic Clinic Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" xlink:label="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" xlink:to="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember_lbl" xml:lang="en-US">Singapore Sports Orthopaedic Services Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCPteLtdMember" xlink:label="BMGL_SSOCPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCPteLtdMember" xlink:to="BMGL_SSOCPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SSOCPteLtdMember_lbl" xml:lang="en-US">SSOC Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOSPteLtdMember" xlink:label="BMGL_SSOSPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOSPteLtdMember" xlink:to="BMGL_SSOSPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SSOSPteLtdMember_lbl" xml:lang="en-US">SSOS Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" xlink:label="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" xlink:to="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_lbl" xml:lang="en-US">Singapore Knee Sports and Orthopaedic Clinic Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" xlink:label="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" xlink:to="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember_lbl" xml:lang="en-US">Singapore Knee Sports Orthopaedic Services Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PharmaAvenuePteLtdMember" xlink:label="BMGL_PharmaAvenuePteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PharmaAvenuePteLtdMember" xlink:to="BMGL_PharmaAvenuePteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_PharmaAvenuePteLtdMember_lbl" xml:lang="en-US">Pharma Avenue Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BaselMedflowPteLtdMember" xlink:label="BMGL_BaselMedflowPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BaselMedflowPteLtdMember" xlink:to="BMGL_BaselMedflowPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_BaselMedflowPteLtdMember_lbl" xml:lang="en-US">Basel Medflow Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BethesdaMedicalPteLtdMember" xlink:label="BMGL_BethesdaMedicalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BethesdaMedicalPteLtdMember" xlink:to="BMGL_BethesdaMedicalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_BethesdaMedicalPteLtdMember_lbl" xml:lang="en-US">Bethesda Medical Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OasisMedicalClinicPteLtdMember" xlink:label="BMGL_OasisMedicalClinicPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OasisMedicalClinicPteLtdMember" xlink:to="BMGL_OasisMedicalClinicPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OasisMedicalClinicPteLtdMember_lbl" xml:lang="en-US">Oasis Medical Clinic Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="ifrs-full_MachineryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MachineryMember" xlink:to="ifrs-full_MachineryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MachineryMember_lbl" xml:lang="en-US">Machinery [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="ifrs-full_FixturesAndFittingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixturesAndFittingsMember" xlink:to="ifrs-full_FixturesAndFittingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FixturesAndFittingsMember_lbl" xml:lang="en-US">Fixtures and fittings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Other property, plant and equipment [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RenovationMember" xlink:label="BMGL_RenovationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RenovationMember" xlink:to="BMGL_RenovationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_RenovationMember_lbl" xml:lang="en-US">Renovation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AirConditionerMember" xlink:label="BMGL_AirConditionerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AirConditionerMember" xlink:to="BMGL_AirConditionerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AirConditionerMember_lbl" xml:lang="en-US">Air Conditioner [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SoftwareMember" xlink:label="BMGL_SoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SoftwareMember" xlink:to="BMGL_SoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SoftwareMember_lbl" xml:lang="en-US">Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US">Products and services [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MedicalServicesMember" xlink:label="BMGL_MedicalServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MedicalServicesMember" xlink:to="BMGL_MedicalServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_MedicalServicesMember_lbl" xml:lang="en-US">Medical Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xml:lang="en-US">Goods or services transferred at point in time [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US">Gross carrying amount [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AccumulatedDepreciationMember" xlink:label="BMGL_AccumulatedDepreciationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AccumulatedDepreciationMember" xlink:to="BMGL_AccumulatedDepreciationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AccumulatedDepreciationMember_lbl" xml:lang="en-US">Accumulated Depreciation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MedicalEquipmentMember" xlink:label="BMGL_MedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MedicalEquipmentMember" xlink:to="BMGL_MedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_MedicalEquipmentMember_lbl" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ComputerAndOfficeEquipmentMember" xlink:label="BMGL_ComputerAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ComputerAndOfficeEquipmentMember" xlink:to="BMGL_ComputerAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computer and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ThridPartiesMember" xlink:label="BMGL_ThridPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ThridPartiesMember" xlink:to="BMGL_ThridPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ThridPartiesMember_lbl" xml:lang="en-US">Thrid Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CustodianServicesMember" xlink:label="BMGL_CustodianServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CustodianServicesMember" xlink:to="BMGL_CustodianServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CustodianServicesMember_lbl" xml:lang="en-US">Custodian Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RainforestCapitalVCCMember" xlink:label="BMGL_RainforestCapitalVCCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RainforestCapitalVCCMember" xlink:to="BMGL_RainforestCapitalVCCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_RainforestCapitalVCCMember_lbl" xml:lang="en-US">Rainforest capital VCC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" xlink:label="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" xlink:to="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember_lbl" xml:lang="en-US">Dr Kevin Yip and Singmed Investment Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DrKevinYipMember" xlink:label="BMGL_DrKevinYipMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DrKevinYipMember" xlink:to="BMGL_DrKevinYipMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DrKevinYipMember_lbl" xml:lang="en-US">Dr Kevin Yip [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsMember" xlink:label="BMGL_DirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DirectorsMember" xlink:to="BMGL_DirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DirectorsMember_lbl" xml:lang="en-US">Directors [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OthersRelatedPartiesMember" xlink:label="BMGL_OthersRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OthersRelatedPartiesMember" xlink:to="BMGL_OthersRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OthersRelatedPartiesMember_lbl" xml:lang="en-US">Others Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanOneMember" xlink:label="BMGL_TermLoanOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanOneMember" xlink:to="BMGL_TermLoanOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanOneMember_lbl" xml:lang="en-US">Term loan #1 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwoMember" xlink:label="BMGL_TermLoanTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTwoMember" xlink:to="BMGL_TermLoanTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTwoMember_lbl" xml:lang="en-US">Term loan #2 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanThreeMember" xlink:label="BMGL_TermLoanThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanThreeMember" xlink:to="BMGL_TermLoanThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanThreeMember_lbl" xml:lang="en-US">Term loan #3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanFourMember" xlink:label="BMGL_TermLoanFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanFourMember" xlink:to="BMGL_TermLoanFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanFourMember_lbl" xml:lang="en-US">Term loan #4 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSixMember" xlink:label="BMGL_TermLoanSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanSixMember" xlink:to="BMGL_TermLoanSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanSixMember_lbl" xml:lang="en-US">Term loan #6 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSevenMember" xlink:label="BMGL_TermLoanSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanSevenMember" xlink:to="BMGL_TermLoanSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanSevenMember_lbl" xml:lang="en-US">Term loan #7 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanNineMember" xlink:label="BMGL_TermLoanNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanNineMember" xlink:to="BMGL_TermLoanNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanNineMember_lbl" xml:lang="en-US">Term loan #9 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenMember" xlink:label="BMGL_TermLoanTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenMember" xlink:to="BMGL_TermLoanTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTenMember_lbl" xml:lang="en-US">Term loan #10 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenMember" xlink:label="BMGL_TermLoanElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanElevenMember" xlink:to="BMGL_TermLoanElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanElevenMember_lbl" xml:lang="en-US">Term loan #11 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwelveMember" xlink:label="BMGL_TermLoanTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTwelveMember" xlink:to="BMGL_TermLoanTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTwelveMember_lbl" xml:lang="en-US">Term loan #12 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanMember" xlink:label="BMGL_TermLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanMember" xlink:to="BMGL_TermLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanMember_lbl" xml:lang="en-US">Term loan [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenOneMember" xlink:label="BMGL_TermLoanTenOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenOneMember" xlink:to="BMGL_TermLoanTenOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTenOneMember_lbl" xml:lang="en-US">Term loan #10 One [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenTwoMember" xlink:label="BMGL_TermLoanTenTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenTwoMember" xlink:to="BMGL_TermLoanTenTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTenTwoMember_lbl" xml:lang="en-US">Term loan #10 two [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenThreeMember" xlink:label="BMGL_TermLoanTenThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenThreeMember" xlink:to="BMGL_TermLoanTenThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTenThreeMember_lbl" xml:lang="en-US">Term loan #10 three [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenFourMember" xlink:label="BMGL_TermLoanTenFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenFourMember" xlink:to="BMGL_TermLoanTenFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanTenFourMember_lbl" xml:lang="en-US">Term loan #10 four [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenOneMember" xlink:label="BMGL_TermLoanElevenOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanElevenOneMember" xlink:to="BMGL_TermLoanElevenOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TermLoanElevenOneMember_lbl" xml:lang="en-US">Term loan #11 one [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_lbl" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US">Lease liabilities [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ifrs-full_ShorttermBorrowingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowingsMember" xlink:to="ifrs-full_ShorttermBorrowingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermBorrowingsMember_lbl" xml:lang="en-US">Short-term borrowings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:label="ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:to="ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_lbl" xml:lang="en-US">Assets held to hedge liabilities arising from financing activities [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InitialPublicOfferingMember" xlink:label="BMGL_InitialPublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InitialPublicOfferingMember" xlink:to="BMGL_InitialPublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_InitialPublicOfferingMember_lbl" xml:lang="en-US">Initial Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverAllotmentOptionsMember" xlink:label="BMGL_OverAllotmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OverAllotmentOptionsMember" xlink:to="BMGL_OverAllotmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OverAllotmentOptionsMember_lbl" xml:lang="en-US">OverAllotment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryAxis" xlink:label="BMGL_CategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryAxis" xlink:to="BMGL_CategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CategoryAxis_lbl" xml:lang="en-US">Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryOneMember" xlink:label="BMGL_CategoryOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryOneMember" xlink:to="BMGL_CategoryOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CategoryOneMember_lbl" xml:lang="en-US">Category I [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryTwoMember" xlink:label="BMGL_CategoryTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryTwoMember" xlink:to="BMGL_CategoryTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CategoryTwoMember_lbl" xml:lang="en-US">Category II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryThreeMember" xlink:label="BMGL_CategoryThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryThreeMember" xlink:to="BMGL_CategoryThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CategoryThreeMember_lbl" xml:lang="en-US">Category Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryFourMember" xlink:label="BMGL_CategoryFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryFourMember" xlink:to="BMGL_CategoryFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CategoryFourMember_lbl" xml:lang="en-US">Category IV [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US">Types of risks [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LifeTimeExpectedCreditLossMember" xlink:label="BMGL_LifeTimeExpectedCreditLossMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LifeTimeExpectedCreditLossMember" xlink:to="BMGL_LifeTimeExpectedCreditLossMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_LifeTimeExpectedCreditLossMember_lbl" xml:lang="en-US">Life time expected credit loss [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember" xlink:label="ifrs-full_AllowanceForCreditLossesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllowanceForCreditLossesMember" xlink:to="ifrs-full_AllowanceForCreditLossesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllowanceForCreditLossesMember_lbl" xml:lang="en-US">Allowance for credit losses [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US">Carrying amount [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TwelveExpectedCreditLossMember" xlink:label="BMGL_TwelveExpectedCreditLossMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TwelveExpectedCreditLossMember" xlink:to="BMGL_TwelveExpectedCreditLossMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TwelveExpectedCreditLossMember_lbl" xml:lang="en-US">Twelve expected credit loss [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="ifrs-full_PastDueStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PastDueStatusAxis" xlink:to="ifrs-full_PastDueStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PastDueStatusAxis_lbl" xml:lang="en-US">Past due status [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NotPastDueMember" xlink:label="BMGL_NotPastDueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NotPastDueMember" xlink:to="BMGL_NotPastDueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_NotPastDueMember_lbl" xml:lang="en-US">Not past due [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US">Credit risk [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl" xml:lang="en-US">Later than one month and not later than two months [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" xlink:label="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" xlink:to="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_lbl" xml:lang="en-US">Later than two months and not later than four months [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFourMonthsMember" xlink:label="ifrs-full_LaterThanFourMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFourMonthsMember" xlink:to="ifrs-full_LaterThanFourMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanFourMonthsMember_lbl" xml:lang="en-US">Later than four months [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearMember" xlink:to="ifrs-full_LaterThanOneYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xml:lang="en-US">Later than one year [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ContractualCashFlowsMember" xlink:label="BMGL_ContractualCashFlowsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ContractualCashFlowsMember" xlink:to="BMGL_ContractualCashFlowsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ContractualCashFlowsMember_lbl" xml:lang="en-US">Contractual cash flows [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US">Not later than one year [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xml:lang="en-US">Categories of financial assets [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCNovenaPteLtdMember" xlink:label="BMGL_SSOCNovenaPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCNovenaPteLtdMember" xlink:to="BMGL_SSOCNovenaPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SSOCNovenaPteLtdMember_lbl" xml:lang="en-US">SSOC Novena Pte Ltd [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NonadjustingEventsAfterReportingPeriodMember" xlink:label="BMGL_NonadjustingEventsAfterReportingPeriodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NonadjustingEventsAfterReportingPeriodMember" xlink:to="BMGL_NonadjustingEventsAfterReportingPeriodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_NonadjustingEventsAfterReportingPeriodMember_lbl" xml:lang="en-US">Nonadjusting Events After Reporting Period [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCOrchardPteLtdMember" xlink:label="BMGL_SSOCOrchardPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCOrchardPteLtdMember" xlink:to="BMGL_SSOCOrchardPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SSOCOrchardPteLtdMember_lbl" xml:lang="en-US">SSOC Orchard Pte Ltd [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCFarrerParkPteLtdMember" xlink:label="BMGL_SSOCFarrerParkPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCFarrerParkPteLtdMember" xlink:to="BMGL_SSOCFarrerParkPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_SSOCFarrerParkPteLtdMember_lbl" xml:lang="en-US">SSOC Farrer Park Pte Ltd [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EyetrustMedicalPteLtdMember" xlink:label="BMGL_EyetrustMedicalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EyetrustMedicalPteLtdMember" xlink:to="BMGL_EyetrustMedicalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_EyetrustMedicalPteLtdMember_lbl" xml:lang="en-US">Eyetrust Medical Pte Ltd [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CharteredImagingPteLtdMember" xlink:label="BMGL_CharteredImagingPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CharteredImagingPteLtdMember" xlink:to="BMGL_CharteredImagingPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CharteredImagingPteLtdMember_lbl" xml:lang="en-US">Chartered Imaging Pte Ltd [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses" xlink:label="ifrs-full_OtherGainsLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherGainsLosses_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:label="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:to="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses_lbl" xml:lang="en-US">Consumables, medical supplies and other related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Employee benefit expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US">Other operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="ifrs-full_ImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ImpairmentLoss_lbl" xml:lang="en-US">Impairment loss on goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">(Loss)/Profit before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">(Loss)/Profit after tax</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProfitLossAndNetComprehensiveIncome" xlink:label="BMGL_ProfitLossAndNetComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProfitLossAndNetComprehensiveIncome" xlink:to="BMGL_ProfitLossAndNetComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="BMGL_ProfitLossAndNetComprehensiveIncome_lbl" xml:lang="en-US">(Loss)/Profit for the year, representing total comprehensive income for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">(Loss)/Profit attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProfitLossIncludingMinorityInterest" xlink:label="BMGL_ProfitLossIncludingMinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProfitLossIncludingMinorityInterest" xlink:to="BMGL_ProfitLossIncludingMinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="BMGL_ProfitLossIncludingMinorityInterest_lbl" xml:lang="en-US">(Loss)/Profit for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="BMGL_IfrsStatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IfrsStatementLineItems" xlink:to="BMGL_IfrsStatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IfrsStatementLineItems_lbl" xml:lang="en-US">IfrsStatementLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use-assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_lbl" xml:lang="en-US">Investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total Non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredOfferingCost" xlink:label="BMGL_DeferredOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredOfferingCost" xlink:to="BMGL_DeferredOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DeferredOfferingCost_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LongtermBorrowings_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowings" xlink:to="ifrs-full_ShorttermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xml:lang="en-US">Amount due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="BMGL_AmountDueToFormerDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AmountDueToFormerDirector" xlink:to="BMGL_AmountDueToFormerDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AmountDueToFormerDirector_lbl" xml:lang="en-US">Amount due to a former director</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US">Asset retirement obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xml:lang="en-US">Provision for income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="ifrs-full_NetAssetsLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NetAssetsLiabilities_lbl" xml:lang="en-US">NET ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Capital attributable to equity holders of the Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MergerReserveArisingFromGroupRestructuring" xlink:label="BMGL_MergerReserveArisingFromGroupRestructuring" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MergerReserveArisingFromGroupRestructuring" xlink:to="BMGL_MergerReserveArisingFromGroupRestructuring_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_MergerReserveArisingFromGroupRestructuring_lbl" xml:lang="en-US">Merger reserve arising from group restructuring</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Retained earnings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Translation reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Issuance of share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share based payment reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MinorityInterestInSubsidiary" xlink:label="BMGL_MinorityInterestInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MinorityInterestInSubsidiary" xlink:to="BMGL_MinorityInterestInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_MinorityInterestInSubsidiary_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax_lbl" xml:lang="en-US">Loss for the year, representing total comprehensive income for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve" xlink:label="ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve" xlink:to="ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve_lbl" xml:lang="en-US">Merger reserve arising from group restructuring</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_2_lbl" xml:lang="en-US">Profit/(Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_2_lbl" xml:lang="en-US">(Loss)/Profit before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff" xlink:label="ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff" xlink:to="ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff_lbl" xml:lang="en-US">Bad debts written off</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditLossExpenseReversal" xlink:label="BMGL_CreditLossExpenseReversal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CreditLossExpenseReversal" xlink:to="BMGL_CreditLossExpenseReversal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_CreditLossExpenseReversal_lbl" xml:lang="en-US">Reversal of estimated credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xml:lang="en-US">Provision for estimated credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" xlink:label="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" xlink:to="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset_lbl" xml:lang="en-US">Amortisation of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:label="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:to="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets_lbl" xml:lang="en-US">Loss on written off fixed asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:to="ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill_lbl" xml:lang="en-US">Impairment loss on goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="ifrs-full_AdjustmentsForInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForInterestExpense" xlink:to="ifrs-full_AdjustmentsForInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForInterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US">Operating cash flows before changes in working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:label="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US">Trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US">Cash (used in)/ generated from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Income tax paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in)/generated from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Acquisition of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Acquisition of new subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentProperty" xlink:label="ifrs-full_PurchaseOfInvestmentProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentProperty" xlink:to="ifrs-full_PurchaseOfInvestmentProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentProperty_lbl" xml:lang="en-US">(Increase) in investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Cash provided by/ (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProceedsFromDeferredOfferingCosts" xlink:label="BMGL_ProceedsFromDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProceedsFromDeferredOfferingCosts" xlink:to="BMGL_ProceedsFromDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_ProceedsFromDeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DecreaseInAmountDueFromDirector" xlink:label="BMGL_DecreaseInAmountDueFromDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DecreaseInAmountDueFromDirector" xlink:to="BMGL_DecreaseInAmountDueFromDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_DecreaseInAmountDueFromDirector_lbl" xml:lang="en-US">Decrease in amount due from a director</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseInAmountDueToRelatedParties" xlink:label="BMGL_IncreaseInAmountDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseInAmountDueToRelatedParties" xlink:to="BMGL_IncreaseInAmountDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_IncreaseInAmountDueToRelatedParties_lbl" xml:lang="en-US">Increase in amount due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:label="ifrs-full_CashAdvancesAndLoansFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAdvancesAndLoansFromRelatedParties_lbl" xml:lang="en-US">Decrease/(Increase) in amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseInBankOverdraft" xlink:label="BMGL_IncreaseInBankOverdraft" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseInBankOverdraft" xlink:to="BMGL_IncreaseInBankOverdraft_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_IncreaseInBankOverdraft_lbl" xml:lang="en-US">Increase in bank overdraft</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromCurrentBorrowings" xlink:to="ifrs-full_ProceedsFromCurrentBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings_lbl" xml:lang="en-US">Proceeds from borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Payment of principal portion of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DecreaseincreaseInAmountDueToFormerDirector" xlink:label="BMGL_DecreaseincreaseInAmountDueToFormerDirector" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DecreaseincreaseInAmountDueToFormerDirector" xlink:to="BMGL_DecreaseincreaseInAmountDueToFormerDirector_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_DecreaseincreaseInAmountDueToFormerDirector_lbl" xml:lang="en-US">(Decrease)/Increase in amount due to former director</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:to="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US">Share issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash generated from/(used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of financial period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effects of currency translation on cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_3_lbl" xml:lang="en-US">Cash and cash equivalents at end of financial year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" xlink:label="BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" xlink:to="BMGL_DisclosureOfChangesInAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfChangesInAccountingPoliciesAbstract_lbl" xml:lang="en-US">General</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US">General</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Notes and other explanatory information [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">Material accounting policy information</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:label="BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:to="BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract_lbl" xml:lang="en-US">Significant Accounting Judgements And Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US">Significant accounting judgements and estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRevenueAbstract" xlink:label="BMGL_DisclosureRevenueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureRevenueAbstract" xlink:to="BMGL_DisclosureRevenueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureRevenueAbstract_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfOtherIncomeAbstract" xlink:label="BMGL_DisclosureOfOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfOtherIncomeAbstract" xlink:to="BMGL_DisclosureOfOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xml:lang="en-US">Finance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLossprofitBeforeTaxAbstract" xlink:label="BMGL_DisclosureLossprofitBeforeTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureLossprofitBeforeTaxAbstract" xlink:to="BMGL_DisclosureLossprofitBeforeTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureLossprofitBeforeTaxAbstract_lbl" xml:lang="en-US">Lossprofit Before Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" xlink:label="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" xlink:to="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory_lbl" xml:lang="en-US">(Loss)/Profit before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Deferred tax expense (income) [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">Income tax (benefit)/expense</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRightofuseAssetAbstract" xlink:label="BMGL_DisclosureRightofuseAssetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureRightofuseAssetAbstract" xlink:to="BMGL_DisclosureRightofuseAssetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureRightofuseAssetAbstract_lbl" xml:lang="en-US">Right Of Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="BMGL_DisclosurePropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosurePropertyPlantAndEquipmentAbstract" xlink:to="BMGL_DisclosurePropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosurePropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfInventoriesAbstract" xlink:label="BMGL_DisclosureOfInventoriesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfInventoriesAbstract" xlink:to="BMGL_DisclosureOfInventoriesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureOfInventoriesAbstract_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:label="BMGL_DisclosureTradeAndOtherReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:to="BMGL_DisclosureTradeAndOtherReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureTradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Trade And Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">Trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureCashAndCashEquivalentsAbstract" xlink:label="BMGL_DisclosureCashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureCashAndCashEquivalentsAbstract" xlink:to="BMGL_DisclosureCashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash And Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" xlink:label="BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" xlink:to="BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract_lbl" xml:lang="en-US">Amount Due Fromto Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">Amount due from/to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="BMGL_DisclosureBorrowingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureBorrowingsAbstract" xlink:to="BMGL_DisclosureBorrowingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureBorrowingsAbstract_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:label="BMGL_DisclosureTradeAndOtherPayablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:to="BMGL_DisclosureTradeAndOtherPayablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureTradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Trade And Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountDueToRelatedPartyAbstract" xlink:label="BMGL_DisclosureAmountDueToRelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureAmountDueToRelatedPartyAbstract" xlink:to="BMGL_DisclosureAmountDueToRelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureAmountDueToRelatedPartyAbstract_lbl" xml:lang="en-US">Amount Due To Former Director</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" xlink:label="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" xlink:to="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory_lbl" xml:lang="en-US">Amount due to a former director</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureShareCapitalAbstract" xlink:label="BMGL_DisclosureShareCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureShareCapitalAbstract" xlink:to="BMGL_DisclosureShareCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureShareCapitalAbstract_lbl" xml:lang="en-US">Share Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">Share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLeasesAbstract" xlink:label="BMGL_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureLeasesAbstract" xlink:to="BMGL_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:label="BMGL_DisclosureRelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:to="BMGL_DisclosureRelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Significant Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfSignificantRelatedPartyExplanatory" xlink:label="BMGL_DisclosureOfSignificantRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfSignificantRelatedPartyExplanatory" xlink:to="BMGL_DisclosureOfSignificantRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfSignificantRelatedPartyExplanatory_lbl" xml:lang="en-US">Significant related party transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:label="BMGL_DisclosureImpairmentLossOnGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:to="BMGL_DisclosureImpairmentLossOnGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureImpairmentLossOnGoodwillAbstract_lbl" xml:lang="en-US">Impairment Loss On Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGoodwillExplanatory" xlink:label="ifrs-full_DisclosureOfGoodwillExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoodwillExplanatory" xlink:to="ifrs-full_DisclosureOfGoodwillExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfGoodwillExplanatory_lbl" xml:lang="en-US">Impairment loss on goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract" xlink:label="BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract" xlink:to="BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Fair Value Of Assets And Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair value of assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="BMGL_DisclosureFinancialRiskManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureFinancialRiskManagementAbstract" xlink:to="BMGL_DisclosureFinancialRiskManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureFinancialRiskManagementAbstract_lbl" xml:lang="en-US">Financial Risk Management</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US">Financial risk management</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialInstrumentsAbstract" xlink:label="BMGL_DisclosureFinancialInstrumentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureFinancialInstrumentsAbstract" xlink:to="BMGL_DisclosureFinancialInstrumentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments By Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments by category</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureCapitalManagementAbstract" xlink:label="BMGL_DisclosureCapitalManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureCapitalManagementAbstract" xlink:to="BMGL_DisclosureCapitalManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureCapitalManagementAbstract_lbl" xml:lang="en-US">Capital Management</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CapitalManagementExplanatory" xlink:label="BMGL_CapitalManagementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CapitalManagementExplanatory" xlink:to="BMGL_CapitalManagementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CapitalManagementExplanatory_lbl" xml:lang="en-US">Capital management</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">Events occurring after the reporting period</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" xlink:label="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_lbl" xml:lang="en-US">Compliance with International Financial Reporting Standards (&#8220;IFRS&#8221;)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xml:lang="en-US">New and amended standards adopted by the Group</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" xlink:label="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_lbl" xml:lang="en-US">New standards and interpretations not yet adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" xlink:label="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US">Revenue from contracts with customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US">Segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US">Government grants</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation" xlink:label="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation" xlink:to="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation_lbl" xml:lang="en-US">Basis of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" xlink:label="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Offsetting of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US">Provisions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_lbl" xml:lang="en-US">Impairment of non-financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_lbl" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US">Earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_lbl" xml:lang="en-US">Share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForReservesExplanatory" xlink:label="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory_lbl" xml:lang="en-US">Merger reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" xlink:label="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_lbl" xml:lang="en-US">Deferred Offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory_lbl" xml:lang="en-US">Dividend to Company&#8217;s shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_lbl" xml:lang="en-US">Schedule of activities of subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDepreciationRatesExplanatory" xlink:label="BMGL_DisclosureOfDepreciationRatesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDepreciationRatesExplanatory" xlink:to="BMGL_DisclosureOfDepreciationRatesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDepreciationRatesExplanatory_lbl" xml:lang="en-US">Schedule of expected useful lives for property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" xlink:label="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" xlink:to="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_lbl" xml:lang="en-US">Summary of revenue from transfer of goods and services</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:label="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_lbl" xml:lang="en-US">Schedule of Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory" xlink:label="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory_lbl" xml:lang="en-US">Schedule of Finance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" xlink:label="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_lbl" xml:lang="en-US">Schedule of Profit before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" xlink:label="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_lbl" xml:lang="en-US">Schedule of component of income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" xlink:label="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" xlink:to="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_lbl" xml:lang="en-US">Schedule of reconciliation between tax expense and corporate tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets" xlink:label="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets" xlink:to="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets_lbl" xml:lang="en-US">Schedule of Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory" xlink:label="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory_lbl" xml:lang="en-US">Schedule of Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfTradeAndOtherReceivableExplanatory" xlink:label="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory" xlink:to="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory_lbl" xml:lang="en-US">Schedule of trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xlink:label="ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xlink:to="ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory_lbl" xml:lang="en-US">Schedule of movement in allowance for expected credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfCashAndCashEquivalentExplanatory" xlink:label="BMGL_DisclosureOfCashAndCashEquivalentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfCashAndCashEquivalentExplanatory" xlink:to="BMGL_DisclosureOfCashAndCashEquivalentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfCashAndCashEquivalentExplanatory_lbl" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">Schedule of amount due from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US">Schedule of borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" xlink:label="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" xlink:to="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_lbl" xml:lang="en-US">Schedule of breakdown borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutBorrowings" xlink:label="BMGL_DisclosureOfDetailedInformationAboutBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutBorrowings" xlink:to="BMGL_DisclosureOfDetailedInformationAboutBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutBorrowings_lbl" xml:lang="en-US">Schedule of details borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xml:lang="en-US">Schedule of reconciliation of liabilities arising from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:label="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Schedule of trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock" xlink:label="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock" xlink:to="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of amounts recognized in profit or loss</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory" xlink:label="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory" xlink:to="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory_lbl" xml:lang="en-US">Schedule of transactions with related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" xlink:label="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" xlink:to="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">Schedule of compensation of key management personnel</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xml:lang="en-US">Schedule of fair value of identifiable assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" xlink:label="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" xlink:to="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of group&#8217;s current credit risk grading framework</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" xlink:label="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" xlink:to="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_lbl" xml:lang="en-US">Schedule of financial assets, minimum exposure to credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfExpectedCreditRiskExplanatory" xlink:label="BMGL_ScheduleOfExpectedCreditRiskExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfExpectedCreditRiskExplanatory" xlink:to="BMGL_ScheduleOfExpectedCreditRiskExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ScheduleOfExpectedCreditRiskExplanatory_lbl" xml:lang="en-US">Schedule of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US">Schedule of remaining contractual undiscounted repayment obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" xlink:label="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" xlink:to="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_lbl" xml:lang="en-US">Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xml:lang="en-US">Disclosure of offsetting of financial assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="ifrs-full_NameOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfSubsidiary" xlink:to="ifrs-full_NameOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NameOfSubsidiary_lbl" xml:lang="en-US">Name of entity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:to="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_lbl" xml:lang="en-US">Principal activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporation" xlink:label="ifrs-full_CountryOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporation" xlink:to="ifrs-full_CountryOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CountryOfIncorporation_lbl" xml:lang="en-US">Country of business / incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NumberOfSharesSubscribed" xlink:label="BMGL_NumberOfSharesSubscribed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NumberOfSharesSubscribed" xlink:to="BMGL_NumberOfSharesSubscribed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_NumberOfSharesSubscribed_lbl" xml:lang="en-US">Number of shares subscribe</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_2_lbl" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xml:lang="en-US">Number of shares held</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xml:lang="en-US">Expected useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoriesTotal" xlink:label="ifrs-full_InventoriesTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_InventoriesTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoriesTotal_lbl" xml:lang="en-US">Inventories total</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OthersReceivables" xlink:label="BMGL_OthersReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OthersReceivables" xlink:to="BMGL_OthersReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OthersReceivables_lbl" xml:lang="en-US">Others receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_2_lbl" xml:lang="en-US">Rendering of services - Medical services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfOtherIncomeAbstract" xlink:to="BMGL_DisclosureOfOtherIncomeAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureOfOtherIncomeAbstract_2_lbl" xml:lang="en-US">Schedule Of Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US">Government grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ServiceIncome" xlink:label="BMGL_ServiceIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ServiceIncome" xlink:to="BMGL_ServiceIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ServiceIncome_lbl" xml:lang="en-US">Service income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalIncome" xlink:label="ifrs-full_RentalIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalIncome" xlink:to="ifrs-full_RentalIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalIncome_lbl" xml:lang="en-US">Rental income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ReversalOfExpectedCreditLosses" xlink:label="BMGL_ReversalOfExpectedCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ReversalOfExpectedCreditLosses" xlink:to="BMGL_ReversalOfExpectedCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ReversalOfExpectedCreditLosses_lbl" xml:lang="en-US">Reversal of ECL</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherGainsLosses" xlink:to="ifrs-full_OtherGainsLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherGainsLosses_2_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBorrowings" xlink:to="ifrs-full_InterestExpenseOnBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnBorrowings_lbl" xml:lang="en-US">Interest expense on bank borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest expenses on lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceCosts_2_lbl" xml:lang="en-US">Finance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureLossprofitBeforeTaxAbstract" xlink:to="BMGL_DisclosureLossprofitBeforeTaxAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureLossprofitBeforeTaxAbstract_2_lbl" xml:lang="en-US">Schedule Of Profit Before Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Marketing and advertisement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US">Legal and professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US">Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransportationExpense" xlink:label="ifrs-full_TransportationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransportationExpense" xlink:to="ifrs-full_TransportationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransportationExpense_lbl" xml:lang="en-US">Transportation</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BadDebtsWrittenOff" xlink:label="BMGL_BadDebtsWrittenOff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BadDebtsWrittenOff" xlink:to="BMGL_BadDebtsWrittenOff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_BadDebtsWrittenOff_lbl" xml:lang="en-US">Bad debts written off</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProvisionForExpectedCreditLosses" xlink:label="BMGL_ProvisionForExpectedCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProvisionForExpectedCreditLosses" xlink:to="BMGL_ProvisionForExpectedCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ProvisionForExpectedCreditLosses_lbl" xml:lang="en-US">Provision for expected credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DepreciationOfPropertyAndEquipment" xlink:label="BMGL_DepreciationOfPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DepreciationOfPropertyAndEquipment" xlink:to="BMGL_DepreciationOfPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DepreciationOfPropertyAndEquipment_lbl" xml:lang="en-US">Depreciation of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="ifrs-full_AmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationExpense" xlink:to="ifrs-full_AmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AmortisationExpense_lbl" xml:lang="en-US">Amortisation of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RecruitmentExpenses" xlink:label="BMGL_RecruitmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RecruitmentExpenses" xlink:to="BMGL_RecruitmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_RecruitmentExpenses_lbl" xml:lang="en-US">Recruitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubscriptionCirculationRevenue" xlink:label="ifrs-full_SubscriptionCirculationRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubscriptionCirculationRevenue" xlink:to="ifrs-full_SubscriptionCirculationRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SubscriptionCirculationRevenue_lbl" xml:lang="en-US">Membership and subscription</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TelephoneExpense" xlink:label="BMGL_TelephoneExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TelephoneExpense" xlink:to="BMGL_TelephoneExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TelephoneExpense_lbl" xml:lang="en-US">Telephone</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EmployeeBenefitsExpenses" xlink:label="BMGL_EmployeeBenefitsExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EmployeeBenefitsExpenses" xlink:to="BMGL_EmployeeBenefitsExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_EmployeeBenefitsExpenses_lbl" xml:lang="en-US">Employee benefit expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsSalariesAndBonuses" xlink:label="BMGL_DirectorsSalariesAndBonuses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DirectorsSalariesAndBonuses" xlink:to="BMGL_DirectorsSalariesAndBonuses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DirectorsSalariesAndBonuses_lbl" xml:lang="en-US">Director's salaries and bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsCentralProvidentFund" xlink:label="BMGL_DirectorsCentralProvidentFund" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DirectorsCentralProvidentFund" xlink:to="BMGL_DirectorsCentralProvidentFund_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DirectorsCentralProvidentFund_lbl" xml:lang="en-US">Director's CPF</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EmployeesSalariesAndBonus" xlink:label="BMGL_EmployeesSalariesAndBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EmployeesSalariesAndBonus" xlink:to="BMGL_EmployeesSalariesAndBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_EmployeesSalariesAndBonus_lbl" xml:lang="en-US">Employees' salaries and bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EmployeesCentralProvidentFund" xlink:label="BMGL_EmployeesCentralProvidentFund" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EmployeesCentralProvidentFund" xlink:to="BMGL_EmployeesCentralProvidentFund_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_EmployeesCentralProvidentFund_lbl" xml:lang="en-US">Employees' CPF</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherStaffExpenses" xlink:label="BMGL_OtherStaffExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OtherStaffExpenses" xlink:to="BMGL_OtherStaffExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OtherStaffExpenses_lbl" xml:lang="en-US">Other staff expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xml:lang="en-US">Current income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">- Current year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US">- Deferred income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UnderprovisionInRespectOfPriorYears" xlink:label="BMGL_UnderprovisionInRespectOfPriorYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UnderprovisionInRespectOfPriorYears" xlink:to="BMGL_UnderprovisionInRespectOfPriorYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_UnderprovisionInRespectOfPriorYears_lbl" xml:lang="en-US">-Underprovision in respect of prior years</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverprovisionInRespectOfPriorYears" xlink:label="BMGL_OverprovisionInRespectOfPriorYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OverprovisionInRespectOfPriorYears" xlink:to="BMGL_OverprovisionInRespectOfPriorYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OverprovisionInRespectOfPriorYears_lbl" xml:lang="en-US">- Overprovision in respect of prior years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xml:lang="en-US">Income tax (benefit)/expense recognized in profit or loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US">Income tax using the statutory tax rate of 17% (2024: 17%)</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NondeductibleExpenses" xlink:label="BMGL_NondeductibleExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NondeductibleExpenses" xlink:to="BMGL_NondeductibleExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_NondeductibleExpenses_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xml:lang="en-US">Income not subject to tax</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncomeTaxExemption" xlink:label="BMGL_IncomeTaxExemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncomeTaxExemption" xlink:to="BMGL_IncomeTaxExemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncomeTaxExemption_lbl" xml:lang="en-US">Income tax exemption</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UtilisationOfCapitalAllowance" xlink:label="BMGL_UtilisationOfCapitalAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UtilisationOfCapitalAllowance" xlink:to="BMGL_UtilisationOfCapitalAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_UtilisationOfCapitalAllowance_lbl" xml:lang="en-US">(Loss)/Profit before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UtilisationOfDeferredTaxAssets" xlink:label="BMGL_UtilisationOfDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UtilisationOfDeferredTaxAssets" xlink:to="BMGL_UtilisationOfDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_UtilisationOfDeferredTaxAssets_lbl" xml:lang="en-US">- Utilisation of deferred tax assets not recognised in prior year</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:label="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:to="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses_lbl" xml:lang="en-US">Deferred tax asset not recognized during the financial year</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredIncomeTax" xlink:label="BMGL_DeferredIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredIncomeTax" xlink:to="BMGL_DeferredIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_DeferredIncomeTax_lbl" xml:lang="en-US">Deferred income tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UnderprovisionInRespectOfPriorYears" xlink:to="BMGL_UnderprovisionInRespectOfPriorYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_UnderprovisionInRespectOfPriorYears_2_lbl" xml:lang="en-US">Underprovision in respect of prior years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OverprovisionInRespectOfPriorYears" xlink:to="BMGL_OverprovisionInRespectOfPriorYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_OverprovisionInRespectOfPriorYears_2_lbl" xml:lang="en-US">Overprovision in respect of prior years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_lbl" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_RightofuseAssets_2_lbl" xml:lang="en-US">At beginning of financial year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets_lbl" xml:lang="en-US">Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_WrittenOffRightofuseAssets" xlink:label="BMGL_WrittenOffRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_WrittenOffRightofuseAssets" xlink:to="BMGL_WrittenOffRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_WrittenOffRightofuseAssets_lbl" xml:lang="en-US">Written off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_RightofuseAssets_3_lbl" xml:lang="en-US">At end of financial year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_2_lbl" xml:lang="en-US">At June 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Written off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_3_lbl" xml:lang="en-US">At June 30, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_lbl" xml:lang="en-US">At June 30, 2024</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_2_lbl" xml:lang="en-US">At June 30, 2025</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfInventoriesAbstract" xlink:to="BMGL_DisclosureOfInventoriesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfInventoriesAbstract_2_lbl" xml:lang="en-US">Schedule Of Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Inventories_2_lbl" xml:lang="en-US">Medicine,drugs and medical devices</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_lbl" xml:lang="en-US">Inventories recognized as an expense in cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">- third parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CurrentTradeReceivables_2_lbl" xml:lang="en-US">Trade receivables - third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AllowanceForExpectedCreditLoss" xlink:label="BMGL_AllowanceForExpectedCreditLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AllowanceForExpectedCreditLoss" xlink:to="BMGL_AllowanceForExpectedCreditLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_AllowanceForExpectedCreditLoss_lbl" xml:lang="en-US">Less: Allowance for expected credit loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US">Trade Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermDeposits" xlink:to="ifrs-full_LongtermDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LongtermDeposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments" xlink:label="ifrs-full_Prepayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Prepayments_lbl" xml:lang="en-US">Prepayments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_2_lbl" xml:lang="en-US">Other receivables - third parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:to="BMGL_DisclosureTradeAndOtherReceivablesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureTradeAndOtherReceivablesAbstract_2_lbl" xml:lang="en-US">Schedule Of Movement In Allowance For Expected Credit Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AllowanceForExpectedCreditLoss" xlink:to="BMGL_AllowanceForExpectedCreditLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BMGL_AllowanceForExpectedCreditLoss_2_lbl" xml:lang="en-US">Beginning of financial year</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionAllowanceForExpectedCreditLosses" xlink:label="BMGL_AdditionAllowanceForExpectedCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdditionAllowanceForExpectedCreditLosses" xlink:to="BMGL_AdditionAllowanceForExpectedCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AdditionAllowanceForExpectedCreditLosses_lbl" xml:lang="en-US">Allowance for expected credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ReversalOfAllowanceForExpectedCreditLosses" xlink:label="BMGL_ReversalOfAllowanceForExpectedCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ReversalOfAllowanceForExpectedCreditLosses" xlink:to="BMGL_ReversalOfAllowanceForExpectedCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BMGL_ReversalOfAllowanceForExpectedCreditLosses_lbl" xml:lang="en-US">Less: Reversal of allowance for expected credit losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AllowanceForExpectedCreditLoss" xlink:to="BMGL_AllowanceForExpectedCreditLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BMGL_AllowanceForExpectedCreditLoss_3_lbl" xml:lang="en-US">End of financial year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureCashAndCashEquivalentsAbstract" xlink:to="BMGL_DisclosureCashAndCashEquivalentsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureCashAndCashEquivalentsAbstract_2_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOnHand" xlink:label="ifrs-full_CashOnHand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BalancesWithBanks_lbl" xml:lang="en-US">Cash at banks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" xlink:label="ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" xlink:to="ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_lbl" xml:lang="en-US">Provisional consideration amount for transfer of share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" xlink:label="ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" xlink:to="ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_lbl" xml:lang="en-US">Estimated settlement liability</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashPaidOnClosingInitialSettlement" xlink:label="BMGL_CashPaidOnClosingInitialSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CashPaidOnClosingInitialSettlement" xlink:to="BMGL_CashPaidOnClosingInitialSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CashPaidOnClosingInitialSettlement_lbl" xml:lang="en-US">Cash paid on closing initial settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" xlink:label="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" xlink:to="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare_lbl" xml:lang="en-US">Percentage of provisional consideration amount for transfer of share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances" xlink:label="ifrs-full_LoansAndAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansAndAdvances" xlink:to="ifrs-full_LoansAndAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansAndAdvances_lbl" xml:lang="en-US">Loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US">Professional medical practitioner salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables" xlink:label="ifrs-full_OtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Salary payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsReceivableRelatedPartyTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountsReceivableRelatedPartyTransactions_lbl" xml:lang="en-US">Receivables from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:to="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_lbl" xml:lang="en-US">Related party advance for IPO expenses paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="ifrs-full_ReceivablesDueFromAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesDueFromAssociates" xlink:to="ifrs-full_ReceivablesDueFromAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesDueFromAssociates_lbl" xml:lang="en-US">Partial settlement of related party receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashReceivedToFullySettleRelatedPartyReceivables" xlink:label="BMGL_CashReceivedToFullySettleRelatedPartyReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CashReceivedToFullySettleRelatedPartyReceivables" xlink:to="BMGL_CashReceivedToFullySettleRelatedPartyReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CashReceivedToFullySettleRelatedPartyReceivables_lbl" xml:lang="en-US">Final settlement under repayment deed</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureBorrowingsAbstract" xlink:to="BMGL_DisclosureBorrowingsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureBorrowingsAbstract_2_lbl" xml:lang="en-US">Schedule Of Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CurrentPortionOfBorrowingsAbstract" xlink:label="BMGL_CurrentPortionOfBorrowingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CurrentPortionOfBorrowingsAbstract" xlink:to="BMGL_CurrentPortionOfBorrowingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CurrentPortionOfBorrowingsAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">- Bank overdraft</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">- Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BankBorrowings" xlink:label="BMGL_BankBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BankBorrowings" xlink:to="BMGL_BankBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_BankBorrowings_lbl" xml:lang="en-US">- Bank borrowings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowings" xlink:to="ifrs-full_ShorttermBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermBorrowings_2_lbl" xml:lang="en-US">Borrowings Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract" xlink:to="ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_lbl" xml:lang="en-US">Non-current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">- Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:to="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_lbl" xml:lang="en-US">- Bank borrowings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_LongtermBorrowings_2_lbl" xml:lang="en-US">Borrowings Non-Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived" xlink:label="ifrs-full_LoansReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US">Term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US">Term loan facility amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Borrowings interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsMaturity" xlink:to="ifrs-full_BorrowingsMaturity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsMaturity_lbl" xml:lang="en-US">Borrowing maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_lbl" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_2_lbl" xml:lang="en-US">Lease liabilities current, beginnings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:to="ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_lbl" xml:lang="en-US">Cash flows lease liabilities and bank borrowings current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromCurrentBorrowings" xlink:to="ifrs-full_ProceedsFromCurrentBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings_2_lbl" xml:lang="en-US">Proceed from bank borrowings and lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US">Addition lease liabilities current</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" xlink:to="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_lbl" xml:lang="en-US">Accretion of interests current</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" xlink:label="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" xlink:to="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_lbl" xml:lang="en-US">Other non cash changes current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_3_lbl" xml:lang="en-US">Lease liabilities current, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_2_lbl" xml:lang="en-US">Lease liabilities non-current, beginnings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" xlink:label="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" xlink:to="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_lbl" xml:lang="en-US">Cash flows lease liabilities and bank borrowings noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="ifrs-full_ProceedsFromNoncurrentBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:to="ifrs-full_ProceedsFromNoncurrentBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromNoncurrentBorrowings_lbl" xml:lang="en-US">Proceed from bank borrowings and lease liabilities, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" xlink:label="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" xlink:to="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_lbl" xml:lang="en-US">Addition lease liabilities non current</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" xlink:to="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_lbl" xml:lang="en-US">Accretion of interests noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" xlink:label="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" xlink:to="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_lbl" xml:lang="en-US">Other non cash changes non current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_3_lbl" xml:lang="en-US">Lease liabilities non-current, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BankBorrowings" xlink:to="BMGL_BankBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="BMGL_BankBorrowings_2_lbl" xml:lang="en-US">Bank borrowings, beginnings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionBankBorrowingsCurrent" xlink:label="BMGL_AdditionBankBorrowingsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdditionBankBorrowingsCurrent" xlink:to="BMGL_AdditionBankBorrowingsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AdditionBankBorrowingsCurrent_lbl" xml:lang="en-US">Addition bank borrowings current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BankBorrowings" xlink:to="BMGL_BankBorrowings_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="BMGL_BankBorrowings_3_lbl" xml:lang="en-US">Bank borrowings, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:to="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_2_lbl" xml:lang="en-US">Bank borrowings non current, beginnings</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionBankBorrowingsNonCurrent" xlink:label="BMGL_AdditionBankBorrowingsNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdditionBankBorrowingsNonCurrent" xlink:to="BMGL_AdditionBankBorrowingsNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AdditionBankBorrowingsNonCurrent_lbl" xml:lang="en-US">Addition bank borrowings non current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:to="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_3_lbl" xml:lang="en-US">Bank borrowings non current, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US">Reconciliation of liabilities financing activities current and non current, beginnings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US">Cash flows lease liabilities and bank borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Proceed from bank borrowings and lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" xlink:label="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" xlink:to="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_lbl" xml:lang="en-US">Addition bank lease liabilities current and non current</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" xlink:to="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_lbl" xml:lang="en-US">Accretion of interests current and non current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US">Other non cash changes current and non current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_2_lbl" xml:lang="en-US">Reconciliation of liabilities financing activities current and non current, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:to="BMGL_DisclosureTradeAndOtherPayablesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureTradeAndOtherPayablesAbstract_2_lbl" xml:lang="en-US">Schedule Of Trade And Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payable- third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals" xlink:label="ifrs-full_Accruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxPayables" xlink:label="ifrs-full_ValueAddedTaxPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ValueAddedTaxPayables" xlink:to="ifrs-full_ValueAddedTaxPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ValueAddedTaxPayables_lbl" xml:lang="en-US">GST payables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherPayables_2_lbl" xml:lang="en-US">Other payables third parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TradePayablesMaturity" xlink:label="BMGL_TradePayablesMaturity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TradePayablesMaturity" xlink:to="BMGL_TradePayablesMaturity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TradePayablesMaturity_lbl" xml:lang="en-US">Trade payable, maturity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ValueOfSharesAuthorised" xlink:label="BMGL_ValueOfSharesAuthorised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ValueOfSharesAuthorised" xlink:to="BMGL_ValueOfSharesAuthorised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ValueOfSharesAuthorised_lbl" xml:lang="en-US">Ordinary shares, amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_2_lbl" xml:lang="en-US">Share subscription price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureLeasesAbstract" xlink:to="BMGL_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Amounts Recognized In Profit Or Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_2_lbl" xml:lang="en-US">Depreciation of right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_2_lbl" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US">Expense relating to short-term leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" xlink:label="ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" xlink:to="ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_lbl" xml:lang="en-US">Total amount recognized in profit or loss</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LeaseTermOfContract" xlink:label="BMGL_LeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LeaseTermOfContract" xlink:to="BMGL_LeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_LeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_lbl" xml:lang="en-US">Weighted average borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Cash outflow for leases</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InterestIncomeOnLoansAndReceivable" xlink:label="BMGL_InterestIncomeOnLoansAndReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InterestIncomeOnLoansAndReceivable" xlink:to="BMGL_InterestIncomeOnLoansAndReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_InterestIncomeOnLoansAndReceivable_lbl" xml:lang="en-US">Interest income on loan to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ManagementFee" xlink:label="BMGL_ManagementFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ManagementFee" xlink:to="BMGL_ManagementFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ManagementFee_lbl" xml:lang="en-US">Management fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:to="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_2_lbl" xml:lang="en-US">Payment made on behalf to related parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:to="BMGL_DisclosureRelatedPartyTransactionsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureRelatedPartyTransactionsAbstract_2_lbl" xml:lang="en-US">Schedule Of Compensation Of Key Management Personnel</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WagesAndSalaries_2_lbl" xml:lang="en-US">Salaries and bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CentralProvidentFund" xlink:label="BMGL_CentralProvidentFund" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CentralProvidentFund" xlink:to="BMGL_CentralProvidentFund_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CentralProvidentFund_lbl" xml:lang="en-US">CPF</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:to="BMGL_DisclosureImpairmentLossOnGoodwillAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_DisclosureImpairmentLossOnGoodwillAbstract_2_lbl" xml:lang="en-US">Schedule Of Fair Value Of Identifiable Assets And Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US">Purchase Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentRecognisedAsOfAcquisitionDate" xlink:label="BMGL_InvestmentRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentRecognisedAsOfAcquisitionDate" xlink:to="BMGL_InvestmentRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_InvestmentRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FairValueOfAcquiredReceivables" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_lbl" xml:lang="en-US">Trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueRecognisedAsOfAcquisitionDate" xlink:label="BMGL_AmountDueRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AmountDueRecognisedAsOfAcquisitionDate" xlink:to="BMGL_AmountDueRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AmountDueRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Amount due to director</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Net identifiable liabilities acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Add: Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossOfCombinedEntity" xlink:label="ifrs-full_ProfitLossOfCombinedEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossOfCombinedEntity" xlink:to="ifrs-full_ProfitLossOfCombinedEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossOfCombinedEntity_lbl" xml:lang="en-US">Purchase consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2_lbl" xml:lang="en-US">Consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashTransferred" xlink:to="ifrs-full_CashTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US">Consideration transferred cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="ifrs-full_RevenueOfAcquiree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueOfAcquiree" xlink:to="ifrs-full_RevenueOfAcquiree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueOfAcquiree_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossOfAcquiree" xlink:label="ifrs-full_ProfitLossOfAcquiree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossOfAcquiree" xlink:to="ifrs-full_ProfitLossOfAcquiree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossOfAcquiree_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementTable" xlink:label="BMGL_IfrsStatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IfrsStatementTable" xlink:to="BMGL_IfrsStatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IfrsStatementTable_lbl" xml:lang="en-US">IfrsStatementTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfCreditRisk" xlink:label="BMGL_DescriptionOfCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfCreditRisk" xlink:to="BMGL_DescriptionOfCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfCreditRisk_lbl" xml:lang="en-US">Definition of category</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BasisForRecognizingExpectedCreditLoss" xlink:label="BMGL_BasisForRecognizingExpectedCreditLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BasisForRecognizingExpectedCreditLoss" xlink:to="BMGL_BasisForRecognizingExpectedCreditLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_BasisForRecognizingExpectedCreditLoss_lbl" xml:lang="en-US">Basis for recognizing ECL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditRiskTradeReceivables" xlink:label="BMGL_CreditRiskTradeReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CreditRiskTradeReceivables" xlink:to="BMGL_CreditRiskTradeReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CreditRiskTradeReceivables_lbl" xml:lang="en-US">Trade receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ExpectedCreditLosses" xlink:label="BMGL_ExpectedCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ExpectedCreditLosses" xlink:to="BMGL_ExpectedCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ExpectedCreditLosses_lbl" xml:lang="en-US">Expected credit losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:to="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties_2_lbl" xml:lang="en-US">Amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="ifrs-full_DisclosureOfProvisionMatrixTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProvisionMatrixTable" xlink:to="ifrs-full_DisclosureOfProvisionMatrixTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfProvisionMatrixTable_lbl" xml:lang="en-US">Disclosure of provision matrix [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedCreditLossRate" xlink:label="ifrs-full_ExpectedCreditLossRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedCreditLossRate" xlink:to="ifrs-full_ExpectedCreditLossRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedCreditLossRate_lbl" xml:lang="en-US">ECL rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeReceivables_2_lbl" xml:lang="en-US">Estimated total gross carrying amount at</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ExpectedCreditLosses" xlink:to="BMGL_ExpectedCreditLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_ExpectedCreditLosses_2_lbl" xml:lang="en-US">ECL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_lbl" xml:lang="en-US">Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalUndiscountedFinancialAssets" xlink:label="BMGL_TotalUndiscountedFinancialAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TotalUndiscountedFinancialAssets" xlink:to="BMGL_TotalUndiscountedFinancialAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TotalUndiscountedFinancialAssets_lbl" xml:lang="en-US">Total undiscounted financial assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_2_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl" xml:lang="en-US">Amount due to related parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Borrowings_2_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US">Total undiscounted financial liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalNetUndiscountedFinancialAssetsliabilities" xlink:label="BMGL_TotalNetUndiscountedFinancialAssetsliabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TotalNetUndiscountedFinancialAssetsliabilities" xlink:to="BMGL_TotalNetUndiscountedFinancialAssetsliabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_TotalNetUndiscountedFinancialAssetsliabilities_lbl" xml:lang="en-US">Total net undiscounted financial assets/(liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PercentageOfTradeReceivables" xlink:label="BMGL_PercentageOfTradeReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PercentageOfTradeReceivables" xlink:to="BMGL_PercentageOfTradeReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_PercentageOfTradeReceivables_lbl" xml:lang="en-US">Percentage of trade receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TotalUndiscountedFinancialAssets" xlink:to="BMGL_TotalUndiscountedFinancialAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BMGL_TotalUndiscountedFinancialAssets_2_lbl" xml:lang="en-US">Total financial assets measured at amortized cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_2_lbl" xml:lang="en-US">Total financial liabilities measured at amortized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsPercentage" xlink:label="BMGL_InvestmentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentsPercentage" xlink:to="BMGL_InvestmentsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_InvestmentsPercentage_lbl" xml:lang="en-US">Investments percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsSalePercentage" xlink:label="BMGL_InvestmentsSalePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentsSalePercentage" xlink:to="BMGL_InvestmentsSalePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_InvestmentsSalePercentage_lbl" xml:lang="en-US">Investments sale percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsHoldPercentage" xlink:label="BMGL_InvestmentsHoldPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentsHoldPercentage" xlink:to="BMGL_InvestmentsHoldPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_InvestmentsHoldPercentage_lbl" xml:lang="en-US">Investments hold percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt" xlink:label="ifrs-full_NetDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDebt" xlink:to="ifrs-full_NetDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDebt_lbl" xml:lang="en-US">Loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:to="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses_doc" xml:lang="en-US">Consumables medical supplies and other related expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredOfferingCost" xlink:to="BMGL_DeferredOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DeferredOfferingCost_doc" xml:lang="en-US">Deferred offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AmountDueToFormerDirector" xlink:to="BMGL_AmountDueToFormerDirector_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AmountDueToFormerDirector_doc" xml:lang="en-US">Amount due to former director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MergerReserveArisingFromGroupRestructuring" xlink:to="BMGL_MergerReserveArisingFromGroupRestructuring_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_MergerReserveArisingFromGroupRestructuring_doc" xml:lang="en-US">Merger reserve arising from group restructuring.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" xlink:to="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_doc" xml:lang="en-US">The disclosure of detailed information about revenue from transfer of goods and services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BankBorrowings" xlink:to="BMGL_BankBorrowings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_BankBorrowings_doc" xml:lang="en-US">Bank borrowings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MedicalServicesMember" xlink:to="BMGL_MedicalServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_MedicalServicesMember_doc" xml:lang="en-US">Medical Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MinorityInterestInSubsidiary" xlink:to="BMGL_MinorityInterestInSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_MinorityInterestInSubsidiary_doc" xml:lang="en-US">Minority interest in subsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanOneMember" xlink:to="BMGL_TermLoanOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanOneMember_doc" xml:lang="en-US">Term loan one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" xlink:to="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_doc" xml:lang="en-US">Disclosure of detailed information about breakdown of borrowings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTwoMember" xlink:to="BMGL_TermLoanTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTwoMember_doc" xml:lang="en-US">Term loan two [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanSixMember" xlink:to="BMGL_TermLoanSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanSixMember_doc" xml:lang="en-US">Term loan six [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract_doc" xml:lang="en-US">Increase decrease in non cash working capital abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DecreaseincreaseInAmountDueToFormerDirector" xlink:to="BMGL_DecreaseincreaseInAmountDueToFormerDirector_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DecreaseincreaseInAmountDueToFormerDirector_doc" xml:lang="en-US">Decrease increase in amount due to former director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UtilisationOfDeferredTaxAssets" xlink:to="BMGL_UtilisationOfDeferredTaxAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_UtilisationOfDeferredTaxAssets_doc" xml:lang="en-US">Utilisation of deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BaselMedicalGroupPteLtdMember" xlink:to="BMGL_BaselMedicalGroupPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_BaselMedicalGroupPteLtdMember_doc" xml:lang="en-US">Basel Medical Group Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" xlink:to="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember_doc" xml:lang="en-US">Singapore Sports Orthopaedic Clinic Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" xlink:to="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_doc" xml:lang="en-US">Disclosure of effective income tax rate reconciliations explanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCPteLtdMember" xlink:to="BMGL_SSOCPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SSOCPteLtdMember_doc" xml:lang="en-US">SSOC Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOSPteLtdMember" xlink:to="BMGL_SSOSPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SSOSPteLtdMember_doc" xml:lang="en-US">SSOS Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" xlink:to="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember_doc" xml:lang="en-US">Singapore Knee Sports Orthopaedic Services Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PharmaAvenuePteLtdMember" xlink:to="BMGL_PharmaAvenuePteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_PharmaAvenuePteLtdMember_doc" xml:lang="en-US">Pharma Avenue Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BaselMedflowPteLtdMember" xlink:to="BMGL_BaselMedflowPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_BaselMedflowPteLtdMember_doc" xml:lang="en-US">Basel Medflow Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BethesdaMedicalPteLtdMember" xlink:to="BMGL_BethesdaMedicalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_BethesdaMedicalPteLtdMember_doc" xml:lang="en-US">Bethesda Medical Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProvisionForExpectedCreditLosses" xlink:to="BMGL_ProvisionForExpectedCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ProvisionForExpectedCreditLosses_doc" xml:lang="en-US">Provision for expected credit losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OasisMedicalClinicPteLtdMember" xlink:to="BMGL_OasisMedicalClinicPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OasisMedicalClinicPteLtdMember_doc" xml:lang="en-US">Oasis Medical Clinic Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_doc" xml:lang="en-US">Description of accounting policy for basis of preparation explanatory [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_doc" xml:lang="en-US">Description of accounting policy for new standards amendments and interpretations issued but not yet effective explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDepreciationRatesExplanatory" xlink:to="BMGL_DisclosureOfDepreciationRatesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDepreciationRatesExplanatory_doc" xml:lang="en-US">Disclosure of depreciation rates explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RenovationMember" xlink:to="BMGL_RenovationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_RenovationMember_doc" xml:lang="en-US">Renovation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AirConditionerMember" xlink:to="BMGL_AirConditionerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AirConditionerMember_doc" xml:lang="en-US">Air Conditioner [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForReservesExplanatory_doc" xml:lang="en-US">Description of accounting policy for reserves explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MedicalEquipmentMember" xlink:to="BMGL_MedicalEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_MedicalEquipmentMember_doc" xml:lang="en-US">Medical Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SoftwareMember" xlink:to="BMGL_SoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SoftwareMember_doc" xml:lang="en-US">Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanThreeMember" xlink:to="BMGL_TermLoanThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanThreeMember_doc" xml:lang="en-US">Term loan three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdditionAllowanceForExpectedCreditLosses" xlink:to="BMGL_AdditionAllowanceForExpectedCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AdditionAllowanceForExpectedCreditLosses_doc" xml:lang="en-US">Addition allowance for expected credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ReversalOfAllowanceForExpectedCreditLosses" xlink:to="BMGL_ReversalOfAllowanceForExpectedCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ReversalOfAllowanceForExpectedCreditLosses_doc" xml:lang="en-US">Reversal of allowance for expected credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ServiceIncome" xlink:to="BMGL_ServiceIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ServiceIncome_doc" xml:lang="en-US">Service income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanFourMember" xlink:to="BMGL_TermLoanFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanFourMember_doc" xml:lang="en-US">Term loan four [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanSevenMember" xlink:to="BMGL_TermLoanSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanSevenMember_doc" xml:lang="en-US">Term loan seven [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanNineMember" xlink:to="BMGL_TermLoanNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanNineMember_doc" xml:lang="en-US">Term loan nine [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenMember" xlink:to="BMGL_TermLoanTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTenMember_doc" xml:lang="en-US">Term loan ten [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanMember" xlink:to="BMGL_TermLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanMember_doc" xml:lang="en-US">Term loan [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about other income explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutBorrowings" xlink:to="BMGL_DisclosureOfDetailedInformationAboutBorrowings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutBorrowings_doc" xml:lang="en-US">Disclosure of detailed information about borrowings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CreditLossExpenseReversal" xlink:to="BMGL_CreditLossExpenseReversal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CreditLossExpenseReversal_doc" xml:lang="en-US">Credit loss expense reversal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" xlink:to="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AdjustmentsForAmortizationOfRightOfUseAsset_doc" xml:lang="en-US">Adjustments for amortization of right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" xlink:to="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory_doc" xml:lang="en-US">Disclosure of profit loss before tax explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BadDebtsWrittenOff" xlink:to="BMGL_BadDebtsWrittenOff_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_BadDebtsWrittenOff_doc" xml:lang="en-US">Bad debts written off.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OtherStaffExpenses" xlink:to="BMGL_OtherStaffExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OtherStaffExpenses_doc" xml:lang="en-US">Other staff expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TelephoneExpense" xlink:to="BMGL_TelephoneExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TelephoneExpense_doc" xml:lang="en-US">Telephone expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DirectorsSalariesAndBonuses" xlink:to="BMGL_DirectorsSalariesAndBonuses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DirectorsSalariesAndBonuses_doc" xml:lang="en-US">Directors salaries and bonuses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EmployeesSalariesAndBonus" xlink:to="BMGL_EmployeesSalariesAndBonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_EmployeesSalariesAndBonus_doc" xml:lang="en-US">Employees salaries and bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DirectorsCentralProvidentFund" xlink:to="BMGL_DirectorsCentralProvidentFund_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DirectorsCentralProvidentFund_doc" xml:lang="en-US">Directors central provident fund.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" xlink:to="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_doc" xml:lang="en-US">Increase through new leases liabilities arising non current from financing activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EmployeesCentralProvidentFund" xlink:to="BMGL_EmployeesCentralProvidentFund_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_EmployeesCentralProvidentFund_doc" xml:lang="en-US">Employees central provident fund.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdditionBankBorrowingsCurrent" xlink:to="BMGL_AdditionBankBorrowingsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AdditionBankBorrowingsCurrent_doc" xml:lang="en-US">Addition bank borrowings current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AdditionBankBorrowingsNonCurrent" xlink:to="BMGL_AdditionBankBorrowingsNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AdditionBankBorrowingsNonCurrent_doc" xml:lang="en-US">Addition bank borrowings non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" xlink:to="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_doc" xml:lang="en-US">Increase through new leases liabilities and bank borrowings arising from financing activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" xlink:to="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_doc" xml:lang="en-US">Increase decrease in lease liabilities interest and bank borrowings expense current and non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about income tax expense explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseInBankOverdraft" xlink:to="BMGL_IncreaseInBankOverdraft_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseInBankOverdraft_doc" xml:lang="en-US">Increase in bank overdraft.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProceedsFromDeferredOfferingCosts" xlink:to="BMGL_ProceedsFromDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ProceedsFromDeferredOfferingCosts_doc" xml:lang="en-US">Proceeds from deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DecreaseInAmountDueFromDirector" xlink:to="BMGL_DecreaseInAmountDueFromDirector_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DecreaseInAmountDueFromDirector_doc" xml:lang="en-US">Decrease in amount due from director.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseInAmountDueToRelatedParties" xlink:to="BMGL_IncreaseInAmountDueToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseInAmountDueToRelatedParties_doc" xml:lang="en-US">Increase in amount due to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:to="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets_doc" xml:lang="en-US">Recoveries on loans previously written off fixed assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncomeTaxExemption" xlink:to="BMGL_IncomeTaxExemption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncomeTaxExemption_doc" xml:lang="en-US">Income tax exemption.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UtilisationOfCapitalAllowance" xlink:to="BMGL_UtilisationOfCapitalAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_UtilisationOfCapitalAllowance_doc" xml:lang="en-US">Utilisation of capital allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:to="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses_doc" xml:lang="en-US">Deferred Tax Assets Not Recognized On Tax Losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" xlink:to="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory_doc" xml:lang="en-US">Disclosure of amount due to a former director explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OrdinaryShareMember" xlink:to="BMGL_OrdinaryShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OrdinaryShareMember_doc" xml:lang="en-US">Ordinary Share [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about inventories explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about finance cost explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" xlink:to="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember_doc" xml:lang="en-US">Singapore Sports Orthopaedic Services Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfCashAndCashEquivalentExplanatory" xlink:to="BMGL_DisclosureOfCashAndCashEquivalentExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfCashAndCashEquivalentExplanatory_doc" xml:lang="en-US">Disclosure of cash and cash equivalent explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" xlink:to="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_doc" xml:lang="en-US">Singapore Knee Sports and Orthopaedic Clinic Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_doc" xml:lang="en-US">Description of accounting policy revenue from contracts with customers explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CashPaidOnClosingInitialSettlement" xlink:to="BMGL_CashPaidOnClosingInitialSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CashPaidOnClosingInitialSettlement_doc" xml:lang="en-US">Cash paid on closing initial settlement.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForGroupAccounting" xlink:label="BMGL_DescriptionOfAccountingPolicyForGroupAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForGroupAccounting" xlink:to="BMGL_DescriptionOfAccountingPolicyForGroupAccounting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForGroupAccounting_doc" xml:lang="en-US">Description of accounting policy for group accounting.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DrKevinYipMember" xlink:to="BMGL_DrKevinYipMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DrKevinYipMember_doc" xml:lang="en-US">Dr Kevin Yip [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory" xlink:to="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfTradeAndOtherReceivableExplanatory_doc" xml:lang="en-US">Disclosure of Trade and Other Receivable Explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" xlink:to="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember_doc" xml:lang="en-US">Dr Kevin Yip and Singmed Investment Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RainforestCapitalVCCMember" xlink:to="BMGL_RainforestCapitalVCCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_RainforestCapitalVCCMember_doc" xml:lang="en-US">Rainforest capital VCC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory_doc" xml:lang="en-US">Description of accounting policy for inventories explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CashReceivedToFullySettleRelatedPartyReceivables" xlink:to="BMGL_CashReceivedToFullySettleRelatedPartyReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CashReceivedToFullySettleRelatedPartyReceivables_doc" xml:lang="en-US">Cash received to fully settle related party receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_doc" xml:lang="en-US">Description of accounting policy for deferred offering costs explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ComputerAndOfficeEquipmentMember" xlink:to="BMGL_ComputerAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ComputerAndOfficeEquipmentMember_doc" xml:lang="en-US">Computer and Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OthersRelatedPartiesMember" xlink:to="BMGL_OthersRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OthersRelatedPartiesMember_doc" xml:lang="en-US">Others related partiesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets" xlink:to="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets_doc" xml:lang="en-US">Disclosure of detailed information about of right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AllowanceForExpectedCreditLoss" xlink:to="BMGL_AllowanceForExpectedCreditLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AllowanceForExpectedCreditLoss_doc" xml:lang="en-US">Allowance for expected credit loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LeaseTermOfContract" xlink:to="BMGL_LeaseTermOfContract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_LeaseTermOfContract_doc" xml:lang="en-US">Lease term of contract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NumberOfSharesSubscribed" xlink:to="BMGL_NumberOfSharesSubscribed_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_NumberOfSharesSubscribed_doc" xml:lang="en-US">Number of shares subscribed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock" xlink:to="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock_doc" xml:lang="en-US">Disclosure of Lease Related Expenses [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about trade and other payables explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EmployeeBenefitsExpenses" xlink:to="BMGL_EmployeeBenefitsExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_EmployeeBenefitsExpenses_doc" xml:lang="en-US">Employee benefits expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DepreciationOfPropertyAndEquipment" xlink:to="BMGL_DepreciationOfPropertyAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DepreciationOfPropertyAndEquipment_doc" xml:lang="en-US">Depreciation of property and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OthersReceivables" xlink:to="BMGL_OthersReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OthersReceivables_doc" xml:lang="en-US">Others receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DirectorsMember" xlink:to="BMGL_DirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DirectorsMember_doc" xml:lang="en-US">Directors [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" xlink:to="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_doc" xml:lang="en-US">Disclosure in current risk grading framework explanatory text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfCreditRisk" xlink:to="BMGL_DescriptionOfCreditRisk_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfCreditRisk_doc" xml:lang="en-US">Description of credit risk.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryAxis" xlink:to="BMGL_CategoryAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CategoryAxis_doc" xml:lang="en-US">Category [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryOneMember" xlink:to="BMGL_CategoryOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CategoryOneMember_doc" xml:lang="en-US">Category One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BasisForRecognizingExpectedCreditLoss" xlink:to="BMGL_BasisForRecognizingExpectedCreditLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_BasisForRecognizingExpectedCreditLoss_doc" xml:lang="en-US">Basis for recognizing expected credit loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryTwoMember" xlink:to="BMGL_CategoryTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CategoryTwoMember_doc" xml:lang="en-US">Category Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryThreeMember" xlink:to="BMGL_CategoryThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CategoryThreeMember_doc" xml:lang="en-US">Category III [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CategoryFourMember" xlink:to="BMGL_CategoryFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CategoryFourMember_doc" xml:lang="en-US">Category Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" xlink:to="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_doc" xml:lang="en-US">Schedule of financial assets represents the maximum credit exposure explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CentralProvidentFund" xlink:to="BMGL_CentralProvidentFund_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CentralProvidentFund_doc" xml:lang="en-US">Central provident fund.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ContractualCashFlowsMember" xlink:to="BMGL_ContractualCashFlowsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ContractualCashFlowsMember_doc" xml:lang="en-US">Contractual cash flows [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory" xlink:to="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory_doc" xml:lang="en-US">Schedule of transactions with related party explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" xlink:to="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_doc" xml:lang="en-US">Schedule of compensation of key management personnel explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfSignificantRelatedPartyExplanatory" xlink:to="BMGL_DisclosureOfSignificantRelatedPartyExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfSignificantRelatedPartyExplanatory_doc" xml:lang="en-US">Disclosure of significant related party explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TotalUndiscountedFinancialAssets" xlink:to="BMGL_TotalUndiscountedFinancialAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TotalUndiscountedFinancialAssets_doc" xml:lang="en-US">Total undiscounted financial assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TotalNetUndiscountedFinancialAssetsliabilities" xlink:to="BMGL_TotalNetUndiscountedFinancialAssetsliabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TotalNetUndiscountedFinancialAssetsliabilities_doc" xml:lang="en-US">Total net undiscounted financial assets/(liabilities).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" xlink:to="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_doc" xml:lang="en-US">Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" xlink:to="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_doc" xml:lang="en-US">Later than two months and not later than four months [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ScheduleOfExpectedCreditRiskExplanatory" xlink:to="BMGL_ScheduleOfExpectedCreditRiskExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ScheduleOfExpectedCreditRiskExplanatory_doc" xml:lang="en-US">Schedule of expected credit risk explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CapitalManagementExplanatory" xlink:to="BMGL_CapitalManagementExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CapitalManagementExplanatory_doc" xml:lang="en-US">Capital management explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentsPercentage" xlink:to="BMGL_InvestmentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_InvestmentsPercentage_doc" xml:lang="en-US">Investments percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCNovenaPteLtdMember" xlink:to="BMGL_SSOCNovenaPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SSOCNovenaPteLtdMember_doc" xml:lang="en-US">SSOC Novena Pte Ltd [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NotPastDueMember" xlink:to="BMGL_NotPastDueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_NotPastDueMember_doc" xml:lang="en-US">Not past due [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCOrchardPteLtdMember" xlink:to="BMGL_SSOCOrchardPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SSOCOrchardPteLtdMember_doc" xml:lang="en-US">SSOC Orchard Pte Ltd [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SSOCFarrerParkPteLtdMember" xlink:to="BMGL_SSOCFarrerParkPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SSOCFarrerParkPteLtdMember_doc" xml:lang="en-US">SSOC Farrer Park Pte Ltd [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ExpectedCreditLosses" xlink:to="BMGL_ExpectedCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ExpectedCreditLosses_doc" xml:lang="en-US">Expected credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentsSalePercentage" xlink:to="BMGL_InvestmentsSalePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_InvestmentsSalePercentage_doc" xml:lang="en-US">Investments sale percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentsHoldPercentage" xlink:to="BMGL_InvestmentsHoldPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_InvestmentsHoldPercentage_doc" xml:lang="en-US">Investments hold percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_EyetrustMedicalPteLtdMember" xlink:to="BMGL_EyetrustMedicalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_EyetrustMedicalPteLtdMember_doc" xml:lang="en-US">Eyetrust Medical Pte Ltd [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CharteredImagingPteLtdMember" xlink:to="BMGL_CharteredImagingPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CharteredImagingPteLtdMember_doc" xml:lang="en-US">Chartered Imaging Pte Ltd [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_LifeTimeExpectedCreditLossMember" xlink:to="BMGL_LifeTimeExpectedCreditLossMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_LifeTimeExpectedCreditLossMember_doc" xml:lang="en-US">Life time expected credit loss [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TwelveExpectedCreditLossMember" xlink:to="BMGL_TwelveExpectedCreditLossMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TwelveExpectedCreditLossMember_doc" xml:lang="en-US">Twelve expected credit loss [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredIncomeTax" xlink:to="BMGL_DeferredIncomeTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DeferredIncomeTax_doc" xml:lang="en-US">Deferred income tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ReversalOfExpectedCreditLosses" xlink:to="BMGL_ReversalOfExpectedCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ReversalOfExpectedCreditLosses_doc" xml:lang="en-US">Reversal of expected credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" xlink:to="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about profit loss before tax explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_RecruitmentExpenses" xlink:to="BMGL_RecruitmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_RecruitmentExpenses_doc" xml:lang="en-US">Recruitment expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OverprovisionInRespectOfPriorYears" xlink:to="BMGL_OverprovisionInRespectOfPriorYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OverprovisionInRespectOfPriorYears_doc" xml:lang="en-US">Overprovision in respect of prior years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NondeductibleExpenses" xlink:to="BMGL_NondeductibleExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_NondeductibleExpenses_doc" xml:lang="en-US">Nondeductible expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CurrentPortionOfBorrowingsAbstract" xlink:to="BMGL_CurrentPortionOfBorrowingsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CurrentPortionOfBorrowingsAbstract_doc" xml:lang="en-US">Current Portion of Borrowings Abstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PercentageOfTradeReceivables" xlink:to="BMGL_PercentageOfTradeReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_PercentageOfTradeReceivables_doc" xml:lang="en-US">Percentage of trade receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanElevenMember" xlink:to="BMGL_TermLoanElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanElevenMember_doc" xml:lang="en-US">Term loan eleven [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTwelveMember" xlink:to="BMGL_TermLoanTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTwelveMember_doc" xml:lang="en-US">Term loan twelve [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenOneMember" xlink:to="BMGL_TermLoanTenOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTenOneMember_doc" xml:lang="en-US">Term loan ten one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenTwoMember" xlink:to="BMGL_TermLoanTenTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTenTwoMember_doc" xml:lang="en-US">Term loan ten two [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenThreeMember" xlink:to="BMGL_TermLoanTenThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTenThreeMember_doc" xml:lang="en-US">Term loan ten three [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanTenFourMember" xlink:to="BMGL_TermLoanTenFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanTenFourMember_doc" xml:lang="en-US">Term loan ten four [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TermLoanElevenOneMember" xlink:to="BMGL_TermLoanElevenOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TermLoanElevenOneMember_doc" xml:lang="en-US">Term loan eleven one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_NonadjustingEventsAfterReportingPeriodMember" xlink:to="BMGL_NonadjustingEventsAfterReportingPeriodMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_NonadjustingEventsAfterReportingPeriodMember_doc" xml:lang="en-US">Nonadjusting Events After Reporting Period [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" xlink:to="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_doc" xml:lang="en-US">Cash flows from ised in increase decrease in non current borrowings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" xlink:to="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_doc" xml:lang="en-US">Increase decrease in lease liabilities interest and bank borrowings expense current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" xlink:to="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_doc" xml:lang="en-US">Increase decrease in lease liabilities interest and bank borrowings expense non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_TradePayablesMaturity" xlink:to="BMGL_TradePayablesMaturity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_TradePayablesMaturity_doc" xml:lang="en-US">Trade payables maturity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ValueOfSharesAuthorised" xlink:to="BMGL_ValueOfSharesAuthorised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ValueOfSharesAuthorised_doc" xml:lang="en-US">Value of shares authorised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OverAllotmentOptionsMember" xlink:to="BMGL_OverAllotmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OverAllotmentOptionsMember_doc" xml:lang="en-US">OverAllotment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CreditRiskTradeReceivables" xlink:to="BMGL_CreditRiskTradeReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CreditRiskTradeReceivables_doc" xml:lang="en-US">Credit risk trade receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" xlink:to="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare_doc" xml:lang="en-US">Percentage of provisional consideration amount for transfer of share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CustodianServicesMember" xlink:to="BMGL_CustodianServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_CustodianServicesMember_doc" xml:lang="en-US">Custodian Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" xlink:to="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_doc" xml:lang="en-US">Other lease liabilities and bank borrowings arising from financing activities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" xlink:to="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_doc" xml:lang="en-US">Other lease liabilities and bank borrowings arising from financing activities noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InitialPublicOfferingMember" xlink:to="BMGL_InitialPublicOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_InitialPublicOfferingMember_doc" xml:lang="en-US">Initial Public Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AccumulatedDepreciationMember" xlink:to="BMGL_AccumulatedDepreciationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_AccumulatedDepreciationMember_doc" xml:lang="en-US">Accumulated Depreciation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InterestIncomeOnLoansAndReceivable" xlink:to="BMGL_InterestIncomeOnLoansAndReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_InterestIncomeOnLoansAndReceivable_doc" xml:lang="en-US">Interest income on loans and receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProfitLossAndNetComprehensiveIncome" xlink:to="BMGL_ProfitLossAndNetComprehensiveIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ProfitLossAndNetComprehensiveIncome_doc" xml:lang="en-US">Profit loss and net comprehensive income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProfitLossIncludingMinorityInterest" xlink:to="BMGL_ProfitLossIncludingMinorityInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ProfitLossIncludingMinorityInterest_doc" xml:lang="en-US">Profit loss including minority interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_doc" xml:lang="en-US">Property plant and equipment accumulated depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ThridPartiesMember" xlink:to="BMGL_ThridPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ThridPartiesMember_doc" xml:lang="en-US">Thrid Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UnderprovisionInRespectOfPriorYears" xlink:to="BMGL_UnderprovisionInRespectOfPriorYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_UnderprovisionInRespectOfPriorYears_doc" xml:lang="en-US">Under provision in respect of prior years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_WrittenOffRightofuseAssets" xlink:to="BMGL_WrittenOffRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_WrittenOffRightofuseAssets_doc" xml:lang="en-US">Written-off right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_doc" xml:lang="en-US">Written-off other than through business combinations property plant and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ManagementFee" xlink:to="BMGL_ManagementFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_ManagementFee_doc" xml:lang="en-US">Management fee.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SaleAndPurchaseAgreementMember" xlink:label="BMGL_SaleAndPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_SaleAndPurchaseAgreementMember" xlink:to="BMGL_SaleAndPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_SaleAndPurchaseAgreementMember_doc" xml:lang="en-US">Sale and Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation" xlink:to="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation_doc" xml:lang="en-US">The description of the entity's accounting policy for consolidations, including the methods of presentation adopted in the financial statements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:to="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses_3_lbl" xml:lang="en-US">ConsumablesMedicalSuppliesAndOtherRelatedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_2_lbl" xml:lang="en-US">Employee benefits expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_2_lbl" xml:lang="en-US">Rental expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLoss" xlink:to="ifrs-full_ImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLoss_2_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_3_lbl" xml:lang="en-US">Finance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_3_lbl" xml:lang="en-US">Tax expense (income)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProfitLossAndNetComprehensiveIncome" xlink:to="BMGL_ProfitLossAndNetComprehensiveIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ProfitLossAndNetComprehensiveIncome_3_lbl" xml:lang="en-US">ProfitLossAndNetComprehensiveIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProfitLossIncludingMinorityInterest" xlink:to="BMGL_ProfitLossIncludingMinorityInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ProfitLossIncludingMinorityInterest_3_lbl" xml:lang="en-US">ProfitLossIncludingMinorityInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_2_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_2_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_2_lbl" xml:lang="en-US">Non-current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_2_lbl" xml:lang="en-US">Current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetAssetsLiabilities_2_lbl" xml:lang="en-US">Assets (liabilities)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MergerReserveArisingFromGroupRestructuring" xlink:to="BMGL_MergerReserveArisingFromGroupRestructuring_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_MergerReserveArisingFromGroupRestructuring_3_lbl" xml:lang="en-US">MergerReserveArisingFromGroupRestructuring</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_4_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_MinorityInterestInSubsidiary" xlink:to="BMGL_MinorityInterestInSubsidiary_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_MinorityInterestInSubsidiary_3_lbl" xml:lang="en-US">MinorityInterestInSubsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_CreditLossExpenseReversal" xlink:to="BMGL_CreditLossExpenseReversal_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_CreditLossExpenseReversal_3_lbl" xml:lang="en-US">CreditLossExpenseReversal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_2_lbl" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_2_lbl" xml:lang="en-US">Cash flows from (used in) operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_2_lbl" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_2_lbl" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_2_lbl" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentProperty" xlink:to="ifrs-full_PurchaseOfInvestmentProperty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentProperty_2_lbl" xml:lang="en-US">Purchase of investment property</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ProceedsFromDeferredOfferingCosts" xlink:to="BMGL_ProceedsFromDeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ProceedsFromDeferredOfferingCosts_3_lbl" xml:lang="en-US">ProceedsFromDeferredOfferingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DecreaseInAmountDueFromDirector" xlink:to="BMGL_DecreaseInAmountDueFromDirector_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DecreaseInAmountDueFromDirector_3_lbl" xml:lang="en-US">DecreaseInAmountDueFromDirector</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseInAmountDueToRelatedParties" xlink:to="BMGL_IncreaseInAmountDueToRelatedParties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseInAmountDueToRelatedParties_3_lbl" xml:lang="en-US">IncreaseInAmountDueToRelatedParties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_IncreaseInBankOverdraft" xlink:to="BMGL_IncreaseInBankOverdraft_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_IncreaseInBankOverdraft_3_lbl" xml:lang="en-US">IncreaseInBankOverdraft</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_2_lbl" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_2_lbl" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DecreaseincreaseInAmountDueToFormerDirector" xlink:to="BMGL_DecreaseincreaseInAmountDueToFormerDirector_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DecreaseincreaseInAmountDueToFormerDirector_3_lbl" xml:lang="en-US">DecreaseincreaseInAmountDueToFormerDirector</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_2_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_2_lbl" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_2_lbl" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_2_lbl" xml:lang="en-US">Disclosure of other operating income [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" xlink:to="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfProfitLossBeforeTaxExplanatory_3_lbl" xml:lang="en-US">DisclosureOfProfitLossBeforeTaxExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_2_lbl" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_2_lbl" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_2_lbl" xml:lang="en-US">Disclosure of trade and other receivables [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_2_lbl" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_2_lbl" xml:lang="en-US">Disclosure of borrowings [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_2_lbl" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" xlink:to="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory_3_lbl" xml:lang="en-US">DisclosureOfAmountDueToAFormerDirectorExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_2_lbl" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_2_lbl" xml:lang="en-US">Disclosure of leases [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoodwillExplanatory" xlink:to="ifrs-full_DisclosureOfGoodwillExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGoodwillExplanatory_2_lbl" xml:lang="en-US">Disclosure of goodwill [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_2_lbl" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_2_lbl" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" xlink:to="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory_3_lbl" xml:lang="en-US">DescriptionOfAccountingPolicyForInventoriesExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_2_lbl" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_2_lbl" xml:lang="en-US">Description of accounting policy for issued capital [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_2_lbl" xml:lang="en-US">Other income [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_BadDebtsWrittenOff" xlink:to="BMGL_BadDebtsWrittenOff_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_BadDebtsWrittenOff_3_lbl" xml:lang="en-US">BadDebtsWrittenOff</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_3_lbl" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DepreciationOfPropertyAndEquipment" xlink:to="BMGL_DepreciationOfPropertyAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DepreciationOfPropertyAndEquipment_3_lbl" xml:lang="en-US">DepreciationOfPropertyAndEquipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationExpense" xlink:to="ifrs-full_AmortisationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationExpense_2_lbl" xml:lang="en-US">Amortisation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_UtilisationOfCapitalAllowance" xlink:to="BMGL_UtilisationOfCapitalAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_UtilisationOfCapitalAllowance_3_lbl" xml:lang="en-US">UtilisationOfCapitalAllowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_DeferredIncomeTax" xlink:to="BMGL_DeferredIncomeTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_DeferredIncomeTax_3_lbl" xml:lang="en-US">DeferredIncomeTax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_WrittenOffRightofuseAssets" xlink:to="BMGL_WrittenOffRightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_WrittenOffRightofuseAssets_3_lbl" xml:lang="en-US">WrittenOffRightofuseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:to="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation_4_lbl" xml:lang="en-US">PropertyPlantAndEquipmentAccumulatedDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_AllowanceForExpectedCreditLoss" xlink:to="BMGL_AllowanceForExpectedCreditLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_AllowanceForExpectedCreditLoss_5_lbl" xml:lang="en-US">AllowanceForExpectedCreditLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_ReversalOfAllowanceForExpectedCreditLosses" xlink:to="BMGL_ReversalOfAllowanceForExpectedCreditLosses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_ReversalOfAllowanceForExpectedCreditLosses_3_lbl" xml:lang="en-US">ReversalOfAllowanceForExpectedCreditLosses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_4_lbl" xml:lang="en-US">Non-current lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:to="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_4_lbl" xml:lang="en-US">Non-current portion of non-current secured bank loans received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_2_lbl" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_3_lbl" xml:lang="en-US">Liabilities arising from financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_3_lbl" xml:lang="en-US">Trade and other payables [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_2_lbl" xml:lang="en-US">Key management personnel compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">Deferred tax assets recognised as of acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMGL_InvestmentRecognisedAsOfAcquisitionDate" xlink:to="BMGL_InvestmentRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BMGL_InvestmentRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">InvestmentRecognisedAsOfAcquisitionDate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoryRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">Inventory recognised as of acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FairValueOfAcquiredReceivables" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_2_lbl" xml:lang="en-US">Fair value of acquired receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">Borrowings recognised as of acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">Trade and other payables recognised as of acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_2_lbl" xml:lang="en-US">Non-current liabilities recognised as of acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueOfAcquiree" xlink:to="ifrs-full_RevenueOfAcquiree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueOfAcquiree_2_lbl" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_2_lbl" xml:lang="en-US">Current payables to related parties</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>bmgl-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Cover" roleURI="http://baselmedical.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfProfitOrLoss" roleURI="http://baselmedical.com/role/StatementOfProfitOrLoss" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#BalanceSheets" roleURI="http://baselmedical.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfChangesInShareholdersEquityParenthetical" roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfChangesInShareholdersEquity" roleURI="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#StatementOfCashFlows" roleURI="http://baselmedical.com/role/StatementOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#General" roleURI="http://baselmedical.com/role/General" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformation" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformation" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantAccountingJudgementsAndEstimates" roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Revenue" roleURI="http://baselmedical.com/role/Revenue" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#OtherIncome" roleURI="http://baselmedical.com/role/OtherIncome" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinanceCost" roleURI="http://baselmedical.com/role/FinanceCost" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LossprofitBeforeTax" roleURI="http://baselmedical.com/role/LossprofitBeforeTax" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#IncomeTaxBenefitexpense" roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpense" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RightOfUseAssets" roleURI="http://baselmedical.com/role/RightOfUseAssets" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#PropertyAndEquipment" roleURI="http://baselmedical.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Inventories" roleURI="http://baselmedical.com/role/Inventories" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivables" roleURI="http://baselmedical.com/role/TradeAndOtherReceivables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CashAndCashEquivalents" roleURI="http://baselmedical.com/role/CashAndCashEquivalents" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedParties" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedParties" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Borrowings" roleURI="http://baselmedical.com/role/Borrowings" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayables" roleURI="http://baselmedical.com/role/TradeAndOtherPayables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueToFormerDirector" roleURI="http://baselmedical.com/role/AmountDueToFormerDirector" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ShareCapital" roleURI="http://baselmedical.com/role/ShareCapital" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#Leases" roleURI="http://baselmedical.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantRelatedPartyTransactions" roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwill" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FairValueOfAssetsAndLiabilities" roleURI="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagement" roleURI="http://baselmedical.com/role/FinancialRiskManagement" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialInstrumentsByCategory" roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategory" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CapitalManagement" roleURI="http://baselmedical.com/role/CapitalManagement" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#EventsOccurringAfterReportingPeriod" roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformationPolicies" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#GeneralTables" roleURI="http://baselmedical.com/role/GeneralTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#MaterialAccountingPolicyInformationTables" roleURI="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RevenueTables" roleURI="http://baselmedical.com/role/RevenueTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#OtherIncomeTables" roleURI="http://baselmedical.com/role/OtherIncomeTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinanceCostTables" roleURI="http://baselmedical.com/role/FinanceCostTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LossprofitBeforeTaxTables" roleURI="http://baselmedical.com/role/LossprofitBeforeTaxTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#IncomeTaxBenefitexpenseTables" roleURI="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#RightOfUseAssetsTables" roleURI="http://baselmedical.com/role/RightOfUseAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://baselmedical.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#InventoriesTables" roleURI="http://baselmedical.com/role/InventoriesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivablesTables" roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#CashAndCashEquivalentsTables" roleURI="http://baselmedical.com/role/CashAndCashEquivalentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedPartiesTables" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#BorrowingsTables" roleURI="http://baselmedical.com/role/BorrowingsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayablesTables" roleURI="http://baselmedical.com/role/TradeAndOtherPayablesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LeasesTables" roleURI="http://baselmedical.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantRelatedPartyTransactionsTables" roleURI="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwillTables" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagementTables" roleURI="http://baselmedical.com/role/FinancialRiskManagementTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialInstrumentsByCategoryTables" roleURI="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfActivitiesOfSubsidiariesDetails" roleURI="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#GeneralDetailsNarrative" roleURI="http://baselmedical.com/role/GeneralDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" roleURI="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SignificantAccountingJudgementsAndEstimatesDetailsNarrative" roleURI="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" roleURI="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfOtherIncomeDetails" roleURI="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinanceCostDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfProfitBeforeTaxDetails" roleURI="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfComponentOfIncomeTaxExpenseDetails" roleURI="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfRightOfUseAssetsDetails" roleURI="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfInventoriesDetails" roleURI="http://baselmedical.com/role/ScheduleOfInventoriesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTradeAndOtherReceivablesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" roleURI="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherReceivablesDetailsNarrative" roleURI="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCashAndCashEquivalentsDetails" roleURI="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfAmountDueFromRelatedPartyDetails" roleURI="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#AmountDueFromtoRelatedPartiesDetailsNarrative" roleURI="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfBreakdownBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfDetailsBorrowingsDetails" roleURI="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTradeAndOtherPayablesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#TradeAndOtherPayablesDetailsNarrative" roleURI="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ShareCapitalDetailsNarrative" roleURI="http://baselmedical.com/role/ShareCapitalDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfAmountsRecognizedInProfitOrLossDetails" roleURI="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#LeasesDetailsNarrative" roleURI="http://baselmedical.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfTransactionsWithRelatedPartiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCompensationOfKeyManagementPersonnelDetails" roleURI="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" roleURI="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ImpairmentLossOnGoodwillDetailsNarrative" roleURI="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" roleURI="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfCreditRiskDetails" roleURI="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" roleURI="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#FinancialRiskManagementDetailsNarrative" roleURI="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" roleURI="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="bmgl-20250630.xsd#EventsOccurringAfterReportingPeriodDetailsNarrative" roleURI="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_deiContactPersonnelEmailAddress" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelEmailAddress" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfProfitOrLoss" xlink:title="00000002 - Statement - Consolidated Statement of Profit or Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses" xlink:label="loc_ifrs-fullOtherGainsLosses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherGainsLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:label="loc_BMGLConsumablesMedicalSuppliesAndOtherRelatedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_BMGLConsumablesMedicalSuppliesAndOtherRelatedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-fullEmployeeBenefitsExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEmployeeBenefitsExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationExpense" xlink:label="loc_ifrs-fullDepreciationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDepreciationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalExpense" xlink:label="loc_ifrs-fullRentalExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullRentalExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="loc_ifrs-fullOtherOperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherOperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLoss" xlink:label="loc_ifrs-fullImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullFinanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProfitLossAndNetComprehensiveIncome" xlink:label="loc_BMGLProfitLossAndNetComprehensiveIncome" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_BMGLProfitLossAndNetComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-fullProfitLossAttributableToAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProfitLossIncludingMinorityInterest" xlink:label="loc_BMGLProfitLossIncludingMinorityInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_BMGLProfitLossIncludingMinorityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-fullBasicEarningsLossPerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullBasicEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-fullDilutedEarningsLossPerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDilutedEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/BalanceSheets" xlink:title="00000003 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-fullStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartiesMember" xlink:label="loc_ifrs-fullRelatedPartiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ifrs-fullRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-fullNoncurrentAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-fullDeferredTaxAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullDeferredTaxAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-fullInventories" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullInventories" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredOfferingCost" xlink:label="loc_BMGLDeferredOfferingCost" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_BMGLDeferredOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-fullLiabilitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-fullLongtermBorrowings" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullLongtermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-fullShorttermBorrowings" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullShorttermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="loc_ifrs-fullOtherCurrentFinancialLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullOtherCurrentFinancialLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_BMGLAmountDueToFormerDirector" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:label="loc_ifrs-fullCurrentProvisionsForEmployeeBenefits" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentProvisionsForEmployeeBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="loc_ifrs-fullCurrentTaxLiabilitiesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentTaxLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="loc_ifrs-fullNetAssetsLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullNetAssetsLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MergerReserveArisingFromGroupRestructuring" xlink:label="loc_BMGLMergerReserveArisingFromGroupRestructuring" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_BMGLMergerReserveArisingFromGroupRestructuring" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfChangesInShareholdersEquityParenthetical" xlink:title="00000004 - Statement - Consolidated Statement of Changes In Shareholders&apos; Equity (Parenthetical)" />
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statement of Changes In Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-fullStatementOfChangesInEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MergerReserveMember" xlink:label="loc_ifrs-fullMergerReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullMergerReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="loc_ifrs-fullReserveOfExchangeDifferencesOnTranslationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="loc_ifrs-fullIssueOfEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIssueOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MinorityInterestInSubsidiary" xlink:label="loc_BMGLMinorityInterestInSubsidiary" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLMinorityInterestInSubsidiary" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeBeforeTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughTransferToStatutoryReserve" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughTransferToStatutoryReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/StatementOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statement of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-fullStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff" xlink:label="loc_ifrs-fullRecoveriesOnLoansPreviouslyWrittenOff" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullRecoveriesOnLoansPreviouslyWrittenOff" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditLossExpenseReversal" xlink:label="loc_BMGLCreditLossExpenseReversal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_BMGLCreditLossExpenseReversal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="loc_ifrs-fullAdjustmentsForProvisions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForProvisions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdjustmentsForAmortizationOfRightOfUseAsset" xlink:label="loc_BMGLAdjustmentsForAmortizationOfRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_BMGLAdjustmentsForAmortizationOfRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:label="loc_BMGLRecoveriesOnLoansPreviouslyWrittenOffFixedAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_BMGLRecoveriesOnLoansPreviouslyWrittenOffFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:label="loc_ifrs-fullAdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForInterestExpense" xlink:label="loc_ifrs-fullAdjustmentsForInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:label="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInInventories" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperations" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="loc_ifrs-fullIncomeTaxesPaidRefundClassifiedAsOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullIncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-fullInterestPaidClassifiedAsOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullInterestPaidClassifiedAsOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIncreaseDecreaseInNonCashWorkingCapitalAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfInvestmentProperty" xlink:label="loc_ifrs-fullPurchaseOfInvestmentProperty" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPurchaseOfInvestmentProperty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProceedsFromDeferredOfferingCosts" xlink:label="loc_BMGLProceedsFromDeferredOfferingCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_BMGLProceedsFromDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DecreaseInAmountDueFromDirector" xlink:label="loc_BMGLDecreaseInAmountDueFromDirector" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_BMGLDecreaseInAmountDueFromDirector" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseInAmountDueToRelatedParties" xlink:label="loc_BMGLIncreaseInAmountDueToRelatedParties" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_BMGLIncreaseInAmountDueToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseInBankOverdraft" xlink:label="loc_BMGLIncreaseInBankOverdraft" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_BMGLIncreaseInBankOverdraft" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="loc_ifrs-fullProceedsFromCurrentBorrowings" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullProceedsFromCurrentBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullRepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DecreaseincreaseInAmountDueToFormerDirector" xlink:label="loc_BMGLDecreaseincreaseInAmountDueToFormerDirector" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_BMGLDecreaseincreaseInAmountDueToFormerDirector" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests" xlink:label="loc_ifrs-fullProceedsFromContributionsOfNoncontrollingInterests" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullProceedsFromContributionsOfNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-fullEffectOfExchangeRateChangesOnCashAndCashEquivalents" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullEffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/General" xlink:title="999014 - Disclosure - General">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" xlink:label="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformation" xlink:title="999015 - Disclosure - Material accounting policy information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfChangesInAccountingPoliciesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfChangesInAccountingPoliciesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates" xlink:title="999016 - Disclosure - Significant accounting judgements and estimates">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:label="loc_BMGLDisclosureSignificantAccountingJudgementsAndEstimatesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:to="loc_ifrs-fullDisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Revenue" xlink:title="999017 - Disclosure - Revenue">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRevenueAbstract" xlink:label="loc_BMGLDisclosureRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRevenueExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRevenueAbstract" xlink:to="loc_ifrs-fullDisclosureOfRevenueExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/OtherIncome" xlink:title="999018 - Disclosure - Other income">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfOtherIncomeAbstract" xlink:label="loc_BMGLDisclosureOfOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="loc_ifrs-fullDisclosureOfOtherOperatingIncomeExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_ifrs-fullDisclosureOfOtherOperatingIncomeExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinanceCost" xlink:title="999019 - Disclosure - Finance cost">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinanceCostExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinanceCostExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LossprofitBeforeTax" xlink:title="999020 - Disclosure - (Loss)/Profit before tax">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLossprofitBeforeTaxAbstract" xlink:label="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfProfitLossBeforeTaxExplanatory" xlink:label="loc_BMGLDisclosureOfProfitLossBeforeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLDisclosureOfProfitLossBeforeTaxExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/IncomeTaxBenefitexpense" xlink:title="999021 - Disclosure - Income tax (benefit)/expense">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RightOfUseAssets" xlink:title="999022 - Disclosure - Right of use assets">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRightofuseAssetAbstract" xlink:label="loc_BMGLDisclosureRightofuseAssetAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRightofuseAssetAbstract" xlink:to="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/PropertyAndEquipment" xlink:title="999023 - Disclosure - Property and equipment">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_BMGLDisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Inventories" xlink:title="999024 - Disclosure - Inventories">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfInventoriesAbstract" xlink:label="loc_BMGLDisclosureOfInventoriesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInventoriesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfInventoriesAbstract" xlink:to="loc_ifrs-fullDisclosureOfInventoriesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivables" xlink:title="999025 - Disclosure - Trade and other receivables">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTradeAndOtherReceivablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CashAndCashEquivalents" xlink:title="999026 - Disclosure - Cash and cash equivalents">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureCashAndCashEquivalentsAbstract" xlink:label="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCashAndCashEquivalentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_ifrs-fullDisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedParties" xlink:title="999027 - Disclosure - Amount due from/to related parties">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" xlink:label="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" xlink:to="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Borrowings" xlink:title="999028 - Disclosure - Borrowings">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="loc_BMGLDisclosureBorrowingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfBorrowingsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullDisclosureOfBorrowingsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayables" xlink:title="999029 - Disclosure - Trade and other payables">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTradeAndOtherPayablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueToFormerDirector" xlink:title="999030 - Disclosure - Amount due to a former director">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountDueToRelatedPartyAbstract" xlink:label="loc_BMGLDisclosureAmountDueToRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory" xlink:label="loc_BMGLDisclosureOfAmountDueToAFormerDirectorExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureAmountDueToRelatedPartyAbstract" xlink:to="loc_BMGLDisclosureOfAmountDueToAFormerDirectorExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ShareCapital" xlink:title="999031 - Disclosure - Share capital">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureShareCapitalAbstract" xlink:label="loc_BMGLDisclosureShareCapitalAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-fullDisclosureOfClassesOfShareCapitalExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureShareCapitalAbstract" xlink:to="loc_ifrs-fullDisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/Leases" xlink:title="999032 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLeasesAbstract" xlink:label="loc_BMGLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfLeasesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_ifrs-fullDisclosureOfLeasesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantRelatedPartyTransactions" xlink:title="999033 - Disclosure - Significant related party transactions">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:label="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfSignificantRelatedPartyExplanatory" xlink:label="loc_BMGLDisclosureOfSignificantRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_BMGLDisclosureOfSignificantRelatedPartyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwill" xlink:title="999034 - Disclosure - Impairment loss on goodwill">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:label="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGoodwillExplanatory" xlink:label="loc_ifrs-fullDisclosureOfGoodwillExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullDisclosureOfGoodwillExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FairValueOfAssetsAndLiabilities" xlink:title="999035 - Disclosure - Fair value of assets and liabilities">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract" xlink:label="loc_BMGLDisclosureFairValueOfAssetsAndLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFairValueOfAssetsAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagement" xlink:title="999036 - Disclosure - Financial risk management">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinancialRiskManagementExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialRiskManagementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialInstrumentsByCategory" xlink:title="999037 - Disclosure - Financial instruments by category">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialInstrumentsAbstract" xlink:label="loc_BMGLDisclosureFinancialInstrumentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialInstrumentsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CapitalManagement" xlink:title="999038 - Disclosure - Capital management">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureCapitalManagementAbstract" xlink:label="loc_BMGLDisclosureCapitalManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CapitalManagementExplanatory" xlink:label="loc_BMGLCapitalManagementExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureCapitalManagementAbstract" xlink:to="loc_BMGLCapitalManagementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/EventsOccurringAfterReportingPeriod" xlink:title="999039 - Disclosure - Events occurring after the reporting period">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies" xlink:title="999040 - Disclosure - Material accounting policy information (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" xlink:label="loc_BMGLDescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyForBasisOfPreparationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="loc_ifrs-fullDescriptionOfInitialApplicationOfStandardsOrInterpretations" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" xlink:label="loc_BMGLDescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" xlink:label="loc_BMGLDescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForGovernmentGrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation" xlink:label="loc_BMGLDescriptionOfAccountingPolicyForBasisOfConsolidation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyForBasisOfConsolidation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory" xlink:label="loc_BMGLDescriptionOfAccountingPolicyForInventoriesExplanatory" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyForInventoriesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForProvisionsExplanatory" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForLeasesExplanatory" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForIssuedCapitalExplanatory" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForReservesExplanatory" xlink:label="loc_BMGLDescriptionOfAccountingPolicyForReservesExplanatory" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyForReservesExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" xlink:label="loc_BMGLDescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForDividendsExplanatory" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForDividendsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/GeneralTables" xlink:title="999041 - Disclosure - General (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" xlink:label="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/MaterialAccountingPolicyInformationTables" xlink:title="999042 - Disclosure - Material accounting policy information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDepreciationRatesExplanatory" xlink:label="loc_BMGLDisclosureOfDepreciationRatesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDisclosureOfDepreciationRatesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RevenueTables" xlink:title="999043 - Disclosure - Revenue (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRevenueAbstract" xlink:label="loc_BMGLDisclosureRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRevenueAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/OtherIncomeTables" xlink:title="999044 - Disclosure - Other income (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfOtherIncomeAbstract" xlink:label="loc_BMGLDisclosureOfOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutOtherIncomeExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutOtherIncomeExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinanceCostTables" xlink:title="999045 - Disclosure - Finance cost (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutFinanceCostExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutFinanceCostExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LossprofitBeforeTaxTables" xlink:title="999046 - Disclosure - (Loss)/Profit before tax (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLossprofitBeforeTaxAbstract" xlink:label="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/IncomeTaxBenefitexpenseTables" xlink:title="999047 - Disclosure - Income tax (benefit)/expense (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" xlink:label="loc_BMGLDisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLDisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/RightOfUseAssetsTables" xlink:title="999048 - Disclosure - Right of use assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRightofuseAssetAbstract" xlink:label="loc_BMGLDisclosureRightofuseAssetAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutOfRightOfUseAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRightofuseAssetAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutOfRightOfUseAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/PropertyAndEquipmentTables" xlink:title="999049 - Disclosure - Property and equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_BMGLDisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/InventoriesTables" xlink:title="999050 - Disclosure - Inventories (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfInventoriesAbstract" xlink:label="loc_BMGLDisclosureOfInventoriesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutInventoriesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfInventoriesAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutInventoriesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivablesTables" xlink:title="999051 - Disclosure - Trade and other receivables (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfTradeAndOtherReceivableExplanatory" xlink:label="loc_BMGLDisclosureOfTradeAndOtherReceivableExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_BMGLDisclosureOfTradeAndOtherReceivableExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfAllowanceForCreditLossesExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfAllowanceForCreditLossesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/CashAndCashEquivalentsTables" xlink:title="999052 - Disclosure - Cash and cash equivalents (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureCashAndCashEquivalentsAbstract" xlink:label="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfCashAndCashEquivalentExplanatory" xlink:label="loc_BMGLDisclosureOfCashAndCashEquivalentExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_BMGLDisclosureOfCashAndCashEquivalentExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables" xlink:title="999053 - Disclosure - Amount due from/to related parties (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" xlink:label="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/BorrowingsTables" xlink:title="999054 - Disclosure - Borrowings (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="loc_BMGLDisclosureBorrowingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutBreakdownOfBorrowings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutBreakdownOfBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutBorrowings" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutBorrowings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayablesTables" xlink:title="999055 - Disclosure - Trade and other payables (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:label="loc_BMGLDisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_BMGLDisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LeasesTables" xlink:title="999056 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLeasesAbstract" xlink:label="loc_BMGLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock" xlink:label="loc_BMGLDisclosureOfLeaseRelatedExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_BMGLDisclosureOfLeaseRelatedExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables" xlink:title="999057 - Disclosure - Significant related party transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:label="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory" xlink:label="loc_BMGLScheduleOfTransactionsWithRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_BMGLScheduleOfTransactionsWithRelatedPartyExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory" xlink:label="loc_BMGLScheduleOfCompensationOfKeyManagementPersonnelExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_BMGLScheduleOfCompensationOfKeyManagementPersonnelExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwillTables" xlink:title="999058 - Disclosure - Impairment loss on goodwill (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:label="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagementTables" xlink:title="999059 - Disclosure - Financial risk management (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" xlink:label="loc_BMGLDisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_BMGLDisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" xlink:label="loc_BMGLScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_BMGLScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfExpectedCreditRiskExplanatory" xlink:label="loc_BMGLScheduleOfExpectedCreditRiskExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_BMGLScheduleOfExpectedCreditRiskExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="loc_ifrs-fullMaturityAnalysisForNonderivativeFinancialLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_ifrs-fullMaturityAnalysisForNonderivativeFinancialLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialInstrumentsByCategoryTables" xlink:title="999060 - Disclosure - Financial instruments by category (Tables)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialInstrumentsAbstract" xlink:label="loc_BMGLDisclosureFinancialInstrumentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" xlink:label="loc_BMGLScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialInstrumentsAbstract" xlink:to="loc_BMGLScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails" xlink:title="999061 - Disclosure - Schedule of activities of subsidiaries (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" xlink:label="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BaselMedicalGroupPteLtdMember" xlink:label="loc_BMGLBaselMedicalGroupPteLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLBaselMedicalGroupPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember" xlink:label="loc_BMGLSingaporeSportsOrthopaedicClinicPteLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeSportsOrthopaedicClinicPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember" xlink:label="loc_BMGLSingaporeSportsOrthopaedicServicesPteLtdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeSportsOrthopaedicServicesPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCPteLtdMember" xlink:label="loc_BMGLSSOCPteLtdMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOSPteLtdMember" xlink:label="loc_BMGLSSOSPteLtdMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOSPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" xlink:label="loc_BMGLSingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeKneeSportsAndOrthopaedicClinicPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember" xlink:label="loc_BMGLSingaporeKneeSportsOrthopaedicServicesPteLtdMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSingaporeKneeSportsOrthopaedicServicesPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PharmaAvenuePteLtdMember" xlink:label="loc_BMGLPharmaAvenuePteLtdMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLPharmaAvenuePteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BaselMedflowPteLtdMember" xlink:label="loc_BMGLBaselMedflowPteLtdMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLBaselMedflowPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BethesdaMedicalPteLtdMember" xlink:label="loc_BMGLBethesdaMedicalPteLtdMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLBethesdaMedicalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OasisMedicalClinicPteLtdMember" xlink:label="loc_BMGLOasisMedicalClinicPteLtdMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLOasisMedicalClinicPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NameOfSubsidiary" xlink:label="loc_ifrs-fullNameOfSubsidiary" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNameOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:label="loc_ifrs-fullDescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CountryOfIncorporation" xlink:label="loc_ifrs-fullCountryOfIncorporation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCountryOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/GeneralDetailsNarrative" xlink:title="999062 - Disclosure - General (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfChangesInAccountingPoliciesAbstract" xlink:label="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfChangesInAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OrdinaryShareMember" xlink:label="loc_BMGLOrdinaryShareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_BMGLOrdinaryShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NumberOfSharesSubscribed" xlink:label="loc_BMGLNumberOfSharesSubscribed" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLNumberOfSharesSubscribed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="loc_ifrs-fullSharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullSharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails" xlink:title="999063 - Disclosure - Schedule of expected useful lives for property, plant and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="loc_ifrs-fullMachineryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullMachineryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-fullFixturesAndFittingsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullFixturesAndFittingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullOtherPropertyPlantAndEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullOtherPropertyPlantAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RenovationMember" xlink:label="loc_BMGLRenovationMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLRenovationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AirConditionerMember" xlink:label="loc_BMGLAirConditionerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLAirConditionerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-fullComputerEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SoftwareMember" xlink:label="loc_BMGLSoftwareMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative" xlink:title="999064 - Disclosure - Significant accounting judgements and estimates (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:label="loc_BMGLDisclosureSignificantAccountingJudgementsAndEstimatesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-fullInventories" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:to="loc_ifrs-fullInventories" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoriesTotal" xlink:label="loc_ifrs-fullInventoriesTotal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:to="loc_ifrs-fullInventoriesTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OthersReceivables" xlink:label="loc_BMGLOthersReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureSignificantAccountingJudgementsAndEstimatesAbstract" xlink:to="loc_BMGLOthersReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" xlink:title="999065 - Disclosure - Summary of revenue from transfer of goods and services (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRevenueAbstract" xlink:label="loc_BMGLDisclosureRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRevenueAbstract" xlink:to="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-fullProductsAndServicesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_ifrs-fullProductsAndServicesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain" xlink:label="loc_ifrs-fullProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProductsAndServicesAxis" xlink:to="loc_ifrs-fullProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MedicalServicesMember" xlink:label="loc_BMGLMedicalServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProductsAndServicesDomain" xlink:to="loc_BMGLMedicalServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesAxis" xlink:to="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="loc_ifrs-fullGoodsOrServicesTransferredAtPointInTimeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTimingOfTransferOfGoodsOrServicesDomain" xlink:to="loc_ifrs-fullGoodsOrServicesTransferredAtPointInTimeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="loc_ifrs-fullRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfOtherIncomeDetails" xlink:title="999066 - Disclosure - Schedule of Other income (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfOtherIncomeAbstract" xlink:label="loc_BMGLDisclosureOfOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="loc_ifrs-fullRevenueFromGovernmentGrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_ifrs-fullRevenueFromGovernmentGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ServiceIncome" xlink:label="loc_BMGLServiceIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_BMGLServiceIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RentalIncome" xlink:label="loc_ifrs-fullRentalIncome" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_ifrs-fullRentalIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome" xlink:label="loc_ifrs-fullOtherIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_ifrs-fullOtherIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ReversalOfExpectedCreditLosses" xlink:label="loc_BMGLReversalOfExpectedCreditLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_BMGLReversalOfExpectedCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses" xlink:label="loc_ifrs-fullOtherGainsLosses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfOtherIncomeAbstract" xlink:to="loc_ifrs-fullOtherGainsLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinanceCostDetails" xlink:title="999067 - Disclosure - Schedule of Finance cost (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="loc_ifrs-fullInterestExpenseOnBorrowings" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullInterestExpenseOnBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullFinanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails" xlink:title="999068 - Disclosure - Schedule of Profit before tax (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLossprofitBeforeTaxAbstract" xlink:label="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="loc_ifrs-fullSalesAndMarketingExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullSalesAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-fullProfessionalFeesExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullProfessionalFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InsuranceExpense" xlink:label="loc_ifrs-fullInsuranceExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullInsuranceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TransportationExpense" xlink:label="loc_ifrs-fullTransportationExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullTransportationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BadDebtsWrittenOff" xlink:label="loc_BMGLBadDebtsWrittenOff" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLBadDebtsWrittenOff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ProvisionForExpectedCreditLosses" xlink:label="loc_BMGLProvisionForExpectedCreditLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLProvisionForExpectedCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDepreciationPropertyPlantAndEquipment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullDepreciationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DepreciationOfPropertyAndEquipment" xlink:label="loc_BMGLDepreciationOfPropertyAndEquipment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLDepreciationOfPropertyAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationExpense" xlink:label="loc_ifrs-fullAmortisationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullAmortisationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RecruitmentExpenses" xlink:label="loc_BMGLRecruitmentExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLRecruitmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubscriptionCirculationRevenue" xlink:label="loc_ifrs-fullSubscriptionCirculationRevenue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_ifrs-fullSubscriptionCirculationRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TelephoneExpense" xlink:label="loc_BMGLTelephoneExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLTelephoneExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EmployeeBenefitsExpenses" xlink:label="loc_BMGLEmployeeBenefitsExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLEmployeeBenefitsExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsSalariesAndBonuses" xlink:label="loc_BMGLDirectorsSalariesAndBonuses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLDirectorsSalariesAndBonuses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsCentralProvidentFund" xlink:label="loc_BMGLDirectorsCentralProvidentFund" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLDirectorsCentralProvidentFund" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EmployeesSalariesAndBonus" xlink:label="loc_BMGLEmployeesSalariesAndBonus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLEmployeesSalariesAndBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EmployeesCentralProvidentFund" xlink:label="loc_BMGLEmployeesCentralProvidentFund" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLEmployeesCentralProvidentFund" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherStaffExpenses" xlink:label="loc_BMGLOtherStaffExpenses" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLossprofitBeforeTaxAbstract" xlink:to="loc_BMGLOtherStaffExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails" xlink:title="999069 - Disclosure - Schedule of component of income tax expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UnderprovisionInRespectOfPriorYears" xlink:label="loc_BMGLUnderprovisionInRespectOfPriorYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLUnderprovisionInRespectOfPriorYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverprovisionInRespectOfPriorYears" xlink:label="loc_BMGLOverprovisionInRespectOfPriorYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLOverprovisionInRespectOfPriorYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails" xlink:title="999070 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-fullTaxExpenseIncomeAtApplicableTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullTaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NondeductibleExpenses" xlink:label="loc_BMGLNondeductibleExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLNondeductibleExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-fullTaxEffectOfTaxLosses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullTaxEffectOfTaxLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncomeTaxExemption" xlink:label="loc_BMGLIncomeTaxExemption" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLIncomeTaxExemption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UtilisationOfCapitalAllowance" xlink:label="loc_BMGLUtilisationOfCapitalAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLUtilisationOfCapitalAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UtilisationOfDeferredTaxAssets" xlink:label="loc_BMGLUtilisationOfDeferredTaxAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLUtilisationOfDeferredTaxAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:label="loc_BMGLDeferredTaxAssetsNotRecognizedOnTaxLosses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLDeferredTaxAssetsNotRecognizedOnTaxLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DeferredIncomeTax" xlink:label="loc_BMGLDeferredIncomeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLDeferredIncomeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_UnderprovisionInRespectOfPriorYears" xlink:label="loc_BMGLUnderprovisionInRespectOfPriorYears" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLUnderprovisionInRespectOfPriorYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverprovisionInRespectOfPriorYears" xlink:label="loc_BMGLOverprovisionInRespectOfPriorYears" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_BMGLOverprovisionInRespectOfPriorYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical" xlink:title="999071 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-fullApplicableTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ifrs-fullApplicableTaxRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails" xlink:title="999072 - Disclosure - Schedule of Right of use assets (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRightofuseAssetAbstract" xlink:label="loc_BMGLDisclosureRightofuseAssetAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRightofuseAssetAbstract" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="loc_ifrs-fullCarryingAmountMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-fullGrossCarryingAmountMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_ifrs-fullGrossCarryingAmountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AccumulatedDepreciationMember" xlink:label="loc_BMGLAccumulatedDepreciationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_BMGLAccumulatedDepreciationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" xlink:label="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-fullDepreciationRightofuseAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDepreciationRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsRightofuseAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_WrittenOffRightofuseAssets" xlink:label="loc_BMGLWrittenOffRightofuseAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLWrittenOffRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullRightofuseAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999073 - Disclosure - Schedule of Property and equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_BMGLDisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="loc_ifrs-fullCarryingAmountMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-fullGrossCarryingAmountMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_ifrs-fullGrossCarryingAmountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="loc_ifrs-fullAccumulatedDepreciationAndAmortisationMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCarryingAmountMember" xlink:to="loc_ifrs-fullAccumulatedDepreciationAndAmortisationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="loc_ifrs-fullMachineryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullMachineryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixturesAndFittingsMember" xlink:label="loc_ifrs-fullFixturesAndFittingsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullFixturesAndFittingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_MedicalEquipmentMember" xlink:label="loc_BMGLMedicalEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RenovationMember" xlink:label="loc_BMGLRenovationMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLRenovationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AirConditionerMember" xlink:label="loc_BMGLAirConditionerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLAirConditionerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ComputerAndOfficeEquipmentMember" xlink:label="loc_BMGLComputerAndOfficeEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLComputerAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SoftwareMember" xlink:label="loc_BMGLSoftwareMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_BMGLSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_BMGLWrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLWrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDepreciationPropertyPlantAndEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDepreciationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_BMGLPropertyPlantAndEquipmentAccumulatedDepreciation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPropertyPlantAndEquipmentAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation" xlink:label="loc_BMGLPropertyPlantAndEquipmentAccumulatedDepreciation_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPropertyPlantAndEquipmentAccumulatedDepreciation_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfInventoriesDetails" xlink:title="999074 - Disclosure - Schedule of Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureOfInventoriesAbstract" xlink:label="loc_BMGLDisclosureOfInventoriesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="loc_ifrs-fullInventories" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfInventoriesAbstract" xlink:to="loc_ifrs-fullInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="loc_ifrs-fullCostOfInventoriesRecognisedAsExpenseDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureOfInventoriesAbstract" xlink:to="loc_ifrs-fullCostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails" xlink:title="999075 - Disclosure - Schedule of trade and other receivables (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ThridPartiesMember" xlink:label="loc_BMGLThridPartiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLThridPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-fullCurrentTradeReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentTradeReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-fullCurrentTradeReceivables_2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentTradeReceivables_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AllowanceForExpectedCreditLoss" xlink:label="loc_BMGLAllowanceForExpectedCreditLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAllowanceForExpectedCreditLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-fullTradeReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="loc_ifrs-fullLongtermDeposits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLongtermDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments" xlink:label="loc_ifrs-fullPrepayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullPrepayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails" xlink:title="999076 - Disclosure - Schedule of movement in allowance for expected credit losses (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AllowanceForExpectedCreditLoss" xlink:label="loc_BMGLAllowanceForExpectedCreditLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_BMGLAllowanceForExpectedCreditLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionAllowanceForExpectedCreditLosses" xlink:label="loc_BMGLAdditionAllowanceForExpectedCreditLosses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_BMGLAdditionAllowanceForExpectedCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ReversalOfAllowanceForExpectedCreditLosses" xlink:label="loc_BMGLReversalOfAllowanceForExpectedCreditLosses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_BMGLReversalOfAllowanceForExpectedCreditLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AllowanceForExpectedCreditLoss" xlink:label="loc_BMGLAllowanceForExpectedCreditLoss_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_BMGLAllowanceForExpectedCreditLoss_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative" xlink:title="999077 - Disclosure - Trade and other receivables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherReceivablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CustodianServicesMember" xlink:label="loc_BMGLCustodianServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLCustodianServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="loc_ifrs-fullLongtermDeposits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLongtermDeposits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999078 - Disclosure - Schedule of cash and cash equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureCashAndCashEquivalentsAbstract" xlink:label="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_ifrs-fullCashOnHand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BalancesWithBanks" xlink:label="loc_ifrs-fullBalancesWithBanks" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_ifrs-fullBalancesWithBanks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails" xlink:title="999079 - Disclosure - Schedule of amount due from related party (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" xlink:label="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DirectorsMember" xlink:label="loc_BMGLDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OthersRelatedPartiesMember" xlink:label="loc_BMGLOthersRelatedPartiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLOthersRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative" xlink:title="999080 - Disclosure - Amount due from/to related parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract" xlink:label="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureAmountsDueFromToRelatedPartyAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_RainforestCapitalVCCMember" xlink:label="loc_BMGLRainforestCapitalVCCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLRainforestCapitalVCCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember" xlink:label="loc_BMGLDrKevinYipAndSingmedInvestmentPteLtdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLDrKevinYipAndSingmedInvestmentPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DrKevinYipMember" xlink:label="loc_BMGLDrKevinYipMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_BMGLDrKevinYipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" xlink:label="loc_ifrs-fullMeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullMeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" xlink:label="loc_ifrs-fullSettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullSettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashPaidOnClosingInitialSettlement" xlink:label="loc_BMGLCashPaidOnClosingInitialSettlement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCashPaidOnClosingInitialSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare" xlink:label="loc_BMGLPercentageOfProvisionalConsiderationAmountForTransferOfShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPercentageOfProvisionalConsiderationAmountForTransferOfShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansAndAdvances" xlink:label="loc_ifrs-fullLoansAndAdvances" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansAndAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-fullWagesAndSalaries" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullWagesAndSalaries" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-fullOtherPayables" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:label="loc_ifrs-fullAmountsReceivableRelatedPartyTransactions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullAmountsReceivableRelatedPartyTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReceivablesDueFromAssociates" xlink:label="loc_ifrs-fullReceivablesDueFromAssociates" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullReceivablesDueFromAssociates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashReceivedToFullySettleRelatedPartyReceivables" xlink:label="loc_BMGLCashReceivedToFullySettleRelatedPartyReceivables" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCashReceivedToFullySettleRelatedPartyReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfBorrowingsDetails" xlink:title="999081 - Disclosure - Schedule of borrowings (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="loc_BMGLDisclosureBorrowingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CurrentPortionOfBorrowingsAbstract" xlink:label="loc_BMGLCurrentPortionOfBorrowingsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_BMGLCurrentPortionOfBorrowingsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="loc_ifrs-fullBankOverdraftsClassifiedAsCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullBankOverdraftsClassifiedAsCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BankBorrowings" xlink:label="loc_BMGLBankBorrowings" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_BMGLBankBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="loc_ifrs-fullShorttermBorrowings" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullShorttermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract" xlink:label="loc_ifrs-fullNoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullNoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:label="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="loc_ifrs-fullLongtermBorrowings" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullLongtermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="loc_ifrs-fullCurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullCurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails" xlink:title="999082 - Disclosure - Schedule of breakdown borrowings (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="loc_BMGLDisclosureBorrowingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanOneMember" xlink:label="loc_BMGLTermLoanOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwoMember" xlink:label="loc_BMGLTermLoanTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanThreeMember" xlink:label="loc_BMGLTermLoanThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanFourMember" xlink:label="loc_BMGLTermLoanFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSixMember" xlink:label="loc_BMGLTermLoanSixMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSevenMember" xlink:label="loc_BMGLTermLoanSevenMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanNineMember" xlink:label="loc_BMGLTermLoanNineMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenMember" xlink:label="loc_BMGLTermLoanTenMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenMember" xlink:label="loc_BMGLTermLoanElevenMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwelveMember" xlink:label="loc_BMGLTermLoanTwelveMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanMember" xlink:label="loc_BMGLTermLoanMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LoansReceived" xlink:label="loc_ifrs-fullLoansReceived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansReceived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails" xlink:title="999083 - Disclosure - Schedule of details borrowings (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="loc_BMGLDisclosureBorrowingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialInstrumentsTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanOneMember" xlink:label="loc_BMGLTermLoanOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwoMember" xlink:label="loc_BMGLTermLoanTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanThreeMember" xlink:label="loc_BMGLTermLoanThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanFourMember" xlink:label="loc_BMGLTermLoanFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSixMember" xlink:label="loc_BMGLTermLoanSixMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanSevenMember" xlink:label="loc_BMGLTermLoanSevenMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanNineMember" xlink:label="loc_BMGLTermLoanNineMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenMember" xlink:label="loc_BMGLTermLoanTenMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenOneMember" xlink:label="loc_BMGLTermLoanTenOneMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenTwoMember" xlink:label="loc_BMGLTermLoanTenTwoMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenThreeMember" xlink:label="loc_BMGLTermLoanTenThreeMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTenFourMember" xlink:label="loc_BMGLTermLoanTenFourMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTenFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenMember" xlink:label="loc_BMGLTermLoanElevenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanElevenOneMember" xlink:label="loc_BMGLTermLoanElevenOneMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanElevenOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TermLoanTwelveMember" xlink:label="loc_BMGLTermLoanTwelveMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsDomain" xlink:to="loc_BMGLTermLoanTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="loc_ifrs-fullBorrowingsMaturity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsMaturity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails" xlink:title="999084 - Disclosure - Schedule of reconciliation of liabilities arising from financing activities (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureBorrowingsAbstract" xlink:label="loc_BMGLDisclosureBorrowingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:label="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureBorrowingsAbstract" xlink:to="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="loc_ifrs-fullLeaseLiabilitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="loc_ifrs-fullLeaseLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="loc_ifrs-fullShorttermBorrowingsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="loc_ifrs-fullShorttermBorrowingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:label="loc_ifrs-fullAssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="loc_ifrs-fullAssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="loc_ifrs-fullCashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="loc_ifrs-fullProceedsFromCurrentBorrowings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromCurrentBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullIncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" xlink:label="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" xlink:label="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" xlink:label="loc_BMGLCashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="loc_ifrs-fullProceedsFromNoncurrentBorrowings" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromNoncurrentBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" xlink:label="loc_BMGLIncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" xlink:label="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" xlink:label="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLOtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BankBorrowings" xlink:label="loc_BMGLBankBorrowings" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLBankBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionBankBorrowingsCurrent" xlink:label="loc_BMGLAdditionBankBorrowingsCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAdditionBankBorrowingsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BankBorrowings" xlink:label="loc_BMGLBankBorrowings_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLBankBorrowings_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:label="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AdditionBankBorrowingsNonCurrent" xlink:label="loc_BMGLAdditionBankBorrowingsNonCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAdditionBankBorrowingsNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived" xlink:label="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncurrentPortionOfNoncurrentSecuredBankLoansReceived_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullProceedsFromBorrowingsClassifiedAsFinancingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" xlink:label="loc_BMGLIncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" xlink:label="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLIncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="loc_ifrs-fullLiabilitiesArisingFromFinancingActivities_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLiabilitiesArisingFromFinancingActivities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails" xlink:title="999085 - Disclosure - Schedule of trade and other payables (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToTradeSuppliers" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToTradeSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-fullAccruals" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxPayables" xlink:label="loc_ifrs-fullValueAddedTaxPayables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullValueAddedTaxPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-fullOtherPayables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullOtherPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative" xlink:title="999086 - Disclosure - Trade and other payables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TradePayablesMaturity" xlink:label="loc_BMGLTradePayablesMaturity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_BMGLTradePayablesMaturity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ShareCapitalDetailsNarrative" xlink:title="999087 - Disclosure - Share capital (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureShareCapitalAbstract" xlink:label="loc_BMGLDisclosureShareCapitalAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureShareCapitalAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="loc_ifrs-fullComponentsOfEquityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullComponentsOfEquityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InitialPublicOfferingMember" xlink:label="loc_BMGLInitialPublicOfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_BMGLInitialPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_OverAllotmentOptionsMember" xlink:label="loc_BMGLOverAllotmentOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityDomain" xlink:to="loc_BMGLOverAllotmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="loc_ifrs-fullNumberOfSharesAuthorised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesAuthorised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ValueOfSharesAuthorised" xlink:label="loc_BMGLValueOfSharesAuthorised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLValueOfSharesAuthorised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails" xlink:title="999088 - Disclosure - Schedule of amounts recognized in profit or loss (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLeasesAbstract" xlink:label="loc_BMGLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="loc_ifrs-fullDepreciationRightofuseAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_ifrs-fullDepreciationRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="loc_ifrs-fullExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_ifrs-fullExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" xlink:label="loc_ifrs-fullAmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_ifrs-fullAmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/LeasesDetailsNarrative" xlink:title="999089 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureLeasesAbstract" xlink:label="loc_BMGLDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureLeasesAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MachineryMember" xlink:label="loc_ifrs-fullMachineryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentDomain" xlink:to="loc_ifrs-fullMachineryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LeaseTermOfContract" xlink:label="loc_BMGLLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="loc_ifrs-fullWeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-fullCashOutflowForLeases" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashOutflowForLeases" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails" xlink:title="999090 - Disclosure - Schedule of transactions with related parties (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:label="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartiesMember" xlink:label="loc_ifrs-fullRelatedPartiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesDomain" xlink:to="loc_ifrs-fullRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InterestIncomeOnLoansAndReceivable" xlink:label="loc_BMGLInterestIncomeOnLoansAndReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInterestIncomeOnLoansAndReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ManagementFee" xlink:label="loc_BMGLManagementFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLManagementFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails" xlink:title="999091 - Disclosure - Schedule of compensation of key management personnel (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureRelatedPartyTransactionsAbstract" xlink:label="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-fullWagesAndSalaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullWagesAndSalaries" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CentralProvidentFund" xlink:label="loc_BMGLCentralProvidentFund" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_BMGLCentralProvidentFund" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails" xlink:title="999092 - Disclosure - Schedule of fair value of identifiable assets and liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:label="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullIdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullIdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullDeferredTaxAssetsRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentRecognisedAsOfAcquisitionDate" xlink:label="loc_BMGLInvestmentRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_BMGLInvestmentRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullInventoryRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullInventoryRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="loc_ifrs-fullFairValueOfAcquiredReceivables" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullFairValueOfAcquiredReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullCashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_BMGLLeaseLiabilitiesRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_BMGLLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullBorrowingsRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullBorrowingsRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullTradeAndOtherPayablesRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullTradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueRecognisedAsOfAcquisitionDate" xlink:label="loc_BMGLAmountDueRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_BMGLAmountDueRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullGoodwillRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullGoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossOfCombinedEntity" xlink:label="loc_ifrs-fullProfitLossOfCombinedEntity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullProfitLossOfCombinedEntity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative" xlink:title="999093 - Disclosure - Impairment loss on goodwill (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureImpairmentLossOnGoodwillAbstract" xlink:label="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashTransferred" xlink:label="loc_ifrs-fullCashTransferred" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullCashTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossOfCombinedEntity" xlink:label="loc_ifrs-fullProfitLossOfCombinedEntity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullProfitLossOfCombinedEntity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="loc_ifrs-fullRevenueOfAcquiree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullRevenueOfAcquiree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossOfAcquiree" xlink:label="loc_ifrs-fullProfitLossOfAcquiree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureImpairmentLossOnGoodwillAbstract" xlink:to="loc_ifrs-fullProfitLossOfAcquiree" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails" xlink:title="999094 - Disclosure - Schedule of group&#8217;s current credit risk grading framework (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementTable" xlink:label="loc_BMGLIfrsStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_BMGLIfrsStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryAxis" xlink:label="loc_BMGLCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementTable" xlink:to="loc_BMGLCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryDomain" xlink:label="loc_BMGLCategoryDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryAxis" xlink:to="loc_BMGLCategoryDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryOneMember" xlink:label="loc_BMGLCategoryOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryTwoMember" xlink:label="loc_BMGLCategoryTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryThreeMember" xlink:label="loc_BMGLCategoryThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryFourMember" xlink:label="loc_BMGLCategoryFourMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DescriptionOfCreditRisk" xlink:label="loc_BMGLDescriptionOfCreditRisk" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLDescriptionOfCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_BasisForRecognizingExpectedCreditLoss" xlink:label="loc_BMGLBasisForRecognizingExpectedCreditLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLBasisForRecognizingExpectedCreditLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails" xlink:title="999095 - Disclosure - Schedule of financial assets, minimum exposure to credit risk (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-fullBusinessCombinationsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullBusinessCombinationsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain" xlink:label="loc_ifrs-fullBusinessCombinationsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullBusinessCombinationsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="loc_ifrs-fullGrossCarryingAmountMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBusinessCombinationsDomain" xlink:to="loc_ifrs-fullGrossCarryingAmountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AllowanceForCreditLossesMember" xlink:label="loc_ifrs-fullAllowanceForCreditLossesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBusinessCombinationsDomain" xlink:to="loc_ifrs-fullAllowanceForCreditLossesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBusinessCombinationsDomain" xlink:to="loc_ifrs-fullCarryingAmountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryAxis" xlink:label="loc_BMGLCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_BMGLCategoryAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryDomain" xlink:label="loc_BMGLCategoryDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryAxis" xlink:to="loc_BMGLCategoryDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CategoryOneMember" xlink:label="loc_BMGLCategoryOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLCategoryDomain" xlink:to="loc_BMGLCategoryOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-fullTypesOfRisksAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullTypesOfRisksAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-fullTypesOfRisksDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfRisksAxis" xlink:to="loc_ifrs-fullTypesOfRisksDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LifeTimeExpectedCreditLossMember" xlink:label="loc_BMGLLifeTimeExpectedCreditLossMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfRisksDomain" xlink:to="loc_BMGLLifeTimeExpectedCreditLossMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TwelveExpectedCreditLossMember" xlink:label="loc_BMGLTwelveExpectedCreditLossMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfRisksDomain" xlink:to="loc_BMGLTwelveExpectedCreditLossMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditRiskTradeReceivables" xlink:label="loc_BMGLCreditRiskTradeReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCreditRiskTradeReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="loc_ifrs-fullLongtermDeposits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullLongtermDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ExpectedCreditLosses" xlink:label="loc_BMGLExpectedCreditLosses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLExpectedCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfCreditRiskDetails" xlink:title="999096 - Disclosure - Schedule of credit risk (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="loc_ifrs-fullDisclosureOfProvisionMatrixTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfProvisionMatrixTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfProvisionMatrixTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PastDueStatusAxis" xlink:label="loc_ifrs-fullPastDueStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfProvisionMatrixTable" xlink:to="loc_ifrs-fullPastDueStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PastDueStatusDomain" xlink:label="loc_ifrs-fullPastDueStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPastDueStatusAxis" xlink:to="loc_ifrs-fullPastDueStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NotPastDueMember" xlink:label="loc_BMGLNotPastDueMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_BMGLNotPastDueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:label="loc_ifrs-fullLaterThanOneMonthAndNotLaterThanTwoMonthsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_ifrs-fullLaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember" xlink:label="loc_BMGLLaterThanTwoMonthsAndNotLaterThanFourMonthsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_BMGLLaterThanTwoMonthsAndNotLaterThanFourMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFourMonthsMember" xlink:label="loc_ifrs-fullLaterThanFourMonthsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_ifrs-fullLaterThanFourMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-fullLaterThanOneYearMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPastDueStatusDomain" xlink:to="loc_ifrs-fullLaterThanOneYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="loc_ifrs-fullTypesOfRisksAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfProvisionMatrixTable" xlink:to="loc_ifrs-fullTypesOfRisksAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="loc_ifrs-fullTypesOfRisksDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfRisksAxis" xlink:to="loc_ifrs-fullTypesOfRisksDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="loc_ifrs-fullCreditRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfRisksDomain" xlink:to="loc_ifrs-fullCreditRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedCreditLossRate" xlink:label="loc_ifrs-fullExpectedCreditLossRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedCreditLossRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="loc_ifrs-fullTradeReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ExpectedCreditLosses" xlink:label="loc_BMGLExpectedCreditLosses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLExpectedCreditLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CreditRiskTradeReceivables" xlink:label="loc_BMGLCreditRiskTradeReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLCreditRiskTradeReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails" xlink:title="999097 - Disclosure - Schedule of remaining contractual undiscounted repayment obligations (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-fullMaturityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_ifrs-fullMaturityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="loc_ifrs-fullMaturityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullMaturityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember" xlink:label="loc_ifrs-fullCarryingAmountMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_ifrs-fullCarryingAmountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_ContractualCashFlowsMember" xlink:label="loc_BMGLContractualCashFlowsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_BMGLContractualCashFlowsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-fullNotLaterThanOneYearMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_ifrs-fullNotLaterThanOneYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="loc_ifrs-fullLaterThanOneYearMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityDomain" xlink:to="loc_ifrs-fullLaterThanOneYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalUndiscountedFinancialAssets" xlink:label="loc_BMGLTotalUndiscountedFinancialAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLTotalUndiscountedFinancialAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAmountDueToFormerDirector" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalNetUndiscountedFinancialAssetsliabilities" xlink:label="loc_BMGLTotalNetUndiscountedFinancialAssetsliabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLTotalNetUndiscountedFinancialAssetsliabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative" xlink:title="999098 - Disclosure - Financial risk management (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialRiskManagementAbstract" xlink:label="loc_BMGLDisclosureFinancialRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullTopOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullBottomOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PercentageOfTradeReceivables" xlink:label="loc_BMGLPercentageOfTradeReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLPercentageOfTradeReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails" xlink:title="999099 - Disclosure - Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)">
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_DisclosureFinancialInstrumentsAbstract" xlink:label="loc_BMGLDisclosureFinancialInstrumentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLDisclosureFinancialInstrumentsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialAssetsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAxis" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="loc_ifrs-fullFinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsDomain" xlink:to="loc_ifrs-fullFinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherReceivablesDueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_TotalUndiscountedFinancialAssets" xlink:label="loc_BMGLTotalUndiscountedFinancialAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLTotalUndiscountedFinancialAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_AmountDueToFormerDirector" xlink:label="loc_BMGLAmountDueToFormerDirector" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLAmountDueToFormerDirector" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:label="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullDerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative" xlink:title="999100 - Disclosure - Events occurring after the reporting period (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_IfrsStatementLineItems" xlink:label="loc_BMGLIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_BMGLIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="loc_ifrs-fullCounterpartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCNovenaPteLtdMember" xlink:label="loc_BMGLSSOCNovenaPteLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCNovenaPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCOrchardPteLtdMember" xlink:label="loc_BMGLSSOCOrchardPteLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCOrchardPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_SSOCFarrerParkPteLtdMember" xlink:label="loc_BMGLSSOCFarrerParkPteLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLSSOCFarrerParkPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_PharmaAvenuePteLtdMember" xlink:label="loc_BMGLPharmaAvenuePteLtdMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLPharmaAvenuePteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_EyetrustMedicalPteLtdMember" xlink:label="loc_BMGLEyetrustMedicalPteLtdMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLEyetrustMedicalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_CharteredImagingPteLtdMember" xlink:label="loc_BMGLCharteredImagingPteLtdMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesDomain" xlink:to="loc_BMGLCharteredImagingPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_NonadjustingEventsAfterReportingPeriodMember" xlink:label="loc_BMGLNonadjustingEventsAfterReportingPeriodMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodDomain" xlink:to="loc_BMGLNonadjustingEventsAfterReportingPeriodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="loc_ifrs-fullRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeDomain" xlink:to="loc_ifrs-fullTopOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsPercentage" xlink:label="loc_BMGLInvestmentsPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInvestmentsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsSalePercentage" xlink:label="loc_BMGLInvestmentsSalePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInvestmentsSalePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bmgl-20250630.xsd#BMGL_InvestmentsHoldPercentage" xlink:label="loc_BMGLInvestmentsHoldPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_BMGLInvestmentsHoldPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-fullNetDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BMGLIfrsStatementLineItems" xlink:to="loc_ifrs-fullNetDebt" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Basel
Medical Group Ltd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002004489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6
Napier Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Unit
#02-10/11 Gleneagles Medical Centre<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">258499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
    shares with no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMGL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">18,785,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">NLA
DFK Assurance PAC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">6889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6
Napier Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Unit
#02-10/11 Gleneagles Medical Centre<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">258499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dr.
Darren Yen Feng Chhoa<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">contact@baselmedical.com<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Profit or Loss<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 8,900,027<span></span>
</td>
<td class="nump">$ 11,319,944<span></span>
</td>
<td class="nump">$ 10,050,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other income</a></td>
<td class="nump">866,580<span></span>
</td>
<td class="nump">1,102,203<span></span>
</td>
<td class="nump">461,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses', window );">Consumables, medical supplies and other related expenses</a></td>
<td class="num">(1,986,201)<span></span>
</td>
<td class="num">(2,526,250)<span></span>
</td>
<td class="num">(2,248,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee benefit expenses</a></td>
<td class="num">(5,030,217)<span></span>
</td>
<td class="num">(6,397,933)<span></span>
</td>
<td class="num">(3,638,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation expense</a></td>
<td class="num">(928,633)<span></span>
</td>
<td class="num">(1,181,128)<span></span>
</td>
<td class="num">(528,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rent expense</a></td>
<td class="num">(110,917)<span></span>
</td>
<td class="num">(141,075)<span></span>
</td>
<td class="num">(3,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating expense</a></td>
<td class="num">(2,619,403)<span></span>
</td>
<td class="num">(3,331,619)<span></span>
</td>
<td class="num">(1,512,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLoss', window );">Impairment loss on goodwill</a></td>
<td class="num">(8,763,025)<span></span>
</td>
<td class="num">(11,145,691)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost</a></td>
<td class="num">(160,349)<span></span>
</td>
<td class="num">(203,948)<span></span>
</td>
<td class="num">(176,238)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">(Loss)/Profit before tax</a></td>
<td class="num">(9,832,138)<span></span>
</td>
<td class="num">(12,505,497)<span></span>
</td>
<td class="nump">2,404,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">328,165<span></span>
</td>
<td class="nump">417,393<span></span>
</td>
<td class="num">(331,761)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">(Loss)/Profit after tax</a></td>
<td class="num">(9,503,974)<span></span>
</td>
<td class="num">(12,088,104)<span></span>
</td>
<td class="nump">2,072,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ProfitLossAndNetComprehensiveIncome', window );">(Loss)/Profit for the year, representing total comprehensive income for the year</a></td>
<td class="num">(9,503,974)<span></span>
</td>
<td class="num">(12,088,104)<span></span>
</td>
<td class="nump">2,072,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>(Loss)/Profit attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(9,503,580)<span></span>
</td>
<td class="num">(12,087,603)<span></span>
</td>
<td class="nump">2,072,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ProfitLossIncludingMinorityInterest', window );">(Loss)/Profit for the year</a></td>
<td class="num">$ (9,503,974)<span></span>
</td>
<td class="num">$ (12,088,104)<span></span>
</td>
<td class="nump">$ 2,072,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic | (per share)</a></td>
<td class="num">$ (0.506)<span></span>
</td>
<td class="num">$ (0.643)<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted | (per share)</a></td>
<td class="num">$ (0.506)<span></span>
</td>
<td class="num">$ (0.643)<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Basic</a></td>
<td class="nump">18,785,750<span></span>
</td>
<td class="nump">18,785,750<span></span>
</td>
<td class="nump">16,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Diluted</a></td>
<td class="nump">18,785,750<span></span>
</td>
<td class="nump">18,785,750<span></span>
</td>
<td class="nump">16,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consumables medical supplies and other related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ProfitLossAndNetComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss and net comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ProfitLossAndNetComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ProfitLossIncludingMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss including minority interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ProfitLossIncludingMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 130<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_130_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 130<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_130_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use-assets</a></td>
<td class="nump">$ 2,497,462<span></span>
</td>
<td class="nump">$ 3,176,522<span></span>
</td>
<td class="nump">$ 23,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">218,183<span></span>
</td>
<td class="nump">277,507<span></span>
</td>
<td class="nump">34,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">221,702<span></span>
</td>
<td class="nump">281,982<span></span>
</td>
<td class="nump">77,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Investment in associate</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total Non-current assets</a></td>
<td class="nump">2,937,386<span></span>
</td>
<td class="nump">3,736,060<span></span>
</td>
<td class="nump">134,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">295,850<span></span>
</td>
<td class="nump">376,291<span></span>
</td>
<td class="nump">72,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,651,065<span></span>
</td>
<td class="nump">9,731,390<span></span>
</td>
<td class="nump">2,005,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DeferredOfferingCost', window );">Deferred offering costs</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">31,798<span></span>
</td>
<td class="nump">1,588,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total Current assets</a></td>
<td class="nump">10,314,145<span></span>
</td>
<td class="nump">13,118,562<span></span>
</td>
<td class="nump">16,173,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">13,251,531<span></span>
</td>
<td class="nump">16,854,622<span></span>
</td>
<td class="nump">16,308,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">1,020,801<span></span>
</td>
<td class="nump">1,298,357<span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">5,435,180<span></span>
</td>
<td class="nump">6,913,006<span></span>
</td>
<td class="nump">2,575,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Borrowings</a></td>
<td class="nump">1,667,677<span></span>
</td>
<td class="nump">2,121,119<span></span>
</td>
<td class="nump">2,706,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Amount due to related parties</a></td>
<td class="nump">1,291,453<span></span>
</td>
<td class="nump">1,642,599<span></span>
</td>
<td class="nump">1,311,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">111,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Asset retirement obligation</a></td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">443,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,426,906<span></span>
</td>
<td class="nump">11,990,081<span></span>
</td>
<td class="nump">8,746,903<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">NET ASSETS</a></td>
<td class="nump">3,824,625<span></span>
</td>
<td class="nump">4,864,541<span></span>
</td>
<td class="nump">7,561,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Capital attributable to equity holders of the Group</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">25,609,109<span></span>
</td>
<td class="nump">34,208,562<span></span>
</td>
<td class="nump">24,455,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_MergerReserveArisingFromGroupRestructuring', window );">Merger reserve arising from group restructuring</a></td>
<td class="num">(18,362,500)<span></span>
</td>
<td class="num">(24,455,170)<span></span>
</td>
<td class="num">(24,455,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained earnings</a></td>
<td class="num">(3,836,948)<span></span>
</td>
<td class="num">(4,396,611)<span></span>
</td>
<td class="nump">7,561,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="nump">2,751<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Translation reserve</a></td>
<td class="nump">412,213<span></span>
</td>
<td class="num">(495,739)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">3,824,625<span></span>
</td>
<td class="nump">4,864,541<span></span>
</td>
<td class="nump">7,561,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_RelatedPartiesMember', window );">Total for all related parties [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Amount due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,557,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AmountDueToFormerDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to former director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AmountDueToFormerDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DeferredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DeferredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_MergerReserveArisingFromGroupRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger reserve arising from group restructuring.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_MergerReserveArisingFromGroupRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Total for all associates [member]; Total for all joint ventures [member]; Total for all subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_RelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_RelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes In Shareholders' Equity<br></strong></div></th>
<th class="th">
<div>Issued capital [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Issued capital [member] </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Merger reserve [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Merger reserve [member] </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Translation reserve [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Translation reserve [member] </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Retained earnings [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Retained earnings [member] </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Equity attributable to owners of parent [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Equity attributable to owners of parent [member] </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Non-controlling interests [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Non-controlling interests [member] </div>
<div>SGD ($)</div>
</th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>SGD ($)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,488,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,488,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,455,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,455,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve', window );">Merger reserve arising from group restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,455,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,455,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit/(Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072,800<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 18,362,506<span></span>
</td>
<td class="nump">24,455,178<span></span>
</td>
<td class="num">$ (18,362,500)<span></span>
</td>
<td class="num">(24,455,170)<span></span>
</td>
<td class="num">$ (8,686)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,588,403<span></span>
</td>
<td class="nump">7,561,633<span></span>
</td>
<td class="nump">$ 5,579,723<span></span>
</td>
<td class="nump">$ 7,561,641<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,579,723<span></span>
</td>
<td class="nump">7,561,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="nump">7,246,603<span></span>
</td>
<td class="nump">9,753,384<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,246,603<span></span>
</td>
<td class="nump">9,753,384<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,246,603<span></span>
</td>
<td class="nump">9,753,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">420,899<span></span>
</td>
<td class="num">(495,739)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,860<span></span>
</td>
<td class="nump">420,899<span></span>
</td>
<td class="num">(465,879)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">420,899<span></span>
</td>
<td class="num">(465,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment reserve</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,623<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">78,623<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78,623<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_MinorityInterestInSubsidiary', window );">Non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,751<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTax', window );">Loss for the year, representing total comprehensive income for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,503,974)<span></span>
</td>
<td class="num">(12,088,104)<span></span>
</td>
<td class="num">(9,503,974)<span></span>
</td>
<td class="num">(12,088,104)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,503,974)<span></span>
</td>
<td class="num">(12,088,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit/(Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,503,974)<span></span>
</td>
<td class="num">(12,088,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 25,609,109<span></span>
</td>
<td class="nump">$ 34,208,562<span></span>
</td>
<td class="num">$ (18,362,500)<span></span>
</td>
<td class="num">$ (24,455,170)<span></span>
</td>
<td class="nump">$ 412,213<span></span>
</td>
<td class="num">$ (495,739)<span></span>
</td>
<td class="num">$ (3,836,948)<span></span>
</td>
<td class="num">$ (4,396,611)<span></span>
</td>
<td class="nump">$ 3,821,874<span></span>
</td>
<td class="nump">$ 4,861,042<span></span>
</td>
<td class="nump">$ 2,751<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 3,824,625<span></span>
</td>
<td class="nump">$ 4,864,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_MinorityInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest in subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_MinorityInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transfers to a statutory reserve. [Refer: Statutory reserve]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">(Loss)/Profit before tax</a></td>
<td class="num">$ (9,832,138)<span></span>
</td>
<td class="num">$ (12,505,497)<span></span>
</td>
<td class="nump">$ 2,404,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff', window );">Bad debts written off</a></td>
<td class="nump">189,013<span></span>
</td>
<td class="nump">240,405<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CreditLossExpenseReversal', window );">Reversal of estimated credit losses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Provision for estimated credit losses</a></td>
<td class="num">(536,404)<span></span>
</td>
<td class="num">(682,252)<span></span>
</td>
<td class="nump">50,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of property and equipment</a></td>
<td class="nump">84,644<span></span>
</td>
<td class="nump">107,659<span></span>
</td>
<td class="nump">30,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AdjustmentsForAmortizationOfRightOfUseAsset', window );">Amortisation of right-of-use assets</a></td>
<td class="nump">843,989<span></span>
</td>
<td class="nump">1,073,469<span></span>
</td>
<td class="nump">498,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets', window );">Loss on written off fixed asset</a></td>
<td class="nump">138,549<span></span>
</td>
<td class="nump">176,220<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Impairment loss on goodwill</a></td>
<td class="nump">8,763,025<span></span>
</td>
<td class="nump">11,145,691<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForInterestExpense', window );">Interest expense</a></td>
<td class="nump">160,349<span></span>
</td>
<td class="nump">203,948<span></span>
</td>
<td class="nump">176,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flows before changes in working capital</a></td>
<td class="num">(188,973)<span></span>
</td>
<td class="num">(240,357)<span></span>
</td>
<td class="nump">3,103,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="num">(239,218)<span></span>
</td>
<td class="num">(304,261)<span></span>
</td>
<td class="nump">22,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Trade and other receivables</a></td>
<td class="num">(5,727,120)<span></span>
</td>
<td class="num">(7,284,324)<span></span>
</td>
<td class="num">(415,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Trade and other payables</a></td>
<td class="nump">3,409,904<span></span>
</td>
<td class="nump">4,337,057<span></span>
</td>
<td class="nump">387,690<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash (used in)/ generated from operations</a></td>
<td class="num">(2,745,407)<span></span>
</td>
<td class="num">(3,491,885)<span></span>
</td>
<td class="nump">3,099,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(509,704)<span></span>
</td>
<td class="num">(648,292)<span></span>
</td>
<td class="num">(176,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="num">(160,349)<span></span>
</td>
<td class="num">(203,948)<span></span>
</td>
<td class="num">(413,612)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash (used in)/generated from operating activities</a></td>
<td class="num">(3,415,460)<span></span>
</td>
<td class="num">(4,344,125)<span></span>
</td>
<td class="nump">2,509,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment</a></td>
<td class="num">(43,054)<span></span>
</td>
<td class="num">(54,760)<span></span>
</td>
<td class="num">(7,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisition of new subsidiary</a></td>
<td class="num">(8,637,578)<span></span>
</td>
<td class="num">(10,986,135)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentProperty', window );">(Increase) in investment in associate</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash provided by/ (used in) investing activities</a></td>
<td class="num">(8,680,671)<span></span>
</td>
<td class="num">(11,040,944)<span></span>
</td>
<td class="num">(7,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ProceedsFromDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">1,223,544<span></span>
</td>
<td class="nump">1,556,226<span></span>
</td>
<td class="num">(1,588,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DecreaseInAmountDueFromDirector', window );">Decrease in amount due from a director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,320,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseInAmountDueToRelatedParties', window );">Increase in amount due to related parties</a></td>
<td class="nump">260,405<span></span>
</td>
<td class="nump">331,209<span></span>
</td>
<td class="nump">1,311,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties', window );">Decrease/(Increase) in amount due from related parties</a></td>
<td class="nump">8,300,370<span></span>
</td>
<td class="nump">10,557,240<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseInBankOverdraft', window );">Increase in bank overdraft</a></td>
<td class="nump">48,251<span></span>
</td>
<td class="nump">61,371<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceeds from borrowings</a></td>
<td class="nump">3,144,901<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of principal portion of lease liabilities</a></td>
<td class="num">(771,556)<span></span>
</td>
<td class="num">(981,342)<span></span>
</td>
<td class="num">(566,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="num">(6,495,235)<span></span>
</td>
<td class="num">(8,261,290)<span></span>
</td>
<td class="num">(2,356,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DecreaseincreaseInAmountDueToFormerDirector', window );">(Decrease)/Increase in amount due to former director</a></td>
<td class="num">(87,632)<span></span>
</td>
<td class="num">(111,459)<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests', window );">Non-controlling interest contributions</a></td>
<td class="nump">2,751<span></span>
</td>
<td class="nump">3,499<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Share issuance</a></td>
<td class="nump">7,668,358<span></span>
</td>
<td class="nump">9,753,384<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash generated from/(used in) financing activities</a></td>
<td class="nump">13,294,157<span></span>
</td>
<td class="nump">16,908,838<span></span>
</td>
<td class="num">(1,767,760)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">1,198,026<span></span>
</td>
<td class="nump">1,523,769<span></span>
</td>
<td class="nump">733,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of financial period</a></td>
<td class="nump">1,533,967<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="nump">1,217,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of currency translation on cash and cash equivalents</a></td>
<td class="num">(389,763)<span></span>
</td>
<td class="num">(495,739)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of financial year</a></td>
<td class="nump">$ 2,342,230<span></span>
</td>
<td class="nump">$ 2,979,083<span></span>
</td>
<td class="nump">$ 1,951,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AdjustmentsForAmortizationOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortization of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AdjustmentsForAmortizationOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit loss expense reversal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DecreaseInAmountDueFromDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in amount due from director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DecreaseInAmountDueFromDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DecreaseincreaseInAmountDueToFormerDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease increase in amount due to former director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DecreaseincreaseInAmountDueToFormerDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in non cash working capital abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseInAmountDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in amount due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseInAmountDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseInBankOverdraft">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in bank overdraft.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseInBankOverdraft</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ProceedsFromDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ProceedsFromDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recoveries on loans previously written off fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss on goodwill recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Goodwill; Impairment loss; Impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from advances and loans from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investment property. [Refer: Investment property]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the recoveries on loans that were previously written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section B Statement of cash flows for a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_B_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s executive officers oversee the strategic processes to safeguard data and comply with relevant regulations and has overall
responsibility for evaluating cybersecurity risks, as well as related policies and risks in connection with the Company&#8217;s patient
database, suppliers and other service providers. The Company does not currently engage any assessors, consultants, auditors, or other
third parties in connection with any such processes, given the size and scale of the Company, the resources available to it, the anticipated
expenditures, and the risks it faces in terms of cybersecurity. The Company&#8217;s executive officers are responsible for overseeing
and periodically reviewing and identifying risks from cybersecurity threats associated with its use of any third-party service provider.</span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the start of its latest completed fiscal year and up to the date of this annual report, the Company is not aware of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially
affect the registrant, including its business strategy, results of operations, or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_986_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240701__20250630_zZH5ipsVNQRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s board of directors is collectively responsible for oversight of risks from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zUQhdKM1RVea">The Company&#8217;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#8217;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#8217;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#8217;s executive officers will promptly inform, update, and seek the instructions
of the board.</span></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Company&#8217;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#8217;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#8217;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#8217;s executive officers will promptly inform, update, and seek the instructions
of the board.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s board of directors is collectively responsible for oversight of risks from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zUQhdKM1RVea">The Company&#8217;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#8217;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#8217;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#8217;s executive officers will promptly inform, update, and seek the instructions
of the board.</span></span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfChangesInAccountingPoliciesAbstract', window );"><strong>General</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General</a></td>
<td class="text"><p id="xdx_80F_eifrs-full--DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_zC65qhZxHiP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
                                                                                                                                                             <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zBL1s5KWVyBe">General</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basel
Medical Group Ltd. is incorporated and domiciled in British Virgin Islands (BVI) with operations conducted by its fully owned subsidiary,
Basel Medical Group Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.), based in Singapore at 6 Napier Road #03-07 Gleneagles Medical Centre,
Singapore 258499.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal activities of the Company pertain to investment holding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reorganization</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, as part of an internal reorganization, all of the shares in our operating subsidiaries were transferred by our founder,
Dr. Kevin Yip, to Basel Medical Group Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.) Subsequently, in June 2023, Dr. Kevin Yip entered
into an agreement with Rainforest Capital VCC to transfer all the shares he held in Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists
Pte. Ltd.) to Rainforest Capital VCC. Upon completion, Rainforest Capital VCC became the sole shareholder of Basel Medical Group Pte.
Ltd. (F.K.A Singmed Specialists Pte. Ltd.), which holds the shares of all of our subsidiaries. Rainforest Capital VCC is a variable capital
company incorporated in Singapore and is an investment fund managed by AIP Investment Partners Pte. Ltd., a licensed fund manager in
Singapore.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 10, 2023, Basel Medical Group Ltd. was incorporated under the laws of the BVI as our holding Company to facilitate this offering
and the listing of Basel Medical Group Ltd.&#8217;s ordinary shares on Nasdaq, and in connection therewith, Rainforest VCC (an umbrella
fund with multiple sub-funds), through its sub-fund, Basel Medical Fund, subscribed for <span id="xdx_907_ecustom--NumberOfSharesSubscribed_iI_pid_c20230810__ifrs-full--ComponentsOfEquityAxis__custom--OrdinaryShareMember_zx4tpetcKF56" title="Number of shares subscribe">16,250,000</span> ordinary shares in Basel Medical Group
Ltd. amounting to US$<span id="xdx_909_eifrs-full--ProceedsFromIssueOfOrdinaryShares_uUSD_c20230810__20230810_ziTgAO9h8r4e">18,362,500</span> at a subscription price of US$<span id="xdx_90D_eifrs-full--ParValuePerShare_iI_pid_uUSDPShares_c20230810_zxKdq2jIRBce" title="Par value per share">1.13</span> per share. In August 2023, all of the shares in Basel Medical Group
Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.) were transferred to Basel Medical Group Ltd. by Rainforest Capital VCC to prepare for
this listing and offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
between September 2023 and January and April 2024, Rainforest Capital VCC sold certain of the shares it held in Basel Medical Group Ltd.
to certain other investors, following which Rainforest Capital VCC held a total of <span id="xdx_90B_eifrs-full--SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_iI_pid_c20240430__ifrs-full--ComponentsOfEquityAxis__custom--OrdinaryShareMember_zPrG1W62lwVa" title="Number of shares held">12,387,982 </span>ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group were prepared on the basis as if the reorganisation became effective as of the beginning
of the first period presented in the accompanying consolidated financial statements of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eifrs-full--DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_zvthun1QaGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has following subsidiaries as at June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zeoAc06NJlze">Schedule
of activities of subsidiaries</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of entity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>activities</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
    of business and incorporation</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proportion
                                            of ordinary</b></span></p>
                                                                                                                                                                                                                                                          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            held by Group</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 23%; text-align: center"><span id="xdx_902_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zc1BBMfhEro4" title="Name of entity"><span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zNJgHh6AI4Dj" title="Name of entity">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)</span></span></td><td style="text-align: center; width: 2%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-style: normal; width: 25%; font-weight: normal; text-align: center"><span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zdBvBauCsVGg" title="Principal activities"><span id="xdx_90F_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zzFOcucgLfc3" title="Principal activities">Other holding companies</span></span></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 18%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zEwlzLQSSzs5" title="Country of business / incorporation"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_ztcvILYAElq" title="Country of business / incorporation">Singapore</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zltgYElMqL7" title="Ownership percentage">100</span></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_z9bcMuVZrWab" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zOzOyDX03s03" title="Name of entity"><span id="xdx_90F_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zK1XjIDwwyg6" title="Name of entity">Singapore Sports &amp; Orthopaedic Clinic Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zggHx0CDuUkj" title="Principal activities"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zf7sDb0M7y2j" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zXLhuQWSQMki" title="Country of business / incorporation"><span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zWuypqel38i" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_906_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zuhnLnmr1jQ" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zGrdAldIgz43" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90A_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z0XyM9JssMuf" title="Name of entity"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z03jl5uXkGne" title="Name of entity">Singapore Sports &amp; Orthopaedic Services Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zs0LvmA9JQuk" title="Principal activities"><span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z6oqqv8mCxGg" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zY243244fo5i" title="Country of business / incorporation"><span id="xdx_90B_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zhinC50O2bg8" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zS5Ad7cehbb5" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zcwTCZrdaH6f" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zOsl4sc4J3u5" title="Name of entity"><span id="xdx_905_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_z6ILKpDLuAvf" title="Name of entity">SSOC Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zxeaQs8hI2C9" title="Principal activities"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zGpTnKyKVqF2" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zZVrAbsvd5Vb" title="Country of business / incorporation"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zor5f0wkcJki" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zXrspKKGida9" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zWTVjlOy8Km5" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_z12DAYMgkW5g" title="Name of entity"><span id="xdx_906_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zZDzQUcveG27" title="Name of entity">SSOS Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_ztKtziVMD4X" title="Principal activities"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zrIrvPAJmCp8" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90A_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zfmMhjqYiDv1" title="Country of business / incorporation"><span id="xdx_907_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zQcoWaVaenjg" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zpJ3A4fs3j6g" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zkPulwrJ1kPc" title="Ownership percentage">100</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of entity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>activities</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Country
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">business and</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">incorporation</p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proportion
                                            of ordinary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            held by Group</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_za0JX4vZW2ea" title="Name of entity"><span id="xdx_901_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7j4ELHbTVzg" title="Name of entity">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMLArotMAfg6" title="Principal activities"><span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zhGGsa64pb62" title="Principal activities">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7t1hwkMhr7a" title="Country of business / incorporation"><span id="xdx_909_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMUlWcLUNGaj" title="Country of business / incorporation">Singapore</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zuozTzY5mMS4" title="Ownership percentage">100</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zBTjjjM4v6Aa" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zhL15wGo2FK5" title="Name of entity"><span id="xdx_909_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zF22JgZ1SDig" title="Name of entity">Singapore Knee, Sports &amp; Orthopaedic Services Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_900_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zqP7sDJR4V23" title="Principal activities"><span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zIbsDlM7ngif" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90C_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zUbL5K9sCini" title="Country of business / incorporation"><span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zxV2i7KQWzyl" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zY3JPgMM8cj7" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_z0hM1ejPszJ9" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zpFdI0TUDcx3" title="Name of entity"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_z4R9kaqAzQwi" title="Name of entity">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zTxs2Y2CvlX5" title="Principal activities"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zVhIy287sDRb" title="Principal activities">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zcIKhSJZ04Y7" title="Country of business / incorporation"><span id="xdx_906_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zxkKKhZPFVI8" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zz6nw51dbST4" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zQvojkoCY0kb" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZH2ea4faCDi" title="Name of entity"><span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zkI0fpZqUhr6" title="Name of entity">Basel Medflow Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZLgUn3Eh5lh" title="Principal activities"><span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_ziJb3AB8jt3g" title="Principal activities">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zCaVcEFMbzDi" title="Country of business / incorporation"><span id="xdx_90E_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zOaG7nCiOa9h" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zeT4trlE7MCh" title="Ownership percentage">60</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_z5XZTPxD0Xd5" title="Name of entity"><span id="xdx_90E_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zl8nZWrIS3z4" title="Name of entity">Bethesda Medical Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90B_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zdp2H7AmJKxa" title="Principal activities"><span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zcEJL1B7wt2l" title="Principal activities">Clinics and other general medical services (western)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zm4ljxZvbRT6" title="Country of business / incorporation"><span id="xdx_90F_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zHgkJJy0PPIl" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zD7rakTxlHp4" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zPZ6CfUJUr97" title="Name of entity"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zhz8vKyYBJ2c" title="Name of entity">Oasis Medical Clinic Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWJ33wEaTrg9" title="Principal activities"><span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zvRxu6diZxql" title="Principal activities">Clinics and other general medical services (western)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_za40r1XsueIb" title="Country of business / incorporation"><span id="xdx_900_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zOC0OWSKwuIf" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWHW0BmX0go8" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  </table>


<p id="xdx_8A0_z5ckeivur6rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2024, Singmed Specialists Pte. Ltd. changed its corporate name to Basel Medical Group Pte. Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2025, Singapore Sports and Physiotherapy Centre Pte. Ltd. changed its corporate name to Pharma Avenue Pte. Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfChangesInAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfChangesInAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policy information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">Material accounting policy information</a></td>
<td class="text"><p id="xdx_805_eifrs-full--DisclosureOfChangesInAccountingPoliciesExplanatory_zzuAznr5QwX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><b><span id="xdx_828_znF30Q7r0Gva">Material accounting policy information</span></b></td></tr></table>

<p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_zI4sF8qCbosk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><b>2.1</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><b><span id="xdx_86C_z0I5Q3qpuyua">Compliance
                                            with International Financial Reporting Standards (&#8220;IFRS&#8221;)</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;)
and interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS IC&#8221;) applicable to companies reporting under IFRS.
The financial statements comply with IFRS as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared on a going concern basis.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
ability of the Group to continue as going concern is dependent on: (Please refer to Note 26)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of its major shareholder to provide financial support</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of the Group to generate sufficient and sustainable operating profits and cash flows
                                            over the next 12 months from the date of these financial statements to meet its operating
                                            and financial obligations as and when they fall due; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of the Group to procure additional financing and to garner the continuous support
                                            of its existing financiers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_845_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_z8tyN44gZzUj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zaapWlfTeQZ6">New
                                            and amended standards adopted by the Group</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has applied the following amendments for the first time for their annual reporting period commencing July 1, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
                                            of Liabilities as Current or Non-current and Non-current liabilities with covenants &#8211;
                                            Amendments to IAS 1;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
                                            Liability in Sale and Leaseback &#8211; Amendments to IFRS 16; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplier
                                            Finance Arrangements &#8211; Amendments to IAS 7 and IFRS 7.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.</span></p>

<p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_zOSlo6Ziw3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.3</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zw46494mBlR4">New
                                            standards and interpretations not yet adopted</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Certain
new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for June
30, 2025 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected
to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material accounting policy information (Continued)</span></td>
</tr></table>

<p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_z0MFTpCADvNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.4</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zN4EmdCwMtYc">Revenue
                                            from contracts with customers </span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is in the business of providing medical services to patients. Revenue from contracts with customers is recognized when control
of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be
entitled in exchange for those goods or services. Revenue is presented net of goods and services tax, rebates, and discounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the rendering of medical services is recognized at the point in time when the entity satisfies the performance obligation by transferring
a promised good or service to the customer, which is when the customer obtains control of the good or service. This is generally when
the significant acts have been completed, ie, upon the completion of consultations, clinical treatments, medical tests and operations.
The Group considers whether there are other promises in the contract that are separate performance obligations to which a portion of
the transaction price needs to be allocated. The amount of revenue recognized is the amount allocated to the satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
price is the amount of consideration in the contract to which the Group expects to be entitled in exchange for transferring the promised
goods or services. In determining the transaction price for the rendering of medical services the Group considers the effects of variable
consideration. Contracts with customers normally does not include any contractual adjustment such as right of return, volume discount
etc. In rare circumstances where consideration is variable, the Group estimates the amount of consideration to which it will be entitled
in exchange for rendering of service to the customer. The variable consideration is estimated at contract inception and constrained until
it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated
uncertainty with the variable consideration is subsequently resolved.</span></p>

<p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zNlI4GOW3hB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.5</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zjjZCf7gH2k3">Segment
                                            reporting</span></b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the Group&#8217;s internal organizational structure as well as information about geographical
areas, business segments and major clients in the consolidated financial statements for detailing the Group&#8217;s business segments.
Based on the criteria established, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief
Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the
Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. As the Group&#8217;s long-lived assets are substantially located in Singapore, no geographical segments are presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material accounting policy
                                                                                                                                   information (Continued)</span></td>
</tr></table>

<p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForGovernmentGrants_zAuRT15sMxta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.6</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zCgyw8r1jMv5">Government
                                            grants</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
from the government are recognized as a receivable at their fair value when there is reasonable assurance that the grant will be received
and the Group will comply with all the attached conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
grants receivable are recognized as income over the periods necessary to match them with the related costs which they are intended to
compensate, on a systematic basis. Government grants relating to expenses are shown separately as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
grants relating to assets are deducted against the carrying amount of the assets.</span></p>

<p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForBasisOfConsolidation_z38KFzsEqiE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold"><span id="xdx_86D_zk2dNQCWZlJf">Basis of consolidation</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The financial statements
of the subsidiaries used in the preparation of the consolidated financial statements are prepared as of the same reporting date as the
Company. Consistent accounting policies are applied to like transactions and events in similar circumstances.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consolidation
                                            </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed
to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power
over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated
from the date on that control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements, transactions, balances and unrealized gains on transactions between group entities are
eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment indicator of the transferred
asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.
Deferred tax relief on unrealized intra-Group profit is accounted for only to the extent that it is considered recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
interests comprise the portion of a subsidiaries&#8217; net results of operations and its net assets, which is attributable to the interests
that are not owned directly or indirectly by the equity holders of the Group. They are shown separately in the consolidated statement
of profit or loss and other comprehensive income, statement of changes in equity, and statement of financial position. Total comprehensive
income is attributed to the non-controlling interests based on their respective interests in a Subsidiaries, even if this results in
the non-controlling interests having a deficit balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold">Group accounting (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisitions</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition method of accounting is used to account for business combinations entered into by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration transferred for the acquisition of a subsidiary or business comprises the fair value of the assets transferred, the liabilities
incurred and the equity interests issued by the Group. The consideration transferred also includes any contingent consideration arrangement
and any pre-existing equity interest in the subsidiaries measured at their fair values at the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognized in the income statement.
Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. The
part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within
investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition
date is reported within operating cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the consideration transferred, together with the noncontrolling interest, exceeds the fair value of the net assets, liabilities and contingent
liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in
the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is capitalized as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and
associates. Goodwill is denominated in the currency of the operation acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the cost of acquisition is below the Group&#8217;s interest in the net assets acquired, the difference is recognized directly in the
income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold">Group accounting (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
                                            (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisitions
                                            </i>(Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
not all of the equity of a subsidiary is acquired the noncontrolling interest is recognized either at fair value or at the non-controlling
interest&#8217;s share of the net assets of the subsidiary, on a case-by-case basis. Changes in the Group&#8217;s ownership percentage
of subsidiaries are accounted for within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition-related
costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifiable
assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially
at their fair values at the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
an acquisition-by-acquisition basis, the Group recognizes any non-controlling interest in the acquiree at the date of acquisition either
at fair value or at the non-controlling interest&#8217;s proportionate share of the acquiree&#8217;s identifiable net assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
excess of (a) the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair
value of any previous equity interest in the acquiree over the (b) fair value of the identifiable net assets acquired is recorded as
goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disposal</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a change in the Group&#8217;s ownership interest in a subsidiary result in a loss of control over the subsidiary, the assets and liabilities
of the subsidiary including any goodwill are derecognized. Amounts previously recognized in other comprehensive income in respect of
that entity are also reclassified to profit or loss or transferred directly to retained earnings if required by a specific Standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
retained equity interest in the entity is remeasured at fair value. The difference between the carrying amount of the retained interest
at the date when control is lost and its fair value is recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
                                            with non-controlling interests</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in the Group&#8217;s ownership interest in a subsidiary that do not result in a loss of control over the subsidiaries are accounted for
as transactions with equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest
and the fair value of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_zCo3ehzwuvge" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.8</td>
    <td style="font-weight: bold"><span id="xdx_867_zwcwUjFPi41i">Property and equipment</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">All
items of property and equipment are initially recorded at cost. Subsequent to recognition, property and equipment are measured at cost
less accumulated depreciation and any accumulated impairment losses. The cost of property and equipment includes its purchase price and
any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the
manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property and equipment
if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the property and equipment.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zCtkh77xqXQ3">Schedule of expected useful lives for property, plant and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt">Useful lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Machinery</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and Fittings</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Renovation</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3">5</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Air conditioner</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Software</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives">3</span> years</td></tr>
  </table>

<p id="xdx_8A8_zvVjLwhjcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
residual values, estimated useful lives and depreciation method of property and equipment are reviewed, and adjusted prospectively, if
appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
depreciated assets are retained in the consolidated financial statements until they are no longer in use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.
Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
expenditure relating to property and equipment that has already been recognized is added to the carrying amount of the asset only when
it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured
reliably. All other repair and maintenance expenses are recognized in profit or loss when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
disposal of an item of property and equipment, the difference between the disposal proceeds and its carrying amount is recognized in
profit or loss within &#8220;other losses&#8221;. Any amount in revaluation reserve relating to that item is transferred to retained
profits directly.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zDVTBkhz5Ob" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold"><span id="xdx_863_z4k9wJFUQg4l">Financial instruments</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Initial
recognition and measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets are recognized when, and only when the entity becomes party to the contractual provisions of the instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value
through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction
costs of financial assets carried at FVPL are expensed in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are measured at the amount of consideration to which the Group expects to be entitled in exchange for transferring promised
goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant
financing component at initial recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investments
in debt instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
measurement of debt instruments depends on the Group&#8217;s business model for managing the asset and the contractual cash flow characteristics
of the asset. The three measurement categories for classification of debt instruments are amortized cost, fair value through other comprehensive
income (FVOCI) and FVPL. The Group only has debt instruments at amortized cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest
are measured at amortized cost. Financial assets are measured at amortized cost using the effective interest method, less impairment.
Gains and losses are recognized in profit or loss when the assets are derecognized or impaired, and through the amortisation process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investments
in equity instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition of an investment in equity instrument that is not held for trading, the Group may irrevocably elect to present subsequent
changes in fair value in other comprehensive income which will not be reclassified subsequently to profit or loss. Dividends from such
investments are to be recognized in profit or loss when the Group&#8217;s right to receive payments is established. For investments in
equity instruments which the Group has not elected to present subsequent changes in fair value in other comprehensive income, changes
in fair value are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold">Financial instruments (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets (Continued)</span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derecognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset is derecognized where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial
asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or
loss that had been recognized in other comprehensive income for debt instruments is recognized in profit or loss.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Initial
recognition and measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
liabilities are recognized when, and only when, the Group becomes a party to the contractual provisions of the financial instrument.
The Group determines the classification of its financial liabilities at initial recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial liabilities are recognized initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable
transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortized cost using the effective
interest method. Gains and losses are recognized in profit or loss when the liabilities are derecognized, and through the amortisation
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Borrowings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
are presented as current liabilities unless the Group has an unconditional right to defer settlement for at least 12 months after the
balance sheet date, in which case they are presented as non-current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
are initially recognized at fair value (net of transaction costs) and subsequently carried at amortized cost. Any difference between
the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using
the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold">Financial instruments (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derecognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. On derecognition,
the difference between the carrying amounts and the consideration paid is recognized in profit or loss.</span></p>

<p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zTvtswurBuz4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.10</td>
    <td style="font-weight: bold"><span id="xdx_862_ztFFXn91QRf9">Impairment of financial assets</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes an allowance for expected credit losses (&#8220;ECLs&#8221;) for all debt instruments not held at FVPL. ECLs are based
on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects
to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from
the sale of collateral held or other credit enhancements that are integral to the contractual terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition,
ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For
those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is
recognized for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
trade receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit
risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix
that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic
environment which could affect debtors&#8217; ability to pay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers a financial asset in default when contractual payments are 30 days past due. However, in certain cases, the Group may
also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive
the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is
written off when there is no reasonable expectation of recovering the contractual cash flows.</span></p>

<p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_zEbBVId9vcLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.11</td>
    <td style="font-weight: bold"><span id="xdx_868_zrGwJwras9J7">Cash and cash equivalents</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand, deposits with
financial institutions which are subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are presented
as current borrowings on the balance sheet. For cash subjected to restriction, assessment is made on the economic substance of the restriction
and whether they meet the definition of cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForInventoriesExplanatory_zqEuxNn1sUUk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.12</td>
    <td style="font-weight: bold"><span id="xdx_86A_zq3Oz7xXvOa7">Inventories</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost and net realisable value, Cost is calculated using the weighted average basis and includes all costs
of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the
estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make
the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
necessary, allowance is provided for damaged, obsolete and slow-moving item to adjust the carrying value of inventories to the lower
of cost and net realisable value.</span></p>

<p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_z4i3ikD7CKWa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.13</td>
    <td style="font-weight: bold"><span id="xdx_867_z0YCIUDfVGo">Offsetting of financial instruments</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset
and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.</span></p>

<p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForProvisionsExplanatory_znYA0tqHSlMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.14</td>
    <td style="font-weight: bold"><span id="xdx_86C_zS9WURuRBCS6">Provisions</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow
of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated
reliably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that
an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value
of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to
the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Asset
Retirement Obligation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes a liability and capitalize an expense in property and equipment if the Group has a present legal or constructive obligation
to reinstate the leased premises to their original state upon expiry of the lease. The provision is made based on management&#8217;s
best estimate of the expected costs to be incurred to reinstate the leased premises to their original state. The capitalized provision
for reinstatement costs in property and equipment is amortized over the period of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_zR9ayGVXiuC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.15</td>
    <td style="font-weight: bold"><span id="xdx_862_zA0TdvBE7VEi">Impairment of non-financial assets</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, (or, where
applicable, when an annual impairment testing for an asset is required), the Group makes an estimate of the asset&#8217;s recoverable
amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of all non-current assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating
unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available
for use are tested for impairment annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairments
of goodwill are not reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
asset&#8217;s recoverable amount is the higher of an asset&#8217;s or cash-generating unit&#8217;s fair value less costs of disposal
and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent
of those from other assets or group of assets. Where the carrying amount of an asset or cash-generating unit exceeds its recoverable
amount, the asset is considered impaired and is written down to its recoverable amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset&#8217;s
recoverable amount since the last impairment loss was recognized. If that is the case, the carrying amount of the asset is increased
to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had
no impairment loss been recognized previously. Such reversal is recognized in profit or loss.</span></p>

<p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zUuYUw0kOTQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.16</td>
    <td style="font-weight: bold"><span id="xdx_86B_z895DwYRVzTd">Taxes</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            income tax</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid
to the taxation authority. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted
at the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income taxes are recognized in profit or loss except to the extent that the tax relates to items recognized outside profit or loss, either
in other comprehensive income or directly in equity. Management periodically evaluates positions taken in the tax returns with respect
to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: normal; width: 0.5in"><b>2.16</b></td>
    <td style="font-weight: normal"><b>Taxes (Continued)</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: right"></td><td style="width: 0.5in">(b)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
                                            tax</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided using the liability method on temporary differences at the end of the reporting date between the tax bases of assets
and liabilities and their carrying amounts for financial reporting purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability
is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current income tax assets against
current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
                                            and Services Tax (&#8220;GST&#8221;)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues,
expenses and assets are recognized net of the amount of GST except:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the GST incurred on a purchase of assets or services is not recoverable from the taxation
                                            authority, in which case the GST is recognized as part of the cost of acquisition of the
                                            asset or as part of the expense item as applicable; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receivables
                                            and payables that are stated with the amount of GST included.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement
of financial position.</span></p>

<p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zvhp9UbmErB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zXMQr25szXsj">Leases</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control
the use of an identified asset for a period of time in exchange for consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets.
The Group recognizes lease liabilities representing the obligations to make lease payments and right-of-use assets representing the right
to use the underlying leased assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
                                            (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Right-of-use
assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on
a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option,
depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. The
accounting policy for impairment is disclosed in Note 2.15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s right-of-use assets are presented in Note 9.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating the lease, if the lease term reflects the Group exercising the option to terminate. Variable lease payments that do not
depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the
event or condition that triggers the payment occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments
resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase
the underlying asset.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
                                            (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
liabilities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s lease liabilities are included in borrowings (Note 15).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Short-term
leases and leases of low-value assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of office premises (i.e. those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognized
as expense on a straight-line basis over the lease term. The Group has no lease of low-value assets for the year.</span></p>

<p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zLbnIfLbRzwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.18</td>
    <td style="font-weight: bold"><span id="xdx_869_zErVOWCP1J1h">Currency translation</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(a)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Functional
                                            and presentation currency </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment
in which the entity operates (&#8220;functional currency&#8221;). The consolidated financial statements are presented in Singapore Dollar,
which is the functional currency of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
                                            and balances </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in a currency other than the functional currency (&#8220;foreign currency&#8221;) are translated into the functional currency using the
exchange rates at the dates of the transactions. Currency exchange differences resulting from the settlement of such transactions and
from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the end of balance
sheet date are recognized in profit or loss. Monetary items include primarily financial assets (other than equity investments), contract
assets and financial liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a foreign operation is disposed of or any loan forming part of the net investment of the foreign operation is repaid, a proportionate
share of the accumulated currency translation differences is reclassified to profit or loss, as part of the gain or loss on disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange gains and losses that relate to borrowings are presented in the income statement within &#8220;finance expense&#8221;. All other
foreign exchange gains and losses impacting profit or loss are presented in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.18</td>
    <td style="font-weight: bold">Currency translation (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
                                            and balances </i>(Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-monetary
items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(c)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Translation
                                            of Group entities&#8217; financial statements </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a
functional currency different from the presentation currency are translated into the presentation currency as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets
                                            and liabilities are translated at the closing exchange rates at the reporting date;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income
                                            and expenses are translated at average exchange rates (unless the average is not a reasonable
                                            approximation of the cumulative effect of the rates prevailing on the transaction dates,
                                            in which case income and expenses are translated using the exchange rates at the dates of
                                            the transactions); and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            resulting currency translation differences are recognized in other comprehensive income and
                                            accumulated in the currency translation reserve. These currency translation differences are
                                            reclassified to profit or loss on disposal or partial disposal with loss of control of the
                                            foreign operation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Goodwill
and fair value adjustments arising on the acquisition of foreign operations are treated as assets and liabilities of the foreign operations
and translated at the closing rates at the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Translations
of the consolidated balance sheets, consolidated statement of profit or loss and comprehensive income, consolidated statement of changes
in shareholders&#8217; equity and consolidated statements of cash flows from S$ into US$ as of and for the year ended June 30, 2025 are
solely for the convenience of the reader and were calculated at the rate of S$1 = US$1.2719, as set forth in the statistical release
of the Federal Reserve System on June 30, 2025. No representation is made that the S$ amounts could have been, or could be, converted,
realized or settled into US$ at that rate on June 30, 2025, or at any other rate.</span></p>

<p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_z1DrsIFo15i3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.19</td>
    <td style="font-weight: bold"><span id="xdx_860_zakbKSZ3qNXj">Employee benefits</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined
                                            contribution plans</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify; text-indent: -32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to
defined contribution pension schemes are recognized as an expense in the period in which the related service is performed.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.19</td>
    <td style="font-weight: bold">Employee benefits (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
                                            employee benefits</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is
recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result
of past service provided by the employee, and the obligation can be estimated reliably.</span></p>

<p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_z9f4subZNxTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.20</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zAaJgTtYdHae">Derivative
                                            financial instruments</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">A
derivative financial instrument for which no hedge accounting is applied is initially recognized at its fair value on the date the contract
is entered into and is subsequently carried at its fair value. Changes in its fair value are recognized in profit or loss. The Group
does not apply hedge accounting for its derivative financial instruments.</span></p>

<p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zFFrc5tiaJS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.21</td>
    <td style="font-weight: bold"><span id="xdx_866_zyfTi1CoYnAh">Earnings per share</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share is computed by dividing net income attributable to the holders of ordinary shares by the weighted average number of
ordinary shares outstanding during the period presented. Diluted income per share is calculated by dividing net income attributable to
the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number
of ordinary shares and dilutive ordinary share equivalents outstanding during the period. However, ordinary share equivalents are not
included in the denominator of the diluted earnings per share calculation when inclusion of such shares would be anti-dilutive, such
as in a period in which a net loss is recorded.</span></p>

<p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_z7O2XohbwfEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.22</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKVVItQqxjU3">Share
                                            capital</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from issuance of ordinary shares are recognized as share capital in equity. Incremental costs directly attributable to the issuance of
ordinary shares are deducted against share capital.</span></p>

<p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForReservesExplanatory_zzNfiz5l0SJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zdWg2h5Q17nl">Merger
    reserve</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a business combination under common control, any difference between the consideration paid and the carrying amounts of assets and liabilities
received is presented as a change within equity and recorded under merger reserves.</span></p>

<p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_zgQ4rvBzv7Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zM5sPpJ0twd4">Deferred
    Offering cost</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers specific incremental costs directly attributable to an equity securities offering. These costs will be charged against
the gross proceeds of the offering as a reduction of additional paid-in capital. If the Company does not complete the initial public
offering, the deferred costs of the aborted offering will be deferred and charged against the proceeds of a subsequent offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    offering cost (Continued)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
costs related to an aborted offering will be expensed in the period in which the Company elects to abort the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the initial public offering, deferred offering costs, which mainly consist of direct incremental legal, auditing,
accounting, consulting, and other fees relating to the initial public offering, are capitalized on the consolidated balance sheets.</span></p>

<p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForDividendsExplanatory_zt3Xm83uISgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zci6cjHtuHwc">Dividend
    to Company&#8217;s shareholders</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to the Company&#8217;s shareholders are recognized when the dividends are approved for payment.</span></p>

<p id="xdx_854_zriQWrLNMCxf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting judgements and estimates<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract', window );"><strong>Significant Accounting Judgements And Estimates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant accounting judgements and estimates</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zXCSDbolq7Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span id="xdx_821_zy876ojIElb1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant
                                            accounting judgements and estimates</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Group&#8217;s financial statements requires management to make judgments, estimates and assumptions that affect the
reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting
period. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying
amount of the asset or liability affected in the future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.1</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Judgements
                                            made in applying accounting policies </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Management
is of the opinion that there are no significant judgements made in applying accounting estimates and policies that have a significant
risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
                                            sources of estimation uncertainty </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period are discussed
below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances
and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the
Group. Such changes are reflected in the assumptions when they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">3.</td>
    <td style="font-weight: bold">Significant accounting judgements and estimates (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
                                            sources of estimation uncertainty (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
                                            useful lives of property and equipment (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the property and equipment over their estimated useful lives after taking into account of their estimated residual
values. The estimated useful life reflects management&#8217;s estimate of the period that the Group intends to derive future economic
benefits from the use of the Group&#8217;s property and equipment. The residual value reflects management&#8217;s estimated amount that
the Group would currently obtain from the disposal of the asset, after deducting the estimated costs of disposal, as if the asset were
already of the age and in the condition expected at the end of its useful life. Changes in the expected level of usage and technological
developments could affect the economics, useful lives and the residual values of these assets which could then consequentially impact
future depreciation charges. The carrying amounts of the Group&#8217;s property and equipment as at June 30, 2025 and June 30, 2024 were
disclosed in Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory
                                            valuation method</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-down is made based on the current market conditions, historical experience and selling goods of similar nature. It could change
significantly as a result of changes in market conditions. A review is made periodically on inventories for excess inventories, obsolescence
and declines in net realisable value and an allowance is recorded against the inventory balances for any such declines. The realisable
value represents the best estimate of the recoverable amount and is based on the most reliable evidence available and inherently involves
estimates regarding the future expected realisable value. The carrying amount of the Company&#8217;s inventories as at June 30, 2025
was S$<span id="xdx_90B_eifrs-full--Inventories_iI_c20250630_zpsOuY8yYGE1" title="Inventories">376,291</span> (US$<span id="xdx_908_eifrs-full--Inventories_iI_uUSD_c20250630_zjvjJTZUX4Z8" title="Inventories">295,850</span>) (June 30, 2024: S$<span id="xdx_909_eifrs-full--Inventories_iI_c20240630_zq2u45m2aax7" title="Inventories">72,030</span>). If the future expected realisable value was lower by 10% of its carrying amount,
the carrying amount of the Company&#8217;s inventories would have been S$<span id="xdx_902_eifrs-full--InventoriesTotal_iI_c20250630_zUHeDEWTeNHh" title="Inventories total">37,629</span> (US$<span id="xdx_90F_eifrs-full--InventoriesTotal_iI_uUSD_c20250630_zHUl9GmwG5lj" title="Inventories total">29,585</span>) (June 30, 2024: S$<span id="xdx_906_eifrs-full--InventoriesTotal_iI_c20240630_zZUiyrpWwaL4" title="Inventories total">7,203</span>) lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allowance
                                            for expected credit losses of trade receivables</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of
various customer segments that have similar loss patterns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provision matrix is initially based on the Company&#8217;s historical observed default rates. The Company will calibrate the matrix to
adjust historical credit loss experience with forward-looking information. At every reporting date, historical default rates are updated
and changes in the forward-looking estimates are analysed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate.
The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Company&#8217;s historical credit
loss experience and forecast of economic conditions may also not be representative of customer&#8217;s actual default in the future.
The information about the ECLs on the Company&#8217;s trade receivables is disclosed in Note 23 (a). The carrying amount of the Company&#8217;s
trade receivables as at the end of each reporting period were disclosed in Note 12.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">3.</td>
    <td style="font-weight: bold">Significant accounting judgements and estimates (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
                                            sources of estimation uncertainty (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allowance
                                            for expected credit losses of other receivables </b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assessed the latest performance and financial position of the counterparties, adjusted for the outlook of the industry in which
the counterparties operate in, and concluded that there had been no significant increase in credit risk since initial recognition of
the financial assets. Accordingly, the Group measured the impairment loss allowance using 12-month ECL and determined that the ECL is
insignificant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Group&#8217;s other receivables as at June 30, 2025 were S$<span id="xdx_90C_ecustom--OthersReceivables_iI_c20250630_zNZeieUc2Gac">206,391</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(US$<span id="xdx_903_ecustom--OthersReceivables_iI_uUSD_c20250630_zrKhZoRBu6u8">162,070</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
(June 30, 2024: S$<span id="xdx_906_ecustom--OthersReceivables_iI_c20240630_zcicjvmP7p72">213,644</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(e)</td>
    <td style="font-weight: bold">Leases &#8211; estimating the incremental borrowing rate</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate to measure
lease liabilities. The incremental borrowing rate is the rate of interest that the Group would have to pay to borrow over a similar term,
and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic
environment. The incremental borrowing rate therefore reflects what the Group &#8216;would have to pay&#8217;, which requires estimation
when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Group estimates
the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to make certain
entity-specific estimates.<br/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRevenueAbstract', window );"><strong>Disclosure Revenue Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--DisclosureOfRevenueExplanatory_zzVe5du4kQEg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zt9fFz8JZyg9">Revenue</span></b></span></td></tr></table>

<p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zg589ArOBNR8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zgY8SssJj8Ig">Summary
of revenue from transfer of goods and services</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zJSMp0T9YV6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230701__20240630_zxDW9goPP9qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Type of service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Revenue_hifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zUrdzqUB9b12" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">Rendering of services &#8211; Medical services</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zYny4s4eHom6" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Rendering of services - Medical services">8,900,027</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">11,319,944</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">10,050,923</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_zwFhhuC4tmV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--Revenue_uUSD_c20240701__20250630_zqPXIcZVGZpl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">8,900,027</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,319,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,050,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Timing of transfer of service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_hifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_z0kWK0HRvYI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">At a point in time</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zCubJur4o6Si" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services">8,900,027</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,319,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,050,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_z9YYotkhmN3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Revenue_uUSD_c20240701__20250630_zYdCNdgWixj3" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services">8,900,027</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,319,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,050,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z0fN8uP1JDLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other income</a></td>
<td class="text"><p id="xdx_806_eifrs-full--DisclosureOfOtherOperatingIncomeExplanatory_zSDob4D2DEI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zDNDgc47SXNa">Other
income</span></b></span></td></tr></table>

<p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_z0EGt6Y88i3d" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zmEFHk4BxpAd" style="display: none">Schedule
of Other income</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zQcI36fMgvjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230701__20240630_zl8VqLXIeAnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--RevenueFromGovernmentGrants_maOGLzcHg_z6yPseML2Gs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Government grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--RevenueFromGovernmentGrants_uUSD_c20240701__20250630_zsA5obhFXjpj" style="width: 14%; text-align: right" title="Government grant">59,003</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">75,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">19,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--RevenueFromInterest_maOGLzcHg_zqQgjS01vjrl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RevenueFromInterest_uUSD_c20240701__20250630_zx992W9DYSwh" style="text-align: right" title="Interest income">65,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ServiceIncome_maOGLzcHg_zvK55TG9uJh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Service income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ServiceIncome_uUSD_c20240701__20250630_zIoypFFBAt42" style="text-align: right" title="Service income">27,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RentalIncome_maOGLzcHg_zxgglFPtjw4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eifrs-full--RentalIncome_uUSD_c20240701__20250630_zR3YwcLNx32j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Rental income"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,469</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eifrs-full--OtherIncome_maOGLzcHg_ztN1apPL8Wk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--OtherIncome_uUSD_c20240701__20250630_z5Pd0wSjebmg" style="text-align: right" title="Other income">591,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">751,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,688</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ReversalOfExpectedCreditLosses_maOGLzcHg_zS8tDxfRHIaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Reversal of ECL</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ReversalOfExpectedCreditLosses_uUSD_c20240701__20250630_ziAFvIafIb3d" style="border-bottom: Black 1pt solid; text-align: right" title="Reversal of ECL"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">55,741</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherGainsLosses_iT_mtOGLzcHg_zbSfOr8b8zV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--OtherGainsLosses_iT_uUSD_c20240701__20250630_zEDsJGfzVwpe" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">866,580</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,102,203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">461,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zRlA7XZO8Ka9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Other
income pertains to the reversal of long-outstanding payables which are no longer considered due. The reversal was made after confirming
that no obligation remains, as no claims or demands have been received from the creditors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance cost<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">Finance cost</a></td>
<td class="text"><p id="xdx_803_eifrs-full--DisclosureOfFinanceCostExplanatory_zxWbvWEIfUAe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zWoDLbfTk727">Finance
cost</span></b></span></td></tr></table>

<p id="xdx_897_ecustom--DisclosureOfDetailedInformationAboutFinanceCostExplanatory_zqI950I3xYy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zFJdkm8yEad1" style="display: none">Schedule
of Finance cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240701__20250630_zotMZH6LvfGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230701__20240630_zg6OGOwTaZC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense on:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--InterestExpenseOnBorrowings_maFCzCYG_zZQBUxzFcZ27" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">- Bank borrowings</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zvn8O8rQdoyi" style="width: 14%; text-align: right" title="Interest expense on bank borrowings">69,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">88,982</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">160,777</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--InterestExpenseOnBorrowings_zZhIxQtlxiuj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense on bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zLX1Qsmi04Y2" style="text-align: right" title="Interest expense on bank borrowings">69,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,777</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eifrs-full--InterestExpenseOnLeaseLiabilities_maFCzCYG_z2K4eUN2YWag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">- Lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zfQIkmOnEqP7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities">90,389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">114,966</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,461</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--InterestExpenseOnLeaseLiabilities_zlGBw0jgAxJh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense on lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zk5ryB9OmTj7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities">90,389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">114,966</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,461</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eifrs-full--FinanceCosts_iT_mtFCzCYG_zgNgOQGrKinf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Finance costs</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinanceCosts_iT_uUSD_c20240701__20250630_zUmPJJUe9kOe" style="border-bottom: Black 1pt solid; text-align: right" title="Finance costs">160,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203,948</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">176,238</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zAgV9K51z6xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss)/Profit before tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureLossprofitBeforeTaxAbstract', window );"><strong>Lossprofit Before Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfProfitLossBeforeTaxExplanatory', window );">(Loss)/Profit before tax</a></td>
<td class="text"><p id="xdx_809_ecustom--DisclosureOfProfitLossBeforeTaxExplanatory_zYF8sn4ILxRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zDDXbMHmOd9f">(Loss)/Profit before tax</span></b></span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_z2CvdijwpRu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
before tax has been arrived at after charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zV56QQ3MPSJ9" style="display: none">Schedule
of Profit before tax</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zfQRdLsNeQr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zMrtXK5Z5jl5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--SalesAndMarketingExpense_zm4fxnBkkNl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Marketing and advertisement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--SalesAndMarketingExpense_uUSD_c20240701__20250630_zXo0mueiFFY8" style="width: 14%; text-align: right" title="Marketing and advertisement">480,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">611,733</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">698,336</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ProfessionalFeesExpense_zP0bwYtAUvi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProfessionalFeesExpense_uUSD_c20240701__20250630_ztynUwXJj6Q2" style="text-align: right" title="Legal and professional fees">191,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">426,740</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--InsuranceExpense_zO1q2E0mtfTg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InsuranceExpense_uUSD_c20240701__20250630_zDSZI0xvCkbb" style="text-align: right" title="Insurance">269,199</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,112</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TransportationExpense_zR68IiE1L9Nc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transportation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--TransportationExpense_uUSD_c20240701__20250630_zeqSo1EN0jRc" style="text-align: right" title="Transportation">34,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,367</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BadDebtsWrittenOff_zGWzKyGGE3Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debts written off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--BadDebtsWrittenOff_uUSD_c20240701__20250630_z03E7GGYrOV7" style="text-align: right" title="Bad debts written off">189,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProvisionForExpectedCreditLosses_zEvrB05ZeEIj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for expected credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ProvisionForExpectedCreditLosses_uUSD_c20240701__20250630_zOYlbTczwA79" style="text-align: right" title="Provision for expected credit losses">536,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,168</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--DepreciationPropertyPlantAndEquipment_zwKE2H3odbXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--DepreciationOfPropertyAndEquipment_uUSD_c20240701__20250630_zG5S3Y8cTakf" style="text-align: right" title="Depreciation of property and equipment">84,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,093</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--AmortisationExpense_zW5o3xpAYzx1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortisation of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--AmortisationExpense_uUSD_c20240701__20250630_zJ3QwWOoYRkc" style="text-align: right" title="Amortisation of right-of-use assets">843,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,073,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498,635</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--RecruitmentExpenses_z2IYbQCtdvt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recruitment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--RecruitmentExpenses_uUSD_c20240701__20250630_zyvbvwS5XRIc" style="text-align: right" title="Recruitment">1,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,786</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--SubscriptionCirculationRevenue_zF79tmeO4j6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Membership and subscription</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--SubscriptionCirculationRevenue_uUSD_c20240701__20250630_zuJkoceV38bi" style="text-align: right" title="Membership and subscription">16,207</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TelephoneExpense_zgw0ybXBITj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Telephone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--TelephoneExpense_uUSD_c20240701__20250630_z3EWC2y2vs6j" style="text-align: right" title="Telephone">32,689</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EmployeeBenefitsExpenses_zPLHIBxTBCua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefit expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DirectorsSalariesAndBonuses_z2F7ar6XH5C9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Director&#8217;s salaries and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--DirectorsSalariesAndBonuses_uUSD_c20240701__20250630_zJyZVBgcyzv5" style="text-align: right" title="Director's salaries and bonuses">261,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,200</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DirectorsCentralProvidentFund_zrcNNKeVszLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Director&#8217;s CPF</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DirectorsCentralProvidentFund_uUSD_c20240701__20250630_zLRb1v9xpyNk" style="text-align: right" title="Director's CPF">23,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--EmployeesSalariesAndBonus_zonympWtyKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Employees&#8217; salaries and bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--EmployeesSalariesAndBonus_uUSD_c20240701__20250630_z0jOwS3HTZP" style="text-align: right" title="Employees' salaries and bonus">3,773,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,799,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,218,275</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeesCentralProvidentFund_zY7HxnES0T58" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Employees&#8217; CPF</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EmployeesCentralProvidentFund_uUSD_c20240701__20250630_zWqqeuA7E587" style="text-align: right" title="Employees' CPF">346,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,539</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,754</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherStaffExpenses_zLJfRmX5698b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Other staff expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--OtherStaffExpenses_uUSD_c20240701__20250630_zWuFaLYtWFXk" style="text-align: right" title="Other staff expenses">667,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">848,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,576</td><td style="text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A7_zs4kmrQapNAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureLossprofitBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureLossprofitBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfProfitLossBeforeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of profit loss before tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfProfitLossBeforeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (benefit)/expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax (benefit)/expense</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfIncomeTaxExplanatory_zmye4p91Mzl3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
</b></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zegVTmqWCEWc">Income
tax (benefit)/expense</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_zKRKvpvLPn99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
major components of income tax expense recognized in profit or loss for the periods ended June 30, 2025 and 2024 were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B4_zOkcU8aJDK4g" style="display: none">Schedule
of component of income tax expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_z72t25CmNjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230701__20240630_zX7SCv2fJ87k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB_zP0ofMd8SLu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncome_maITECOzPgr_z05qB93wkJF1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- Current year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentTaxExpenseIncome_uUSD_c20240701__20250630_zO3fmtjagek9" style="width: 14%; text-align: right" title="- Current year"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">383,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DeferredTaxExpenseIncome_maITECOzPgr_ztHkHoRmRErc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Deferred income tax</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DeferredTaxExpenseIncome_uUSD_c20240701__20250630_z9A8WG1h4nVb" style="text-align: right" title="- Deferred income tax"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="color: red; text-align: left">&#160;</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="color: red; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,440</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzPgr_zQdnspfq28F6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    Underprovision in respect of prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zXgXqyvHf8mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="-Underprovision in respect of prior years"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OverprovisionInRespectOfPriorYears_maITECOzPgr_zgZj4BoOjNTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">- Overprovision in respect of prior years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zKFKwIK4YRt1" style="border-bottom: Black 1pt solid; text-align: right" title="- Overprovision in respect of prior years">(328,444</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,748</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,252</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzPgr_zcGFYykKQDHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (benefit)/expense recognized in profit or loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zm5SOzgYM9vk" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense recognized in profit or loss">(328,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,393</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">331,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_8AB_zqYqJuh9TNFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Relationship
between tax expense and accounting profit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_zc1V0F7XMD5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation between tax expense and the product of accounting (loss)/profit multiplied by the applicable corporate tax rate for the financial
periods ended June 30, 2025 and 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8BE_zctMmdtSK9Sj" style="display: none">Schedule of reconciliation
between tax expense and corporate tax rate</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zyTwNGAOVeO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230701__20240630_ztlWz7Vx54xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_zd7CrxkW0Ep8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">(Loss)/Profit before tax</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProfitLossBeforeTax_uUSD_c20240701__20250630_zwiWeCGx3CBc" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="(Loss)/Profit before tax">(9,832,138</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(12,505,497</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">2,404,561</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_maITECOzdOp_zaUAzDhHu467" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax using the statutory tax rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eifrs-full--ApplicableTaxRate_pid_dp_c20240701__20250630_zJjAnKz6suE1" title="Statutory tax rate">17</span>% (2024: <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_c20230701__20240630_zoshOBeXpck6" title="Statutory tax rate">17</span>%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_uUSD_c20240701__20250630_zJXyOze5Zkke" style="text-align: right" title="Income tax using the statutory tax rate of 17% (2024: 17%)">(1,671,463</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,125,934</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">408,775</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effects of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NondeductibleExpenses_maITECOzdOp_zt9IEb2eZ20i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--NondeductibleExpenses_uUSD_c20240701__20250630_zRRkNWd47233" style="text-align: right" title="Non-deductible expenses">1,661,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,113,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,416</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TaxEffectOfTaxLosses_maITECOzdOp_zUJpTY9br8C2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Income not subject to tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--TaxEffectOfTaxLosses_uUSD_c20240701__20250630_z8toyypwFmve" style="text-align: right" title="Income not subject to tax"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,039</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxExemption_maITECOzdOp_z4Ao0HfzyZ85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Income tax exemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--IncomeTaxExemption_uUSD_c20240701__20250630_zndnrXr1Xlp2" style="text-align: right" title="Income tax exemption">(13,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,350</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--UtilisationOfCapitalAllowance_iN_di_msITECOzdOp_zPlXDmzsos7h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Utilisation of capital allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UtilisationOfCapitalAllowance_iN_di_uUSD_c20240701__20250630_zFbhGVB59ool" style="text-align: right" title="(Loss)/Profit before tax">(353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(449</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,322</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--UtilisationOfDeferredTaxAssets_maITECOzdOp_zA18jw3pPKTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Utilisation of deferred tax assets not recognised in prior year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--UtilisationOfDeferredTaxAssets_uUSD_c20240701__20250630_z9s7XwgAYLPe" style="text-align: right" title="- Utilisation of deferred tax assets not recognised in prior year"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,037</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_maITECOzdOp_zKr6icq0bUKc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Deferred tax asset not recognized during the financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_uUSD_c20240701__20250630_zj9zG7k3N1R9" style="text-align: right" title="Deferred tax asset not recognized during the financial year">23,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,932</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredIncomeTax_iN_di_msITECOzdOp_zSAuB8w5MtCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Deferred income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DeferredIncomeTax_iN_di_uUSD_c20240701__20250630_ziuDHctyStcg" style="text-align: right" title="Deferred income tax"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,440</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzdOp_zysRGi0csu04" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-Underprovision
    in respect of prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zwZekJQntUE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underprovision in respect of prior years"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--OverprovisionInRespectOfPriorYears_maITECOzdOp_zKEwAKwgm2T9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">-Overprovision in respect of prior years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zAS0PfjbLWgj" style="border-bottom: Black 1pt solid; text-align: right" title="Overprovision in respect of prior years">(328,444</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,748</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,252</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzdOp_zodhLq0HOyjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (benefit)/expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zhUZeXA4zcZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense">(328,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,393</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">331,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A6_zTjUPeBSFAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRightofuseAssetAbstract', window );"><strong>Right Of Use Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right of use assets</a></td>
<td class="text"><p id="xdx_800_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_ziJAZW2Jaev9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">9.</td>
    <td style="font-weight: bold"><span id="xdx_821_zhD4feFeuw2k">Right of use assets</span></td></tr>
  </table>

<p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOfRightOfUseAssets_zcL0wtpCbpq7" style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B9_zyvUX4DjkF5b" style="display: none">Schedule of Right of use assets</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240701__20250630_zo6f1W5XaOWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230701__20240630_zDyKh9Q68n93" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zjygkYC3N1Ok" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">At beginning of financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zj5MhPtewhta" style="width: 14%; text-align: right" title="At beginning of financial year">2,164,551</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,753,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,753,093</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zshkwbPYjof4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlkes6T5WX77" style="text-align: right" title="Additions">2,575,627</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,275,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z58CQbzBjFf7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Additions">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zqreUGnhhKWb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zJ7F3mhHJ3Nl" style="text-align: right" title="Acquisition">3,793,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,825,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zxxlgJhDChf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z8MmI9xatuU6" style="border-bottom: Black 1pt solid; text-align: right" title="Written off">(3,118,402</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,966,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zeomylu1puM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z2XJujeLn8Qh" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">5,415,473</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,887,940</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,753,093</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_z7buZQ04Tbw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">At beginning of financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zepWJUzLP7Za" style="text-align: right" title="At beginning of financial year">2,146,106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,729,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,230,998</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zwpUEpQBLFs2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zTsadXuGUNk9" style="text-align: right" title="Acquisition">2,902,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,691,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zfijastsiDWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zVIs6xVq42Gk" style="text-align: right" title="Depreciation">843,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,073,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498,635</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zi1KIc4mhLS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zYi5sbWCSxW8" style="border-bottom: Black 1pt solid; text-align: right" title="Written off">(2,974,369</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,783,101</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zKF5m2yJUibl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zE4LvUsnRXf5" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">2,918,011</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,711,418</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,729,633</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--RightofuseAssets_iE_zmeDaEoioJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Carrying amount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zxwq0muk8QL9" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">2,497,462</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,176,522</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,460</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--RightofuseAssets_iE_zRhvBajuORCf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zjNFvH4G7Eog" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">2,497,462</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,176,522</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,460</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>
<p id="xdx_8AB_zQ6GOtM1Symc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRightofuseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRightofuseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosurePropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><p id="xdx_806_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zgtPu5hYnpsa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">10.</td>
    <td style="font-weight: bold"><span id="xdx_82C_zEInHxyAxPcg">Property and equipment</span></td></tr>
  </table>


<p id="xdx_89B_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zuLG4kYM29k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zZwBvvjCIXla" style="display: none">Schedule
of Property and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--MachineryMember_zeOKGw84jUB6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Machinery</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--FixturesAndFittingsMember_zu3TCMeEiIui" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Furniture</b></span></p>
                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&amp;
                                            Fittings</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--MedicalEquipmentMember_znlea5dKw731" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Medical</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">equipment</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RenovationMember_z5q4WpdegFRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Renovation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--AirConditionerMember_zpJcwKQZIC31" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Air</b></span></p>
                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>conditioner</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--ComputerAndOfficeEquipmentMember_zau2Ezgx4pfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Computer</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">&amp; office</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">equipment</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--SoftwareMember_zUtHsdyzLZM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Software</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_zr61neq8C6rk" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zCZ5v7VZxk91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; width: 20%">At July 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">47,226</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">100,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">86,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">405,349</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">43,727</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">350,248</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,034,126</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zDaOUZgqvRbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zanp3BM2OHT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,852</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">86,724</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">405,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">358,168</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,042,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zm91ZHPlscU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">Acquisition</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">367,243</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,500,493</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,285,136</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">378,669</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,978</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,618,519</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zw18jBJKfOPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,760</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zsRdT3QzTkZg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    off</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(313,691</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(709,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(315,832</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(253,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,601,659</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlTKXLdOqJSe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iE_zquz533acuMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154,404</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">890,988</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,396,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,145</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">77,978</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,113,666</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zvLDGdQ3vFN1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At July 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,727</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,692</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">977,440</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zmKIBQalHaZf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,888</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,491</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1374">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,093</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zzLVbLoEvcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,664</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">81,533</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">382,200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">352,183</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,007,533</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zFfyPNabMaLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,244,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,192,766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,116,339</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zCHxEv3eKnQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,659</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zUoBhUuwjYa6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(248,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(687,468</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(231,410</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(220,994</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,395,372</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iE_zmfezmVF0xVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">137,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">688,904</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,368,084</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">474,280</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,866</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,836,159</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net book values</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20230701__20240630_eifrs-full--PropertyPlantAndEquipment_iE_zTAn0Sf9Wfsf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1422">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">188</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,513</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_zvQBYqEaqWX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,332</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,084</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,114</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,112</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,507</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">US$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_uUSD_zNRoMjmXqZC6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">158,884</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,694</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">874</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<p id="xdx_8AE_zJN5oUmqopW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosurePropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosurePropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfInventoriesAbstract', window );"><strong>Schedule Of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p id="xdx_80A_eifrs-full--DisclosureOfInventoriesExplanatory_zktgVVJjpAJ9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">11.</td>
    <td style="font-weight: bold"><span id="xdx_822_zS6cZbecu4sc">Inventories</span></td></tr>
  </table>


<p id="xdx_894_ecustom--DisclosureOfDetailedInformationAboutInventoriesExplanatory_z7nkwaMszD7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8BC_zy27EmEnCk38" style="display: none">Schedule
of Inventories</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zjXZUJMhFMC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zjoFjHzeNLT6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Statement of financial position:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Inventories_iI_uSGD_zhGCMKEYdCgi" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">Medicine,drugs and medical devices</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--Inventories_iI_uUSD_c20250630_zUP6NJDGidO1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Medicine,drugs and medical devices">295,850</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">376,291</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">72,030</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Statement of comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Inventories recognized as an expense in cost of sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uUSD_c20240701__20250630_zjPs8IGJFiue" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales">517,713</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20240701__20250630_z7srhafeFRTf" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales">658,479</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20230701__20240630_zquxUcgjmjg8" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales">637,037</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zCyvn2N2Km6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherReceivablesAbstract', window );"><strong>Trade And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and other receivables</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zwS8tszNcRN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">12.</td>
    <td style="font-weight: bold"><span id="xdx_827_zTbDVgTq3op1">Trade and other receivables</span></td></tr>
  </table>


<p id="xdx_896_ecustom--DisclosureOfTradeAndOtherReceivableExplanatory_zProBPpufZgc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zVkSvGDeOPR7" style="display: none">Schedule
of trade and other receivables</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zLxTTTndWmGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_z02274trgh3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade receivables:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentTradeReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zS5i1iY7nyT3" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- third parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentTradeReceivables_iS_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zeAT30Q6n6m8" style="width: 14%; text-align: right" title="Trade receivables - third parties">2,580,313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,281,902</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,133,573</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uSGD_z26AmgvKnYH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Allowance for expected credit loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uUSD_c20250630_zsAyMoFdVC33" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Allowance for expected credit loss">(781,133</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(993,524</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(460,413</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--TradeReceivables_iI_uSGD_zPY9oXipJrh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Receivables</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--TradeReceivables_iI_uUSD_c20250630_zdD1YLxBAWcg" style="text-align: right" title="Trade Receivables">1,799,180</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,288,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,673,160</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LongtermDeposits_iI_uSGD_z9Yjqdoe3dB7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630_zInmKCnGFL1h" style="text-align: right" title="Deposits">5,362,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,820,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,252</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--Prepayments_iI_uSGD_zUR4bP5ubSvj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--Prepayments_iI_uUSD_c20250630_z4Vbs8my1Yma" style="text-align: right" title="Prepayments">326,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherCurrentReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zLMVm3xS6ZJ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--OtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_z7Iu2zWVZEo6" style="border-bottom: Black 1pt solid; text-align: right" title="Other receivables - third parties">162,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">206,391</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">213,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentReceivables_iI_uSGD_zYE5waP2kkl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other receivables</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_98C_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630_z2plWLQfMay8" style="border-bottom: Black 1pt solid; text-align: right" title="Trade and other receivables">7,651,065</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,731,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,005,219</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zuYuNN2ctVzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Trade
receivables are unsecured, non-interest bearing and are generally on 60 days terms (June 30, 2024: 60 days).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">There
is no other class of financial assets that is past due and/or impaired except for trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Trade
and other receivables are denominated in Singapore Dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
deposits include payments made for custodian services amounting to S$<span id="xdx_90D_eifrs-full--LongtermDeposits_iI_uSGD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CustodianServicesMember_zfOGA0XGYu72" title="Deposits">2,300,375</span> (US$<span id="xdx_90D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CustodianServicesMember_zIyQs06tbUU" title="Deposits">1,683,776</span>), which are classified as non-financial
assets and earmarked for use in upcoming mergers and acquisitions within the Singapore market.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">12.</td>
    <td style="font-weight: bold">Trade and other receivables (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eifrs-full--DisclosureOfAllowanceForCreditLossesExplanatory_z6LgFI7dcwuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
movement in allowance for expected credit losses of trade receivables computed based on lifetime ECL was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zFOP7QBl50D6" style="display: none">Schedule
of movement in allowance for expected credit losses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630_zfCV8pkMULRf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20240630_zg9SJ7kNNHCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--AllowanceForExpectedCreditLoss_iS_uSGD_z77Y7vyaYfW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Beginning of financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iS_uUSD_c20240701__20250630_zs9ZH5cHIPNf" style="width: 14%; text-align: right">361,988</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">460,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">465,986</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AdditionAllowanceForExpectedCreditLosses_uSGD_zbPPBjasV45a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for expected credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--AdditionAllowanceForExpectedCreditLosses_uUSD_c20240701__20250630_zYZyCn3xbuDh" style="text-align: right">536,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,168</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uSGD_zCTBSfgSGGGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Reversal of allowance for expected credit losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uUSD_c20240701__20250630_z2IQK6Qs4WWi" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Reversal of allowance for expected credit losses">(117,258</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(149,141</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(55,741</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--AllowanceForExpectedCreditLoss_iE_uSGD_zSUBdrh9wBva" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">End of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForExpectedCreditLoss_iE_uUSD_c20240701__20250630_zXdSXVDETDOl" style="border-bottom: Black 1pt solid; text-align: right">781,133</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">993,524</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">460,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zT5V0tyIHCul" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureCashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_802_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_z90t0Y05TjLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">13.</td>
    <td style="font-weight: bold"><span id="xdx_826_zzcIM0A7ZxYi">Cash and cash equivalents</span></td></tr>
  </table>


<p id="xdx_896_ecustom--DisclosureOfCashAndCashEquivalentExplanatory_zHWzwlOymI9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zyEKgIEHqG6a" style="display: none">Schedule
of cash and cash equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zAPyEzVnff49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20240630_zR2w2f76WZ77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashOnHand_iI_zDzX0CsHdh7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Cash on hand</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashOnHand_iI_uUSD_c20250630_zY27CGCTsgIj" style="width: 14%; text-align: right" title="Cash on hand">310</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">395</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--BalancesWithBanks_iI_zJHDCQxJfTT7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash at banks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--BalancesWithBanks_iI_uUSD_c20250630_zveTKI9tORR9" style="border-bottom: Black 1pt solid; text-align: right" title="Cash at banks">2,341,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,978,688</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,949,553</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CashAndCashEquivalents_i02I_zT8cFh5xiaK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630_zt2A4KpjDhbi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents">2,342,230</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,979,083</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,951,053</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AE_znEVVkCNIcJ5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Amount due from/to related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract', window );"><strong>Amount Due Fromto Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Amount due from/to related parties</a></td>
<td class="text"><p id="xdx_800_eifrs-full--DisclosureOfRelatedPartyExplanatory_zWtzHhk5mmWc" style="font: bold 10pt Times New Roman, Times, Serif; display: none; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">14.</td>
    <td style="font-weight: bold"><span id="xdx_82E_zwTlFbkOmlBh">Amount due from/to related parties</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Amount
due from related parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2023, Rainforest Capital VCC (the &#8220;Purchaser&#8221;) entered into a sale and purchase agreement with Dr. Kevin Yip (the
&#8220;Seller&#8221;) for the transfer of the entire share capital of Basel Medical Group Pte. Ltd. According to the sales and purchase
agreement, the Provisional Consideration shall be an aggregate amount equivalent to the sum of S$<span id="xdx_90D_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zGqIez1SBZU6" title="Provisional consideration amount for transfer of share">24,000,000</span> (US$<span id="xdx_904_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_uUSD_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zbfu8XIKOoNd" title="Provisional consideration amount">18,191,465</span>) and the Agreed
Amount. The Agreed Amount is computed based on the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net
amount due from a former director (Dr. Kevin Yip) to the Group less the net assets of the Group as at June 30, 2023. The Agreed Amount
will be a negative figure if the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net amount due from
a director to the Group is more than the net assets of the Group as of June 30, 2023. The Agreed Amount was initially estimated to be
negative S$<span id="xdx_907_eifrs-full--SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_c20230630__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z6blSUkAO8Lf" title="Estimated settlement liability">5,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#8239;
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2023, S$<span id="xdx_90C_ecustom--CashPaidOnClosingInitialSettlement_c20230701__20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zIdQ0hvJdIq3" title="Cash paid on closing initial settlement">11,800,000</span> (US$<span id="xdx_909_ecustom--CashPaidOnClosingInitialSettlement_uUSD_c20230701__20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zGFg2Dj6NvT1" title="Cash paid on closing initial settlement">8,944,137</span>) was paid from the Purchaser to the Seller. This was computed based on <span id="xdx_904_ecustom--PercentageOfProvisionalConsiderationAmountForTransferOfShare_iI_dp_c20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zOvv3D7iPKR5" title="Percentage of provisional consideration amount for transfer of share">70</span>% of S$<span id="xdx_902_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zBgdhcl1glgg" title="Provisional consideration amount for transfer of share">24,000,000</span> and
Estimated Agreed Amount of negative S$<span id="xdx_907_eifrs-full--SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_c20230630__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z90apEOgBox3" title="Estimated settlement liability">5,000,000</span>.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">14.</td>
    <td style="font-weight: bold">Amount due from/to related parties (continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the agreement on the purchase consideration between Rainforest Capital VCC as the buyer and Dr. Kevin Yip as the seller for the
purchase of the shares of Basel Medical Group Pte. Ltd. under the sale and purchase agreement dated June 27, 2023, the outstanding receivables
due from director, Dr. Kevin Yip, and related party, Singmed Investment Pte Ltd, have been assigned to and are borne by Rainforest Capital
VCC. On August 23, 2024, Rainforest Capital VCC entered into a deed of undertaking (the &#8220;Repayment Deed&#8221;) with the Group,
undertaking to fully transfer and pay to the Group, any and all outstanding receivables that is owed by Singmed Investment Pte Ltd and
Dr. Kevin Yip to the Group, being S$<span id="xdx_907_eifrs-full--LoansAndAdvances_iI_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipAndSingmedInvestmentPteLtdMember_zPZ5t0DRBnv5" title="Loan amount">11,877,624</span> (the &#8220;Loan Amount&#8221;), to the Group by September 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out the amounts owed to the Group by Rainforest Capital VCC, which has assumed the obligations of Dr. Kevin Yip
and Singmed Investment Pte Ltd pursuant to the Repayment Deed as of the date indicated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zPtPEuMmPGsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zC2JEy5rSo2l">Schedule
of amount due from related party</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June 30,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230630_znLudtLnW56h" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June 30,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">US$</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">S$</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zFT09TOy3V76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">Amount due from a director</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzuSgYcTlDH" style="width: 10%; text-align: right" title="Amount due from a director">976,453</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,320,457</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z6SSlYJZFT3d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z81emXwnUhV5" style="border-bottom: Black 1pt solid; text-align: right" title="Amount due from related parties">7,806,823</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,557,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zAkXyPtHolqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630_zXCUsdqcUWKf" style="border-bottom: Black 1pt solid; text-align: right" title="Total">8,783,276</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,877,624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zXcBg8Jag026" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the financial year ended June 30, 2024, the Group incurred an aggregate sum of S$<span id="xdx_904_eifrs-full--WagesAndSalaries_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zdrR2Ds9PCf" title="Professional medical practitioner salary">900,000</span> (US$<span id="xdx_902_eifrs-full--WagesAndSalaries_uUSD_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zN9jp70PYZpj" title="Professional medical practitioner salary">682,180</span>) for professional medical practitioner
salaries owed to Dr. Kevin Yip for his services from July 1, 2023 to June 30, 2024. Such sum of US$<span id="xdx_90C_eifrs-full--OtherPayables_iI_uUSD_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zDcVpgHjemdb" title="Salary payable">682,180</span> will be set-off by the Group
against the amounts owed to the Group by Dr. Kevin Yip and Singmed Investment Pte Ltd. Thus, following such set-off, as of June 30, 2024,
total amounts due from Dr. Kevin Yip and Singmed Investment Pte Ltd is estimated to amount to US$<span id="xdx_90D_eifrs-full--AmountsReceivableRelatedPartyTransactions_iI_uUSD_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipAndSingmedInvestmentPteLtdMember_zlybycqXgAne" title="Receivables from related parties">8,101,096</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Rainforest Capital VCC has paid an aggregate sum of US$<span id="xdx_90F_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z71kNQwuc7V6" title="Related party advance for IPO expenses paid">599,730</span> for the period from July 1, 2023 to June 30, 2024 on behalf
of the Group for professional fees incurred in connection with the group&#8217;s initial public offering. On February 27, 2024, July
22, 2024 and July 31, 2024, Rainforest Capital VCC also repaid a sum of US$<span id="xdx_902_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240227__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zCu9XYqPzJo" title="Partial settlement of related party receivables">20,000</span>, US$<span id="xdx_901_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240722__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zFxwjeFUVA2a" title="Partial settlement of related party receivables">630,000</span> and US$<span id="xdx_901_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240731__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zuyZMkF4bQB7" title="Partial settlement of related party receivables">4,048,000</span> respectively to the Group
to partially settle the amounts due from a director and related parties. Finally, Rainforest Capital VCC has paid US$<span id="xdx_907_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240815__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z6O0HzkJH0Nf" title="Final settlement under repayment deed">750,000</span> on August
15, 2024, US$<span id="xdx_90E_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240816__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_za5uQHDQPiy9" title="Final settlement under repayment deed">750,000</span> on August 16, 2024, US$<span id="xdx_90F_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240920__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zzrmPel3Injb" title="Final settlement under repayment deed">651,000</span> on September 20, 2024 and a final US$<span id="xdx_907_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240923__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zgALa3JqZGe5" title="Final settlement under repayment deed">652,366</span> on September 23, 2024 pursuant to the
Repayment Deed as final settlement of such amounts owed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
such repayment, the full amount due from a former director and Singmed Investment Pte Ltd, that has been assigned to Rainforest Capital
VCC, has been fully paid off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Amount
due to related parties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount
due to related parties consist of amount due to shareholders and directors. The amounts are non-trade in nature, unsecured, interest-bearing,
repayable on demand and is to be settled in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount
due to a related parties represents advances provided to cover various business expenses and other expenditures incurred by the Group
in the ordinary course of business.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureBorrowingsAbstract', window );"><strong>Schedule Of Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Borrowings</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfBorrowingsExplanatory_zZcTqjS6HeTd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold"><span id="xdx_82E_zZ6TWi4fwlc3">Borrowings</span></td></tr>
  </table>


<p id="xdx_89A_eifrs-full--DisclosureOfDetailedInformationAboutBorrowingsExplanatory_zmN8Qhr6RF51" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zdt7LE6MD55l" style="display: none">Schedule
of borrowings</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zwlNex0l6wPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zZKEthUKq2Cf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--CurrentPortionOfBorrowingsAbstract_iB_zQ729fu69Byb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_z9MC6pvOiik3" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- Bank overdraft</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_uUSD_c20250630_zHRARvdwfRui" style="width: 14%; text-align: right" title="- Bank overdraft">48,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">61,371</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentLeaseLiabilities_iI_zU5gGaaZhtb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--CurrentLeaseLiabilities_iI_uUSD_c20250630_zpuJBUb8KF36" style="text-align: right" title="- Lease liabilities">1,619,426</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,059,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,500</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--BankBorrowings_iI_zFSQaeP0Gxvl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- Bank borrowings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--BankBorrowings_iI_uUSD_c20250630_zvfOsocVggXl" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1620">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,677,856</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--ShorttermBorrowings_iI_maCBACPzDNY_zA3J4qZPVtCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings Current</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ShorttermBorrowings_iI_uUSD_c20250630_zhZW43QmPIC3" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Current">1,667,677</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,121,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,706,356</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_iB_zB4QdRluA1O1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_zfmOzutEoqvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iI_uUSD_c20250630_ztiRF4DFLkPl" style="text-align: right" title="- Lease liabilities">1,020,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,298,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1634">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_zbiryHuikNkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">- Bank borrowings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_uUSD_c20250630_zSeXumxc9Os7" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1638">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--LongtermBorrowings_iI_maCBACPzDNY_z5BJ7i2ZDasg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings Non-Current</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LongtermBorrowings_iI_uUSD_c20250630_zef1XgI4UvVa" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Non-Current">1,020,801</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,298,357</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_mtCBACPzDNY_zQITjCNLUDph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_uUSD_c20250630_zNR5XqMpmVPe" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings">2,688,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,419,476</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,289,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zmpOgHyCWPSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
breakdown of borrowings are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_ziCBI0sPKCS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zWDdgdsTb0mh">Schedule
of breakdown borrowings</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zNdeaiaRKbB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zfwvnxKW8Slf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zxoPc4KMg4pd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Term loan #1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zY1xyzDrTAa1" style="width: 14%; text-align: right" title="Term loan #1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1658">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1655">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">206,695</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zeBcMdLSjO1h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zqLwc4NbzFN5" style="text-align: right" title="Term loan #2"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,233</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zkl0zIS7Oz7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_z5YP4TD0ZUD4" style="text-align: right" title="Term loan #3"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1665">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,565</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zxKTBFvAzdC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zvDBLiBftzX5" style="text-align: right" title="Term loan #4"><span style="-sec-ix-hidden: xdx2ixbrl1673">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,299</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zIPzY2ktgdY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zetrWLakq162" style="text-align: right" title="Term loan #6"><span style="-sec-ix-hidden: xdx2ixbrl1678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,708</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zoOhaJDdCZj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zCeq04oCt6Ie" style="text-align: right" title="Term loan #7"><span style="-sec-ix-hidden: xdx2ixbrl1683">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,239</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zcDk25wLaR07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zwdcDI3cuEua" style="text-align: right" title="Term loan #9"><span style="-sec-ix-hidden: xdx2ixbrl1688">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322,818</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_z7aQ7Mv5s3C7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zrUrbxCAElk5" style="text-align: right" title="Term loan #10"><span style="-sec-ix-hidden: xdx2ixbrl1693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,573,744</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zB8fnSzo1QW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zwI8CWYChySb" style="text-align: right" title="Term loan #11"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1695">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691,989</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z5m3JcKwdPS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Term loan #12</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z371D7LxwDO2" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan #12"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1700">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1701">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zJQcXa01mFGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    loan</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zu6KKmPCkRq5" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan"><span style="-sec-ix-hidden: xdx2ixbrl1708">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1705">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,261,290</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>




<p id="xdx_8A8_zcOobwGxFTUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutBorrowings_z7Z3O9OHS2Jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of borrowings are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zqwfwL5RQPh5">Schedule
of details borrowings</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Term loan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Facility</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">amount</p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Effective</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">interest rate</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maturity date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%
                                            p.a.</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Term loan #1</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zmwe5qGEnbYi" style="width: 20%; text-align: right" title="Term loan facility amount">S$600,000</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zXftvuI5Mfvc" title="Borrowings interest rate">2.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: right"><span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_z96JMNsqrX5i" title="Borrowing maturity date">October 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #2</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zo27zLqEwcfl" style="text-align: right" title="Term loan facility amount">S$1,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_z3zLZh8Q6KB7" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zCEof4omSSu5" title="Borrowing maturity date">October 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #3</td><td>&#160;</td>
    <td id="xdx_983_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zZScS99VHdce" style="text-align: right" title="Term loan facility amount">S$600,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zEQDShG6OZE4" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zATvoJ4ZG6d" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #4</td><td>&#160;</td>
    <td id="xdx_989_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zJP4gzAywMp5" style="text-align: right" title="Term loan facility amount">S$700,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_z4GhlSEknfH4" title="Borrowings interest rate">2.50</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zRa8gabc442g" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #6</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zSWuZ6MrwTv7" style="text-align: right" title="Term loan facility amount">S$1,400,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zcKiNqHB0Io6" title="Borrowings interest rate">2.25</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zOL0DfbOCMVj" title="Borrowing maturity date">April 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #7</td><td>&#160;</td>
    <td id="xdx_980_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zjvSjDiIMNV" style="text-align: right" title="Term loan facility amount">S$1,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zyyRWErTzY9j" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zVCjHKippPUk" title="Borrowing maturity date">October 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #9</td><td>&#160;</td>
    <td id="xdx_981_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_z8kNMs3jXSLd" style="text-align: right" title="Term loan facility amount">S$850,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zpW1oRi2kVWd" title="Borrowings interest rate">2.25</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zsJvLxwgL8rb" title="Borrowing maturity date">April 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #10</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zRLLPOyMADtc" style="text-align: right" title="Term loan facility amount">S$600,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zqoQHJtVtV5l" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_za5oe8qgkVF" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zIBpnDvgdMni" style="text-align: right" title="Term loan facility amount">S$1,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zvK0ob31ByUi" title="Borrowings interest rate">3.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zqiD5Y1yqA1h" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zjvXaaZgKAs1" style="text-align: right" title="Term loan facility amount">S$500,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_z9IZjshJeJtc" title="Borrowings interest rate">2.50</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zsx6e8CUqMi5" title="Borrowing maturity date">March 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_z3O9f7OqgR45" style="text-align: right" title="Term loan facility amount">S$529,890</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zXsBAnX0tHZ6" title="Borrowings interest rate">1.53</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zSZRyAqhlFXb" title="Borrowing maturity date">December 2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zDLFxKuDwkR7" style="text-align: right" title="Term loan facility amount">S$501,670</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zn8aOp0JAuJh" title="Borrowings interest rate">1.53</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_z8ws7KhQnl6k" title="Borrowing maturity date">December 2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #11</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_z27O3M099r9a" style="text-align: right" title="Term loan facility amount">S$400,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zCRg2dGta2K3" title="Borrowings interest rate">2.25</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zQ2J0zJXvgW8" title="Borrowing maturity date">January 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_z7nETdPtOQOd" style="text-align: right" title="Term loan facility amount">S$1,500,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zKHmVImFfpe3" title="Borrowings interest rate">2.50</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zZGx25X3Jklc" title="Borrowing maturity date">December 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #12</td><td>&#160;</td>
    <td id="xdx_985_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zUpZt2bPFomb" style="text-align: right" title="Term loan facility amount">S$4,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zeo2FBScLV3" title="Borrowings interest rate">4.30</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z1FRr2XA00V1" title="Borrowing maturity date">One-month term, upon maturity</span></td></tr>
  </table>

<p id="xdx_8A5_zsOZjll8XZX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
loan #1 to #12 was fully settled during the financial year, and as at June 30, 2025, there are no outstanding bank borrowings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eifrs-full--DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_zbFJuUGQizij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of liabilities arising from financing activities is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfiMpdyhrmdg">Schedule
of reconciliation of liabilities arising from financing activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Beginning of</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proceed from</b></span></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>Non-cash changes</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">End of</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">financial
                                            year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
    flows</b></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>
                                                                                                                                                                                                                              <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>bank</b></span></p>
                                                                                                                                                                                                                              <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>borrowings</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Addition</b></span></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Accretion
                                            of</p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">interests</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">financial</p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">period</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 10%">- Current</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zt3WYqOApUYi" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings">22,407</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zULAica0qbTb" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows">(861,945</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z4Dg6eG11iNa" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zumGlwPxqnyi" style="width: 10%; text-align: right" title="Addition lease liabilities current">3,557,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z9m5DJkhsgUe" style="width: 10%; text-align: right" title="Accretion of interests current">90,389</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zh1GdGMnjdt9" style="width: 10%; text-align: right" title="Other non cash changes current">(1,188,472</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z5rjM5nVLmag" style="width: 10%; text-align: right" title="Lease liabilities current, ending">1,619,426</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zCCXuDOVsfz8" style="text-align: right" title="Lease liabilities non-current, beginnings"><span style="-sec-ix-hidden: xdx2ixbrl1818">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeIUBS8onrIf" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z8GsKz6zc8pi" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"><span style="-sec-ix-hidden: xdx2ixbrl1822">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zl07H7xrRPMc" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"><span style="-sec-ix-hidden: xdx2ixbrl1824">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjmqj9cSZSb3" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"><span style="-sec-ix-hidden: xdx2ixbrl1826">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zFhyROnbMh28" style="text-align: right" title="Other non cash changes non current">1,020,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zIWHiFuDIeF9" style="text-align: right" title="Lease liabilities non-current, ending">1,020,801</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--BankBorrowings_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zQ03przyNmv" style="text-align: right" title="Bank borrowings, beginnings">2,105,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zgjyNKdFBFcb" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current">(5,320,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUDWSvmuBqW7" style="text-align: right" title="Proceed from bank borrowings, current">3,144,901</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionBankBorrowingsCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zrOoTURCPyA6" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUYIJbWaaAYl" style="text-align: right" title="Accretion of interests bank borrowings current">69,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zue9Q6PgASn2" style="text-align: right" title="Other non cash changes bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1842">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--BankBorrowings_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zcs3uL1C2UCc" style="text-align: right" title="Bank borrowings, ending"><span style="-sec-ix-hidden: xdx2ixbrl1844">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z44DTK1GAyWf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings">1,244,936</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zIzI3cBpoz22" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent">(1,244,936</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zFFvWz4hnZ4h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"><span style="-sec-ix-hidden: xdx2ixbrl1850">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionBankBorrowingsNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zWdV86ZXOPIg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1852">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsYQmTbr5FZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1854">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUHbvi6QWvH1" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1856">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zMzTr4m7Mze4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zs1RvxrtUEc8" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings">3,372,741</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zZCSZn4dJfob" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings">(7,427,140</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z3nhdVOyuJ1a" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current">3,144,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zcTmyKWWRvvf" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current">3,557,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zGdOLaZ5eRq2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current">160,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zFJbavN0oYCh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current">(161,671</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zu66LVzQlkT2" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending">2,640,227</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Beginning of</p></td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Proceed
                                            from</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Non-cash changes</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">End
    of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">financial
                                            year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Cash flows</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">bank</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">borrowings</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Addition</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Accretion
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">interests</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
year</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 10%">- Current</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--CurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zZkCagR1EcP6" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings">28,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbdVKp4xYHC8" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows">(1,096,308</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zS9GRUWFcb4" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1878">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeo4YnIcGu9g" style="width: 10%; text-align: right" title="Addition lease liabilities current">4,524,209</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z6YbZ6hH5uBh" style="width: 10%; text-align: right" title="Accretion of interests current">114,966</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zouRKEM8rSE" style="width: 10%; text-align: right" title="Other non cash changes current">(1,511,619</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--CurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zSqlGB2becgi" style="width: 10%; text-align: right" title="Lease liabilities current, ending">2,059,748</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NoncurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJZH4bRh0yR9" style="text-align: right" title="Lease liabilities non-current, beginnings"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zny0HBAasPxi" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zfqmOtgZKqBj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbUZvdy7iVyg" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z3NFbRxnAbLj" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"><span style="-sec-ix-hidden: xdx2ixbrl1896">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_ziFc4frHhLQe" style="text-align: right" title="Other non cash changes non current">1,298,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NoncurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJVjOxYKgQlf" style="text-align: right" title="Lease liabilities non-current, ending">1,298,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--BankBorrowings_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zd4RJQm3TgO9" style="text-align: right" title="Bank borrowings, beginnings">2,677,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuTsUG1V7vCd" style="text-align: right" title="Bank borrowings current cash flows">(6,766,838</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5OjWXPNfgOe" style="text-align: right" title="Proceed from bank borrowings, current">4,000,000</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AdditionBankBorrowingsCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zhyTlkOGjvIi" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1908">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z1Nibn0iDCo1" style="text-align: right" title="Accretion of interests bank borrowings current">88,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsgrdK3gkz03" style="text-align: right" title="Other non cash changes bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1912">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--BankBorrowings_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zTGx3TRaq7n6" style="text-align: right" title="Bank borrowings, ending"><span style="-sec-ix-hidden: xdx2ixbrl1914">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8wHAK9WGSy5" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zN6tU9fiYlHd" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current cash flows">(1,583,434</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zV6SjydDYlTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"><span style="-sec-ix-hidden: xdx2ixbrl1920">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zpAp65clDFN2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1922">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5uIHhwvKCQ2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1924">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEVJi6rswpba" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1926">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z0gDTthVuxd4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"><span style="-sec-ix-hidden: xdx2ixbrl1928">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z7z9f1IDrXx1" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings">4,289,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zsY8H7j33HD1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayment of lease and bank liabilities cash flows">(9,446,580</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zMqxQZUOx8Yk" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current">4,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zD75IkMb2AWj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current">4,524,209</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z99G6ECJKoNl" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current">203,948</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zEuO6YN4I9Ue" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current">(213,262</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zBp1vkK8bi2c" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending">3,358,105</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--CurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zP372ZNlPoXd" style="text-align: right" title="Lease liabilities current, beginnings">566,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zERGdLLo45K1" style="text-align: right" title="Repayment of lease liabilities cash flows">(553,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_znqo69272iEe" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1948">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm5A180JBrke" style="text-align: right" title="Addition lease liabilities current"><span style="-sec-ix-hidden: xdx2ixbrl1950">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm31aQcXiosa" style="text-align: right" title="Accretion of interests current">15,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zRAessjprRXe" style="text-align: right" title="Other non cash changes current"><span style="-sec-ix-hidden: xdx2ixbrl1954">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjGwJ26L4kX5" style="text-align: right" title="Lease liabilities current, ending">28,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NoncurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zBAk8eJkwj5b" style="text-align: right" title="Lease liabilities non-current, beginnings">28,500</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zc1p5vsFZ4Ik" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zdsbCwzQf6cj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1962">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOBAqgc2SVQi" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zUih1hJ51mS1" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"><span style="-sec-ix-hidden: xdx2ixbrl1966">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOao7WUyTys8" style="text-align: right" title="Other non cash changes non current">(28,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zMb6CDB6D4hf" style="text-align: right" title="Lease liabilities non-current, ending"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--BankBorrowings_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEtuzHIWPoK" style="text-align: right" title="Bank borrowings, beginnings">3,223,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPeo5LD0MS4c" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current">(2,517,707</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zvbuW1upupy1" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1976">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionBankBorrowingsCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPAvYTRS1XVa" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1978">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuf9MMclmfQi" style="text-align: right" title="Accretion of interests current">160,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zfBjlNMJHAxh" style="text-align: right" title="Other non cash changes current">1,811,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--BankBorrowings_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zJeXZUJvbral" style="text-align: right" title="Bank borrowings, ending">2,677,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zmqSRO5hu3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings">3,395,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zdzCUTrf0gYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zLUypYBpj3N5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1990">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8Tzxwk0Qalb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z45tYKiRywPe" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1994">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_ztaPrbh1zlF6" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes non current">(1,811,636</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zSgZjzQPcqV1" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z8KcFElCssf7" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings">7,212,759</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zOqXe0pjd2Ri" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings">(3,070,707</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zpsjjnUBMeG5" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings and lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2004">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zLto3361fobj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"><span style="-sec-ix-hidden: xdx2ixbrl2006">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zuuNTzX4WiXf" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current">176,238</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zIJpZq6y9ihh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"><span style="-sec-ix-hidden: xdx2ixbrl2010">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zF7NmYHGg4K5" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending">4,289,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zjUGRqdZzZqa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><p id="xdx_80F_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zdpindPSPCMc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">16.</td>
    <td style="font-weight: bold"><span id="xdx_82E_zQ9gVc9pFpKc">Trade and other payables</span></td></tr>
  </table>


<p id="xdx_89B_ecustom--DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_zKxJ7xXfueWl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z6Nk7R5z831k" style="display: none">Schedule
of trade and other payables</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20250630_zLTYgA4E3Ym9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_zYyqsXkpafxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_maTAOPzVdB_zi02tmFckYoa" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: left">- third parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_uUSD_c20250630_zVy5PUMftfL8" style="width: 10%; text-align: right" title="Trade payable- third parties">1,649,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">2,097,415</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">829,324</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Accruals_iI_maTAOPzVdB_zbLoTrZPRdcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--Accruals_iI_uUSD_c20250630_zVtkIXLjXUeb" style="text-align: right" title="Accruals">1,222,998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,074,868</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ValueAddedTaxPayables_iI_maTAOPzVdB_zhilMtwv2CYk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">GST payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ValueAddedTaxPayables_iI_uUSD_c20250630_zgh4jgwuoOui" style="text-align: right" title="GST payables">219,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">391,330</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--OtherPayables_iI_maTAOPzVdB_zNPe2CehumO4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--OtherPayables_iI_uUSD_c20250630_zLHXbmlFvPd5" style="border-bottom: Black 1pt solid; text-align: right" title="Other payables third parties">2,343,283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,980,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">280,427</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherPayables_iTI_mtTAOPzVdB_zuyH3ZABFMDe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TradeAndOtherPayables_iTI_uUSD_c20250630_zodGfcyXNFAi" style="border-bottom: Black 1pt solid; text-align: right" title="Total">5,435,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,913,006</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,575,949</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zPkVeAP2qu8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
payables are non-interest bearing and are normally settled on <span id="xdx_908_ecustom--TradePayablesMaturity_c20240701__20250630_zwvGO3jKESWh" title="Trade payable, maturity">30 to 90 days terms</span> (June 30, 2024: <span id="xdx_90C_ecustom--TradePayablesMaturity_c20230701__20240630_zwtSdzmqiGE7" title="Trade payable, maturity">30 to 90 days</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
payables are non-trade related, unsecured, non-interest bearing, repayable on demand and are to be settled in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
and other payables are denominated in Singapore Dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Amount due to a former director<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureAmountDueToRelatedPartyAbstract', window );"><strong>Amount Due To Former Director</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory', window );">Amount due to a former director</a></td>
<td class="text"><p id="xdx_807_ecustom--DisclosureOfAmountDueToAFormerDirectorExplanatory_zhgZNHaNFPv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">17.</td>
    <td style="font-weight: bold"><span id="xdx_820_zFQmBjqwhKjf">Amount due to a former director</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Amount
due to a former director is denominated in Singapore Dollar. Please refer to Note 14 for the terms of the sale and purchase agreement
between Rainforest Capital VCC and Dr. Kevin Yip, a former director. </span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureAmountDueToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureAmountDueToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of amount due to a former director explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureShareCapitalAbstract', window );"><strong>Share Capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><p id="xdx_802_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zW1VXfZQBfy9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">18.</td>
    <td style="font-weight: bold"><span id="xdx_82F_z8qKF0k7Ysd7">Share capital</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company was established under the laws of BVI on August 10, 2023 with authorized share of <span id="xdx_907_eifrs-full--NumberOfSharesAuthorised_iI_c20230810_zpUDIhfvuD7e" title="Ordinary shares, authorized">16,250,000</span> ordinary shares amounting to S$<span id="xdx_902_ecustom--ValueOfSharesAuthorised_iI_c20230810_zTfIUUysnkxb" title="Ordinary shares, amount">24,455,178</span>
(US$<span id="xdx_908_ecustom--ValueOfSharesAuthorised_iI_uUSD_c20230810_zGJS85MeZv5h" title="Ordinary shares, amount">18,362,500</span>) at a subscription price of US$<span id="xdx_90E_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20230810_zbGJnWe72Qdh" title="Share subscription price">1.13</span> per share at the time of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 96pt; text-align: justify; text-indent: -0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is authorized to issue one class of ordinary share.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
holders of ordinary shares are entitled to receive dividends as and when declared by the Group. All ordinary shares carry one vote per
share without restrictions. The ordinary shares have no par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
February 2025, following the Company&#8217;s initial public offering on Nasdaq, <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_c20250228__ifrs-full--ComponentsOfEquityAxis__custom--InitialPublicOfferingMember_zoovN8LMXNTf" title="Share issue on capital market">2,205,000</span> ordinary shares at a subscription price of
US$<span id="xdx_90B_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20250228__ifrs-full--ComponentsOfEquityAxis__custom--InitialPublicOfferingMember_zB7kD3RbJtx3" title="Share subscription price">4.00</span> per share were issued. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
March 2025, following the exercise of the overallotment option by the underwriter, <span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--ComponentsOfEquityAxis__custom--OverAllotmentOptionsMember_zNvzOvn22j29" title="Share issue on capital market">330,750</span> ordinary shares at a subscription price of
US$<span id="xdx_908_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20250331__ifrs-full--ComponentsOfEquityAxis__custom--OverAllotmentOptionsMember_zTRP35jlTVw7" title="Share subscription price">4.00</span> per share were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">As
of June 30, 2025, <span id="xdx_90A_eifrs-full--NumberOfSharesIssued_iI_c20250630_zzXGYbeBvZl8" title="Number of share issued">18,785,750</span> ordinary shares of the Company were issued in total.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfLeasesExplanatory_zNrnzAX0gSI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">19.</td>
    <td style="font-weight: bold"><span id="xdx_825_zNNwkJ1JBg1k">Leases</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Company
as a lessee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company has lease contracts for clinics. The Company&#8217;s obligations under these leases are secured by the lessor&#8217;s title to
the leased assets. The Company is restricted from assigning and subleasing the leased assets. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company also has certain leases of machinery with lease terms of <span id="xdx_905_ecustom--LeaseTermOfContract_dtM_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zkZGmHGA9lRa" title="Lease term">12</span> months or less and leases of office equipment with low value. The
Company applies the &#8216;short-term lease&#8217; and &#8216;lease of low-value assets&#8217; recognition exemptions for these leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(a)</td>
    <td style="font-weight: bold">Carrying amounts of right-of-use assets under leasing arrangements</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
carrying amounts of right-of-use assets under leasing arrangements are disclosed in Note 9.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(b)</td>
    <td style="font-weight: bold">Lease liabilities</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 56.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of lease liabilities (included under borrowings) and the movements during the year are disclosed in Note 15 and the maturity
analysis of lease liabilities is disclosed in Note 22 under liquidity risk. The Company adopt <span id="xdx_904_eifrs-full--WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_iI_dp_uPure_c20250630_zAEK63GqtCC9" title="Weighted average borrowing rate">5</span>% as weighted average borrowings rate
to determine the present value of the lease payments. The weighted average remaining life of the lease was 1 year.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">19.</td>
    <td style="font-weight: bold">Leases (Continued)</td></tr>
  </table>


<p id="xdx_892_ecustom--DisclosureOfLeaseRelatedExpensesTableTextBlock_zEdUSPhrJEv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zzvUbXrLCC2g">Schedule
of amounts recognized in profit or loss</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(c)</td>
    <td style="font-weight: bold">Amounts recognized in profit or loss</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630_zMIG3aDMmcqd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230701__20240630_zoA8EUzu3Dxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--DepreciationRightofuseAssets_zr0aogHlwPNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: justify">Depreciation of right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630_zjHtOc7VspNl" style="width: 10%; text-align: right" title="Depreciation of right-of-use assets">843,989</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,073,469</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">498,635</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InterestExpenseOnLeaseLiabilities_zajyIKN3s6Vh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zQRGWEPLldXg" style="text-align: right" title="Interest expense on lease liabilities">90,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease expense not capitalized in lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_zuzdLirjcTX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">- Expense relating to short-term leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_uUSD_c20240701__20250630_zTg9aLWWruhc" style="border-bottom: Black 1pt solid; text-align: right" title="Expense relating to short-term leases"><span style="-sec-ix-hidden: xdx2ixbrl2090">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2087">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_zuOZvYvg1lE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total amount recognized in profit or loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_uUSD_c20240701__20250630_zeeVw7pGL8G9" style="border-bottom: Black 1pt solid; text-align: right" title="Total amount recognized in profit or loss">934,378</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,188,435</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">517,276</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zjXndZ1SG6S5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(d)</td>
    <td style="font-weight: bold">Total cash outflow</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had total cash outflows for leases of S$<span id="xdx_900_eifrs-full--CashOutflowForLeases_c20240701__20250630_zPA3DTp2Cvu2" title="Cash outflow for leases">1,096,308</span> (US$<span id="xdx_90F_eifrs-full--CashOutflowForLeases_uUSD_c20240701__20250630_zOclcdB87uci" title="Cash outflow for leases">861,945</span>) (June 30, 2024: S$<span id="xdx_90B_eifrs-full--CashOutflowForLeases_c20230701__20240630_zggItRhNyzTk" title="Cash outflow for leases">566,039</span>).</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(e)</td>
    <td style="font-weight: bold">Extension options</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has several lease contracts that include extension options. These options are negotiated by management to provide flexibility
in managing the leased-asset portfolio and align with the Company&#8217;s business needs. Management exercises significant judgement
in determining whether these extension options are reasonably certain to be exercised.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRelatedPartyTransactionsAbstract', window );"><strong>Significant Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfSignificantRelatedPartyExplanatory', window );">Significant related party transactions</a></td>
<td class="text"><p id="xdx_805_ecustom--DisclosureOfSignificantRelatedPartyExplanatory_zVXmrBJcPg7e" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">20.</td>
    <td style="font-weight: bold"><span id="xdx_822_zcjNc75MDGRb">Significant related party transactions</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--ScheduleOfTransactionsWithRelatedPartyExplanatory_zGuasCrT7mLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
addition to the related party information disclosed elsewhere in the consolidated financial statements, the following transactions with
related parties took place at terms agreed between the parties during the financial period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span id="xdx_8BC_zb9wgXRCFjXl" style="display: none">Schedule of transactions with
related parties</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zgyvd0rOAcl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zZmR0Df9i1y6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--InterestIncomeOnLoansAndReceivable_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_z57jlsdK27Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Interest income on loan to related party</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_ecustom--InterestIncomeOnLoansAndReceivable_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zghxAXZ9dL0h" title="Interest income on loan to related party">1,507</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ManagementFee_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zCp1F2zFTJmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ManagementFee_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zojJerwhMhXa" title="Management fee">3,852,504</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2113">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zfpY8fj25SHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Payment made on behalf to related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zBpXczlu1ZRe" title="Payment made on behalf to related parties">3,715</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,725</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,311,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zVZr7J9zHg6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif"><i>Compensation
of key management personnel</i></span></p>

<p id="xdx_899_ecustom--ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_z4XNVvVbHTid" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span id="xdx_8B7_zC8yZ2n2EV39" style="display: none">Schedule of
compensation of key management personnel</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zctqUncmGv89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20240630_z2iqErxQlKz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--WagesAndSalaries_maKMPCzbwJ_zGlLrYwfMeUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left">Salaries and bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">544,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">693,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">121,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CentralProvidentFund_maKMPCzbwJ_zq33XkIqskpb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">CPF</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">46,540</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">59,194</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">137</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--KeyManagementPersonnelCompensation_iT_mtKMPCzbwJ_zecM9P1e6kK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">591,394</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">752,194</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">121,337</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zXzeaS786D76" style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfSignificantRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant related party explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfSignificantRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment loss on goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract', window );"><strong>Impairment Loss On Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoodwillExplanatory', window );">Impairment loss on goodwill</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfGoodwillExplanatory_zJn8lmsAotUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">21.</td>
    <td style="font-weight: bold"> <span id="xdx_82F_zo5HLuKJIash">Impairment loss on goodwill</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition of Bethesda Medical Pte Ltd and its subsidiary, Oasis Medical Clinic Pte Ltd (&#8220;Bethesda Group Acquisition&#8221;)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">On April 30, 2025, the Company completed its acquisition on all of the ordinary shares in the issued and paid-up share capital of Bethesda
Medical Pte Ltd, a company incorporated in Singapore. Pursuant to the Sale and Purchase Agreement, the aggregate consideration is S$<span id="xdx_90E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_c20250430_zAb6XuybgHpl" title="Consideration transferred">10,308,000</span>
(US$<span id="xdx_907_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_uUSD_c20250430_zR4ylFwOhXAf" title="Consideration transferred">8,000,000</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the completion of the acquisition, Bethesda Medical Pte Ltd became a wholly owned indirect subsidiary of Basel Medical Group
Ltd.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eifrs-full--DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_zvMglfu9Iu7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
fair value of identifiable assets and liabilities of Bethesda Group as at the acquisition date were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; display: none">&#160;<span id="xdx_8BA_z7nji0UumfN2">Schedule
of fair value of identifiable assets and liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250430_zIGEZzMVyiPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_znTdXUgmookc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-bottom: 1pt">Purchase Consideration</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">10,308,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Assets and liabilities recognised as a result of the acquisition:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_iI_zFFMwjARNYb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,180</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_z427Po6Vqe38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,133,786</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DeferredTaxAssetsRecognisedAsOfAcquisitionDate_iI_zBDHMaHsycg8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,700</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--InvestmentRecognisedAsOfAcquisitionDate_iI_zFOsNFqmAT69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InventoryRecognisedAsOfAcquisitionDate_iI_zyfjupa7QVKk" style="vertical-align: bottom; background-color: White">
    <td>Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,077</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--FairValueOfAcquiredReceivables_iI_zBwWrZZfQNlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">669,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_iI_zUM2ni11yyYf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,895</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LeaseLiabilitiesRecognisedAsOfAcquisitionDate_iI_zVzLSQOUwhCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(431,744</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--BorrowingsRecognisedAsOfAcquisitionDate_iNI_di_zzsyeNLArTV9" style="vertical-align: bottom; background-color: White">
    <td>Borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(453,250</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_iNI_di_zjngBgwWr8Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,544,185</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--AmountDueRecognisedAsOfAcquisitionDate_iI_zbEBiQ0upnh7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amount due to director</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(193,945</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_zhyQkKtUZaQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net identifiable liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(837,691</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_zbPR2aYXYPj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Add: Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,145,691</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Purchase consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zW29lKC3N9k4" title="Purchase consideration">10,308,000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_ziYlOJwKHpF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">As
the new subsidiary&#8217;s operation has yet to be turned around, an impairment loss on the goodwill from this investment has been fully
recognised in year ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase consideration of S$<span id="xdx_909_eifrs-full--CashTransferred_iI_c20250430_zNXplRcECIug" title="Consideration transferred cash">10,308,000</span> was settled by cash hence, there is a S$<span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zUHBbXapDN5d" title="Purchase consideration">10,308,000</span> of net cash outflow impact on the acquisition.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goodwill is attributable to Basel Medical Group&#8217;s expansion strategy in Singapore and the broader Southeast Asian healthcare market.
By broadening its service offerings and integrating advanced medical solutions, Basel Medical Group is positioning itself as a key player
in the region&#8217;s evolving healthcare ecosystem.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquired business contributed revenue of S$<span id="xdx_90B_eifrs-full--RevenueOfAcquiree_c20250501__20250630_zAJB3wOWwUu" title="Revenue">895,362</span> and net loss of S$<span id="xdx_903_eifrs-full--ProfitLossOfAcquiree_c20250501__20250630_zgDA3nQrh578" title="Net loss">448,857</span> to the Group for the period from 1 May 2025 to 30 June 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureImpairmentLossOnGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract', window );"><strong>Fair Value Of Assets And Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Fair value of assets and liabilities</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zpQPBL6iYbS6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">22.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span><span id="xdx_82C_zbIWqI0kpMOa">Fair value of assets and liabilities</span></span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assets
and liabilities not measured at fair value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and cash equivalents, other receivables, amount due from/(to) related parties, other payables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of these balances approximate their fair values due to the short-term nature of these balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade
receivables and trade payables</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of these receivables and payables approximate their fair values as they are subject to normal trade credit terms.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Borrowings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of borrowings approximate their fair values as they are subject to interest rates close to market rate of interests
for similar arrangements with financial institutions.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureFinancialRiskManagementAbstract', window );"><strong>Financial Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial risk management</a></td>
<td class="text"><p id="xdx_802_eifrs-full--DisclosureOfFinancialRiskManagementExplanatory_zutlzvfpcVk6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">23.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"> <span id="xdx_824_zoH2nrhmmYM1">Financial risk management</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s activities expose it to a variety of financial risks from its operations. The key financial risks include credit risk,
market risk (including foreign currency risk, interest rate risk) and liquidity risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors review and agree policies and procedures for the management of these risks, which are executed by the management team. It is,
and has been throughout the current and previous financial year, the Group&#8217;s policy that no trading in derivatives for speculative
purposes shall be undertaken.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sections provide details regarding the Group&#8217;s exposure to the abovementioned financial risks and the objectives, policies
and processes for the management of these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been no change to the Group&#8217;s exposure to these financial risks or the manner in which it manages and measures the risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk refers to the risk that the counterparty will default on its contractual obligations resulting in a loss to the Group. The Group&#8217;s
exposure to credit risk arises primarily from trade and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has adopted a policy of only dealing with creditworthy counterparties. The Group performs ongoing credit evaluation of its counterparties&#8217;
financial condition and generally do not require a collateral.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit
risk on an ongoing basis throughout each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has determined the default event on a financial asset to be when internal and/or external information indicates that the financial
asset is unlikely to be received, which could include default of contractual payments due for more than 60 days, default of interest
due for more than 30 days or there is significant difficulty of the counterparty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
minimise credit risk, the Group has developed and maintained the Group&#8217;s credit risk gradings to categorise exposures according
to their degree of risk of default. The credit rating information is supplied by publicly available financial information and the Group&#8217;s
own trading records to rate its major customers and other debtors. The Group considers available reasonable and supportive forward-looking
information which includes the following indicators:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
                                            or expected significant adverse changes in business, financial or economic conditions that
                                            are expected to cause a significant change to the debtor&#8217;s ability to meet its obligations</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
                                            or expected significant changes in the operating results of the debtor</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            increases in credit risk on other financial instruments of the same debtor</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
                                            changes in the expected performance and behaviour of the debtor, including changes in the
                                            payment status of debtors in the Group and changes in the operating results of the debtor.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.9pt; text-align: justify; text-indent: -21.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the analysis above, a significant increase in credit risk is presumed if a debtor is more than 30 days past due in making contractual
payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group determined that its financial assets are credit-impaired when:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is significant difficulty of the debtor</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            breach of contract, such as a default or past due event</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            is becoming probable that the debtor will enter bankruptcy or other financial reorganisation</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            is a disappearance of an active market for that financial asset because of financial difficulty</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group categorises a receivable for potential write-off when a debtor fails to make contractual payments more than 120 days past due.
Financial assets are written off when there is evidence indicating that the debtor is in severe financial difficulty and the debtor has
no realistic prospect of recovery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89E_ecustom--DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_zog6lTZLQyq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s current credit risk grading framework comprises the following categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8B2_zYzUwT9fUvRi" style="display: none">Schedule of group&#8217;s current
credit risk grading framework</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definition
    of category</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
                                            for recognising</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expected
    credit loss</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ECL)</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zVczdX1ZFn16" title="Definition of category">Counterparty
    has a low risk of default and does not have any past-due amounts.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zNyyOW8P7z1j" title="Basis for recognizing ECL">12-month
    ECL</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zRLruJZXQntb" title="Definition of category">Amount
    is &gt;30 days past due or there has been a significant increase in credit risk since initial recognition.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zkukHFujJcZ" title="Basis for recognizing ECL">Lifetime
    ECL - not credit-impaired</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z9U7FpNFObC9" title="Definition of category">Amount
    is &gt;60 days past due or there is evidence indicating the asset is credit-impaired (in default).</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z4YRgcfhBHXh" title="Basis for recognizing ECL">Lifetime
    ECL - credit impaired</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zt9RtvWDB877" title="Definition of category">There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zYzuI04ZA2wj" title="Basis for recognizing ECL">Amount
    is written off</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_8AC_zqYNOEEcEJq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_zKm570U498u4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the credit quality of the Group&#8217;s financial assets, as well as maximum exposure to credit risk by credit risk
rating categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span id="xdx_8B8_zrG1GeTypH5h" style="display: none">Schedule of financial assets,
minimum exposure to credit risk</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>12-month
                                            or</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lifetime</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ECL</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>allowance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.85pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_ziTubbL19H18" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">2,580,313</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zlUyH4k8RT1a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">(781,133</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_z7fiYqAVot4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">1,799,180</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z3LbbXTeA2P4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">5,362,632</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUWmScCAw49k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"><span style="-sec-ix-hidden: xdx2ixbrl2211">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zME7G9b0uaXh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">5,362,632</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits">(781,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>12-month
                                            or</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lifetime
                                            </b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ECL</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>allowance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.65pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zI5oyuT6Qu42" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">3,281,902</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zsLG2ZF2P4Sd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">(993,524</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zr47nPmnEtz8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">2,288,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.65pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zqKJeUcVd6Gd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">6,820,731</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWCpyLh8alNh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"><span style="-sec-ix-hidden: xdx2ixbrl2223">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zIbc0ZOVrFui" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">6,820,731</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--ExpectedCreditLosses_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zKUfOFKE1Taf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses">(993,524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zq5uK3F5IJVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">2,133,573</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zwDyLLeajhh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">(460,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zPcX0KAr0NH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">1,673,160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z7EHk61iRdth" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits">90,252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zJzifXoOaLn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zBxg9HJHStW4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits">90,252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">Amount due from&#160;&#160;related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUPrVPwObpD" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWrqjJ0jJc96" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl2243">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zhC9d4R2trJ8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zGTw3eF0G8f3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses">(460,413</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zp9uUKXq0Ri8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Trade
receivables</span></b> (Note 1)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all
trade receivables. The Group determines the ECL by using a provision matrix, estimated based on historical credit loss experience based
on the past due status of the debtors, adjusted as appropriate to reflect current conditions and estimates of future economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p id="xdx_89B_ecustom--ScheduleOfExpectedCreditRiskExplanatory_z7GFIIDMZome" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span id="xdx_8B8_z0PTqeAx9RTg" style="display: none">Schedule of credit risk</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zSWj97CBRD38" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_z8VWMWkzkBS5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zxdsx6dfxx67" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zrhImKX3LN81" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zbYszB9rMicc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20250630_zDHftNBWLb35" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Days past due</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not past</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>due</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">1 &#8211; 60</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">61 &#8211; 120</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 120 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 365 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zOQLD6ESaT5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">41</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2256">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TradeReceivables_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zB4qKU2FXWRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703,914</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">843,949</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">133,126</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">644,290</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">255,034</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,580,315</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExpectedCreditLosses_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zyrjjlngKzb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(130,816</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(97,778</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(34,150</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(263,355</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(255,034</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(781,133</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630_z7aXZHiS2tO" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">1,799,182</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zhq2ibgnSIne" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zoN70IEmx7P4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_z4hJs9mERKW3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49A_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zKpbcz8XHpYi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zi6k2QOgYn5c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20250630_zDcRTUyZPDdi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Days past due</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not past</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>due</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">1 &#8211; 60</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">61 &#8211; 120</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 120 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 365 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFtwuIwycojf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">41</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2279">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeReceivables_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zb1J5GV3pMq2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">895,308</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,073,420</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">169,323</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">819,473</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">324,378</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,281,902</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ExpectedCreditLosses_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFqaNuN7FvK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(166,385</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(124,365</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(43,436</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(334,960</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(324,378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(993,524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--CreditRiskTradeReceivables_iI_c20250630_zJ6JINQ8o1d1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">2,288,378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zcJwzkYlvbrf" title="ECL rate">1.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zQsdCAPyt6Hh" title="ECL rate">2.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zUJ39UpmVr8a" title="ECL rate">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zy7ZnMYaXuI6" title="ECL rate">10.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zUhfYuAVsWdf" title="ECL rate">89.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zge5wyrSroV9" title="Estimated total gross carrying amount at">814,544</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zPtCBonBXbLg" title="Estimated total gross carrying amount at">321,783</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zE32rCuLq1L2" title="Estimated total gross carrying amount at">227,123</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zCkKjpLhdN08" title="Estimated total gross carrying amount at">323,323</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zd8w0DKwHK1h" title="Estimated total gross carrying amount at">446,800</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zMh3HipymTd3" title="Estimated total gross carrying amount at">2,133,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zpBBQn7jbiyj" title="ECL">(15,880</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_908_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zt9l4iR1bBlk" title="ECL">(6,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_90E_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zRTtaH1tSFkk" title="ECL">(5,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zJxe2eSSgzUd" title="ECL">(34,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_90A_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_znOSSRDaQy3" title="ECL">(398,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zPSKFY2iDg8h" title="ECL">(460,413</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20240630_zwIIwwVh3NK9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">1,673,160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table><div style="clear: both"></div>

<p id="xdx_8A4_zdoHYasj5Hte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding movement of loss of allowance of trade receivables is disclosed in Note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Excessive
risk concentration</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentrations
arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have
economic features that would cause their ability to meet contractual obligations to be similarly affected by changes in economic, political
or other conditions. Concentrations indicate the relative sensitivity of the Group&#8217;s performance to developments affecting a particular
industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exposure
to credit risk</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group have no significant concentration of credit risk other than those balances with related company comprising <span id="xdx_907_ecustom--PercentageOfTradeReceivables_dp_c20240701__20250630_zFBePr3Vba25" title="Percentage of trade receivables">1</span>% (June 30, 2024: <span id="xdx_908_ecustom--PercentageOfTradeReceivables_dp_c20230701__20240630__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zDomN74dqWdb" title="Percentage of trade receivables">2</span>%
and <span id="xdx_904_ecustom--PercentageOfTradeReceivables_dp_c20230701__20240630__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zffazXWcOzwd" title="Percentage of trade receivables">1</span>%) of trade receivables. The Group has credit policies and procedures in place to minimise and mitigate its credit risk exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Other
receivables, amount due from related parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assessed the latest performance and financial position of the counterparties, adjusted for the future outlook of the industry in
which the counterparties operate in, and concluded that there has been no significant increase in the credit risk since the initial recognition
of the financial assets. Accordingly, the Group measured the impairment loss allowance using 12-month ECL and determined that the ECL
is insignificant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">b)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Market risk</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
risk is the risk that changes in market prices, such as interest rates and foreign exchange rates will affect the Group&#8217;s income.
The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing
the return on risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Foreign
currency risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s foreign exchange risk results mainly from cash flows from transactions denominated in foreign currencies. At present, the
Group does not have any formal policy for hedging against currency risk. The Group ensures that the net exposure is kept to an acceptable
level by buying or selling foreign currencies at spot rates, where necessary, to address short term imbalances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has transactional currency exposures arising from sales or purchases that are denominated in a currency other than the functional
currency of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group determined that sensitivity to the exchange rate changes does not impose significant impact on the results and operations of the
Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">b)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Market risk (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Interest
rate risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
rate risk is the risk that the fair value or future cash flows of the Group&#8217;s financial instruments will fluctuate because of changes
in market interest rates. The Group&#8217;s exposure to interest rate risk arises primarily from fixed deposits. These transactions and
balances were not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not expect any significant effect on the Group&#8217;s profit or loss arising from the effects of reasonably possible changes
to interest rates on interest bearing financial instruments at the end of the financial year due to those interest-bearing assets and
liabilities are insignificant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">c)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Liquidity risk</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
risk refers to the risk that the Group will encounter difficulties in meeting its short-term obligations due to shortage of funds. The
Group&#8217;s exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. It is
managed by matching the payment and receipt cycles. The Group&#8217;s objective is to maintain a balance between continuity of funding
and flexibility through the use of standby credit facilities. The Group finances its working capital requirements through funds generated
from operations of the Group. Management is satisfied that funds are available to finance the operation of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_893_eifrs-full--MaturityAnalysisForNonderivativeFinancialLiabilities_zHuwj19Xz6Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarises the maturity profile of the Group&#8217;s financial assets and liabilities at the reporting date based on contractual
undiscounted repayment obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span id="xdx_8B8_zTqCxxh6D5Qg" style="display: none">Schedule of remaining contractual
undiscounted repayment obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zDDiv7Uyiqie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zfr36bvkRSbc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zLkTVD1YOtD2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zvbVnaM9Of34" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_zvJDoZzrgjHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,323,882</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,323,882</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,323,882</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_uUSD_zmW9cWmnPnXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zs51y2g0Ooci" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_ziLkbRfhBvgb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,666,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,666,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,666,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2359">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Financial
                                            risk management</span> (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">c)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Liquidity risk (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="display: none"></span></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znO760aU70nh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zurfTvoC7Yye" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zb5RlKmYKbZb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhWJyUO6pjGd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025 (Continued)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_uUSD_zsHKTzy7TL71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2364">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_zrIw9nuG007f" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AmountDueToFormerDirector_iI_zcxyvuJAgCp9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Borrowings_iI_uUSD_zqkAZygjtpY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,688,478</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,688,478</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,667,677</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,020,802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_z2zpiHjOhMxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,903,800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,903,800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,882,999</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,020,802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_uUSD_zvvGDwrZUDEl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total net undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,762,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,762,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,783,113</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,020,802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zhdhZnAY4t68" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zW4tLDXGLexd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zNgEeiziSPd8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhhxnr1PC8wj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years to</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_zMSKFELmFdhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2394">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zgJePvqtm8xi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2399">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_zJXtpSinTMGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2404">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zspTpalBKRai" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2409">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Borrowings_iI_zkkKL6iOu2D8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,419,476</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,419,476</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,121,119</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,298,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_zjnCSjWNQJw3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,052,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,052,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,754,487</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,298,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_z5LgE80ohDmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total net undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,241,739</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,241,739</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,540,096</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,298,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znN8DpCkgdq6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zY9OSMmQ8S63" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zlWNv2tbOdO" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zqIuGgJuqj83" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_z9OLBq9OEQF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2429">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zNPISg6gTXh4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2434">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_z3wIzxMYjFO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2439">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_ztvSrpCVRiw9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2444">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zodiNqYuKph3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2449">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z8RYXNGOL424" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2454">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AmountDueToFormerDirector_iI_zWRDy7mbp5w5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2459">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--Borrowings_iI_zDMi5kh8vIKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,289,790</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,289,790</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,706,356</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,583,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z8tOCrqCxNie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,897,258</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,897,258</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,313,824</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,583,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_zEskyGVecE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total net undiscounted financial assets/(liabilities)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,374,447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,374,447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,957,881</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,583,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_z6PafSkHHsDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureFinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureFinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments by category<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureFinancialInstrumentsAbstract', window );"><strong>Financial Instruments By Category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments by category</a></td>
<td class="text"><p id="xdx_803_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zFzaAV8cAUle" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">24.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span id="xdx_82A_zIFdHuv9GwKb">Financial instruments by category</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the reporting date, the aggregate carrying amounts of financial assets, at FVPL, financial assets measured at amortized cost and financial
liabilities at amortized cost were as follows:</span></p>

<p id="xdx_89E_ecustom--ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_zmCC3cVS4V3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zZnnlwFhzcd8" style="display: none">Schedule
of financial assets measured at amortized cost and financial
liabilities at amortized cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zVEFq3dl8azk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zmZEV0hdg5X9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financial assets measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--TradeAndOtherCurrentReceivables_iI_z0LKC611wQmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zC2ElVRk1an3" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Trade and other receivables">7,324,082</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iI_zxW5T2z5Aw84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zTqqPBT1zTHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and cash equivalents">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zwvylzcMY9hh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2490">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TotalUndiscountedFinancialAssets_iI_zGe8bkeB0v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total financial assets measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zZgeX7zugoW8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial assets measured at amortized cost">9,666,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financial liabilities measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeAndOtherPayables_iI_zt9Vfjrdue9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--TradeAndOtherPayables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zATLIUf99y0j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and other payables">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,369</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z2yV5YWknT0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zpqOqmykWp4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl2506">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2503">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AmountDueToFormerDirector_iI_zgR4cCpHnL2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--AmountDueToFormerDirector_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zNcRi8uGR6ai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to a former director"><span style="-sec-ix-hidden: xdx2ixbrl2511">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2508">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Borrowings_iI_zy6Wr8d5EP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--Borrowings_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zYAiDlnSzWja" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Borrowings">48,251</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">61,371</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,261,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z2g9QyNok5Ie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total financial liabilities measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zLxzGpFYvJzg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial liabilities measured at amortized cost">5,263,573</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,694,739</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,868,758</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zkAu9wq9lKU4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureCapitalManagementAbstract', window );"><strong>Capital Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CapitalManagementExplanatory', window );">Capital management</a></td>
<td class="text"><p id="xdx_807_ecustom--CapitalManagementExplanatory_zKWYOklXuIm4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; display: none; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">25.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"> <span id="xdx_829_zDrs2MakOlxk">Capital management</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of the Group&#8217;s capital management is to safeguard the entity&#8217;s ability to continue as a going concern.
The related parties have undertaken not to recall the amounts due to them until such time the Company is in the position to repay these
amounts without impairing its liquidity position and to provide continuing financial support and adequate funds to enable the Company
to meet its liabilities as and when they fall due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
changes were made in the objectives, policies or processes during the financial year ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is not subjected to either internal or external imposed capital requirement. The Group&#8217;s overall strategy remains unchanged
from 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CapitalManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital management explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CapitalManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureCapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureCapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events occurring after the reporting period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory', window );">Events occurring after the reporting period</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_zrE0f8up98E8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">26.</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span id="xdx_824_zQoD25TCaUnc">Events occurring after the reporting period</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no significant events that occurred after the financial year ended June 30, 2025, which require adjustment to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
the following non-adjusting events occurred subsequent to the reporting period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, the Company has appointed NLA DFK Assurance PAC as its new auditor, in place of
                                            Onestop Assurance PAC.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, the Company has put on hold the plan for the acquisition of Bitcoin in exchange
                                            for the issue of ordinary shares in the Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, Basel Medical Group Pte Ltd has made <span id="xdx_905_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zHz1BQ46TLka" title="Investments percentage"><span id="xdx_905_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zyzkgV3yp9zh" title="Investments percentage"><span id="xdx_909_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zzgm5LhtVKJa" title="Investments percentage">60</span></span></span>% investments in SSOC Novena Pte. Ltd.,
                                            SSOC Orchard Pte. Ltd. and SSOC Farrer Park Pte. Ltd. In September 2025, <span id="xdx_90E_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zrPqT0yIUyXa" title="Investments sale percentage"><span id="xdx_90F_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1lqMQe4h8zd" title="Investments sale percentage"><span id="xdx_905_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zYRCPWbpxRdg" title="Investments sale percentage">7</span></span></span>% of these investments
                                            in each of the 3 companies has been sold to external party, such that the company holds <span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zifyCwlFvWJe" title="Investments hold percentage"><span id="xdx_90D_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zti3fExn0fBl" title="Investments hold percentage"><span id="xdx_908_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zcLO6L8LAk1j" title="Investments hold percentage">53</span></span></span>%
                                            of the share capital in each of the 3 companies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            July 2025, the Company&#8217;s subsidiary, Pharma Avenue Pte Ltd, increased its share capital
                                            to <span id="xdx_90D_eifrs-full--NumberOfSharesIssued_iI_c20250731__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zdYrgspkxlX2" title="Number of shares issued">100,000</span> shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            August 2025, Mr Tan Boon Chye (Darren) was appointed as the Chief Commercial Officer of the
                                            Company. In the same month, Mr Vincent Teo resigned as Chief Partnership Officer from the
                                            Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2025, Eyetrust Medical Pte Ltd was incorporated with Basel Medical Group Pte Ltd
                                            holding <span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--EyetrustMedicalPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_znrYhAnyo6z8" title="Investments hold percentage">65</span>% of the ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2025, the Company&#8217;s subsidiary, Bethesda Medical Pte Ltd, has fully disposed
                                            its investment in associate company, Cereza Bethesda Medical Pte Ltd.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            October 2025, Chartered Imaging Pte Ltd was incorporated with Basel Medical Group Pte Ltd
                                            holding <span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20251001__20251031__ifrs-full--CounterpartiesAxis__custom--CharteredImagingPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_ziYrHvnXvOD4" title="Investments hold percentage">100</span>% of the ordinary shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            October 2025, Basel Medical Group Pte Ltd has obtained a S$<span id="xdx_901_eifrs-full--NetDebt_iI_c20251031__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1Hr2BKEC9t2" title="Loan">3,000,000</span> term loan facility for
                                            a 3 year tenor.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                                            <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">j)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The major shareholder, Rainforest Capital VCC has agreed to provide financial support for at least 12 months from the date of the auditor&#8217;s
report.</td></tr>
                                                                            </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policy information (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory', window );">Compliance with International Financial Reporting Standards (&#8220;IFRS&#8221;)</a></td>
<td class="text"><p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_zI4sF8qCbosk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><b>2.1</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><b><span id="xdx_86C_z0I5Q3qpuyua">Compliance
                                            with International Financial Reporting Standards (&#8220;IFRS&#8221;)</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;)
and interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS IC&#8221;) applicable to companies reporting under IFRS.
The financial statements comply with IFRS as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared on a going concern basis.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
ability of the Group to continue as going concern is dependent on: (Please refer to Note 26)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of its major shareholder to provide financial support</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of the Group to generate sufficient and sustainable operating profits and cash flows
                                            over the next 12 months from the date of these financial statements to meet its operating
                                            and financial obligations as and when they fall due; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font: normal 10pt Times New Roman, Times, Serif">the
                                            ability of the Group to procure additional financing and to garner the continuous support
                                            of its existing financiers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New and amended standards adopted by the Group</a></td>
<td class="text"><p id="xdx_845_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_z8tyN44gZzUj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.2</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zaapWlfTeQZ6">New
                                            and amended standards adopted by the Group</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has applied the following amendments for the first time for their annual reporting period commencing July 1, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
                                            of Liabilities as Current or Non-current and Non-current liabilities with covenants &#8211;
                                            Amendments to IAS 1;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
                                            Liability in Sale and Leaseback &#8211; Amendments to IFRS 16; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplier
                                            Finance Arrangements &#8211; Amendments to IAS 7 and IFRS 7.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory', window );">New standards and interpretations not yet adopted</a></td>
<td class="text"><p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_zOSlo6Ziw3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.3</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zw46494mBlR4">New
                                            standards and interpretations not yet adopted</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Certain
new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for June
30, 2025 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected
to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material accounting policy information (Continued)</span></td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory', window );">Revenue from contracts with customers</a></td>
<td class="text"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_z0MFTpCADvNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.4</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zN4EmdCwMtYc">Revenue
                                            from contracts with customers </span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is in the business of providing medical services to patients. Revenue from contracts with customers is recognized when control
of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be
entitled in exchange for those goods or services. Revenue is presented net of goods and services tax, rebates, and discounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from the rendering of medical services is recognized at the point in time when the entity satisfies the performance obligation by transferring
a promised good or service to the customer, which is when the customer obtains control of the good or service. This is generally when
the significant acts have been completed, ie, upon the completion of consultations, clinical treatments, medical tests and operations.
The Group considers whether there are other promises in the contract that are separate performance obligations to which a portion of
the transaction price needs to be allocated. The amount of revenue recognized is the amount allocated to the satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction
price is the amount of consideration in the contract to which the Group expects to be entitled in exchange for transferring the promised
goods or services. In determining the transaction price for the rendering of medical services the Group considers the effects of variable
consideration. Contracts with customers normally does not include any contractual adjustment such as right of return, volume discount
etc. In rare circumstances where consideration is variable, the Group estimates the amount of consideration to which it will be entitled
in exchange for rendering of service to the customer. The variable consideration is estimated at contract inception and constrained until
it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated
uncertainty with the variable consideration is subsequently resolved.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zNlI4GOW3hB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.5</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zjjZCf7gH2k3">Segment
                                            reporting</span></b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the Group&#8217;s internal organizational structure as well as information about geographical
areas, business segments and major clients in the consolidated financial statements for detailing the Group&#8217;s business segments.
Based on the criteria established, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief
Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the
Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. As the Group&#8217;s long-lived assets are substantially located in Singapore, no geographical segments are presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material accounting policy
                                                                                                                                   information (Continued)</span></td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government grants</a></td>
<td class="text"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForGovernmentGrants_zAuRT15sMxta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.6</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zCgyw8r1jMv5">Government
                                            grants</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grants
from the government are recognized as a receivable at their fair value when there is reasonable assurance that the grant will be received
and the Group will comply with all the attached conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
grants receivable are recognized as income over the periods necessary to match them with the related costs which they are intended to
compensate, on a systematic basis. Government grants relating to expenses are shown separately as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
grants relating to assets are deducted against the carrying amount of the assets.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation', window );">Basis of consolidation</a></td>
<td class="text"><p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForBasisOfConsolidation_z38KFzsEqiE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold"><span id="xdx_86D_zk2dNQCWZlJf">Basis of consolidation</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The financial statements
of the subsidiaries used in the preparation of the consolidated financial statements are prepared as of the same reporting date as the
Company. Consistent accounting policies are applied to like transactions and events in similar circumstances.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consolidation
                                            </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed
to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power
over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated
from the date on that control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements, transactions, balances and unrealized gains on transactions between group entities are
eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment indicator of the transferred
asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.
Deferred tax relief on unrealized intra-Group profit is accounted for only to the extent that it is considered recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-controlling
interests comprise the portion of a subsidiaries&#8217; net results of operations and its net assets, which is attributable to the interests
that are not owned directly or indirectly by the equity holders of the Group. They are shown separately in the consolidated statement
of profit or loss and other comprehensive income, statement of changes in equity, and statement of financial position. Total comprehensive
income is attributed to the non-controlling interests based on their respective interests in a Subsidiaries, even if this results in
the non-controlling interests having a deficit balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold">Group accounting (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisitions</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
acquisition method of accounting is used to account for business combinations entered into by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consideration transferred for the acquisition of a subsidiary or business comprises the fair value of the assets transferred, the liabilities
incurred and the equity interests issued by the Group. The consideration transferred also includes any contingent consideration arrangement
and any pre-existing equity interest in the subsidiaries measured at their fair values at the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognized in the income statement.
Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. The
part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within
investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition
date is reported within operating cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the consideration transferred, together with the noncontrolling interest, exceeds the fair value of the net assets, liabilities and contingent
liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in
the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is capitalized as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and
associates. Goodwill is denominated in the currency of the operation acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the cost of acquisition is below the Group&#8217;s interest in the net assets acquired, the difference is recognized directly in the
income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.7</td>
    <td style="font-weight: bold">Group accounting (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
                                            (Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisitions
                                            </i>(Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
not all of the equity of a subsidiary is acquired the noncontrolling interest is recognized either at fair value or at the non-controlling
interest&#8217;s share of the net assets of the subsidiary, on a case-by-case basis. Changes in the Group&#8217;s ownership percentage
of subsidiaries are accounted for within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition-related
costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifiable
assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially
at their fair values at the acquisition date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
an acquisition-by-acquisition basis, the Group recognizes any non-controlling interest in the acquiree at the date of acquisition either
at fair value or at the non-controlling interest&#8217;s proportionate share of the acquiree&#8217;s identifiable net assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
excess of (a) the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair
value of any previous equity interest in the acquiree over the (b) fair value of the identifiable net assets acquired is recorded as
goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disposal</i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a change in the Group&#8217;s ownership interest in a subsidiary result in a loss of control over the subsidiary, the assets and liabilities
of the subsidiary including any goodwill are derecognized. Amounts previously recognized in other comprehensive income in respect of
that entity are also reclassified to profit or loss or transferred directly to retained earnings if required by a specific Standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
retained equity interest in the entity is remeasured at fair value. The difference between the carrying amount of the retained interest
at the date when control is lost and its fair value is recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
                                            with non-controlling interests</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in the Group&#8217;s ownership interest in a subsidiary that do not result in a loss of control over the subsidiaries are accounted for
as transactions with equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest
and the fair value of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_zCo3ehzwuvge" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.8</td>
    <td style="font-weight: bold"><span id="xdx_867_zwcwUjFPi41i">Property and equipment</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">All
items of property and equipment are initially recorded at cost. Subsequent to recognition, property and equipment are measured at cost
less accumulated depreciation and any accumulated impairment losses. The cost of property and equipment includes its purchase price and
any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the
manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property and equipment
if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the property and equipment.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zCtkh77xqXQ3">Schedule of expected useful lives for property, plant and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt">Useful lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Machinery</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and Fittings</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Renovation</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3">5</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Air conditioner</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Software</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives">3</span> years</td></tr>
  </table>

<p id="xdx_8A8_zvVjLwhjcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
residual values, estimated useful lives and depreciation method of property and equipment are reviewed, and adjusted prospectively, if
appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
depreciated assets are retained in the consolidated financial statements until they are no longer in use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.
Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
expenditure relating to property and equipment that has already been recognized is added to the carrying amount of the asset only when
it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured
reliably. All other repair and maintenance expenses are recognized in profit or loss when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
disposal of an item of property and equipment, the difference between the disposal proceeds and its carrying amount is recognized in
profit or loss within &#8220;other losses&#8221;. Any amount in revaluation reserve relating to that item is transferred to retained
profits directly.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zDVTBkhz5Ob" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold"><span id="xdx_863_z4k9wJFUQg4l">Financial instruments</span></td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Initial
recognition and measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets are recognized when, and only when the entity becomes party to the contractual provisions of the instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value
through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction
costs of financial assets carried at FVPL are expensed in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are measured at the amount of consideration to which the Group expects to be entitled in exchange for transferring promised
goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant
financing component at initial recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investments
in debt instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
measurement of debt instruments depends on the Group&#8217;s business model for managing the asset and the contractual cash flow characteristics
of the asset. The three measurement categories for classification of debt instruments are amortized cost, fair value through other comprehensive
income (FVOCI) and FVPL. The Group only has debt instruments at amortized cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest
are measured at amortized cost. Financial assets are measured at amortized cost using the effective interest method, less impairment.
Gains and losses are recognized in profit or loss when the assets are derecognized or impaired, and through the amortisation process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investments
in equity instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
initial recognition of an investment in equity instrument that is not held for trading, the Group may irrevocably elect to present subsequent
changes in fair value in other comprehensive income which will not be reclassified subsequently to profit or loss. Dividends from such
investments are to be recognized in profit or loss when the Group&#8217;s right to receive payments is established. For investments in
equity instruments which the Group has not elected to present subsequent changes in fair value in other comprehensive income, changes
in fair value are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold">Financial instruments (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets (Continued)</span></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derecognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial asset is derecognized where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial
asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or
loss that had been recognized in other comprehensive income for debt instruments is recognized in profit or loss.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Initial
recognition and measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
liabilities are recognized when, and only when, the Group becomes a party to the contractual provisions of the financial instrument.
The Group determines the classification of its financial liabilities at initial recognition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial liabilities are recognized initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable
transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Subsequent
measurement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortized cost using the effective
interest method. Gains and losses are recognized in profit or loss when the liabilities are derecognized, and through the amortisation
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Borrowings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
are presented as current liabilities unless the Group has an unconditional right to defer settlement for at least 12 months after the
balance sheet date, in which case they are presented as non-current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings
are initially recognized at fair value (net of transaction costs) and subsequently carried at amortized cost. Any difference between
the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using
the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.9</td>
    <td style="font-weight: bold">Financial instruments (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derecognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. On derecognition,
the difference between the carrying amounts and the consideration paid is recognized in profit or loss.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment of financial assets</a></td>
<td class="text"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zTvtswurBuz4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.10</td>
    <td style="font-weight: bold"><span id="xdx_862_ztFFXn91QRf9">Impairment of financial assets</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes an allowance for expected credit losses (&#8220;ECLs&#8221;) for all debt instruments not held at FVPL. ECLs are based
on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects
to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from
the sale of collateral held or other credit enhancements that are integral to the contractual terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition,
ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For
those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is
recognized for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
trade receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit
risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix
that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic
environment which could affect debtors&#8217; ability to pay.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers a financial asset in default when contractual payments are 30 days past due. However, in certain cases, the Group may
also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive
the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is
written off when there is no reasonable expectation of recovering the contractual cash flows.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_zEbBVId9vcLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">2.11</td>
    <td style="font-weight: bold"><span id="xdx_868_zrGwJwras9J7">Cash and cash equivalents</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand, deposits with
financial institutions which are subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are presented
as current borrowings on the balance sheet. For cash subjected to restriction, assessment is made on the economic substance of the restriction
and whether they meet the definition of cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForInventoriesExplanatory_zqEuxNn1sUUk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.12</td>
    <td style="font-weight: bold"><span id="xdx_86A_zq3Oz7xXvOa7">Inventories</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost and net realisable value, Cost is calculated using the weighted average basis and includes all costs
of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the
estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make
the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
necessary, allowance is provided for damaged, obsolete and slow-moving item to adjust the carrying value of inventories to the lower
of cost and net realisable value.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory', window );">Offsetting of financial instruments</a></td>
<td class="text"><p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_z4i3ikD7CKWa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.13</td>
    <td style="font-weight: bold"><span id="xdx_867_z0YCIUDfVGo">Offsetting of financial instruments</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset
and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForProvisionsExplanatory_znYA0tqHSlMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.14</td>
    <td style="font-weight: bold"><span id="xdx_86C_zS9WURuRBCS6">Provisions</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow
of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated
reliably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that
an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value
of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to
the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Asset
Retirement Obligation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes a liability and capitalize an expense in property and equipment if the Group has a present legal or constructive obligation
to reinstate the leased premises to their original state upon expiry of the lease. The provision is made based on management&#8217;s
best estimate of the expected costs to be incurred to reinstate the leased premises to their original state. The capitalized provision
for reinstatement costs in property and equipment is amortized over the period of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of non-financial assets</a></td>
<td class="text"><p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_zR9ayGVXiuC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.15</td>
    <td style="font-weight: bold"><span id="xdx_862_zA0TdvBE7VEi">Impairment of non-financial assets</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, (or, where
applicable, when an annual impairment testing for an asset is required), the Group makes an estimate of the asset&#8217;s recoverable
amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of all non-current assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating
unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available
for use are tested for impairment annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairments
of goodwill are not reversed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
asset&#8217;s recoverable amount is the higher of an asset&#8217;s or cash-generating unit&#8217;s fair value less costs of disposal
and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent
of those from other assets or group of assets. Where the carrying amount of an asset or cash-generating unit exceeds its recoverable
amount, the asset is considered impaired and is written down to its recoverable amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses are recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset&#8217;s
recoverable amount since the last impairment loss was recognized. If that is the case, the carrying amount of the asset is increased
to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had
no impairment loss been recognized previously. Such reversal is recognized in profit or loss.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zUuYUw0kOTQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.16</td>
    <td style="font-weight: bold"><span id="xdx_86B_z895DwYRVzTd">Taxes</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            income tax</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid
to the taxation authority. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted
at the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income taxes are recognized in profit or loss except to the extent that the tax relates to items recognized outside profit or loss, either
in other comprehensive income or directly in equity. Management periodically evaluates positions taken in the tax returns with respect
to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: normal; width: 0.5in"><b>2.16</b></td>
    <td style="font-weight: normal"><b>Taxes (Continued)</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: right"></td><td style="width: 0.5in">(b)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
                                            tax</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided using the liability method on temporary differences at the end of the reporting date between the tax bases of assets
and liabilities and their carrying amounts for financial reporting purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability
is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current income tax assets against
current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
                                            and Services Tax (&#8220;GST&#8221;)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues,
expenses and assets are recognized net of the amount of GST except:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the GST incurred on a purchase of assets or services is not recoverable from the taxation
                                            authority, in which case the GST is recognized as part of the cost of acquisition of the
                                            asset or as part of the expense item as applicable; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receivables
                                            and payables that are stated with the amount of GST included.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement
of financial position.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zvhp9UbmErB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td>
                                                                    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zXMQr25szXsj">Leases</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control
the use of an identified asset for a period of time in exchange for consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets.
The Group recognizes lease liabilities representing the obligations to make lease payments and right-of-use assets representing the right
to use the underlying leased assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
                                            (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Right-of-use
assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on
a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option,
depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. The
accounting policy for impairment is disclosed in Note 2.15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s right-of-use assets are presented in Note 9.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating the lease, if the lease term reflects the Group exercising the option to terminate. Variable lease payments that do not
depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the
event or condition that triggers the payment occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments
resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase
the underlying asset.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.17</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
                                            (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in">(a)</td>
    <td>As lessee (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
liabilities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s lease liabilities are included in borrowings (Note 15).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Short-term
leases and leases of low-value assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of office premises (i.e. those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognized
as expense on a straight-line basis over the lease term. The Group has no lease of low-value assets for the year.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Currency translation</a></td>
<td class="text"><p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zLbnIfLbRzwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.18</td>
    <td style="font-weight: bold"><span id="xdx_869_zErVOWCP1J1h">Currency translation</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(a)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Functional
                                            and presentation currency </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment
in which the entity operates (&#8220;functional currency&#8221;). The consolidated financial statements are presented in Singapore Dollar,
which is the functional currency of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
                                            and balances </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in a currency other than the functional currency (&#8220;foreign currency&#8221;) are translated into the functional currency using the
exchange rates at the dates of the transactions. Currency exchange differences resulting from the settlement of such transactions and
from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the end of balance
sheet date are recognized in profit or loss. Monetary items include primarily financial assets (other than equity investments), contract
assets and financial liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a foreign operation is disposed of or any loan forming part of the net investment of the foreign operation is repaid, a proportionate
share of the accumulated currency translation differences is reclassified to profit or loss, as part of the gain or loss on disposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange gains and losses that relate to borrowings are presented in the income statement within &#8220;finance expense&#8221;. All other
foreign exchange gains and losses impacting profit or loss are presented in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.18</td>
    <td style="font-weight: bold">Currency translation (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transactions
                                            and balances </i>(Continued)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-monetary
items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(c)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Translation
                                            of Group entities&#8217; financial statements </i></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a
functional currency different from the presentation currency are translated into the presentation currency as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets
                                            and liabilities are translated at the closing exchange rates at the reporting date;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">income
                                            and expenses are translated at average exchange rates (unless the average is not a reasonable
                                            approximation of the cumulative effect of the rates prevailing on the transaction dates,
                                            in which case income and expenses are translated using the exchange rates at the dates of
                                            the transactions); and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            resulting currency translation differences are recognized in other comprehensive income and
                                            accumulated in the currency translation reserve. These currency translation differences are
                                            reclassified to profit or loss on disposal or partial disposal with loss of control of the
                                            foreign operation.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Goodwill
and fair value adjustments arising on the acquisition of foreign operations are treated as assets and liabilities of the foreign operations
and translated at the closing rates at the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Translations
of the consolidated balance sheets, consolidated statement of profit or loss and comprehensive income, consolidated statement of changes
in shareholders&#8217; equity and consolidated statements of cash flows from S$ into US$ as of and for the year ended June 30, 2025 are
solely for the convenience of the reader and were calculated at the rate of S$1 = US$1.2719, as set forth in the statistical release
of the Federal Reserve System on June 30, 2025. No representation is made that the S$ amounts could have been, or could be, converted,
realized or settled into US$ at that rate on June 30, 2025, or at any other rate.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_z1DrsIFo15i3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.19</td>
    <td style="font-weight: bold"><span id="xdx_860_zakbKSZ3qNXj">Employee benefits</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined
                                            contribution plans</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify; text-indent: -32pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to
defined contribution pension schemes are recognized as an expense in the period in which the related service is performed.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.19</td>
    <td style="font-weight: bold">Employee benefits (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
                                            employee benefits</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is
recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result
of past service provided by the employee, and the obligation can be estimated reliably.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory', window );">Derivative financial instruments</a></td>
<td class="text"><p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_z9f4subZNxTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.20</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zAaJgTtYdHae">Derivative
                                            financial instruments</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">A
derivative financial instrument for which no hedge accounting is applied is initially recognized at its fair value on the date the contract
is entered into and is subsequently carried at its fair value. Changes in its fair value are recognized in profit or loss. The Group
does not apply hedge accounting for its derivative financial instruments.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zFFrc5tiaJS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.21</td>
    <td style="font-weight: bold"><span id="xdx_866_zyfTi1CoYnAh">Earnings per share</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings per share is computed by dividing net income attributable to the holders of ordinary shares by the weighted average number of
ordinary shares outstanding during the period presented. Diluted income per share is calculated by dividing net income attributable to
the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number
of ordinary shares and dilutive ordinary share equivalents outstanding during the period. However, ordinary share equivalents are not
included in the denominator of the diluted earnings per share calculation when inclusion of such shares would be anti-dilutive, such
as in a period in which a net loss is recorded.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_z7O2XohbwfEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.22</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKVVItQqxjU3">Share
                                            capital</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from issuance of ordinary shares are recognized as share capital in equity. Incremental costs directly attributable to the issuance of
ordinary shares are deducted against share capital.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyForReservesExplanatory', window );">Merger reserve</a></td>
<td class="text"><p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForReservesExplanatory_zzNfiz5l0SJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_865_zdWg2h5Q17nl">Merger
    reserve</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a business combination under common control, any difference between the consideration paid and the carrying amounts of assets and liabilities
received is presented as a change within equity and recorded under merger reserves.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory', window );">Deferred Offering cost</a></td>
<td class="text"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_zgQ4rvBzv7Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zM5sPpJ0twd4">Deferred
    Offering cost</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defers specific incremental costs directly attributable to an equity securities offering. These costs will be charged against
the gross proceeds of the offering as a reduction of additional paid-in capital. If the Company does not complete the initial public
offering, the deferred costs of the aborted offering will be deferred and charged against the proceeds of a subsequent offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: transparent">
    <td style="font-weight: bold; width: 0.5in">2.</td>
    <td style="font-weight: bold">Material accounting policy information (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    offering cost (Continued)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
costs related to an aborted offering will be expensed in the period in which the Company elects to abort the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of the initial public offering, deferred offering costs, which mainly consist of direct incremental legal, auditing,
accounting, consulting, and other fees relating to the initial public offering, are capitalized on the consolidated balance sheets.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory', window );">Dividend to Company&#8217;s shareholders</a></td>
<td class="text"><p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForDividendsExplanatory_zt3Xm83uISgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zci6cjHtuHwc">Dividend
    to Company&#8217;s shareholders</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to the Company&#8217;s shareholders are recognized when the dividends are approved for payment.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for consolidations, including the methods of presentation adopted in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for basis of preparation explanatory [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for deferred offering costs explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for inventories explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for new standards amendments and interpretations issued but not yet effective explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyForReservesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for reserves explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyForReservesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy revenue from contracts with customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for derivative financial instruments and hedging. [Refer: Classes of financial instruments [domain]; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the offsetting of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfChangesInAccountingPoliciesAbstract', window );"><strong>General</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Schedule of activities of subsidiaries</a></td>
<td class="text"><p id="xdx_895_eifrs-full--DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_zvthun1QaGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has following subsidiaries as at June 30, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zeoAc06NJlze">Schedule
of activities of subsidiaries</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of entity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>activities</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
    of business and incorporation</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proportion
                                            of ordinary</b></span></p>
                                                                                                                                                                                                                                                          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            held by Group</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 23%; text-align: center"><span id="xdx_902_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zc1BBMfhEro4" title="Name of entity"><span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zNJgHh6AI4Dj" title="Name of entity">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)</span></span></td><td style="text-align: center; width: 2%; font-weight: bold; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; font-style: normal; width: 25%; font-weight: normal; text-align: center"><span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zdBvBauCsVGg" title="Principal activities"><span id="xdx_90F_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zzFOcucgLfc3" title="Principal activities">Other holding companies</span></span></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 18%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zEwlzLQSSzs5" title="Country of business / incorporation"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_ztcvILYAElq" title="Country of business / incorporation">Singapore</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zltgYElMqL7" title="Ownership percentage">100</span></td><td style="text-align: center; width: 2%; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_z9bcMuVZrWab" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-style: normal; font-weight: normal; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zOzOyDX03s03" title="Name of entity"><span id="xdx_90F_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zK1XjIDwwyg6" title="Name of entity">Singapore Sports &amp; Orthopaedic Clinic Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zggHx0CDuUkj" title="Principal activities"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zf7sDb0M7y2j" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zXLhuQWSQMki" title="Country of business / incorporation"><span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zWuypqel38i" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_906_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zuhnLnmr1jQ" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zGrdAldIgz43" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90A_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z0XyM9JssMuf" title="Name of entity"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z03jl5uXkGne" title="Name of entity">Singapore Sports &amp; Orthopaedic Services Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zs0LvmA9JQuk" title="Principal activities"><span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z6oqqv8mCxGg" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zY243244fo5i" title="Country of business / incorporation"><span id="xdx_90B_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zhinC50O2bg8" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zS5Ad7cehbb5" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zcwTCZrdaH6f" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zOsl4sc4J3u5" title="Name of entity"><span id="xdx_905_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_z6ILKpDLuAvf" title="Name of entity">SSOC Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zxeaQs8hI2C9" title="Principal activities"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zGpTnKyKVqF2" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zZVrAbsvd5Vb" title="Country of business / incorporation"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zor5f0wkcJki" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zXrspKKGida9" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zWTVjlOy8Km5" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span id="xdx_904_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_z12DAYMgkW5g" title="Name of entity"><span id="xdx_906_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zZDzQUcveG27" title="Name of entity">SSOS Pte. Ltd.</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_ztKtziVMD4X" title="Principal activities"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zrIrvPAJmCp8" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90A_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zfmMhjqYiDv1" title="Country of business / incorporation"><span id="xdx_907_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zQcoWaVaenjg" title="Country of business / incorporation">Singapore</span></span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_907_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zpJ3A4fs3j6g" title="Ownership percentage">100</span></td><td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zkPulwrJ1kPc" title="Ownership percentage">100</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
                                            (Continued)</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of entity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>activities</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Country
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">business and</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">incorporation</p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proportion
                                            of ordinary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            held by Group</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td>&#160;</td>
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_za0JX4vZW2ea" title="Name of entity"><span id="xdx_901_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7j4ELHbTVzg" title="Name of entity">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMLArotMAfg6" title="Principal activities"><span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zhGGsa64pb62" title="Principal activities">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7t1hwkMhr7a" title="Country of business / incorporation"><span id="xdx_909_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMUlWcLUNGaj" title="Country of business / incorporation">Singapore</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zuozTzY5mMS4" title="Ownership percentage">100</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zBTjjjM4v6Aa" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zhL15wGo2FK5" title="Name of entity"><span id="xdx_909_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zF22JgZ1SDig" title="Name of entity">Singapore Knee, Sports &amp; Orthopaedic Services Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_900_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zqP7sDJR4V23" title="Principal activities"><span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zIbsDlM7ngif" title="Principal activities">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90C_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zUbL5K9sCini" title="Country of business / incorporation"><span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zxV2i7KQWzyl" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zY3JPgMM8cj7" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_z0hM1ejPszJ9" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zpFdI0TUDcx3" title="Name of entity"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_z4R9kaqAzQwi" title="Name of entity">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zTxs2Y2CvlX5" title="Principal activities"><span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zVhIy287sDRb" title="Principal activities">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zcIKhSJZ04Y7" title="Country of business / incorporation"><span id="xdx_906_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zxkKKhZPFVI8" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zz6nw51dbST4" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zQvojkoCY0kb" title="Ownership percentage">100</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZH2ea4faCDi" title="Name of entity"><span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zkI0fpZqUhr6" title="Name of entity">Basel Medflow Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZLgUn3Eh5lh" title="Principal activities"><span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_ziJb3AB8jt3g" title="Principal activities">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zCaVcEFMbzDi" title="Country of business / incorporation"><span id="xdx_90E_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zOaG7nCiOa9h" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zeT4trlE7MCh" title="Ownership percentage">60</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_z5XZTPxD0Xd5" title="Name of entity"><span id="xdx_90E_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zl8nZWrIS3z4" title="Name of entity">Bethesda Medical Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90B_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zdp2H7AmJKxa" title="Principal activities"><span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zcEJL1B7wt2l" title="Principal activities">Clinics and other general medical services (western)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zm4ljxZvbRT6" title="Country of business / incorporation"><span id="xdx_90F_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zHgkJJy0PPIl" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zD7rakTxlHp4" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zPZ6CfUJUr97" title="Name of entity"><span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zhz8vKyYBJ2c" title="Name of entity">Oasis Medical Clinic Pte. Ltd.</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWJ33wEaTrg9" title="Principal activities"><span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zvRxu6diZxql" title="Principal activities">Clinics and other general medical services (western)</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_za40r1XsueIb" title="Country of business / incorporation"><span id="xdx_900_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zOC0OWSKwuIf" title="Country of business / incorporation">Singapore</span></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWHW0BmX0go8" title="Ownership percentage">100</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">-</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfChangesInAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfChangesInAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policy information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDepreciationRatesExplanatory', window );">Schedule of expected useful lives for property, plant and equipment</a></td>
<td class="text"><p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zCtkh77xqXQ3">Schedule of expected useful lives for property, plant and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt">Useful lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Machinery</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and Fittings</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Medical equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Renovation</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3">5</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Air conditioner</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives">3</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Software</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives">3</span> years</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDepreciationRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of depreciation rates explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDepreciationRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRevenueAbstract', window );"><strong>Disclosure Revenue Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices', window );">Summary of revenue from transfer of goods and services</a></td>
<td class="text"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zg589ArOBNR8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zgY8SssJj8Ig">Summary
of revenue from transfer of goods and services</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zJSMp0T9YV6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230701__20240630_zxDW9goPP9qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Type of service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Revenue_hifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zUrdzqUB9b12" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">Rendering of services &#8211; Medical services</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zYny4s4eHom6" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Rendering of services - Medical services">8,900,027</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">11,319,944</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">10,050,923</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_zwFhhuC4tmV2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--Revenue_uUSD_c20240701__20250630_zqPXIcZVGZpl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">8,900,027</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,319,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,050,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Timing of transfer of service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_hifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_z0kWK0HRvYI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">At a point in time</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zCubJur4o6Si" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services">8,900,027</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,319,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,050,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Revenue_z9YYotkhmN3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Revenue_uUSD_c20240701__20250630_zYdCNdgWixj3" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services">8,900,027</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,319,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,050,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about revenue from transfer of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory', window );">Schedule of Other income</a></td>
<td class="text"><p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_z0EGt6Y88i3d" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zmEFHk4BxpAd" style="display: none">Schedule
of Other income</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zQcI36fMgvjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230701__20240630_zl8VqLXIeAnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--RevenueFromGovernmentGrants_maOGLzcHg_z6yPseML2Gs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Government grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--RevenueFromGovernmentGrants_uUSD_c20240701__20250630_zsA5obhFXjpj" style="width: 14%; text-align: right" title="Government grant">59,003</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">75,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">19,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--RevenueFromInterest_maOGLzcHg_zqQgjS01vjrl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RevenueFromInterest_uUSD_c20240701__20250630_zx992W9DYSwh" style="text-align: right" title="Interest income">65,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ServiceIncome_maOGLzcHg_zvK55TG9uJh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Service income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ServiceIncome_uUSD_c20240701__20250630_zIoypFFBAt42" style="text-align: right" title="Service income">27,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RentalIncome_maOGLzcHg_zxgglFPtjw4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eifrs-full--RentalIncome_uUSD_c20240701__20250630_zR3YwcLNx32j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Rental income"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,469</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eifrs-full--OtherIncome_maOGLzcHg_ztN1apPL8Wk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--OtherIncome_uUSD_c20240701__20250630_z5Pd0wSjebmg" style="text-align: right" title="Other income">591,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">751,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,688</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ReversalOfExpectedCreditLosses_maOGLzcHg_zS8tDxfRHIaf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Reversal of ECL</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ReversalOfExpectedCreditLosses_uUSD_c20240701__20250630_ziAFvIafIb3d" style="border-bottom: Black 1pt solid; text-align: right" title="Reversal of ECL"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">55,741</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherGainsLosses_iT_mtOGLzcHg_zbSfOr8b8zV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Other income</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--OtherGainsLosses_iT_uUSD_c20240701__20250630_zEDsJGfzVwpe" style="border-bottom: Black 1pt solid; text-align: right" title="Other income">866,580</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,102,203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">461,029</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other income explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance cost (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory', window );">Schedule of Finance cost</a></td>
<td class="text"><p id="xdx_897_ecustom--DisclosureOfDetailedInformationAboutFinanceCostExplanatory_zqI950I3xYy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zFJdkm8yEad1" style="display: none">Schedule
of Finance cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20240701__20250630_zotMZH6LvfGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230701__20240630_zg6OGOwTaZC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense on:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--InterestExpenseOnBorrowings_maFCzCYG_zZQBUxzFcZ27" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">- Bank borrowings</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zvn8O8rQdoyi" style="width: 14%; text-align: right" title="Interest expense on bank borrowings">69,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">88,982</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">160,777</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--InterestExpenseOnBorrowings_zZhIxQtlxiuj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense on bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zLX1Qsmi04Y2" style="text-align: right" title="Interest expense on bank borrowings">69,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,777</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eifrs-full--InterestExpenseOnLeaseLiabilities_maFCzCYG_z2K4eUN2YWag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">- Lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zfQIkmOnEqP7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities">90,389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">114,966</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,461</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--InterestExpenseOnLeaseLiabilities_zlGBw0jgAxJh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense on lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zk5ryB9OmTj7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities">90,389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">114,966</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,461</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eifrs-full--FinanceCosts_iT_mtFCzCYG_zgNgOQGrKinf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Finance costs</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinanceCosts_iT_uUSD_c20240701__20250630_zUmPJJUe9kOe" style="border-bottom: Black 1pt solid; text-align: right" title="Finance costs">160,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203,948</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">176,238</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about finance cost explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss)/Profit before tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureLossprofitBeforeTaxAbstract', window );"><strong>Lossprofit Before Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory', window );">Schedule of Profit before tax</a></td>
<td class="text"><p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_z2CvdijwpRu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
before tax has been arrived at after charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zV56QQ3MPSJ9" style="display: none">Schedule
of Profit before tax</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zfQRdLsNeQr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zMrtXK5Z5jl5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--SalesAndMarketingExpense_zm4fxnBkkNl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Marketing and advertisement</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--SalesAndMarketingExpense_uUSD_c20240701__20250630_zXo0mueiFFY8" style="width: 14%; text-align: right" title="Marketing and advertisement">480,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">611,733</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">698,336</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ProfessionalFeesExpense_zP0bwYtAUvi3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProfessionalFeesExpense_uUSD_c20240701__20250630_ztynUwXJj6Q2" style="text-align: right" title="Legal and professional fees">191,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">426,740</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--InsuranceExpense_zO1q2E0mtfTg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InsuranceExpense_uUSD_c20240701__20250630_zDSZI0xvCkbb" style="text-align: right" title="Insurance">269,199</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,112</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TransportationExpense_zR68IiE1L9Nc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transportation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--TransportationExpense_uUSD_c20240701__20250630_zeqSo1EN0jRc" style="text-align: right" title="Transportation">34,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,367</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BadDebtsWrittenOff_zGWzKyGGE3Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bad debts written off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--BadDebtsWrittenOff_uUSD_c20240701__20250630_z03E7GGYrOV7" style="text-align: right" title="Bad debts written off">189,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProvisionForExpectedCreditLosses_zEvrB05ZeEIj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for expected credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ProvisionForExpectedCreditLosses_uUSD_c20240701__20250630_zOYlbTczwA79" style="text-align: right" title="Provision for expected credit losses">536,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,168</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--DepreciationPropertyPlantAndEquipment_zwKE2H3odbXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--DepreciationOfPropertyAndEquipment_uUSD_c20240701__20250630_zG5S3Y8cTakf" style="text-align: right" title="Depreciation of property and equipment">84,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,093</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--AmortisationExpense_zW5o3xpAYzx1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortisation of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--AmortisationExpense_uUSD_c20240701__20250630_zJ3QwWOoYRkc" style="text-align: right" title="Amortisation of right-of-use assets">843,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,073,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498,635</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--RecruitmentExpenses_z2IYbQCtdvt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Recruitment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--RecruitmentExpenses_uUSD_c20240701__20250630_zyvbvwS5XRIc" style="text-align: right" title="Recruitment">1,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,786</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--SubscriptionCirculationRevenue_zF79tmeO4j6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Membership and subscription</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--SubscriptionCirculationRevenue_uUSD_c20240701__20250630_zuJkoceV38bi" style="text-align: right" title="Membership and subscription">16,207</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,614</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--TelephoneExpense_zgw0ybXBITj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Telephone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--TelephoneExpense_uUSD_c20240701__20250630_z3EWC2y2vs6j" style="text-align: right" title="Telephone">32,689</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EmployeeBenefitsExpenses_zPLHIBxTBCua" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employee benefit expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DirectorsSalariesAndBonuses_z2F7ar6XH5C9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Director&#8217;s salaries and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--DirectorsSalariesAndBonuses_uUSD_c20240701__20250630_zJyZVBgcyzv5" style="text-align: right" title="Director's salaries and bonuses">261,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,200</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DirectorsCentralProvidentFund_zrcNNKeVszLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Director&#8217;s CPF</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DirectorsCentralProvidentFund_uUSD_c20240701__20250630_zLRb1v9xpyNk" style="text-align: right" title="Director's CPF">23,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--EmployeesSalariesAndBonus_zonympWtyKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Employees&#8217; salaries and bonus</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--EmployeesSalariesAndBonus_uUSD_c20240701__20250630_z0jOwS3HTZP" style="text-align: right" title="Employees' salaries and bonus">3,773,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,799,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,218,275</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeesCentralProvidentFund_zY7HxnES0T58" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Employees&#8217; CPF</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EmployeesCentralProvidentFund_uUSD_c20240701__20250630_zWqqeuA7E587" style="text-align: right" title="Employees' CPF">346,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,539</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,754</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--OtherStaffExpenses_zLJfRmX5698b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Other staff expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--OtherStaffExpenses_uUSD_c20240701__20250630_zWuFaLYtWFXk" style="text-align: right" title="Other staff expenses">667,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">848,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,576</td><td style="text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureLossprofitBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureLossprofitBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about profit loss before tax explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (benefit)/expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory', window );">Schedule of component of income tax expense</a></td>
<td class="text"><p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_zKRKvpvLPn99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
major components of income tax expense recognized in profit or loss for the periods ended June 30, 2025 and 2024 were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B4_zOkcU8aJDK4g" style="display: none">Schedule
of component of income tax expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_z72t25CmNjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230701__20240630_zX7SCv2fJ87k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB_zP0ofMd8SLu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncome_maITECOzPgr_z05qB93wkJF1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- Current year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentTaxExpenseIncome_uUSD_c20240701__20250630_zO3fmtjagek9" style="width: 14%; text-align: right" title="- Current year"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">383,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DeferredTaxExpenseIncome_maITECOzPgr_ztHkHoRmRErc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Deferred income tax</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DeferredTaxExpenseIncome_uUSD_c20240701__20250630_z9A8WG1h4nVb" style="text-align: right" title="- Deferred income tax"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="color: red; text-align: left">&#160;</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="color: red; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,440</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzPgr_zQdnspfq28F6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    Underprovision in respect of prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zXgXqyvHf8mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="-Underprovision in respect of prior years"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1136">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OverprovisionInRespectOfPriorYears_maITECOzPgr_zgZj4BoOjNTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">- Overprovision in respect of prior years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zKFKwIK4YRt1" style="border-bottom: Black 1pt solid; text-align: right" title="- Overprovision in respect of prior years">(328,444</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,748</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,252</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzPgr_zcGFYykKQDHb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (benefit)/expense recognized in profit or loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zm5SOzgYM9vk" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense recognized in profit or loss">(328,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,393</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">331,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory', window );">Schedule of reconciliation between tax expense and corporate tax rate</a></td>
<td class="text"><p id="xdx_89A_ecustom--DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_zc1V0F7XMD5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation between tax expense and the product of accounting (loss)/profit multiplied by the applicable corporate tax rate for the financial
periods ended June 30, 2025 and 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8BE_zctMmdtSK9Sj" style="display: none">Schedule of reconciliation
between tax expense and corporate tax rate</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zyTwNGAOVeO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230701__20240630_ztlWz7Vx54xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_zd7CrxkW0Ep8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">(Loss)/Profit before tax</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProfitLossBeforeTax_uUSD_c20240701__20250630_zwiWeCGx3CBc" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="(Loss)/Profit before tax">(9,832,138</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(12,505,497</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">2,404,561</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_maITECOzdOp_zaUAzDhHu467" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax using the statutory tax rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eifrs-full--ApplicableTaxRate_pid_dp_c20240701__20250630_zJjAnKz6suE1" title="Statutory tax rate">17</span>% (2024: <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_c20230701__20240630_zoshOBeXpck6" title="Statutory tax rate">17</span>%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_uUSD_c20240701__20250630_zJXyOze5Zkke" style="text-align: right" title="Income tax using the statutory tax rate of 17% (2024: 17%)">(1,671,463</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,125,934</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">408,775</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effects of:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NondeductibleExpenses_maITECOzdOp_zt9IEb2eZ20i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--NondeductibleExpenses_uUSD_c20240701__20250630_zRRkNWd47233" style="text-align: right" title="Non-deductible expenses">1,661,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,113,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,416</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TaxEffectOfTaxLosses_maITECOzdOp_zUJpTY9br8C2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Income not subject to tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--TaxEffectOfTaxLosses_uUSD_c20240701__20250630_z8toyypwFmve" style="text-align: right" title="Income not subject to tax"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,039</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxExemption_maITECOzdOp_z4Ao0HfzyZ85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Income tax exemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--IncomeTaxExemption_uUSD_c20240701__20250630_zndnrXr1Xlp2" style="text-align: right" title="Income tax exemption">(13,700</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,350</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--UtilisationOfCapitalAllowance_iN_di_msITECOzdOp_zPlXDmzsos7h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Utilisation of capital allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--UtilisationOfCapitalAllowance_iN_di_uUSD_c20240701__20250630_zFbhGVB59ool" style="text-align: right" title="(Loss)/Profit before tax">(353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(449</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,322</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--UtilisationOfDeferredTaxAssets_maITECOzdOp_zA18jw3pPKTj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Utilisation of deferred tax assets not recognised in prior year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--UtilisationOfDeferredTaxAssets_uUSD_c20240701__20250630_z9s7XwgAYLPe" style="text-align: right" title="- Utilisation of deferred tax assets not recognised in prior year"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,037</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_maITECOzdOp_zKr6icq0bUKc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Deferred tax asset not recognized during the financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_uUSD_c20240701__20250630_zj9zG7k3N1R9" style="text-align: right" title="Deferred tax asset not recognized during the financial year">23,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,932</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredIncomeTax_iN_di_msITECOzdOp_zSAuB8w5MtCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Deferred income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DeferredIncomeTax_iN_di_uUSD_c20240701__20250630_ziuDHctyStcg" style="text-align: right" title="Deferred income tax"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,440</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzdOp_zysRGi0csu04" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-Underprovision
    in respect of prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zwZekJQntUE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underprovision in respect of prior years"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--OverprovisionInRespectOfPriorYears_maITECOzdOp_zKEwAKwgm2T9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">-Overprovision in respect of prior years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zAS0PfjbLWgj" style="border-bottom: Black 1pt solid; text-align: right" title="Overprovision in respect of prior years">(328,444</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,748</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,252</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzdOp_zodhLq0HOyjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (benefit)/expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zhUZeXA4zcZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense">(328,165</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(417,393</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">331,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about income tax expense explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of effective income tax rate reconciliations explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of use assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRightofuseAssetAbstract', window );"><strong>Right Of Use Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets', window );">Schedule of Right of use assets</a></td>
<td class="text"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOfRightOfUseAssets_zcL0wtpCbpq7" style="margin-top: 0; margin-bottom: 0"><span id="xdx_8B9_zyvUX4DjkF5b" style="display: none">Schedule of Right of use assets</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20240701__20250630_zo6f1W5XaOWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230701__20240630_zDyKh9Q68n93" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zjygkYC3N1Ok" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">At beginning of financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zj5MhPtewhta" style="width: 14%; text-align: right" title="At beginning of financial year">2,164,551</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,753,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,753,093</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zshkwbPYjof4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlkes6T5WX77" style="text-align: right" title="Additions">2,575,627</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,275,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z58CQbzBjFf7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Additions">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zqreUGnhhKWb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zJ7F3mhHJ3Nl" style="text-align: right" title="Acquisition">3,793,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,825,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zxxlgJhDChf1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z8MmI9xatuU6" style="border-bottom: Black 1pt solid; text-align: right" title="Written off">(3,118,402</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,966,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zeomylu1puM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z2XJujeLn8Qh" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">5,415,473</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,887,940</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,753,093</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_z7buZQ04Tbw1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">At beginning of financial year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zepWJUzLP7Za" style="text-align: right" title="At beginning of financial year">2,146,106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,729,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,230,998</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zwpUEpQBLFs2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zTsadXuGUNk9" style="text-align: right" title="Acquisition">2,902,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,691,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zfijastsiDWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zVIs6xVq42Gk" style="text-align: right" title="Depreciation">843,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,073,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498,635</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zi1KIc4mhLS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zYi5sbWCSxW8" style="border-bottom: Black 1pt solid; text-align: right" title="Written off">(2,974,369</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,783,101</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zKF5m2yJUibl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zE4LvUsnRXf5" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">2,918,011</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,711,418</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,729,633</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--RightofuseAssets_iE_zmeDaEoioJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Carrying amount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zxwq0muk8QL9" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">2,497,462</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,176,522</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,460</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--RightofuseAssets_iE_zRhvBajuORCf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">At end of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zjNFvH4G7Eog" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year">2,497,462</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,176,522</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,460</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRightofuseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRightofuseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosurePropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and equipment</a></td>
<td class="text"><p id="xdx_89B_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zuLG4kYM29k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zZwBvvjCIXla" style="display: none">Schedule
of Property and equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--MachineryMember_zeOKGw84jUB6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Machinery</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--FixturesAndFittingsMember_zu3TCMeEiIui" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Furniture</b></span></p>
                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&amp;
                                            Fittings</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--MedicalEquipmentMember_znlea5dKw731" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Medical</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">equipment</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RenovationMember_z5q4WpdegFRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Renovation</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--AirConditionerMember_zpJcwKQZIC31" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Air</b></span></p>
                                                                                                                                                                                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>conditioner</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--ComputerAndOfficeEquipmentMember_zau2Ezgx4pfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Computer</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">&amp; office</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">equipment</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--SoftwareMember_zUtHsdyzLZM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Software</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_zr61neq8C6rk" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zCZ5v7VZxk91" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; width: 20%">At July 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">47,226</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">100,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">86,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">405,349</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">43,727</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">350,248</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,034,126</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zDaOUZgqvRbh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1296">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1298">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zanp3BM2OHT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,852</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">86,724</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">405,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">358,168</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,042,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zm91ZHPlscU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">Acquisition</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1314">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">367,243</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,500,493</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,285,136</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">378,669</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,978</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,618,519</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zw18jBJKfOPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,760</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zsRdT3QzTkZg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    off</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(313,691</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(709,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(315,832</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(253,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,601,659</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlTKXLdOqJSe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iE_zquz533acuMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154,404</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">890,988</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,396,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,145</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">77,978</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,113,666</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zvLDGdQ3vFN1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At July 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,727</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,692</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">977,440</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zmKIBQalHaZf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,888</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,431</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,491</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1374">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,093</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zzLVbLoEvcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">100,664</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">81,533</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">382,200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">352,183</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,007,533</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zFfyPNabMaLd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,244,797</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,192,766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,144</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,116,339</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zCHxEv3eKnQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,347</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,659</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zUoBhUuwjYa6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Written off</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1404">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(248,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(687,468</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(231,410</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(220,994</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,395,372</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iE_zmfezmVF0xVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">At June 30, 2025</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">137,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">688,904</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,368,084</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">43,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">474,280</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,866</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,836,159</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net book values</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20230701__20240630_eifrs-full--PropertyPlantAndEquipment_iE_zTAn0Sf9Wfsf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1422">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">188</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,191</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,985</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,513</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_zvQBYqEaqWX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,332</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,084</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,114</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,865</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,112</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,507</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">US$</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_uUSD_zNRoMjmXqZC6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">At June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">158,884</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,104</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1444">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,694</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">874</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosurePropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosurePropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfInventoriesAbstract', window );"><strong>Schedule Of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory', window );">Schedule of Inventories</a></td>
<td class="text"><p id="xdx_894_ecustom--DisclosureOfDetailedInformationAboutInventoriesExplanatory_z7nkwaMszD7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8BC_zy27EmEnCk38" style="display: none">Schedule
of Inventories</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zjXZUJMhFMC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zjoFjHzeNLT6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Statement of financial position:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--Inventories_iI_uSGD_zhGCMKEYdCgi" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt">Medicine,drugs and medical devices</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--Inventories_iI_uUSD_c20250630_zUP6NJDGidO1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Medicine,drugs and medical devices">295,850</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">376,291</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">72,030</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Statement of comprehensive income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Inventories recognized as an expense in cost of sales</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uUSD_c20240701__20250630_zjPs8IGJFiue" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales">517,713</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20240701__20250630_z7srhafeFRTf" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales">658,479</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20230701__20240630_zquxUcgjmjg8" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales">637,037</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about inventories explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherReceivablesAbstract', window );"><strong>Trade And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfTradeAndOtherReceivableExplanatory', window );">Schedule of trade and other receivables</a></td>
<td class="text"><p id="xdx_896_ecustom--DisclosureOfTradeAndOtherReceivableExplanatory_zProBPpufZgc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zVkSvGDeOPR7" style="display: none">Schedule
of trade and other receivables</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zLxTTTndWmGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_z02274trgh3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade receivables:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentTradeReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zS5i1iY7nyT3" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- third parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentTradeReceivables_iS_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zeAT30Q6n6m8" style="width: 14%; text-align: right" title="Trade receivables - third parties">2,580,313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,281,902</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,133,573</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uSGD_z26AmgvKnYH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Allowance for expected credit loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uUSD_c20250630_zsAyMoFdVC33" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Allowance for expected credit loss">(781,133</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(993,524</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(460,413</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--TradeReceivables_iI_uSGD_zPY9oXipJrh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Receivables</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--TradeReceivables_iI_uUSD_c20250630_zdD1YLxBAWcg" style="text-align: right" title="Trade Receivables">1,799,180</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,288,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,673,160</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LongtermDeposits_iI_uSGD_z9Yjqdoe3dB7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630_zInmKCnGFL1h" style="text-align: right" title="Deposits">5,362,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,820,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,252</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--Prepayments_iI_uSGD_zUR4bP5ubSvj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--Prepayments_iI_uUSD_c20250630_z4Vbs8my1Yma" style="text-align: right" title="Prepayments">326,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415,890</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--OtherCurrentReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zLMVm3xS6ZJ6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--OtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_z7Iu2zWVZEo6" style="border-bottom: Black 1pt solid; text-align: right" title="Other receivables - third parties">162,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">206,391</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">213,644</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentReceivables_iI_uSGD_zYE5waP2kkl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other receivables</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"></td><td id="xdx_98C_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630_z2plWLQfMay8" style="border-bottom: Black 1pt solid; text-align: right" title="Trade and other receivables">7,651,065</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,731,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,005,219</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory', window );">Schedule of movement in allowance for expected credit losses</a></td>
<td class="text"><p id="xdx_89E_eifrs-full--DisclosureOfAllowanceForCreditLossesExplanatory_z6LgFI7dcwuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
movement in allowance for expected credit losses of trade receivables computed based on lifetime ECL was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zFOP7QBl50D6" style="display: none">Schedule
of movement in allowance for expected credit losses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630_zfCV8pkMULRf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20240630_zg9SJ7kNNHCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_ecustom--AllowanceForExpectedCreditLoss_iS_uSGD_z77Y7vyaYfW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Beginning of financial year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iS_uUSD_c20240701__20250630_zs9ZH5cHIPNf" style="width: 14%; text-align: right">361,988</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">460,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">465,986</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AdditionAllowanceForExpectedCreditLosses_uSGD_zbPPBjasV45a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance for expected credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--AdditionAllowanceForExpectedCreditLosses_uUSD_c20240701__20250630_zYZyCn3xbuDh" style="text-align: right">536,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,168</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uSGD_zCTBSfgSGGGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Reversal of allowance for expected credit losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uUSD_c20240701__20250630_z2IQK6Qs4WWi" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Reversal of allowance for expected credit losses">(117,258</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(149,141</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(55,741</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--AllowanceForExpectedCreditLoss_iE_uSGD_zSUBdrh9wBva" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">End of financial year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForExpectedCreditLoss_iE_uUSD_c20240701__20250630_zXdSXVDETDOl" style="border-bottom: Black 1pt solid; text-align: right">781,133</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">993,524</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">460,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfTradeAndOtherReceivableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade and Other Receivable Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfTradeAndOtherReceivableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the allowance relating to impairments of financial assets due to credit losses. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureCashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfCashAndCashEquivalentExplanatory', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><p id="xdx_896_ecustom--DisclosureOfCashAndCashEquivalentExplanatory_zHWzwlOymI9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zyEKgIEHqG6a" style="display: none">Schedule
of cash and cash equivalents</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20250630_zAPyEzVnff49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20240630_zR2w2f76WZ77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashOnHand_iI_zDzX0CsHdh7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Cash on hand</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashOnHand_iI_uUSD_c20250630_zY27CGCTsgIj" style="width: 14%; text-align: right" title="Cash on hand">310</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">395</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--BalancesWithBanks_iI_zJHDCQxJfTT7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash at banks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--BalancesWithBanks_iI_uUSD_c20250630_zveTKI9tORR9" style="border-bottom: Black 1pt solid; text-align: right" title="Cash at banks">2,341,920</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,978,688</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,949,553</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CashAndCashEquivalents_i02I_zT8cFh5xiaK6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630_zt2A4KpjDhbi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents">2,342,230</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,979,083</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,951,053</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfCashAndCashEquivalentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of cash and cash equivalent explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfCashAndCashEquivalentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Amount due from/to related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract', window );"><strong>Amount Due Fromto Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of amount due from related party</a></td>
<td class="text"><p id="xdx_894_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zPtPEuMmPGsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zC2JEy5rSo2l">Schedule
of amount due from related party</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June 30,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230630_znLudtLnW56h" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">June 30,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">US$</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">S$</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zFT09TOy3V76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">Amount due from a director</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzuSgYcTlDH" style="width: 10%; text-align: right" title="Amount due from a director">976,453</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,320,457</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z6SSlYJZFT3d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z81emXwnUhV5" style="border-bottom: Black 1pt solid; text-align: right" title="Amount due from related parties">7,806,823</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,557,167</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zAkXyPtHolqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630_zXCUsdqcUWKf" style="border-bottom: Black 1pt solid; text-align: right" title="Total">8,783,276</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,877,624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureBorrowingsAbstract', window );"><strong>Schedule Of Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of borrowings</a></td>
<td class="text"><p id="xdx_89A_eifrs-full--DisclosureOfDetailedInformationAboutBorrowingsExplanatory_zmN8Qhr6RF51" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zdt7LE6MD55l" style="display: none">Schedule
of borrowings</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zwlNex0l6wPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zZKEthUKq2Cf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--CurrentPortionOfBorrowingsAbstract_iB_zQ729fu69Byb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_z9MC6pvOiik3" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">- Bank overdraft</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_uUSD_c20250630_zHRARvdwfRui" style="width: 14%; text-align: right" title="- Bank overdraft">48,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">61,371</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentLeaseLiabilities_iI_zU5gGaaZhtb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">- Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--CurrentLeaseLiabilities_iI_uUSD_c20250630_zpuJBUb8KF36" style="text-align: right" title="- Lease liabilities">1,619,426</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,059,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,500</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--BankBorrowings_iI_zFSQaeP0Gxvl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- Bank borrowings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--BankBorrowings_iI_uUSD_c20250630_zvfOsocVggXl" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1620">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,677,856</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--ShorttermBorrowings_iI_maCBACPzDNY_zA3J4qZPVtCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings Current</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ShorttermBorrowings_iI_uUSD_c20250630_zhZW43QmPIC3" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Current">1,667,677</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,121,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,706,356</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_iB_zB4QdRluA1O1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_zfmOzutEoqvc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">- Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iI_uUSD_c20250630_ztiRF4DFLkPl" style="text-align: right" title="- Lease liabilities">1,020,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,298,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1634">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_zbiryHuikNkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">- Bank borrowings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_uUSD_c20250630_zSeXumxc9Os7" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1638">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--LongtermBorrowings_iI_maCBACPzDNY_z5BJ7i2ZDasg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings Non-Current</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LongtermBorrowings_iI_uUSD_c20250630_zef1XgI4UvVa" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Non-Current">1,020,801</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,298,357</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_mtCBACPzDNY_zQITjCNLUDph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_uUSD_c20250630_zNR5XqMpmVPe" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings">2,688,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,419,476</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,289,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings', window );">Schedule of breakdown borrowings</a></td>
<td class="text"><p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_ziCBI0sPKCS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zWDdgdsTb0mh">Schedule
of breakdown borrowings</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630_zNdeaiaRKbB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zfwvnxKW8Slf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zxoPc4KMg4pd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Term loan #1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zY1xyzDrTAa1" style="width: 14%; text-align: right" title="Term loan #1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1658">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1655">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">206,695</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zeBcMdLSjO1h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zqLwc4NbzFN5" style="text-align: right" title="Term loan #2"><span style="-sec-ix-hidden: xdx2ixbrl1663">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,233</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zkl0zIS7Oz7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_z5YP4TD0ZUD4" style="text-align: right" title="Term loan #3"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1665">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,565</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zxKTBFvAzdC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zvDBLiBftzX5" style="text-align: right" title="Term loan #4"><span style="-sec-ix-hidden: xdx2ixbrl1673">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,299</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zIPzY2ktgdY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zetrWLakq162" style="text-align: right" title="Term loan #6"><span style="-sec-ix-hidden: xdx2ixbrl1678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1675">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">531,708</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zoOhaJDdCZj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zCeq04oCt6Ie" style="text-align: right" title="Term loan #7"><span style="-sec-ix-hidden: xdx2ixbrl1683">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,239</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zcDk25wLaR07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zwdcDI3cuEua" style="text-align: right" title="Term loan #9"><span style="-sec-ix-hidden: xdx2ixbrl1688">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">322,818</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_z7aQ7Mv5s3C7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zrUrbxCAElk5" style="text-align: right" title="Term loan #10"><span style="-sec-ix-hidden: xdx2ixbrl1693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1690">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,573,744</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zB8fnSzo1QW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zwI8CWYChySb" style="text-align: right" title="Term loan #11"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1695">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">691,989</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z5m3JcKwdPS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Term loan #12</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z371D7LxwDO2" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan #12"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1700">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1701">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zJQcXa01mFGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    loan</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zu6KKmPCkRq5" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan"><span style="-sec-ix-hidden: xdx2ixbrl1708">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1705">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,261,290</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>




<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutBorrowings', window );">Schedule of details borrowings</a></td>
<td class="text"><p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutBorrowings_z7Z3O9OHS2Jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of borrowings are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zqwfwL5RQPh5">Schedule
of details borrowings</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Term loan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Facility</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">amount</p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Effective</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">interest rate</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maturity date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%
                                            p.a.</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Term loan #1</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zmwe5qGEnbYi" style="width: 20%; text-align: right" title="Term loan facility amount">S$600,000</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zXftvuI5Mfvc" title="Borrowings interest rate">2.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: right"><span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_z96JMNsqrX5i" title="Borrowing maturity date">October 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #2</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zo27zLqEwcfl" style="text-align: right" title="Term loan facility amount">S$1,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_z3zLZh8Q6KB7" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zCEof4omSSu5" title="Borrowing maturity date">October 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #3</td><td>&#160;</td>
    <td id="xdx_983_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zZScS99VHdce" style="text-align: right" title="Term loan facility amount">S$600,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zEQDShG6OZE4" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zATvoJ4ZG6d" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #4</td><td>&#160;</td>
    <td id="xdx_989_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zJP4gzAywMp5" style="text-align: right" title="Term loan facility amount">S$700,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_z4GhlSEknfH4" title="Borrowings interest rate">2.50</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zRa8gabc442g" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #6</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zSWuZ6MrwTv7" style="text-align: right" title="Term loan facility amount">S$1,400,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zcKiNqHB0Io6" title="Borrowings interest rate">2.25</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zOL0DfbOCMVj" title="Borrowing maturity date">April 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #7</td><td>&#160;</td>
    <td id="xdx_980_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zjvSjDiIMNV" style="text-align: right" title="Term loan facility amount">S$1,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zyyRWErTzY9j" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_904_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zVCjHKippPUk" title="Borrowing maturity date">October 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #9</td><td>&#160;</td>
    <td id="xdx_981_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_z8kNMs3jXSLd" style="text-align: right" title="Term loan facility amount">S$850,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zpW1oRi2kVWd" title="Borrowings interest rate">2.25</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zsJvLxwgL8rb" title="Borrowing maturity date">April 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term loan #10</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zRLLPOyMADtc" style="text-align: right" title="Term loan facility amount">S$600,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zqoQHJtVtV5l" title="Borrowings interest rate">2.75</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_za5oe8qgkVF" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zIBpnDvgdMni" style="text-align: right" title="Term loan facility amount">S$1,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zvK0ob31ByUi" title="Borrowings interest rate">3.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zqiD5Y1yqA1h" title="Borrowing maturity date">November 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zjvXaaZgKAs1" style="text-align: right" title="Term loan facility amount">S$500,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_z9IZjshJeJtc" title="Borrowings interest rate">2.50</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zsx6e8CUqMi5" title="Borrowing maturity date">March 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_z3O9f7OqgR45" style="text-align: right" title="Term loan facility amount">S$529,890</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zXsBAnX0tHZ6" title="Borrowings interest rate">1.53</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zSZRyAqhlFXb" title="Borrowing maturity date">December 2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zDLFxKuDwkR7" style="text-align: right" title="Term loan facility amount">S$501,670</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zn8aOp0JAuJh" title="Borrowings interest rate">1.53</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_z8ws7KhQnl6k" title="Borrowing maturity date">December 2035</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #11</td><td>&#160;</td>
    <td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_z27O3M099r9a" style="text-align: right" title="Term loan facility amount">S$400,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zCRg2dGta2K3" title="Borrowings interest rate">2.25</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zQ2J0zJXvgW8" title="Borrowing maturity date">January 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_z7nETdPtOQOd" style="text-align: right" title="Term loan facility amount">S$1,500,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zKHmVImFfpe3" title="Borrowings interest rate">2.50</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zZGx25X3Jklc" title="Borrowing maturity date">December 2025</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term loan #12</td><td>&#160;</td>
    <td id="xdx_985_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zUpZt2bPFomb" style="text-align: right" title="Term loan facility amount">S$4,000,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zeo2FBScLV3" title="Borrowings interest rate">4.30</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z1FRr2XA00V1" title="Borrowing maturity date">One-month term, upon maturity</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Schedule of reconciliation of liabilities arising from financing activities</a></td>
<td class="text"><p id="xdx_89F_eifrs-full--DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_zbFJuUGQizij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of liabilities arising from financing activities is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfiMpdyhrmdg">Schedule
of reconciliation of liabilities arising from financing activities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Beginning of</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Proceed from</b></span></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><b>Non-cash changes</b></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">End of</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">financial
                                            year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
    flows</b></span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>
                                                                                                                                                                                                                              <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>bank</b></span></p>
                                                                                                                                                                                                                              <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>borrowings</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Addition</b></span></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Accretion
                                            of</p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">interests</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">financial</p>
                                                                              <p style="text-align: center; margin-top: 0; margin-bottom: 0">period</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 10%">- Current</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zt3WYqOApUYi" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings">22,407</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zULAica0qbTb" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows">(861,945</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z4Dg6eG11iNa" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zumGlwPxqnyi" style="width: 10%; text-align: right" title="Addition lease liabilities current">3,557,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z9m5DJkhsgUe" style="width: 10%; text-align: right" title="Accretion of interests current">90,389</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zh1GdGMnjdt9" style="width: 10%; text-align: right" title="Other non cash changes current">(1,188,472</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z5rjM5nVLmag" style="width: 10%; text-align: right" title="Lease liabilities current, ending">1,619,426</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zCCXuDOVsfz8" style="text-align: right" title="Lease liabilities non-current, beginnings"><span style="-sec-ix-hidden: xdx2ixbrl1818">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeIUBS8onrIf" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z8GsKz6zc8pi" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"><span style="-sec-ix-hidden: xdx2ixbrl1822">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zl07H7xrRPMc" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"><span style="-sec-ix-hidden: xdx2ixbrl1824">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjmqj9cSZSb3" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"><span style="-sec-ix-hidden: xdx2ixbrl1826">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zFhyROnbMh28" style="text-align: right" title="Other non cash changes non current">1,020,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zIWHiFuDIeF9" style="text-align: right" title="Lease liabilities non-current, ending">1,020,801</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--BankBorrowings_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zQ03przyNmv" style="text-align: right" title="Bank borrowings, beginnings">2,105,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zgjyNKdFBFcb" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current">(5,320,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUDWSvmuBqW7" style="text-align: right" title="Proceed from bank borrowings, current">3,144,901</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionBankBorrowingsCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zrOoTURCPyA6" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUYIJbWaaAYl" style="text-align: right" title="Accretion of interests bank borrowings current">69,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zue9Q6PgASn2" style="text-align: right" title="Other non cash changes bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1842">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--BankBorrowings_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zcs3uL1C2UCc" style="text-align: right" title="Bank borrowings, ending"><span style="-sec-ix-hidden: xdx2ixbrl1844">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z44DTK1GAyWf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings">1,244,936</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zIzI3cBpoz22" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent">(1,244,936</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zFFvWz4hnZ4h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"><span style="-sec-ix-hidden: xdx2ixbrl1850">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionBankBorrowingsNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zWdV86ZXOPIg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1852">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsYQmTbr5FZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1854">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUHbvi6QWvH1" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1856">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zMzTr4m7Mze4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zs1RvxrtUEc8" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings">3,372,741</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zZCSZn4dJfob" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings">(7,427,140</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z3nhdVOyuJ1a" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current">3,144,901</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zcTmyKWWRvvf" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current">3,557,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zGdOLaZ5eRq2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current">160,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zFJbavN0oYCh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current">(161,671</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zu66LVzQlkT2" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending">2,640,227</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">15.</td>
    <td style="font-weight: bold">Borrowings (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Beginning of</p></td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Proceed
                                            from</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Non-cash changes</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">End
    of</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">financial
                                            year</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Cash flows</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">bank</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">borrowings</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Addition</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Accretion
                                            of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">interests</p></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
year</span></td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">S$</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">June 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 10%">- Current</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--CurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zZkCagR1EcP6" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings">28,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbdVKp4xYHC8" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows">(1,096,308</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zS9GRUWFcb4" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1878">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeo4YnIcGu9g" style="width: 10%; text-align: right" title="Addition lease liabilities current">4,524,209</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z6YbZ6hH5uBh" style="width: 10%; text-align: right" title="Accretion of interests current">114,966</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zouRKEM8rSE" style="width: 10%; text-align: right" title="Other non cash changes current">(1,511,619</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--CurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zSqlGB2becgi" style="width: 10%; text-align: right" title="Lease liabilities current, ending">2,059,748</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NoncurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJZH4bRh0yR9" style="text-align: right" title="Lease liabilities non-current, beginnings"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zny0HBAasPxi" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"><span style="-sec-ix-hidden: xdx2ixbrl1890">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zfqmOtgZKqBj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbUZvdy7iVyg" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z3NFbRxnAbLj" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"><span style="-sec-ix-hidden: xdx2ixbrl1896">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_ziFc4frHhLQe" style="text-align: right" title="Other non cash changes non current">1,298,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NoncurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJVjOxYKgQlf" style="text-align: right" title="Lease liabilities non-current, ending">1,298,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--BankBorrowings_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zd4RJQm3TgO9" style="text-align: right" title="Bank borrowings, beginnings">2,677,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuTsUG1V7vCd" style="text-align: right" title="Bank borrowings current cash flows">(6,766,838</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5OjWXPNfgOe" style="text-align: right" title="Proceed from bank borrowings, current">4,000,000</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AdditionBankBorrowingsCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zhyTlkOGjvIi" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1908">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z1Nibn0iDCo1" style="text-align: right" title="Accretion of interests bank borrowings current">88,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsgrdK3gkz03" style="text-align: right" title="Other non cash changes bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1912">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--BankBorrowings_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zTGx3TRaq7n6" style="text-align: right" title="Bank borrowings, ending"><span style="-sec-ix-hidden: xdx2ixbrl1914">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8wHAK9WGSy5" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zN6tU9fiYlHd" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current cash flows">(1,583,434</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zV6SjydDYlTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"><span style="-sec-ix-hidden: xdx2ixbrl1920">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zpAp65clDFN2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1922">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5uIHhwvKCQ2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1924">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEVJi6rswpba" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1926">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z0gDTthVuxd4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"><span style="-sec-ix-hidden: xdx2ixbrl1928">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z7z9f1IDrXx1" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings">4,289,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zsY8H7j33HD1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayment of lease and bank liabilities cash flows">(9,446,580</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zMqxQZUOx8Yk" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current">4,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zD75IkMb2AWj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current">4,524,209</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z99G6ECJKoNl" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current">203,948</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zEuO6YN4I9Ue" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current">(213,262</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zBp1vkK8bi2c" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending">3,358,105</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--CurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zP372ZNlPoXd" style="text-align: right" title="Lease liabilities current, beginnings">566,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zERGdLLo45K1" style="text-align: right" title="Repayment of lease liabilities cash flows">(553,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_znqo69272iEe" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1948">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm5A180JBrke" style="text-align: right" title="Addition lease liabilities current"><span style="-sec-ix-hidden: xdx2ixbrl1950">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm31aQcXiosa" style="text-align: right" title="Accretion of interests current">15,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zRAessjprRXe" style="text-align: right" title="Other non cash changes current"><span style="-sec-ix-hidden: xdx2ixbrl1954">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjGwJ26L4kX5" style="text-align: right" title="Lease liabilities current, ending">28,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NoncurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zBAk8eJkwj5b" style="text-align: right" title="Lease liabilities non-current, beginnings">28,500</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zc1p5vsFZ4Ik" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zdsbCwzQf6cj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1962">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOBAqgc2SVQi" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zUih1hJ51mS1" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"><span style="-sec-ix-hidden: xdx2ixbrl1966">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOao7WUyTys8" style="text-align: right" title="Other non cash changes non current">(28,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zMb6CDB6D4hf" style="text-align: right" title="Lease liabilities non-current, ending"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--BankBorrowings_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEtuzHIWPoK" style="text-align: right" title="Bank borrowings, beginnings">3,223,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPeo5LD0MS4c" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current">(2,517,707</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zvbuW1upupy1" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"><span style="-sec-ix-hidden: xdx2ixbrl1976">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionBankBorrowingsCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPAvYTRS1XVa" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"><span style="-sec-ix-hidden: xdx2ixbrl1978">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuf9MMclmfQi" style="text-align: right" title="Accretion of interests current">160,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zfBjlNMJHAxh" style="text-align: right" title="Other non cash changes current">1,811,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--BankBorrowings_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zJeXZUJvbral" style="text-align: right" title="Bank borrowings, ending">2,677,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">- Non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zmqSRO5hu3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings">3,395,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zdzCUTrf0gYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zLUypYBpj3N5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1990">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8Tzxwk0Qalb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z45tYKiRywPe" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl1994">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_ztaPrbh1zlF6" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes non current">(1,811,636</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zSgZjzQPcqV1" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending">1,583,434</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z8KcFElCssf7" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings">7,212,759</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zOqXe0pjd2Ri" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings">(3,070,707</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zpsjjnUBMeG5" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings and lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2004">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zLto3361fobj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"><span style="-sec-ix-hidden: xdx2ixbrl2006">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zuuNTzX4WiXf" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current">176,238</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zIJpZq6y9ihh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"><span style="-sec-ix-hidden: xdx2ixbrl2010">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zF7NmYHGg4K5" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending">4,289,790</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about breakdown of borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory', window );">Schedule of trade and other payables</a></td>
<td class="text"><p id="xdx_89B_ecustom--DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_zKxJ7xXfueWl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z6Nk7R5z831k" style="display: none">Schedule
of trade and other payables</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20250630_zLTYgA4E3Ym9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20240630_zYyqsXkpafxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_maTAOPzVdB_zi02tmFckYoa" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: left">- third parties</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_uUSD_c20250630_zVy5PUMftfL8" style="width: 10%; text-align: right" title="Trade payable- third parties">1,649,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">2,097,415</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">829,324</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Accruals_iI_maTAOPzVdB_zbLoTrZPRdcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--Accruals_iI_uUSD_c20250630_zVtkIXLjXUeb" style="text-align: right" title="Accruals">1,222,998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,074,868</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ValueAddedTaxPayables_iI_maTAOPzVdB_zhilMtwv2CYk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">GST payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ValueAddedTaxPayables_iI_uUSD_c20250630_zgh4jgwuoOui" style="text-align: right" title="GST payables">219,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">391,330</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--OtherPayables_iI_maTAOPzVdB_zNPe2CehumO4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">- third parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--OtherPayables_iI_uUSD_c20250630_zLHXbmlFvPd5" style="border-bottom: Black 1pt solid; text-align: right" title="Other payables third parties">2,343,283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,980,422</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">280,427</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherPayables_iTI_mtTAOPzVdB_zuyH3ZABFMDe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TradeAndOtherPayables_iTI_uUSD_c20250630_zodGfcyXNFAi" style="border-bottom: Black 1pt solid; text-align: right" title="Total">5,435,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,913,006</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,575,949</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about trade and other payables explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock', window );">Schedule of amounts recognized in profit or loss</a></td>
<td class="text"><p id="xdx_892_ecustom--DisclosureOfLeaseRelatedExpensesTableTextBlock_zEdUSPhrJEv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zzvUbXrLCC2g">Schedule
of amounts recognized in profit or loss</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; width: 0.5in">&#160;</td>
    <td style="font-weight: bold; width: 0.5in">(c)</td>
    <td style="font-weight: bold">Amounts recognized in profit or loss</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630_zMIG3aDMmcqd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230701__20240630_zoA8EUzu3Dxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--DepreciationRightofuseAssets_zr0aogHlwPNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: justify">Depreciation of right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630_zjHtOc7VspNl" style="width: 10%; text-align: right" title="Depreciation of right-of-use assets">843,989</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,073,469</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">498,635</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InterestExpenseOnLeaseLiabilities_zajyIKN3s6Vh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zQRGWEPLldXg" style="text-align: right" title="Interest expense on lease liabilities">90,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease expense not capitalized in lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_zuzdLirjcTX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">- Expense relating to short-term leases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_uUSD_c20240701__20250630_zTg9aLWWruhc" style="border-bottom: Black 1pt solid; text-align: right" title="Expense relating to short-term leases"><span style="-sec-ix-hidden: xdx2ixbrl2090">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2087">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,180</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_zuOZvYvg1lE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total amount recognized in profit or loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_uUSD_c20240701__20250630_zeeVw7pGL8G9" style="border-bottom: Black 1pt solid; text-align: right" title="Total amount recognized in profit or loss">934,378</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,188,435</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">517,276</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Lease Related Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant related party transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRelatedPartyTransactionsAbstract', window );"><strong>Significant Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory', window );">Schedule of transactions with related parties</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfTransactionsWithRelatedPartyExplanatory_zGuasCrT7mLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">In
addition to the related party information disclosed elsewhere in the consolidated financial statements, the following transactions with
related parties took place at terms agreed between the parties during the financial period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"><span id="xdx_8BC_zb9wgXRCFjXl" style="display: none">Schedule of transactions with
related parties</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zgyvd0rOAcl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zZmR0Df9i1y6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--InterestIncomeOnLoansAndReceivable_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_z57jlsdK27Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Interest income on loan to related party</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_ecustom--InterestIncomeOnLoansAndReceivable_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zghxAXZ9dL0h" title="Interest income on loan to related party">1,507</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ManagementFee_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zCp1F2zFTJmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ManagementFee_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zojJerwhMhXa" title="Management fee">3,852,504</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2113">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zfpY8fj25SHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt">Payment made on behalf to related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zBpXczlu1ZRe" title="Payment made on behalf to related parties">3,715</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,725</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,311,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory', window );">Schedule of compensation of key management personnel</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_z4XNVvVbHTid" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"><span id="xdx_8B7_zC8yZ2n2EV39" style="display: none">Schedule of
compensation of key management personnel</span><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20250630_zctqUncmGv89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20240630_z2iqErxQlKz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--WagesAndSalaries_maKMPCzbwJ_zGlLrYwfMeUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: left">Salaries and bonuses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">544,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">693,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">121,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CentralProvidentFund_maKMPCzbwJ_zq33XkIqskpb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">CPF</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">46,540</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">59,194</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">137</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--KeyManagementPersonnelCompensation_iT_mtKMPCzbwJ_zecM9P1e6kK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">591,394</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">752,194</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">121,337</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of compensation of key management personnel explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of transactions with related party explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment loss on goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract', window );"><strong>Impairment Loss On Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Schedule of fair value of identifiable assets and liabilities</a></td>
<td class="text"><p id="xdx_89D_eifrs-full--DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_zvMglfu9Iu7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
fair value of identifiable assets and liabilities of Bethesda Group as at the acquisition date were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; display: none">&#160;<span id="xdx_8BA_z7nji0UumfN2">Schedule
of fair value of identifiable assets and liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250430_zIGEZzMVyiPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">S$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_znTdXUgmookc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-bottom: 1pt">Purchase Consideration</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">10,308,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Assets and liabilities recognised as a result of the acquisition:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_iI_zFFMwjARNYb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,180</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_z427Po6Vqe38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,133,786</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--DeferredTaxAssetsRecognisedAsOfAcquisitionDate_iI_zBDHMaHsycg8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,700</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--InvestmentRecognisedAsOfAcquisitionDate_iI_zFOsNFqmAT69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--InventoryRecognisedAsOfAcquisitionDate_iI_zyfjupa7QVKk" style="vertical-align: bottom; background-color: White">
    <td>Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,077</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--FairValueOfAcquiredReceivables_iI_zBwWrZZfQNlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">669,746</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_iI_zUM2ni11yyYf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,895</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LeaseLiabilitiesRecognisedAsOfAcquisitionDate_iI_zVzLSQOUwhCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(431,744</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eifrs-full--BorrowingsRecognisedAsOfAcquisitionDate_iNI_di_zzsyeNLArTV9" style="vertical-align: bottom; background-color: White">
    <td>Borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(453,250</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_iNI_di_zjngBgwWr8Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,544,185</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--AmountDueRecognisedAsOfAcquisitionDate_iI_zbEBiQ0upnh7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Amount due to director</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(193,945</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eifrs-full--NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_zhyQkKtUZaQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net identifiable liabilities acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(837,691</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_zbPR2aYXYPj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Add: Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,145,691</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Purchase consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zW29lKC3N9k4" title="Purchase consideration">10,308,000</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureImpairmentLossOnGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureFinancialRiskManagementAbstract', window );"><strong>Financial Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock', window );">Schedule of group&#8217;s current credit risk grading framework</a></td>
<td class="text"><p id="xdx_89E_ecustom--DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_zog6lTZLQyq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s current credit risk grading framework comprises the following categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span id="xdx_8B2_zYzUwT9fUvRi" style="display: none">Schedule of group&#8217;s current
credit risk grading framework</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definition
    of category</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
                                            for recognising</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expected
    credit loss</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(ECL)</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zVczdX1ZFn16" title="Definition of category">Counterparty
    has a low risk of default and does not have any past-due amounts.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zNyyOW8P7z1j" title="Basis for recognizing ECL">12-month
    ECL</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zRLruJZXQntb" title="Definition of category">Amount
    is &gt;30 days past due or there has been a significant increase in credit risk since initial recognition.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zkukHFujJcZ" title="Basis for recognizing ECL">Lifetime
    ECL - not credit-impaired</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z9U7FpNFObC9" title="Definition of category">Amount
    is &gt;60 days past due or there is evidence indicating the asset is credit-impaired (in default).</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z4YRgcfhBHXh" title="Basis for recognizing ECL">Lifetime
    ECL - credit impaired</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IV</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zt9RtvWDB877" title="Definition of category">There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zYzuI04ZA2wj" title="Basis for recognizing ECL">Amount
    is written off</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory', window );">Schedule of financial assets, minimum exposure to credit risk</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_zKm570U498u4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the credit quality of the Group&#8217;s financial assets, as well as maximum exposure to credit risk by credit risk
rating categories:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span id="xdx_8B8_zrG1GeTypH5h" style="display: none">Schedule of financial assets,
minimum exposure to credit risk</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>12-month
                                            or</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lifetime</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ECL</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>allowance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.85pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_ziTubbL19H18" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">2,580,313</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zlUyH4k8RT1a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">(781,133</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_z7fiYqAVot4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">1,799,180</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z3LbbXTeA2P4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">5,362,632</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUWmScCAw49k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"><span style="-sec-ix-hidden: xdx2ixbrl2211">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zME7G9b0uaXh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">5,362,632</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits">(781,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>12-month
                                            or</b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>lifetime
                                            </b></span></p>
                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ECL</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>allowance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.65pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zI5oyuT6Qu42" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">3,281,902</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zsLG2ZF2P4Sd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">(993,524</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zr47nPmnEtz8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables">2,288,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.65pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zqKJeUcVd6Gd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">6,820,731</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWCpyLh8alNh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"><span style="-sec-ix-hidden: xdx2ixbrl2223">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zIbc0ZOVrFui" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits">6,820,731</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--ExpectedCreditLosses_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zKUfOFKE1Taf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses">(993,524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">Trade receivables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">Note 1</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Lifetime ECL (simplified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zq5uK3F5IJVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">2,133,573</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zwDyLLeajhh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">(460,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zPcX0KAr0NH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">1,673,160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt">Deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z7EHk61iRdth" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits">90,252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zJzifXoOaLn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zBxg9HJHStW4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits">90,252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">Amount due from&#160;&#160;related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">14</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">I</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">12-month ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUPrVPwObpD" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWrqjJ0jJc96" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl2243">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zhC9d4R2trJ8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zGTw3eF0G8f3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses">(460,413</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ScheduleOfExpectedCreditRiskExplanatory', window );">Schedule of credit risk</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfExpectedCreditRiskExplanatory_z7GFIIDMZome" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span id="xdx_8B8_z0PTqeAx9RTg" style="display: none">Schedule of credit risk</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zSWj97CBRD38" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_z8VWMWkzkBS5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zxdsx6dfxx67" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zrhImKX3LN81" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zbYszB9rMicc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20250630_zDHftNBWLb35" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Days past due</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not past</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>due</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">1 &#8211; 60</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">61 &#8211; 120</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 120 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 365 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zOQLD6ESaT5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">41</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2256">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TradeReceivables_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zB4qKU2FXWRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">703,914</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">843,949</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">133,126</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">644,290</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">255,034</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,580,315</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ExpectedCreditLosses_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zyrjjlngKzb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(130,816</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(97,778</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(34,150</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(263,355</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(255,034</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">(781,133</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630_z7aXZHiS2tO" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">1,799,182</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zhq2ibgnSIne" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zoN70IEmx7P4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_z4hJs9mERKW3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49A_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zKpbcz8XHpYi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zi6k2QOgYn5c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49F_20250630_zDcRTUyZPDdi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Trade receivables</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Days past due</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not past</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>due</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">1 &#8211; 60</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">61 &#8211; 120</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">days</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 120 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&gt; 365 days</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFtwuIwycojf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">41</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">100</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2279">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeReceivables_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zb1J5GV3pMq2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">895,308</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,073,420</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">169,323</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">819,473</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">324,378</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,281,902</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ExpectedCreditLosses_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFqaNuN7FvK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(166,385</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(124,365</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(43,436</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(334,960</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(324,378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(993,524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--CreditRiskTradeReceivables_iI_c20250630_zJ6JINQ8o1d1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">2,288,378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">ECL rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zcJwzkYlvbrf" title="ECL rate">1.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zQsdCAPyt6Hh" title="ECL rate">2.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zUJ39UpmVr8a" title="ECL rate">2.61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zy7ZnMYaXuI6" title="ECL rate">10.54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zUhfYuAVsWdf" title="ECL rate">89.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated total gross carrying amount at</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zge5wyrSroV9" title="Estimated total gross carrying amount at">814,544</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zPtCBonBXbLg" title="Estimated total gross carrying amount at">321,783</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zE32rCuLq1L2" title="Estimated total gross carrying amount at">227,123</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zCkKjpLhdN08" title="Estimated total gross carrying amount at">323,323</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zd8w0DKwHK1h" title="Estimated total gross carrying amount at">446,800</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zMh3HipymTd3" title="Estimated total gross carrying amount at">2,133,573</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">ECL</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zpBBQn7jbiyj" title="ECL">(15,880</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_908_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zt9l4iR1bBlk" title="ECL">(6,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_90E_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zRTtaH1tSFkk" title="ECL">(5,939</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zJxe2eSSgzUd" title="ECL">(34,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span id="xdx_90A_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_znOSSRDaQy3" title="ECL">(398,007</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zPSKFY2iDg8h" title="ECL">(460,413</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20240630_zwIIwwVh3NK9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables">1,673,160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table><div style="clear: both"></div>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Schedule of remaining contractual undiscounted repayment obligations</a></td>
<td class="text"><p id="xdx_893_eifrs-full--MaturityAnalysisForNonderivativeFinancialLiabilities_zHuwj19Xz6Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarises the maturity profile of the Group&#8217;s financial assets and liabilities at the reporting date based on contractual
undiscounted repayment obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span id="xdx_8B8_zTqCxxh6D5Qg" style="display: none">Schedule of remaining contractual
undiscounted repayment obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zDDiv7Uyiqie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zfr36bvkRSbc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zLkTVD1YOtD2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zvbVnaM9Of34" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_zvJDoZzrgjHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,323,882</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,323,882</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,323,882</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_uUSD_zmW9cWmnPnXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zs51y2g0Ooci" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_ziLkbRfhBvgb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,666,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,666,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,666,112</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2359">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Financial
                                            risk management</span> (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify; text-indent: -7.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">c)</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif">Liquidity risk (Continued)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="display: none"></span></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znO760aU70nh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zurfTvoC7Yye" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zb5RlKmYKbZb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhWJyUO6pjGd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025 (Continued)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_uUSD_zsHKTzy7TL71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2364">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_zrIw9nuG007f" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AmountDueToFormerDirector_iI_zcxyvuJAgCp9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Borrowings_iI_uUSD_zqkAZygjtpY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,688,478</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,688,478</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,667,677</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,020,802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_z2zpiHjOhMxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,903,800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,903,800</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,882,999</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,020,802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_uUSD_zvvGDwrZUDEl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total net undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,762,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,762,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,783,113</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,020,802</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zhdhZnAY4t68" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zW4tLDXGLexd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zNgEeiziSPd8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhhxnr1PC8wj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years to</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_zMSKFELmFdhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2394">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zgJePvqtm8xi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2399">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_zJXtpSinTMGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2404">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zspTpalBKRai" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,368</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2409">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--Borrowings_iI_zkkKL6iOu2D8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,419,476</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,419,476</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,121,119</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,298,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_zjnCSjWNQJw3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,052,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,052,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,754,487</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,298,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_z5LgE80ohDmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total net undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,241,739</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,241,739</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,540,096</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,298,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basel
                                            Medical Group Ltd. and its Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
year ended June 30, 2025 and 2024</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            risk management (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
                                            risk (Continued)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Analysis
of financial instruments by remaining contractual maturities</span> (Continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znN8DpCkgdq6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Carrying</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">amount</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zY9OSMmQ8S63" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Contractual</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">cash flows</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zlWNv2tbOdO" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">One year</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">or less</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zqIuGgJuqj83" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Two years</p>
                                                                  <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">to five years</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">June 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_z9OLBq9OEQF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2429">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zNPISg6gTXh4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2434">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_z3wIzxMYjFO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2439">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_ztvSrpCVRiw9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2444">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify">Financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zodiNqYuKph3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2449">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z8RYXNGOL424" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2454">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AmountDueToFormerDirector_iI_zWRDy7mbp5w5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2459">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--Borrowings_iI_zDMi5kh8vIKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,289,790</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,289,790</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,706,356</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,583,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z8tOCrqCxNie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total undiscounted financial liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,897,258</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,897,258</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,313,824</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,583,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_zEskyGVecE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total net undiscounted financial assets/(liabilities)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,374,447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,374,447</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,957,881</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,583,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureFinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureFinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in current risk grading framework explanatory text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ScheduleOfExpectedCreditRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of expected credit risk explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ScheduleOfExpectedCreditRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of financial assets represents the maximum credit exposure explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments by category (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureFinancialInstrumentsAbstract', window );"><strong>Financial Instruments By Category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory', window );">Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_zmCC3cVS4V3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zZnnlwFhzcd8" style="display: none">Schedule
of financial assets measured at amortized cost and financial
liabilities at amortized cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zVEFq3dl8azk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zmZEV0hdg5X9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">US$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">S$</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financial assets measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--TradeAndOtherCurrentReceivables_iI_z0LKC611wQmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify">Trade and other receivables</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zC2ElVRk1an3" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Trade and other receivables">7,324,082</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">9,315,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,763,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iI_zxW5T2z5Aw84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zTqqPBT1zTHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and cash equivalents">2,342,230</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,979,083</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,951,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zwvylzcMY9hh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amount due from related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2490">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,557,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--TotalUndiscountedFinancialAssets_iI_zGe8bkeB0v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total financial assets measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zZgeX7zugoW8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial assets measured at amortized cost">9,666,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,294,583</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,271,705</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financial liabilities measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--TradeAndOtherPayables_iI_zt9Vfjrdue9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade and other payables</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--TradeAndOtherPayables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zATLIUf99y0j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and other payables">5,215,322</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,633,369</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,184,619</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z2yV5YWknT0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zpqOqmykWp4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl2506">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2503">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311,390</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AmountDueToFormerDirector_iI_zgR4cCpHnL2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount due to a former director</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_ecustom--AmountDueToFormerDirector_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zNcRi8uGR6ai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to a former director"><span style="-sec-ix-hidden: xdx2ixbrl2511">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2508">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">111,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--Borrowings_iI_zy6Wr8d5EP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Borrowings</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--Borrowings_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zYAiDlnSzWja" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Borrowings">48,251</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">61,371</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,261,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z2g9QyNok5Ie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total financial liabilities measured at amortized cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zLxzGpFYvJzg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial liabilities measured at amortized cost">5,263,573</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,694,739</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,868,758</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of activities of subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_BaselMedicalGroupPteLtdMember', window );">Basel Medical Group Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)<span></span>
</td>
<td class="text">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Other holding companies<span></span>
</td>
<td class="text">Other holding companies<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember', window );">Singapore Sports Orthopaedic Clinic Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Singapore Sports & Orthopaedic Clinic Pte. Ltd.<span></span>
</td>
<td class="text">Singapore Sports & Orthopaedic Clinic Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember', window );">Singapore Sports Orthopaedic Services Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Singapore Sports & Orthopaedic Services Pte. Ltd.<span></span>
</td>
<td class="text">Singapore Sports & Orthopaedic Services Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCPteLtdMember', window );">SSOC Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">SSOC Pte. Ltd.<span></span>
</td>
<td class="text">SSOC Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SSOSPteLtdMember', window );">SSOS Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">SSOS Pte. Ltd.<span></span>
</td>
<td class="text">SSOS Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember', window );">Singapore Knee Sports and Orthopaedic Clinic Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.<span></span>
</td>
<td class="text">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)<span></span>
</td>
<td class="text">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember', window );">Singapore Knee Sports Orthopaedic Services Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Singapore Knee, Sports & Orthopaedic Services Pte. Ltd.<span></span>
</td>
<td class="text">Singapore Knee, Sports & Orthopaedic Services Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
<td class="text">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_PharmaAvenuePteLtdMember', window );">Pharma Avenue Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)<span></span>
</td>
<td class="text">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy<span></span>
</td>
<td class="text">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_BaselMedflowPteLtdMember', window );">Basel Medflow Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Basel Medflow Pte. Ltd.<span></span>
</td>
<td class="text">Basel Medflow Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)<span></span>
</td>
<td class="text">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_BethesdaMedicalPteLtdMember', window );">Bethesda Medical Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Bethesda Medical Pte. Ltd.<span></span>
</td>
<td class="text">Bethesda Medical Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western)<span></span>
</td>
<td class="text">Clinics and other general medical services (western)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_OasisMedicalClinicPteLtdMember', window );">Oasis Medical Clinic Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of entity</a></td>
<td class="text">Oasis Medical Clinic Pte. Ltd.<span></span>
</td>
<td class="text">Oasis Medical Clinic Pte. Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Clinics and other general medical services (western)<span></span>
</td>
<td class="text">Clinics and other general medical services (western)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Country of business / incorporation</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">Singapore<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The country in which the entity is incorporated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 138<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_138_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the nature of the entity's operations and principal activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 138<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_138_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of a subsidiary. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_12_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_BaselMedicalGroupPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_BaselMedicalGroupPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SSOCPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SSOSPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SSOSPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_PharmaAvenuePteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_PharmaAvenuePteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_BaselMedflowPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_BaselMedflowPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_BethesdaMedicalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_BethesdaMedicalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_OasisMedicalClinicPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_OasisMedicalClinicPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="nump">$ 18,362,500<span></span>
</td>
<td class="nump">$ 7,668,358<span></span>
</td>
<td class="nump">$ 9,753,384<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=BMGL_OrdinaryShareMember', window );">Ordinary Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_NumberOfSharesSubscribed', window );">Number of shares subscribe</a></td>
<td class="nump">16,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates', window );">Number of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,387,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_NumberOfSharesSubscribed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares subscribed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_NumberOfSharesSubscribed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=BMGL_OrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=BMGL_OrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of expected useful lives for property, plant and equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures and fittings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Other property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_RenovationMember', window );">Renovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_AirConditionerMember', window );">Air Conditioner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_SoftwareMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_RenovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_RenovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_AirConditionerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_AirConditionerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting judgements and estimates (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract', window );"><strong>Significant Accounting Judgements And Estimates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">$ 295,850<span></span>
</td>
<td class="nump">$ 376,291<span></span>
</td>
<td class="nump">$ 72,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Inventories total</a></td>
<td class="nump">29,585<span></span>
</td>
<td class="nump">37,629<span></span>
</td>
<td class="nump">7,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OthersReceivables', window );">Others receivables</a></td>
<td class="nump">$ 162,070<span></span>
</td>
<td class="nump">$ 206,391<span></span>
</td>
<td class="nump">$ 213,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_OthersReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Others receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_OthersReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of revenue from transfer of goods and services (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Rendering of services - Medical services</a></td>
<td class="nump">$ 8,900,027<span></span>
</td>
<td class="nump">$ 11,319,944<span></span>
</td>
<td class="nump">$ 10,050,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Goods or services transferred at point in time [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Rendering of services - Medical services</a></td>
<td class="nump">8,900,027<span></span>
</td>
<td class="nump">11,319,944<span></span>
</td>
<td class="nump">10,050,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=BMGL_MedicalServicesMember', window );">Medical Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Rendering of services - Medical services</a></td>
<td class="nump">$ 8,900,027<span></span>
</td>
<td class="nump">$ 11,319,944<span></span>
</td>
<td class="nump">$ 10,050,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=BMGL_MedicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=BMGL_MedicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Other income (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Government grant</a></td>
<td class="nump">$ 59,003<span></span>
</td>
<td class="nump">$ 75,046<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">65,466<span></span>
</td>
<td class="nump">83,267<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ServiceIncome', window );">Service income</a></td>
<td class="nump">27,518<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RentalIncome', window );">Rental income</a></td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">157,040<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">591,124<span></span>
</td>
<td class="nump">751,850<span></span>
</td>
<td class="nump">385,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ReversalOfExpectedCreditLosses', window );">Reversal of ECL</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55,741<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other income</a></td>
<td class="nump">$ 866,580<span></span>
</td>
<td class="nump">$ 1,102,203<span></span>
</td>
<td class="nump">$ 461,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ReversalOfExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ReversalOfExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ServiceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ServiceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised from rental activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Finance cost (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on bank borrowings</a></td>
<td class="nump">$ 69,960<span></span>
</td>
<td class="nump">$ 88,982<span></span>
</td>
<td class="nump">$ 160,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expenses on lease liabilities</a></td>
<td class="nump">90,389<span></span>
</td>
<td class="nump">114,966<span></span>
</td>
<td class="nump">15,461<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="nump">$ 160,349<span></span>
</td>
<td class="nump">$ 203,948<span></span>
</td>
<td class="nump">$ 176,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Profit before tax (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureLossprofitBeforeTaxAbstract', window );"><strong>Lossprofit Before Tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Marketing and advertisement</a></td>
<td class="nump">$ 480,960<span></span>
</td>
<td class="nump">$ 611,733<span></span>
</td>
<td class="nump">$ 698,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and professional fees</a></td>
<td class="nump">191,393<span></span>
</td>
<td class="nump">243,433<span></span>
</td>
<td class="nump">426,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance</a></td>
<td class="nump">269,199<span></span>
</td>
<td class="nump">342,394<span></span>
</td>
<td class="nump">48,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransportationExpense', window );">Transportation</a></td>
<td class="nump">34,789<span></span>
</td>
<td class="nump">44,248<span></span>
</td>
<td class="nump">38,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BadDebtsWrittenOff', window );">Bad debts written off</a></td>
<td class="nump">189,013<span></span>
</td>
<td class="nump">240,405<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ProvisionForExpectedCreditLosses', window );">Provision for expected credit losses</a></td>
<td class="nump">536,404<span></span>
</td>
<td class="nump">682,252<span></span>
</td>
<td class="nump">50,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,659<span></span>
</td>
<td class="nump">30,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DepreciationOfPropertyAndEquipment', window );">Depreciation of property and equipment</a></td>
<td class="nump">84,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortisation of right-of-use assets</a></td>
<td class="nump">843,989<span></span>
</td>
<td class="nump">1,073,469<span></span>
</td>
<td class="nump">498,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_RecruitmentExpenses', window );">Recruitment</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">131,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubscriptionCirculationRevenue', window );">Membership and subscription</a></td>
<td class="nump">16,207<span></span>
</td>
<td class="nump">20,614<span></span>
</td>
<td class="nump">38,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TelephoneExpense', window );">Telephone</a></td>
<td class="nump">32,689<span></span>
</td>
<td class="nump">41,806<span></span>
</td>
<td class="nump">32,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DirectorsSalariesAndBonuses', window );">Director's salaries and bonuses</a></td>
<td class="nump">261,813<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
<td class="nump">121,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DirectorsCentralProvidentFund', window );">Director's CPF</a></td>
<td class="nump">23,764<span></span>
</td>
<td class="nump">30,226<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_EmployeesSalariesAndBonus', window );">Employees' salaries and bonus</a></td>
<td class="nump">3,773,252<span></span>
</td>
<td class="nump">4,799,198<span></span>
</td>
<td class="nump">3,218,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_EmployeesCentralProvidentFund', window );">Employees' CPF</a></td>
<td class="nump">346,363<span></span>
</td>
<td class="nump">440,539<span></span>
</td>
<td class="nump">177,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OtherStaffExpenses', window );">Other staff expenses</a></td>
<td class="nump">$ 667,075<span></span>
</td>
<td class="nump">$ 848,452<span></span>
</td>
<td class="nump">$ 121,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_BadDebtsWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bad debts written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_BadDebtsWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DepreciationOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DepreciationOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DirectorsCentralProvidentFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors central provident fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DirectorsCentralProvidentFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DirectorsSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DirectorsSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureLossprofitBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureLossprofitBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_EmployeesCentralProvidentFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employees central provident fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_EmployeesCentralProvidentFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_EmployeesSalariesAndBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employees salaries and bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_EmployeesSalariesAndBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_OtherStaffExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other staff expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_OtherStaffExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ProvisionForExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for expected credit losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ProvisionForExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_RecruitmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recruitment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_RecruitmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_TelephoneExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Telephone expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_TelephoneExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubscriptionCirculationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of circulation revenue derived from subscriptions. [Refer: Revenue; Circulation revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubscriptionCirculationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransportationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from transportation services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransportationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of component of income tax expense (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract', window );"><strong>Current income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">- Current year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 383,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">- Deferred income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_UnderprovisionInRespectOfPriorYears', window );">-Underprovision in respect of prior years</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OverprovisionInRespectOfPriorYears', window );">- Overprovision in respect of prior years</a></td>
<td class="num">(328,444)<span></span>
</td>
<td class="num">(417,748)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax (benefit)/expense recognized in profit or loss</a></td>
<td class="num">$ (328,165)<span></span>
</td>
<td class="num">$ (417,393)<span></span>
</td>
<td class="nump">$ 331,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_OverprovisionInRespectOfPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overprovision in respect of prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_OverprovisionInRespectOfPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_UnderprovisionInRespectOfPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Under provision in respect of prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_UnderprovisionInRespectOfPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation between tax expense and corporate tax rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">(Loss)/Profit before tax</a></td>
<td class="num">$ (9,832,138)<span></span>
</td>
<td class="num">$ (12,505,497)<span></span>
</td>
<td class="nump">$ 2,404,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Income tax using the statutory tax rate of 17% (2024: 17%)</a></td>
<td class="num">(1,671,463)<span></span>
</td>
<td class="num">(2,125,934)<span></span>
</td>
<td class="nump">408,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_NondeductibleExpenses', window );">Non-deductible expenses</a></td>
<td class="nump">1,661,686<span></span>
</td>
<td class="nump">2,113,498<span></span>
</td>
<td class="nump">16,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Income not subject to tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncomeTaxExemption', window );">Income tax exemption</a></td>
<td class="num">(13,700)<span></span>
</td>
<td class="num">(17,425)<span></span>
</td>
<td class="num">(75,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_UtilisationOfCapitalAllowance', window );">(Loss)/Profit before tax</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="num">(1,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_UtilisationOfDeferredTaxAssets', window );">- Utilisation of deferred tax assets not recognised in prior year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(56,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses', window );">Deferred tax asset not recognized during the financial year</a></td>
<td class="nump">23,830<span></span>
</td>
<td class="nump">30,310<span></span>
</td>
<td class="nump">7,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DeferredIncomeTax', window );">Deferred income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(49,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_UnderprovisionInRespectOfPriorYears', window );">Underprovision in respect of prior years</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OverprovisionInRespectOfPriorYears', window );">Overprovision in respect of prior years</a></td>
<td class="num">(328,444)<span></span>
</td>
<td class="num">(417,748)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax (benefit)/expense recognized in profit or loss</a></td>
<td class="num">$ (328,165)<span></span>
</td>
<td class="num">$ (417,393)<span></span>
</td>
<td class="nump">$ 331,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DeferredIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DeferredIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Not Recognized On Tax Losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncomeTaxExemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax exemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncomeTaxExemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_NondeductibleExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_NondeductibleExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_OverprovisionInRespectOfPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Overprovision in respect of prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_OverprovisionInRespectOfPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_UnderprovisionInRespectOfPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Under provision in respect of prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_UnderprovisionInRespectOfPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_UtilisationOfCapitalAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Utilisation of capital allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_UtilisationOfCapitalAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_UtilisationOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Utilisation of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_UtilisationOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Right of use assets (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">At beginning of financial year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="nump">$ 843,989<span></span>
</td>
<td class="nump">1,073,469<span></span>
</td>
<td class="nump">$ 498,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">At end of financial year</a></td>
<td class="nump">2,497,462<span></span>
</td>
<td class="nump">3,176,522<span></span>
</td>
<td class="nump">23,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">At beginning of financial year</a></td>
<td class="nump">2,164,551<span></span>
</td>
<td class="nump">2,753,093<span></span>
</td>
<td class="nump">2,753,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets', window );">Additions</a></td>
<td class="nump">2,575,627<span></span>
</td>
<td class="nump">3,275,940<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">3,793,697<span></span>
</td>
<td class="nump">4,825,203<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffRightofuseAssets', window );">Written off</a></td>
<td class="num">(3,118,402)<span></span>
</td>
<td class="num">(3,966,296)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">At end of financial year</a></td>
<td class="nump">5,415,473<span></span>
</td>
<td class="nump">6,887,940<span></span>
</td>
<td class="nump">2,753,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=BMGL_AccumulatedDepreciationMember', window );">Accumulated Depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">At beginning of financial year</a></td>
<td class="nump">2,146,106<span></span>
</td>
<td class="nump">2,729,633<span></span>
</td>
<td class="nump">2,230,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation</a></td>
<td class="nump">843,989<span></span>
</td>
<td class="nump">1,073,469<span></span>
</td>
<td class="nump">498,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets', window );">Acquisition</a></td>
<td class="nump">2,902,285<span></span>
</td>
<td class="nump">3,691,417<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffRightofuseAssets', window );">Written off</a></td>
<td class="num">(2,974,369)<span></span>
</td>
<td class="num">(3,783,101)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">At end of financial year</a></td>
<td class="nump">$ 2,918,011<span></span>
</td>
<td class="nump">$ 3,711,418<span></span>
</td>
<td class="nump">$ 2,729,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_WrittenOffRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written-off right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_WrittenOffRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in right-of-use assets resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=BMGL_AccumulatedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=BMGL_AccumulatedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Property and equipment (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,659<span></span>
</td>
<td class="nump">$ 30,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="nump">$ 218,183<span></span>
</td>
<td class="nump">277,507<span></span>
</td>
<td class="nump">34,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures and fittings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="nump">13,627<span></span>
</td>
<td class="nump">17,332<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="nump">158,884<span></span>
</td>
<td class="nump">202,084<span></span>
</td>
<td class="nump">5,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_RenovationMember', window );">Renovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="nump">22,104<span></span>
</td>
<td class="nump">28,114<span></span>
</td>
<td class="nump">23,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_AirConditionerMember', window );">Air Conditioner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="nump">22,694<span></span>
</td>
<td class="nump">28,865<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_SoftwareMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="nump">$ 874<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,042,046<span></span>
</td>
<td class="nump">1,034,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,760<span></span>
</td>
<td class="nump">7,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,601,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,113,666<span></span>
</td>
<td class="nump">1,042,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Fixtures and fittings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,852<span></span>
</td>
<td class="nump">100,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,404<span></span>
</td>
<td class="nump">100,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,724<span></span>
</td>
<td class="nump">86,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,101<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(709,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,988<span></span>
</td>
<td class="nump">86,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Renovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,349<span></span>
</td>
<td class="nump">405,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,545<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396,198<span></span>
</td>
<td class="nump">405,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Air Conditioner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Computer and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,168<span></span>
</td>
<td class="nump">350,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,114<span></span>
</td>
<td class="nump">7,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,145<span></span>
</td>
<td class="nump">358,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,978<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,116,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,395,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,659<span></span>
</td>
<td class="nump">30,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,533<span></span>
</td>
<td class="nump">977,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,836,159<span></span>
</td>
<td class="nump">1,007,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
<td class="nump">47,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Fixtures and fittings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,664<span></span>
</td>
<td class="nump">100,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,072<span></span>
</td>
<td class="nump">100,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(687,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,042<span></span>
</td>
<td class="nump">5,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,533<span></span>
</td>
<td class="nump">75,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,904<span></span>
</td>
<td class="nump">81,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Renovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,528<span></span>
</td>
<td class="nump">18,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,200<span></span>
</td>
<td class="nump">363,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,368,084<span></span>
</td>
<td class="nump">382,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Air Conditioner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
<td class="nump">43,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Computer and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,347<span></span>
</td>
<td class="nump">5,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,183<span></span>
</td>
<td class="nump">346,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,280<span></span>
</td>
<td class="nump">352,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation and amortisation [member] | Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation', window );">At June 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,866<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written-off other than through business combinations property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_RenovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_RenovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_AirConditionerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_AirConditionerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_SoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=BMGL_SoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Inventories (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureOfInventoriesAbstract', window );"><strong>Schedule Of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Medicine,drugs and medical devices</a></td>
<td class="nump">$ 295,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,030<span></span>
</td>
<td class="nump">$ 376,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Inventories recognized as an expense in cost of sales</a></td>
<td class="nump">$ 517,713<span></span>
</td>
<td class="nump">$ 658,479<span></span>
</td>
<td class="nump">$ 637,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of trade and other receivables (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AllowanceForExpectedCreditLoss', window );">Less: Allowance for expected credit loss</a></td>
<td class="num">$ (781,133)<span></span>
</td>
<td class="num">$ (993,524)<span></span>
</td>
<td class="num">$ (361,988)<span></span>
</td>
<td class="num">$ (460,413)<span></span>
</td>
<td class="num">$ (465,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade Receivables</a></td>
<td class="nump">1,799,180<span></span>
</td>
<td class="nump">2,288,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">5,362,632<span></span>
</td>
<td class="nump">6,820,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">326,983<span></span>
</td>
<td class="nump">415,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,651,065<span></span>
</td>
<td class="nump">9,731,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,005,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_ThridPartiesMember', window );">Thrid Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">- third parties</a></td>
<td class="nump">2,580,313<span></span>
</td>
<td class="nump">3,281,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,133,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables - third parties</a></td>
<td class="nump">$ 162,070<span></span>
</td>
<td class="nump">$ 206,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AllowanceForExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AllowanceForExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_ThridPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_ThridPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of movement in allowance for expected credit losses (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherReceivablesAbstract', window );"><strong>Trade And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AllowanceForExpectedCreditLoss', window );">Beginning of financial year</a></td>
<td class="nump">$ 361,988<span></span>
</td>
<td class="nump">$ 460,413<span></span>
</td>
<td class="nump">$ 465,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AdditionAllowanceForExpectedCreditLosses', window );">Allowance for expected credit losses</a></td>
<td class="nump">536,403<span></span>
</td>
<td class="nump">682,252<span></span>
</td>
<td class="nump">50,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ReversalOfAllowanceForExpectedCreditLosses', window );">Less: Reversal of allowance for expected credit losses</a></td>
<td class="num">(117,258)<span></span>
</td>
<td class="num">(149,141)<span></span>
</td>
<td class="num">(55,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AllowanceForExpectedCreditLoss', window );">End of financial year</a></td>
<td class="nump">$ 781,133<span></span>
</td>
<td class="nump">$ 993,524<span></span>
</td>
<td class="nump">$ 460,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AdditionAllowanceForExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition allowance for expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AdditionAllowanceForExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AllowanceForExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AllowanceForExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ReversalOfAllowanceForExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of allowance for expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ReversalOfAllowanceForExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other receivables (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">$ 5,362,632<span></span>
</td>
<td class="nump">$ 6,820,731<span></span>
</td>
<td class="nump">$ 90,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_CustodianServicesMember', window );">Custodian Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">$ 1,683,776<span></span>
</td>
<td class="nump">$ 2,300,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_CustodianServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_CustodianServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of cash and cash equivalents (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureCashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash on hand</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Cash at banks</a></td>
<td class="nump">2,341,920<span></span>
</td>
<td class="nump">2,978,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,949,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,342,230<span></span>
</td>
<td class="nump">$ 2,979,083<span></span>
</td>
<td class="nump">$ 1,533,967<span></span>
</td>
<td class="nump">$ 1,951,053<span></span>
</td>
<td class="nump">$ 1,217,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of amount due from related party (Details) - Jun. 30, 2023<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>SGD ($)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Total</a></td>
<td class="nump">$ 8,783,276<span></span>
</td>
<td class="nump">$ 11,877,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DirectorsMember', window );">Directors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Total</a></td>
<td class="nump">976,453<span></span>
</td>
<td class="nump">1,320,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_OthersRelatedPartiesMember', window );">Others Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Total</a></td>
<td class="nump">$ 7,806,823<span></span>
</td>
<td class="nump">$ 10,557,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_OthersRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_OthersRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Amount due from/to related parties (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2023 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Sep. 23, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 20, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Feb. 27, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Professional medical practitioner salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Salary payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,343,283<span></span>
</td>
<td class="nump">$ 2,980,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_RainforestCapitalVCCMember', window );">Rainforest capital VCC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration', window );">Provisional consideration amount for transfer of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,191,465<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions', window );">Estimated settlement liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CashPaidOnClosingInitialSettlement', window );">Cash paid on closing initial settlement</a></td>
<td class="nump">$ 8,944,137<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare', window );">Percentage of provisional consideration amount for transfer of share</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties', window );">Related party advance for IPO expenses paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesDueFromAssociates', window );">Partial settlement of related party receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,048,000<span></span>
</td>
<td class="nump">$ 630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CashReceivedToFullySettleRelatedPartyReceivables', window );">Final settlement under repayment deed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 652,366<span></span>
</td>
<td class="nump">$ 651,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember', window );">Dr Kevin Yip and Singmed Investment Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansAndAdvances', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,877,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,101,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DrKevinYipMember', window );">Dr Kevin Yip [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Professional medical practitioner salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682,180<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Salary payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 682,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CashPaidOnClosingInitialSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid on closing initial settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CashPaidOnClosingInitialSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CashReceivedToFullySettleRelatedPartyReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received to fully settle related party receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CashReceivedToFullySettleRelatedPartyReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of provisional consideration amount for transfer of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of advances and loans from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansAndAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans and advances the entity has made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansAndAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of measurement period adjustments recognised for particular assets, liabilities, non-controlling interests or items of consideration if the initial accounting for a business combination is incomplete. The measurement period is the period after the acquisition date during which the acquirer may adjust the provisional amounts recognised for a business combination. [Refer: Non-controlling interests; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_a_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesDueFromAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from associates. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesDueFromAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities settled by the entity on behalf of a related party in related party transactions. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_RainforestCapitalVCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_RainforestCapitalVCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DrKevinYipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=BMGL_DrKevinYipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of borrowings (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CurrentPortionOfBorrowingsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">- Bank overdraft</a></td>
<td class="nump">$ 48,251<span></span>
</td>
<td class="nump">$ 61,371<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">- Lease liabilities</a></td>
<td class="nump">1,619,426<span></span>
</td>
<td class="nump">2,059,748<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BankBorrowings', window );">- Bank borrowings</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,677,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Borrowings Current</a></td>
<td class="nump">1,667,677<span></span>
</td>
<td class="nump">2,121,119<span></span>
</td>
<td class="nump">2,706,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract', window );"><strong>Non-current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">- Lease liabilities</a></td>
<td class="nump">1,020,801<span></span>
</td>
<td class="nump">1,298,357<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived', window );">- Bank borrowings</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings Non-Current</a></td>
<td class="nump">1,020,801<span></span>
</td>
<td class="nump">1,298,357<span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Borrowings</a></td>
<td class="nump">$ 2,688,478<span></span>
</td>
<td class="nump">$ 3,419,476<span></span>
</td>
<td class="nump">$ 4,289,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_BankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_BankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CurrentPortionOfBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Portion of Borrowings Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CurrentPortionOfBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current secured bank loans received. [Refer: Secured bank loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of breakdown borrowings (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanOneMember', window );">Term loan #1 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 206,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwoMember', window );">Term loan #2 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">280,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanThreeMember', window );">Term loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">178,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanFourMember', window );">Term loan #4 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">195,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSixMember', window );">Term loan #6 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">531,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSevenMember', window );">Term loan #7 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">280,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanNineMember', window );">Term loan #9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">322,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenMember', window );">Term loan #10 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,573,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenMember', window );">Term loan #11 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">691,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwelveMember', window );">Term loan #12 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanMember', window );">Term loan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,261,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of details borrowings (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanOneMember', window );">Term loan #1 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">October 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwoMember', window );">Term loan #2 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">October 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanThreeMember', window );">Term loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">November 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanFourMember', window );">Term loan #4 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">November 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSixMember', window );">Term loan #6 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">April 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSevenMember', window );">Term loan #7 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">October 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanNineMember', window );">Term loan #9 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">April 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenMember', window );">Term loan #10 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">November 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenOneMember', window );">Term loan #10 One [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">November 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenTwoMember', window );">Term loan #10 two [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">March 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenThreeMember', window );">Term loan #10 three [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 529,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">1.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">December 2035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenFourMember', window );">Term loan #10 four [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 501,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">1.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">December 2035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenMember', window );">Term loan #11 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">January 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenOneMember', window );">Term loan #11 one [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">December 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwelveMember', window );">Term loan #12 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Term loan facility amount</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowing maturity date</a></td>
<td class="text">One-month term, upon maturity<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTenFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanElevenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=BMGL_TermLoanTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of reconciliation of liabilities arising from financing activities (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities current, beginnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceed from bank borrowings and lease liabilities, current</a></td>
<td class="nump">$ 3,144,901<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities current, ending</a></td>
<td class="nump">1,619,426<span></span>
</td>
<td class="nump">2,059,748<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities non-current, beginnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities non-current, ending</a></td>
<td class="nump">1,020,801<span></span>
</td>
<td class="nump">1,298,357<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BankBorrowings', window );">Bank borrowings, beginnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,677,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BankBorrowings', window );">Bank borrowings, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,677,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived', window );">Bank borrowings non current, beginnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived', window );">Bank borrowings non current, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities current, beginnings</a></td>
<td class="nump">22,407<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
<td class="nump">566,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Cash flows lease liabilities and bank borrowings current</a></td>
<td class="num">(861,945)<span></span>
</td>
<td class="num">(1,096,308)<span></span>
</td>
<td class="num">(553,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceed from bank borrowings and lease liabilities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Addition lease liabilities current</a></td>
<td class="nump">3,557,047<span></span>
</td>
<td class="nump">4,524,209<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent', window );">Accretion of interests current</a></td>
<td class="nump">90,389<span></span>
</td>
<td class="nump">114,966<span></span>
</td>
<td class="nump">15,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent', window );">Other non cash changes current</a></td>
<td class="num">(1,188,472)<span></span>
</td>
<td class="num">(1,511,619)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities current, ending</a></td>
<td class="nump">1,619,426<span></span>
</td>
<td class="nump">2,059,748<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities non-current, beginnings</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings', window );">Cash flows lease liabilities and bank borrowings noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceed from bank borrowings and lease liabilities, noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities', window );">Addition lease liabilities non current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent', window );">Accretion of interests noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent', window );">Other non cash changes non current</a></td>
<td class="nump">1,020,801<span></span>
</td>
<td class="nump">1,298,357<span></span>
</td>
<td class="num">(28,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities non-current, ending</a></td>
<td class="nump">1,020,801<span></span>
</td>
<td class="nump">1,298,357<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ShorttermBorrowingsMember', window );">Short-term borrowings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Cash flows lease liabilities and bank borrowings current</a></td>
<td class="num">(5,320,259)<span></span>
</td>
<td class="num">(6,766,838)<span></span>
</td>
<td class="num">(2,517,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceed from bank borrowings and lease liabilities, current</a></td>
<td class="nump">3,144,901<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent', window );">Accretion of interests current</a></td>
<td class="nump">69,960<span></span>
</td>
<td class="nump">88,982<span></span>
</td>
<td class="nump">160,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent', window );">Other non cash changes current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,811,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings', window );">Cash flows lease liabilities and bank borrowings noncurrent</a></td>
<td class="num">(1,244,936)<span></span>
</td>
<td class="num">(1,583,434)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Proceed from bank borrowings and lease liabilities, noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent', window );">Accretion of interests noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent', window );">Other non cash changes non current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,811,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BankBorrowings', window );">Bank borrowings, beginnings</a></td>
<td class="nump">2,105,398<span></span>
</td>
<td class="nump">2,677,856<span></span>
</td>
<td class="nump">3,223,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AdditionBankBorrowingsCurrent', window );">Addition bank borrowings current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BankBorrowings', window );">Bank borrowings, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,677,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived', window );">Bank borrowings non current, beginnings</a></td>
<td class="nump">1,244,936<span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
<td class="nump">3,395,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AdditionBankBorrowingsNonCurrent', window );">Addition bank borrowings non current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived', window );">Bank borrowings non current, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember', window );">Assets held to hedge liabilities arising from financing activities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Reconciliation of liabilities financing activities current and non current, beginnings</a></td>
<td class="nump">3,372,741<span></span>
</td>
<td class="nump">4,289,790<span></span>
</td>
<td class="nump">7,212,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows lease liabilities and bank borrowings</a></td>
<td class="num">(7,427,140)<span></span>
</td>
<td class="num">(9,446,580)<span></span>
</td>
<td class="num">(3,070,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceed from bank borrowings and lease liabilities</a></td>
<td class="nump">3,144,901<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities', window );">Addition bank lease liabilities current and non current</a></td>
<td class="nump">3,557,047<span></span>
</td>
<td class="nump">4,524,209<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent', window );">Accretion of interests current and non current</a></td>
<td class="nump">160,349<span></span>
</td>
<td class="nump">203,948<span></span>
</td>
<td class="nump">176,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other non cash changes current and non current</a></td>
<td class="num">(161,671)<span></span>
</td>
<td class="num">(213,262)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Reconciliation of liabilities financing activities current and non current, ending</a></td>
<td class="nump">$ 2,640,227<span></span>
</td>
<td class="nump">$ 3,358,105<span></span>
</td>
<td class="nump">$ 4,289,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AdditionBankBorrowingsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition bank borrowings current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AdditionBankBorrowingsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AdditionBankBorrowingsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition bank borrowings non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AdditionBankBorrowingsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_BankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_BankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flows from ised in increase decrease in non current borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities interest and bank borrowings expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities interest and bank borrowings expense current and non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities interest and bank borrowings expense non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase through new leases liabilities and bank borrowings arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase through new leases liabilities arising non current from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other lease liabilities and bank borrowings arising from financing activities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other lease liabilities and bank borrowings arising from financing activities noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current secured bank loans received. [Refer: Secured bank loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ShorttermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ShorttermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of trade and other payables (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payable- third parties</a></td>
<td class="nump">$ 1,649,041<span></span>
</td>
<td class="nump">$ 2,097,415<span></span>
</td>
<td class="nump">$ 829,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accruals</a></td>
<td class="nump">1,222,998<span></span>
</td>
<td class="nump">1,555,531<span></span>
</td>
<td class="nump">1,074,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAddedTaxPayables', window );">GST payables</a></td>
<td class="nump">219,858<span></span>
</td>
<td class="nump">279,638<span></span>
</td>
<td class="nump">391,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables third parties</a></td>
<td class="nump">2,343,283<span></span>
</td>
<td class="nump">2,980,422<span></span>
</td>
<td class="nump">280,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Total</a></td>
<td class="nump">$ 5,435,180<span></span>
</td>
<td class="nump">$ 6,913,006<span></span>
</td>
<td class="nump">$ 2,575,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAddedTaxPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables related to a value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAddedTaxPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TradePayablesMaturity', window );">Trade payable, maturity</a></td>
<td class="text">30 to 90 days terms<span></span>
</td>
<td class="text">30 to 90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_TradePayablesMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade payables maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_TradePayablesMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share capital (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2023 </div>
<div>SGD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,250,000<span></span>
</td>
<td class="nump">16,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ValueOfSharesAuthorised', window );">Ordinary shares, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,362,500<span></span>
</td>
<td class="nump">$ 24,455,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share subscription price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of share issued</a></td>
<td class="nump">18,785,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=BMGL_InitialPublicOfferingMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share subscription price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=BMGL_OverAllotmentOptionsMember', window );">OverAllotment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share subscription price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ValueOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ValueOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=BMGL_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=BMGL_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=BMGL_OverAllotmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=BMGL_OverAllotmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of amounts recognized in profit or loss (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">$ 843,989<span></span>
</td>
<td class="nump">$ 1,073,469<span></span>
</td>
<td class="nump">$ 498,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">90,389<span></span>
</td>
<td class="nump">114,966<span></span>
</td>
<td class="nump">15,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16', window );">Total amount recognized in profit or loss</a></td>
<td class="nump">$ 934,378<span></span>
</td>
<td class="nump">$ 1,188,435<span></span>
</td>
<td class="nump">$ 517,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised in profit or loss for the reporting period to reflect changes in lease payments that arise from rent concessions occurring as a direct consequence of the covid-19 pandemic, to which the lessee has applied the practical expedient in paragraph 46A of IFRS 16.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 60A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_60A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average borrowing rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow for leases</a></td>
<td class="nump">$ 861,945<span></span>
</td>
<td class="nump">$ 1,096,308<span></span>
</td>
<td class="nump">$ 566,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_LeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_LeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_LeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of transactions with related parties (Details) - Total for all related parties [member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InterestIncomeOnLoansAndReceivable', window );">Interest income on loan to related party</a></td>
<td class="nump">$ 1,507<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ManagementFee', window );">Management fee</a></td>
<td class="nump">3,852,504<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties', window );">Payment made on behalf to related parties</a></td>
<td class="nump">$ 3,715<span></span>
</td>
<td class="nump">$ 4,725<span></span>
</td>
<td class="nump">$ 1,311,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_InterestIncomeOnLoansAndReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on loans and receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_InterestIncomeOnLoansAndReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Management fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of advances and loans from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_RelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_RelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of compensation of key management personnel (Details) - SGD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureRelatedPartyTransactionsAbstract', window );"><strong>Significant Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries and bonuses</a></td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="nump">$ 121,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CentralProvidentFund', window );">CPF</a></td>
<td class="nump">59,194<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 752,194<span></span>
</td>
<td class="nump">$ 121,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CentralProvidentFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Central provident fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CentralProvidentFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of fair value of identifiable assets and liabilities (Details) - Apr. 30, 2025<br></strong></div></th>
<th class="th"><div>SGD ($)</div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>SGD ($)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract', window );"><strong>Impairment Loss On Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Purchase Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 10,308,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,133,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentRecognisedAsOfAcquisitionDate', window );">Investment in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfAcquiredReceivables', window );">Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(431,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(453,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,544,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueRecognisedAsOfAcquisitionDate', window );">Amount due to director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Net identifiable liabilities acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(837,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Add: Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,145,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfCombinedEntity', window );">Purchase consideration</a></td>
<td class="nump">$ 10,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AmountDueRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AmountDueRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureImpairmentLossOnGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_InvestmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_InvestmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfAcquiredReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of receivables acquired in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph h<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_h_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfAcquiredReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Non-current liabilities; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfCombinedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Total for all business combinations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_q_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfCombinedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment loss on goodwill (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract', window );"><strong>Impairment Loss On Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">$ 10,308,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Consideration transferred cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfCombinedEntity', window );">Purchase consideration</a></td>
<td class="nump">$ 10,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfAcquiree', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DisclosureImpairmentLossOnGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DisclosureImpairmentLossOnGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfCombinedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Total for all business combinations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_q_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfCombinedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of group&#8217;s current credit risk grading framework (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CategoryAxis=BMGL_CategoryOneMember', window );">Category I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfCreditRisk', window );">Definition of category</a></td>
<td class="text">Counterparty
    has a low risk of default and does not have any past-due amounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BasisForRecognizingExpectedCreditLoss', window );">Basis for recognizing ECL</a></td>
<td class="text">12-month
    ECL<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CategoryAxis=BMGL_CategoryTwoMember', window );">Category II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfCreditRisk', window );">Definition of category</a></td>
<td class="text">Amount
    is >30 days past due or there has been a significant increase in credit risk since initial recognition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BasisForRecognizingExpectedCreditLoss', window );">Basis for recognizing ECL</a></td>
<td class="text">Lifetime
    ECL - not credit-impaired<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CategoryAxis=BMGL_CategoryThreeMember', window );">Category Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfCreditRisk', window );">Definition of category</a></td>
<td class="text">Amount
    is >60 days past due or there is evidence indicating the asset is credit-impaired (in default).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BasisForRecognizingExpectedCreditLoss', window );">Basis for recognizing ECL</a></td>
<td class="text">Lifetime
    ECL - credit impaired<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CategoryAxis=BMGL_CategoryFourMember', window );">Category IV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_DescriptionOfCreditRisk', window );">Definition of category</a></td>
<td class="text">There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_BasisForRecognizingExpectedCreditLoss', window );">Basis for recognizing ECL</a></td>
<td class="text">Amount
    is written off<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_BasisForRecognizingExpectedCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis for recognizing expected credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_BasisForRecognizingExpectedCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_DescriptionOfCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_DescriptionOfCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CategoryAxis=BMGL_CategoryOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CategoryAxis=BMGL_CategoryOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CategoryAxis=BMGL_CategoryTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CategoryAxis=BMGL_CategoryTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CategoryAxis=BMGL_CategoryThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CategoryAxis=BMGL_CategoryThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CategoryAxis=BMGL_CategoryFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CategoryAxis=BMGL_CategoryFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of financial assets, minimum exposure to credit risk (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CreditRiskTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">$ 1,799,182<span></span>
</td>
<td class="nump">$ 2,288,378<span></span>
</td>
<td class="nump">$ 1,673,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">5,362,632<span></span>
</td>
<td class="nump">6,820,731<span></span>
</td>
<td class="nump">90,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,783,276<span></span>
</td>
<td class="nump">$ 11,877,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Category I [Member] | Life time expected credit loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CreditRiskTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">2,580,313<span></span>
</td>
<td class="nump">3,281,902<span></span>
</td>
<td class="nump">2,133,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Category I [Member] | Twelve expected credit loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">5,362,632<span></span>
</td>
<td class="nump">6,820,731<span></span>
</td>
<td class="nump">90,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,557,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowance for credit losses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">Expected credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(993,524)<span></span>
</td>
<td class="num">(460,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowance for credit losses [member] | Category I [Member] | Life time expected credit loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CreditRiskTradeReceivables', window );">Trade receivables</a></td>
<td class="num">(781,133)<span></span>
</td>
<td class="num">(993,524)<span></span>
</td>
<td class="num">(460,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_AllowanceForCreditLossesMember', window );">Allowance for credit losses [member] | Category I [Member] | Twelve expected credit loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount [member] | Category I [Member] | Life time expected credit loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CreditRiskTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">1,799,180<span></span>
</td>
<td class="nump">2,288,378<span></span>
</td>
<td class="nump">1,673,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount [member] | Category I [Member] | Twelve expected credit loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Deposits</a></td>
<td class="nump">$ 5,362,632<span></span>
</td>
<td class="nump">$ 6,820,731<span></span>
</td>
<td class="nump">90,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,557,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CreditRiskTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit risk trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CreditRiskTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CategoryAxis=BMGL_CategoryOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CategoryAxis=BMGL_CategoryOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=BMGL_LifeTimeExpectedCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=BMGL_LifeTimeExpectedCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=BMGL_TwelveExpectedCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=BMGL_TwelveExpectedCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_AllowanceForCreditLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_AllowanceForCreditLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrs-full_CarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of credit risk (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 1,799,180<span></span>
</td>
<td class="nump">$ 2,288,378<span></span>
</td>
<td class="nump">$ 1,673,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_CreditRiskTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">$ 1,799,182<span></span>
</td>
<td class="nump">$ 2,288,378<span></span>
</td>
<td class="nump">1,673,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">ECL rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 2,580,315<span></span>
</td>
<td class="nump">$ 3,281,902<span></span>
</td>
<td class="nump">2,133,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">ECL</a></td>
<td class="num">$ (781,133)<span></span>
</td>
<td class="num">$ (993,524)<span></span>
</td>
<td class="num">$ (460,413)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=BMGL_NotPastDueMember', window );">Not past due [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">ECL rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 703,914<span></span>
</td>
<td class="nump">$ 895,308<span></span>
</td>
<td class="nump">$ 814,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">ECL</a></td>
<td class="num">$ (130,816)<span></span>
</td>
<td class="num">$ (166,385)<span></span>
</td>
<td class="num">$ (15,880)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember', window );">Later than one month and not later than two months [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">ECL rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 843,949<span></span>
</td>
<td class="nump">$ 1,073,420<span></span>
</td>
<td class="nump">$ 321,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">ECL</a></td>
<td class="num">$ (97,778)<span></span>
</td>
<td class="num">$ (124,365)<span></span>
</td>
<td class="num">$ (6,494)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember', window );">Later than two months and not later than four months [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">ECL rate</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">2.61%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 133,126<span></span>
</td>
<td class="nump">$ 169,323<span></span>
</td>
<td class="nump">$ 227,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">ECL</a></td>
<td class="num">$ (34,150)<span></span>
</td>
<td class="num">$ (43,436)<span></span>
</td>
<td class="num">$ (5,939)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanFourMonthsMember', window );">Later than four months [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">ECL rate</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">10.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 644,290<span></span>
</td>
<td class="nump">$ 819,473<span></span>
</td>
<td class="nump">$ 323,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">ECL</a></td>
<td class="num">$ (263,355)<span></span>
</td>
<td class="num">$ (334,960)<span></span>
</td>
<td class="num">$ (34,093)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member] | Credit risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedCreditLossRate', window );">ECL rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">89.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Estimated total gross carrying amount at</a></td>
<td class="nump">$ 255,034<span></span>
</td>
<td class="nump">$ 324,378<span></span>
</td>
<td class="nump">$ 446,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_ExpectedCreditLosses', window );">ECL</a></td>
<td class="num">$ (255,034)<span></span>
</td>
<td class="num">$ (324,378)<span></span>
</td>
<td class="num">$ (398,007)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_CreditRiskTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit risk trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_CreditRiskTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_ExpectedCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_ExpectedCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedCreditLossRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of expected credit losses, calculated as percentage of the gross carrying amount. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph IG20D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG20D&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedCreditLossRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=BMGL_NotPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=BMGL_NotPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanFourMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanFourMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of remaining contractual undiscounted repayment obligations (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">$ 7,651,065<span></span>
</td>
<td class="nump">$ 9,731,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,005,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="nump">$ 1,533,967<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,217,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,783,276<span></span>
</td>
<td class="nump">$ 11,877,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">5,435,180<span></span>
</td>
<td class="nump">6,913,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_CarryingAmountMember', window );">Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,323,882<span></span>
</td>
<td class="nump">9,315,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,557,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalUndiscountedFinancialAssets', window );">Total undiscounted financial assets</a></td>
<td class="nump">9,666,112<span></span>
</td>
<td class="nump">12,294,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,271,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">5,215,322<span></span>
</td>
<td class="nump">6,633,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Amount due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,688,478<span></span>
</td>
<td class="nump">3,419,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,289,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total undiscounted financial liabilities</a></td>
<td class="nump">7,903,800<span></span>
</td>
<td class="nump">10,052,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,897,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalNetUndiscountedFinancialAssetsliabilities', window );">Total net undiscounted financial assets/(liabilities)</a></td>
<td class="nump">1,762,312<span></span>
</td>
<td class="nump">2,241,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,374,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=BMGL_ContractualCashFlowsMember', window );">Contractual cash flows [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,323,882<span></span>
</td>
<td class="nump">9,315,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,557,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalUndiscountedFinancialAssets', window );">Total undiscounted financial assets</a></td>
<td class="nump">9,666,112<span></span>
</td>
<td class="nump">12,294,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,271,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">5,215,322<span></span>
</td>
<td class="nump">6,633,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Amount due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,688,478<span></span>
</td>
<td class="nump">3,419,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,289,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total undiscounted financial liabilities</a></td>
<td class="nump">7,903,800<span></span>
</td>
<td class="nump">10,052,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,897,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalNetUndiscountedFinancialAssetsliabilities', window );">Total net undiscounted financial assets/(liabilities)</a></td>
<td class="nump">1,762,312<span></span>
</td>
<td class="nump">2,241,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,374,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,323,882<span></span>
</td>
<td class="nump">9,315,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,557,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalUndiscountedFinancialAssets', window );">Total undiscounted financial assets</a></td>
<td class="nump">9,666,112<span></span>
</td>
<td class="nump">12,294,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,271,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">5,215,322<span></span>
</td>
<td class="nump">6,633,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Amount due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">1,667,677<span></span>
</td>
<td class="nump">2,121,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,706,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total undiscounted financial liabilities</a></td>
<td class="nump">6,882,999<span></span>
</td>
<td class="nump">8,754,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,313,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalNetUndiscountedFinancialAssetsliabilities', window );">Total net undiscounted financial assets/(liabilities)</a></td>
<td class="nump">2,783,113<span></span>
</td>
<td class="nump">3,540,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,957,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalUndiscountedFinancialAssets', window );">Total undiscounted financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Amount due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">1,020,802<span></span>
</td>
<td class="nump">1,298,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total undiscounted financial liabilities</a></td>
<td class="nump">1,020,802<span></span>
</td>
<td class="nump">1,298,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalNetUndiscountedFinancialAssetsliabilities', window );">Total net undiscounted financial assets/(liabilities)</a></td>
<td class="num">$ (1,020,802)<span></span>
</td>
<td class="num">$ (1,298,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,583,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AmountDueToFormerDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to former director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AmountDueToFormerDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_TotalNetUndiscountedFinancialAssetsliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total net undiscounted financial assets/(liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_TotalNetUndiscountedFinancialAssetsliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_TotalUndiscountedFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total undiscounted financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_TotalUndiscountedFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_CarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_CarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=BMGL_ContractualCashFlowsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=BMGL_ContractualCashFlowsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PercentageOfTradeReceivables', window );">Percentage of trade receivables</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PercentageOfTradeReceivables', window );">Percentage of trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_PercentageOfTradeReceivables', window );">Percentage of trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_PercentageOfTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_PercentageOfTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>SGD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>SGD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">$ 7,651,065<span></span>
</td>
<td class="nump">$ 9,731,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,005,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="nump">$ 1,533,967<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,217,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,783,276<span></span>
</td>
<td class="nump">$ 11,877,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">5,435,180<span></span>
</td>
<td class="nump">6,913,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">7,324,082<span></span>
</td>
<td class="nump">9,315,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,763,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,342,230<span></span>
</td>
<td class="nump">2,979,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,557,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_TotalUndiscountedFinancialAssets', window );">Total financial assets measured at amortized cost</a></td>
<td class="nump">9,666,312<span></span>
</td>
<td class="nump">12,294,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,271,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">5,215,322<span></span>
</td>
<td class="nump">6,633,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Amount due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_AmountDueToFormerDirector', window );">Amount due to a former director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">48,251<span></span>
</td>
<td class="nump">61,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,261,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total financial liabilities measured at amortized cost</a></td>
<td class="nump">$ 5,263,573<span></span>
</td>
<td class="nump">$ 6,694,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,868,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_AmountDueToFormerDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to former director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_AmountDueToFormerDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_TotalUndiscountedFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total undiscounted financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_TotalUndiscountedFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables due from related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events occurring after the reporting period (Details Narrative) - SGD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,785,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=BMGL_NonadjustingEventsAfterReportingPeriodMember', window );">Nonadjusting Events After Reporting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Loan</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCNovenaPteLtdMember', window );">SSOC Novena Pte Ltd [member] | Nonadjusting Events After Reporting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsPercentage', window );">Investments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsSalePercentage', window );">Investments sale percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsHoldPercentage', window );">Investments hold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCOrchardPteLtdMember', window );">SSOC Orchard Pte Ltd [member] | Nonadjusting Events After Reporting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsPercentage', window );">Investments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsSalePercentage', window );">Investments sale percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsHoldPercentage', window );">Investments hold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCFarrerParkPteLtdMember', window );">SSOC Farrer Park Pte Ltd [member] | Nonadjusting Events After Reporting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsPercentage', window );">Investments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsSalePercentage', window );">Investments sale percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsHoldPercentage', window );">Investments hold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_PharmaAvenuePteLtdMember', window );">Pharma Avenue Pte Ltd [Member] | Nonadjusting Events After Reporting Period [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_EyetrustMedicalPteLtdMember', window );">Eyetrust Medical Pte Ltd [member] | Nonadjusting Events After Reporting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsHoldPercentage', window );">Investments hold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=BMGL_CharteredImagingPteLtdMember', window );">Chartered Imaging Pte Ltd [member] | Nonadjusting Events After Reporting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BMGL_InvestmentsHoldPercentage', window );">Investments hold percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_InvestmentsHoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments hold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_InvestmentsHoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_InvestmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_InvestmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BMGL_InvestmentsSalePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments sale percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BMGL_InvestmentsSalePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BMGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=BMGL_NonadjustingEventsAfterReportingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=BMGL_NonadjustingEventsAfterReportingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCNovenaPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SSOCNovenaPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCOrchardPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SSOCOrchardPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_SSOCFarrerParkPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_SSOCFarrerParkPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_PharmaAvenuePteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_PharmaAvenuePteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_EyetrustMedicalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_EyetrustMedicalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=BMGL_CharteredImagingPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=BMGL_CharteredImagingPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>305</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Statement of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/StatementOfProfitOrLoss</Role>
      <ShortName>Consolidated Statement of Profit or Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statement of Changes In Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/StatementOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated Statement of Changes In Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/StatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999014 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Material accounting policy information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/MaterialAccountingPolicyInformation</Role>
      <ShortName>Material accounting policy information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Significant accounting judgements and estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates</Role>
      <ShortName>Significant accounting judgements and estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/OtherIncome</Role>
      <ShortName>Other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Finance cost</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinanceCost</Role>
      <ShortName>Finance cost</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999020 - Disclosure - (Loss)/Profit before tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/LossprofitBeforeTax</Role>
      <ShortName>(Loss)/Profit before tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Income tax (benefit)/expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/IncomeTaxBenefitexpense</Role>
      <ShortName>Income tax (benefit)/expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Right of use assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/RightOfUseAssets</Role>
      <ShortName>Right of use assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Trade and other receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/TradeAndOtherReceivables</Role>
      <ShortName>Trade and other receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Amount due from/to related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/AmountDueFromtoRelatedParties</Role>
      <ShortName>Amount due from/to related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Amount due to a former director</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/AmountDueToFormerDirector</Role>
      <ShortName>Amount due to a former director</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ShareCapital</Role>
      <ShortName>Share capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Significant related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/SignificantRelatedPartyTransactions</Role>
      <ShortName>Significant related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Impairment loss on goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ImpairmentLossOnGoodwill</Role>
      <ShortName>Impairment loss on goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Fair value of assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FairValueOfAssetsAndLiabilities</Role>
      <ShortName>Fair value of assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Financial risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinancialRiskManagement</Role>
      <ShortName>Financial risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Financial instruments by category</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinancialInstrumentsByCategory</Role>
      <ShortName>Financial instruments by category</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Capital management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/CapitalManagement</Role>
      <ShortName>Capital management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Events occurring after the reporting period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/EventsOccurringAfterReportingPeriod</Role>
      <ShortName>Events occurring after the reporting period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Material accounting policy information (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies</Role>
      <ShortName>Material accounting policy information (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999041 - Disclosure - General (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/GeneralTables</Role>
      <ShortName>General (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/General</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Material accounting policy information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/MaterialAccountingPolicyInformationTables</Role>
      <ShortName>Material accounting policy information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/MaterialAccountingPolicyInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/Revenue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/OtherIncomeTables</Role>
      <ShortName>Other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/OtherIncome</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Finance cost (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinanceCostTables</Role>
      <ShortName>Finance cost (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/FinanceCost</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999046 - Disclosure - (Loss)/Profit before tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/LossprofitBeforeTaxTables</Role>
      <ShortName>(Loss)/Profit before tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/LossprofitBeforeTax</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Income tax (benefit)/expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/IncomeTaxBenefitexpenseTables</Role>
      <ShortName>Income tax (benefit)/expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/IncomeTaxBenefitexpense</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Right of use assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/RightOfUseAssetsTables</Role>
      <ShortName>Right of use assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/RightOfUseAssets</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Property and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/PropertyAndEquipment</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/Inventories</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Trade and other receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/TradeAndOtherReceivablesTables</Role>
      <ShortName>Trade and other receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/TradeAndOtherReceivables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/CashAndCashEquivalents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Amount due from/to related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables</Role>
      <ShortName>Amount due from/to related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/AmountDueFromtoRelatedParties</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/Borrowings</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/TradeAndOtherPayables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/Leases</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Significant related party transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables</Role>
      <ShortName>Significant related party transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/SignificantRelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Impairment loss on goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ImpairmentLossOnGoodwillTables</Role>
      <ShortName>Impairment loss on goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/ImpairmentLossOnGoodwill</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Financial risk management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinancialRiskManagementTables</Role>
      <ShortName>Financial risk management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/FinancialRiskManagement</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Financial instruments by category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinancialInstrumentsByCategoryTables</Role>
      <ShortName>Financial instruments by category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://baselmedical.com/role/FinancialInstrumentsByCategory</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Schedule of activities of subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails</Role>
      <ShortName>Schedule of activities of subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999062 - Disclosure - General (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/GeneralDetailsNarrative</Role>
      <ShortName>General (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/GeneralTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Schedule of expected useful lives for property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Schedule of expected useful lives for property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Significant accounting judgements and estimates (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative</Role>
      <ShortName>Significant accounting judgements and estimates (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Summary of revenue from transfer of goods and services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails</Role>
      <ShortName>Summary of revenue from transfer of goods and services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Schedule of Other income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfOtherIncomeDetails</Role>
      <ShortName>Schedule of Other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Schedule of Finance cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfFinanceCostDetails</Role>
      <ShortName>Schedule of Finance cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of Profit before tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails</Role>
      <ShortName>Schedule of Profit before tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Schedule of component of income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails</Role>
      <ShortName>Schedule of component of income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails</Role>
      <ShortName>Schedule of reconciliation between tax expense and corporate tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical</Role>
      <ShortName>Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Right of use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails</Role>
      <ShortName>Schedule of Right of use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfInventoriesDetails</Role>
      <ShortName>Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Schedule of trade and other receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails</Role>
      <ShortName>Schedule of trade and other receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Schedule of movement in allowance for expected credit losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails</Role>
      <ShortName>Schedule of movement in allowance for expected credit losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Trade and other receivables (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative</Role>
      <ShortName>Trade and other receivables (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/TradeAndOtherReceivablesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999078 - Disclosure - Schedule of cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Schedule of cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999079 - Disclosure - Schedule of amount due from related party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails</Role>
      <ShortName>Schedule of amount due from related party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999080 - Disclosure - Amount due from/to related parties (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative</Role>
      <ShortName>Amount due from/to related parties (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999081 - Disclosure - Schedule of borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfBorrowingsDetails</Role>
      <ShortName>Schedule of borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999082 - Disclosure - Schedule of breakdown borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails</Role>
      <ShortName>Schedule of breakdown borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999083 - Disclosure - Schedule of details borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails</Role>
      <ShortName>Schedule of details borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999084 - Disclosure - Schedule of reconciliation of liabilities arising from financing activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails</Role>
      <ShortName>Schedule of reconciliation of liabilities arising from financing activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999085 - Disclosure - Schedule of trade and other payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails</Role>
      <ShortName>Schedule of trade and other payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999086 - Disclosure - Trade and other payables (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative</Role>
      <ShortName>Trade and other payables (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/TradeAndOtherPayablesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999087 - Disclosure - Share capital (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ShareCapitalDetailsNarrative</Role>
      <ShortName>Share capital (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/ShareCapital</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>999088 - Disclosure - Schedule of amounts recognized in profit or loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails</Role>
      <ShortName>Schedule of amounts recognized in profit or loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>999089 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/LeasesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>999090 - Disclosure - Schedule of transactions with related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails</Role>
      <ShortName>Schedule of transactions with related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>999091 - Disclosure - Schedule of compensation of key management personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails</Role>
      <ShortName>Schedule of compensation of key management personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>999092 - Disclosure - Schedule of fair value of identifiable assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of fair value of identifiable assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>999093 - Disclosure - Impairment loss on goodwill (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative</Role>
      <ShortName>Impairment loss on goodwill (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/ImpairmentLossOnGoodwillTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>999094 - Disclosure - Schedule of group???s current credit risk grading framework (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails</Role>
      <ShortName>Schedule of group???s current credit risk grading framework (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>999095 - Disclosure - Schedule of financial assets, minimum exposure to credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails</Role>
      <ShortName>Schedule of financial assets, minimum exposure to credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>999096 - Disclosure - Schedule of credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfCreditRiskDetails</Role>
      <ShortName>Schedule of credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>999097 - Disclosure - Schedule of remaining contractual undiscounted repayment obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails</Role>
      <ShortName>Schedule of remaining contractual undiscounted repayment obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>999098 - Disclosure - Financial risk management (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative</Role>
      <ShortName>Financial risk management (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/FinancialRiskManagementTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>999099 - Disclosure - Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails</Role>
      <ShortName>Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>999100 - Disclosure - Events occurring after the reporting period (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative</Role>
      <ShortName>Events occurring after the reporting period (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://baselmedical.com/role/EventsOccurringAfterReportingPeriod</ParentRole>
      <Position>94</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bmgl-20250630.xsd</File>
    <File>bmgl-20250630_cal.xml</File>
    <File>bmgl-20250630_def.xml</File>
    <File>bmgl-20250630_lab.xml</File>
    <File>bmgl-20250630_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="form20-f.htm">form20-f.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
    <BaseTaxonomy items="1092">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>114
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form20-f.htm": {
   "nsprefix": "BMGL",
   "nsuri": "http://baselmedical.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "bmgl-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bmgl-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bmgl-20250630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bmgl-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmgl-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form20-f.htm"
     ]
    }
   },
   "keyStandard": 256,
   "keyCustom": 108,
   "axisStandard": 17,
   "axisCustom": 1,
   "memberStandard": 28,
   "memberCustom": 59,
   "hidden": {
    "total": 240,
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 165,
    "http://baselmedical.com/20250630": 72,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 305,
   "entityCount": 1,
   "segmentCount": 90,
   "elementCount": 681,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1092,
    "http://xbrl.sec.gov/dei/2024": 44,
    "http://xbrl.sec.gov/cyd/2024": 3,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://baselmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://baselmedical.com/role/StatementOfProfitOrLoss",
     "longName": "00000002 - Statement - Consolidated Statement of Profit or Loss",
     "shortName": "Consolidated Statement of Profit or Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://baselmedical.com/role/BalanceSheets",
     "longName": "00000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statement of Changes In Shareholders' Equity",
     "shortName": "Consolidated Statement of Changes In Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://baselmedical.com/role/StatementOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://baselmedical.com/role/General",
     "longName": "999014 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://baselmedical.com/role/MaterialAccountingPolicyInformation",
     "longName": "999015 - Disclosure - Material accounting policy information",
     "shortName": "Material accounting policy information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates",
     "longName": "999016 - Disclosure - Significant accounting judgements and estimates",
     "shortName": "Significant accounting judgements and estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://baselmedical.com/role/Revenue",
     "longName": "999017 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://baselmedical.com/role/OtherIncome",
     "longName": "999018 - Disclosure - Other income",
     "shortName": "Other income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://baselmedical.com/role/FinanceCost",
     "longName": "999019 - Disclosure - Finance cost",
     "shortName": "Finance cost",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://baselmedical.com/role/LossprofitBeforeTax",
     "longName": "999020 - Disclosure - (Loss)/Profit before tax",
     "shortName": "(Loss)/Profit before tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfProfitLossBeforeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfProfitLossBeforeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://baselmedical.com/role/IncomeTaxBenefitexpense",
     "longName": "999021 - Disclosure - Income tax (benefit)/expense",
     "shortName": "Income tax (benefit)/expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://baselmedical.com/role/RightOfUseAssets",
     "longName": "999022 - Disclosure - Right of use assets",
     "shortName": "Right of use assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://baselmedical.com/role/PropertyAndEquipment",
     "longName": "999023 - Disclosure - Property and equipment",
     "shortName": "Property and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://baselmedical.com/role/Inventories",
     "longName": "999024 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://baselmedical.com/role/TradeAndOtherReceivables",
     "longName": "999025 - Disclosure - Trade and other receivables",
     "shortName": "Trade and other receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://baselmedical.com/role/CashAndCashEquivalents",
     "longName": "999026 - Disclosure - Cash and cash equivalents",
     "shortName": "Cash and cash equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://baselmedical.com/role/AmountDueFromtoRelatedParties",
     "longName": "999027 - Disclosure - Amount due from/to related parties",
     "shortName": "Amount due from/to related parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://baselmedical.com/role/Borrowings",
     "longName": "999028 - Disclosure - Borrowings",
     "shortName": "Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://baselmedical.com/role/TradeAndOtherPayables",
     "longName": "999029 - Disclosure - Trade and other payables",
     "shortName": "Trade and other payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://baselmedical.com/role/AmountDueToFormerDirector",
     "longName": "999030 - Disclosure - Amount due to a former director",
     "shortName": "Amount due to a former director",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfAmountDueToAFormerDirectorExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfAmountDueToAFormerDirectorExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://baselmedical.com/role/ShareCapital",
     "longName": "999031 - Disclosure - Share capital",
     "shortName": "Share capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://baselmedical.com/role/Leases",
     "longName": "999032 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://baselmedical.com/role/SignificantRelatedPartyTransactions",
     "longName": "999033 - Disclosure - Significant related party transactions",
     "shortName": "Significant related party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://baselmedical.com/role/ImpairmentLossOnGoodwill",
     "longName": "999034 - Disclosure - Impairment loss on goodwill",
     "shortName": "Impairment loss on goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://baselmedical.com/role/FairValueOfAssetsAndLiabilities",
     "longName": "999035 - Disclosure - Fair value of assets and liabilities",
     "shortName": "Fair value of assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://baselmedical.com/role/FinancialRiskManagement",
     "longName": "999036 - Disclosure - Financial risk management",
     "shortName": "Financial risk management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://baselmedical.com/role/FinancialInstrumentsByCategory",
     "longName": "999037 - Disclosure - Financial instruments by category",
     "shortName": "Financial instruments by category",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://baselmedical.com/role/CapitalManagement",
     "longName": "999038 - Disclosure - Capital management",
     "shortName": "Capital management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:CapitalManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:CapitalManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://baselmedical.com/role/EventsOccurringAfterReportingPeriod",
     "longName": "999039 - Disclosure - Events occurring after the reporting period",
     "shortName": "Events occurring after the reporting period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies",
     "longName": "999040 - Disclosure - Material accounting policy information (Policies)",
     "shortName": "Material accounting policy information (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://baselmedical.com/role/GeneralTables",
     "longName": "999041 - Disclosure - General (Tables)",
     "shortName": "General (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://baselmedical.com/role/MaterialAccountingPolicyInformationTables",
     "longName": "999042 - Disclosure - Material accounting policy information (Tables)",
     "shortName": "Material accounting policy information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDepreciationRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDepreciationRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://baselmedical.com/role/RevenueTables",
     "longName": "999043 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://baselmedical.com/role/OtherIncomeTables",
     "longName": "999044 - Disclosure - Other income (Tables)",
     "shortName": "Other income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://baselmedical.com/role/FinanceCostTables",
     "longName": "999045 - Disclosure - Finance cost (Tables)",
     "shortName": "Finance cost (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://baselmedical.com/role/LossprofitBeforeTaxTables",
     "longName": "999046 - Disclosure - (Loss)/Profit before tax (Tables)",
     "shortName": "(Loss)/Profit before tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "BMGL:DisclosureOfProfitLossBeforeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "BMGL:DisclosureOfProfitLossBeforeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://baselmedical.com/role/IncomeTaxBenefitexpenseTables",
     "longName": "999047 - Disclosure - Income tax (benefit)/expense (Tables)",
     "shortName": "Income tax (benefit)/expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://baselmedical.com/role/RightOfUseAssetsTables",
     "longName": "999048 - Disclosure - Right of use assets (Tables)",
     "shortName": "Right of use assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://baselmedical.com/role/PropertyAndEquipmentTables",
     "longName": "999049 - Disclosure - Property and equipment (Tables)",
     "shortName": "Property and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://baselmedical.com/role/InventoriesTables",
     "longName": "999050 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://baselmedical.com/role/TradeAndOtherReceivablesTables",
     "longName": "999051 - Disclosure - Trade and other receivables (Tables)",
     "shortName": "Trade and other receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://baselmedical.com/role/CashAndCashEquivalentsTables",
     "longName": "999052 - Disclosure - Cash and cash equivalents (Tables)",
     "shortName": "Cash and cash equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfCashAndCashEquivalentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfCashAndCashEquivalentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables",
     "longName": "999053 - Disclosure - Amount due from/to related parties (Tables)",
     "shortName": "Amount due from/to related parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://baselmedical.com/role/BorrowingsTables",
     "longName": "999054 - Disclosure - Borrowings (Tables)",
     "shortName": "Borrowings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://baselmedical.com/role/TradeAndOtherPayablesTables",
     "longName": "999055 - Disclosure - Trade and other payables (Tables)",
     "shortName": "Trade and other payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://baselmedical.com/role/LeasesTables",
     "longName": "999056 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables",
     "longName": "999057 - Disclosure - Significant related party transactions (Tables)",
     "shortName": "Significant related party transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://baselmedical.com/role/ImpairmentLossOnGoodwillTables",
     "longName": "999058 - Disclosure - Impairment loss on goodwill (Tables)",
     "shortName": "Impairment loss on goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://baselmedical.com/role/FinancialRiskManagementTables",
     "longName": "999059 - Disclosure - Financial risk management (Tables)",
     "shortName": "Financial risk management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://baselmedical.com/role/FinancialInstrumentsByCategoryTables",
     "longName": "999060 - Disclosure - Financial instruments by category (Tables)",
     "shortName": "Financial instruments by category (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails",
     "longName": "999061 - Disclosure - Schedule of activities of subsidiaries (Details)",
     "shortName": "Schedule of activities of subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember",
      "name": "ifrs-full:NameOfSubsidiary",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:NameOfSubsidiary",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember",
      "name": "ifrs-full:NameOfSubsidiary",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:NameOfSubsidiary",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://baselmedical.com/role/GeneralDetailsNarrative",
     "longName": "999062 - Disclosure - General (Details Narrative)",
     "shortName": "General (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2023-08-102023-08-10",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-102023-08-10",
      "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
     "longName": "999063 - Disclosure - Schedule of expected useful lives for property, plant and equipment (Details)",
     "shortName": "Schedule of expected useful lives for property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_ifrs-full_MachineryMember",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDepreciationRatesExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_ifrs-full_MachineryMember",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDepreciationRatesExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative",
     "longName": "999064 - Disclosure - Significant accounting judgements and estimates (Details Narrative)",
     "shortName": "Significant accounting judgements and estimates (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:Inventories",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:InventoriesTotal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails",
     "longName": "999065 - Disclosure - Summary of revenue from transfer of goods and services (Details)",
     "shortName": "Summary of revenue from transfer of goods and services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember",
      "name": "ifrs-full:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails",
     "longName": "999066 - Disclosure - Schedule of Other income (Details)",
     "shortName": "Schedule of Other income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://baselmedical.com/role/ScheduleOfFinanceCostDetails",
     "longName": "999067 - Disclosure - Schedule of Finance cost (Details)",
     "shortName": "Schedule of Finance cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails",
     "longName": "999068 - Disclosure - Schedule of Profit before tax (Details)",
     "shortName": "Schedule of Profit before tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory",
       "BMGL:DisclosureOfProfitLossBeforeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory",
       "BMGL:DisclosureOfProfitLossBeforeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails",
     "longName": "999069 - Disclosure - Schedule of component of income tax expense (Details)",
     "shortName": "Schedule of component of income tax expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2023-07-012024-06-30",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails",
     "longName": "999070 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details)",
     "shortName": "Schedule of reconciliation between tax expense and corporate tax rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical",
     "longName": "999071 - Disclosure - Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)",
     "shortName": "Schedule of reconciliation between tax expense and corporate tax rate (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:ApplicableTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails",
     "longName": "999072 - Disclosure - Schedule of Right of use assets (Details)",
     "shortName": "Schedule of Right of use assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999073 - Disclosure - Schedule of Property and equipment (Details)",
     "shortName": "Schedule of Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://baselmedical.com/role/ScheduleOfInventoriesDetails",
     "longName": "999074 - Disclosure - Schedule of Inventories (Details)",
     "shortName": "Schedule of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:Inventories",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutInventoriesExplanatory",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails",
     "longName": "999075 - Disclosure - Schedule of trade and other receivables (Details)",
     "shortName": "Schedule of trade and other receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "BMGL:AllowanceForExpectedCreditLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:Prepayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails",
     "longName": "999076 - Disclosure - Schedule of movement in allowance for expected credit losses (Details)",
     "shortName": "Schedule of movement in allowance for expected credit losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "BMGL:AllowanceForExpectedCreditLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:AdditionAllowanceForExpectedCreditLosses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative",
     "longName": "999077 - Disclosure - Trade and other receivables (Details Narrative)",
     "shortName": "Trade and other receivables (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:LongtermDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_CustodianServicesMember",
      "name": "ifrs-full:LongtermDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails",
     "longName": "999078 - Disclosure - Schedule of cash and cash equivalents (Details)",
     "shortName": "Schedule of cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:CashOnHand",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfCashAndCashEquivalentExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:CashOnHand",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfCashAndCashEquivalentExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails",
     "longName": "999079 - Disclosure - Schedule of amount due from related party (Details)",
     "shortName": "Schedule of amount due from related party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_custom_DirectorsMember",
      "name": "ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
     "longName": "999080 - Disclosure - Amount due from/to related parties (Details Narrative)",
     "shortName": "Amount due from/to related parties (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfCompensationOfKeyManagementPersonnelExplanatory",
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-06-272023-06-27_custom_RainforestCapitalVCCMember",
      "name": "ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://baselmedical.com/role/ScheduleOfBorrowingsDetails",
     "longName": "999081 - Disclosure - Schedule of borrowings (Details)",
     "shortName": "Schedule of borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:BankOverdraftsClassifiedAsCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:BankOverdraftsClassifiedAsCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
     "longName": "999082 - Disclosure - Schedule of breakdown borrowings (Details)",
     "shortName": "Schedule of breakdown borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_TermLoanOneMember",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutBreakdownOfBorrowings",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_TermLoanOneMember",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutBreakdownOfBorrowings",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails",
     "longName": "999083 - Disclosure - Schedule of details borrowings (Details)",
     "shortName": "Schedule of details borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_custom_TermLoanOneMember",
      "name": "ifrs-full:Borrowings",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutBorrowings",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_TermLoanOneMember",
      "name": "ifrs-full:Borrowings",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutBorrowings",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails",
     "longName": "999084 - Disclosure - Schedule of reconciliation of liabilities arising from financing activities (Details)",
     "shortName": "Schedule of reconciliation of liabilities arising from financing activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "ifrs-full:DisclosureOfBorrowingsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails",
     "longName": "999085 - Disclosure - Schedule of trade and other payables (Details)",
     "shortName": "Schedule of trade and other payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative",
     "longName": "999086 - Disclosure - Trade and other payables (Details Narrative)",
     "shortName": "Trade and other payables (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:TradePayablesMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:TradePayablesMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://baselmedical.com/role/ShareCapitalDetailsNarrative",
     "longName": "999087 - Disclosure - Share capital (Details Narrative)",
     "shortName": "Share capital (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "AsOf2023-08-10",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-10",
      "name": "BMGL:ValueOfSharesAuthorised",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails",
     "longName": "999088 - Disclosure - Schedule of amounts recognized in profit or loss (Details)",
     "shortName": "Schedule of amounts recognized in profit or loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30",
      "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://baselmedical.com/role/LeasesDetailsNarrative",
     "longName": "999089 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:CashOutflowForLeases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails",
     "longName": "999090 - Disclosure - Schedule of transactions with related parties (Details)",
     "shortName": "Schedule of transactions with related parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember",
      "name": "BMGL:InterestIncomeOnLoansAndReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory",
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember",
      "name": "BMGL:InterestIncomeOnLoansAndReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory",
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails",
     "longName": "999091 - Disclosure - Schedule of compensation of key management personnel (Details)",
     "shortName": "Schedule of compensation of key management personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfCompensationOfKeyManagementPersonnelExplanatory",
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:CentralProvidentFund",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfCompensationOfKeyManagementPersonnelExplanatory",
       "BMGL:DisclosureOfSignificantRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails",
     "longName": "999092 - Disclosure - Schedule of fair value of identifiable assets and liabilities (Details)",
     "shortName": "Schedule of fair value of identifiable assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative",
     "longName": "999093 - Disclosure - Impairment loss on goodwill (Details Narrative)",
     "shortName": "Impairment loss on goodwill (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "ifrs-full:CashTransferred",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfGoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails",
     "longName": "999094 - Disclosure - Schedule of group\u2019s current credit risk grading framework (Details)",
     "shortName": "Schedule of group\u2019s current credit risk grading framework (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_CategoryOneMember",
      "name": "BMGL:DescriptionOfCreditRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_CategoryOneMember",
      "name": "BMGL:DescriptionOfCreditRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
     "longName": "999095 - Disclosure - Schedule of financial assets, minimum exposure to credit risk (Details)",
     "shortName": "Schedule of financial assets, minimum exposure to credit risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "BMGL:CreditRiskTradeReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfExpectedCreditRiskExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember",
      "name": "BMGL:CreditRiskTradeReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
     "longName": "999096 - Disclosure - Schedule of credit risk (Details)",
     "shortName": "Schedule of credit risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:TradeReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_ifrs-full_CreditRiskMember",
      "name": "ifrs-full:TradeReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfExpectedCreditRiskExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails",
     "longName": "999097 - Disclosure - Schedule of remaining contractual undiscounted repayment obligations (Details)",
     "shortName": "Schedule of remaining contractual undiscounted repayment obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_ifrs-full_CarryingAmountMember",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative",
     "longName": "999098 - Disclosure - Financial risk management (Details Narrative)",
     "shortName": "Financial risk management (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:PercentageOfTradeReceivables",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "BMGL:PercentageOfTradeReceivables",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
     "longName": "999099 - Disclosure - Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)",
     "shortName": "Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:DisclosureOfTradeAndOtherReceivableExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "BMGL:ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
     "longName": "999100 - Disclosure - Events occurring after the reporting period (Details Narrative)",
     "shortName": "Events occurring after the reporting period (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-31_custom_NonadjustingEventsAfterReportingPeriodMember",
      "name": "ifrs-full:NetDebt",
      "unitRef": "SGD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ifrs-full_Accruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Accruals",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r54",
      "r359",
      "r363",
      "r364",
      "r365"
     ]
    },
    "BMGL_AccumulatedDepreciationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AccumulatedDepreciationMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation [Member]",
        "documentation": "Accumulated Depreciation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Consideration",
        "verboseLabel": "Consideration transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisition",
        "label": "Acquisitions through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in right-of-use assets resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "BMGL_AdditionAllowanceForExpectedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AdditionAllowanceForExpectedCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for expected credit losses",
        "documentation": "Addition allowance for expected credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_AdditionBankBorrowingsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AdditionBankBorrowingsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition bank borrowings current",
        "documentation": "Addition bank borrowings current."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_AdditionBankBorrowingsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AdditionBankBorrowingsNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition bank borrowings non current",
        "documentation": "Addition bank borrowings non current."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "BMGL_AdjustmentsForAmortizationOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AdjustmentsForAmortizationOfRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortisation of right-of-use assets",
        "documentation": "Adjustments for amortization of right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade and other receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation of property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss on goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss on goodwill recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Goodwill; Impairment loss; Impairment loss recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade and other payables",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "ifrs-full_AdjustmentsForInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for estimated credit losses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r273",
      "r287",
      "r313"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r276",
      "r290",
      "r316"
     ]
    },
    "BMGL_AirConditionerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AirConditionerMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Air Conditioner [Member]",
        "documentation": "Air Conditioner [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r308"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r308",
      "r317",
      "r321",
      "r329"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r327"
     ]
    },
    "ifrs-full_AllowanceForCreditLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AllowanceForCreditLossesMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for credit losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an allowance account used to record impairments to financial assets due to credit losses."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "BMGL_AllowanceForExpectedCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AllowanceForExpectedCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Allowance for expected credit loss",
        "periodStartLabel": "Beginning of financial year",
        "periodEndLabel": "End of financial year",
        "documentation": "Allowance for expected credit loss.",
        "label": "AllowanceForExpectedCreditLoss"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortisation of right-of-use assets",
        "label": "Amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "BMGL_AmountDueRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AmountDueRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due to director"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_AmountDueToFormerDirector": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "AmountDueToFormerDirector",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due to a former director",
        "documentation": "Amount due to former director."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total amount recognized in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised in profit or loss for the reporting period to reflect changes in lease payments that arise from rent concessions occurring as a direct consequence of the covid-19 pandemic, to which the lessee has applied the practical expedient in paragraph 46A of IFRS 16."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120",
      "r121",
      "r122",
      "r183",
      "r186"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets held to hedge liabilities arising from financing activities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for assets held to hedge liabilities arising from financing activities. [Refer: Assets; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r216"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248",
      "r269"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248",
      "r269"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248",
      "r269"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "BMGL_BadDebtsWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "BadDebtsWrittenOff",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Bad debts written off",
        "documentation": "Bad debts written off.",
        "label": "BadDebtsWrittenOff"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash at banks"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "BMGL_BankBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "BankBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Bank borrowings",
        "periodStartLabel": "Bank borrowings, beginnings",
        "periodEndLabel": "Bank borrowings, ending",
        "documentation": "Bank borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Bank overdraft"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "BMGL_BaselMedflowPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "BaselMedflowPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basel Medflow Pte Ltd [Member]",
        "documentation": "Basel Medflow Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_BaselMedicalGroupPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "BaselMedicalGroupPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basel Medical Group Pte Ltd [Member]",
        "documentation": "Basel Medical Group Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "BMGL_BasisForRecognizingExpectedCreditLoss": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "BasisForRecognizingExpectedCreditLoss",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis for recognizing ECL",
        "documentation": "Basis for recognizing expected credit loss."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_BethesdaMedicalPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "BethesdaMedicalPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bethesda Medical Pte Ltd [Member]",
        "documentation": "Bethesda Medical Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan facility amount",
        "verboseLabel": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_BorrowingsMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsMaturity",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing maturity date"
       }
      },
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Borrowings",
        "label": "Borrowings recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer: Borrowings; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r124",
      "r143",
      "r149",
      "r219",
      "r220",
      "r373"
     ]
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_BusinessCombinationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r269"
     ]
    },
    "BMGL_CapitalManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CapitalManagementExplanatory",
     "presentation": [
      "http://baselmedical.com/role/CapitalManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital management",
        "documentation": "Capital management explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r51",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r157",
      "r167",
      "r168"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r82",
      "r83",
      "r85",
      "r86",
      "r157",
      "r167",
      "r168"
     ]
    },
    "ifrs-full_CashAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAdvancesAndLoansFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease/(Increase) in amount due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from advances and loans from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails",
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of financial period",
        "periodEndLabel": "Cash and cash equivalents at end of financial year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r98",
      "r115"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash generated from/(used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r100"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows lease liabilities and bank borrowings current"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "BMGL_CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows lease liabilities and bank borrowings noncurrent",
        "documentation": "Cash flows from ised in increase decrease in non current borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by/ (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r100"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/generated from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r100"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash (used in)/ generated from operations",
        "label": "Cash flows from (used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r214"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flows before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r370"
     ]
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of new subsidiary",
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "BMGL_CashPaidOnClosingInitialSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CashPaidOnClosingInitialSettlement",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid on closing initial settlement",
        "documentation": "Cash paid on closing initial settlement."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CashReceivedToFullySettleRelatedPartyReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CashReceivedToFullySettleRelatedPartyReceivables",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final settlement under repayment deed",
        "documentation": "Cash received to fully settle related party receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party advance for IPO expenses paid",
        "verboseLabel": "Payment made on behalf to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of advances and loans from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration transferred cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails",
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails",
      "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails",
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails",
      "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "BMGL_CategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CategoryAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category [Axis]",
        "documentation": "Category [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CategoryDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CategoryDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "auth_ref": []
    },
    "BMGL_CategoryFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CategoryFourMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category IV [Member]",
        "documentation": "Category Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CategoryOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CategoryOneMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category I [Member]",
        "documentation": "Category One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CategoryThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CategoryThreeMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category Three [Member]",
        "documentation": "Category III [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CategoryTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CategoryTwoMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category II [Member]",
        "documentation": "Category Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CentralProvidentFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CentralProvidentFund",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CPF",
        "documentation": "Central provident fund."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "BMGL_CharteredImagingPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CharteredImagingPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chartered Imaging Pte Ltd [member]",
        "documentation": "Chartered Imaging Pte Ltd [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r171"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r171"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative",
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative",
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative",
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative",
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "BMGL_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer and Office Equipment [Member]",
        "documentation": "Computer and Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "BMGL_ConsumablesMedicalSuppliesAndOtherRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ConsumablesMedicalSuppliesAndOtherRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Consumables, medical supplies and other related expenses",
        "documentation": "Consumables medical supplies and other related expenses.",
        "label": "ConsumablesMedicalSuppliesAndOtherRelatedExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ContractualCashFlowsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ContractualCashFlowsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual cash flows [member]",
        "documentation": "Contractual cash flows [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories recognized as an expense in cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_CountryOfIncorporation": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CountryOfIncorporation",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country of business / incorporation"
       }
      },
      "en": {
       "role": {
        "documentation": "The country in which the entity is incorporated."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CreditLossExpenseReversal",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reversal of estimated credit losses",
        "documentation": "Credit loss expense reversal.",
        "label": "CreditLossExpenseReversal"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r227"
     ]
    },
    "BMGL_CreditRiskTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CreditRiskTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "documentation": "Credit risk trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current assets",
        "label": "Current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r112",
      "r218"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Borrowings",
        "label": "Current borrowings and current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Lease liabilities",
        "periodStartLabel": "Lease liabilities current, beginnings",
        "periodEndLabel": "Lease liabilities current, ending"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_CurrentPortionOfBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CurrentPortionOfBorrowingsAbstract",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:",
        "documentation": "Current Portion of Borrowings Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset retirement obligation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Current year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- third parties",
        "periodStartLabel": "Trade receivables - third parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197"
     ]
    },
    "BMGL_CustodianServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "CustodianServicesMember",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Custodian Services [Member]",
        "documentation": "Custodian Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r339"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r339"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r341"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r341"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r334"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r335"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r335"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r333"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r336"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r338"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r338"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r339"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r340"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r337"
     ]
    },
    "BMGL_DecreaseInAmountDueFromDirector": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DecreaseInAmountDueFromDirector",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in amount due from a director",
        "documentation": "Decrease in amount due from director.",
        "label": "DecreaseInAmountDueFromDirector"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DecreaseincreaseInAmountDueToFormerDirector": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DecreaseincreaseInAmountDueToFormerDirector",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Decrease)/Increase in amount due to former director",
        "documentation": "Decrease increase in amount due to former director.",
        "label": "DecreaseincreaseInAmountDueToFormerDirector"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DeferredIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DeferredIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax",
        "documentation": "Deferred income tax.",
        "label": "DeferredIncomeTax"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DeferredOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DeferredOfferingCost",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Deferred offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r17",
      "r43"
     ]
    },
    "BMGL_DeferredTaxAssetsNotRecognizedOnTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DeferredTaxAssetsNotRecognizedOnTaxLosses",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset not recognized during the financial year",
        "documentation": "Deferred Tax Assets Not Recognized On Tax Losses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets",
        "label": "Deferred tax assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Deferred income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation expense",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "BMGL_DepreciationOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DepreciationOfPropertyAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation of property and equipment",
        "documentation": "Depreciation of property and equipment.",
        "label": "DepreciationOfPropertyAndEquipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation of property and equipment",
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r50",
      "r53"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation of right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted financial liabilities",
        "verboseLabel": "Total financial liabilities measured at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "BMGL_DescriptionOfAccountingPolicyForBasisOfConsolidation": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidation",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of consolidation",
        "documentation": "The description of the entity's accounting policy for consolidations, including the methods of presentation adopted in the financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compliance with International Financial Reporting Standards (\u201cIFRS\u201d)",
        "documentation": "Description of accounting policy for basis of preparation explanatory [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering cost",
        "documentation": "Description of accounting policy for deferred offering costs explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for derivative financial instruments and hedging. [Refer: Classes of financial instruments [domain]; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDividendsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend to Company\u2019s shareholders"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "BMGL_DescriptionOfAccountingPolicyForInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForInventoriesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "documentation": "Description of accounting policy for inventories explanatory.",
        "label": "DescriptionOfAccountingPolicyForInventoriesExplanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share capital",
        "label": "Description of accounting policy for issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "BMGL_DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New standards and interpretations not yet adopted",
        "documentation": "Description of accounting policy for new standards amendments and interpretations issued but not yet effective explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting of financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the offsetting of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "BMGL_DescriptionOfAccountingPolicyForReservesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyForReservesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger reserve",
        "documentation": "Description of accounting policy for reserves explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment reporting"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "BMGL_DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "documentation": "Description of accounting policy revenue from contracts with customers explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "BMGL_DescriptionOfCreditRisk": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DescriptionOfCreditRisk",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Definition of category",
        "documentation": "Description of credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New and amended standards adopted by the Group"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the nature of the entity's operations and principal activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "BMGL_DirectorsCentralProvidentFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DirectorsCentralProvidentFund",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director's CPF",
        "documentation": "Directors central provident fund."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DirectorsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors [member]",
        "documentation": "Directors [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DirectorsSalariesAndBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DirectorsSalariesAndBonuses",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director's salaries and bonuses",
        "documentation": "Directors salaries and bonuses."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureAmountDueToRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureAmountDueToRelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount Due To Former Director"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureAmountsDueFromToRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureAmountsDueFromToRelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount Due Fromto Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Borrowings",
        "label": "Schedule Of Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureCapitalManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureCapitalManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents",
        "verboseLabel": "Schedule Of Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureFairValueOfAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureFairValueOfAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments By Category"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureFinancialRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureFinancialRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Risk Management"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureImpairmentLossOnGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureImpairmentLossOnGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Loss On Goodwill",
        "verboseLabel": "Schedule Of Fair Value Of Identifiable Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of group\u2019s current credit risk grading framework",
        "documentation": "Disclosure in current risk grading framework explanatory text block."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Amounts Recognized In Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureLossprofitBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureLossprofitBeforeTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lossprofit Before Tax",
        "verboseLabel": "Schedule Of Profit Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant accounting judgements and estimates"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfAllowanceForCreditLossesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAllowanceForCreditLossesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of movement in allowance for expected credit losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the allowance relating to impairments of financial assets due to credit losses. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "BMGL_DisclosureOfAmountDueToAFormerDirectorExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfAmountDueToAFormerDirectorExplanatory",
     "presentation": [
      "http://baselmedical.com/role/AmountDueToFormerDirector"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount due to a former director",
        "documentation": "Disclosure of amount due to a former director explanatory.",
        "label": "DisclosureOfAmountDueToAFormerDirectorExplanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/Borrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Borrowings",
        "label": "Disclosure of borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "BMGL_DisclosureOfCashAndCashEquivalentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfCashAndCashEquivalentExplanatory",
     "presentation": [
      "http://baselmedical.com/role/CashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of cash and cash equivalents",
        "documentation": "Disclosure of cash and cash equivalent explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "BMGL_DisclosureOfChangesInAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfChangesInAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material accounting policy information"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://baselmedical.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "BMGL_DisclosureOfDepreciationRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDepreciationRatesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/MaterialAccountingPolicyInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expected useful lives for property, plant and equipment",
        "documentation": "Disclosure of depreciation rates explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutBorrowings": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutBorrowings",
     "presentation": [
      "http://baselmedical.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of details borrowings",
        "documentation": "Disclosure of detailed information about borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "BMGL_DisclosureOfDetailedInformationAboutBreakdownOfBorrowings": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutBreakdownOfBorrowings",
     "presentation": [
      "http://baselmedical.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of breakdown borrowings",
        "documentation": "Disclosure of detailed information about breakdown of borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of identifiable assets and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "BMGL_DisclosureOfDetailedInformationAboutFinanceCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutFinanceCostExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinanceCostTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finance cost",
        "documentation": "Disclosure of detailed information about finance cost explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory",
     "presentation": [
      "http://baselmedical.com/role/IncomeTaxBenefitexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of component of income tax expense",
        "documentation": "Disclosure of detailed information about income tax expense explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventories",
        "documentation": "Disclosure of detailed information about inventories explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutOfRightOfUseAssets": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutOfRightOfUseAssets",
     "presentation": [
      "http://baselmedical.com/role/RightOfUseAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right of use assets",
        "documentation": "Disclosure of detailed information about of right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutOtherIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExplanatory",
     "presentation": [
      "http://baselmedical.com/role/OtherIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other income",
        "documentation": "Disclosure of detailed information about other income explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory",
     "presentation": [
      "http://baselmedical.com/role/LossprofitBeforeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Profit before tax",
        "documentation": "Disclosure of detailed information about profit loss before tax explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://baselmedical.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "BMGL_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices",
     "presentation": [
      "http://baselmedical.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of revenue from transfer of goods and services",
        "documentation": "The disclosure of detailed information about revenue from transfer of goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of trade and other payables",
        "documentation": "Disclosure of detailed information about trade and other payables explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "BMGL_DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/IncomeTaxBenefitexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation between tax expense and corporate tax rate",
        "documentation": "Disclosure of effective income tax rate reconciliations explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FairValueOfAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of assets and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceCostExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinanceCost"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinancialInstrumentsByCategory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments by category"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r169",
      "r175"
     ]
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial risk management"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGoodwillExplanatory",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment loss on goodwill",
        "label": "Disclosure of goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://baselmedical.com/role/IncomeTaxBenefitexpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax (benefit)/expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "BMGL_DisclosureOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Schedule Of Inventories"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "BMGL_DisclosureOfLeaseRelatedExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfLeaseRelatedExpensesTableTextBlock",
     "presentation": [
      "http://baselmedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of amounts recognized in profit or loss",
        "documentation": "Disclosure of Lease Related Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events occurring after the reporting period"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOffsettingOfFinancialAssetsTable",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the offsetting of financial assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "BMGL_DisclosureOfOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "verboseLabel": "Schedule Of Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://baselmedical.com/role/OtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income",
        "label": "Disclosure of other operating income [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "BMGL_DisclosureOfProfitLossBeforeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfProfitLossBeforeTaxExplanatory",
     "presentation": [
      "http://baselmedical.com/role/LossprofitBeforeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Loss)/Profit before tax",
        "documentation": "Disclosure of profit loss before tax explanatory.",
        "label": "DisclosureOfProfitLossBeforeTaxExplanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://baselmedical.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DisclosureOfProvisionMatrixTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfProvisionMatrixTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the provision matrix."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://baselmedical.com/role/RightOfUseAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due from/to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://baselmedical.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/GeneralTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of activities of subsidiaries"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r75",
      "r119"
     ]
    },
    "BMGL_DisclosureOfSignificantRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfSignificantRelatedPartyExplanatory",
     "presentation": [
      "http://baselmedical.com/role/SignificantRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant related party transactions",
        "documentation": "Disclosure of significant related party explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade and other payables",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "BMGL_DisclosureOfTradeAndOtherReceivableExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureOfTradeAndOtherReceivableExplanatory",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of trade and other receivables",
        "documentation": "Disclosure of Trade and Other Receivable Explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade and other receivables",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of amount due from related party"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails",
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails",
      "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "BMGL_DisclosurePropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosurePropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureRelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureRelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Related Party Transactions",
        "verboseLabel": "Schedule Of Compensation Of Key Management Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureRightofuseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureRightofuseAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureSignificantAccountingJudgementsAndEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureSignificantAccountingJudgementsAndEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Judgements And Estimates"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureTradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureTradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Payables",
        "verboseLabel": "Schedule Of Trade And Other Payables"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DisclosureTradeAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DisclosureTradeAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Receivables",
        "verboseLabel": "Schedule Of Movement In Allowance For Expected Credit Losses"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248",
      "r269"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248",
      "r269",
      "r309"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "BMGL_DrKevinYipAndSingmedInvestmentPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DrKevinYipAndSingmedInvestmentPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Kevin Yip and Singmed Investment Pte Ltd [Member]",
        "documentation": "Dr Kevin Yip and Singmed Investment Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_DrKevinYipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "DrKevinYipMember",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Kevin Yip [Member]",
        "documentation": "Dr Kevin Yip [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of currency translation on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Employee benefit expenses",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r38",
      "r193"
     ]
    },
    "BMGL_EmployeeBenefitsExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "EmployeeBenefitsExpenses",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefit expenses",
        "documentation": "Employee benefits expenses."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_EmployeesCentralProvidentFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "EmployeesCentralProvidentFund",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees' CPF",
        "documentation": "Employees central provident fund."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_EmployeesSalariesAndBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "EmployeesSalariesAndBonus",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees' salaries and bonus",
        "documentation": "Employees salaries and bonus."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r25",
      "r102",
      "r104",
      "r120",
      "r121",
      "r122"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital attributable to equity holders of the Group"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r262",
      "r273",
      "r287",
      "r313"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r270",
      "r284",
      "r310"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_ExpectedCreditLossRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedCreditLossRate",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ECL rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The rate of expected credit losses, calculated as percentage of the gross carrying amount. Expected credit losses are the weighted average of credit losses with the respective risks of a default occurring as the weights."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r231"
     ]
    },
    "BMGL_ExpectedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ExpectedCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected credit losses",
        "verboseLabel": "ECL",
        "documentation": "Expected credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_EyetrustMedicalPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "EyetrustMedicalPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eyetrust Medical Pte Ltd [member]",
        "documentation": "Eyetrust Medical Pte Ltd [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FairValueOfAcquiredReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FairValueOfAcquiredReceivables",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade and other receivables",
        "label": "Fair value of acquired receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of receivables acquired in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 9.0
      },
      "http://baselmedical.com/role/ScheduleOfFinanceCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinanceCostDetails",
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance cost",
        "totalLabel": "Finance costs",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FixturesAndFittingsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixtures and fittings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r317"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r317"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r317"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r317"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r317"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Add: Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r81",
      "r84",
      "r87",
      "r157",
      "r168",
      "r170",
      "r228"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r248",
      "r269"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r226"
     ]
    },
    "BMGL_IfrsStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IfrsStatementLineItems",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative",
      "http://baselmedical.com/role/GeneralDetailsNarrative",
      "http://baselmedical.com/role/LeasesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails",
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails",
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails",
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails",
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative",
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity",
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails",
      "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IfrsStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IfrsStatementTable",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfGroupsCurrentCreditRiskGradingFrameworkDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment loss on goodwill",
        "label": "Impairment loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IncomeTaxExemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncomeTaxExemption",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax exemption",
        "documentation": "Income tax exemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails",
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income tax (benefit)/expense recognized in profit or loss",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r40",
      "r41",
      "r42",
      "r68",
      "r118",
      "r182"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r205"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of interests current",
        "documentation": "Increase decrease in lease liabilities interest and bank borrowings expense current."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of interests current and non current",
        "documentation": "Increase decrease in lease liabilities interest and bank borrowings expense current and non current."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of interests noncurrent",
        "documentation": "Increase decrease in lease liabilities interest and bank borrowings expense non current."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IncreaseDecreaseInNonCashWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseDecreaseInNonCashWorkingCapitalAbstract",
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital:",
        "documentation": "Increase decrease in non cash working capital abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows lease liabilities and bank borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non cash changes current and non current"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based payment reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransferToStatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger reserve arising from group restructuring"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transfers to a statutory reserve. [Refer: Statutory reserve]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "BMGL_IncreaseInAmountDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseInAmountDueToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in amount due to related parties",
        "documentation": "Increase in amount due to related parties.",
        "label": "IncreaseInAmountDueToRelatedParties"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IncreaseInBankOverdraft": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseInBankOverdraft",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in bank overdraft",
        "documentation": "Increase in bank overdraft.",
        "label": "IncreaseInBankOverdraft"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition bank lease liabilities current and non current",
        "documentation": "Increase through new leases liabilities and bank borrowings arising from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition lease liabilities current"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r214"
     ]
    },
    "BMGL_IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition lease liabilities non current",
        "documentation": "Increase through new leases liabilities arising non current from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r266",
      "r277",
      "r291",
      "r308",
      "r317",
      "r321",
      "r329"
     ]
    },
    "BMGL_InitialPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "InitialPublicOfferingMember",
     "presentation": [
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Public Offering [Member]",
        "documentation": "Initial Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r327"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r332"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r332"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r332"
     ]
    },
    "ifrs-full_InsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InsuranceExpense",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfFinanceCostDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinanceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense on bank borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfFinanceCostDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountsRecognizedInProfitOrLossDetails",
      "http://baselmedical.com/role/ScheduleOfFinanceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expenses on lease liabilities",
        "verboseLabel": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "BMGL_InterestIncomeOnLoansAndReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "InterestIncomeOnLoansAndReceivable",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income on loan to related party",
        "documentation": "Interest income on loans and receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfInventoriesDetails",
      "http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "verboseLabel": "Medicine,drugs and medical devices"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r196"
     ]
    },
    "ifrs-full_InventoriesTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InventoriesTotal",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]"
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_InventoryRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InventoryRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r226"
     ]
    },
    "BMGL_InvestmentRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "InvestmentRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in associate",
        "label": "InvestmentRecognisedAsOfAcquisitionDate"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_InvestmentsHoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "InvestmentsHoldPercentage",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments hold percentage",
        "documentation": "Investments hold percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Total for all associates [member]; Total for all joint ventures [member]; Total for all subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "BMGL_InvestmentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "InvestmentsPercentage",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments percentage",
        "documentation": "Investments percentage."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_InvestmentsSalePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "InvestmentsSalePercentage",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments sale percentage",
        "documentation": "Investments sale percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_LaterThanFourMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanFourMonthsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than four months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four months."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one month and not later than two months [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than two months."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r231",
      "r351"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "BMGL_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "LaterThanTwoMonthsAndNotLaterThanFourMonthsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than two months and not later than four months [member]",
        "documentation": "Later than two months and not later than four months [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r216"
     ]
    },
    "BMGL_LeaseLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "LeaseLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_LeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "LeaseTermOfContract",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Lease term of contract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120",
      "r121",
      "r122",
      "r183",
      "r187"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Reconciliation of liabilities financing activities current and non current, beginnings",
        "periodEndLabel": "Reconciliation of liabilities financing activities current and non current, ending",
        "label": "Liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "BMGL_LifeTimeExpectedCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "LifeTimeExpectedCreditLossMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Life time expected credit loss [member]",
        "documentation": "Life time expected credit loss [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansAndAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LoansAndAdvances",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans and advances the entity has made."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails": {
       "parentTag": "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings",
        "verboseLabel": "Borrowings Non-Current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_LongtermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermDeposits",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails",
      "http://baselmedical.com/role/TradeAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of long-term deposits held by the entity."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_MachineryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MachineryMember",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "BMGL_ManagementFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ManagementFee",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management fee",
        "documentation": "Management fee."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r282"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r283"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r283"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r283"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r283"
     ]
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of remaining contractual undiscounted repayment obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r126",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r148",
      "r163",
      "r174",
      "r203",
      "r229"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r126",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r148",
      "r163",
      "r203",
      "r229",
      "r230"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisional consideration amount for transfer of share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of measurement period adjustments recognised for particular assets, liabilities, non-controlling interests or items of consideration if the initial accounting for a business combination is incomplete. The measurement period is the period after the acquisition date during which the acquirer may adjust the provisional amounts recognised for a business combination. [Refer: Non-controlling interests; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "BMGL_MedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "MedicalEquipmentMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Equipment [Member]",
        "documentation": "Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_MedicalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "MedicalServicesMember",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical Services [Member]",
        "documentation": "Medical Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_MergerReserveArisingFromGroupRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "MergerReserveArisingFromGroupRestructuring",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Merger reserve arising from group restructuring",
        "documentation": "Merger reserve arising from group restructuring.",
        "label": "MergerReserveArisingFromGroupRestructuring"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MergerReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MergerReserveMember",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity that may result in relation to a business combination outside the scope of IFRS 3."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "BMGL_MinorityInterestInSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "MinorityInterestInSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "documentation": "Minority interest in subsidiary",
        "label": "MinorityInterestInSubsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NameOfSubsidiary": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NameOfSubsidiary",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of entity"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of a subsidiary. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r107",
      "r110"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET ASSETS",
        "label": "Assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r351"
     ]
    },
    "ifrs-full_NetDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetDebt",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "BMGL_NonadjustingEventsAfterReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "NonadjustingEventsAfterReportingPeriodMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonadjusting Events After Reporting Period [Member]",
        "documentation": "Nonadjusting Events After Reporting Period [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r106",
      "r109"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-current assets",
        "label": "Non-current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r113",
      "r218"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "- Lease liabilities",
        "periodStartLabel": "Lease liabilities non-current, beginnings",
        "periodEndLabel": "Lease liabilities non-current, ending",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net identifiable liabilities acquired",
        "label": "Non-current liabilities recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Non-current liabilities; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentPortionOfNoncurrentSecuredBankLoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "- Bank borrowings",
        "periodStartLabel": "Bank borrowings non current, beginnings",
        "periodEndLabel": "Bank borrowings non current, ending",
        "label": "Non-current portion of non-current secured bank loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current secured bank loans received. [Refer: Secured bank loans received]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "BMGL_NondeductibleExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "NondeductibleExpenses",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses",
        "documentation": "Nondeductible expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r136",
      "r137",
      "r148",
      "r229",
      "r232"
     ]
    },
    "BMGL_NotPastDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "NotPastDueMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not past due [member]",
        "documentation": "Not past due [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and other explanatory information [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, authorized"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share issued",
        "verboseLabel": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "BMGL_NumberOfSharesSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "NumberOfSharesSubscribed",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares subscribe",
        "documentation": "Number of shares subscribed."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_OasisMedicalClinicPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OasisMedicalClinicPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oasis Medical Clinic Pte Ltd [Member]",
        "documentation": "Oasis Medical Clinic Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_OrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OrdinaryShareMember",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Share [Member]",
        "documentation": "Ordinary Share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss for the year, representing total comprehensive income for the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r36"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r116"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due from related parties",
        "verboseLabel": "Other receivables - third parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_OtherGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails",
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "totalLabel": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income",
        "label": "Other income [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r193",
      "r194"
     ]
    },
    "BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non cash changes current",
        "documentation": "Other lease liabilities and bank borrowings arising from financing activities current."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non cash changes non current",
        "documentation": "Other lease liabilities and bank borrowings arising from financing activities noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary payable",
        "verboseLabel": "Other payables third parties"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "BMGL_OtherStaffExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OtherStaffExpenses",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other staff expenses",
        "documentation": "Other staff expenses."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_OthersReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OthersReceivables",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/SignificantAccountingJudgementsAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others receivables",
        "documentation": "Others receivables."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_OthersRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OthersRelatedPartiesMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others Related Parties [Member]",
        "documentation": "Others related partiesMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r275",
      "r289",
      "r315"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r278",
      "r292",
      "r318"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r267",
      "r278",
      "r292",
      "r318"
     ]
    },
    "BMGL_OverAllotmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OverAllotmentOptionsMember",
     "presentation": [
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OverAllotment Options [Member]",
        "documentation": "OverAllotment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_OverprovisionInRespectOfPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "OverprovisionInRespectOfPriorYears",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      },
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Overprovision in respect of prior years",
        "verboseLabel": "Overprovision in respect of prior years",
        "documentation": "Overprovision in respect of prior years."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative",
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "verboseLabel": "Share subscription price"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_PastDueStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PastDueStatusAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Past due status [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_PastDueStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PastDueStatusDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r296"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of principal portion of lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "BMGL_PercentageOfProvisionalConsiderationAmountForTransferOfShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "PercentageOfProvisionalConsiderationAmountForTransferOfShare",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of provisional consideration amount for transfer of share",
        "documentation": "Percentage of provisional consideration amount for transfer of share."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_PercentageOfTradeReceivables": {
     "xbrltype": "percentItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "PercentageOfTradeReceivables",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of trade receivables",
        "documentation": "Percentage of trade receivables."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_PharmaAvenuePteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "PharmaAvenuePteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharma Avenue Pte Ltd [Member]",
        "documentation": "Pharma Avenue Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed from bank borrowings and lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_ProceedsFromContributionsOfNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromContributionsOfNoncontrollingInterests",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest contributions"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from proceeds from contributions of non-controlling interests. [Refer: Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ifrs-full_ProceedsFromCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromCurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails",
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings",
        "verboseLabel": "Proceed from bank borrowings and lease liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "BMGL_ProceedsFromDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ProceedsFromDeferredOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs",
        "documentation": "Proceeds from deferred offering costs.",
        "label": "ProceedsFromDeferredOfferingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative",
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance",
        "verboseLabel": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromNoncurrentBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed from bank borrowings and lease liabilities, noncurrent"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r221"
     ]
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r221"
     ]
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and professional fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "BMGL_ProfitLossAndNetComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity",
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss)/Profit after tax",
        "label": "Profit/(Loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r30",
      "r89",
      "r103",
      "r105",
      "r183",
      "r185",
      "r218",
      "r223"
     ]
    },
    "BMGL_ProfitLossAndNetComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ProfitLossAndNetComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss)/Profit for the year, representing total comprehensive income for the year",
        "documentation": "Profit loss and net comprehensive income.",
        "label": "ProfitLossAndNetComprehensiveIncome"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss)/Profit attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "BMGL_ProfitLossIncludingMinorityInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r31",
      "r108"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "BMGL_ProfitLossIncludingMinorityInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails",
      "http://baselmedical.com/role/StatementOfCashFlows",
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss)/Profit before tax",
        "label": "(Loss)/Profit before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r193",
      "r194",
      "r233",
      "r234"
     ]
    },
    "BMGL_ProfitLossIncludingMinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ProfitLossIncludingMinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss)/Profit for the year",
        "documentation": "Profit loss including minority interest.",
        "label": "ProfitLossIncludingMinorityInterest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_ProfitLossOfCombinedEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossOfCombinedEntity",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase consideration"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Total for all business combinations [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "periodStartLabel": "At June 30, 2024",
        "periodEndLabel": "At June 30, 2025"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51"
     ]
    },
    "BMGL_PropertyPlantAndEquipmentAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "PropertyPlantAndEquipmentAccumulatedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "At June 30, 2024",
        "periodEndLabel": "At June 30, 2025",
        "documentation": "Property plant and equipment accumulated depreciation.",
        "label": "PropertyPlantAndEquipmentAccumulatedDepreciation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r226"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r111"
     ]
    },
    "BMGL_ProvisionForExpectedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ProvisionForExpectedCreditLosses",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for expected credit losses",
        "documentation": "Provision for expected credit losses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfInvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfInvestmentProperty",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) in investment in associate",
        "label": "Purchase of investment property"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investment property. [Refer: Investment property]"
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of property and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "BMGL_RainforestCapitalVCCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "RainforestCapitalVCCMember",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rainforest capital VCC [Member]",
        "documentation": "Rainforest capital VCC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r124",
      "r143",
      "r149",
      "r219",
      "r220",
      "r373"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r124",
      "r143",
      "r149",
      "r219",
      "r220",
      "r373"
     ]
    },
    "ifrs-full_ReceivablesDueFromAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReceivablesDueFromAssociates",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partial settlement of related party receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from associates. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_RecoveriesOnLoansPreviouslyWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RecoveriesOnLoansPreviouslyWrittenOff",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bad debts written off"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the recoveries on loans that were previously written off."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "BMGL_RecoveriesOnLoansPreviouslyWrittenOffFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "RecoveriesOnLoansPreviouslyWrittenOffFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on written off fixed asset",
        "documentation": "Recoveries on loans previously written off fixed assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r259",
      "r270",
      "r284",
      "r310"
     ]
    },
    "BMGL_RecruitmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "RecruitmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recruitment",
        "documentation": "Recruitment expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartiesMember",
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfTransactionsWithRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total for all related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Total for all joint ventures [member]; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "BMGL_RenovationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "RenovationMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovation [Member]",
        "documentation": "Renovation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RentalExpense",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Rent expense",
        "label": "Rental expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised on rental activities."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "ifrs-full_RentalIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RentalIncome",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rental income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income recognised from rental activities."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of borrowings",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r195"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r271",
      "r285",
      "r311"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r272",
      "r286",
      "r312"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r279",
      "r293",
      "r319"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r195"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/StatementOfProfitOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss",
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "verboseLabel": "Rendering of services - Medical services"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r114",
      "r160",
      "r180",
      "r184",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r218"
     ]
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government grant"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r181",
      "r188",
      "r351"
     ]
    },
    "ifrs-full_RevenueOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ImpairmentLossOnGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue",
        "label": "Revenue of acquiree since acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "BMGL_ReversalOfAllowanceForExpectedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ReversalOfAllowanceForExpectedCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfMovementInAllowanceForExpectedCreditLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Reversal of allowance for expected credit losses",
        "documentation": "Reversal of allowance for expected credit losses.",
        "label": "ReversalOfAllowanceForExpectedCreditLosses"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ReversalOfExpectedCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ReversalOfExpectedCreditLosses",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversal of ECL",
        "documentation": "Reversal of expected credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use-assets",
        "periodStartLabel": "At beginning of financial year",
        "periodEndLabel": "At end of financial year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r133"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "BMGL_SSOCFarrerParkPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SSOCFarrerParkPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SSOC Farrer Park Pte Ltd [member]",
        "documentation": "SSOC Farrer Park Pte Ltd [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SSOCNovenaPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SSOCNovenaPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SSOC Novena Pte Ltd [member]",
        "documentation": "SSOC Novena Pte Ltd [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SSOCOrchardPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SSOCOrchardPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SSOC Orchard Pte Ltd [member]",
        "documentation": "SSOC Orchard Pte Ltd [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SSOCPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SSOCPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SSOC Pte Ltd [Member]",
        "documentation": "SSOC Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SSOSPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SSOSPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SSOS Pte Ltd [Member]",
        "documentation": "SSOS Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and advertisement"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "BMGL_ScheduleOfCompensationOfKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ScheduleOfCompensationOfKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of compensation of key management personnel",
        "documentation": "Schedule of compensation of key management personnel explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ScheduleOfExpectedCreditRiskExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ScheduleOfExpectedCreditRiskExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of credit risk",
        "documentation": "Schedule of expected credit risk explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinancialInstrumentsByCategoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost",
        "documentation": "Schedule of financial assets measured at amortized cost and financial liabilities at amortized cost explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory",
     "presentation": [
      "http://baselmedical.com/role/FinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial assets, minimum exposure to credit risk",
        "documentation": "Schedule of financial assets represents the maximum credit exposure explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ScheduleOfTransactionsWithRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ScheduleOfTransactionsWithRelatedPartyExplanatory",
     "presentation": [
      "http://baselmedical.com/role/SignificantRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of transactions with related parties",
        "documentation": "Schedule of transactions with related party explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "BMGL_ServiceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ServiceIncome",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service income",
        "documentation": "Service income."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions",
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated settlement liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities settled by the entity on behalf of a related party in related party transactions. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "auth_ref": []
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares held"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_ShorttermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails": {
       "parentTag": "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
       "weight": 1.0,
       "order": 1.0
      },
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Borrowings",
        "label": "Borrowings Current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "ifrs-full_ShorttermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermBorrowingsMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term borrowings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r216"
     ]
    },
    "BMGL_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore Knee Sports and Orthopaedic Clinic Pte Ltd [Member]",
        "documentation": "Singapore Knee Sports and Orthopaedic Clinic Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SingaporeKneeSportsOrthopaedicServicesPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SingaporeKneeSportsOrthopaedicServicesPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore Knee Sports Orthopaedic Services Pte Ltd [Member]",
        "documentation": "Singapore Knee Sports Orthopaedic Services Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SingaporeSportsOrthopaedicClinicPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SingaporeSportsOrthopaedicClinicPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore Sports Orthopaedic Clinic Pte Ltd [Member]",
        "documentation": "Singapore Sports Orthopaedic Clinic Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SingaporeSportsOrthopaedicServicesPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SingaporeSportsOrthopaedicServicesPteLtdMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfActivitiesOfSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Singapore Sports Orthopaedic Services Pte Ltd [Member]",
        "documentation": "Singapore Sports Orthopaedic Services Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_SoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "SoftwareMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails",
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software [Member]",
        "documentation": "Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://baselmedical.com/role/GeneralDetailsNarrative",
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative",
      "http://baselmedical.com/role/StatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r263",
      "r274",
      "r288",
      "r314"
     ]
    },
    "ifrs-full_SubscriptionCirculationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubscriptionCirculationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Membership and subscription"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of circulation revenue derived from subscriptions. [Refer: Revenue; Circulation revenue]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income not subject to tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax using the statutory tax rate of 17% (2024: 17%)"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "BMGL_TelephoneExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TelephoneExpense",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Telephone",
        "documentation": "Telephone expense."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanElevenMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #11 [member]",
        "documentation": "Term loan eleven [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanElevenOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanElevenOneMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #11 one [member]",
        "documentation": "Term loan eleven one [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanFourMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #4 [member]",
        "documentation": "Term loan four [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan [member]",
        "documentation": "Term loan [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanNineMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #9 [member]",
        "documentation": "Term loan nine [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanOneMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #1 [member]",
        "documentation": "Term loan one [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanSevenMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #7 [member]",
        "documentation": "Term loan seven [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanSixMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #6 [member]",
        "documentation": "Term loan six [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTenFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTenFourMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #10 four [member]",
        "documentation": "Term loan ten four [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTenMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #10 [member]",
        "documentation": "Term loan ten [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTenOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTenOneMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #10 One [member]",
        "documentation": "Term loan ten one [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTenThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTenThreeMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #10 three [member]",
        "documentation": "Term loan ten three [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTenTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTenTwoMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #10 two [member]",
        "documentation": "Term loan ten two [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanThreeMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #3 [Member]",
        "documentation": "Term loan three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTwelveMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #12 [member]",
        "documentation": "Term loan twelve [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_TermLoanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TermLoanTwoMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfBreakdownBorrowingsDetails",
      "http://baselmedical.com/role/ScheduleOfDetailsBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan #2 [member]",
        "documentation": "Term loan two [member]"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_ThridPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ThridPartiesMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thrid Parties [Member]",
        "documentation": "Thrid Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://baselmedical.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://baselmedical.com/role/EventsOccurringAfterReportingPeriodDetailsNarrative",
      "http://baselmedical.com/role/FinancialRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r124",
      "r143",
      "r149",
      "r219",
      "r220",
      "r373"
     ]
    },
    "BMGL_TotalNetUndiscountedFinancialAssetsliabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TotalNetUndiscountedFinancialAssetsliabilities",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total net undiscounted financial assets/(liabilities)",
        "documentation": "Total net undiscounted financial assets/(liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "BMGL_TotalUndiscountedFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TotalUndiscountedFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted financial assets",
        "verboseLabel": "Total financial assets measured at amortized cost",
        "documentation": "Total undiscounted financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amount due to related parties",
        "label": "Current payables to related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]"
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/BalanceSheets": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/BalanceSheets",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r23"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "verboseLabel": "Trade and other payables",
        "label": "Trade and other payables [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFairValueOfIdentifiableAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade and other payables",
        "label": "Trade and other payables recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payable- third parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivablesDueFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfAmountDueFromRelatedPartyDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfRemainingContractualUndiscountedRepaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "verboseLabel": "Amount due from related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables due from related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "BMGL_TradePayablesMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TradePayablesMaturity",
     "presentation": [
      "http://baselmedical.com/role/TradeAndOtherPayablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payable, maturity",
        "documentation": "Trade payables maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Receivables",
        "verboseLabel": "Estimated total gross carrying amount at"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransportationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TransportationExpense",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfProfitBeforeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transportation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from transportation services."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "BMGL_TwelveExpectedCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "TwelveExpectedCreditLossMember",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twelve expected credit loss [member]",
        "documentation": "Twelve expected credit loss [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r162",
      "r165",
      "r166",
      "r192"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfCreditRiskDetails",
      "http://baselmedical.com/role/ScheduleOfFinancialAssetsMinimumExposureToCreditRiskDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r162",
      "r165",
      "r166",
      "r192"
     ]
    },
    "BMGL_UnderprovisionInRespectOfPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "UnderprovisionInRespectOfPriorYears",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      },
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfComponentOfIncomeTaxExpenseDetails",
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "-Underprovision in respect of prior years",
        "verboseLabel": "Underprovision in respect of prior years",
        "documentation": "Under provision in respect of prior years."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfExpectedUsefulLivesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected useful lives"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "BMGL_UtilisationOfCapitalAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "UtilisationOfCapitalAllowance",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Loss)/Profit before tax",
        "documentation": "Utilisation of capital allowance.",
        "label": "UtilisationOfCapitalAllowance"
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_UtilisationOfDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "UtilisationOfDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfReconciliationBetweenTaxExpenseAndCorporateTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Utilisation of deferred tax assets not recognised in prior year",
        "documentation": "Utilisation of deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValueAddedTaxPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ValueAddedTaxPayables",
     "crdr": "credit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GST payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payables related to a value added tax."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "BMGL_ValueOfSharesAuthorised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "ValueOfSharesAuthorised",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ShareCapitalDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, amount",
        "documentation": "Value of shares authorised."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://baselmedical.com/role/AmountDueFromtoRelatedPartiesDetailsNarrative",
      "http://baselmedical.com/role/ScheduleOfCompensationOfKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional medical practitioner salary",
        "verboseLabel": "Salaries and bonuses"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "presentation": [
      "http://baselmedical.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average borrowing rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://baselmedical.com/role/StatementOfProfitOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://baselmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "BMGL_WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written off",
        "documentation": "Written-off other than through business combinations property plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "BMGL_WrittenOffRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://baselmedical.com/20250630",
     "localname": "WrittenOffRightofuseAssets",
     "crdr": "credit",
     "presentation": [
      "http://baselmedical.com/role/ScheduleOfRightOfUseAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Written off",
        "documentation": "Written-off right of use assets.",
        "label": "WrittenOffRightofuseAssets"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_138_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "60A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_60A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "h",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_h_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_q_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_a_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "13C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_13C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_21_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "B Statement of cash flows for a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_B_TI",
   "URIDate": "2024-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2024-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG20D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>115
<FILENAME>0001493152-25-023940-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-023940-xbrl.zip
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MW,F*]QP>Z 5E(6;YYG 1-M1!L+%.7[B576,V!TL'[\CCRGW:@@G_S,7E4U4
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MM7B/FI_S6RLN@>K7BI4J42Q"H>8$1X%HTG:=+?HMLG!H+84R'OVXM'3<W^P
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MW^A",U[5- :)-#1C6(M4]U&'9DQ6^_4:@3AB>)9)=.M?-]QD"GT&]+6;L=F
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M<O9!9 9R0^^PF[#E<GOVYO&>WVH&UJ-2*\,U+V47U/1 KN<WDA75N-NN'DD
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MN<IW*Q0$NWH_*I47&EJA\BK'H,H'S4:^6F&Z8(OA9TJ>XF5V,5BE>FD'*R"
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M2AQ-'GDM6%=V;K9O6FSY($OZZ!.O%D:5A&,(&@-GU3<2NND1GCY&4)_!T=+
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MT=&&AI@I.XXWM6HP@4,0C<$T,"#QA82+&-/5.:&4//'+;\I95VEM0OBH(8"
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M>>(5+Z\)Y27Z7#;,+BCS1^(O)(+,='4G@S6OR7S7\<4^RVHWF"DV3I%&<\/
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MJNH0WRQ3^R!0;];VX1.VC(/N9 4'0L>9Q5W8B;5#H=N/F#X8^I 6' YMXS;
M<"CR",!9;&0Z'#)N075V[-)./$_HH,B#>K(H^YBN; WF0=T;[4G."$W3L@Z_
MNL/L!RRFM7:]P58$30:]"\G $=&Q;RH?G+6[5UTWD^'1YQ\$P4"/LI,3@#]6
MI+^CB+Z)"7UEXSISMO:R[2,IG1X,=?<U*\9/7V*# \WPD^.<\<)O,/IS'WN3
MJ.%8:D70BN%RA&3@B.C8E=&)S31SRHZ(=S7[D,E#H$^)P:%AZD$S^^<!XF"R
MC]DR1/J0&APF;;WWX8T7$2.Z6*)PT7$^2Q??,7EL]2@P.*QR@8GQ+MO>4^1A
M-AF$@#.T3=]&AR_2_J2Z2!MS8@X*/8=P<LXZHS?4L]4J8;XA2A%#!LND>E^6
MZKY.$F=/K^^GN)>(X@NT]F,4Z(CRH0(0)^"X*04I_Z=;RS77/78\3N?9$G 3
M7OTS\>-M[57DVJY6WB_65(C%EX8OR&I-0EY,9CI/):M]R #H,>(U8%V8*AG=
M2N&MR-:NBJ!1NA[L,]JS!&H@ZG&S\:)ME]"9?76V(W@'?53@AFL.!;/D,?#=
MZ7R.*3-YE97#%#UZ@$>W?EC=5"'Z @R64['!=!($)!9+^IIK"+YU*#(&P XC
M/C[00/$U_-L4 _Z6<+:G<V&,1Y,D7A+F.M8<Z@)]'GXRWXU6\@X!U_%2]1L*
M$JRE<MX<:&VPLNNXMLA<FR$J))EA*D11GGZ4VAJ,D)IG</TR#Y_B=+Z)HJ3)
MTI6VMP$GD&_0O#(AAC=9D81MJ+S2TR+T_\5S_F>4S/UX2K^02!7-^ZB*YJ&4
MK"B/E])U_-!9"\I,?H=U&BRREQX$Z<2_/I5%2KN> E]'ENMC(VJ-:;R=!4B<
MGG#C;<WY;U2.KXZ*E>&PYFJR.3*VJ[P,2JK]Y&<-!4,*Z&DB"KX&J*4G*ZRT
M>I$:O ]92V/TMT#U@&N.NY5!N0&A-SQH-\SPL*["W5?D+ME.2;?UA;!*3<=_
M;E1WJI;!E C2]7(.F)O"J.6O&4SG%VP(4^1">4*2E@9[8BJ.NPX;]3@9?L?^
M8AEC;[+!%"WP%\S&&3]]<ZD0'QT*L_/:^9/U.O"Q=T_*N4R91\>LP4E\R1I.
MYUDL6O1PLXJ^-]>W=V?O51-N!'8,'F.CJ\4FDP]%RVD2SP/R=$W2VX>U=<[*
M[6T8"B#?&D&Z49.WPH@_1$#"Z'<_7M[B@$GLS1!5/X?PZ75-%M>>JO/$R#HT
MI>NL4\*G!P]:15#R:)WC^ GCL A8HTB*+C7K(RK-U&9S9(7)M"#4YQ9I4<+:
MB$I-3T,B*0V1K*[1.OJQ9%N%1-%PHVO[CA8YT0-('U<K(R4]0FMX9*0?^*V+
MA!2%J ^'R-J/%Q/1G8QE&"$I!@J([*[],.^-K/ T%/4 )J&7E@0 #*LTNZNN
MX^#U^9M>B=(2H.OH"8##5Q0R5YHS?8TAE1?:&*[=*J]6F1D1\PG7:+M*$^XF
MW@:%KKA%*48)O[=4G+=UOGTS:@9C>ZQ41L<%>)(EV]:SR-/?\?8PBF>81B0,
M<:"(#IRIH@-NCC;_^W>\=59[\LYZ1W^HS)"#U-?(IUD^W(W'>/'G/E_]TD<G
M.)R'D)U"^#<JX>?L$\Z&?X/_S<]]Q4'B,^+*6/[UR(&T<+-:,];$B"=1- T_
M$^(]^8'.C;%/;\L2'XBE.3X,Z$5&;X3[;WM\/U.2K'=%GRXH:QC?^M'WSQ1Y
MX@XF6N$G0K\KL%6^ KK@Y/_CWS^^.?OPY\C)*@PYKOB.0]F'6 OQ)6>^^]0?
M+1"FPQ 4I*HP8V'\"9)AF- 26/I86.30!;2TZ&^^R?#1GAJ]$8C3@7R#W4=!
M!SS/V4A!%% Y$N7U%A;I3G]&1BJ:ZWC0JU6[3T]#K+S64VDW=+! ,18EFBRP
M.?",OW\B6JK<MQO\1EHS71;Y!)79ES99*[VAF6LY^%6SAAHM<0JNJ3WI])HD
M5$NEAX:C>-7Z&BTQ"JZ>'2OT$D<N]=>IRWOP#@"M JT-3E6HXWJ@^-XYBOSH
MFM#=91/F#_'"2FZ,O90A[G\"2M?J:S@$^C)H;'7C18BR:D4H>Y+S*_O(*EDQ
M281G?$\.@TOA3BMK <UW7\@B(__IK-*/.#C[BA.3@GO]!W.F!\HJ.4\BQF@4
M79#5(U.Y.%QOE$BB(&"3[]Y4MF%\^AX'@4RVND01N(\A*2+U@)7AKE.#%0<U
M,B'JTP54O<;* :F%0P<_&_,^NH;0R A*'S!;E]_QF3(3[P)1NN75'L4EZ?HD
M#[#3:)D>&A.O#*)2"(N66UY4YHF?\C)#_F"UZ^3JJ'N.5\^H!9@:HG0>8.HU
MUZ'9A)0.X]'*(K7 #Q1@Z!"6P0=3Q]F8^@=6'=>8/QU8G0ZL3@=61A]8&5BD
MZ9Y]E6?M^M'WVD! M:UMB[-"%'#\FXU9O;<H:SV6HP^J786/C8[]L1 9N;-T
M >.@>\T7?X[OF=S5PQ;EUE/7;33O6S$K2#/VNU[M  #NGW"P::I^=:?!#[(;
M:E^#>U#Y'6O_<!XG7J8XW.T /2^PP\.9V2>L=9Q#*C=PZ_A"PD6,Z>H2KTGD
MQ^IW(TMM38:IANFN(X' G*A.3' VR)J:K& USS;Y)/D7>7)3^3+!S2X?-2)D
M,K3'2*2QU8]XZ4@G9:3RT%+A:M$I&>3X(JT;GWL&7U%,_>>FI5DE?:U/ 5&I
MQ.+LCQF*8K92<*4DM=$>26-#PCU*=*I5U &9K3AT+'!?'TB0-A\KV -K7HF1
MC>&>XV$R.^!S%)2#AGR^D3AC01EC*#<;+:2C&OI$S:]%R]@7M@O3^R4*^3$)
M&WU+\9)NO/\UOZ+"?ZV13-&0U'C9%1K('B44"'_756,K3)28$W<WU.B)L&13
M.N,E5FA.RG82@?N:R?-6 ^/J8*Z(/UKHMM5<E+(/[F,FH\=6E?_&"+XR)EV'
M#CT>WEF%6Y5W"+1W!H+VASB0;^2AZ9_%FQBK/)W%F^Z<G<[B!SV+[S-==Q\M
MUDC5+;4U^-!>R;-%:V'U\(F7P%>!).]AQ4F,BG6+3ILU,@.*AT^6) 74,'TZ
M;;;KM/F4X=(VP\6(8]Y;S#7AAXO=VSP)"GX-/>8Q\&LHV-O7TIP^!OXBN\D"
M'PA_4!T(T]VW'/?P,2?)?8TUR3[GD,/W3J?'K4Z/LW=D[\DY'Y-D@]DXG=([
M'#.XO,F<^^0B(RZ-I/!K8[L'M&0U-IG_'O,QPA!4$CXG\?(;^4HH3X;@?Z1A
MN,.'Q)?9L"(T9D.!O[#3Z%S;-JFL/W&W3>'6YP)\17%"_1BZB+=O6&QG2'S)
MTM%2?0JPBH$5YWD[QNO#*>668T6[I*J&\+ QRM46$K.C6RU@LR^JU<4E]+&B
M6\"4T;IW/F!ISX,GP$OW7P?D27U8#7<8+Z% K6H-KCO/&.AQ4N2/T;6/+\%.
MXZ42:,X/->=6I@P<>^@\6K* )F0*MFU*$BC<*,C>26@2#X:[/GPR-J#62 2+
MHOE\U6?2\#_X<^0;%/#W:=3&A*R'#= I.+?(DQKIKI,%^#87:*!#AWL2%Z/7
MI;JX@$E9U\U@3+39USB$,'+BS="VV6ZWZV P:!J,0W"],QRN;*/>R7)/6BZ3
M-72L U=''@CSG[I=)%-'GZW5]^2:T!6FES[%;JYW:74$VQL,0CW?D++?FS?!
MS@FEY,D/%^I:T/M6!N,"<0NA\<$\-"XQ9>8.?REOO\WF#BSRV_ ^T*,\VFQ.
MS@9\VXH%#82//1B*WW"LL)IRKSZJS$9M(@:CUE(8"*M/X^6U[#D6F9K[9TQU
MGLW\6,Y<V=-**QCD'D65/9IY2DS13TQ)U8>]FW#.-F:1XS-Y)$E\V!0:981H
MD[,^%:.AXBS.@;A%X0+7)4#D&AF2_= 4H#+8%;&MB)0)KNM/MPO-QLHVJ&I8
MBH&->0;-83 [PZ 15-;E%MR3]70N!*@_ARNW'>^D6S8Y*H$/&;<VG7"?DS@F
M*VUT),W'.]76 0ABN//#;,# G;'=E4U]9DY/YYJW U1=!K\$W<RSJF5=XQ33
MG)<%,>*6CC>))RN>2_DOYL"3*)Z$GLS/+[52W!OXU.3M06>5<>&@V$&[+S@N
M^X2#0B_7/N>R2MJ>KA6T\=Y*(Z*1JR;O:[U?IE*)Q4Y8]H*"S[.S2R+6N6:U
M70UQV)3(5?,:M/1AA<^FD*7>A=#H/)9_IXM1 VQM] 7[A==LO[&W(6"=CUF6
M/KY&/OT-!0F^7U*2+)8S2N9^/*5?Q$. Z7LY]0[/$61'RX;7G]_E87&DM!;M
M"3TFG Z=,MQ#PJDJ?=C N=]9PJD%T"DXMW7Z#9=P:@&^S04";34[$D[-Q42;
M?=!.,GSBM4\X-1<T#<8AN$X)IW:NDCKR0)@;FW!J+@CU?$/*_B,DG)J+"\0M
MA,8IX526F6D!OFW%@@;"Q_$.WZXVW'N9NBY;POG%_$+IDAF3DWCU"8UGKU^7
MC]12N@[9$780I^RPW8*7W4K).VM!_Y3B>.0AV70^9Y8PU^AQ!V;U=*P_/--5
ME<T':6+EH>O4]JH].Y.T-N2X3!NK2H0&U( 5H9DB^QHG*-+VHYV)P<I7XV3E
MR5<'4!E^OG4<G(,^^G1W-[WX1ICA@68Q_A)[RM(^\L;C'1FIY@+18;OK%4ZA
MY"EUEXAZFEJ6M!XOI[2)GB'&04WWH.IK9A+SZ!G]KJEM>8?Q<D2;*%S!.[@K
M=)TNRA!?H0F;8 G6T#C4_.&]Z?I6<@[&C[HNC+[%S(B.XJ^I6ZJA<$6/AP^F
MZ[R.>3!0U'4=/(9]S&N:WJS0@OOY]7I7=7GX:+KB:[D'(S,&^@??2(B\?[!A
MQ 1)PRRRJ$V=X]>$BNT.87.-6?'0BIY8]5Y),SIC.98M0&PW#FQT1,<8"F8[
MK@,/EX%?-]9AK.;E8WT2HSG%K>8K:2^D16N_I7?66V_A&I?5#4SV.5U6MQ0&
ML_>VTV7U?1I2^?KW:'&75I?5E;&6CM-';\(-CF(^LJ+#+6'H%%S6]N%LZ*AM
MLY0H!=.0CCNVRW(<W*$ -U%SL;U%JI8Q/M!11(Z+OY+ :Z+N8GN+U"UCW"*S
M]5O"]3&=WRT1Q=%-%"6';"6I/RII;S):&HQ;9+Y^P_$E?HR5 *5-[, DSRL$
M0RX'O;]</"%TA-T?%V3S"KM>FHLWVZROGK&;\ RXW!7",-CF>.KGNQ/A)HL5
MIO_OW82>O_&]! 7]?FSRA*AWSSKV+Q)/A^?IDY1RZZZDQVP<\?_Q)$SVF_\'
M4$L#!!0    (  B-<5MT)MAO8I@  "6<"  5    8FUG;"TR,#(U,#8S,%]L
M86(N>&ULW+WKDN0VDB;Z_YCM.^!H[.Q*9E5=NO1T;VMF=BVOU3F=59&;F9+.
M'-F8C!E$1+*+042#C,R,>?H#@'?B2@8#\%#_:%55N#L_)S\X'([;O_[OMTV*
M7C#-$Y+]VU??_>';KQ#.EB1.LO6_??73P_NSAXN;FZ]07D19'*4DP__V54:^
M^M__Z[_]7XC][U__[_?OT76"T_A'=$F6[V^R%?D7]#G:X!_11YQA&A6$_@OZ
M.4IW_%_(=9)BBB[(9IOB K,?R@?_B/[TAQ\B]/Z]@]F?<183^M/]36/VN2BV
M^8\?/KR^OOXA(R_1*Z%?\C\LR<;-X$,1%;N\L?;MV[?5_TKU?TV3[,N/_/^>
MHAPC]KJR_,>W//FWK_ASJ\>^_O '0M<?OO_VV^\^_+^?;A^6SW@3O4\R_MJ6
M^*M:BUM1Z7WWE[_\Y8/XM1:5)-^>:%H_XX</-9S&,OLU,<AWD.3)C[F =TN6
M42&^NO4Q2"O!__:^%GO/_^G]=]^__^&[/[SE\5?URQ=OD)(4W^,5$F[^6.RW
MC$EYPHGP5?5OSQ2OU&!22C]P_0\97D<%COF#_L(?]-V?^(/^J?KGV^@)IU\A
M+LGXH?7K+SU;E=('WV#O,$U(?)5-0SW4#@2?M1U:'.! 5]^["X^DB-))X+N:
MWF%_QM/>>*OG_TVS,(^GO>F.YE%@%S+DT:]7_5Y3_H^W[$\]B/BM8!T8CFN0
MW(0A HLGB(ZALMU8)\N>W91'<T)EWWG/*&SF>/F'-7GY$..$V?[^C_P/[_D?
MA-OL+[]=9452[,_BF.(\QWGUAT=F_^PMR6O3PJ]_^\I%X<,0-%<]HS7RB"XM
M[E<2'Y:$=5[;XGU:ONA2?47)Q@U']:*(B_1OZ5/SA/+5,A :5WIBS C9T24>
M]66[_CB_V KB)F4J/$W#V?N?'K[Z7Z42:K3>U7]$7!']RE7_\U\_M,_R0*GS
M79YD#,(%R8IH67S"FR=,%0YKY'P1R BSYHU2" 1=3,B&+*EE426,?BW%YV5&
MLJ*Y %]$;R0CF[W@QWN6'G[_YP^K79K^QB7:/[U?$OI;*R+X(_Y=2%RPKF!-
M:(+SQ>H>IR)_8(D#^[LB,+FK^6#76"<XV5QU@G-O)- A%5LE1%:(EFIH6^JA
M7Z/9X]6\K.S[J0QM-F&_##0![O-.)0F(;09X0XZ)5!VM"$51FLH<V\"/?62S
M)1G."M:RKOZQXVF!,>9IQ#W'.B/H08Q3R@)BFQ&@%-,:81[3L!"''\IN\GR'
MXXMHF[#68HED2EF_]#+ [7-+(0B(6'IT0U:5DFA9BIY"V/J$Z1K3>YQC^H(M
MC%+*^F64 6Z?40I!0(S2HQLRJI1D':(0/05&55ZQ&/RV?&:NX,MDM<(4LZ^;
M+[)'&F5Y*@K:UDQLI!W?2=HD-X?YVR@C@!@\#;F4];5RIT7Q(F*#\_@JHEF2
MK>UC"K6X;\*:0 ]YJ9(%13\#P"'+:F&$*^E3X%B5P18%39YV1?24XD>R>,TP
M9=DM&U"QS-7".G<#?GDXUK$^,UVU 7%U)&2I7%R.3:*./BH((L("'[QLA8U3
MX/1GQ@^2%>R=L>>M;[*"=1AY80N?%BV_['5RH4]9HPH@GKK@')*3Z;SO**&D
MUIJ-CD^;=<KG*O[YVS_]\*W@T_FGC[>_+6B<9!'=/SPS]BL)I!?SP1@;2$X1
MG4QP3EB #4E02R(A>A(3%63'B;IUF9Q0B/HNTNG #@MT0[G@1'( )Q?FNH(S
ME>0T0>0\RG'Z"<?),DH_4K+;WA7XMHCUX<2BX"VP. %O0HQ1.CA'G"%*,Z1<
M!U5*2&@AIH:8WFPQ2$.<!];715M"\0/[OR)?T.*9;"..Y((I)TL;C\;I>Z/5
M%+<:EHU1AD&Z"8B''&Q,H-(&ZAA!I97PG'S ]"59XGPZ*]46 /#2Y)H#,U7J
MT+EIP#R*G;4=;_Q\6%Q8&2C)^..8!E[+HH$ $)ZH44E,8&(>/_2#PX=^"/>A
ME?"Z'_H!Y(=6H5)\Z ?O/<[?,ES%J;,LGIX,C3'CO^\9[Z3< ;G; $*ZR<#U
M71$W5?='419#R)A:[P[)FD98"<G>R=F3LPFPW#TTB^I2-V0J=?<<T4UT]H*S
M';;14R_KC80VN W5=((P"&5!-Z1-*8Y*>5_,J.LHJY2\NA:S9%GO=2P=7*F$
M-12$P0P+.FWABLM[8P8NGG$>1U6]S$H.D[@_?MA!MQ31RP)AB16@1)1*HRER
M>N+*(LJ3O'JF6PYOT_ WY>8$O9U],XK#X(T31FE.CBLUO#E27GW,&;HTXGOC
M%JL[2K:8%OL[YE[!!A]\.<1V@]F?C;-VCNJ>9_)&.368W7/2#<[8B8"E6<!2
M62QOJ=3?H2TW(,:,N#8!?\G^IVCYG&28[FV+JX=RGA=6JV$.%E7WA0"138U,
M6DQ=2YW"8JGKY*W8L3?%6LQU4A0.ZTP-&G[)9(7>IY56'!#!;!B'5*OE1;A:
M51JG0+L%2SFI-F1;&.BF[)>,8QSJ\])%$Q!%1\"5LD6N:NMIC[N@[Q[S,Z&T
M^T(T,M[&%3IXS4AB*!"<&"94\@KY6NS80\NSA%Z0+$[XLS#5?VJUG+?/;8+9
M?'*5$(S/;D V_/1,%'5D3V)L2#;;78&I:Z^DE?>_V=H 6]YMK1 .3B]7A*K]
MUES:7X?R0%;%JW%Q^%#"WZR<$EH[X];[.?@GUV.29LHJH5,((BQ1BG=+,9]=
M3]\9*TI:>;]!Q *['T0TPL$9Y8I0FE*KI$5FFM>3KD==(EY54&MP^F"B$?06
M4XQ F]"BE K.!RLT>5=\6==N)MY/(. \)ILD6R]68L_S"M/%ZB,A<;Z@3N''
M4=MO,!KE4C\T.:D&)^8TO-(N=Z'+:]E%I<W_O.;ZB-"Y ]D1*3QPN7X7%,=G
MQ1U)LN(F8[[:CA$9:<4OI2>YV*?V*!. *#X%]Y#J'R52%ZT9%!5HRPVA)$,%
M,W4*]="+B-(]:[YG&[XQ[6RYW&UVXG"R2[RE>)F(J@G[D19)7OXYBV\VVRBA
M8HHKBS]2DN<#*^;3$(_U0-_G*![WQ0U/8#S.TP"USR.[*)_Z6 JB2$B^0U'[
M1!1W'OF.2S0/%;EYTCQ6_'7-'XR6?8,GT-W)[\O6M>DU/'=C-NB#+DLG#HC^
M-HQ25Z0FW7&+3II6::ASFQ7\%;Q=@+>5;Y-T<,XX0Y1JX9T(UU4Z]J1(-9PU
MU[.-DK[+#(8:MD$,!C.,V'25AJNV;'U<+M2%<K[/9K5B*;0#*^PZWOCA"K]A
MBDT!!F<<46IG/<1&)Z%X!"8=,07299E9W$TT+5G1."-^$Z4I#O9SIS$6@I/Y
M(-BF[K([(!!L[XT)CIQU/3[3Q'B^NU;*6US40VPBH2P2G"YF7%*=DPNBN_KD
MGB/WD[N\('$29?:I&:VHOU[1#+;M#-5R,'A@!B=U?;7T_),TNA5D49*M"#]]
MKCJJ^^>+"\-:,H.TOU5E5LCM^C*M* QV6/%):\X:A>:\=*9R;))<TK_AER3[
MCV3+IYR3;+W!\4WVPE#PE,RVS6F,MC<2C7>I(96[*@R2C<8[)-TE1<("8B9$
MFE(90:T57YOL6E]<^!:055;NP&2(.P^._:$3EADS84.&(HGX^\QJ<.U7[O\.
MY",K04G?N)8Z^EFT?/5\[G#-E%7:WS99*^1VBZQ6% 89K/B4FQUR5&G,/E[Q
ML2GV.LFBC(VVTYLL+^B.=UN64VSMFH&VPMI<T>R"U:D%Y^1XK(:]KZM:$R6M
MZG$7/#YBNKDE4;;(#"NG%4+^*BDZ@&TA92@1G!1&6%(9A<FAE FB?_KNZ)6S
M"M/C*[%_[8Z0]Z\M 92^=B,!ZVL/81F^]O?>OC:3<FC=/3'_7UP&*7_S5@;8
M5Y> &;[[#\<>@=2HKIFC]L_>E?+^U66(TD=O16!]<PF7X9/_T5=3?TC>[%^\
M(^3]@TL I>_=2,#ZW$-8AJ_])V]?&[]@PV(CI9C_+RZ#E+]Y*P/LJTO #-_]
MS[Z^^^?$)5OO2GG_ZC)$Z:.W(K"^N83+\,G_XBV'<VGHCP&;N010SMY@-O$A
M+-/X[%M?G_LJ=0OM?3GO'UT%4_KN72%8GUZ!S/3U/0[/<:JYGMD@%V"0+L-4
MC--;(5A?7X',]/6]#=?MWSW8%[=\:XA?V?'[^NO&G2JM?;D0G;F]WMH5@O7-
M%<C,O3J3]L@ M^HK#EN 5<!4,0!J&59&9F9 \4I\,L"Q(HM#%V654)4\ %N:
M56&S<('+>V2#6YUV(!B""P[5VIX4.":,J=DR(JR8N-\1GU-R((D&&O?94X2!
M'"P^J,&9!X!DQD3AB"M';I/H*4D3<?<N3?(D6U^SCU@M3,C69\LB>4FL=R&/
MM.)W1<DD%_NK2T:9",[=PW /:=VQ@:+2".*ON%Z#PK=0-W;@[]V_Q5&..SXI
M@ZA=W#.%C: '7%7*0B*E":#$/BZ,T@X'3R"H/CP36A2L.S@GE))7AQ/:#1I^
MF6:%WB>;5AP0WVP8I<,JN?Q[KH">&HU3H-U9GN,B_RM.XT?R5QROL7/XM[#S
M<,.>]^[.]"(&^WD/M JH2<SDBK3O5YA%S\PN*@C[+[/<B]T.^<-QQU W&7M,
ME-[MGM)DN5BM,&7/UX^CC.+>QE(.H)OQE$$V./\< 0Y956F@4@75.D>_Z^P%
MT[,T)6+OUV++MZN;-F\8I/UMWK!";C=O:$5AT,2*3]J\T55 E<;1]YI'!5X3
MNE<,CA6_^]M5KH#5;B7O_ CC6RL0R6?.E2+HU[,C;G&HGV*LK2F$O']8?3U-
MDH#UB6TUM.8[W_AJNL8I-H60]V^MGUR3)&!]:]NT6ONM_7UL\VR:4LS_!S?,
MHRED@'UTZPQ:\]D?R\DS/U_>/'.FDO+^W0US9K((K*]NG2UKV_K/I["?]GS'
MAJDXSR_(YHF-4D4N:9P T2OXK7S8@/<K&CKIX.1RABA=C%V)HV5''OZDQ"-[
M:KY8W2?Y%\MM#Y*@YXL=-$ '=S@,I #Q20--FLOE8GRC->6"Q]U8?9NL,#\_
M_^IMBY<%CB\HCI/BEN2&<H-=QUOWY0J_Z<QL"L'9,@:E/%NZPN45!KA21$NA
MB5)^ZO0IS"*D*7F-V#>_)K1UVCY'8%'S/ /@Y,2@OF_4"<[*D4"EVGRMA%:$
M=CEY&E.JHT[;AW#0OOL9^\"/UQ]QLOZ%WS/URVT98[I-FX:_Y7%.T-M5<D;Q
MX&1QQRCE64+I9/O*NR@O+G?XH8B*G>662%G2\_V0.JB#FR&'8L')9<<FW0;)
MY%"\PR@7DL?-WC^3HL*E#SNRC+= HX/7A):A0/#O;4(U_-),#&WKKWT"\:*,
MBGSP:<M@)$'/V8L&Z"!S&4@%YXX5FI2QE/T-'^6? G]NHP+3Q^?RJ#"2%<]G
M6<S:0///?,J%_[-U5>M8.YZ7NTYS<[ .=IP10-R=AERJ1'!Q5#!YL1=APS7$
MR<89"YII^R/?SR9^//KB*]F!@6-B&D'/WZE&_)7"ICK8UL;&6@A.VX-@&SC;
MH:6"M&*_U<RL]1&W+0QWT@@4BTW<=1 /3E1WC 96GBKO6$_R'SA2SX#;Q</U
M_C)H?2??RD+DF@J@I<O>,_E38-D]\P$;JQ\=";]<DJ#UZ=/\#(@Q0TSR]2CL
M]Q.8TB;;Q4I@M00=6=#SE+8&Z&!*>R %B# ::%*IE6S%A'9)'_A1Y9P4!=FX
M<4@IZWGEC1[N8-&-+ B(3'ITTE(;(7E2E/H4%3N:%*KE^CHAOR12 >RSIRL!
MB#8*6-*%N97(<<OQ%RPWI]&RV$7I190_7Z?DU70!H$':X\VX-LB=.W%UHL&Y
MX(9/O@>W44!+IH%67.448DFWNN$VNC)H^(TR5NC]D*,5#\XY=XRJB:/T-$=;
MU5+JI'>!3+GSUGS3CTW/]_H8)S>&2V6,2H (Z894LTP^&5[R$Y4;J\$/^H:>
M%M=10G^.TAU^?*9DMWZ^HV25% O*%X;4>P(L8?,@FWXY/8/[?;X?8!!06SC<
MBV$[N1ZVC*A *V84O7"K_%@^;A9MA5U$J%A0](YE&/4NTN-.=#T\+"X^DQ><
M1;9[8W62WI)/,]0F\52+!>>8'9MTN L31J5T>Y\K_$[_,\FB^.^[O$BR]=6+
MN"=NQ;*7>[PEE/_;':8)B8W]_Q@3OO/1L<X-$U17_>"$/0"TG,)F[QL+" L3
M*.(V$*V-H*VP<NP5<"Z>F%;'C='WN')NO%N=577NRL%).16Q@I$M(4L;2!A!
MC15T5Q'RN+M^>91?T.5S1&.7'E@IZK4+-H#M]<$*.1CT,8-3]L*5^.S=L($3
MUQ&EF-Y%](L++7327IEAAMPCAUH4#C^,^)04*37X3<Q??-'D:H\+RF+8)QPG
MRRBU\<0H[HTH#J ;IAAD85#%#G#(E5H#52J^N'+!XA?KWG!\LXG6O(^TD,4L
M[V_"P0%V.^5@$(;!%P>$4IVM5D&5SG''@CE>_F%-7C[$.!&C0/X'3J<_"BJQ
MO_QVE15\]BR.V9O)<?X8/:5XX*M>S =Q;" Y7W0RP6EB 2:%$R&*&EGTJY .
MS(G;),,W!=X,1_AFT4#<D,!J^-'(0>3($)R=)UP#"17?9+DDRQT_^9 ?7*'P
MK/^S+U*H0-5$Z/X&XN,K  T_>"V"N(SG#WS&'ASSAU^GT5H!?_"[KT^LA%5_
MX]Z/(#ZR"I%T4D(M@[A0J,]\B?,E3<0QIB8_>F+>/[H"I/3M.S*P*" #TS.A
M(QLHL-_C=9(75)QHQ7= 8_Z/AC"FD?<=^HVPAWV!4A@$:5P0:GN+KA)JM +Q
MZ"S+=E%:%F0-CO;%?+-&!7)(EJX,*(XH@&FI4<I6]?% C/@_.S$83O=64DB2
MOGFA@3JDQD ,%#O4V+0$:<3#<N211EF>\ !F)8DLZGVXH0$K#3T&<J!XH@&G
M'Y(T\F&9\O",T_2";+919@\H*F'?;-$#'O)%E@3%&"T\+6>$!JI4X-!&3!U?
MLC3)T=F.?$CR2+!-_&F$P5)HB-"114(-<;U 3"I7&+ TF]HX)$GZ9H\&ZI W
M S%0C%%CTW*E6OXAY,.3Y"J+G2C2R(4AR "FFAZ5$$!R])'9J,&D0Q+C.LGY
MG+/ <LW^337;8I#U31 MW"%))$%01-&ATY*E5*@Y(U2"$H9O.'*C2T<R#%DD
MJ&JJ-&( B3+$9J,)EP]"DHL=I3W4^AY'+^J+)C:P-4]T<B"(8@$G+00IQ7M$
M"=0#E;/)UTF*/^\4"XC4(GZG]V5P_6G]]G<07-" TDSC<SE4"@;Y\O4L059\
MCC;ZQ3]#,;\,4(/LLZ O X@)2F :-K2RB L'8<0%YIOCTYLLQF]_PWNM7Y*<
M7TYH8/9),1 "Q HU,@TM*F$DI!$3#T*,.YIL(KI_2):6KD(6]$L-'= ^-X92
M@,BA@:9A1R6-'FXN0O8DC]';3<R(FJR2I9ATMK!$*^^7+!;8?<YHA %1QXQ0
MPR"FA/I:(8ETDRT)W9+.<H<+?J\'W5^06)^A6+3\DLK)A3ZUC"J ".:"4T.S
MGNJ[<DT*WR9?&4#<0LC5SM5_;I,,?Z?U7RD;9+VS"JYRP7-7$!"3].C,2Y[?
MU7] 7 <M,BBD^7Z$J]^')\WWKJ3Y'C1IOI]"FL=7 H0T/XQP]8?PI/G!E30_
M@";-#Y-(PZ^.#DF;"_;'!7TDKZK%V5K)()21H2H)TXK!HXN$S486KL#S&:X2
MDB8BL5K0.TI>DFRI3YEUXD$(HP&M9,U %AYUU !M_&D2XEHO:*PIDW)K(ZG%
MPD29/DAUB"EEX)&D#\P:7$KID)2X(WD1I?]?LC4.Q-7"0>BA!*PD24\2'E54
M\&R$*7404PHQL*[HRB<TE%O)!K][FVU6P6JFF+L_@B"!"I%\F'%9/2F%?']F
MSE&*(TU$Z/_L[2,K0#7?N/,;C$\L Y*^L&C73"9$0[XE?(W4,\GT"P1D$5]?
M6@>N_MK#WT%\<0THZ5H>(M::<;E U?BW F>Y.GQW?O/6LP_A-!UY_0.(KSM$
M(W73]>^>O^8O-"G8DR_(9K/+JED>U;I!C9ROKVR$67]QI1"(KV]"-F1")8OZ
MPIYI\4#29)GP0Q(_\8/IDTCEE4K(%R'T &LVR!(@J*"%)9TYUPBB6M(S">XH
MYB3$[$.(38 XBS%=K%;*WMXD[(L4=L U.?22($ABA2?=,D_Q^V5' Y4J2.B$
MI<U-GN\P'44>A4H@"FG!:X@DR4.DDPZDE52E8DAN/>"EN+?IN^^?'I-">2R=
M+.*M3]* :WJDP>\@N*$!)5W8QW_C]X!\]_W73]^@6LOSY_],'FD4LR[Q8;]Y
M(JGF]"FEE"\2&"#6/%"(@*""'I=\N#:J1%$I&^)TJAY8A3N#WWT10 FK_O2]
M'T%\=!4BJ?'WOG6@D'_UMGSF=SMJ-B2HQ7R'?A7(8?CORH"@@ &8-"BI1%$M
M&V)#0MMEK>U)P#I8$K"V) %KB$G VC4)6 =+ NK'-O<X+)[29!UI#B<T2OLF
MA0'RD!\*45!4T>/3QHSVXHU6Q_>)EN*(LYML1>A&//^:_4'AI4;.VYF6)IC-
MH98J(1 <,2&3CK4L#YWK"",N[9L7NS@I<%R":2YT:XY'5%7$[2K>V.((OB&.
M11X&A]Q 2G0JU>JS#-N[^5K-(&ME?L%I^K>,O&8/.,I)AN.REJ*:*3++^UTQ
M8X'=7S2C$09!)Q>$FJ4S7.G]%ZZ%:K6J$A:$23^3=)<5$15[R:G^ 'Y)SB]S
M-##[C!D( 6**&IF&(8TP*J7#;- N3X]HDBP>\)1'P)C%/6_7-H(>[-I6R@+B
MC!&@;@]W=>9'FQN76H&V6!:81LLB><&741%5V+3^ZL1];ZHT@1[NIE3) J*0
M$:!V_V2CPX^*B6I.!3LRAM;7)FO='$CY/SA&@BB?'=.( **'"I?A!!F*:MD@
M7'C81&EZOLN3#.?ZCF@@Y9<+2HA]+O1$ '%!A4O#!2&*:MD@7+C:8,KO-OM(
MR6OQ7)W/JO5-(^V7&T;(?8XH10%QQ81/PYE:!94Z]9&Z8<CSUAXH7IZRJ/=4
M(>J9-EJP \Y(<I (HP,GL27%2UYO^4P*]$C03SE&Q3-&8CEKS/Z]<Q)\:2?4
M32/+)=\046;E61Q1%85,PMYO'=$"ENX>D21!$,D*3W\/2:.!:A7/K%DP#M/N
M.$Z X'?I:7<[V%5\,<@5?,TCFSP(-CF"'')*J/4'UT)1W(L8\C2C[N'V^A2O
M)^0Y,U8 '"3&'0D0'-'"TJ7%W;L"PIR=MWM*D^5U2B)]E:4GX_G$/!G>X+"\
M5@ 0 V14NB/RA" 2DD&^_WF4?:&[;;'<WU&RQ)BOLLJ;:&6KOSEJ^^7,*)?Z
M;')2!<2S,7@U#&Q-H(Z-=YT>*V0QCR\:YZ>YD>67A^>(O<#%KLAY#\J Z:O@
M1B7/TPL.#@PF&0P:@*CG %,WX2 TD5!]ATIEU-$.-#[+VU, <7R^O\<K3/F^
M@T?\5IRS!WTQC# <='V/WIS=&0[FK(H@2#@6K6ZHEZ.N ?3$UXA5)M"OW @2
M5GS?7WY!LB):\AMC<I)E.-4L.5:+^3NS0@^R/;I"E@%!( ,P^2 +(8H:V1!+
MCH=XKS91DE9GJCBXUQ</Q1 5:!U3NK(@&:, :&>.4*K/PO%,H9OEBHK5:82>
M%05F_:U8&:G>PF02]D4?.^":/'I)$-2QPAL2Y^;B^AY5&JBC$F*74WO9$$OW
M-L45I81>$#8F6!KHXZ+D_\(GFP/RW4\Z#1"T<H9IN!%*6IV*A!G4VD&_<DN^
M,Z"*_)K$I_>KUU7.?4B]!<WE3R"8(>-1+E-FWSE *E,]FI\CI-DR(TEX_L1#
M:(//7/\,Z5,/,.D^=RT6YI-?)W1SHYKW'/SN^7/W80T^=ODCI$_=0Z3[T%P(
MW5S.^IV3%<T%U")Z(QG9[,77?O_M#^^___.'U2Y-?^,2[9_>LY'U;ZV(8(/X
M=R'!!]X;W/0[9T_\@JGEL-CL(.^#+<ZP.7NLPL'9Y(I0/I"#K)*"'P6<DCQ'
MOT:5^+S9P;P\N\<O.-L-LPC%[WYY-(#5YTWU(R">]!$->5']"I@%8A[^8Y1D
M^2UC+A[63$R"?GFA ]HGR% *$%,TT-0+(Q(1?@[ES=-FG?*$XY^__=,/WXH/
M?_[IXRVOV.2[3?24XOP3CI-EE#[LMMLTP?E9%E?K.5)>][UZV^),)L54(SX(
M<YB#G$S3+/@AVE]*HF5XS9]]J^#;0>@5=;K:SCNT*2VAO#*%HBQ&1+"5EM80
MKLP!CG=7FVU*]AB?XPRS+CNOWH"VU6KE_48_"^Q^$-0(0Z&H*U!IGK221D^E
M^"G0[1)O*5XF8FQIHYI2UB_-#'#[%%,(PJ.7'J14^.M(UK0"S*I[-B*)4AN?
M!E*^TW@%Q&$RWQ&!QQX5/#F_SXH3X(OH\A=;S&]RS-;ET-;&'J-.@-3?#%\Q
M"E K0!L0&%&JQP:D5CD!YMULME%">06%#WKTU9:!F.?2E1+DH&+5DX$7K93X
MI.G31JBL4['.;DU(_)JD\YX=."^'RLDX?$%RZ;@?G9!?_J@ ]MG3E8#''06Z
M(7,J$;1D,H"I4M9A>0LXQRM"\6/TIO5:*>N7. :X??XH!+UV9 5AJ9"91'J(
M0RY]S86^^5#5S)^$-&*?'S"ORLZ9N53USWP!4Y+M^"%[96<LW\TQ5CG$;(V;
M0ZJI&[,FO! W K74:0I53M 3R+?:5NC04,.%.UN4@QO<G&):M"I8GCY#2-,4
M\%LX9UG\&1=\IQS%S_R>HA=<\E55%G92\U:D'^%$4Y9WT(%!G9%HS71B':38
MN[_'$7V'**]5Y;C<ABT L*RL8[B:.^IIG43$.BL*FCSM"C[?\$BLZQ[LBJ&B
MF]D17<Q3:P&J5SA"M83&CBIC[X\GR,S%:X9IOEC=18I-H./58;!4[90;5_NZ
M)\!8)6"IV":$^*'J/(H>8S.Z'[I^9K1@V2Y[7:DH,[+4!)LJ*:/MP""PQ4TW
M)FN,G "ES<CE:V*R]QUQEC)4\D=/6%G:D^[X=M9/249H?; B>[0Y@3*H!4A8
MK4XH$E:M#LB$U8;6/6$%'#'/HSQ97D4TXUO[N0-WF(I]U]K69]#P&P6MT/OQ
M3BL.*++9, XI)^0!L^LR27=\B=48?AEU/"\%L<,?+ G1*P!BF1VEM#:DU #,
MM%]PLG[F5S*\8!JM<7ETA/8-:*3]LLL(N<\KI:A71K$'/Y$<FTN$)IBG%KK.
MXK_O<N;+.&)9M/P2S,F%/M&,*O (YP+W]&+999(O4Y+O*%ZLQ!&ED=ALFY_C
MXA7CK%JWS ;N18+S1S[V,83Z\:9\][%3G1UVO6/M@.J1)X*7R5T;$D6;CBGT
M5-IJ%JIO2VOH5S%Z/GB7EF;4>\-\;':0W289YF=;*C=3Z"2]C6W-4)OAK%HL
M.)GLV*1)7:4P^I7_41Q!FD/>NG>6Y[C(K3,D0S'//; 2Y*#+[<D$YY$%F+2G
M^.'AZO$!,$]X4; \I="1,7H%O]RQ >^S2"<-B$\6B,KZ;'4!4204 +/LGN>?
M9+7+<>F;]B7(@I[W)&B #K8E#*0 L4@#3=J5P,7>D]5[)O@>/'WN*%_07NSO
MF _%619?_6.7;#>6F56=AO>Y*#-T:=9)+0Z(8C:,BI,/A+S8#8IK8<!TN^3G
M6%(</T9OEG"ED/2]&T\#=;@7;R &B$XZ;/(&O%).++,$'[)NLA><%]4YJP^[
MISR)DXBR >6_DR0K?F;_S@:A?-$7\YGP;86&JMDD6[X7"T]V=[AV>+0A0%R>
MCEY>4EQ;0DG&Z5Z* V;\,']U3G1#CQS<1@PPYN"M^(8\>A2K/T]JL' Q:CRJ
MD?9+*2/D/J^4HH!"F F?=/C'J5"*1].,/3"Q]+*-C/_><P!/[A4K 4!4D5&I
M>K%* C ['FD4X_K8F^8BZ"5.7L2Y-EK_K7I^6>3H1I]9%B5 ;'-#*O5_7*MW
M#E&C 9B1%U'^S%SE_^&CZY<HY2FE/F9KQ#UW@D;0@UY0*0N(;4: 4C_(I 3'
MEOP/N)4'3+&QP0Y(D!L5W. 'M7'![&S#[]9$\0XC_EZ&<]5'FJ.N"R^+%?LO
MOQR+J)=BJ^6\S4^;8#:STRJAX'2P(=-6PD@E*\Y<@!QL+IP* Q<AJP)*B(:A
M&[1Z@ J<NAAP,J,V"UW"\,1$$)C,<* $>"K<)M%3DB:\E[-6A)2R?DEB@-MG
MC$(P>'?D@FY(H]N;L_.;VYO'FZO36.PRAD\6K5#%:V>.&54 L<T%IVD53%II
M0=Z!>TNR=8'IYIQ02E[Y]A)]XU.(>HYB6K"#(";) 6*5%IRTXZ(1 ,R?B_'A
MRZ02),5V#EQZ>4#\LH+439JDK09@PJFJKG?1?GQAO%4*7Q4?.F OB=<:@(CG
M --6#-]6XH#Y]_!,:.'88RIE_;+- +=/,H4@O/UC>I GV7EV6TIS?6,G<#M5
M:=6*X8K@)D?TU7"5%J#8Y@C54!\OB*?J>/G,RQU^)->$;C"]3/CMGZUVM\AK
M$/96)[<";HKE6LG@3'&"9V9'Q(\@84HHKK0 !ZZZ=Z?D)<GY;D7F[_!B%%N"
M:E$.,A)P<D@Y)C!J!J?G)+@277E-E@6Q@O%3K ,E3VFRGO\*TJ-0]3%ZZX3K
MZA]M;TFC%(2:1@>4E%1JP*.B":9BYT9)6W%<4]*<<@R8?R[I7,#,S9JDA<K'
M'.:1[/E7.9ET&H6-S[B:*W5AC%K8<^7? 'A0\%=(0B.3 :-4X[]Z1.#W4?-%
M8L7>6HP=BGF^(E )<G S8$\&4/^E!":OQ-LF8D*[?X:P6)-7[-$S2>/.B:T?
M*=EM 9/J)L]W.*Y\TKZ8@93GI>LJB(/%ZUT10(12X1KR21R5A):ES)$J")\P
M7?/K5G-,7_ 990E7MKYFKUFPD_US07?+8L?7>:E&P6.TO=48QKO4%!W<5:%<
M(3(-]I!II0%$2PLH*DV4ZSS7W C_J;4".&K=XR)*LO8 16T#E 5]7T"I!CJ\
M@[(O!2B"::#)5U"68@A7<H#),_8H<B!'CH\Z6AS^$>+S'!4.F&;5#><BUEKF
M?5JI ),\0XB*&9U:!!!]5+@4<]%9GI;7*5>='F"^E(,/R]@DS'#.-(R#-NKO
MH5)7C\J1&F J-&<"+E87SPP_SF^RTB_S6:-6/<\K%=S<&*Q:,"L!"D%N2*7A
M7JW%*P3+4H^?OU&5#QS. @W=X+_W^@VVF"8D9F^-%DX-_WO=\I$HY7?' F[U
MHEBP6%GZ@8%4@%+,$**B%%.+ &JM*ES260),1EPPS)IF/F=9YN@KCN0[_3YC
M%I?$5:-ED+E,^$X^S+S+%UDG,[(LD#G$<(@52X>_"-6*INE6 ;6 F5R1+N4F
M%"?K#)5[));[\LSK%/HJ N8[Q5&.+W'YW\=G2G;K9U&-?6)_C^^B/>^FNX>!
MZX/+)&/>+UN>[+!T^?)H2X#:P0'PU;5[H<17.HNT;J:1IJZ2/[@)JW,&W#!G
M<)#W5ZUW@-W6YPW"4%8PNP+]O12R%/W&.5ZQT,\ZCM$]3D<31HX@N>*6!#1J
M@**;*U9I>RW)\]_W'<^:N"_"/$MX'@D?FN\8HGU55QS;@Y@L@>CK[:XZ=?1Z
M,X#:P53L1YPT/>HG;V_-5'_+]G?/!1SS9U+ 4BP192(?RLL](1?&?@A0&+O*
ME L&M-A.KRS6+;-&^?-U2E[M.Y+-2N'*X#H']#7PH0:@MNL TUS]YD?9K;@6
M^C6J]"!?>-0XR5?=_,3&?#?9@K7"B.='9VR<^.*X6WZD&?]'+(YW4CYZT=T&
M($9/ JX\JK&DM<@22&T!18T) &F"9<RC$ 2:.,CXS/>"/PEYX)M,RGLUQ3'_
MUX3>8_YQDQ2W7MOO77.W$.)2U!&NJ2Y(=5 '1-:QF*6->JT^'VW_")BXW+D7
MS(_C7F2WA VV[BA^2<@N3_>_T*0H<+98K;0ORE';]R+.$2X-5W8ZJ (BZAB\
M\E B1C%^8A1]+47YX:%'*H-?4!R7+>?J;8NS'-]C!CN7MC#8A+T5P*V F^JW
M5A+48G0;2GF!</DSS_MQ7B0;<6["4EA!*3,#>B=?/WZW6ZT= WY7(61?*P,W
M=:VM-*  98%HWEY\ZL2[Y 5Y?DD3<ZAJ=HXO2JD9DHH&5TR<5*B!):<>JWS:
M=BO) ^3V*-<9ZDZ7Z8$^VQ!:)/\EH"Q6X@[/Q>JGZJI/54<P2MW?"33CG6K/
MI''7#<Z]B8 5Y]8PG;PA(.W<W3K3R<T:]CDEG-?)&XZ51W5/M.&-AU/=:\@X
MU@ ,1DY$K9R39HSLC"?0BFN5G#R9?OMFLXT2RO_&/>(O9YTEHKI85@ 6E/_[
M1T+BUR1U[5[&&@W9VT][ :9$8)S%X*UB5C>D9<N-$9'0\A:SKC1.IXE4ZZ#&
MI;625E"2JUTPLKBO I>F2ISR57RE%,*E&&#RZ2=ZV%BRG%!H]O3\0N@7?EN.
MY8R,0TQ"F>)S==YUNL]F#]KFP8,]&3:)9O:P.]E=34!U-G^]EK:.? K(<$G4
M3?:99-SEOBN:F:5I)KQEVA.=:Q+MD?K!0_4!H*4):RT1(4\T#8LM]1NH_^MR
M(>\H&V'+90[NF0MG!@-0%M4? OXT[P6V^5F>P+]<\F.%V\L;)[\VG3E8U#8[
M/8[E:ENG1WBC'[^/&XF'0XYAU]9]!=4M%,[#%R=;80>/(]PU#RD=#$&92I[#
MB=_!#23&8<>TP0JH,>6$8>-)C0Q-"T&_WO'-H4GVS0>TQAG78'_MK@ME^H"I
M66X>>XS><'X7)?$]7NVR^"*-\CQ9);Q\KU@?JWV)TXQYWSHUV6%I]]1H2_ "
M\P%>:.N#6V8(-.=+G-S?Z50?8<,WPT>[-R2VLP&(?!X+7J9Q?4D!="*[;6>8
MT.>%I.\XIZ9L3#F=W,.!K9]Q4=:>VT1$G8<X[T^!1VI>Z\D/WX5E-!.<Y Y.
M6LENL!&\H'T@<-LNK*2V<!HLOV.O])F-?!>KNVHQX!USKSC+XJMZ/6"W]U*\
M'^WKG<.TW]8PW\L8['$[V"Z\_&8VGZ0U@DNFGR?'7:/JH]^H>M G?F(YGR,K
M3^-9K)JS>_BR-2K.43G?Y4F&^1KQJ8WMR$\-U"L=\Q5J.K%C/!)>Z_7AKJ5A
M9_@5Y<TQ5H ;=!OI2E\WY2V((BHYA$>54JAN3>^ KL.2->"1V0&MM%.[KOQ_
MPU<C)(T:_QOC-N&;)$YL7=FDWL*B#G$P<L@@Y 1&W.[Q5(P\MGSC6<R&V$_[
M#^W0^]1&(8KW4-V5?>A8VV@F.+T=G+32W& #]EC;#MPVUE[5%F9DN69-(^M/
MEAC' OXE7F%*<;S@YQ>+I$F^UL=5R=NZ16<'FI6*5@THF< HM/*>R%*6;_H1
MPFC)I8]$HW:A07/ENP \N+>^ZYA5Q1N%',$W!++(@Z*/&U:9/*662!N%'HIW
MN Q.$8HKY2,OL^Y ?B3W..5^WD54D0"ZJWE?3NW@A+2$VJ #BEON>!53@"I^
M%0314AUM2WW@N=U9_,)/?\S/LEALT^1-R\C4\>K^<SEWI^0<SJX++'=S!JP+
MD1_Z0^YAM)R9S]:0>1YE7Q8OF,8T6AEWH$BB 4*C$JPB'/;D@(9 %493V'MB
M\HC4"H#C7#<!O1!WE!3GA%+R:KPXUJ+EN5#HXH)T?*->!5 ,<\&I.-1'Z)01
MZJD1ATS"\G*0?+&ZY0WH-HF>DE2,B[LU>\7(6__BIEOT3-Y#71\0>ZHY*'%W
M/E>D=E'=0"-F9Q.FLXU2M.4GNY0S.ZF(W6G[&, -YAYOF[?3!H2IC66B-=_'
M3![@\O#8R0FFX#600]R0#R#<MLUCOC[#4D]*5$/,:T(WF+K4EIS4O=>91C@E
MU9P<=*'P<")N:4JS-O'-!WW98"4LS5:9\I5.\U4)R=-.;&)9K"PWU)MS/T=3
M 1/O4<X:LG$G.U!3]#'@7>\^0\NNU1/A?G6?[(+&K NB>W$3H!O5-9KAF&UT
M14]DI1I0WIJPJB]U3*J[@ '3T6WN]L"I7YBS\8?,PI_ 8A/WM+;9WM'?U/&A
M77)RC,EXC[?TW8CS;,ZRF/^'+V%^B5(^(BA/8[I:K5C"M%C5=Q??LS=0'6>C
M?=\S/B'LK7X'OQKS;7^3S4-K8',[IFJ#]?C@P]<Q[DRGB*;)5\B+/^#V6<$N
M %*[;I@1DV0]7P-4WG/W4$2TL,=1 UKEHB75IT$1OR-HG61\X36O%E01E!?3
M!!; T=- WH6&]=KW.<F6WXAX@+N#&QS'&P*4Z4Y'/VP4I:5<W,XG9F.6>U3P
M*U/3ZFSPWVE( WEUIP7KJ("&^7DXW5 V^V7-.5[^84U>/N!E+$(8_P.OC/Y1
MA"CVE]_N7K:/BE.;^C_Y"" J,)PFW7\/WKP58!03/N@E1W>8\OHA'ZVBRR1?
MIB3?L1'LKT)UW@LU[1_YZ@TO=VR<@2]8$%H3NC][2X9]C$'.U^<WPJRYH!0"
M00P3,BFFU[*H%D:_<G'?S+C)8C;\C'=1JJ'$4, 7%]3 :A+T?P7Q]960Y,4Z
MM5"8SWT6__V17)#-5O.U![_[^MA*6/6W[OT(XE.K$.EOA^1325P89]5=+D&^
M_"<V_&4=D.:[]W[U]=45D.IOWOD)Q!>7\0R_=R41YN/6*<DC?BO.F<$OAK2E
M(^,[K9/@#?.[1@#$1]>A&I7QO4/"AF="7) 'G+)!(XXK7GZ.-JH47R/GBQA&
MF#4YE$(@"&)")@T$60\097M4:Z Z8' =S^S@CXR;#'2Q6B5+3//KS!0^''1\
ML<89?LT@JP((-KFBE"K=7 ^U XI:\QVZ)J3(R,Q[\QUZ(XSI1TIV6S'!:R.6
M4=I;#V6'W/15>E$0-++CD_HOIH&$"JIT@E&G+)#&C0]FZABEO?5A=LA-3Z87
M!4$=.S[U+24Q:BD4,.J01S[M*,9EF^$V):6$O^BBA-9&E-[/(*B@QB1%CJL%
M$F+] 6ZY&M/_]S];%KLH3??B&%D3#92"'ME@ -HAA4(*"C?TT%04J:41%P=
M%5&_85YP).8>1BOIM3*FA]JKD<EB(.ABQF:HFST2Q-G3Y4NPWN4SR9@+GQGS
M7]:6;D8OZFV 9 ';C(LT<B!H8P&G6L?,V?*9QYL73*,U!M,U=5T17G2BIYU#
M2HT05#) 5S%*(0Z.6'J,+OSJ,ZO7R87KUQKW''LWO;S7/LX&N]?3Z81!\,L%
MH7FVJ,NU'L<"=7Y\H4NQ_SE*=P+&69[O-EO^I\N$GP.%V=<U$VVL 6\+#B8Y
MUJQ$&*4-@IN3($MK%X01U%A!K1G4V@E70QK$])]SD0>('23/)(TQO2_,9:61
M!OS-EDQQK)U&&:,-@JV3(*LF7C2=]$O^ARI'[)A$][C8T2PX:3_CHKKF:115
M56KA"*IW0D]+60<H&;5 1U*0;U4H#04GG32C.8Y\)O5P)+0[I2>C7A<H*:V
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M'IUJ0B8-9\*>DEI"O7K;)M3.AZ&87SJH0?;9T)<!1 8E,'D.MA8*1X7+78E
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MN?6E3_=)_N43 UR>_>X8:VW*(6*LFT.JV&K6#,Z]27#5YW?RZUZX&FKU3B6
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MMD^H'8URR+"+E&5SJZ9QS7-U;:AV]4@N<8'I)LDPGX4E&0\2NKLQIKWXD8\
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M1M#?C5$FH.UU42JIX,RQ0I-NQ"#9^U;X%,INO$FL5J)?9G]4[C*P"?L/53K
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MX^$?LPP6;M5%>Z;,(XUBS'J9WAW/#I?'&?7@'&0P";7I9CEA 3$3J&SPM1'
MW:K2Z4<B_OEAM]VF":;Z_M)1VV]'.,JE?@1S4@74=8W!*QTH*<A:W<G^'A7/
M"3V%FZUY0KN+4L,-[(V YPO6!\ &]Z=7OP(BSP"2:N3 ?P;,A9^C=(?/XAC'
MC]%;37^MOQIIORPQ0NY31BD*B#\F?$,R?7QXK$--N#LF>E%2_<Y[(G R%1M
M]7BC?N$G$]N5W=FXS@]$LC$BN8!VG8,)I)1!<'-'*LD*'/7S-6?[F@2]%42-
M0)NQD5(J>"RW0C/FC.^:@WT!AY3/N\T3IHO5PW/$WMK9KG@F;&QONA5+J^#Y
MXBL+\,&".XUT<(HY0Y2Z,!HG643W*!?R[U!4:OP7CH\4<D0^8V6*6=1;V+&
M;0*/1BXX+QS V1EAO?_@N$LM(BH<N,-4>*!913&0@IA4:C%*Q2[^*\IW3_F2
M)EM1Y-S29 GY4/=^V+G)\YUS\*^%0P;^/F!3T"\E@S=L)WC2O:]"E!?,1=M&
MB1 .6_PN5SXX5+O[@G#:MQM,4SW[3 38'/%YC77&NUYTDZ$[2E9)@184W9(\
MW&C^$F\I7I93+??)^KD@JUV.S_(<%YH!F$D#SF<;B5>Z$:"C).X$X(KOR>H]
M4T61T WVR>IU#=4RAH6T\$$W[VQ1@_CQW$$/OV"MB7"IBE0'LP#N<2N/[W'*
M2)BM'TES\7T9@JX)_>4Y63Y74843]>H-;T0Z\=<H/\<X^\DT0IO-OM]^?>;7
MTF\B,QD'E#W,Z]&PC576$:W,HX*PU(,]X'TA[ED3CP#<QLJ>N?)='/A7]LH+
MROMD]F[N\99O5\O6=V+QPR.YQZL4+XMJ04NUYNPNVI=77CY'!5_S@/F*AWOV
M+Q><T7G.WF6^6/(U"7P!1'Z94&Z"_2/^QPXSB<7J@KPD\7=_N8NR&&^2Y2,1
M'^66Z6)\)B8@XSN>;R3+*.4O/4Z8=88VHM&:1MOG/_[I;+&ZN;Y_^.Y/^HFJ
MWZ6SGF<G?Y?O4#G3^COT%%!<_AV_7N7\1E5E$G=K56.@A%<]Q!B(4)1:QD '
M%"3%B^+W?G)GL]XPM#O$4XIY*T0:0#9C985,<$9;@*G/2.+) >"LX!?,!WLX
M/F,CE&B-R[:0B_6MO+%%:;.2G-\"6C621S(<F;2-^ZRX9(*LF? $*TJ%QK*Z
MO\[2:0?!XK=/#?BZ^UU> "#!VR\$[X=!HD:"HA)*NTD0^CVZ?-/O8E?P;;^L
M"R]'6-H7KA;V?].>#K!\C]Y0$A![#?"4.[-)*8M6//>899BJW117EJ%80R(;
M7K_B!YR<97%YQHGBEEMG+8^;U5Q=Z&P\LZD$Y\XXG-KJ8B(T17&1WRI?D+(8
M@LN%8@>OZ="PZE.4L<#(X_(U5A)H(."-*TI@#2UZO\)@@ K2\&.W,FB%C?W/
MT8,U&Q960[[%ZBQ^B?@HC_%5\+8<^PGRW96+%/6A?)P=B#,#!W@A'4M0&D$;
MOBR+[Z;&SU&Z&K9ERW3!\:=2.][L'RESD0_+V5C>87+5I@KG T\%;IJ O2 ;
M7J<N)_/8W_^&]ZC3IN\PS4F68>,BS.,.@1@43MR'*(VHMMT.I>!\- >,TO>I
M!,JS<$BV.UX*=H%Y32*]H[S4Q0/]+E,N1U/+^;N'R0"SO6))(02C(S4@DS+P
MNVO @S@6'=K@T,2&;@S1LM]%U>\ S]V9?JRQZT%;<N^,>/3Z^^/W[#>;;910
M#IQ7_Q?91T+BUR1-'7IVFRJ<3F(J<%//?LU,(+'HDO_MAL>=9)7P<1LJ%_B(
M;<2W)['@XVSYCUV2BRGXF.4\W+5J9:]@*)^U88&5"BJ+5&B%*34L\)ALS_>&
MSX/<'NX/G60L> \ZEP?2R(:!>^93+CT]P(V I0];S'+].^8&/YGGBKV-+0\2
MG;HR'^RU;XD7F;5O<ZHY[Z<-'N"T=-S@!%N &L!!#DC\YT;$$ /79@"3O]M_
MW60%<R1A?RH[LFG\/\"BYV.7#G5]L-9UJCE #>%0'Z1C=<8M80[<%BYQV;$]
M1F^'-("Q9ORR?IJ3P^7X8VQ &0P<B%]>KE\:08Q[,W%;.Y_W@O-B;$8R3M7C
MS-XH9SK3>TYZ4,@V ;,\WU=K\W5KC&&$;PZ!O!:!(\[8 _<3,P='==^G,XYQ
M:KC_Q447"F<GXE;QEBO#+GUT1KG"+1;)VQEX_0H:FYI?;KHYT>>D60<>%YWP
MJH^[X(,P(@[4H:T&8$[R^64V_.3_X4/0ERCE\\S3@NDD6_Y7@DUT5UY=,-(0
M/)Y/=T*YVHQS7QQ9BUMCQUSMKEZ/Z9:ECC3@=X7\6,?Z:^==M8,7 29#MMY)
M##C@MN>S3PNRSOI^ ^M(M_K!U%'9#V'_4A(VPVN^),<<0,<!E^[W.X5KD91G
MO$VC[A13  [HFT#H\7;@<7NR#[;$V.5HST/NP!5;\"YW>'1.X*KI[S[<4:ZT
MM^(ZJ<'H_D=AE4X=+G=;QCO,5['&8MLGH8"#:7L9[,3<]3!3GL^FFNRL[GY@
M6)GMF& ZV0?I\"M<H*2[ *AWX6)5K #< NKU3]-([ZCME^>C7.I3VTDU>*">
MAE=QB]N/J#8 F*'E"05BM=[J@FR>D@S'5ZR]22<*NZEX7V-C 2^MH]'( V*=
M%:1V/=C2=3W8[W_M'Y@%LO.Y(A4ANPJH:#4 1QM>.'59YBK)^:^;6ZDY$ (4
M0=3(G/DCJMJ 272/7W#6F:W2)U *2;]$TD+M4TD2@Q>]=!#E>]Z$'&#Z=/M7
M*X/4PN&R'#./5)* XI(!GFK@=\3CHVX8IH>"]<)\\<^C]L &A92_95Q:B.V*
M+4DD^,<VXY(6LDB"Z%?QG_\\TG>_Q,WI["RY9GU=4MPG^1>5$UI1;PRP@&WW
MC:GE8'#!#$ZQY#,I#RSEYS.S[XK7A![KO(WS*$_*4_G*X^N2;,T/PUL6."Z!
M\DBE\LE1T1M11CG2T,9)"P:)QD"5IAVYKC@2B+;:Z.KB%G"*TFZH7*S.=WF2
MX3PO2P$B6<]5/=9H;<^KXL>X-%@,[Z(:G*C3\$H!L-'E 3#&192DXEA-1N!-
M.5*+GLBN0$^58;1L+:-?BV-VGFWT%G.<^L6<5FE_QR]8(;>',&A%@U/+#9]Z
M(GK&=9D:6LB16$T(M9PW*IA@-B10"<'X_ 9DJ@/<N2A:"EDQC@IXM6AO946'
MMI<[['JXU2@3$&N_TQPP+ #@+WG,05: $AIQF P_Q/I35-#DS3V742N&2V-,
MCN@S&)56\! S&JHY;]G6BOP:3*8Y5V)RY)M9^O'UWC0UKQ/W?V^*'K1\#8HL
M"XAY1H!2'W=Q:STW^/B]FG4KD)2J0>V;5!BE=YX7R49T..+D)K2FA(\_(DKW
M?$A=7080^;YU\L#L#LP7L4-4- + $;7;DU2WY3V2<['RD;T%'"_H RX*-KH]
M6Q68/K[B] 5_(EGQS"L]%RG?\,WG"<2^;W[^9[ORBU^,P>\DB)+,:/B<%,^?
MR2=">>K%_\,4L^Z#Q).;2SGX:A[W;.347 J7)YW:F[)E<*?E#Z >_N1?HCGK
MC:HK00N"GD3AI7PXOPDG+Q^/(FX>%>*!:".>*$K3R](Y8:4\XHYO(/C_N[NV
MYKAQ8_U74,G#V:W:3;8V)WG+PTBV-JJU-2I+SE;*#R[.$-0PYI 3D-0EOSYH
M7$@.<2'(&0OM?5EKI>YF U_C#GP]O.S:\!+"!2\H8LB7-KRDI*SX1YA\C2!^
MX%;*T>>E2TP7F<#=I*^\D2CN.WTL4UY[4 Z:7N5E4FXAG\11BM+AP#BM\VH[
M2:'N=_..*87H372.E_9,4.U CV1:,7925>NCGH M)BV*9W(8ZNAKO49ZK2=X
ME_(9@2XG9$RS;1?Z:VG22,1G=X$%] 3KA 7D$1SFO?\I5%Q"?]O[6#ML_=\Q
M=BP6[[[))[QO*,L?DR9_I-T -I@I#@<XN"=[551/[FYDD:W7IIM;7-PQY]QL
M0]$G+N?P?M:$YHRL"[[)\0UM/#.Q@1/.B=P,"Z\[<9Y=M.-I=+!Z]-A<[K,]
M(DO:^*?9?_YN8.I[S#WT8!_@C;KB<MW?<%G!!9=^J G?D@NV%6\O;&9QW9M0
M@8:BMX)S>+_\DE1G[BOO:-Q27E5EDSS :ZZ RU%^^5?KD$/<[KI?GW#T, OU
MT'@[V:E *#7GOC+U2IWH:$0)[S'MBO&Z1U]!W'VA32MZ1,YVU=_+C0?[D [M
MV]D 1;,<GN>N?:)F0+6G"<"8DJ2!K7O6Y/^%VWE5_=I'Y4A6C6C0/D\QIJ)@
M>(RS+!3.0FU>]V.=+>@=@A%HRRV.6DC*!U+1^_I)U]S,XS4Y=,)?/P3NDH(&
MA\%8.$8HV!VVA<.Q)+J0L+KG"XN:*[QJ;/RC*M+@V!@+QX@-N\.VV#B61!<;
M5O=\L;'C"H&Q\55G$3?M?D/9.KO;);QNKNNZ=9%EV"0QS@.\?AJ/U(4PS,YK
M(4YR(8]XT7A#FS=TT[B+K__^RMQYQVZ-0D?^,7JK=7EDT#-7R6N3+\D'8E59
MMWNQ;?&>IODV*>[:PZ'(1>IF]?!$G)/"'=/2=C]VMH7/:;5]-4SXMUKH_FS9
M>D]RWT:,H^SP^;HP1&IEZ2CC@3QUILK:GZ*DFU4YDM89_S<O'R[Y2L+ U2:$
M"SJ/A\ZL4)62%:NG*)7?L;G>5U<5VU/V1G&R&@@X)7'!,.6F_QI&)E0Z8MHH
MD+RG[ ':>4W9(UVQO.8! B_L?F%5>^"_;EB[;5H(&P.C<%5<H,WV>XRB-,#[
M,V&!)-*$?&+X $;@3[V5./U<P.&1HIZ"LFOVLW4&%)S0_]_QLN5;RZ!W-LNX
MHN+<Q3(VN7:4I*'G<$Q^2(:49IH#G0?XF!A3:_6Y*-%UD91?[)>W+'_&A;/5
M-Y,#I?PR. R-TS'+&9F"^3V%I9.E#[9(X:IPGXMFSRIGCUJ8?)+B44YMWN=E
MQ?+FY;IL*'3HU^5=NZGS-$_8BPF$1Q@9'M.>&K H%=Y321U(_UAW6E&.U"C;
MP\)Q75)'TS D<,'@<L\8-[@<*;@@J4I*/NWCM8>@^RB,)E_2ZJE<9Y[Q8;$E
M7!">6HSEUW2T49"+.TSI,+Y_JB;:82>!"T27>^YVV#Q54=NA]O@N?YZH\DX"
M9Y6/W7-7>0V4&!&K_+K<,D@B]X;*?Z_+FZJ$@^W?*O8%ME^20]XDQ6K#EWW)
MUMQ0FJF/"ZYESIO',5*;]VOJ!SZ'*'F7)E)"/DE3_'^$+=[/26.1]@BEAWFI
M"QR^<35#%Q?*\QTW-QH[8'N$$W0[7A^;O,CK1!*LZLW1^^39<17++XX+PR!?
MQ[ -E.2T0VT7-\FSNH\5:8NAIH5:#XJ=N=N&OFM2QXCGE<8%4HBK%DY6[II>
M'0LMPM4(UXNZ1+[C?79RJ!B]@]?P]9HUN^J0@)N77#3?>C&;HXP+P@6>CQ'M
M3!!I@PR,$&D%!<+#-<[;+./==O[(QX9MM:>\8P'"*2"-*+>\#Y%DK6^?#[R@
M<$AO;I*<8@Q7!)RA)/[5']5&833E5D5W# 1>@KUB8!B.4[7E*%W W?K2W\Q'
M KB ='AG-%<NAJ(]<D?NIJK[#G5UV[RS5/<=CNK6W?2O)35[>[U-'3;,!9M
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ME?Z[53R3?$V\DAS%Z@W6A_QAUZRSCS453[ L.SS!NKA0F^^XN<_361#[ ,G
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M-:V.#*HEOON7!,*,G!J*MYR])?(V]LY/%YB\F#"EW<,VQR.53^J]:X%P560
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M?!T,Y,!PA*R$H]3\30O=]#H3U]7JNW8#DZ<--5DT7(*X,)CP<@R$% <0:J%
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M!M+]!T_HKD#6E87",[R8DPI"^^IH(/%_](3X*G0=4?]I@:*(1U"#&"3[LO%
M#OSD"0?4*'O  Y%#N&;'$)P-I2E 3OSL(2<JB#MB1IZG898 !;"A,AC(@$^>
M,$"!K%/2W\0AE/"[H6 7RRNZ'V'JB.JW.)D&4;ZB6_8[11!2,QQ*?=<>KA%C
MIQSX!PHHF/ZEP5#JNW9Z#=B>F/9%P=-^,=IM1ST:2GW7[JX)WQ.3/U\Y?PCF
M:Z:. U='0<GMVL55X>>$S-L01YSRMVYTI#X>"26W:\]6AZ<3DH\0KV:+[N(0
MO?X=;70TKPR%$MVU1ZO%U G5'RCF+1>>\-2\JU3'0NGNVH_5X^J$\)/@=5OD
MG3\G9::_<@J4#:Z=6!#F3KC!>S'D%_*W,>T1+Z:EFQ$)M=N_82*4,ZZ]6PLJ
M..%/@43Q!\?DO8XKTN'@3)<7O-!@[ D'/MAQX .< ZZ]7B/&GG#@HQT'/L(Y
MX-KS-6+LD@,C]N.83LB+(M&N' REOFO/UX"M2]J+4VG,&[NM<?XNIXD!E1E0
M+OCA$.OQ=JH&N6T T8'M2"CI_7".Y7BZ)/D#2=(@^O_PRF26RL=#R>^'FZS#
M^=2ASUP$>+1$55UU- 1*:M>>L12S4U.7+Y:B0"W4AR.@M'7M[LKP.C%I[PE/
MVRQ(K T:5T=!2>S:;U7A=^I-FM]P2I1[0^F?P:5^KK?@8XQ.3-'?*$[9"D9D
MN<SB(DZD2/,IAD(I[=K9U&)Z8JH_B2M^_.[M]H$<.<EEXZ#T=NU:JG$\,;$?
M*.),1\R<%U5N_(XD'<]FJEU:-QY*?->>I1EGMTRX2Y(,45M62&9!&>+:R83B
M?^J-J'B"_?V'YPF__:O8ABJCH&1W[6"J\#LQF;^2XF[WTV;Y3"+U_1SI0"BQ
M7;N3&BQ/3.^#=<@I?30$2F/7?J04,T>;QLWK=,$;+:A+-^0CH;1V[5?J\'2V
M3\]!^_3<<I]V[5^J\'-$YEUKG'UK)SW%I1/ =YX\(;X&ZU-?MA37KTJ/A/('
MO^4<4 R%TMZU5ZK%]-14ST*<HC!?TJX!UN[FH2(L8)X%Y85KCQ6*OY/,Q&\H
MBOX>DY?X"04)B5&8NQ"ZY(1R"I0AKKU8$.9.N/$KB3)&,"KJ:*FV.4IE*)3Z
MKEU6+:9N2E?S2O'=.<554W4I03\#R@/7_BL$;T>%?"GBC:3P&ET':5"L4,<*
MU0PH*UQ[MQ"\G5U5H-M7''4<.!H();QKEU>#I1-Z/RV#*-HVU-'1^V@@E-ZN
MW5X-ED[H?;-$=,YVO<^4O*2+XDZNCNZ*"5#ZN_:% 5B[X</KOD% ?D-1RP3)
M:' S"C\XH,375>^5W6NDS "(PX J&* ;#V6!:[_8C/.)F5 \WK6WP,1B^/)U
M%1_F65"&N':.H?B[.9)+W1JT)_+!."CI_7"#93BZN<J6/4=X>AN10&OO'PR#
MDMH/GU>"H1-*7P7Q-YJMTNF&]X)&B&=^DIT. GPN(  H=_SPAJVHXB9.099+
M?K&+3+^)MZ62<98F?,=DZ]-&*[3SH%SRPU&&T,"1'97L[]^A\&KSB&:(\L*,
M"7I-K]B'ONG-*L!T**M<N];6%#EY/;AH5[M[>$J=:9:/A/+!M<NMP],QR6^6
M 8X*)&"D/YP!98%KKQN"]XE9<3>=49&3(G28IBC)B:8N'M*-![<B=,P&,\[.
M.B&QPVR9WE!*Z(@P&V.J9P9D'I0IOCCC9AJXR%@3JCX6#@9 R>W:U99@Y8:N
M]V2JJ7VI#(+2U[4_K<#.#8UO,5W>*0)Y1T.@]'7M1$LQDU#W/]]6T&!@OVW_
M5?J/!]!J/'BTJ^88S\IOX^Y6>? $TH?!F\%N@G@#*4Y(A$-N)9?^@<P&.2S&
M@8& UEA\\(PF@DEI\$IBLMP((7KS[N.;#S^]G651]#L?L?_I#3/??]\/$4(F
M?B]&<.M^B78+UCRNM)NCG-)<-=K%[1&M49S)MO_=F-T0H *UKCYFJA[J4'7E
M'>Q0[;)!A(<_!SA.N (@F:NP&UP="VZ2Z@UG5/@V95'U5<BK+Y_ON5>69$OQ
MEOJ7?$M[RE:KB#]*63RU7KP^??/*7V^6TI\#J@$'W,['-6]JXE?A&T-PAIAQ
M&][GM%.@\2D_4&(TY_#$6/_4\F:YBL@&H2L4(W9 )07:.NU43@%?J74M"&94
MSIKGUXAA,\6"+P!^2X>#2]>]X;4&ZS/E\R-G2 3@\-% <!6&-[R58GJF7!6'
MU'B%>'/ >)Y3"L!C[31P\,\;C@.HX+$Q?+=<!<SY98B6?4NIFW4T$LBI]O-&
MM3DEQ_5,E3._%(+XZ^]:MAZ. S*U_214;:;*\#Q3EN:1&RZ[5VA&*)H$KSK.
M2H<#&=Q^BJLV@S58V_/Y8\[GE+!#VE,NY_1A6!:'",_VX3CC=QWS0T;>]>:(
MOJ;YX#"&/X)@0YBSWP%@B@_GLT?QJBJ2[O1<$>/:+W$8AU]1RFL=*5KP]EAK
ME..KB&J!9D*9YD<@RX(89[EAE_!/4XJ?LY0']28$DKLPSX7*@D>Q+"A!/':+
M5"B,7V)$D_'L(5#4LQJ)< P!RM\.XU=@?D$9+:=2#]G]E3#1CU-&S$CX]BEB
MW-'[4]:@H +089"K=0$PT*VCS--^-6S'BC)>OOL%QX1N[\*R)1A/9<U,**/<
MQZ; *)WQJ7P5)'AZ$]"8E]QS,CP@*JJ[=<JKF03EOD?Q+B,)/-Z1KW&4\=RG
M)0.UTZ L]"BZ!2"#QTS\#>'Y@K>I63/_?([RRQ4Z]BDF0!GG4=1*BWKM#9<!
M>R8)\G3+'8;_S!*&LS7;#1/!91W^L!]$BI;%P$6-XE40\>C[TP*A5%&9^%%7
MF5C,'Q0 /!/H4@7FKL?6 \FOV4.\>]A\W]3X&B?3B"091>.9:"L0B-KYY JE
M+PC%1542\^U2C)()-_CU)[(]-)/"5]2G(ZVWX;_DZ+9'O!QU;],SNF.+VB%S
M?UP/?>0,J0;[PI7Z\EGVCU18E@\3WS2SZ"G$T!K/#M$<OF+M"6N:>3Z\!:-<
M*M3M#Y^OR3+ LDLN +2W<WWA-4R:+?BZ17!?&^\;8P_7^P4INK&4JLEDX]U7
MMT(%5%(>IR: QX[L,$F8>0HQ^8Y'NKK'H3OB5#Z+%$F/N<*CS'D+#3A_U'/<
M7^Q0,."83R:T/>;8(_>&R2Q+4+YT[=Y7&>O^>H>1])7]3H&PQSQZH&2%:+IY
M8)YY.HS#FW]E>+4T9SM5D]R?5M9<,Y+ 8_9=%X&D2?!JUC')8/?7*:S9I439
M8S;=Q6N4I$5#FZ?L.<$A#KA!]=\$Q^FO[/?,!^(%-0PCPN^*Z".HM<"YOUUA
MS>H&9/-8&([)8&/ ^'!EPIJ-*H3/,A,]LK51%1/<7[@ <E>+L,=JR#>7.!5N
MK6FOW0US?V%"3VW9!GJ$H\<<X4^(H>UUZ-W3 E.$U^+>M(Y+QJGN;T+8<0Y(
M"X^Y.0J2!4. _\$MZG40(?E3/:4XDWR&![<7[)BG1]UCGM70O*8:U^5=!#NN
M=:QJBF3=UIT1CZWR-K%$6;<H'^K!]0$0G=48>*\6(ZBY/JIEJW=9S6^Y<?UA
MS'0S+VV9V&&,!,B]/P#;[G'PC",LTH8 WTHZW%T)?HTTC09ACS?,O<=OR3##
M1 ^*\G4,40<^^LG&>Q+/4T275X12\L)+DK7*)AGM01T]C D5O5.B[C&_1K5T
M3C?+@R)Z&ZZ9"> Q]V0N_T.PJ17[V,_SH)H>P!5(^..8%AZS\FE!: K?.:7#
M/:B#K\$X#>9G>@^B+**[NN$2R:#!$_E<J!1T'T6QD0(H33J*J0R7_&FVZPQ-
M"'^U'-%KS%O"$UGU'9^@&0^E?_?1%0#]#;AXOVUN-WI*UCCAA< ,@^-6F0!+
MQC ?RM+NHS(U3!L0;?QG\21X+2&O?C#L&'W%/"A+.XS1U&>IEA8>LQ)XQM4Z
MSCJL0K'R K5'UOF$U;ZB(N8+Y*E\/)2YOD1G-$B?)9=Y+C+=0$("QR.AG.TP
MC&/#63FB'F^E=TF2H7 4K#"3'FTURN% *%\Z#,\H:%VI1)%AV)'Y_P71.>^G
MGR"Z1D/*S*5X?LM6_IF2;,5^G=)LFF94_N8EAV # ,J"#N,K>A;8(E1W ^Q%
M2\5'E 8XWK?8T.E:=2RXN-VYNJGP]'@/K-%]JVF7K8\=1DV C.JX=U;7<:]B
M2S$'N?8#H;SI,*("Y(T40X\YDJ-EMNO@/.@P! +DP2%.K9KECE]Y&RV">([X
MQ0;>)F9!(D;R)$<W[Z2X0"F?O,/]H,_*]^ 7X(KO#.[B0?E+_W>P(LE_#/(/
M#OYT\,D_EXCDD QRS']H%7./F]#L* /WVR"S?=NUU&LV=ILQ3O6E^0&<J]6$
MF@G'2Q>91@PXKY8Q9+DB,2\V'\\*^3*UBE',Z"GCC'CYW >FLF1 _Q?E'%\8
MJ!=) -^.^KS\Y"'G#H);YCXOTN'N&U)8<DJ#M,<^TD$DS,PJZ7#WG2DL6:5!
MVF-6%>ME&+Y.Q=9_C?FU$11/43*.1;^P2- <TEG)$I3[-A:6+*Y)+*_9?QC"
MA'!9/L-]DPMK9NI0]YAG!6Z:YR',7(3#<-_1PI*OMN3QF-.*N+69O8:)[MM;
M6/(41 B/&=EZT+A]"[7&M:F6PL8K1#$)V7=IZFE"4UCA6T$U.AW[@<YLV!K,
ME.+HL4KEU<_5=]&^HG0\$R\:ZDTT8S*M$6QGIFT-SK=%28^%A2%$49"@:Y3_
M.5E0DLT7(F'!DR?A0[#AQ"KW1];J>2UXSDSD.MM! XIU57%T]-92J5N9;%,6
M)3G:*<Y,6S@_S$@T/'S[<.VGNC6!'FL&3'9F"+>X3>N></:-GXI=16PB3&@G
MA-,C8RO:%*&6&INP#IBS?F_M[<!F6GG,_\X>6VZ_]K8&Q[2O+/O&"JA+^OL'
MAWW=:CNE?-6MN*4W\7&5K>N*IB!9W$;D1?$TU(_PPAT&:)!#\DPT9=C:%N94
MY_FF@+LE\AKQ7YA%?1>/F<PQF8GG0V90K^&])2PAN7I  <@H5=*Z%KT\WH'W
MQP7(G)4.]R"A78\MZK.S3_9L_B:AZ)U]2^@CFI)XBB-4>L,9\KX)'(C[I'@M
MU;4FD\<LYZMG3C-_IR>^)\P6?Z!HC4F61)O?F)?.CO;Q;*9/H(( N$^.VW.M
MFF*UH%5'4:,1L_?RY=Z\KIC?C!X16U(BO0'()VC&NT]QUV:) ;.ZIG(OKJ,=
M$FW?VP&^)Y?GN,^'-]=+$T4\WGX/EWZ-&/GYFQ1L]850P[DJG>P^-=XV>S4T
MZJHST,'WATM"4_QO\?WQ3+S>-)[]4KS>I-B$K2!X\(A#DVVY!K4ZXAOHN+[%
MKRA4-O;E<.S!N'_QH1$'Z]*M-]OLW7(58"KB;XP4'-UYC(6KEQ-H3/GO/Q,2
MON!(VUJA&5SW[TNTO3G7HVQ_!*=(65J?S96)'CQ/T3KOY<3QF+GJ6(]X3YK'
M;7;WAWXC]!M_?,#<;J4)5 _>OV@N%LW)ZJZ3DNI>XU'R\B[^2F*.Y^'Z->$Q
MD?JQA>+!,QTV ;):.'J_2QR['UN\MG\"WP2S N/N$9 F/#0Y;@#*G6GACXD2
M>>OJZ92W8=T_(]1$G%00W;U,<DK)TM/S#R%D55*7B5+T1;>Q8$'@'+^3THEX
M65'R3(/.6INNMC7L\G&6-N4%1)VS; ^:UVQ.@E>4/ 0X?$2S+ Y'49 D>(9Y
M@$B2/#<40=: Y^[%F#:EJ DMSW3;V<84.#T:294%&'?/U[0K3-:4.U,9@E7T
M-"](<_ELSFD.LW:$I@>GFH0$W%=-6JEEU$+RX &?MJH9 13S..KSD-'I@FG1
M>/9 "1/_=/,0!7$ZC$->D;WB]"EOJQ)DM<6/+4#WX96?>ERO%$NV1NMS/\**
M[?B9M_H03R&+)@+CV>X&'4_:4G&UZBI+<(R2!"4-Y+3C#_OP4%([(GP2#IVI
M=._5/\>=Z_MV(X!MHK)Y/KS8U/;VJ*;/F8H&C(+-#3 _7H-J>2L"T>R/8K\7
M+PJV8+]K(7GP5E5;]CN 8AT5[K'-;8I0*-9R7<CDF#?K$ >J_'T'/A$PSX/G
MIFJ2FECAZ?Y44/!V'YW8/3HIT- _MFF<Y<%C4\WY"J2-AUS=9UY+3XD^HHA_
M[B&@BD.Z'+72SO3@R:KFW+6@T1E;<\-P'?"62\RY%[7%G)Q&03G@ @2"!P]L
M-1,8:XP[/9#WHGL5Q-_&:T1#&LQ,96Z5T1X\A=6F&DMI<::J6S8YBM=F8<_4
M&R9Z\.A62XH*HI#/ >^\ 5HRGMUS\2Z_+ER*3DDHH^5^?: >//G5EF0TI>R9
M[BF/:+6CS%Y5&DA;38 >/&S6DJ0UHJB';L76(<(RT_F6T"6B0,<1! $J"*>-
M =9T(BUH=J;[R\&)S/,PO($ZK\@;SVJ\&UH'&E2@NNPVWX%U8T5+GTV>$E)%
MO^@Q#1EUZ$8TA@7+@V(RE/W>!AMMD/6>VS!2-$\&P/GN;3#2&N,SSB55R^I$
M2"8.^1^\/F4=1-SBRB\VWLQF[&C=OZCSR,['XK*CH>RYK8] A:_#6&FM#%3K
M=#Y+:933Q!@RE<R RDF'(=+:F4HU!<[XU0Z-R(\5NJ*3BUK@P"W#/!.:!K3S
MW*)I8S.PZ(G\?8>!V!:W@][V2Q8+2=#T+W.R?HNF8;Z6A_7J&B?3B"09W=\T
MS!LE?_KT V/*X,U@/X+]Y2'8#-;)X %1=EHN>?:H]._-&R275\C%D__ XS??
M"PEE?^'AY%^3TN?W7[_7/ O-9H(F-M=$  ;KE>HQ<;[,W;\Z?C072K)#_3G
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MV45?RMF.GTS9CBV 01"' PX%A6R@@\1'&9,*<W09$,7$TX0NBX6$Y448S7[
M-*"V=*\J6K8<!#J!I#CQ5B5?UU>2%DLS1.HLI@-9=H) 4C.>:6CC=@N<;HHM
M<+1Y1C0I<M././GV)8B#/(<QC,.GE.W;:+Y1WN5\)_Y[_^%X:SP .^!P!WO
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M%#;O( PH S%8[F!TK.&*E8,5W#B_&]?CKN@DGO+/?F8>IHCZ!$OT0NBWDIS
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MZ4&>UXS$6><B#D)X=EPW3NU!TA>.C*?YA"]D+3"\B_7&ES;#\*,NP[ LOC#
M\2#8?F,P(U0\6<._,IB*SPPB\9T_:MK!0W^@XQ2>;?B_2Q?A-+Y=47UN4C45
M5\'3/<G1UF*P)8TZNX?)SMTDB,:SFLRR >#4/6_&+GLZ>?B<9P=[K$6XK!N?
MO,MM]LS*U@PU%5\#RA\R7".9Z?/3L>DS 114#'8@_V VSJ6TXE):<2FMN)16
M7$HK+J45E]**DY16C+(D)2$.XB=$UWAJJ*]0CNYGD84!>8^CZ"=)./D0.+7(
M-[F-E(Z"9,'?]69_\&L]ZR#B"1E-5/1G751TRL#D;W7S'] >8-?A3SD:8,?
M--TW/>(+'<=_8Y36GS[[47[$1F%LDIPRQ^AZO,==!1$/,22_X71Q%<3?M)N<
M9+ G4<Z:K%)B[S''Y*B:-$LVPY.09P,U4]/!NZ,K[_I\G:%;1H:2[;31G%Z?
M=*=7(  .P@P-.&4'-(<Y6'&@79]@.39)@<Z$E!$"GV,P(+[IWR7(58.)ET!7
MWX(AET#7)=!U"72YYG7/ EW7F*(I&ZP/<%5&]3.PI4"VHV((D41*#M>FI;)N
M@@=-V6L0W$P"C]TV98*[XA$8FH18 NI1&+(6B3QQ] [<NY0<B;2YB.'G=\>^
MWO#0OWN;D@,7#Y^REN'B[EW<O8N[=W'W_%//B[MW<?<N[IXC=^^1P9X11JMT
M%*QP&D2_CD;Z)W,T$_KI!)I)T)$_>$W_CM8X_@=>,8OY"<=S9I+RWFI)RG?O
MAQ3=IZ'>"[< X,%3.W4<=&L2=<XK($<\>EBG$=U[XYU_00$_885<B*KX8?C/
M+)>34IO"6T(%\M,L"N@P25":W./@&4>8$^0KB:<D3AEUV9KG=W&*^+:0C*DP
MH\:S$3NT,>.7JB_O;C4.%M.C*($S5GDLOD\H32-!DO&LA.;5YB9.<;H9QU=H
M$42S Q7>E'\N&Y8ZT6SY0WUJ9M,)C;MZZ2U(%@\!#L?QB+D.0L398H,2#HHC
M"#*Q)XULX#3HB EL=YIRNLR1>"1MC1-&H" ZV%OR< K;K(1PS! =SYX6C @*
M]C0#V8/^-,V1]'ZOOB=LQ?P=]W M:L]TVVUU;+_:V,@Q]9@YOS&IXTM^"IC9
M8$C$5,?VJ:&-"E./F2/R0@_!!M;+9C^P=QULCG'TF"=%/F"?K:MC55H Z5,_
M&FO:>,QG;DT][EI@C6?;/9WM(&*;M\MAUX$&Y/S//G"^/K4\%H%J1I[YU82_
MHJ-GMGX>D*V??& KA (=>G3YYU$X(;=L,9O<D3GT-G5-O[9.D1T8L(ON@;M7
MAT">U(_L+PI<$4K)"_-7-??:?GZONQGPO(/0]36 _5K!52"R*>W>M15]WQX(
MY:PID].P1,A$/^ZEJ5$ZO'<+)83'9PZ_E#5>(QK28)8FXLUY/,/\P2"+^T\6
M0#RYSF;F<!WDO.=V(;+WB&V1I1"KUI)43?'D<IL%)PW8=V18</G9+U*Q-QX/
M\J2K%FPCE&/HL1H\+=B>S>_C:_FR3TS(ACN-$]82?PW6'O.*9Q*/#MK]K_:8
M7&TF;'D:"V0'L29 IZ''6OQN1+E>2(3-.::;Y31^V9"W@-/LG%IQ:X7Z";$?
M4,C/(Q$%VKJKM;<#-4"G8=+VMP,3Y<Y4FK9]>6!V@&RTTZ!I+3E0XWRF3!X=
MGWB\J07@8 1X135@.@W'-G&;:M.OMEBE) TB#UKGED*'% 7?0O(2@V*('[0Q
MQ"VH/T@T\40WR&YQ',13'$1W,5MN)M)#5I?&- "\NB=FH<! ]"X7P2PO"QEE
MK?=WOWBPDQ>FRS U7O\R3^XU4VT0]?G>EV[U@*M?D.F^\!DLSW8\[OC98&:K
M<Y]L'"/]J\'5<1[<^()+U\&[P2J<.XK1;[\W>2$@&I?&.8O4MT7C"LY=TYB-
M@DGRP4@/;L@UI',5[XXI?4LR"B)T>:"SP%9;=*YBW3&9G_ KB,JE<<Z" &T1
MN8)SUS1&:Q3#J%P>"3T _3T!)8AW3.JO&&AHE ="">WO,5A%N^MS$"C0$WMQ
M]O@0/+$PWT3@C>-P*)34_IZ#,M0[-Y]1M ;:=@=#H=3V]T"4H=XQM4%TMFU(
MZ.])V)M6!^#4<[V4L@]U^J8<L1_9FB*9 LK5?-3E:L*B"^ E4W/)U%PR-9=,
MC7^*=<G47#(UETS-)5-SR=1<,C7MT?B2J;ED:BZ9FDNFYI*IN61J_"'T)5-S
MCID:]CVHW7PXM/^9&AGJW5,;;$&C&D:TSYD:">HGH#;<ED:US&F/,S=R]+NG
M.=BJ/AH+I;B_1Z04^9ZGVC_X>U8Z2+7GGX2>F)714)K[>V@J"-#S"H</'I^;
M'50X=-G8"'2/L\;-3!_R[[WJX+%?[/8=@$>&*(PKAS/ZU,U>CW4OV/4E2#.*
MTPV,5?O1/>A?KUV_DD5NRUGXVQMLVXYPD-^Y+C7]&%+,&_#SAIG%YA[/A],4
MKW'I=<P=8J6RE^]U92_TX(/\-]'^DX,@_Z9X.W,PVWYU$.P^>ZF1:5PC4YOE
M5H4T3;]R#M4V36EP*<FQK-YH1[3[7K<#QMI4PV,)Z/PEHBYE/"X @A_XQF(@
M:U"^"$PMA:DO$RT5#'4I%$?]WY2QB3WRBAGN:Y!J"GB5O5J:>.Q[25ITFOFI
MF>2L26GK+#52QF.NYJ\C_@U%X83\#85S!":*F?G-8;LO(VI+1MJBL\>BY*"!
MMP]1&GCG;KL.<ROQOBE;"$U];5X8)(O;B+R(%VU^2?C[RG?QE')"7*/\S[NX
MTJ%/*P\U(?8I^-J,:A[K_P,E4X1"@9<5UPT3^Q2R!='@3'N9;J5XLJ DFR^^
MHA>Q)R;@DTXG(RT =_IN@:4<M4;+CG+.U1WK^/S;9I:&<7CX!L/-ZPK%"2JT
M0Q4M; ^^T\<08&QO&>-..2_>J#Q>6F5)>N'4\[[5+SA]&@'._0ZHZK&ET)ZG
M\/L'QR\DM.,L<#1:<1=NXM!3Z\#9RQA>O ;;X9L8+?F)FJ<GC=X*PPYB\(N'
MZ>K#<_J< 7PK;TPQCS?NLGMC^RR!>:[3YP<:.'K !P:ZL+_-_L%>TN!>5]D>
M;>4+X/B,)T9XBV3UU@';8]"9#U;^A+M+E*?VPZJ$]=@5,TI!VQ^!RH'+<%X7
M>'M_MK=MH%NX9AU<Z&W51O?%/7/PBNM[UW$QXP.N/GE+PS#$G("'B]9OL(8Y
M[FYKV_$)A'I'!V$-!;#9G5Q&CN0K]V$SNCRDV>'U_4;'URG?T'2QGQIM5O,T
M*&==!Y.@!.B%7>E2F6WV>R\"3+6Q//.SH95J@O:K!CZX#%W5P<N/??\$Y2C;
M0$X1T]L18Q>G;[4^I<VON>NNTJ!BI7UR>WRVE;, ):>'-S/ ,XS"86(I1C4!
M0B7%NQHY:Z(YS*?8Q?X:I%5L/^2N)U#[V95Z1/8VR5*8Z>R?3Y!ND7\,*AVN
M WW=$MOC0T1Q<HH$Q&@1Q/.62VC;^8Z[SECM&2>-2.RQ1)W61[)PK3]X481G
MA5E'[K3;=BT3&H2([9-" 1Z"#;^DKFO%\H.N%4O*@0V".!P0#FZP*N!UW6-%
MB@2XW8IAMF\J+5WNA(A?/V6K5801U:HS$(#+BW>6K*WHM16-/-Z^A],IS8)(
MR\[]&*=WWYJR[!A5C[GR:Q!E:!BR+7<2O&X1U+%(,<'I=;:F_-(2P6/F'6"I
M8]K10*=WQIHR2XKTF5X^E%+(^CQT?%NLDP.P,>-3D@:1!^:KSFC]&E#*/K3>
MMUHJ6:\_'ENO$Y/%.MC!^\/8KJKFPOQ3VT]HFFZ*;KSRL3TT*378*(\Z)Q[=
M@E%@%*PPTU"()OQ4\>,X@,$TAW Z\2^O&RSU\DF^'42[.,1X5D26[N*;?V5,
M=HQ]+XU3O6IFJ>-AM462";5+CTI ,R*@;/6]\>2(+%<D9NM-QK,</>,KL8H9
M/66<$2^/&T%6EPQX_E4YQQ<&ZD42P+=N7W>]BW&*@^@A>X[P=#QCQCV.Y]J7
M(+0SG(4H  24)0Z-R'=U 8OYQ,,H(JE0[14GC[HMGKA4I)G@P1.P%D0WH^YQ
M-.AKQA<ZG@D3)AEFZ8)0G!BJ3I5S>M2KSH1X1WHBHH8@<O/ARM$]Z/*F7;_W
M>O$04+'X!T3%ZK65:I6QO>K3IL#T3*.CAWI_ER29S6:W'=^G!FHZC'T)WNS2
M\<,ER=BIRYO,SV/\;]XRY(&2&4['])XDNL3\S[K$?)"#%6^EY' '.&9RS2$S
M9@W8I,Z3]'F%'SC&<SS<-T6Z1DP*IODK (]XODC)+$M0WMQ7IU#Z>7Y$2.6L
MJKY, B#!F6ZCVP+$HMYP7*E0U)??&2=[DLH'"@*8&F<J#07>CRAB#(KG$[+K
M Y\3\);0WQ9XNBBV=<[$FU>T%+[2WX+D"J'X%X/3T=HG/"DZ $I6RY3UV.+.
M3_X"C^3XX&=X/J(5O_X7SQ]$(>&$/*)9A*;I+HPH*/(0;,1+F9-%D/*21L0+
M&A_9;T8DGJ(DX=[Y>,HO#_+ZQN0:4PZ"_1+]*T-LQ'@V(FL<OO_T$# C9HFG
M$R((?,_F(C04I5/A ^<9-V$X>T+,H+/5!C28TV"U^/['X7AV=_OX]/Y';=G2
M6>+K294(4+O.DP=>F?8Y)R 9V4_'!GP^]72IV',ST$N/=C&Q7B&:;AZB0-P*
MX3'-%9=9JQ<(35"\2LI";7@+_"Z96<NWXF!BU_LD[?;%;B6ZQJ0M$$+_>6R-
MLL_Y72,*@'PO&(8OO+>3]AI\]_\QOR\!(U*,Z,;\\%=EJ/OG^VS%ML)"!?H=
M9<S$.3YA#B^WDF.=:28=Z7]*4KET[UWVWQ />J)PN$;,#T&YNY*(&Z8<XV#_
M;/LC(T+AQTS(<7!L[W\-TVLVD'DR>1V#F#$MWIDU>]1.EM.#3*Q; GDOQ;P=
MRSA+9Q%Y81Y_[C9HCVSI^#ZE?'48>Q(V.+B@&R<\]$'BY#><+D0H%(4/ 15O
M32H3@I_>&6[J[J .7AC8 <WA#E8YX*ZS@24T-F44P>$',P#?%*WL-917?(72
M%X3B0\9:!2:@T+P*4$ E0!NR@&)^"5U8NK5V MK[$ 9;[IQ0S-V"0S2-H0O#
MS//A+1AEGT,6RJ4#0A7&N;[P&B;-%GSU/R1QN%YS7$(^WH/@!%! *\S3$:"S
MGFAYU0=SH,B2%WWP_K/#.,Q;T"KLE[Q,WSRQ'W$+. DZXL&7(&:>+%_G+5*1
M^VA,#SQVR:I[X48_HE61"A_/AN$ZX-EO)@U"*O*<>%E)34ZV+;2^N>#UJ-5R
M"9E;YY[?LT',%LM#1G]'F[W4/R":D#A&D<;%?Z]S\:<EV/SOW]!FL-R!'ZRV
M\"^>?ON!849D+LI/0110@Z97Q_I1 US;/5<A[[+V4_6D*>*Y!MZ&>(U#?M)D
ML>HJDGRH)V6ZMKQ2(^3],2O?(\O[J$[9(+,]*9"MK7]P"O6^#]#^(+T-,"UN
MV]UQ:<8SS*WO_"X"-RKVZ1O->?I!=Y[.V"<&:_X-_C=<^LH@$)\1;82B_8>Z
M/ECOEBNV)&%OD209QY\)"5]P!&^C8@;@F_8/I__*<"+*O$.F'26N3[A(\II2
MQA@J!$PH32[4VCKDNB#].*:A0B#IM]B(E!X?$<JZCE+BEKL<>P+P+*Y.1NI"
M],0\J"TCS2CIL8B4SX@[QI!XCG>G16TI:0#4$YNCMJ TIJ?'LG)=6$:3X+6A
M@-A"\N0R26VIJ$<Y#_W$NWB-DK3.$9('B8&S/>DX:LMO*QS=\[C36\%K1@%"
M-_7/$" $H*AT\^1&&P>&%:7.5%Q*-K= G&&U3QQI@X:FF4#QZ.8-CA;$ T:9
M,Q4+GAMAQC;_@QO<ZR!"<0.KHQ8XH !U\]QQ"P+4@(8>VA^:"F2P%6() R@
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MD)V4-HQG7H.+*NE@JB*DQ;ORP7M<H8T^O'>S;K W3.7.D&P7;BF8&2-8.<3
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M3W@?J"S$F #72I";0*8T:LE28(-P37A7J@)NO59@QEZ;&\D12AJY2:C*%!H
MK1J(\O-9;U# [8Q%2B_L-0YDG#[)K8:-N6,Y&FUIR@U;MS>B6P[(GP'(\57P
MWAA+BL06>"MD"9&,+A0.A?68<2,\XP -<J($!9H)8':BI)U1<VH6@V&)9>DZ
ME#90VF;H1]QKM,IAE!H=B! ?VWKM+9 3"N PA\?193#CR51X-?PI4_!K]SUO
M[7;?BG>^[VXWS*_R2TGR-<GQ2Q,PHKX56.=((V/NF*A>HYG*B:*UB2),1(ZN
M@1VW23&\BK;-YN]T9?+L+G" .!06PR.@OF[>#[<FU?2 9_;A7:BV3@2K9LJK
MM<X,!@#!S:4ESO0"0"1^()+S5T)AE;.-4-QC,:_7)9Z:!9G3'0G>A256*QER
MY\V<6!E*;B29+W-)X4M(0L-DEJJ\3USK-8'$SMK-M!4PQX'0J5?*D0)!IC@5
M!GCE3:@(FK(A5Q^KJ@GO)H(:@KW17X3;C98? /"3&X!_,/G=P/W#:7,3_.NU
MZ_BG9LB9N0RI1'"K$TX5@EMD!*E<?#CE)BR!AT20?"*5=$L2$IOFI2ST&/7P
MR_-GK>F56*K7?"6Z+%Q*,Y,"_]9+GR#0)O06>,$\%0D$C4(:X(Y(*<&H"78#
M.=3]412*SG8CY0< >P"PBSE7F2=! H*((CI"FR."]KK\K!3, _@\O]RL2#VO
MHR/8V.:B=Z(S.K^[;?Z'E!Q>M1:DZ:-5ZMV\4V.3<K?@D[58!QC4K]<P^E8'
M]@? 9DA$G ?^)H)('Q;*TM^YB=%'<"\I"1T$F2&,W"C<]=H:?,2U(RO?>\9M
MI46(]3R(1>@+@C>ZX.HE4_)"X,4?9%QKW[S3#S+C;D?Z[!6UWU3N=__9AL^?
MBE9(;U[1$M%DK*U#B.D+A!6&(GZ[!^!T!%'IDG4E7!G&H8:=-K:2 ?X##!C'
MTCDA;N/_B8;*H)NAA&E^A+= .O+%$IWCE=1XD4:H,%\S"=/)A2A+_!<T]MWK
MKNX;[^KHO(KDIO^N$*&A77L@!<!3E.]J<[40_(+*<2[V?$'V0M4?W99'5P^
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MD:T'Z79MOFTB]X@6U[XPR=^@V!<M?P)02P,$%     @ "(UQ6U"N>O.+ P
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M2+R;>G##"7E]3-^MV$C>CDA?ETC>JO@#4$L#!!0    (  B-<5ML/ YJ8!<
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M+!9&+XP2I01>#9'F[DU*G8A,@ZC+&5QYF(N;L4BODC.=JW39GI _C><;#F"
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M=[W&?4X:=[/7MW?R(];OY*5SD_X=VG<%[3&IA DC();,I2CL"L*2(IWA=E<
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M2ID>(3DW4!&VI'>M=(XI&;G&Z AZ\%P>!F4"=:U;3%GVV<K# =VQ5@LXDHJ
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MX%$21[N:.2J6O2XE-:OY1HX&KKOZFRO@WD;O:#L5\'#[,K@O+8-[^U?+X%Y
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M^'_]V]7/VL'!BH\\:GS'T7^?'_7W8-2K/^KX&&\Z+I^5*Z^X^^3\.P6^AP'
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MUB6Q?K0 9 PL%7W=4I^F40($W*=3:CA(A%][<6ES;C^B\OA*.M,PT&?H1%1
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MWZ>Q?/8MF%.IG*5@Z"1+X'&R2^TRDSDBPM3J1_CR&>-^%2H3-L32HC+9.H.
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M)*_2D)&ZCAV1 Q7AR+,L;#O"L7ORH"(419&-+$4H=D].5(0AGU*1B;J.C,N
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M<.^BU5;3_-PT+]=]:I;E$5,Z9^/EVIZX^O#3E]K??](DY=KEWKQ8G\:)=91
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M!6KM*W0!7+?:C>:G.^T?7]K-SE6S[A?7?JYUM?MVXRL>.]6\$^?Z;>D<% 7
MBBH%P%L"X'\H $X*@(]A8N\ZS2MLPM>N">R];]TTDVT/HU"U*/B53:H4JJZ"
MJK\I5$T*54_V+NK?+AOMH/F+@M(L,X>B*BM0FL].IM73L)-IRJU,3RM*Z!55
M.R;T.=&?U%G(B>'E^^CQG)UNK2L.FM^*0:H 55&E '4K@*K..U: J@!54:4
M-2% 5><=)P:HYUC)^;EYV50@FFV^4%1E!43SZ=L[*H=(H#7OKAI_* =?1KA9
M4:4D/U7)K^Q==)J?[FK=1%. 8Z6^.KL([US2,^E%Z9?Q^L\?$3Y@\&R\-/PO
M_K6I<>KXHE0J_?(?!P?:-:.F\4&[)P/Z$>[^RZ.6#G=5/VJML<MLR_F ;^E0
M'?_XJ'TEIH</U0X._"DVV$- 8<_F!N4'/=MU[=$'[=($#M,J,#S'-ID1C/P
MN$^,/OP@N.%4++&86I@"TQP3PV#6X->]\I[X&XC7@[]G7PGL:9*Q Y0%OWW4
M'IGA#G'\Y?^*XZ2I'+VH]9FT+^X(F2GNM*7(Z^#:R-0&D_I1ZT[&\/X;^Y%R
ML6H?M3LRHG+R[VR<4A:]\5UP)WXSY;^ ^7YY!U,?LPB<DA\'/=JW.3QZ+-8U
M.O&G,1-?WI6)GYWD$ Q<6]_37.;B)5TQ"KNOU>'-L#;.#& =/%(V&(*D]FS3
MV+L0%XLI7/6?R(,EY#RW+-'%Q$464I,<:*0,$#L#;K_T_(<QX]<]Q_A>+L/.
MX ^EWKK#9&5,4BZ)YK_M!IZ^UKWYAF< 76G=1OL6+,C>Q2:&_J?GN*P_\3]D
MED'QX>7#LQ-F39<@ 0)6>ZUX:X)^#JOD#IFC$<ORB*EQ.K:YNZ]YEDD=1W.'
M@"TH.4^N9L,?_)$Y%"[ZRV,<GXK?8RUZM?RQ;H^ ILF^^+/R,?CXDCC4U&ZI
M@9@1?$<L Q[2IQR!$MYB!U<_TN#^DO^)YX1/M &#&(R2\.C-SM#V3$/K4: 9
MP,UQ;=O )_;HW"MF*-$^@1(UUFY<8U\CVN77IM;S'&;AF'4Y$(U9NLUA-HA+
MC1*SQ%CQ0B2>N?!BK^<P@Q'.J'.8#B,>5F&UM\(6R2/+5H91A\V*,*M$1J R
MNXY8NS'EB&: [,C?Q-7(>$R!I\02STL"C&"B639H0]Y(,SR*C"34;]A94UKT
MV(G:?:#Y(A"E-$41QT7)0JE>$6QB%^A#.HN0;5E*AT[8D26( Z"54%+N 4YM
MRP+4?&0P\Y9F>UP"9WI[;_:!;);6)=*:Y "F^VAI;A\5&]R;-S=MNKGM]D3E
M8Z6OOP4JT'1Y^\PBELY@:2>P5>V+?2R\O%JN'OFW[,]\>AS5MZ)?G,PP$+X
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MS7/$<FNF;?_0#$K'\*7O >_9QD3<)JX!1!QS6Z>&QV$,^&QJE.#U 7&*4S+
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M@#=[IBML)WM,.0D?,RU#U&W+8,)B$O&C(>4"!<'NHOMXI>\[,R@=4;_G0U@
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M[6LZ>V#B8?#4'E8:./OK4:3[5<UR>]2)"U1Q>SS$H-!#J 4'-'VR#9F<3QR
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MJF_/8..L"A^\3- Q\T*$1('00EE%-11L7&9AJK/ 4$?JXL1U15K@@W@<LQY
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M3XQMQST(^W82U!ZIX4?\'5=X-4=T9'/XQ!O).@SD%Q]*B2-.[Q4N2]&"E#F
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MMI:X8"O%LB.$E>&XI&+N9K032UJ/EIG=;MHBAEC7FSKY=97[R[PEBZZLK_<
M47XZW/MT[;SM9XEMZ<A.;I [+<28$#\N%_%/0@23UR3JL-9YQ_$(7F"5H T=
M>\-6(A.3QBS1TTD0H<&YN_%$2"\)U^G0TG424EXXP1<2MCNIX:G0GD=B%=7V
MH(&-A0<'LRSGR_Q(IF+U; DL4^]<,<5BQJF!TAS21O&X:./E;!@1+,DV?&(^
M/AP?!N-\Y-/<;-/-=_^Q3XCN?I$ B7^Y#7QKT^.ACLZJ77&O&<JG_HZ5 B.+
MU6V73@15Y%Z5'BU1BO!6N)@=.@/*Y"SYQU:].?=F6S2&]";OH%O053V\%/Z3
MCV1(M2VS%E]<"B.=NRJ<L2E?%3HM&:+4XQM2P> %41CE+/G9:5,G%H3NST(S
MA8Q8$;#(N"P?7MYN-"J:DNA2#C;[&T-1VN2%;5"GHV%YK8J0>J_!\KV7"JX<
M';@K!BH;0:3M'74.2"S&,6NIJ!R7,(\961-A9)7P2M1&S9&R>*_O>8W@C?55
MCQ_-!59W5V#UQ5Q@-1=8'86=]KOEI>B6J]L01B;E3?J6C2Z^F7QUQ/N&3SDE
M<.L_,E9RT_X98P-]+#U'?53NDJ5.<]OE3NNNQ1/C6+.X:5SL@39W/%[NXQ+=
M:ER#4;527Y.$9C3R")N QTU3+ZZ*5<]5/88EPL@!]&^RT$+#JUI0S/X#%(%!
M#P2H):2M-1>$S@.I[Q'(L?>[M:<@<LEOP!<Q'SMXP5S?4I;6M\_%)]P'65Q!
M=?'(4+$%<TM25PE"\7E;:_DY;>.ZX>HG,EW>OU\Z.R+O7C/HT>$,L'<=ROQ,
M&/8%0>KVA*9YLT4-UQCQC;9>K%43&*YV0_R)/KC.^22LI8 N+QKN#(-4-47'
M/;'I(D<X; %+>KJ@) 2T0HG(%";&C3@L^P5FR4T%9J<:9+EW@ON#@U6G>?%$
MX!O%(^Q<VQD@'RNE%81P&QJ7]2^6GE66#.&IS"RW!_6<7^<2N67,Q-#=YMW&
MD'X3V4'$9QAB#\*=FG"#E(A?/CY3IRI;]RZ 9PBF34UZ"]6>P%4C,T$[]D:P
M7!+"J9&.;H?87 4D9%-PN>ES"TO[KYJ4T;CZ-4EK+VD;C;IS&;6%CN'YNRO(
MD[W7.NK;"$M2X_RQ^$UKQ0&@9"A8F".')S"AITF,PA>EREBO.:5G &#?%EHG
MBXH0^)M]*U*F ! 6E?(%J@6CA2Y9&#G_$9"A[! @=)5P* 6'H^4H(!^3_2(;
M$?FX4O\=C]*ZU]+36L$QW"C?DHQ.E26-N#:#)[!R:RX--V20<N=3,F2KH <!
M$')[!\L8.NE9WFQ>#7H@I+5A[7^;V)NTWDBGN@J#B]L- KL#K1@Y*D)>9X5:
M1?5++Z "Z[S+K=->'X1+@^O>U I?-713H51.(?J2QEWY],$:1ST+M6^\!"H-
MK?@!8RC:R9K;@XVC:C9E(["NY.1MIGMWK]&QM7(O*_)"'-TM+RN&Q60<Z/VZ
MN0$"$ZK"YXOB!"8$W"0ZPU"41O5A>XML@FWZ+GT@D0\ (,E1Y@LB4^0D5AK:
MKD GNBS64:=/1V;)@#G)/42::MD4DJ7<DC5.+MZF_2C!XTMS#/E&X7%L7%Z-
MD)BD-H1K$\==7?XN P 07P;;>@N #T-([3F$$\LS=]:P--,($L6?=W3_-=S"
ML>!J6.YT"*J7DSK%$#9*\C%#D#'KM2H8!>.G>#$8N**=1*Z ;N2FL2NWTID6
MH2W.SUFA?$?7=W?9,#CMJKC@"DM2T.N'Y 5M#5ED-(Z ,#&U^2@<%N6O, -:
M?C+ DT)31CLJ@]3::ZW.M"LMYA^:!,R(+8T!U72B[P\)L@'(2^B->VL9RZ\I
M41FY^,FW F#C(QH#MD70;M56J(=X%]V0"Q(7CSS+)<&8.@(A/N,Y*/T0C'LS
M8WQQR:"<*[FYG"OS]A.G.*,=90]V1>+@\<>< H#2PA@,A>24HTC/"FC!M;8>
MP?61_6@28Z0*AU 78@!LPH=G;R1%M$8D6!6?A-N7)/F]3&Z_EU,U1N/CQX<9
M[^+&TB5;.$@S"=GE#3HDPVG9EA9BUC)HUAY<UU^6VABYR0Y2J,O)>1=3:WKR
MR=L%^:2-E7MD=_T42U-\*;-YST=0S[.:Z)= *:H8*&\BJV%7A'?R]-#BIM5;
M(MSN[:[MW":JVO"QU*0[V/P[]U6=SH08A\AT,QDL5P5W($M8<@06L2<Y<6=0
MDT-)+R^Q]:(VI3PMB^']L[3?7@!'O[K(!,2,03.EZ5\-L""72RG=P:T?!2W$
ME+(2U[JYH,OOWQ*!&G:%<]Q5&MZ%Q,7EKU=HHK+0;?0F*<WA:&LRPF RK$N2
M:)'\&]AROLU%AR\<&MW9 QI<!?'A#>[\H,T>R^[<Z[ I$:BMF4]\EKDN6!^X
MBO=D56P*1#U\*VQD5[G5A=QA@Z9\VG5.B4S$_I)#]M&MH9_^P!3(K U^A39X
MRTTP >UA/51!.!CPKQ+; G%PC2-R.3H?.'V:<LW2-86F<8;,H*\ ;M*WPNLW
M0R,GX#0X<BW7EJ(7PG&AL2H$GUR*-JZ;9T1*C/[/!B> CQH344AR)I&2_G#)
MXBCU\,BNBJ9O-3#6QY >'5.3L7[#^5:W:8SKM@?KB[]%6L3;U:(N!1'E+1L#
M:@$?C_0*S:W<^.41^(KL2'J[Q4["8M\CD;]W9WC0(<GI>?K_:TX@;HI6VV0%
M.Y9A%X)0 8E6POOL:;,LJ"1)Z8SVLI2%2A/CI$;]B$(/(WZ4Q#G$A^>^SN1
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M"7FC)@EQ-=#1:TU8F5];:B'<PV;!^#")X?AOO&-O!H8O+1;C:+GCY/QEL1
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M[W^:OE/M=M$F4:&V;Z0A7P9@(IPJ1]( KLKR$C.Z[&E^3'C?2+#/^+=8]K0
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M.@^M+K>]U[:]@SAC(F->U44EQ&<)5Z;YQXYM2ZV(TY[#H+ZS?8*C(+R#/L"
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M5/\6(>DW.5+^88@3G@5/#Y'XAFR*<N?]+:%G?[,3# &+[H_R!]%#DTEW9>4
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MUQXJ=F+Q;XF"#!HPXZ\G_/7!,[V?'[$/730.S4$B]WOSS/PZ#E8P2[%^C>]
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M!'[F_QHAQ#/]K]Y]DI$:ALZ2:P9'PT)/GXE<M$%#'^H%;KLN"L"V)^(UXU"
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M7<A$A4[B\[EH.S+IBT' =L 4PM$G?N!2/F0H;U(["$!W(6(UK!>RZ\>[3 ,
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M_*]V@MD?!P-WFCRMAKG_^\GE^=7IS=G-V>7%"UOS.[WZZSY.".]<\-VK_O1
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MI1KGII@;)^67*N70:C-1#T<(#X<YD_R #,8^R$VDA7+23#K,74\,P%YJ!4=
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MR":BDG2[3U4EZ;9N2]ZPI+MR0Q$P-P>Y1*V<2';H5@,U&X4=\DW58RMO I>
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ME&TA[^O\=XT"/*Z=A!6),\K]A<E+L:SJ_95!,X#E,7/5M%.&R_6R% 6^-(+
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M<B(#"XFQS>:Q_^S!V U'0F%BMNLY<OW1$0B?UG[-IJPZ^9@?JA$L-8()L'V
MB)?-#@8=C^R] P+6['2Z3KO5WD?,)3^Q[]V$>FRIYN,1J,1Y\!_1C.::*9D=
MT8G*0Z=YU'9:S;9LW738/,2&./N.]<A(NNT2@V([K=:A4Y?3;3GM>L_IU=L2
MJ+\X$F:JAVD4YPT(T<#H,BYWL]5SFHTCF."?V-K)]ZPBC':SWD+4;E[5+JQP
MN\<?@2]$$T$MF.C!;ALLEAX#AW: FD.DQ@_+0*'TKM?L8[ ?$.X["U*&=U1@
M5I9,>"PM+UO 16^UV["*';48C8[3[M8KU-)MN?UD0.8IK6IK%THHY@'O*6&\
M#N=/-=;K'M6=[F$C1[R7G8/< 1BDB:\0GD-Q3TBBON=+V#5JTM<[ZCJ-5L>2
M8\$%ZAP>J=X6A0$>:I9I=]K.H>PJVF[!'7Q9>-Q=[F2QD0F!!+ &B_4\I8G4
M\JA@>N61<]22;(_R=9U&YW"?!$#QZ,%1&0CN<,(]%?PDR1";G,<"1MAI.:TC
M/L&'3K>+_56.@-^K1#'JW9JW;R3:RCMAU4$<@?QHU^5M:-6!'Q]BJVE)A$09
M-W!YI;"HPY.JE5++:0"W[-4;U'"6:0"FGS>?G6MT+;MPH21L-KNJ"U>SY73:
M6BYJ<8/K0T2[08 7;XA(?WWLT&; D,_3=X32"-:X3C<3!&ZOXS1;LGVF\5Z.
MD#Z-8G55%]K*R'4_:J G@U?]D,BOY,&V7$E$/I=27^%7N_WH3C@E/;V6(Z&K
M0^?A :,C"H?RL-OC2X"_ *,1^',+$2?GD-;;<'6MAW#4%][H5$S^QZ[#5G?_
MD/T^K-/_[^KTXOW9S=<OI]<V-0*YO+@YN_AX>G%C?SX[?G?V^>SF;)W=0*I=
MWOCEN$&X>>L>_LL.(Z +S"&,:2B3D=IN>'Z:Q2AKR#9+P<"T@6N!+CO7]E:V
MN76H-5.&0/)DT2$PO<@52T;T9>!Z>!4_>QM&]Z&%[8U 3LYU,WR#W.EA1/K#
M"I%^A8CTG0J1OD*DWR:Q\B*(]-NNH5R??;PX^W!V<GQQ8QV?G%Q^);W$OKK\
M?'8"&HE]\ND8U)1*,]F8SF#)_JAH.4]!K@Q04N?=NZC338+<  QCEYK>D^&2
M:LGO4>M$[3!-"J#_#N@= P'S4T#[AE.[Y,,6.JK]9) ETM=&KSR*X@]TL9LV
MC5XO,/]NJ< K9B,\F._]_2?W?^OUUD^*69S=G)Y;W9K]_NS+Z<G-Y9=K&.7T
MXNSRBWU^?''\\?0<+2 TB$[/KSY?_NMT5S@-3%F=@362N]7S/ZZ9+</ _+@6
MH0]<Y-P-0=' V_T6M[)42#QTS]<J._)N+JP4)X)[JJ1CT(=C[$0)3!Q^!FN4
M&^0&'!.3/<_$-S$ ZY-:YJ)I*3?:R[<]48XVY/ZZUXL;AAE(@%B@0[5F?0T#
MD4BC]MY/!(L&CR-S_2P!\Q;^#+IZC/]+_2CAXU[A<)60XB?4BTZUO\G=N///
MHEEK=<$BF?H@^+Y$+GSZ:^BG]M_JS8-&_9=&P_X8B%"X(PR$GK-M;9_ ML0"
MUA<6Q)UBG+C9.6KW>B\BL]:.5SK72\:TC.8MIV?/KV X+36PYIO)/'W\QY"6
ME]CG_3*$ZZ=\<<7<1G--G?QZJ@_LI3S<!5Y4DM6U(=)+&.7S4,:_>P_6?3U0
MH(W$;B[[+A"W0^?@*N*(_?R42C+P?Y1GE>7J_^WDY/3TPX=%=O9L!MP^6BDB
MZGL7J_*(JG^!Y?E!@*)P,AY'[BH.I2;ZI5%<GR_6?GYA4;T2HIMKI[IU]-;.
MP983V&JOE,*3L2^&1-2"NK(R+KG(#>_+:Y1_7%E<W<+\PW<1&(-(_)RM9@O7
M3_4J#]PRX;8[;/+1$,X:^&6W.BH5M<H8U+8@L5G[@W:C5RP6?5DNZYWOHBB$
M%9H)>X^UT7U[5S:ZXK<;YK?M3G54*FIS+?8DFDQ$_$(\=@5&_?K7Y@^AM%@1
M@6W_(8/_VOOBSB91Z.WOR@97?';3?+97'96*VA*]UO5C>%,%#-]%;NR];:WV
MRLT"HN]#+#*, H_=H"B%MIGZBM%NF-%V&]51J:@]"SU!V75A2F0JQOO6E=F;
M*)RQGC\6X:YL9L53*YZZ!0O]UJE=,T_=;L;YQ[VXY2 _.ENOX;]&N[)O%?O<
M,/OL5+9_1>WSV*="-MO*W/ 5U7E\=U)XL[UJP$"LU?!_?Q_7+ Z@<0:7\]^_
M^+]COIN]=_[>_OC^T[E]?GSRZ73?D45$')5<2/RHV>_Q/SS27Y$?(LZ'PEK
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ME&;)W7"S=!S%5.1/ZT?VJT(M@<V/!SYC?9'UR9OJY,@VMK&_+J$H2/^I-(R
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M]5F&#$E""J_< )68X84^5I6Z6]W.G=B2W;F=12G*&/T$CD0>*U5:XXE_9^Y
MY3^ION^! J&776E5,%]=;2!03!.=/$]8D(2.-,QQ8.4()(6ITQW(U3=Q1*I;
MNW5;LCNWE@5H,","]166V9\N]<93]9KS=W<A(H"=D47\)C:XNG-;MR6[<^=D
M8AO1ER ")(BP@-/!.'%-YMJM1G'%U]["_E=7<NNV9'>NI(YQ2CF('ILXF"FU
M]:$T3'/_9+[7[L0FMY%.SOXH=.DYR=-TJC20C::!+$FL,K-!=.:'4Y;'\,1L
M$#W(RI- W"<D@:A>+.5)9 E/%=XO2THCW -3C\Z=R>G\H$D:9P-$BBC@W@0!
M83LG7!";/^X4D#J?TI:("^!*6BM@\K^$!]78QJF$3%7S5/GW'K?052@,6!!5
MF 0B7(C A^TA9&?,U7]P_:IDCRK9XVWH%*9#C/#@HY0<5<:U@$-RBUG@6'%7
MWIM*QG=ON=H.KQ&P.E>B/"Q33]AV,)"&_2J^M%6'HS("MF]/M*#6<6"9(*G[
M.3SC_B9F(UAZF<IA)U&2JJZQ^;,E!T';$H;LTQ)MHT58S:H(:W5%6.UZ5815
M%6%MM AKTSKKZ@3>C^BJS?;TVUL5?(N::D'&E?8 7(5&6KFFM^P@5%KI]NV)
M&1(JB=(:J8KAS ZB<'1 < 5^B#H*&I+%NPQJY[\S1*60O<S@[5'L<EJQ:C-M
M )9@9B/G6/6C,$L$_<Q5 [ICCVQ=+7M1!T,LCE2X:_2516=YKMV^2:F[8E_Y
MA2YH)3_@211/(W3&V1_1@ D)"*6JH]P.![I1?(Q[-=![-<KWJMROON U+Y98
MEA5A+OK5]2 6#;+$NVZ_@'<]+![:1Q;"<+J7*1>, RD4IC<U>\RP'6(!0X>Q
M=4J4&3\T>S=:2@.:0T$O^:["J]6$)O.3>\HN+_6(6Y5'_'5YQ-^VE2%-!65H
MT"61:,9+[A>ZU?A>L^X2BP/]X]*W'.KFAYA.!OB5AF<$GJD &I&((DBC,<J;
M4(,KRV3KMF27+G2Q;HHS2?-*QY+[3)*5&U(_4<)*M\&(<!?@$F.6J3O G&^8
MSR"1,(U) :G!88)T*P28@]$(@:RF.Q<L'=4\=Z@*I?$#677SM^J453=_^_:D
MB&/ R>*Y<'] GG/OH E; P7HXH2!$'/ )<D2YK/,51*LZ=4@*DS\I[R9N1SE
MF?IXBC"XE7MRVXY=Q0JV;T_ 3$7<8L4+\%H&?@Z]R] _CW8Z,?/?<O]FH>J$
M'J;N*SYUY]+(0D;?D31BSR0W%I&]P7*2JJ3==3HB/T2Q@%-F7<7^';+6,RS^
MB^UK;.)7X2=NU/'(?C?+],?9G6Z#W'6M_;WC?=6!(+'WZ-H.L'V?'U)#@2E'
M]KB-DVS^HQMZX:U-Z.\2_%@@##<<A'!?]3J4Y\*6Y\*2YP)34(=1$$3WY$$;
MHV>.*E=BA)%'7 7&N ]\D>6-!HM^1_R=\CW6:?:X"G-/(K&Z31)PFU@".%@%
M[&?IC)C+SQ6I;'L$A/"'FIWZ7A]7+8>=7_Q6&OO]+,W+T\G%B#;+1**I)?G0
M5F%H;]_1W2!TQRO':''E:I1_ J3^E=F;875=1"EUSE)VU07L4<Z435KWY-(U
M._L.^3S_&?'QP.R*I/31=AWHX[X^"[B;DDCM0R[@[JGUTCV?]'R*@RS@;I9#
M\9FTZ?73$']PH+&O@=P@^!*??_LLQ+QJ7IGS'/G][/P +\-!*[\%^):U<'05
M2Z,Q207F3EQ\BA\ZO(5.?\ICGM"Q=8PSA8XK>0PDWGB2]6%AL)>*G$,.:*XA
M#AB-'3;$+ Q#:D"+)<]XQLBF>&KT^A;N&UYWX$ZZ'X+1 DV]8*EI,8PY<@-8
MK;'?]].\(X<YJ/Y2X-Z_=M3RW98.QXF5X\/)G92G+9 2(\;CZH!5Q9=?@=@;
MAU\*#.P]4&I=Y<?'N!;J+9.O*S#)PJ<-?$X"VUU3+&031^=9>7G?&1\QLP'K
M"QF8]57F8%D_5C" "_[+#R5RO4C1P39:8E+)LY_Q?^=N?"O2:> .A"%#010U
M]HNRT!88)D;]47A: :$&F[+)7TDKG^<0@L(&^T+*-K1FZQ13J!F!5Z/[-K"L
M.>)+#+W-GO U>T%> 4$;<QY5K*]B?2;W:#Z/]>6UXLE@+#P8R7L6';HG&GR)
M2RRC,)@MX7JJ5G-/YN;DU6($U )FN,S0V7>>1<1#W+19PDV-]+TM]>2\2.^2
MAZID6E65S JK9!I5E<QKK))9[;VL'5;F6J6SO"V=I5F?TU:6^>_W2_48V<X6
M^^:B0Y?=U7G'3?Q[+/#/Z(H-(QOQC^-GT4SUKU$H[)EP5;-&=.^(T%,>_'G7
MY-!/X)C2"P?P6&7,[1Q!E3%7,<:-,T8P7IY@R?F&Z8-I2*!]#[C;PC>$&7H.
M%=R=A3[(C;!M X6:\I$QH)-S5&W[U>RSE$U*-T@B/<8@FOKD^GX6%1A,E5_G
MN;@J6UI67VS;K=DZ[K5U!%7LM&*G&V:GK0YF+"0R&X*T-C\>9!/LB8=!/>YJ
MP0XLD\5Q>2IH<P:??18MTQBA4K !>DAPXJ[LM9WDS3-\1!<+0UD6@OKOK_:>
M[*ON#N";Q23S!"SE6SMZGAJ+4,B<<^*&7)0EM=;?;$HUX*+:@[Z+,8R%ZGD)
MY>28-2JJ?/9Y,B:*J28P"V#=TX0^CHD.MNPT2(AQA(-.V:OPY[O]0J,2$Y5&
M L8"=2(F,;1M#&#K&/'6$51)ADHR;%8RY+E+3XR:Z%0\U(;=42QDVL>SN#&6
M\!@@!2@"$/<Z]O+,XW2,(@=I[,^TZR*'X_(P/P7%A8*U5 S]680,?4I.B>UA
M%H=^,L;L**E]8_L+(]\LS]9*LOY?$@/%: W5:!_C*XWVB>PN^QPRGM!XMD1*
MECI?0CAS!;>/_,OW!+7RF)81N(]U^E E;W:.H$K>5/)F\_+&^P['SD)6]K,%
MSGP&-WJ+##[Y4)1\IQ,4=SJW]68LK),Y$9>GHAK%Q;*D ?02\0U,,S:6EF<Z
M8Y[K.U7/Q!^0?1SMO2_BCE+93CVR._?M9KU9MR*.>\C>[[)HDK0"[#>OD]%9
MM0'R9-8K&)[1P'=- U:=<#=1M=24,"*KHZI4ZXW4#9U$GL#49>-0Y$5NIU3D
M]A9KH+;G+/TI+,Y5E4WDL)"&ZQ(?V+*:_2?F5HE;@AZ0?]9UC%2["&;,#"MU
MX#<I_DOB"<T70KI3^'& \L#"@@AY_Y7Z+Y'ZGT 1N^&BC(LTIK$?#OPI\@H0
MAK"<+.Q&&<8/L#A2TZJ9WD%.F6.A3!MAIJVCH1GQ4\"@9 610O*'X6@&@N0>
MFFXFW(KV;VFG%A?[?$N9V=U'\2V80@-!ZXE8#&B8 'E)1H/"JQ;YK5PYHN'C
MXA5EMU4^&V"1H8C-\INYY2B4;NDJU'M$RV+= >V3411Y3&K" !")10@0:(FY
M#"85\=M],7:#X7IY:\5&^[^_KUFGZ@Q5_/)9_'+5V4_'B06J]3^R4-BMNH-*
M3(O^NTT7!O[1X5++CW&43=7-1[[*,.G QNB%(WK\J&D/LR X2.&;!I>03,>_
M$ZS"7,.5<T&]%AO58EXBCVQ+C_)IS;I&H\:^O$?^.O:G;_$6_H#]LNJSH_?!
M*FK_VIHA&S1!NP0C_T5HPI)N(OZ<:)29Y-RQ_K &%C<V[KTV\[YPI"_8>4AX
MUA563MLW9D2)*&G^=ESVK@*,)-K]1&68L0G]4M+T#5_G#S7K/?O;L>J::JN^
M4,=(V,!4'Z%C#:CW10RP9-,^C6-0:*,L ;9\? _FL72LJ*CF6V0*FSEL%U%J
MY;;#*[HR#Y=/M*ORB1663S2K\HG76#ZQ$Q)M&6_9:K'!@_G>WW]R_[=>;_^D
MI,?9S>FYA5K2\3\NO]C7GXZ_G'ZZ_/S^],NU?7SQWOYR^OGXYO2]?77\Y>9?
M]LV7XXOKXY.;L\N+ZTI@KJOJ9\7S/ZY9BVKL&]^]C?AK,7+#KCV"I2'^:Z0@
MFKD5',%1B''<>F+@HP]"&4_(N2_Q$3>>\<XF$AWR O1= K]O'))WHP.6U$NA
MB[R.>K7GR6,=5[8693)'QHO/QRB%BQ'W#<71UQP=QQCV\S)CX6C#X;\-X92C
M^9\EW..@]!+@49]$C+P5VIV?2RY$$6^2U9H?W=C%G5QW1LM+9<QL#.K4+J"=
MOLEMV:5;6MH\;=$OMQ1LN-KNZA9NY[9L\!:ZP?/2MYYR U$?=.T1!K-*<8)M
M RIX93IAKZ>U:Z46'G1;TW6>A!>V!U:J0C^P7#MKY[S3FIJ5FRM^HAM2":\\
MNUWDR(B4_GUZ(E-/$$<;?G_'8*Z4AGXG$NZ",XWNL4RKV(J3^N50^@3^%3,@
MX*8(O!M4J#^($!MWH%OZH40S["H. N?E6#7[C+-?LE199&%&%I;"$T@,[328
MT6"45^<JE18[#!(](D8?*/K."I8<Y7SRLXX:4N.6RC'&+G<;(,9*.2L#2@:E
MR<."=NNVY\XXQ4^NF6>BD*=CX 2C,=$!S"(>^ D'4$*@>*KZ$7%:"G]#+B(L
M%W8-E_EZ]#@])%=HQADUYM180Y@W3\TULGB-_$0N+.+DR;Y%;N+3&6@<.8='
M'>>P4U\8"<OF9,9AE*58L4<S7&+_UNRO84#PZDCV/4X[C."+#!&L,W# F$2X
M9^[0A.FW3U1T<!)=^\*=^O#-+Y$+B_XUA%/UMWKSH%'_I=&P/P8P<W>$9_N<
M\I "^P26*A9.GAY@-3M'[5ZORA+8ZAF]B"?B:5&$^49P\QH;!XI@-'=PBSI
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MY).Y".D J<6P3&0$"4I7= Q.+%C&"M+-02>LV#8;OR-#):*A8]STONWWHU%
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MII0<OX8&Y#-V6JKN+[MV[]'I6L=%NM82T[4.BW2M(EUK,]*U8MY2 (O'YLU
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M8Q<LA<1TZA3).Q%.)U>FN0T-1:Y$Z4QPI%\74RQ12?&5\.=$=^SOC"==3OW
MR%V'-M.WO?GY4]N7Q);.*MS/9!762_K_VVYVFNTOS;/_;VO6M.HC*' H-I*)
MK_1F'&1O1@,,RL]GK:Y^>O7I4ZO;;?)68^>MR\;E*:)3-/^\;K:[Q:5Y[B2F
MGF?Z%JJ_2>OE(>4/8HH0Q45(IEV;D:.?^RS"J0Q-!V00=SS8/"TQ#K_UXWR
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M]!/;0Q;^D9E...QCLO1C<Y/GYKVE9U@PY1<QJX(I+Z^@I%R0R3-SY0KHBP?
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M6<'*"E;V.%96+5C9TEC9LK2R@I45K*Q@98];Y_%AX2E;$B<[/HR5,F\T9F[
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MB]8V]ZZLC$VIF]N->Z F+(]J9G>N;"$L0Y*ZM(<*HRGI+4ATR]IL6G\T?&;
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M>2Q*BN)PN56H!?\.D"JZ?U]^I:@IBC R &CNGWYC'W+7'$!T$']Y<8!_\ ;
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M.H (0SAW6(!;&3-XK9[K5.\=+J]U,EX>"/T1=."0X[=6@5I."I6,1L\O-5Q
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M*(+:]>?1B!@1LR6>EG:"6JK'#IZG)S><6.N*)T]$=Y=3[Y=PVI6-D2),?F&
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MP%JJJC_<4='412&11!')X@R76,#Y2VN.-(G))9(78AB<#-$:_ V(F2(M@PP
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M]P39IVEXAQ$"$#5GT.U&+XPZLB,R3A,7&WO .A8*THN $%)#0D=O(_(85:8
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M2]O$2E[/+4JO10I-VU8?W:HO\5&M^F)1K8@'-B=WPX>[4>[I\O9G)PM@[78
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M_05I_I\_TK^3-O;F'BNR;8>_]FFN^43Z(DG/JJT3$S8\7H"\T'8.I+B -(Q
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MVGS1GF$A1(5*-I+@D2DM,>1[PM0A:[^$2XM?PF>.,T3:H3K07=6(OX&+"]W
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M(+X?VD@T KX-M2[BQ>''K,0^WK+('0<MBW3/;$Y^']X<8>W]MWK:6X-QL:6
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M5]J7ICKZK6TF*QY[N*]?K3EQZYV32>W;GW&W_N$+.P7>W&:G,U=]O$OY#V+
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M*1UR.'U_[$(UJD!BJ:/R&D*9G>;-+-Q;/#OI^U:6HZH5LK.3G9U7.3M)W8-
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M#52BK) -8-/E!.*3R+NP1%I4WC]C@<3'S- !UGZ-:$\*Z,DBM9 [0L@,%,9
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MJ[:ZA@8T[C^UK2XP>J#9L[X(CY87(52?P (".N =? J>L\D"PV<R:D'MV<&
MG=M1M,4GI=;'1%U@<>O8ISKN@@\"W6O2K<:#QNZZ]6#!&U*QJ6"3%IELTN+J
MEU%.6F2R28NN=$_[I,5,!8540:D?'IC-?\SF/[I>=]]F_F-D6B";CA@:X\TE
MM87] 6\T=3!1Y#\=@LO?])J*&)V.)7AWH$9S;]RF)\YMPF/)$:C1Q[->Y]QU
MIWS!RZW/23M,T'^/\9?^<+I E0<.G>39)JP80=6=N*B!1S^!GVV"RU>& ?2>
MVE;&X&U8J7"-?4*@6!T\%;X UD%^ARCJ%J!?^75>KM;XVWR/)8J<'T"_H*3/
M4/XRE+^HH>WH5SL \G;A01B]W]Q?W[5_(E&X5SM<[(Y8O^3?*Y7S0C-#_LN0
M_PY^;1GR7Y+(?Q9, [\X+_5E323//_/3F?3<?A1CJ8ETAV3+*\ 4&,",@"6A
M#GW6;9&+$YXM #Y.W66TBRZ^G+.M\XM:I1T..RU*- Z61.^[XTA<%+R[\@\>
MERM2>A/(56=^T4]^++UI6_E&GN/"<"R0;[NT)R*]G1J3U\H%V%WP#>Y;5_2E
M;F[6:ODW27]@6"G.?F5O""\EZD;F' I-'/7N\\NL,*"_FI-B-WA7\T(6?2X"
M:=(02R*GYEF:P\&U?EB]O$E0%!VU0: B0" X.(JZSR-B2>36'Y; 22XL<(^M
MWBQL=,2= M2>+O6LH5-;+:%6-H"1A4:^WN[4S\[.>OL'C%SM 5JZ_D)RJ6F'
M+87AA*/6IBYNK[A;G7E\5+<P)8.2*BZ$2?^;1=-B%(KELBC9(GD@D]['[H<#
M&L;-0))'1N]B1)QD(FM[S1B(=.LA=W*Q+,Y'SCW;6Y#S'YHH+:^]^GU>UKKB
M9WX:H]O@<->58);:*Y2SQZLL%XB<CG?7DUQ_>BB6&L5J+_KNTBA!<UD*Q;*+
M ]WXFW;F1\LLY+&@$2,<9\SRCO-1R#YHQ"C'Z+VE0),UV =B/+LX+TPVFLRS
M)LI4JQ7W!%66XMP+<PJ2WLT-9/@_I8^).I5ZL,#7>7XJY5B6X_FDU[E(C(EG
M@FV\77>BFYYJ@PJ1C4Y%+:NCD4>G<J_S>>OBALCQ+U_/ZO$IE .CZJX%_Z)L
M)"+AP:DL)3@.3K45V<!C4[V>\CH_?YQ_]JJS_H48JAC-^#^WBJKXAZ.67^>S
MTE7GHG3^<<9)?FJI6IYRD!5-9453$=4'F4>CYFJSTOQAT&XSXD\D!6<JD+JC
M/JDVSSV^\'Q6()452!W\VK("J?T42%EK\J'!4QV<@[L=MHS/B_,GHJ"?RUV^
MLX=2*,/<!)YJ%RPGR=JGO M)MH'7GBF^<%9HZ)V+MW7*QKSNR"9&KE?A/W9"
MH[CCBS(GTAN0Z^!+;D(2%[G&AA:]<>E^#G%M TDT2H'><@8,2T0HNSZP-O-2
M#X;.]$=UW,U+@W<#;&-^>5XLW'Y=MAL-%&#-<!F'A9L^!L\%J]E[Q-()0]J6
M;MOJ=:HTKB[$<?7N3K2JU]7VXD2RW%EA .V DD=;3N&E&1(7J90A(J8N<!T-
MFU#*T)8H/2(OX)R/4N",34'89'\=H "B+Z\#D1%QEHTUL^ V.]XV@/ZJ$A2X
M(QI"J]QEOU3I"F720&3%6+&!+\-=K[&774/&J;B>1%^<V[VCQE2.N1J]%;M-
M=>N.LMEVG/>5_9+]:T,&V5^ EQ8%)#&[M!+C%;+[ 6\N$2=\#(_*>!685[;7
M%Q/"FQ$AD'F\U]<J3^>:%R^]S@>EAX?W0N6B=<FB)D0CAQ*(%$ C[KP]P[KG
M[4W0BS/G;#WAF*UW^/[K_'$\/^^^L_W^8PN5<UMV0;H9^?US^@QR3A\<Y,]&
MK]Q\K_9[^>[Q:<X =S7 F=M JO\:#S%M(4>;*53NR?VHP'32)4,'B/#[K[KD
MYM&*F[NL5",$)]L+'@S8Y(I=4>XE.I8A2V%U<&3 D5&\ 4=&X]B=I X@;J4^
MQ@K22!T#$CT4"M@?$ OV?_\C4!3Q3VVBM;J2KFC&O\E__L2,/)"!Q0V.LH3I
MP%HQ/)'1\I.8U-&4!10.A);%BMIO[$J9J@/L61T9SSY:/KL.%*;IP09(.WCS
M6),&>EO1#' B\&_P)%53,+UK8.$NUPE^9T #;L']U<;*[P7F7Z[5 I;:$E0:
M/@8N5+>L]&B]4MSX1$T;3E4=6#_@<87A0%>!H2<9%AMX=Z^'->%&P?; MSI
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M 1"?\H@^-M8[  )<H*.-U6UU30"EO['_(1+2J%3MY(=?]$_R/[BD_ ^;[%1
M\]TMAQZ!=V#;]1QL\AB;31ZSML!$,WF,S2:/N=(][9/'TG3.DYO#E<W62MFZ
M*]ELK6RVUF$5#'D7!&%_0*LPV(@M!% ,I\#OSZC\0=Y23C^"?%IE@C;5'LNL
MW;H.Q.KG-I7QIZ(,G&I.I$5:K3F9 ?\7GF5KV<CRU[H1CUI5BARM7[5<B^$T
MZ]ZU(1- &6U=%.)4O2(;,KE5,@._-)R,]3'X$@PDFN9F;:JB5FDUW+H+W'B3
M6=AGN$,F#ZX3Q[H2<$N;D&IP '1GL,B9&1.<-06"D8"E-6<V)#T")/V-50=8
M;M(!,H'!E4/EZ%CRLU74(T,7&9#1(-18>H<[-5<%W2G+P>Y8$7QR7<%CU/NL
MTX/XD?GKX+G0?YQMHAP&V:69)?<(231;[+#7<R(T3$P::>/A)XQ$SEQH:#C_
M5E&ROJZIP(=[N?[70[#FW$#.R5.CQPA&)Q<HA2*BVU[4C!6!!8''+M>_63Y8
M/5C\RHVOO;!CHGB7'TPWH4JX(M_U"MO+=RHM%TW.MO\%;CG?H5(1/(]SMIAZ
MRU2$208-"BPNDY4 XM8\-I0,930V%FF(?X39PVT=N[@&LXO#94MP0.%B:*"A
M#PR3:%%3,!DOKA*#F<MCO<U)>\6%8Y]=M=4%FA+.)-0G4 L8*KH)-B8M!MP#
M/6;1 $=0O;BH#' 5Z!-I4\UG57;+H@?X"WA! (T)[Q@C):* K44H8BE@61)C
M0#F/K@5SO#"_,"*LBM49?(UQ;&4(\E"@@,>UTN2F7SO30V&Q^= 94;9'.J*Q
M%:C+THS5ZD.J9\5=VZXRLI@J>\->DR;CH1_H-8[=.$#:PN. 7T7U>6P]@Y"]
M: A(:W88/!NUXNGOK9QD@U]8M'\"+ ,:S\:\^8"4"TOD#;89M4FSS ?7$WE\
M/7ADN6[&!W]\B 8^*V7GR 9]+6Z!#+%:A,7:(@A8FQ",4>? Q*_"0>=W&R>K
M.%'@?6Z]%:'?TT7Q=I8.L;YR:<H-0FQ49_0#'P\TP?)*X*E?#B&>W$X=\,II
MWQ\26&!6F,OH4?W0;<[,)_7.<ZO1*YZO?4UG6NV@CQ%H&$Z!=NXVIV[MO5JW
MM65Q(M>]BSR',SZZI=,(KW48K$$?[X+3% &88U?P%B4X5R%Y[6D\7+=^8EUB
M7J_WGB]?R@U:C@<';.UGVEXVVZIAIQ\T->@KY-Y5K1L;!5+I/WT.[KL/K*/:
MW:)MG$@OD1]ZY[U;SS^/#!'#XP+!X0*5P8ZDG\GH>"4$SK(\3G+>6CXJO*U<
M.+TQS[T_S6KC\V'OXSUV$"YW7=T8CJ7>WN5YHY&I2#7R_*EPK\L?K?O'JTVS
ME;'E@U"46R<$Q0Q:UOWS HU3O/>(Y4P-QLM"9.A'USQ8PN.*:'"N6OF.<"EU
M"(J+.?B=)<RL6X+U3C#/9!WM9U/]Q.#F[MU!:Z+!7+X%J\(1DL*:(WF4.@K,
M%->EGE')M]6UQ:#'&=;IY)7)*VMW5%$7:X6VN4NBK>C+-HG^LGAC9 @_%']%
M@_4:DN:C2GU['_YF5>[FOFW-%^1F!1&ATXYRYX]-:UV43*J(;R.>J#V_C-X.
MC$L"BI%I7*%P7CDI.')I 50S\B+"D;[<U#J=;2U#@0^!776ZHDW5%OB8X>.9
M6VGA=RRG_#=6G[2ZJZ-L(RO6V(1QH=6DF7&;62RF*"6DV'H8=<[?E+[<7$N(
MP<\9+.Z![_:6 \M*W7 /?;(>V8GT8#VV@FW0E?')L-V&=0EKQ7LD=21UH/LH
M9=@J;7.M1H"]EQ-P1VP*)W1#!A8+P&T@&!C\: S-WO4:U@&$(.^%Y546I(9E
M;AC\S4;PK"F%1>!"W]A2CDU040NE=RU5;]:<M3Z>.KF!LA97D]%G'VGQ%&#?
M.PXFW,$JKX00S<(D0>*$:.<T1 Z[D-7>HF_I8G $+7[(&L=2SNZJK=O._K,Y
MN^4=6.IUP1,0SU7)(!!%HXK0QA>/U 1Q:V?DR??*[>>DQ3]PIK-K*E'!I,5J
MC<OUHE;%E*^1,M"5!4'\ ?$&VWPPB\5O Z. [/ZSHHCSMC#9BPMLA;$W,IJ%
M?=@<F%&Z#3LZCRS0/SLV4%M1](WO >X80)B!LJ#SNBX8!K=&L%J3Y/]98P)A
MHTFSI[: >+;!J@8=HW"YK#2U"30BEJ77P,6!ZSRBJ.6ZX/5EK)PF/6J; :5@
MB\'B3+@<!*NEO1L)R.GZ$'AAXQUCBHJAB;PP$9^>/VKSR^'&[H;/L&!6P(U8
M:K3,5=+>XNZV1:>+BD+H[A:0\ZV4J[^$VW&11.4B3U&1<['\]?FFE.\?<I24
M+C;R)V"W =DHHGM4M&>'?K2LI*/'"YG,7F[>RTSS-L^GC95T8/P/$=E#8G""
M$5R9"=X.)[RK4Z5G[>T ;LG"HC9@X!8TLSA+-@4F.QTS@&>_L;(Z@,_P-H%L
MA(JW(A<M**[(C6$9=J<LT VLT 5KEFQ)F4"RT2/&58GS^?OE.5'91,6,W9IE
M;-&^I*W+TF&WCB=\49"-.HF:< *V'%34D+T2GG77&L-5>],1R:Y, !N&ER)D
M.!<YPR5V<GM>O*VI,S&=#.<",QS9>/7-<(SD7!A>CHSA(A6]$S/7^C6E1U\,
MWIHI9+AX0@7V5D1D\XZ#PT?<&6YNX#)9_I*1%.G%J^!%BHZ<_9W<M41??KR<
M*6PZV4\'9#]'H)N%+(73G&/0:8O]RQ;6[?:LH]WVK/8V/2&>%HR:FJ.R64@K
M'2&M\BJP?62P:"WTBY0F/'@[;4F[F,WNL6Q\T3 ,K<*=9FK[WFE\\^%%T_("
M/[+=3D-[7X3X4"D8(V(W#R8%0T0.G<BN%%Y ,^B&8C0=+O!! T&A.^R!^V<Q
M*V-UQ/0%L/=*@T+\ :"R3\:P> 9&^P;2>*(I.-#P.KA^-04<.G6))'C25"08
MU\./C,.]@&<:@(NA;]SD R/79&"!+W7V(GP(KK3?V-[E("SB<UKU=0AADG;$
M"? 5,%HQ!&,9,E^@I\H+)=L:3H&VG@(I&$Z 6IWHZ@#BZ*^C\U &AC 'O/B1
MK$)9,D63+6E6=0$S8@QW@0'BUA 8! 8$R.K!%B7]+84F 0"C@#"!7 83& =,
M()?!!!X23*"%QZ.>.CZI*QUHBJY82Q"T<5#V<:"3]$(24E"IQ^=;P"8&:>;.
M(!93MNX,8M$7Q&+,PVTY@G:'B<D/-<V((SCCP<!4@ ,>C.VW7^<OK<;'6YT[
M5QIR5".),PA))PA)-LS,V1>N\:@R[<]>BSX^W7#3:[9LY%+J 6945,:2VH/U
M?(N0*9SWT!Q.QCZD5\PY2F^@I[[.^Q7AMJMQ=V66#-/1L0A[NKA&D>JFF*R7
M+72D_.M<'O/7)>ZFR+*;SC$++),5,ZFY*VM) R0M0P'>%KA(_T(]OE%WBRT9
M8SW7$8&GV*@:.SP5>*(C6&D,^]R@%I5@-26[:'#\[%64+Z+'?=::/Y$4Y*:P
M=/YR51IW[Z\^J$([!E(P49 B&L DMU.%?H!\DL(&'LDW_V-?W+=:6WS"XG=G
M=MMP?M(!/MBVN9\PU0K 4/-@7!MJT'PR>P2YICZ&J>E7%5@'MSPEMB><F)\U
M8VGG]Y"P!8N7:_W;E60!M8E-Y[3W!WU+7+88>P&TUISGI<%[%4B3K$GML5[H
MP41U6U7DG X+/$KK.?,+9 GQIL"-IE55?:>C@_Y96HH,9XN.=(+!)6+#U1J3
MQ$ICT4FUKNE96E+G=[F[J?S9OINHZR*<[:WM0)LQ:/A9OA=J6Y/#VD +<"1Z
M]2Y4.^1!PI>EB/P$:O\W1^(T_[W(;W;+3W2E=:)^G71565; 9\"YI=2OIM8#
M-".!\K $8Z+"8[-"*"YOQFM%TA73=#I#7]ZSG3-)>NF.FRCZ,A@2STI=&@M9
MC]<S(:*%NIB<,'1<=K^M D>3R_Q]4[@JTYQ)!>XLU];:\GGT'%83X* )J'J.
MQ#E2Q!G*&P5G3P9$_+1#AI^A<((5<9X1?@+M&%O:<<BT$W#6MIXYM*&8VW@J
M\$K;>">&:BO7;R6E1IQ]37OQH$#"53K BBT-)W,<-#408WDWJFVKQ&F[J@];
M#YW.4V_;*MQL+A28F,_+DJ*=+\L?@]KEEU9$1BN7Q@"KU/M7@10R1".%<SR/
M"VPL '2VJI&V3FGN#K7Q6-'ZUL/>EPKY7*$V+U:>7^<Y^I+Y>*D]C MJ(I:@
M@^:,;?+'9NO8\C+T?T*24LV^N+:MHKLOCPQ]VZ]=%#8#K7<W&R?@H\U"_1ME
M5!B#EN/AR<I@'1-A5 CKF:1(G"3%C%$1,\K^GD(WU7&>X' Z]GLJ+FL\Q9'N
M;#&![!?"<A-6AHNN!U,J:O.CS1')SV#EN"4UE6=NY;O>)$=6R?VEIL!:3UI9
M>NKP%N-C5-!&#FWCJ^U^=3X9EX8?TU9\08@D@JI<@%UO6ZAC]:[,%,O7[[5>
M7'%5YP7Y-W!HE'MS:8D2%($+A'<:(Z7AP4C(AS[D%J=$ 9@=WH;\OLCG,_!"
M,\Z!EW@OP?JBP12&-@Q4OA7P@:&$FJHV.Y^H[Y7WSCY=^S0'1?EH2+VM^>K*
MTZ3_U1*K.K_?\"GCDFO\,4Z7WU,L9+3R?V$$."'^75@:&4Z>Q%F!QADZUCD1
M%BUMK<&Y'@XZ'I%6-G_)J]1+4=)1U'&XQ%02X57H[J0VQ$KZX-:V%E?:Y%/G
M@KF?/DAV$5;3?N.,LNZNU;]MQB1@VF:J,0(^)6!#9WP*Q"?;^XEA#N=^(NS*
MH4R5W -YN\S;+K;VJC; -38V76.W%XVW0N7ZOCCJ?O.$8?IN,38ZGFY?=I4[
M]NGC9M1_J"DVEUV<%QSJ-ORK5Q89EH_".4' &=Z[ "Q3KTEQDT')'!M*&"A@
M6 J9#03<#S?MKU1DEP]<(H*(\Z)WC6'LHP'+K_/^J-HYGQ4>:_7WF!O)5\M,
M$8(:\F7;Z"I'!BB3//P<8)86<@-7#R*8&J"8^M]I1(Z+%#8H:OP%=HT28I2_
M^0))6+'"W/.W!;W ;>I(D1_Y.E<+^0M"KUT5ZGP$DS2WCTALQN&2;UM("877
M^6-1[LAZHTGTNUN8"&OISM 1D*[.#!W!99_VZ @569%4Z>ZJF6=^(BG,Z CM
MS^G@Z^I1J/<R=(0,'>'PUY:A(\3^8-MH6F$K?["5 .Z:PS*PL1;.12BO9E5?
M#'1@GAF#]*S3$1J*UH?/J@Z4U5"$KV&MQ5S==)B1'$MXS;VI'2X(ZX$58?\A
MMR4SN89VK_SZ:V34?B:_9O.BULA)Y#KJ9::!W\[WQ<:"_G^_F6G6)3-]0 W2
M,1"&_1:$\4Y9^,RFK^:5[$CZEF>(7BE.<#@GLM&U[>]!V38^AZOCK^1;-_)U
M_:U*HN0R?)=IFC0*%7%]II"DXC11[N/ZL\54FO-RA;53G/:7;\""',ZE]S/E
M%8&<2RMF2FM!D97,6BJL2H9#;YL4"&# T'&TCN?CU2Q=35F;%N\]8GY1YZMS
M/IG&2HN:H2-6,V*B:L9,1O:YQC2*Q,M]D;%3-'0DBL;%ODJ[HG&Q@+Z=HMG(
MQ9:J0;9G2%[ 6<[;GD%0-1XW<TA54QY.M+7+>-7(EZ>YN5Q@$[)BF$.V8LRD
MFQ;SUVJ^/9X_V9HQ3!3:A3]<,X;_06;,1BRLRH5'MF-(D<4IT;O[&4&YT+$J
ME[KZM3H@%[7Y,_4^[LC/5/)6#'?(:L9$1&6L/5Y+[Q\D1]EI&2X2+7.X-@S_
M@VR8M51L*1ED"X:E29PGP@*4V2H9#Z,_K))1ILI@=4*&U:YT690++V]<0B8,
M'[%NH1+5+6;:%90/@AD6QMR%8J==^"BTBW"X-HSP@VP8DUQ8]8L0,A@3BQ&3
MBU6_5-1-FJ=5?*?8SVOICN"3MV+$0]8T9BI^RJWB!=V:E":2G:(1(U$TAVO&
M"#_(C-F(Q9:>0;9C:(K"!3(6.Z88;]!W<Q/STBU_,V5UNH"B9E"L&)*(6+EX
MI-XB#O1N2*?=:\VO0J[4>[<-Q)!$%,I%/%PK1OQ!5DS#WH81T0,Q.,O3.,]X
M-]^E+J54ZIE-_;S0'M3G0_+V,7DSAB0C5C5$DJK&2L?/"Z'P^%SHSNI-6VU#
M1J)M#M>4$7^0*6.6C"V%@VS, %V%B\(!1GX;GTIONLF]]NG+UM6G7*O':,\X
M]/>:CR.U3;?4( ;%7G!C9@?-DT7^^NNS6+4-(Y/^^Q[050-/9(#L_FF5 ;+[
MIU6T2%5[< 17Q_3RMO4D$62_?/;V+0$2X'Z--4&UDSZ,! \F1ZN@5SR?<%=7
M_5KA_>[#QGU-1"UGX&7^:>5BW?X86L5E3ML8TCR!;$@#/<A!B*-D>OR//-K\
MA==YJSIL?IY]E1OWH=K\W1<708>[W>,W?>;*5ZLWD973?__GY 0KJTI/_ANK
M21UP,]25CXDR: %E+_+8R<E29&5UZE?6EOW&X^%HN8[E#U9?X(R[*5"SLW>[
M,DD0OVQN*I<N.; ^6Q+97[.+KC'+ZXY/RR=F\JT(]P\&P<C_QG*:U%1;_V 5
M<+ 6Q*T,(4%IWORMOU9?@[_:2.5*)/_]"U#>A@>PI_RDJ8 S!9X],AAGICMG
M0W?B4.ANH?&_$M;5H#;XSWC8>@6ZQ+G!$A@FQN:&;:P M16XL__]2_(@JID5
MD$<+-IA.2"P',;)S[@?^()2M]V_S-"_I2N_H1I$A&[$S8*R.L.NQ_!N3!L#L
M&NM8?=+455F5- -]O'D:'5!'$MM;\>+0UEVI-DKUHT85:YR7L$*U4J]>7Q1S
MC5(1*U]4<I7"1>X:JS? #VY*E4;=97^V"IWXS5K[X0-2(.+-EH?:T4R1-$P9
MR(J,74X&"D83. ;->$,.%[WX6WL\VF4C5!0! 7G@W48X\-0.),9\N)%0/7RO
MT:*$+??NKO9'1?.PZ6-?OM; $CD^)=G?MK:MC7XV8:?^ 56T.I@H\I].MEBH
M$^@#1BD1+1(QI@\/\Z!!,7V<@'Q* 8%\3.@]_ M=%:OG=>JR%\X*WCL0$P2@
MDHT=ZS\<?NIPCENRX$[ Z?OX;']>LW>WM2YK!7=:28XSM--W1'@*B9^SE5G>
M=N1MOAUU7,4G.,OF2'A>KD _P\$I,X/36,1_ JQ#Z@\G$'Y]M!,?"4/6^)"U
M FRMU&XKK;$Z5?9-8Q4N7=''F":-%3M2A\/#2H_\WTCCB0:$&I.-C6ZE56+(
M;/A2'&C5!O:X/R[&JLMS$9;I\ZMV@>RPINFO0&=E]%OZ;3%C ZT_:@[%,#LR
M<1F+J1[&^X-I8H9O7"HZ<EPJI]I6Z^R/.,"E^I\*^W%6&C2?59MZC?;29, 6
M=_8VTA1%V&,%U?_KE;KQAZGM#RJ(AT4EB#50!($3A'?B)G;0I6V)LBC9M71L
MS4O8$/%B>=W?@4L02LI(E5_ET>ND!KSE6,3FJ3V>3B[8FS:<';D[=L9B?G@G
M\NPW$H5D^)V%<5$I ^$&:@)F92F3F$ *'I]2OUD[(0F.Z?4KE&0YG;=M,:$<
MQ&1E+!DBP1 \0;Z^QB <(G=Y4]$_M"=6W14.8*R:++:U;'B'GX(SGSMVD;05
M+8Y/JZWQ$'P96\#&;J56S3Q.9$JT;QPNIY;QF.X,$Z[6D.+GUQ^ESU:[%^#.
M2/">L$=[XDGDH0PDO"5<;XI8BZ$W)YO=ZP5@D@%Z?OW2%6ZYJSR?B@O @>44
M$=4%P-L!\/@L/O\55$H<N)_;@UXW\;Q0&K:98;]>G[")Z'4GGE(ITNNQ8J!M
M5#R=B(HW8YJ]U%MU47PXEUMV'?MI4/(.2%L\A3P S<L=^!E*WBP%I=MBO7O&
M55]*3#K4O"/3_9;O'82B)_>AZ,U\SS6FPTOFY8R3D]'TCFP5_.GZRG!J?#M]
M1KP[#)T3>F5,&MX,*W=98SKSW.SS9F37S9P"!>\ =L;3?FVZ'?W.IT._,WO5
M[V898,ZZO7KI?= ^3X=Z=V2YWPA?A'&<^+0[MP?M;N;ZG21TI&:+8:A.(MK=
MD:M,FI1[K#B "0=K3+A^]<?)"W>C?3:F?#K5O#W:'$^CX^7B3#KTO)/3EHR>
M-\E ZTJM?)SGB8LAEPHU[\1RO_$Y3RU/I<"&=SKH<6IY$\^KUT2QW:P6;A[>
M$E'R#CQE"'\Z/C?2U!Y4\%RJK'=W!$8GG)"XM+H9'N1M6G\KJA<WE8>4JG4'
MQ J>0<[6IB8*[V3 ):38S6(PF]T]EK3&_%FT.>;[4.V.;(\L%9N& (V3"Q>K
M<C?S_:'P=GZECD8UV..9A'IWY&N:LJRQHF!NM+U3>"Y2;6]&M13>*S<Z_?94
MOY;3J>T=L!9Y!CGE*K"9JK?(P.B1'-ZIU/O#HTU,=@^:WHGE;&0IUS18\>4]
M*'HSU_7+Z?779^=:T)J)Z'E'KOI,NJ;4CO? (-VH=J>+/=I$Z^8>O[N^KE5G
M-[GBN)5.S6X/=,FSAYYD=7+/$TJR;B3@8WA[?CE^&#^PO53H=2>&?ZL$ZUXJ
M:38\E]BA(GQTWA_*R:17'5B:JN0JBNWNHW%@H]J=>!ZU:C=5PE[D1X/BM"/?
M#()4UR>KW1VJ9SGD+&MJPC3%?:MXDR1,KXAADR;SLWN;FNC]:'DGQD>4:Z5_
MVTI PHK>209B5O0FSG^H1?:9G'WDX/SF9)2]$V=3E6_U;<8'4O*)]$\!$IO*
M8M^F3Y+TTKG*Z61JE;Q#*2WZ4%(V'2K>R3U/3,6;Y$"\>'G3NY?*Y3@=/5$N
M;(\LT9J&<AJGRKF85;R)\_H7IPB%^X\;-:'">$?.\C[3K3>2UNK&&Z:)W9Y/
MINU)L1;&TE6QS5<_.G=,2JLFK0O>D@[DU"M+B;C@@G":D+IW:FQ,3MV;9>%)
MS^<&3\3X_"4=936NK(\H_4K^9NG]J_P]6?46[M=?[F:YCVZO_)1,9-Z5NSZ3
ML$6EM;+LZ4.S[).*S)LK98O7Y:^K2?'S_2ZEQ9.6]6[)!'+JE25(G./WKNR=
MLNR)*7NS) P$J3HB+G.32QLO?C^ZWHGQ0D0)V'2H^CU%ZLV\%SYU_JI[.^AQ
MR=3:N/'69QHV&44?[[2VA%6_=?H:Q5?I&T(4-=%NCFP*-+_C2#!>0$[-IJ1N
M?K]Q>ZL<%.XZE'PVEJ@K.A5ZWX7MD25HTU!WD]^#VK=R_I:Z).:73]/.HY"(
MUG?AK,\\[:4TF$C:+"75-^G+S2XH;$K-\(-20ZZ-J[?5E)95;JW8*A9BB QM
M2L+WI11H>I,\7)WW'R[ZY?9(29.R=V+_M^J)W4<0?X?_+V=?%/M$7[[W;#(X
ML:E\)_[ZS-::3/V45>>837V_6&9.V"<18YF91Y;>CU[&5+-6'O;M!BVGX!8P
M+W=+1D(,+4M)D<Y^(2VMDJ ,J7*^WKI^2(?Z=^%[1 E<YC>= MV_#[A**^/)
M\IU&/>4(XH%,)L+CQ%F!\)G !9?&21^\N8L!V>KCV&0$1'"U4%^WP'J*C>LX
M0?9UKE=?WGH]X>GEB0DS2"71^1M1#P])P3P4*#M'R]L4&P_AG8I]PN$O0$1F
MF*Z,@=3*F P$ (CLN*M@[=5AP.!8*MR8004^+XVMLZEP^&$X1P;\-QABP\E8
M'X./PJ<TI<&[:6[([P,=QK*/23+!QE@*V1C+U2^C'&,I9&,L7>G^K<98^CB5
MV4S+]&POFVF9S;3,9EI^MYF6MA=.K(9<Q-,K!<(FPVX>/7FG@'? D) Q=;+:
MOE:!\=%3QT )YS15!U2&[UTZHH-.#HX#,WY;^AKUI($T'FJSK2&7UB+VJ%_V
M.F^6+R?W9[?J7'T[\$F8N2/-0A%H@?0V- $^C$$4K VHLO)_P#^E-5TP5<\&
M9D9UEN.?:\F_SMOJS4B>=;6^W+'.M0PI";;3+R,G5ZQ#-?TY#:@WT*Y3YB?*
MNW+?(A[EZ.L5@48UYA7P@P&4B6';;D"BW1O##4U,#YG\KR_Z'4>[O8CMW9HV
M;"G T(5:PV7"(,J^(B<+N1,]< P4V=(-N#+#P4E+TKM8JRL-.BLG\N<<@Q)P
M8.#ACV?'?K.M*=>\P67+0S/;?<%36\<P3S?DBM;1]4#+@L[TM[EMHA*-*#5X
M >@S8\UM:."'U^%[O.V0M#J"!>LI_HXA[CB&7*?K3[+TC/(@P-S==F1NW]2,
M]\\!\VH=H-OB6.+'.966[B&IQ-A3) <LYCG >!BKV1;R^&4NI89/. LTUVII
M"J1G(+V^B':DRY9>5=;IF6EL77\5EN9D!(GLR*R=MO2=@1'0FT,YS@,03_FW
M@TBYK\5'MM-OB;''5RTEIQ'=8_?U_[HXEE'N)2-:1K2,:!G1,J)E1,N(9KN7
M"'N9_;0LV]AD 1N@O#_HNW\Z6TRVF&PQ@1<3;Q^LC>ZVU,VFD"#98K+%9(M)
M@WIQ0%>QT2FF4N 4TB!;3+:8;#%IT"@HP!W7BJ0KYG+J%-(D6TRVF&PQ:= P
M#C;+*D4%7[8(_YC:$GX=GYY@A8FF*8/Q]DJ7'Z)^N0:]5H_ZY2/8Y32Y=[D
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M:F4#UVQNYMF&LMD57'RE57UK4G-2Y$176B?JUTE7E64%? 80CE*_FEH/B(P
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M-KXOM0135VP+V)+@,=+*5S1'A]NKAV'2^FGK+ED8.MY# @418,@Q:1*6KM9
M,A<"@(CF*9QGO"N:#M6MX6UQMU:QEV6[Z)K.ZQQ!:H"XPI_ ET+]9<#(E^TA
M>I5I##F9752OZ)@2.&,3\7D,4&'MD-CA<8;B<9+Q+N2),+&3U)FD'%,VIF+$
MGJ3K:EM5Y)Q^D,>.'G3EA^IL<DF&ADW<OO7BO.F0N+'O\X8,>^N_HO=0[[]2
M,(R$8&'C])_"5J,_NWI\O)M.VP[9,$?0ROA/G:44-3JN[/LTAJBO]PN'>:BG
MD8BA?AO\.KGT3?@3>297KZ475KG[H'S";29\$*-ER+X/(SI: D?@-./=0'6H
M1['HQS$TTH^%1=+Q&[F$Y<NF-*T0P^="UR=":)1G$-4A1&+&GL\?'R TXU3C
MQY$XQT=FH:;)$2RB!CYCSS.'/V,3CKM^F-_VWAM4+('/"++7L08]8S]9(=K8
M.8; *2H6,W.5Q/AK+#5[RNG1T;\C<]O@H@/#:[9S7](Z*G@\8?>VW8G1JVJX
M 21';[.>9;W!*.PJ##DB,$KX3;/;%'@#YJS:GBU_J YD!3Z>4 ?'JS<#&BM?
MK=Y$5D[__9^3$ZRL @GX&ZM)'>4?\*J/B3)H*7]CHHB=G"R5C:Q._<KU8I$G
MX^$(O!4N;OF#U1<X8S2VP0RLI?1Z2Y8:8@'_#6C46OW;^LK6L->31CI8VNIO
MIB%+$'!X=P*W<^8*K,^6E_;=0BT%6IJ6UQV?ED_,Y%L1[A^L,1N!%>0T<)9:
M_V 5<(@7Q*T,(4%IT?RMOU9?@[_:".Q*6O_]"U#>A@?@%GX_:2K@N(%GCPS&
MF>G.V="=.!2Z6VC\KX1U-:@H_C,>MEZ!FG'N+CX^;1B; TJ\ +7?8*S_^Y?D
M050S*R"/%FPPG9 ]G=3(AM#OJ)X(U=]R U$N]]_F:1X8F#V#.W[_W"@R%#'L
M#%BE(^QZ+/\V;F<5>*SU25-795725#C8L7D:G0Y.@A0KYAW:NBO51JE^U*AB
MC?,25JA6ZM7KBV*N42IBY8M*KE*XR%UC]0;XP4VITJB[[,_VLB%^L];B]X 4
MB'BSY:%V-%,D#1J BHQ9YI\;<@AMXIT]'NVR$2HQ).UBSU,[O;(2*&,%P2Z#
M@&NT7! 6FV#W9CKV567B8U+T^K5 1.!V2?:W/]R.X]--[ C[ UX?ZF"BR'\Z
MF)#?[4Y DP4_F_9G0J *P*Z)Y@>C;67,^6QE BN&A/J_8\JV/]WE:1LI\3P
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M+F;VS?YXV@6T5S0;EBV2E>!5JI%D!ES6%L-Q,5F=JF -,OC$8OK,9U>!*6K
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MD*P-WY_\J?<?V4KG<K"C7A&+@:%Z4%RHCBAJ5[%28T'"L8H>& JC_F*T0LY
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M;U.V]'G^1*L;G.=]^ /,YW\/K2EG=E$2Z9:ZK5"-B2:/YLW3:&_G6@K=F(\
M2M-#L!"\,%(H833"G6;@YZ'-(BL0+I0^%#3X/KNCCZSK)K!@!06*5(30P!]P
MAJMZP5A8 "--"?CU:!FH-%6;J!I.&(3/[D!Y+<!_@V/JUM1T4["Z]Z)7=@0H
MYM$+X2_$(>H5W$#]?I LL[8F#."_!_!)N-\0]'LU*Q\ @GRY#;L_\](#:]2D
MJ EEY$]A9*).3\AW.O,^#_=^Z@-- ]*#?(63+RNE,KJ:;/2JO\UI;W Y&;DM
MVGU+,=SOAI@.$V]1?HNOH;?[EOE17K;SX@=)2VB0P+H:@T+0,(%:4D2?I[W:
ME+\K3T?-U_;P=Z.?#\K'B8-9$P@0T=<1?D/G_'3Z6<7.T,K/4K.K%F)KNJ;;
M;PTW:<,:P;8DL$!UV8!>;5KT@ C9!\KTUR%\WI127Q4LRR4\9LIC<6"=@+K1
M^CO,%E"'62]=,T+6K=&1N'_(K_</SX$AR",T16S>E*_14TWCU&Y.#U5_#^IR
MW#AN=4+A^4H?,N;S'V8O-X-1W^2OS-IC#IL@HGD%?:@!J!>D A"(<4A=[LO8
M\<33 JS+><\,>9\Q;IG.@HX[%?KYBD+ZA7H%&DBP#6&&>""A;:0GV#]3"VFE
M]BX64E(;#[.:\BB7[LUQO\6ZR:<HIS@R.!;KV_8["X;G/@0EFD8-9X1-N%IQ
M^1$^+;#TX-I]5U\O_LYN?D[E6SFK&9+1\[L..'5MC_E>S:1\CYG2E7[?#\:J
M^B2FF0Y67TR?67-U.'>)?0M?F? 3@0=#,E6,+*&PCZS&RR)*W8<KQ[\E6><]
MK\PRVNZV?-N\H3"<&S&).>!0-W\PV4V&O+N'9ZE:2/D$CQ*B9B2CZZ/E=36"
MC4%M/N$76X'PW[HY,@+<K$_9IN^J[-E;39U FD]OH<UO-!3I FYH@@)S[FAC
MQ$D>ECR'+(F%:;-Y\_K8N&O]Z=732VZ# A*M#)\+<-:6,JDWR:=X-(L@GN+/
M5"ZQ-%/?+)MBP(;UP>;*8RI?*8:@#&3X-XN'-B.GS-9NU>K/9\#%04[TK)VC
MDSMTLD6U7S1UQ[3?,XAB4S "CN('B6F&X^A:??-T[AA(JOO#%,#2WEWA+2Q\
M3L\O;X1+?2H.4A4\SLHH0WC+!F:BT2H"4&+G=G)ENA;"%HJ!$M[;JO4%Z$9(
MI=366\WG<:-;Y7<D6MS5H5LPB!-51(,L]P(5NZMH*')%@$><H<M6VX6@*<%;
M0X/QJR*X705%*S>#8]I_-"="[<?/[W$:+2^:U<Z+/7UM]J5+0I$@_(%78OM'
M;*U*EVJ;L\BV/G6/4XBW":6BVS57M]3$ZR_M[]_^C];H<4>B #JCDG71K>))
ML)J[HCTC9#VY(B CMFE:K?)TK9R*05%;:L4$C7+T'V28OP@CU,]DLW"XOV$5
MF6&FTS_]-*T*//@=041$?P'N"O>,D!ADBP";^)9HM4[7^<VM>V+ YMRU,*[1
M^.AKU^W?C):?L^O.C_;]Z_!,WI%PP6OTWT6D"IA_UI@8D>@5 281[% TDOM_
M1\4EBX-CH)@)2D7?A)=_UT#%GW)TJFH:OGS?A)/6U8,D/\QF^A2TKAM:]V<<
MFW31['#?OA\ N"(C)!TBG']\0[/"04:*XXBL.W;_A3K6[E!$MI%NOQ6F6'6&
M0\"C,C@=0'.D?A^G#C0)4V1BKW??F(E.Q/#PJ<8W6VE4#L_4X^B9=0"JNRJF
M,89':IR;8+-NZ5V<RC]*YD09UG9>-6PMDY),@)(WK40@5<MQ'<XZ-1;N3"(
M,()UO$)_,3Q'\^7$6A6N Z?_6K6E*J*I:=#H"V\'V=)M./WQ]-VX_RO\8'8D
MW5K \&=K>*]L!-O!V;>HBT[1"$B+;5#7N1I=Y9F$!5W#AR6G9"F$J+N]8X4_
MO__</NY!U$G2)^KKO(0FMQ)N$PY#G48$Z,6?'\303+D2"GT[OC%/K!!\GLTA
MKLOFR!.XEB>H^6^/^[)QK>HZ[ES9DQ4@74"I;$P]*?Z>I*]?+#_Z?L:U^*>R
MVXTZD&2A;F%7O#NP<-;&\DI4QW8]-A=4[+R$]OQA)O\9M;^]?K^<-!/*VWV?
M"?J1MM'0"R@I1(&_=U/G4:T=4_NL4RAGP"IH@6BGI@!71_6@F6UJ*.M>P *)
MIA"W+5=ZHN<ZU9Y4'R(:_D1&)5WSNR?TT!Z:G8Z88UKPY*W("GR;H%$ [E2B
MOID*F!>6)5AP\NZA$K_'QQ 4)H%"$*49+9=B\4OA[M5U;:W?D]&=>'%V90XV
M5U?AD'2X2'&LM+M:.FEW& K4*\2_#@RX0XGJ3:WH^A H(L 5AAJJ>Z2$ &IN
MI]#N+T][OX7)>:LB94RAU6+?U(0@-L2E @48)K)J&OV1^HJEEF@XPLJ3&7=<
M2$?*U%:*F QV/]]*.LPE/\*P86ARS[1J#J &"2C+FJL<\ 97H2.LZ0:JTQU,
M?86Z.#R(#JNGJ0+$*=6!9SD$@FY0#5V&ZX=_'QE#$14'0Y(\ >.X<#JU/ZV@
MXC-<EPZT%UE$!110'J!@L%6Q#O$Z0,B'GQ*L20(2-;97"<U-$]<:T4'+1[N<
MJ!9V[)> 4=]*OT3=P5')!] *=CFS!@9V1;NUY1=U](*^Y5D[5(7Z5#? ."5U
M]WZ Z(16J)Y=.(8%$\8C_*$&7H!BE=(LRUE_IZ\[ZZ/SVVA@B]>*OXUVX]LI
M]]K^]7IOSJ6K_<W-XG3I%:ND:,4WD&1!BL:/L_ 5FJNR*T4H8A(D0RT++XAB
MW$K-M)YH@_,&I_S0AI5:?4ZUEOVF:%IH*\K%G]52KM/URLI1T$Y3 4M6P%?@
M?T'C6E8ERS1FJ!MABNU;]%FN9-F\2_;NGA@RN".1QWUC*@^S<V#^+?_YJ97_
MEG-8=YG+<L+%DO;_%(M44P8CZ1-U*PS 9_BI9Q,9E&CQ9:I8M,,TDOP2-K[B
M:T.$-K'0B*B*^R5%*B?<7"1H=4!:;LNT.DX&UQ?8$BHX&F95=?E>=W32+'KI
MYU#N,]6=3N *&IK0D\7/5 O*'HNZ+141M%SV?NNC\S7T*S<,XL1 OGR$E \X
M PT(3\4>@((!/GN"3\Y+]VH W4MYH;N/QE\$:J@AJ?E?0Q4?2B5F==4@U-YX
M<U#/G"%)CM.-A U$]1X%.B,,^1TQ<BJ&4^KSQ;_T3K ]B^D7]H_?]D4=%>8M
MGSI.% EG^RQV3\L3659U@,O3'EKM[D6GT&U3W<L+ZJS=ZK2OK\X;W8MSJGG5
M:K3.KAK75*<+?W!ST>IVUNPU4$U _>PO=-Z"&@EOO*EJA5411(Q5:_K*PGZ3
M[Z)1V]!%8Y[D>@-]6/@3%!>-TW%QPW,>9I,?MZ?75?E/KU.-VYXP/(HWC7?+
M;AO%\"B.TG Q^N*=9HSLZF:,H1]JL];BX#/V[&'6N_KU?%5ZFMRT!6@ ^3I+
MA&LF$:Y[8Z9E9-IR?D^Q#[@SJ^"JL%@?K*@&-;;$A(2:Q+@=15(C0D07Z "[
M*<8_1QGGWQ>"\N_IY:(-FA+<=#@46OCXCZ'^NS@EF5Y*L5P<2)FS@X=4<LX^
MI9WL,X8I"IHVQ6%I?+:Z7<NO ZHGC/#$6TJ83#3U31ZC!D_P5Y"C7;;6G=Q(
M%'72AZIF%*'[.X:&B0%EP/+#,G'%2F2 #]TX";G@873K)@2G3!,NSOP)KN?B
MQ6-U#G0#5PLZ^N&40A=&NME[1 T0(9?;X4,+&R)4\C+\,>3W#7R](S^ ,/IZ
M!O#6RA!VSN@YK6+GWOSPXK$NNH+6@&Y0Z.I;IY![CQ6W=96-?XJ[_MD?TPOH
M+DF7X28$#3Y+$Q1K.(<._4AC2/5E!2IT&0H#68%4,:P;;/^-DC?F/8$>0K$#
M!N@13JB[9%\<I#Z0HLYL")4XF[F3]2=W#LGJ: F[.EJR\5$/,],8S5[Z$_'G
MTYX")ND*2A* "1> X1()P"Q-RB@_S-1+5M&&X_&?&^;H9(Y(2H.0]$R3/YA(
MRP%J:Z0%_-E+Z-K_Q8JR@+<)$MXRENL"E/N:# S<E;KO.VO=2@! =R?S=%O]
MF(+/QIE#BQ^6%7%DNG8=^B%=<-0#@LX_UB>08D+WB9 :E%72(TZM3_N5#/[9
MOW:8[]F4X4.MSQ$G,(-H.[>+&U&3OQ<9?A6=FX &4U 3=22+SN!F:'J(0#+1
M" TGV\05*1Z_ T&*IEZ'LCC$I@AX R+.B^I-%[]D &%\3%T9E*S3.!@US]XV
MAI '!D/5M/I-VP5D]CK@,E53]\ 8W<K0;C;,G'7P^M%;!0-Z,-A[P9ET"B5!
M@KQ OGBQ=Z-/X")'^ <H"1FQF8[F@8Q&*#<==TPTA">@$ 1G$,']^10 '> <
M*1V!%<T-A>>,.KXC: \$37(&!2REAV(;SHEF"3WU!>,3/@G"=E%:.MFB*K:P
M$8+H.:,4YHRBZV'XA, I>W#20&$NAJ#0$(?( ?)EVZU"#CS51;"X %" A@2/
M)1>AEK4P8<')OCG1K4S>PP1&2MWAH_D%B3@%\/'0(U@RW",[ A\7&Y7'>$:R
MEWO"O[[;NN56ZN%6F/[]ZAFV5"/E%R&V6MJ=-^<K3XX/),%"("RE2U9FA11.
M<C/V86)/0T.M/75'VN(?8>O-&N]C(B\#73=.*5P'(H&^@-M0*]C7P4GXT%TR
MT?2V'EROY?C8S:IMRT^P4LV]\MSRC'RBO> 5[1Z_"%JT,M+L$TV&Y(+;M:L0
M5W>\2T>2E_GC:LY5_*ZVL#32"+QA=_=D?6ISA:0VIY':7"&IS=E.;<8Q>8=%
M=L7M),^9Y#EG;0\DSSEBGO-^[OZSF@.<*5<S68#@"ZQT_$2WGY!FZ3;<$RA9
M>#LAFLCNHS>.]P_2LK)B FG99T['J]Q9AL5J\4UB."2&L^\8SAXX[P"<[5W$
M<>97U_@:3Y#4";KU$YQ;..B9J,IH2DD +D$96-E$5FCE5=6,X=0;X($6L"<J
M@\K:41$]Z@$U4-&7[9 ,0*E/@M,CR(H!>9]AAW,*;EA>5!7)FEN++)D!4( F
MH)G/DHIK&#2 2_WAJK&W9Z#?D@A.)D#EM!&R;DDFFMJSRD\PLIQ(H#E!L4 %
MGC"Z@K&:?SGPP-5'^-A?AP"'Z:R.2//;'@%WHY7[4%'@*3809 )*MU!LN%DA
M2@R=.1![@B[KWNMJ((A#^.8)A#3ZO=60(1T(E8[95;=D!$$KQ)($4-HRZBF%
M8>3@!C5)P7%DP7.%9P'&:D\'(:-862X*^HTB?52A@_1F_UMV!XKCN?$B3K6<
M1Z[GCRQ8CX2(,961_ 2@X+$>;P6,@>0D3D Q-I+FB3GS.'??%^.>"%,K,1/7
MY<#UC%$W(_A6A:J6*$F80JIXONKDZ!26/\Y9'[>O*ZTN85Y>D.0^_!M\SM09
M^>@-QA,!N4]XJP4(9WDLZ_X$+D]S& OW+V"D3I!"1A?. @2#,.<"_ZVV][IC
M8*7,X/L2!.J!BNX_YA??*#M-5'%B1<&Z49$U^"J</ 2!8LG+N72V-+KS>,&^
MD?%P#@2=.9F,9"M9:&+VH.$ 641X$>01=CV\R<?N]YR,#/\-COJJS#-^D";0
M)+P+G*"&+(6Q\ CA;O6E1UK%O;V10 _E0WD-$%?YN(M!VD%5K"GI\+MHZ4CH
MOV#F>A4TJ3A2U2=$&N]B[00 B[,M7>;FK]BR [[\T\'Q%'$>/:M-P'5D$_8=
MBUGW&1M8ZT5R&+&.G@ 1.2)>?29(\$R1P,3)/2@#=M[*C?8(&?1UR/GJV"I&
ML!P'2Z]'6H:5!FFO TM2/'_5MR1_GI$E@MP<8-O2164; !D0*+/7O>%>YP,3
MMB-LEQ6V\[ ;SJ"T<M.Q?D89&D[UHHU^@FJ"ZM10W7%A&0G:3E1 =\,"E!,6
ML*Q'?X&<9EHNFHUL71@3>!-X9Q;>"Q)Z+L7M "QJY8"=G1X8"J@*0_.+;)IR
M*X7\CXJT"CNP 2DA&*9N>9#8)7/693EEN'U)))5RO(/;@EKIF%_A8BW<7Q=9
M!B(SV0O.G$<S[G"=Q@C:X07[X 1%&$U1C!679= ;@[26-$:]LQ$"QFCP0Q]^
MR3I_]//EJ-<$M?I&03'XD+'PA,'KAMD*-AI3BN&27.%XP5Q?(%>P7**%T*V.
M'2\+%D5KF@C P7^%1%>(Q4 LAH#*ITBF\*8[ F+G$M2F'9R(A%B4.2X.O==H
M-*6;J$Y9QR:"?56FN18!OA<D""8(3@W!5Q'C#RA7053'.+< YT",@'O1;%NY
MN#@*%VU0/4%YTLR)@1)PM*4(A094;2 HLBY8\QD)S@G.LV1?0*$,L3F9 $'#
MH0>4Q:-8'5&<64QVD3WJ.;N0N 'Y!-^S^-JCN%8*21S,TA9B5NE5295>&E5Z
M55*E1ZKT#E)@P7?E*G1'"@Q)@2$I,,Q*@2&I+R3UA1O13>H+XTIO$F0@]86D
MOC#'=M..*\+F!0DH4N3V7,(AH8F*W"L4\GG59 ,4U7[?*N*9YP+T<6=(W G]
M"007UKBY @R[D"QP7&@&W3:CE\$74_/7S>MI &I(B;QH.\G?:D;I#]S*.)%%
M!R_H.T%!JWFM@_V%H: 7%!65(HQD2&D1Q811+U-<\(.J'N"3<EZ?LP:UB;>+
MYYQV\:<W7Z\]G>*OE#.K RUJ[O[5*BII:O"3KZKVY&GQWH7O/QVIXM.1KVT\
M?_$ K$(3;\_XR ]]F*F#ZJC[]_K']#FA<<@[95BWPLANYQM0:43U'0K \QQ/
M+.;V%\DX; ]2*I)9W7O4H<K\8$_9A]F?V?UKE^_?O]S)\T.19!T>WQ2-75;
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ML[:K,#B:9RO7/54L;G8Y9O,[E\L?Y*L'\[YSCE.5[01EN:_IQ;XY&A6+I_8
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MNA?G5/.JU6B=736NJ4X7_N#FHM7MK-EKH!8J'5?BN$"!U$AXXTU5*TR!H%%
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MQ,0NG"F7JW0]L.L]88W$6(/="6O,;H;<I3R9CKL2EUUD+P WMC/.T@S'T97
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M]\8;>,?15OQ=#&Z4&Z0J4--,44J3+F/#PH;K(O)T]+;Y3WK0,<%/#60&F[T
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MQ(^OCFO)L4A.1J)=IRXG'22F(>1WLH&&43"&@-+ 1(485 :4!(^)IM#/A,%
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M6?LIC$S0'4(O<S"\U=2^;+2U:U77[0=/K5CMP^SG1?.9DT9U8?9$SC;AL[U
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M+3(P,C4P-C,P+GAS9%!+ 0(4 Q0    (  B-<5NU_885Y!L  $Q3 0 5
M          "  :(<  !B;6=L+3(P,C4P-C,P7V-A;"YX;6Q02P$"% ,4
M"  (C7%;V$@(WLP[   >P , %0              @ &Y.   8FUG;"TR,#(U
M,#8S,%]D968N>&UL4$L! A0#%     @ "(UQ6W0FV&]BF   )9P( !4
M         ( !N'0  &)M9VPM,C R-3 V,S!?;&%B+GAM;%!+ 0(4 Q0    (
M  B-<5N6;:L&*&0  !&'!@ 5              "  4T- 0!B;6=L+3(P,C4P
M-C,P7W!R92YX;6Q02P$"% ,4    "  (C7%;(!>U4Q0_  #@U $ "@
M        @ &H<0$ 97@Q,2TR+FAT;5!+ 0(4 Q0    (  B-<5M(6K'AN <
M +LQ   *              "  >2P 0!E>#$R+3$N:'1M4$L! A0#%     @
M"(UQ6Y[S.@3R!P  'C,   H              ( !Q+@! &5X,3(M,BYH=&U0
M2P$"% ,4    "  (C7%;-0F YBT$  "N&0  "@              @ '>P $
M97@Q,RTQ+FAT;5!+ 0(4 Q0    (  B-<5M*'%%K'@0  &\9   *
M      "  3/% 0!E>#$S+3(N:'1M4$L! A0#%     @ "(UQ6U"N>O.+ P
M7#$   D              ( !><D! &5X."TQ+FAT;5!+ 0(4 Q0    (  B-
M<5ML/ YJ8!<  ):D   *              "  2O- 0!E>#DW+3$N:'1M4$L!
M A0#%     @ "(UQ6WKV17MD9@, E9DH  P              ( !L^0! &9O
@<FTR,"UF+FAT;5!+!08     #0 -  P#  !!2P4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>form20-f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BMGL="http://baselmedical.com/20250630"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bmgl-20250630.xsd" xlink:type="simple"/>
    <context id="From2024-07-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_MergerReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_MergerReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_MergerReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_MergerReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_MergerReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:MergerReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-10_custom_OrdinaryShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="From2023-08-102023-08-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <startDate>2023-08-10</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_OrdinaryShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:OrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedicalGroupPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedicalGroupPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SSOCPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SSOCPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SSOSPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOSPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SSOSPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOSPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SingaporeKneeSportsOrthopaedicServicesPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:PharmaAvenuePteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:PharmaAvenuePteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedflowPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BaselMedflowPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BethesdaMedicalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:BethesdaMedicalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:OasisMedicalClinicPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:OasisMedicalClinicPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_OtherPropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_MedicalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">BMGL:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_MedicalServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">BMGL:MedicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AccumulatedDepreciationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_AccumulatedDepreciationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_AccumulatedDepreciationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">BMGL:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_MedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_RenovationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_AirConditionerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:AirConditionerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">BMGL:SoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ThridPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:ThridPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ThridPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:ThridPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CustodianServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:CustodianServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="From2023-06-302023-06-30_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-07-01_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-01_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-01</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipAndSingmedInvestmentPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_DrKevinYipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DrKevinYipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DrKevinYipAndSingmedInvestmentPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-27_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="AsOf2024-07-22_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-22</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-15_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="AsOf2024-08-16_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-16</instant>
        </period>
    </context>
    <context id="AsOf2024-09-20_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-20</instant>
        </period>
    </context>
    <context id="AsOf2024-09-23_custom_RainforestCapitalVCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:RainforestCapitalVCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-23</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_OthersRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">BMGL:OthersRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTenOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTenOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTenTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTenTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTenThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTenThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanTenFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTenFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTenFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TermLoanElevenOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanElevenOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanElevenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TermLoanTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">BMGL:TermLoanTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_ShorttermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-28_custom_InitialPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_OverAllotmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">BMGL:OverAllotmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:RelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-04-302025-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CategoryOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CategoryTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CategoryThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CategoryFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:LifeTimeExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="BMGL:CategoryAxis">BMGL:CategoryOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">BMGL:TwelveExpectedCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrs-full:AllowanceForCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:NotPastDueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:LaterThanTwoMonthsAndNotLaterThanFourMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanFourMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:NotPastDueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">BMGL:LaterThanTwoMonthsAndNotLaterThanFourMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanFourMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CreditRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_TopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_ifrs-full_BottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_CarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ContractualCashFlowsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">BMGL:ContractualCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_CarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:CarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ContractualCashFlowsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">BMGL:ContractualCashFlowsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-07-31_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCNovenaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-31_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCOrchardPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-31_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCFarrerParkPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCNovenaPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCOrchardPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:SSOCFarrerParkPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-31_custom_PharmaAvenuePteLtdMember_ifrs-full_TopOfRangeMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:PharmaAvenuePteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_EyetrustMedicalPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:EyetrustMedicalPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_custom_CharteredImagingPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">BMGL:CharteredImagingPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_NonadjustingEventsAfterReportingPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002004489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">BMGL:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="SGD">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="SGDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:SGD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-07-01to2025-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-07-01to2025-06-30" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-07-01to2025-06-30" id="Fact000005">0002004489</dei:EntityCentralIndexKey>
    <ifrs-full:ImpairmentLoss
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0099"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0137"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0192"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_RelatedPartiesMember"
      id="xdx2ixbrl0219"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_RelatedPartiesMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0267"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0277"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0311"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherReserves
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0316"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0384"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0387"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0391"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0392"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0395"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0398"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0399"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0403"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0406"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0407"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0411"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0414"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0415"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0418"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0422"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0423"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      id="xdx2ixbrl0424"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0427"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0439"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0444"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0449"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0450"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve
      contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0453"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve
      contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0455"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0458"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0459"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0463"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember"
      id="xdx2ixbrl0464"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0490"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:CreditLossExpenseReversal
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0494"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:CreditLossExpenseReversal
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0515"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0520"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0581"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInvestmentProperty
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0586"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:DecreaseInAmountDueFromDirector
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0603"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:DecreaseInAmountDueFromDirector
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:IncreaseInBankOverdraft
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0619"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0624"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0644"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0649"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0669"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromInterest
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0973"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:ServiceIncome
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0978"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:RentalIncome
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0983"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:ReversalOfExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0992"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:ReversalOfExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:BadDebtsWrittenOff
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl1056"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1125"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1128"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1130"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1133"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:UnderprovisionInRespectOfPriorYears
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl1136"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1171"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1174"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:UtilisationOfDeferredTaxAssets
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1186"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:UtilisationOfDeferredTaxAssets
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1189"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:DeferredIncomeTax
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1196"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:DeferredIncomeTax
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:UnderprovisionInRespectOfPriorYears
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl1202"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember"
      id="xdx2ixbrl1226"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember"
      id="xdx2ixbrl1234"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:WrittenOffRightofuseAssets
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember"
      id="xdx2ixbrl1239"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets
      contextRef="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember"
      id="xdx2ixbrl1254"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:WrittenOffRightofuseAssets
      contextRef="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember"
      id="xdx2ixbrl1264"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      id="xdx2ixbrl1293"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1296"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      id="xdx2ixbrl1297"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      id="xdx2ixbrl1298"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      id="xdx2ixbrl1299"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      id="xdx2ixbrl1300"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      id="xdx2ixbrl1302"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      id="xdx2ixbrl1311"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1314"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      id="xdx2ixbrl1318"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1323"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      id="xdx2ixbrl1324"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      id="xdx2ixbrl1327"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      id="xdx2ixbrl1329"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1332"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      id="xdx2ixbrl1336"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      id="xdx2ixbrl1365"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1368"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      id="xdx2ixbrl1372"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      id="xdx2ixbrl1374"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      id="xdx2ixbrl1383"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1386"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      id="xdx2ixbrl1390"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1395"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      id="xdx2ixbrl1399"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      id="xdx2ixbrl1404"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      id="xdx2ixbrl1408"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_MachineryMember"
      id="xdx2ixbrl1422"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_custom_AirConditionerMember"
      id="xdx2ixbrl1426"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_custom_SoftwareMember"
      id="xdx2ixbrl1428"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_MachineryMember"
      id="xdx2ixbrl1431"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_AirConditionerMember"
      id="xdx2ixbrl1435"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_MachineryMember"
      id="xdx2ixbrl1440"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_AirConditionerMember"
      id="xdx2ixbrl1444"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1611"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:BankBorrowings
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1620"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:BankBorrowings
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1623"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1634"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1638"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1641"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanOneMember"
      id="xdx2ixbrl1655"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanOneMember"
      id="xdx2ixbrl1658"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanTwoMember"
      id="xdx2ixbrl1660"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanTwoMember"
      id="xdx2ixbrl1663"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanThreeMember"
      id="xdx2ixbrl1665"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanThreeMember"
      id="xdx2ixbrl1668"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanFourMember"
      id="xdx2ixbrl1670"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanFourMember"
      id="xdx2ixbrl1673"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanSixMember"
      id="xdx2ixbrl1675"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanSixMember"
      id="xdx2ixbrl1678"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanSevenMember"
      id="xdx2ixbrl1680"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanSevenMember"
      id="xdx2ixbrl1683"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanNineMember"
      id="xdx2ixbrl1685"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanNineMember"
      id="xdx2ixbrl1688"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanTenMember"
      id="xdx2ixbrl1690"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanTenMember"
      id="xdx2ixbrl1693"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanElevenMember"
      id="xdx2ixbrl1695"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanElevenMember"
      id="xdx2ixbrl1698"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember"
      id="xdx2ixbrl1700"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanTwelveMember"
      id="xdx2ixbrl1701"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember"
      id="xdx2ixbrl1703"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanMember"
      id="xdx2ixbrl1705"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LoansReceived
      contextRef="AsOf2025-06-30_custom_TermLoanMember"
      id="xdx2ixbrl1708"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1808"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1818"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1820"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1822"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1824"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1826"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:AdditionBankBorrowingsCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1838"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1842"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:BankBorrowings
      contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1844"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1850"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:AdditionBankBorrowingsNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1852"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1854"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1856"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1858"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1878"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1888"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1890"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1892"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1894"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1896"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AdditionBankBorrowingsCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1908"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1912"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:BankBorrowings
      contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1914"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1920"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AdditionBankBorrowingsNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1922"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1924"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1926"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2025-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1928"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1948"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1950"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1954"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1960"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1962"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1964"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1966"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember"
      id="xdx2ixbrl1970"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1976"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AdditionBankBorrowingsCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1978"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1988"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1990"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AdditionBankBorrowingsNonCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1992"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      id="xdx2ixbrl1994"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      id="xdx2ixbrl2004"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities
      contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      id="xdx2ixbrl2006"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      id="xdx2ixbrl2010"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl2087"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl2090"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:InterestIncomeOnLoansAndReceivable
      contextRef="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember"
      id="xdx2ixbrl2108"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:ManagementFee
      contextRef="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember"
      id="xdx2ixbrl2113"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      id="xdx2ixbrl2211"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      id="xdx2ixbrl2223"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      id="xdx2ixbrl2237"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      id="xdx2ixbrl2243"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember"
      id="xdx2ixbrl2256"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember"
      id="xdx2ixbrl2279"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2344"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2349"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2359"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2364"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2394"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2399"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2404"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2409"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2429"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2434"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2439"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2444"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2449"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2454"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      id="xdx2ixbrl2459"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      id="xdx2ixbrl2490"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      id="xdx2ixbrl2503"
      unitRef="SGD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      id="xdx2ixbrl2506"
      unitRef="USD"
      xsi:nil="true"/>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      id="xdx2ixbrl2508"
      unitRef="SGD"
      xsi:nil="true"/>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      id="xdx2ixbrl2511"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-07-01to2025-06-30" id="Fact000014">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="From2024-07-01to2025-06-30" id="Fact000015">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="From2024-07-01to2025-06-30" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-07-01to2025-06-30" id="Fact000017">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-07-01to2025-06-30" id="Fact000018">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-07-01to2025-06-30" id="Fact000019">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-07-01to2025-06-30" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2024-07-01to2025-06-30" id="Fact000021">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="From2024-07-01to2025-06-30" id="Fact000022">001-42527</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-07-01to2025-06-30" id="Fact000023">Basel Medical Group Ltd</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-07-01to2025-06-30" id="Fact000024">D8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2024-07-01to2025-06-30" id="Fact000025">6 Napier Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-07-01to2025-06-30" id="Fact000026">Unit #02-10/11 Gleneagles Medical Centre</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-07-01to2025-06-30" id="Fact000027">Singapore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2024-07-01to2025-06-30" id="Fact000028">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-07-01to2025-06-30" id="Fact000029">258499</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000030">Dr. Darren Yen Feng Chhoa</dei:ContactPersonnelName>
    <dei:ContactPersonnelEmailAddress
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000031">contact@baselmedical.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000032">6 Napier Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000033">Unit #02-10/11 Gleneagles Medical Centre</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000034">Singapore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000035">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="From2024-07-012025-06-30_dei_BusinessContactMember"
      id="Fact000036">258499</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="From2024-07-01to2025-06-30" id="Fact000037">Ordinary     shares with no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-07-01to2025-06-30" id="Fact000038">BMGL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-07-01to2025-06-30" id="Fact000039">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">18785750</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-07-01to2025-06-30" id="Fact000041">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-07-01to2025-06-30" id="Fact000042">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-07-01to2025-06-30" id="Fact000043">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-07-01to2025-06-30" id="Fact000044">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-07-01to2025-06-30" id="Fact000045">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-07-01to2025-06-30" id="Fact000046">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-07-01to2025-06-30" id="Fact000047">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-07-01to2025-06-30" id="Fact000048">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-07-01to2025-06-30" id="Fact000049">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="From2024-07-01to2025-06-30" id="Fact000050">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="From2024-07-01to2025-06-30" id="Fact000051">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-07-01to2025-06-30" id="Fact000052">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000056">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s executive officers oversee the strategic processes to safeguard data and comply with relevant regulations and has overall
responsibility for evaluating cybersecurity risks, as well as related policies and risks in connection with the Company&#x2019;s patient
database, suppliers and other service providers. The Company does not currently engage any assessors, consultants, auditors, or other
third parties in connection with any such processes, given the size and scale of the Company, the resources available to it, the anticipated
expenditures, and the risks it faces in terms of cybersecurity. The Company&#x2019;s executive officers are responsible for overseeing
and periodically reviewing and identifying risks from cybersecurity threats associated with its use of any third-party service provider.&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
the start of its latest completed fiscal year and up to the date of this annual report, the Company is not aware of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially
affect the registrant, including its business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;

&lt;p class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_986_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240701__20250630_zZH5ipsVNQRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s board of directors is collectively responsible for oversight of risks from cybersecurity threats. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zUQhdKM1RVea"&gt;The Company&#x2019;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#x2019;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#x2019;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#x2019;s executive officers will promptly inform, update, and seek the instructions
of the board.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000057">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s board of directors is collectively responsible for oversight of risks from cybersecurity threats. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zUQhdKM1RVea"&gt;The Company&#x2019;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#x2019;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#x2019;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#x2019;s executive officers will promptly inform, update, and seek the instructions
of the board.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000058">The Company&#x2019;s executive officers oversee the overall processes to safeguard data and comply with relevant regulations and will report material cybersecurity
incidents to the board. The Company&#x2019;s executive officers have limited experience in the area of cybersecurity, but where necessary
in the view of the Company&#x2019;s executive officers, the Company will consult with external advisers to manage and remediate any cybersecurity
incidents. For material cybersecurity incidents, the Company&#x2019;s executive officers will promptly inform, update, and seek the instructions
of the board.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <dei:AuditorName contextRef="From2024-07-01to2025-06-30" id="Fact000059">NLA DFK Assurance PAC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-07-01to2025-06-30" id="Fact000060">Singapore</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2024-07-01to2025-06-30" id="Fact000061">6889</dei:AuditorFirmId>
    <ifrs-full:Revenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000066"
      unitRef="USD">8900027</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000063"
      unitRef="SGD">11319944</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000064"
      unitRef="SGD">10050923</ifrs-full:Revenue>
    <ifrs-full:OtherGainsLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">866580</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000068"
      unitRef="SGD">1102203</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000069"
      unitRef="SGD">461029</ifrs-full:OtherGainsLosses>
    <BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">1986201</BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses>
    <BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000073"
      unitRef="SGD">2526250</BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses>
    <BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="SGD">2248136</BMGL:ConsumablesMedicalSuppliesAndOtherRelatedExpenses>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000081"
      unitRef="USD">5030217</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000078"
      unitRef="SGD">6397933</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000079"
      unitRef="SGD">3638942</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DepreciationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">928633</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000083"
      unitRef="SGD">1181128</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000084"
      unitRef="SGD">528727</ifrs-full:DepreciationExpense>
    <ifrs-full:RentalExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000091"
      unitRef="USD">110917</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000088"
      unitRef="SGD">141075</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000089"
      unitRef="SGD">3180</ifrs-full:RentalExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000096"
      unitRef="USD">-2619403</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000093"
      unitRef="SGD">-3331619</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000094"
      unitRef="SGD">-1512168</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:ImpairmentLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000101"
      unitRef="USD">8763025</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="SGD">11145691</ifrs-full:ImpairmentLoss>
    <ifrs-full:FinanceCosts
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">160349</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000103"
      unitRef="SGD">203948</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000104"
      unitRef="SGD">176238</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000111"
      unitRef="USD">-9832138</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000108"
      unitRef="SGD">-12505497</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000109"
      unitRef="SGD">2404561</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000116"
      unitRef="USD">-328165</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000113"
      unitRef="SGD">-417393</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000114"
      unitRef="SGD">331761</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">-9503974</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000118"
      unitRef="SGD">-12088104</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000119"
      unitRef="SGD">2072800</ifrs-full:ProfitLoss>
    <BMGL:ProfitLossAndNetComprehensiveIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000126"
      unitRef="USD">-9503974</BMGL:ProfitLossAndNetComprehensiveIncome>
    <BMGL:ProfitLossAndNetComprehensiveIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000123"
      unitRef="SGD">-12088104</BMGL:ProfitLossAndNetComprehensiveIncome>
    <BMGL:ProfitLossAndNetComprehensiveIncome
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000124"
      unitRef="SGD">2072800</BMGL:ProfitLossAndNetComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000134"
      unitRef="USD">-9503580</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000131"
      unitRef="SGD">-12087603</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000132"
      unitRef="SGD">2072800</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000139"
      unitRef="USD">-394</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000136"
      unitRef="SGD">-501</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <BMGL:ProfitLossIncludingMinorityInterest
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000144"
      unitRef="USD">-9503974</BMGL:ProfitLossIncludingMinorityInterest>
    <BMGL:ProfitLossIncludingMinorityInterest
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000141"
      unitRef="SGD">-12088104</BMGL:ProfitLossIncludingMinorityInterest>
    <BMGL:ProfitLossIncludingMinorityInterest
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000142"
      unitRef="SGD">2072800</BMGL:ProfitLossIncludingMinorityInterest>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000146"
      unitRef="USDPShares">-0.506</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000148"
      unitRef="USDPShares">-0.506</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000150"
      unitRef="SGDPShares">-0.643</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000152"
      unitRef="SGDPShares">-0.643</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000154"
      unitRef="SGDPShares">0.13</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000156"
      unitRef="SGDPShares">0.13</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">18785750</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">18785750</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">18785750</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">18785750</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">16250000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">16250000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">2497462</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000176"
      unitRef="SGD">3176522</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="SGD">23460</ifrs-full:RightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">218183</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000181"
      unitRef="SGD">277507</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000182"
      unitRef="SGD">34513</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DeferredTaxAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">221702</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000186"
      unitRef="SGD">281982</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="SGD">77005</ifrs-full:DeferredTaxAssets>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">39</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000191"
      unitRef="SGD">49</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">2937386</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000196"
      unitRef="SGD">3736060</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000197"
      unitRef="SGD">134978</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">295850</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000204"
      unitRef="SGD">376291</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000205"
      unitRef="SGD">72030</ifrs-full:Inventories>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">7651065</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000209"
      unitRef="SGD">9731390</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000210"
      unitRef="SGD">2005219</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000214"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000215"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2024-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact000220"
      unitRef="SGD">10557240</ifrs-full:OtherCurrentReceivables>
    <BMGL:DeferredOfferingCost
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">25000</BMGL:DeferredOfferingCost>
    <BMGL:DeferredOfferingCost
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000224"
      unitRef="SGD">31798</BMGL:DeferredOfferingCost>
    <BMGL:DeferredOfferingCost
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000225"
      unitRef="SGD">1588024</BMGL:DeferredOfferingCost>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">10314145</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000229"
      unitRef="SGD">13118562</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000230"
      unitRef="SGD">16173566</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000237"
      unitRef="USD">13251531</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000234"
      unitRef="SGD">16854622</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000235"
      unitRef="SGD">16308544</ifrs-full:Assets>
    <ifrs-full:LongtermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">1020801</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000245"
      unitRef="SGD">1298357</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000246"
      unitRef="SGD">1583434</ifrs-full:LongtermBorrowings>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000255"
      unitRef="USD">5435180</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000253"
      unitRef="SGD">6913006</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000254"
      unitRef="SGD">2575949</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:ShorttermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">1667677</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000257"
      unitRef="SGD">2121119</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000258"
      unitRef="SGD">2706356</ifrs-full:ShorttermBorrowings>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000265"
      unitRef="USD">1291453</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000262"
      unitRef="SGD">1642599</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000263"
      unitRef="SGD">1311390</ifrs-full:OtherCurrentFinancialLiabilities>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000268"
      unitRef="SGD">111459</BMGL:AmountDueToFormerDirector>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000275"
      unitRef="USD">11795</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000272"
      unitRef="SGD">15000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000273"
      unitRef="SGD">15000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000278"
      unitRef="SGD">443315</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000285"
      unitRef="USD">9426906</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000282"
      unitRef="SGD">11990081</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000283"
      unitRef="SGD">8746903</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000290"
      unitRef="USD">3824625</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000287"
      unitRef="SGD">4864541</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000288"
      unitRef="SGD">7561641</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000298"
      unitRef="USD">25609109</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000295"
      unitRef="SGD">34208562</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000296"
      unitRef="SGD">24455178</ifrs-full:IssuedCapital>
    <BMGL:MergerReserveArisingFromGroupRestructuring
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000303"
      unitRef="USD">18362500</BMGL:MergerReserveArisingFromGroupRestructuring>
    <BMGL:MergerReserveArisingFromGroupRestructuring
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000300"
      unitRef="SGD">24455170</BMGL:MergerReserveArisingFromGroupRestructuring>
    <BMGL:MergerReserveArisingFromGroupRestructuring
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000301"
      unitRef="SGD">24455170</BMGL:MergerReserveArisingFromGroupRestructuring>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-3836948</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000305"
      unitRef="SGD">-4396611</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000306"
      unitRef="SGD">7561633</ifrs-full:RetainedEarnings>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000313"
      unitRef="USD">2751</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000310"
      unitRef="SGD">3499</ifrs-full:NoncontrollingInterests>
    <ifrs-full:OtherReserves
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000318"
      unitRef="USD">412213</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000315"
      unitRef="SGD">-495739</ifrs-full:OtherReserves>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000323"
      unitRef="USD">3824625</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000320"
      unitRef="SGD">4864541</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000321"
      unitRef="SGD">7561641</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">18362506</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">-18362500</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">-8686</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">5588403</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">5579723</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000332"
      unitRef="USD">5579723</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">7246603</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">7246603</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000340"
      unitRef="USD">7246603</ifrs-full:IssueOfEquity>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">420899</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">420899</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000348"
      unitRef="USD">420899</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">78623</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">78623</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000356"
      unitRef="USD">78623</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">2751</BMGL:MinorityInterestInSubsidiary>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000364"
      unitRef="USD">2751</BMGL:MinorityInterestInSubsidiary>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-9503974</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">-9503974</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-9503974</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">25609109</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-18362500</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">412213</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-3836948</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">3821874</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="0"
      id="Fact000379"
      unitRef="USD">2751</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000380"
      unitRef="USD">3824625</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000382"
      unitRef="SGD">24455178</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000383"
      unitRef="SGD">-24455170</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000385"
      unitRef="SGD">7561633</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000386"
      unitRef="SGD">7561641</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000388"
      unitRef="SGD">7561641</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000390"
      unitRef="SGD">9753384</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000394"
      unitRef="SGD">9753384</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000396"
      unitRef="SGD">9753384</ifrs-full:IssueOfEquity>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      decimals="0"
      id="Fact000400"
      unitRef="SGD">-495739</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000401"
      unitRef="SGD">29860</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000402"
      unitRef="SGD">-465879</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000404"
      unitRef="SGD">-465879</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000409"
      unitRef="SGD">100000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000410"
      unitRef="SGD">100000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000412"
      unitRef="SGD">100000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="0"
      id="Fact000419"
      unitRef="SGD">3499</BMGL:MinorityInterestInSubsidiary>
    <BMGL:MinorityInterestInSubsidiary
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000420"
      unitRef="SGD">3499</BMGL:MinorityInterestInSubsidiary>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000425"
      unitRef="SGD">-12088104</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-012025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000426"
      unitRef="SGD">-12088104</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:OtherComprehensiveIncomeBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000428"
      unitRef="SGD">-12088104</ifrs-full:OtherComprehensiveIncomeBeforeTax>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000430"
      unitRef="SGD">34208562</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000431"
      unitRef="SGD">-24455170</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"
      decimals="0"
      id="Fact000432"
      unitRef="SGD">-495739</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000433"
      unitRef="SGD">-4396611</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="0"
      id="Fact000434"
      unitRef="SGD">4861042</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="0"
      id="Fact000435"
      unitRef="SGD">3499</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000436"
      unitRef="SGD">4864541</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000438"
      unitRef="SGD">8</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000440"
      unitRef="SGD">5488833</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000441"
      unitRef="SGD">5488841</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000443"
      unitRef="SGD">8</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000445"
      unitRef="SGD">5488833</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000446"
      unitRef="SGD">5488841</ifrs-full:Equity>
    <ifrs-full:IssueOfEquity
      contextRef="From2023-07-012024-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000448"
      unitRef="SGD">24455170</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000451"
      unitRef="SGD">24455170</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve
      contextRef="From2023-07-012024-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000454"
      unitRef="SGD">-24455170</ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve>
    <ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000456"
      unitRef="SGD">-24455170</ifrs-full:IncreaseDecreaseThroughTransferToStatutoryReserve>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000460"
      unitRef="SGD">2072800</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000461"
      unitRef="SGD">2072800</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000465"
      unitRef="SGD">2072800</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000466"
      unitRef="SGD">2072800</ifrs-full:ProfitLoss>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000468"
      unitRef="SGD">24455178</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000469"
      unitRef="SGD">-24455170</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000470"
      unitRef="SGD">7561633</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000471"
      unitRef="SGD">7561641</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_IssuedCapitalMember"
      decimals="0"
      id="Fact000473"
      unitRef="SGD">24455178</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_MergerReserveMember"
      decimals="0"
      id="Fact000474"
      unitRef="SGD">-24455170</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30_ifrs-full_RetainedEarningsMember"
      decimals="0"
      id="Fact000475"
      unitRef="SGD">7561633</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000476"
      unitRef="SGD">7561641</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000484"
      unitRef="USD">-9832138</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000481"
      unitRef="SGD">-12505497</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000482"
      unitRef="SGD">2404561</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000492"
      unitRef="USD">189013</ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff>
    <ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000489"
      unitRef="SGD">240405</ifrs-full:RecoveriesOnLoansPreviouslyWrittenOff>
    <BMGL:CreditLossExpenseReversal
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000495"
      unitRef="SGD">55741</BMGL:CreditLossExpenseReversal>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000502"
      unitRef="USD">-536404</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000499"
      unitRef="SGD">-682252</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000500"
      unitRef="SGD">50168</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000507"
      unitRef="USD">84644</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000504"
      unitRef="SGD">107659</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000505"
      unitRef="SGD">30093</ifrs-full:AdjustmentsForDepreciationExpense>
    <BMGL:AdjustmentsForAmortizationOfRightOfUseAsset
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">843989</BMGL:AdjustmentsForAmortizationOfRightOfUseAsset>
    <BMGL:AdjustmentsForAmortizationOfRightOfUseAsset
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000509"
      unitRef="SGD">1073469</BMGL:AdjustmentsForAmortizationOfRightOfUseAsset>
    <BMGL:AdjustmentsForAmortizationOfRightOfUseAsset
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000510"
      unitRef="SGD">498635</BMGL:AdjustmentsForAmortizationOfRightOfUseAsset>
    <BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000517"
      unitRef="USD">138549</BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets>
    <BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000514"
      unitRef="SGD">176220</BMGL:RecoveriesOnLoansPreviouslyWrittenOffFixedAssets>
    <ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000522"
      unitRef="USD">8763025</ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000519"
      unitRef="SGD">11145691</ifrs-full:AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000527"
      unitRef="USD">160349</ifrs-full:AdjustmentsForInterestExpense>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000524"
      unitRef="SGD">203948</ifrs-full:AdjustmentsForInterestExpense>
    <ifrs-full:AdjustmentsForInterestExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000525"
      unitRef="SGD">176238</ifrs-full:AdjustmentsForInterestExpense>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000532"
      unitRef="USD">-188973</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000529"
      unitRef="SGD">-240357</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000530"
      unitRef="SGD">3103954</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000540"
      unitRef="USD">-239218</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000537"
      unitRef="SGD">-304261</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000538"
      unitRef="SGD">22571</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000545"
      unitRef="USD">-5727120</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000542"
      unitRef="SGD">-7284324</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000543"
      unitRef="SGD">-415080</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000550"
      unitRef="USD">-3409904</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000547"
      unitRef="SGD">-4337057</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000548"
      unitRef="SGD">-387690</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000555"
      unitRef="USD">-2745407</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000552"
      unitRef="SGD">-3491885</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000553"
      unitRef="SGD">3099135</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000560"
      unitRef="USD">509704</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000557"
      unitRef="SGD">648292</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000558"
      unitRef="SGD">176238</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000565"
      unitRef="USD">160349</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000562"
      unitRef="SGD">203948</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000563"
      unitRef="SGD">413612</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000570"
      unitRef="USD">-3415460</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000567"
      unitRef="SGD">-4344125</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000568"
      unitRef="SGD">2509285</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000578"
      unitRef="USD">43054</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000575"
      unitRef="SGD">54760</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000576"
      unitRef="SGD">7920</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">8637578</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000580"
      unitRef="SGD">10986135</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentProperty
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000588"
      unitRef="USD">39</ifrs-full:PurchaseOfInvestmentProperty>
    <ifrs-full:PurchaseOfInvestmentProperty
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000585"
      unitRef="SGD">49</ifrs-full:PurchaseOfInvestmentProperty>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000593"
      unitRef="USD">-8680671</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000590"
      unitRef="SGD">-11040944</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000591"
      unitRef="SGD">-7920</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <BMGL:ProceedsFromDeferredOfferingCosts
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">-1223544</BMGL:ProceedsFromDeferredOfferingCosts>
    <BMGL:ProceedsFromDeferredOfferingCosts
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000598"
      unitRef="SGD">-1556226</BMGL:ProceedsFromDeferredOfferingCosts>
    <BMGL:ProceedsFromDeferredOfferingCosts
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000599"
      unitRef="SGD">1588024</BMGL:ProceedsFromDeferredOfferingCosts>
    <BMGL:DecreaseInAmountDueFromDirector
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000604"
      unitRef="SGD">-1320457</BMGL:DecreaseInAmountDueFromDirector>
    <BMGL:IncreaseInAmountDueToRelatedParties
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000611"
      unitRef="USD">-260405</BMGL:IncreaseInAmountDueToRelatedParties>
    <BMGL:IncreaseInAmountDueToRelatedParties
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000608"
      unitRef="SGD">-331209</BMGL:IncreaseInAmountDueToRelatedParties>
    <BMGL:IncreaseInAmountDueToRelatedParties
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000609"
      unitRef="SGD">-1311390</BMGL:IncreaseInAmountDueToRelatedParties>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000616"
      unitRef="USD">8300370</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000613"
      unitRef="SGD">10557240</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000614"
      unitRef="SGD">-73</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <BMGL:IncreaseInBankOverdraft
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000621"
      unitRef="USD">-48251</BMGL:IncreaseInBankOverdraft>
    <BMGL:IncreaseInBankOverdraft
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000618"
      unitRef="SGD">-61371</BMGL:IncreaseInBankOverdraft>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000626"
      unitRef="USD">3144901</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000623"
      unitRef="SGD">4000000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">771556</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000628"
      unitRef="SGD">981342</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000629"
      unitRef="SGD">566039</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000636"
      unitRef="USD">6495235</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000633"
      unitRef="SGD">8261290</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000634"
      unitRef="SGD">2356930</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <BMGL:DecreaseincreaseInAmountDueToFormerDirector
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000641"
      unitRef="USD">87632</BMGL:DecreaseincreaseInAmountDueToFormerDirector>
    <BMGL:DecreaseincreaseInAmountDueToFormerDirector
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000638"
      unitRef="SGD">111459</BMGL:DecreaseincreaseInAmountDueToFormerDirector>
    <BMGL:DecreaseincreaseInAmountDueToFormerDirector
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000639"
      unitRef="SGD">-111459</BMGL:DecreaseincreaseInAmountDueToFormerDirector>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000646"
      unitRef="USD">2751</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000643"
      unitRef="SGD">3499</ifrs-full:ProceedsFromContributionsOfNoncontrollingInterests>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000651"
      unitRef="USD">7668358</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000648"
      unitRef="SGD">9753384</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000656"
      unitRef="USD">13294157</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000653"
      unitRef="SGD">16908838</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000654"
      unitRef="SGD">-1767760</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000661"
      unitRef="USD">1198026</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000658"
      unitRef="SGD">1523769</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000659"
      unitRef="SGD">733605</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000666"
      unitRef="USD">1533967</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000663"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000664"
      unitRef="SGD">1217448</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000671"
      unitRef="USD">-389763</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000668"
      unitRef="SGD">-495739</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000676"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000673"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000674"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000678">&lt;p id="xdx_80F_eifrs-full--DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_zC65qhZxHiP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
                                                                                                                                                             &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zBL1s5KWVyBe"&gt;General&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basel
Medical Group Ltd. is incorporated and domiciled in British Virgin Islands (BVI) with operations conducted by its fully owned subsidiary,
Basel Medical Group Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.), based in Singapore at 6 Napier Road #03-07 Gleneagles Medical Centre,
Singapore 258499.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal activities of the Company pertain to investment holding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reorganization&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, as part of an internal reorganization, all of the shares in our operating subsidiaries were transferred by our founder,
Dr. Kevin Yip, to Basel Medical Group Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.) Subsequently, in June 2023, Dr. Kevin Yip entered
into an agreement with Rainforest Capital VCC to transfer all the shares he held in Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists
Pte. Ltd.) to Rainforest Capital VCC. Upon completion, Rainforest Capital VCC became the sole shareholder of Basel Medical Group Pte.
Ltd. (F.K.A Singmed Specialists Pte. Ltd.), which holds the shares of all of our subsidiaries. Rainforest Capital VCC is a variable capital
company incorporated in Singapore and is an investment fund managed by AIP Investment Partners Pte. Ltd., a licensed fund manager in
Singapore.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 10, 2023, Basel Medical Group Ltd. was incorporated under the laws of the BVI as our holding Company to facilitate this offering
and the listing of Basel Medical Group Ltd.&#x2019;s ordinary shares on Nasdaq, and in connection therewith, Rainforest VCC (an umbrella
fund with multiple sub-funds), through its sub-fund, Basel Medical Fund, subscribed for &lt;span id="xdx_907_ecustom--NumberOfSharesSubscribed_iI_pid_c20230810__ifrs-full--ComponentsOfEquityAxis__custom--OrdinaryShareMember_zx4tpetcKF56" title="Number of shares subscribe"&gt;16,250,000&lt;/span&gt; ordinary shares in Basel Medical Group
Ltd. amounting to US$&lt;span id="xdx_909_eifrs-full--ProceedsFromIssueOfOrdinaryShares_uUSD_c20230810__20230810_ziTgAO9h8r4e"&gt;18,362,500&lt;/span&gt; at a subscription price of US$&lt;span id="xdx_90D_eifrs-full--ParValuePerShare_iI_pid_uUSDPShares_c20230810_zxKdq2jIRBce" title="Par value per share"&gt;1.13&lt;/span&gt; per share. In August 2023, all of the shares in Basel Medical Group
Pte. Ltd. (F.K.A Singmed Specialists Pte. Ltd.) were transferred to Basel Medical Group Ltd. by Rainforest Capital VCC to prepare for
this listing and offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequently,
between September 2023 and January and April 2024, Rainforest Capital VCC sold certain of the shares it held in Basel Medical Group Ltd.
to certain other investors, following which Rainforest Capital VCC held a total of &lt;span id="xdx_90B_eifrs-full--SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_iI_pid_c20240430__ifrs-full--ComponentsOfEquityAxis__custom--OrdinaryShareMember_zPrG1W62lwVa" title="Number of shares held"&gt;12,387,982 &lt;/span&gt;ordinary shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group were prepared on the basis as if the reorganisation became effective as of the beginning
of the first period presented in the accompanying consolidated financial statements of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;General
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eifrs-full--DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_zvthun1QaGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has following subsidiaries as at June 30, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zeoAc06NJlze"&gt;Schedule
of activities of subsidiaries&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Name of entity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Country
    of business and incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Proportion
                                            of ordinary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                                          &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;shares
                                            held by Group&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 23%; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zc1BBMfhEro4" title="Name of entity"&gt;&lt;span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zNJgHh6AI4Dj" title="Name of entity"&gt;Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; font-weight: bold; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; font-style: normal; width: 25%; font-weight: normal; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zdBvBauCsVGg" title="Principal activities"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zzFOcucgLfc3" title="Principal activities"&gt;Other holding companies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 18%; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zEwlzLQSSzs5" title="Country of business / incorporation"&gt;&lt;span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_ztcvILYAElq" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zltgYElMqL7" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_z9bcMuVZrWab" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zOzOyDX03s03" title="Name of entity"&gt;&lt;span id="xdx_90F_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zK1XjIDwwyg6" title="Name of entity"&gt;Singapore Sports &amp;amp; Orthopaedic Clinic Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zggHx0CDuUkj" title="Principal activities"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zf7sDb0M7y2j" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_901_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zXLhuQWSQMki" title="Country of business / incorporation"&gt;&lt;span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zWuypqel38i" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zuhnLnmr1jQ" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zGrdAldIgz43" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90A_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z0XyM9JssMuf" title="Name of entity"&gt;&lt;span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z03jl5uXkGne" title="Name of entity"&gt;Singapore Sports &amp;amp; Orthopaedic Services Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zs0LvmA9JQuk" title="Principal activities"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z6oqqv8mCxGg" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zY243244fo5i" title="Country of business / incorporation"&gt;&lt;span id="xdx_90B_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zhinC50O2bg8" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zS5Ad7cehbb5" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zcwTCZrdaH6f" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zOsl4sc4J3u5" title="Name of entity"&gt;&lt;span id="xdx_905_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_z6ILKpDLuAvf" title="Name of entity"&gt;SSOC Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zxeaQs8hI2C9" title="Principal activities"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zGpTnKyKVqF2" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zZVrAbsvd5Vb" title="Country of business / incorporation"&gt;&lt;span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zor5f0wkcJki" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zXrspKKGida9" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zWTVjlOy8Km5" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_z12DAYMgkW5g" title="Name of entity"&gt;&lt;span id="xdx_906_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zZDzQUcveG27" title="Name of entity"&gt;SSOS Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_ztKtziVMD4X" title="Principal activities"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zrIrvPAJmCp8" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90A_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zfmMhjqYiDv1" title="Country of business / incorporation"&gt;&lt;span id="xdx_907_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zQcoWaVaenjg" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zpJ3A4fs3j6g" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zkPulwrJ1kPc" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;General
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Name of entity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Country
                                            of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;business and&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;incorporation&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Proportion
                                            of ordinary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;shares
                                            held by Group&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_za0JX4vZW2ea" title="Name of entity"&gt;&lt;span id="xdx_901_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7j4ELHbTVzg" title="Name of entity"&gt;Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMLArotMAfg6" title="Principal activities"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zhGGsa64pb62" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7t1hwkMhr7a" title="Country of business / incorporation"&gt;&lt;span id="xdx_909_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMUlWcLUNGaj" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zuozTzY5mMS4" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zBTjjjM4v6Aa" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_902_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zhL15wGo2FK5" title="Name of entity"&gt;&lt;span id="xdx_909_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zF22JgZ1SDig" title="Name of entity"&gt;Singapore Knee, Sports &amp;amp; Orthopaedic Services Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_900_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zqP7sDJR4V23" title="Principal activities"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zIbsDlM7ngif" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90C_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zUbL5K9sCini" title="Country of business / incorporation"&gt;&lt;span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zxV2i7KQWzyl" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zY3JPgMM8cj7" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_z0hM1ejPszJ9" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zpFdI0TUDcx3" title="Name of entity"&gt;&lt;span id="xdx_900_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_z4R9kaqAzQwi" title="Name of entity"&gt;Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zTxs2Y2CvlX5" title="Principal activities"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zVhIy287sDRb" title="Principal activities"&gt;Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zcIKhSJZ04Y7" title="Country of business / incorporation"&gt;&lt;span id="xdx_906_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zxkKKhZPFVI8" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zz6nw51dbST4" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zQvojkoCY0kb" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZH2ea4faCDi" title="Name of entity"&gt;&lt;span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zkI0fpZqUhr6" title="Name of entity"&gt;Basel Medflow Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZLgUn3Eh5lh" title="Principal activities"&gt;&lt;span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_ziJb3AB8jt3g" title="Principal activities"&gt;Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zCaVcEFMbzDi" title="Country of business / incorporation"&gt;&lt;span id="xdx_90E_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zOaG7nCiOa9h" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zeT4trlE7MCh" title="Ownership percentage"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;-&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_z5XZTPxD0Xd5" title="Name of entity"&gt;&lt;span id="xdx_90E_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zl8nZWrIS3z4" title="Name of entity"&gt;Bethesda Medical Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zdp2H7AmJKxa" title="Principal activities"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zcEJL1B7wt2l" title="Principal activities"&gt;Clinics and other general medical services (western)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zm4ljxZvbRT6" title="Country of business / incorporation"&gt;&lt;span id="xdx_90F_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zHgkJJy0PPIl" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zD7rakTxlHp4" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;-&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zPZ6CfUJUr97" title="Name of entity"&gt;&lt;span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zhz8vKyYBJ2c" title="Name of entity"&gt;Oasis Medical Clinic Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWJ33wEaTrg9" title="Principal activities"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zvRxu6diZxql" title="Principal activities"&gt;Clinics and other general medical services (western)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_za40r1XsueIb" title="Country of business / incorporation"&gt;&lt;span id="xdx_900_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zOC0OWSKwuIf" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWHW0BmX0go8" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;-&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_z5ckeivur6rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;General
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 14, 2024, Singmed Specialists Pte. Ltd. changed its corporate name to Basel Medical Group Pte. Ltd.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 23, 2025, Singapore Sports and Physiotherapy Centre Pte. Ltd. changed its corporate name to Pharma Avenue Pte. Ltd.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <BMGL:NumberOfSharesSubscribed
      contextRef="AsOf2023-08-10_custom_OrdinaryShareMember"
      decimals="INF"
      id="Fact000680"
      unitRef="Shares">16250000</BMGL:NumberOfSharesSubscribed>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="From2023-08-102023-08-10"
      decimals="0"
      id="Fact000681"
      unitRef="USD">18362500</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2023-08-10"
      decimals="INF"
      id="Fact000683"
      unitRef="USDPShares">1.13</ifrs-full:ParValuePerShare>
    <ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates
      contextRef="AsOf2024-04-30_custom_OrdinaryShareMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">12387982</ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000687">&lt;p id="xdx_895_eifrs-full--DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_zvthun1QaGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has following subsidiaries as at June 30, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zeoAc06NJlze"&gt;Schedule
of activities of subsidiaries&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Name of entity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Country
    of business and incorporation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Proportion
                                            of ordinary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                                          &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;shares
                                            held by Group&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 23%; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zc1BBMfhEro4" title="Name of entity"&gt;&lt;span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zNJgHh6AI4Dj" title="Name of entity"&gt;Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; font-weight: bold; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; font-style: normal; width: 25%; font-weight: normal; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zdBvBauCsVGg" title="Principal activities"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zzFOcucgLfc3" title="Principal activities"&gt;Other holding companies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 18%; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zEwlzLQSSzs5" title="Country of business / incorporation"&gt;&lt;span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_ztcvILYAElq" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zltgYElMqL7" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_z9bcMuVZrWab" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: normal; font-weight: normal; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zOzOyDX03s03" title="Name of entity"&gt;&lt;span id="xdx_90F_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zK1XjIDwwyg6" title="Name of entity"&gt;Singapore Sports &amp;amp; Orthopaedic Clinic Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zggHx0CDuUkj" title="Principal activities"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zf7sDb0M7y2j" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_901_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zXLhuQWSQMki" title="Country of business / incorporation"&gt;&lt;span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zWuypqel38i" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zuhnLnmr1jQ" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicClinicPteLtdMember_zGrdAldIgz43" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90A_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z0XyM9JssMuf" title="Name of entity"&gt;&lt;span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z03jl5uXkGne" title="Name of entity"&gt;Singapore Sports &amp;amp; Orthopaedic Services Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zs0LvmA9JQuk" title="Principal activities"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_z6oqqv8mCxGg" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zY243244fo5i" title="Country of business / incorporation"&gt;&lt;span id="xdx_90B_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zhinC50O2bg8" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zS5Ad7cehbb5" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeSportsOrthopaedicServicesPteLtdMember_zcwTCZrdaH6f" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zOsl4sc4J3u5" title="Name of entity"&gt;&lt;span id="xdx_905_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_z6ILKpDLuAvf" title="Name of entity"&gt;SSOC Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zxeaQs8hI2C9" title="Principal activities"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zGpTnKyKVqF2" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zZVrAbsvd5Vb" title="Country of business / incorporation"&gt;&lt;span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedicalGroupPteLtdMember_zor5f0wkcJki" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zXrspKKGida9" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOCPteLtdMember_zWTVjlOy8Km5" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_z12DAYMgkW5g" title="Name of entity"&gt;&lt;span id="xdx_906_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zZDzQUcveG27" title="Name of entity"&gt;SSOS Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_ztKtziVMD4X" title="Principal activities"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zrIrvPAJmCp8" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90A_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zfmMhjqYiDv1" title="Country of business / incorporation"&gt;&lt;span id="xdx_907_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zQcoWaVaenjg" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zpJ3A4fs3j6g" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SSOSPteLtdMember_zkPulwrJ1kPc" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -7.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;General
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Name of entity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Country
                                            of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;business and&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;incorporation&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Proportion
                                            of ordinary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;shares
                                            held by Group&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_za0JX4vZW2ea" title="Name of entity"&gt;&lt;span id="xdx_901_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7j4ELHbTVzg" title="Name of entity"&gt;Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMLArotMAfg6" title="Principal activities"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zhGGsa64pb62" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90D_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_z7t1hwkMhr7a" title="Country of business / incorporation"&gt;&lt;span id="xdx_909_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zMUlWcLUNGaj" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zuozTzY5mMS4" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember_zBTjjjM4v6Aa" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_902_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zhL15wGo2FK5" title="Name of entity"&gt;&lt;span id="xdx_909_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zF22JgZ1SDig" title="Name of entity"&gt;Singapore Knee, Sports &amp;amp; Orthopaedic Services Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_900_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zqP7sDJR4V23" title="Principal activities"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zIbsDlM7ngif" title="Principal activities"&gt;Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90C_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zUbL5K9sCini" title="Country of business / incorporation"&gt;&lt;span id="xdx_902_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zxV2i7KQWzyl" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_zY3JPgMM8cj7" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--SingaporeKneeSportsOrthopaedicServicesPteLtdMember_z0hM1ejPszJ9" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zpFdI0TUDcx3" title="Name of entity"&gt;&lt;span id="xdx_900_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_z4R9kaqAzQwi" title="Name of entity"&gt;Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zTxs2Y2CvlX5" title="Principal activities"&gt;&lt;span id="xdx_904_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zVhIy287sDRb" title="Principal activities"&gt;Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zcIKhSJZ04Y7" title="Country of business / incorporation"&gt;&lt;span id="xdx_906_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zxkKKhZPFVI8" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zz6nw51dbST4" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember_zQvojkoCY0kb" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZH2ea4faCDi" title="Name of entity"&gt;&lt;span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zkI0fpZqUhr6" title="Name of entity"&gt;Basel Medflow Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90A_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zZLgUn3Eh5lh" title="Principal activities"&gt;&lt;span id="xdx_90E_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_ziJb3AB8jt3g" title="Principal activities"&gt;Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zCaVcEFMbzDi" title="Country of business / incorporation"&gt;&lt;span id="xdx_90E_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zOaG7nCiOa9h" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BaselMedflowPteLtdMember_zeT4trlE7MCh" title="Ownership percentage"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;-&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90B_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_z5XZTPxD0Xd5" title="Name of entity"&gt;&lt;span id="xdx_90E_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zl8nZWrIS3z4" title="Name of entity"&gt;Bethesda Medical Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zdp2H7AmJKxa" title="Principal activities"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zcEJL1B7wt2l" title="Principal activities"&gt;Clinics and other general medical services (western)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zm4ljxZvbRT6" title="Country of business / incorporation"&gt;&lt;span id="xdx_90F_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zHgkJJy0PPIl" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--BethesdaMedicalPteLtdMember_zD7rakTxlHp4" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;-&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_900_eifrs-full--NameOfSubsidiary_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zPZ6CfUJUr97" title="Name of entity"&gt;&lt;span id="xdx_90D_eifrs-full--NameOfSubsidiary_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zhz8vKyYBJ2c" title="Name of entity"&gt;Oasis Medical Clinic Pte. Ltd.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWJ33wEaTrg9" title="Principal activities"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zvRxu6diZxql" title="Principal activities"&gt;Clinics and other general medical services (western)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--CountryOfIncorporation_c20230701__20240630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_za40r1XsueIb" title="Country of business / incorporation"&gt;&lt;span id="xdx_900_eifrs-full--CountryOfIncorporation_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zOC0OWSKwuIf" title="Country of business / incorporation"&gt;Singapore&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90E_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_dp_c20240701__20250630__ifrs-full--CounterpartiesAxis__custom--OasisMedicalClinicPteLtdMember_zWHW0BmX0go8" title="Ownership percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;-&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000689">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000691">Basel Medical Group Pte. Ltd. (F.K.A. Singmed Specialists Pte. Ltd.)</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000693">Other holding companies</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000695">Other holding companies</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000697">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000699">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember"
      decimals="INF"
      id="Fact000701"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_BaselMedicalGroupPteLtdMember"
      decimals="INF"
      id="Fact000703"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      id="Fact000705">Singapore Sports &amp; Orthopaedic Clinic Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      id="Fact000707">Singapore Sports &amp; Orthopaedic Clinic Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      id="Fact000709">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      id="Fact000711">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      id="Fact000713">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      id="Fact000715">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicClinicPteLtdMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000721">Singapore Sports &amp; Orthopaedic Services Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000723">Singapore Sports &amp; Orthopaedic Services Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000725">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000727">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000729">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000731">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeSportsOrthopaedicServicesPteLtdMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember"
      id="Fact000737">SSOC Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SSOCPteLtdMember"
      id="Fact000739">SSOC Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_SSOCPteLtdMember"
      id="Fact000741">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember"
      id="Fact000743">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember"
      id="Fact000745">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_BaselMedicalGroupPteLtdMember"
      id="Fact000747">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SSOCPteLtdMember"
      decimals="INF"
      id="Fact000749"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SSOCPteLtdMember"
      decimals="INF"
      id="Fact000751"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember"
      id="Fact000753">SSOS Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember"
      id="Fact000755">SSOS Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember"
      id="Fact000757">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember"
      id="Fact000759">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember"
      id="Fact000761">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember"
      id="Fact000763">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SSOSPteLtdMember"
      decimals="INF"
      id="Fact000765"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SSOSPteLtdMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      id="Fact000769">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      id="Fact000771">Singapore Knee, Sports and Orthopaedic Clinic Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      id="Fact000773">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      id="Fact000775">Clinics and other general medical services (western) and specialized
    medical services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      id="Fact000777">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      id="Fact000779">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsAndOrthopaedicClinicPteLtdMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000785">Singapore Knee, Sports &amp; Orthopaedic Services Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000787">Singapore Knee, Sports &amp; Orthopaedic Services Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000789">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000791">Clinics and other general medical services (western) and specialized medical
    services (including day surgical centres)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000793">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      id="Fact000795">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_SingaporeKneeSportsOrthopaedicServicesPteLtdMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember"
      id="Fact000801">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember"
      id="Fact000803">Pharma Avenue Pte. Ltd. (F.K.A. Singapore Sports and Physiotherapy Centre Pte.
    Ltd.)</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember"
      id="Fact000805">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember"
      id="Fact000807">Other health services N.E.C (E.g. Physiotherapy, chiropratic, speech therapy)
    and physiotherapy</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember"
      id="Fact000809">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember"
      id="Fact000811">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_PharmaAvenuePteLtdMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2023-07-012024-06-30_custom_PharmaAvenuePteLtdMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember"
      id="Fact000817">Basel Medflow Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember"
      id="Fact000819">Basel Medflow Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember"
      id="Fact000821">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember"
      id="Fact000823">Other information technology and computer service activities, retail sale of
    sports apparel and equipment (including bicycles, boats and healthcare equipment)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_BaselMedflowPteLtdMember"
      id="Fact000825">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember"
      id="Fact000827">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_BaselMedflowPteLtdMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Pure">0.60</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember"
      id="Fact000831">Bethesda Medical Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember"
      id="Fact000833">Bethesda Medical Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember"
      id="Fact000835">Clinics and other general medical services (western)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember"
      id="Fact000837">Clinics and other general medical services (western)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_BethesdaMedicalPteLtdMember"
      id="Fact000839">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember"
      id="Fact000841">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_BethesdaMedicalPteLtdMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember"
      id="Fact000845">Oasis Medical Clinic Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:NameOfSubsidiary
      contextRef="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember"
      id="Fact000847">Oasis Medical Clinic Pte. Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember"
      id="Fact000849">Clinics and other general medical services (western)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
      contextRef="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember"
      id="Fact000851">Clinics and other general medical services (western)</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2023-07-012024-06-30_custom_OasisMedicalClinicPteLtdMember"
      id="Fact000853">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:CountryOfIncorporation
      contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember"
      id="Fact000855">Singapore</ifrs-full:CountryOfIncorporation>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-07-012025-06-30_custom_OasisMedicalClinicPteLtdMember"
      decimals="INF"
      id="Fact000857"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000859">&lt;p id="xdx_805_eifrs-full--DisclosureOfChangesInAccountingPoliciesExplanatory_zzuAznr5QwX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;b&gt;&lt;span id="xdx_828_znF30Q7r0Gva"&gt;Material accounting policy information&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_zI4sF8qCbosk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;b&gt;2.1&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z0I5Q3qpuyua"&gt;Compliance
                                            with International Financial Reporting Standards (&#x201c;IFRS&#x201d;)&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;)
and interpretations issued by the IFRS Interpretations Committee (&#x201c;IFRS IC&#x201d;) applicable to companies reporting under IFRS.
The financial statements comply with IFRS as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group have been prepared on a going concern basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
ability of the Group to continue as going concern is dependent on: (Please refer to Note 26)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;the
                                            ability of its major shareholder to provide financial support&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;the
                                            ability of the Group to generate sufficient and sustainable operating profits and cash flows
                                            over the next 12 months from the date of these financial statements to meet its operating
                                            and financial obligations as and when they fall due; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;the
                                            ability of the Group to procure additional financing and to garner the continuous support
                                            of its existing financiers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_z8tyN44gZzUj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zaapWlfTeQZ6"&gt;New
                                            and amended standards adopted by the Group&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has applied the following amendments for the first time for their annual reporting period commencing July 1, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification
                                            of Liabilities as Current or Non-current and Non-current liabilities with covenants &#x2013;
                                            Amendments to IAS 1;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
                                            Liability in Sale and Leaseback &#x2013; Amendments to IFRS 16; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplier
                                            Finance Arrangements &#x2013; Amendments to IAS 7 and IFRS 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_zOSlo6Ziw3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
                                                                    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zw46494mBlR4"&gt;New
                                            standards and interpretations not yet adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Certain
new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for June
30, 2025 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected
to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Material accounting policy information (Continued)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_z0MFTpCADvNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.4&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zN4EmdCwMtYc"&gt;Revenue
                                            from contracts with customers &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group is in the business of providing medical services to patients. Revenue from contracts with customers is recognized when control
of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be
entitled in exchange for those goods or services. Revenue is presented net of goods and services tax, rebates, and discounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from the rendering of medical services is recognized at the point in time when the entity satisfies the performance obligation by transferring
a promised good or service to the customer, which is when the customer obtains control of the good or service. This is generally when
the significant acts have been completed, ie, upon the completion of consultations, clinical treatments, medical tests and operations.
The Group considers whether there are other promises in the contract that are separate performance obligations to which a portion of
the transaction price needs to be allocated. The amount of revenue recognized is the amount allocated to the satisfied performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction
price is the amount of consideration in the contract to which the Group expects to be entitled in exchange for transferring the promised
goods or services. In determining the transaction price for the rendering of medical services the Group considers the effects of variable
consideration. Contracts with customers normally does not include any contractual adjustment such as right of return, volume discount
etc. In rare circumstances where consideration is variable, the Group estimates the amount of consideration to which it will be entitled
in exchange for rendering of service to the customer. The variable consideration is estimated at contract inception and constrained until
it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated
uncertainty with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zNlI4GOW3hB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.5&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zjjZCf7gH2k3"&gt;Segment
                                            reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are reported in a manner consistent with the Group&#x2019;s internal organizational structure as well as information about geographical
areas, business segments and major clients in the consolidated financial statements for detailing the Group&#x2019;s business segments.
Based on the criteria established, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief
Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the
Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. As the Group&#x2019;s long-lived assets are substantially located in Singapore, no geographical segments are presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Material accounting policy
                                                                                                                                   information (Continued)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForGovernmentGrants_zAuRT15sMxta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zCgyw8r1jMv5"&gt;Government
                                            grants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grants
from the government are recognized as a receivable at their fair value when there is reasonable assurance that the grant will be received
and the Group will comply with all the attached conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Government
grants receivable are recognized as income over the periods necessary to match them with the related costs which they are intended to
compensate, on a systematic basis. Government grants relating to expenses are shown separately as other income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Government
grants relating to assets are deducted against the carrying amount of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForBasisOfConsolidation_z38KFzsEqiE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.7&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86D_zk2dNQCWZlJf"&gt;Basis of consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The financial statements
of the subsidiaries used in the preparation of the consolidated financial statements are prepared as of the same reporting date as the
Company. Consistent accounting policies are applied to like transactions and events in similar circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Consolidation
                                            &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed
to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power
over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated
from the date on that control ceases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements, transactions, balances and unrealized gains on transactions between group entities are
eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment indicator of the transferred
asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.
Deferred tax relief on unrealized intra-Group profit is accounted for only to the extent that it is considered recoverable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-controlling
interests comprise the portion of a subsidiaries&#x2019; net results of operations and its net assets, which is attributable to the interests
that are not owned directly or indirectly by the equity holders of the Group. They are shown separately in the consolidated statement
of profit or loss and other comprehensive income, statement of changes in equity, and statement of financial position. Total comprehensive
income is attributed to the non-controlling interests based on their respective interests in a Subsidiaries, even if this results in
the non-controlling interests having a deficit balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.7&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Group accounting (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Acquisitions&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
acquisition method of accounting is used to account for business combinations entered into by the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consideration transferred for the acquisition of a subsidiary or business comprises the fair value of the assets transferred, the liabilities
incurred and the equity interests issued by the Group. The consideration transferred also includes any contingent consideration arrangement
and any pre-existing equity interest in the subsidiaries measured at their fair values at the acquisition date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognized in the income statement.
Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. The
part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within
investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition
date is reported within operating cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
the consideration transferred, together with the noncontrolling interest, exceeds the fair value of the net assets, liabilities and contingent
liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in
the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is capitalized as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and
associates. Goodwill is denominated in the currency of the operation acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
the cost of acquisition is below the Group&#x2019;s interest in the net assets acquired, the difference is recognized directly in the
income statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.7&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Group accounting (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
                                            (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Acquisitions
                                            &lt;/i&gt;(Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
not all of the equity of a subsidiary is acquired the noncontrolling interest is recognized either at fair value or at the non-controlling
interest&#x2019;s share of the net assets of the subsidiary, on a case-by-case basis. Changes in the Group&#x2019;s ownership percentage
of subsidiaries are accounted for within equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition-related
costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identifiable
assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially
at their fair values at the acquisition date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
an acquisition-by-acquisition basis, the Group recognizes any non-controlling interest in the acquiree at the date of acquisition either
at fair value or at the non-controlling interest&#x2019;s proportionate share of the acquiree&#x2019;s identifiable net assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
excess of (a) the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair
value of any previous equity interest in the acquiree over the (b) fair value of the identifiable net assets acquired is recorded as
goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disposal&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
a change in the Group&#x2019;s ownership interest in a subsidiary result in a loss of control over the subsidiary, the assets and liabilities
of the subsidiary including any goodwill are derecognized. Amounts previously recognized in other comprehensive income in respect of
that entity are also reclassified to profit or loss or transferred directly to retained earnings if required by a specific Standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
retained equity interest in the entity is remeasured at fair value. The difference between the carrying amount of the retained interest
at the date when control is lost and its fair value is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
                                            with non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
in the Group&#x2019;s ownership interest in a subsidiary that do not result in a loss of control over the subsidiaries are accounted for
as transactions with equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest
and the fair value of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_zCo3ehzwuvge" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.8&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_867_zwcwUjFPi41i"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;All
items of property and equipment are initially recorded at cost. Subsequent to recognition, property and equipment are measured at cost
less accumulated depreciation and any accumulated impairment losses. The cost of property and equipment includes its purchase price and
any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the
manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property and equipment
if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the property and equipment.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zCtkh77xqXQ3"&gt;Schedule of expected useful lives for property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"&gt;Useful lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Machinery&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and Fittings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Renovation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Air conditioner&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zvVjLwhjcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
residual values, estimated useful lives and depreciation method of property and equipment are reviewed, and adjusted prospectively, if
appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fully
depreciated assets are retained in the consolidated financial statements until they are no longer in use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.
Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
expenditure relating to property and equipment that has already been recognized is added to the carrying amount of the asset only when
it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured
reliably. All other repair and maintenance expenses are recognized in profit or loss when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
disposal of an item of property and equipment, the difference between the disposal proceeds and its carrying amount is recognized in
profit or loss within &#x201c;other losses&#x201d;. Any amount in revaluation reserve relating to that item is transferred to retained
profits directly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zDVTBkhz5Ob" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.9&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_863_z4k9wJFUQg4l"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Initial
recognition and measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets are recognized when, and only when the entity becomes party to the contractual provisions of the instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value
through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction
costs of financial assets carried at FVPL are expensed in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
receivables are measured at the amount of consideration to which the Group expects to be entitled in exchange for transferring promised
goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant
financing component at initial recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Subsequent
measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Investments
in debt instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
measurement of debt instruments depends on the Group&#x2019;s business model for managing the asset and the contractual cash flow characteristics
of the asset. The three measurement categories for classification of debt instruments are amortized cost, fair value through other comprehensive
income (FVOCI) and FVPL. The Group only has debt instruments at amortized cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest
are measured at amortized cost. Financial assets are measured at amortized cost using the effective interest method, less impairment.
Gains and losses are recognized in profit or loss when the assets are derecognized or impaired, and through the amortisation process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Investments
in equity instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
initial recognition of an investment in equity instrument that is not held for trading, the Group may irrevocably elect to present subsequent
changes in fair value in other comprehensive income which will not be reclassified subsequently to profit or loss. Dividends from such
investments are to be recognized in profit or loss when the Group&#x2019;s right to receive payments is established. For investments in
equity instruments which the Group has not elected to present subsequent changes in fair value in other comprehensive income, changes
in fair value are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.9&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Financial instruments (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            assets (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Derecognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial asset is derecognized where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial
asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or
loss that had been recognized in other comprehensive income for debt instruments is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Initial
recognition and measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
liabilities are recognized when, and only when, the Group becomes a party to the contractual provisions of the financial instrument.
The Group determines the classification of its financial liabilities at initial recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
financial liabilities are recognized initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable
transaction costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Subsequent
measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortized cost using the effective
interest method. Gains and losses are recognized in profit or loss when the liabilities are derecognized, and through the amortisation
process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Borrowings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings
are presented as current liabilities unless the Group has an unconditional right to defer settlement for at least 12 months after the
balance sheet date, in which case they are presented as non-current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings
are initially recognized at fair value (net of transaction costs) and subsequently carried at amortized cost. Any difference between
the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using
the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.9&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Financial instruments (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Derecognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. On derecognition,
the difference between the carrying amounts and the consideration paid is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zTvtswurBuz4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.10&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_862_ztFFXn91QRf9"&gt;Impairment of financial assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes an allowance for expected credit losses (&#x201c;ECLs&#x201d;) for all debt instruments not held at FVPL. ECLs are based
on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects
to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from
the sale of collateral held or other credit enhancements that are integral to the contractual terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ECLs
are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition,
ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For
those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is
recognized for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
trade receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit
risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix
that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic
environment which could affect debtors&#x2019; ability to pay.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group considers a financial asset in default when contractual payments are 30 days past due. However, in certain cases, the Group may
also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive
the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is
written off when there is no reasonable expectation of recovering the contractual cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_zEbBVId9vcLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.11&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_868_zrGwJwras9J7"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand, deposits with
financial institutions which are subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are presented
as current borrowings on the balance sheet. For cash subjected to restriction, assessment is made on the economic substance of the restriction
and whether they meet the definition of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForInventoriesExplanatory_zqEuxNn1sUUk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.12&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86A_zq3Oz7xXvOa7"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost and net realisable value, Cost is calculated using the weighted average basis and includes all costs
of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the
estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make
the sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
necessary, allowance is provided for damaged, obsolete and slow-moving item to adjust the carrying value of inventories to the lower
of cost and net realisable value.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_z4i3ikD7CKWa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.13&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_867_z0YCIUDfVGo"&gt;Offsetting of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset
and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForProvisionsExplanatory_znYA0tqHSlMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.14&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86C_zS9WURuRBCS6"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions
are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow
of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated
reliably.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions
are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that
an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value
of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to
the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Asset
Retirement Obligation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes a liability and capitalize an expense in property and equipment if the Group has a present legal or constructive obligation
to reinstate the leased premises to their original state upon expiry of the lease. The provision is made based on management&#x2019;s
best estimate of the expected costs to be incurred to reinstate the leased premises to their original state. The capitalized provision
for reinstatement costs in property and equipment is amortized over the period of the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_zR9ayGVXiuC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.15&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_862_zA0TdvBE7VEi"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, (or, where
applicable, when an annual impairment testing for an asset is required), the Group makes an estimate of the asset&#x2019;s recoverable
amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying values of all non-current assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating
unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available
for use are tested for impairment annually.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairments
of goodwill are not reversed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
asset&#x2019;s recoverable amount is the higher of an asset&#x2019;s or cash-generating unit&#x2019;s fair value less costs of disposal
and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent
of those from other assets or group of assets. Where the carrying amount of an asset or cash-generating unit exceeds its recoverable
amount, the asset is considered impaired and is written down to its recoverable amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment
losses are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset&#x2019;s
recoverable amount since the last impairment loss was recognized. If that is the case, the carrying amount of the asset is increased
to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had
no impairment loss been recognized previously. Such reversal is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zUuYUw0kOTQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.16&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86B_z895DwYRVzTd"&gt;Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
                                            income tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid
to the taxation authority. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted
at the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income taxes are recognized in profit or loss except to the extent that the tax relates to items recognized outside profit or loss, either
in other comprehensive income or directly in equity. Management periodically evaluates positions taken in the tax returns with respect
to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: normal; width: 0.5in"&gt;&lt;b&gt;2.16&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-weight: normal"&gt;&lt;b&gt;Taxes (Continued)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;(b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
                                            tax&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is provided using the liability method on temporary differences at the end of the reporting date between the tax bases of assets
and liabilities and their carrying amounts for financial reporting purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability
is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current income tax assets against
current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goods
                                            and Services Tax (&#x201c;GST&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues,
expenses and assets are recognized net of the amount of GST except:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;where
                                            the GST incurred on a purchase of assets or services is not recoverable from the taxation
                                            authority, in which case the GST is recognized as part of the cost of acquisition of the
                                            asset or as part of the expense item as applicable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;receivables
                                            and payables that are stated with the amount of GST included.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement
of financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zvhp9UbmErB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.17&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
                                                                    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zXMQr25szXsj"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control
the use of an identified asset for a period of time in exchange for consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td&gt;As lessee&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets.
The Group recognizes lease liabilities representing the obligations to make lease payments and right-of-use assets representing the right
to use the underlying leased assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.17&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td&gt;As lessee (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Right-of-use
assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on
a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option,
depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. The
accounting policy for impairment is disclosed in Note 2.15.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s right-of-use assets are presented in Note 9.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Lease
liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating the lease, if the lease term reflects the Group exercising the option to terminate. Variable lease payments that do not
depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the
event or condition that triggers the payment occurs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments
resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase
the underlying asset.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.17&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td&gt;As lessee (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Lease
liabilities&lt;/span&gt; (Continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s lease liabilities are included in borrowings (Note 15).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Short-term
leases and leases of low-value assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies the short-term lease recognition exemption to its short-term leases of office premises (i.e. those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognized
as expense on a straight-line basis over the lease term. The Group has no lease of low-value assets for the year.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zLbnIfLbRzwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.18&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_869_zErVOWCP1J1h"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Functional
                                            and presentation currency &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment
in which the entity operates (&#x201c;functional currency&#x201d;). The consolidated financial statements are presented in Singapore Dollar,
which is the functional currency of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transactions
                                            and balances &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
in a currency other than the functional currency (&#x201c;foreign currency&#x201d;) are translated into the functional currency using the
exchange rates at the dates of the transactions. Currency exchange differences resulting from the settlement of such transactions and
from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the end of balance
sheet date are recognized in profit or loss. Monetary items include primarily financial assets (other than equity investments), contract
assets and financial liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
a foreign operation is disposed of or any loan forming part of the net investment of the foreign operation is repaid, a proportionate
share of the accumulated currency translation differences is reclassified to profit or loss, as part of the gain or loss on disposal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
exchange gains and losses that relate to borrowings are presented in the income statement within &#x201c;finance expense&#x201d;. All other
foreign exchange gains and losses impacting profit or loss are presented in the income statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.18&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Currency translation (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transactions
                                            and balances &lt;/i&gt;(Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-monetary
items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Translation
                                            of Group entities&#x2019; financial statements &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a
functional currency different from the presentation currency are translated into the presentation currency as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;assets
                                            and liabilities are translated at the closing exchange rates at the reporting date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;income
                                            and expenses are translated at average exchange rates (unless the average is not a reasonable
                                            approximation of the cumulative effect of the rates prevailing on the transaction dates,
                                            in which case income and expenses are translated using the exchange rates at the dates of
                                            the transactions); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;all
                                            resulting currency translation differences are recognized in other comprehensive income and
                                            accumulated in the currency translation reserve. These currency translation differences are
                                            reclassified to profit or loss on disposal or partial disposal with loss of control of the
                                            foreign operation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Goodwill
and fair value adjustments arising on the acquisition of foreign operations are treated as assets and liabilities of the foreign operations
and translated at the closing rates at the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Translations
of the consolidated balance sheets, consolidated statement of profit or loss and comprehensive income, consolidated statement of changes
in shareholders&#x2019; equity and consolidated statements of cash flows from S$ into US$ as of and for the year ended June 30, 2025 are
solely for the convenience of the reader and were calculated at the rate of S$1 = US$1.2719, as set forth in the statistical release
of the Federal Reserve System on June 30, 2025. No representation is made that the S$ amounts could have been, or could be, converted,
realized or settled into US$ at that rate on June 30, 2025, or at any other rate.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_z1DrsIFo15i3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.19&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_860_zakbKSZ3qNXj"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Defined
                                            contribution plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify; text-indent: -32pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to
defined contribution pension schemes are recognized as an expense in the period in which the related service is performed.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.19&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Employee benefits (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
                                            employee benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is
recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result
of past service provided by the employee, and the obligation can be estimated reliably.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_z9f4subZNxTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.20&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zAaJgTtYdHae"&gt;Derivative
                                            financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;A
derivative financial instrument for which no hedge accounting is applied is initially recognized at its fair value on the date the contract
is entered into and is subsequently carried at its fair value. Changes in its fair value are recognized in profit or loss. The Group
does not apply hedge accounting for its derivative financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zFFrc5tiaJS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.21&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_866_zyfTi1CoYnAh"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per share is computed by dividing net income attributable to the holders of ordinary shares by the weighted average number of
ordinary shares outstanding during the period presented. Diluted income per share is calculated by dividing net income attributable to
the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number
of ordinary shares and dilutive ordinary share equivalents outstanding during the period. However, ordinary share equivalents are not
included in the denominator of the diluted earnings per share calculation when inclusion of such shares would be anti-dilutive, such
as in a period in which a net loss is recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_z7O2XohbwfEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.22&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zKVVItQqxjU3"&gt;Share
                                            capital&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
from issuance of ordinary shares are recognized as share capital in equity. Incremental costs directly attributable to the issuance of
ordinary shares are deducted against share capital.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForReservesExplanatory_zzNfiz5l0SJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zdWg2h5Q17nl"&gt;Merger
    reserve&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a business combination under common control, any difference between the consideration paid and the carrying amounts of assets and liabilities
received is presented as a change within equity and recorded under merger reserves.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_zgQ4rvBzv7Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zM5sPpJ0twd4"&gt;Deferred
    Offering cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers specific incremental costs directly attributable to an equity securities offering. These costs will be charged against
the gross proceeds of the offering as a reduction of additional paid-in capital. If the Company does not complete the initial public
offering, the deferred costs of the aborted offering will be deferred and charged against the proceeds of a subsequent offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    offering cost (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
costs related to an aborted offering will be expensed in the period in which the Company elects to abort the offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the completion of the initial public offering, deferred offering costs, which mainly consist of direct incremental legal, auditing,
accounting, consulting, and other fees relating to the initial public offering, are capitalized on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForDividendsExplanatory_zt3Xm83uISgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zci6cjHtuHwc"&gt;Dividend
    to Company&#x2019;s shareholders&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
to the Company&#x2019;s shareholders are recognized when the dividends are approved for payment.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_854_zriQWrLNMCxf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <BMGL:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000861">&lt;p id="xdx_844_ecustom--DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory_zI4sF8qCbosk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;b&gt;2.1&lt;/b&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z0I5Q3qpuyua"&gt;Compliance
                                            with International Financial Reporting Standards (&#x201c;IFRS&#x201d;)&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;)
and interpretations issued by the IFRS Interpretations Committee (&#x201c;IFRS IC&#x201d;) applicable to companies reporting under IFRS.
The financial statements comply with IFRS as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group have been prepared on a going concern basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
ability of the Group to continue as going concern is dependent on: (Please refer to Note 26)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;the
                                            ability of its major shareholder to provide financial support&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;the
                                            ability of the Group to generate sufficient and sustainable operating profits and cash flows
                                            over the next 12 months from the date of these financial statements to meet its operating
                                            and financial obligations as and when they fall due; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;the
                                            ability of the Group to procure additional financing and to garner the continuous support
                                            of its existing financiers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</BMGL:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="From2024-07-01to2025-06-30" id="Fact000863">&lt;p id="xdx_845_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_z8tyN44gZzUj" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zaapWlfTeQZ6"&gt;New
                                            and amended standards adopted by the Group&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has applied the following amendments for the first time for their annual reporting period commencing July 1, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification
                                            of Liabilities as Current or Non-current and Non-current liabilities with covenants &#x2013;
                                            Amendments to IAS 1;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
                                            Liability in Sale and Leaseback &#x2013; Amendments to IFRS 16; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplier
                                            Finance Arrangements &#x2013; Amendments to IAS 7 and IFRS 7.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect
the current or future periods.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <BMGL:DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000865">&lt;p id="xdx_849_ecustom--DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory_zOSlo6Ziw3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; color: red"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
                                                                    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zw46494mBlR4"&gt;New
                                            standards and interpretations not yet adopted&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Certain
new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for June
30, 2025 reporting periods and have not been early adopted by the Group. These standards, amendments or interpretations are not expected
to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; color: red; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Material accounting policy information (Continued)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</BMGL:DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedButNotYetEffectiveExplanatory>
    <BMGL:DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000867">&lt;p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory_z0MFTpCADvNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.4&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zN4EmdCwMtYc"&gt;Revenue
                                            from contracts with customers &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group is in the business of providing medical services to patients. Revenue from contracts with customers is recognized when control
of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be
entitled in exchange for those goods or services. Revenue is presented net of goods and services tax, rebates, and discounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from the rendering of medical services is recognized at the point in time when the entity satisfies the performance obligation by transferring
a promised good or service to the customer, which is when the customer obtains control of the good or service. This is generally when
the significant acts have been completed, ie, upon the completion of consultations, clinical treatments, medical tests and operations.
The Group considers whether there are other promises in the contract that are separate performance obligations to which a portion of
the transaction price needs to be allocated. The amount of revenue recognized is the amount allocated to the satisfied performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction
price is the amount of consideration in the contract to which the Group expects to be entitled in exchange for transferring the promised
goods or services. In determining the transaction price for the rendering of medical services the Group considers the effects of variable
consideration. Contracts with customers normally does not include any contractual adjustment such as right of return, volume discount
etc. In rare circumstances where consideration is variable, the Group estimates the amount of consideration to which it will be entitled
in exchange for rendering of service to the customer. The variable consideration is estimated at contract inception and constrained until
it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated
uncertainty with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/p&gt;

</BMGL:DescriptionOfAccountingPolicyRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000869">&lt;p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zNlI4GOW3hB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.5&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zjjZCf7gH2k3"&gt;Segment
                                            reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are reported in a manner consistent with the Group&#x2019;s internal organizational structure as well as information about geographical
areas, business segments and major clients in the consolidated financial statements for detailing the Group&#x2019;s business segments.
Based on the criteria established, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief
Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the
Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. As the Group&#x2019;s long-lived assets are substantially located in Singapore, no geographical segments are presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Material accounting policy
                                                                                                                                   information (Continued)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="From2024-07-01to2025-06-30" id="Fact000871">&lt;p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForGovernmentGrants_zAuRT15sMxta" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zCgyw8r1jMv5"&gt;Government
                                            grants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grants
from the government are recognized as a receivable at their fair value when there is reasonable assurance that the grant will be received
and the Group will comply with all the attached conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Government
grants receivable are recognized as income over the periods necessary to match them with the related costs which they are intended to
compensate, on a systematic basis. Government grants relating to expenses are shown separately as other income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Government
grants relating to assets are deducted against the carrying amount of the assets.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <BMGL:DescriptionOfAccountingPolicyForBasisOfConsolidation contextRef="From2024-07-01to2025-06-30" id="Fact000873">&lt;p id="xdx_840_ecustom--DescriptionOfAccountingPolicyForBasisOfConsolidation_z38KFzsEqiE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.7&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86D_zk2dNQCWZlJf"&gt;Basis of consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The financial statements
of the subsidiaries used in the preparation of the consolidated financial statements are prepared as of the same reporting date as the
Company. Consistent accounting policies are applied to like transactions and events in similar circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Consolidation
                                            &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed
to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power
over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated
from the date on that control ceases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements, transactions, balances and unrealized gains on transactions between group entities are
eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment indicator of the transferred
asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.
Deferred tax relief on unrealized intra-Group profit is accounted for only to the extent that it is considered recoverable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-controlling
interests comprise the portion of a subsidiaries&#x2019; net results of operations and its net assets, which is attributable to the interests
that are not owned directly or indirectly by the equity holders of the Group. They are shown separately in the consolidated statement
of profit or loss and other comprehensive income, statement of changes in equity, and statement of financial position. Total comprehensive
income is attributed to the non-controlling interests based on their respective interests in a Subsidiaries, even if this results in
the non-controlling interests having a deficit balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.7&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Group accounting (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Acquisitions&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
acquisition method of accounting is used to account for business combinations entered into by the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consideration transferred for the acquisition of a subsidiary or business comprises the fair value of the assets transferred, the liabilities
incurred and the equity interests issued by the Group. The consideration transferred also includes any contingent consideration arrangement
and any pre-existing equity interest in the subsidiaries measured at their fair values at the acquisition date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of contingent consideration liabilities is reassessed at each balance sheet date with changes recognized in the income statement.
Payments of contingent consideration reduce the balance sheet liability and as a result are not recorded in the income statement. The
part of each payment relating to the original estimate of the fair value of the contingent consideration on acquisition is reported within
investing activities in the cash flow statement and the part of each payment relating to the increase in the liability since the acquisition
date is reported within operating cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
the consideration transferred, together with the noncontrolling interest, exceeds the fair value of the net assets, liabilities and contingent
liabilities acquired, the excess is recorded as goodwill. The costs of effecting an acquisition are charged to the income statement in
the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is capitalized as a separate item in the case of subsidiaries and as part of the cost of investment in the case of joint ventures and
associates. Goodwill is denominated in the currency of the operation acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
the cost of acquisition is below the Group&#x2019;s interest in the net assets acquired, the difference is recognized directly in the
income statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.7&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Group accounting (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 21.3pt; text-align: justify; text-indent: 14.15pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
                                            (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Acquisitions
                                            &lt;/i&gt;(Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
not all of the equity of a subsidiary is acquired the noncontrolling interest is recognized either at fair value or at the non-controlling
interest&#x2019;s share of the net assets of the subsidiary, on a case-by-case basis. Changes in the Group&#x2019;s ownership percentage
of subsidiaries are accounted for within equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition-related
costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identifiable
assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially
at their fair values at the acquisition date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
an acquisition-by-acquisition basis, the Group recognizes any non-controlling interest in the acquiree at the date of acquisition either
at fair value or at the non-controlling interest&#x2019;s proportionate share of the acquiree&#x2019;s identifiable net assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
excess of (a) the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair
value of any previous equity interest in the acquiree over the (b) fair value of the identifiable net assets acquired is recorded as
goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Disposal&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
a change in the Group&#x2019;s ownership interest in a subsidiary result in a loss of control over the subsidiary, the assets and liabilities
of the subsidiary including any goodwill are derecognized. Amounts previously recognized in other comprehensive income in respect of
that entity are also reclassified to profit or loss or transferred directly to retained earnings if required by a specific Standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
retained equity interest in the entity is remeasured at fair value. The difference between the carrying amount of the retained interest
at the date when control is lost and its fair value is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
                                            with non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
in the Group&#x2019;s ownership interest in a subsidiary that do not result in a loss of control over the subsidiaries are accounted for
as transactions with equity owners of the Company. Any difference between the change in the carrying amounts of the non-controlling interest
and the fair value of the consideration paid or received is recognized within equity attributable to the equity holders of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</BMGL:DescriptionOfAccountingPolicyForBasisOfConsolidation>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000875">&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_zCo3ehzwuvge" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.8&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_867_zwcwUjFPi41i"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;All
items of property and equipment are initially recorded at cost. Subsequent to recognition, property and equipment are measured at cost
less accumulated depreciation and any accumulated impairment losses. The cost of property and equipment includes its purchase price and
any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the
manner intended by management. Dismantlement, removal or restoration costs are included as part of the cost of property and equipment
if the obligation for dismantlement, removal or restoration is incurred as a consequence of acquiring or using the property and equipment.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zCtkh77xqXQ3"&gt;Schedule of expected useful lives for property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"&gt;Useful lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Machinery&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and Fittings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Renovation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Air conditioner&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zvVjLwhjcRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
residual values, estimated useful lives and depreciation method of property and equipment are reviewed, and adjusted prospectively, if
appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fully
depreciated assets are retained in the consolidated financial statements until they are no longer in use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.
Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
expenditure relating to property and equipment that has already been recognized is added to the carrying amount of the asset only when
it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured
reliably. All other repair and maintenance expenses are recognized in profit or loss when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
disposal of an item of property and equipment, the difference between the disposal proceeds and its carrying amount is recognized in
profit or loss within &#x201c;other losses&#x201d;. Any amount in revaluation reserve relating to that item is transferred to retained
profits directly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <BMGL:DisclosureOfDepreciationRatesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000877">&lt;p id="xdx_89F_ecustom--DisclosureOfDepreciationRatesExplanatory_zajd51oT5vL9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Depreciation
is calculated using the straight-line method to allocate depreciable amounts over their estimated useful lives. The estimated useful
lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0.5in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zCtkh77xqXQ3"&gt;Schedule of expected useful lives for property, plant and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"&gt;Useful lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Machinery&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zMkpm495Eat1"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and Fittings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_905_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--FixturesAndFittingsMember_z62iGgadUYsa"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--OtherPropertyPlantAndEquipmentMember_zhKuhkaaZki5"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Renovation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_903_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--RenovationMember_zypqVSH7j8W3"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Air conditioner&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_906_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--AirConditionerMember_zQo8FOyzT6j7"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_908_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zdexhUnAwEo5" title="Expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--SoftwareMember_z7Ts5AKqR7y8" title="Expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDepreciationRatesExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_MachineryMember"
      id="Fact000878">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_FixturesAndFittingsMember"
      id="Fact000879">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_OtherPropertyPlantAndEquipmentMember"
      id="Fact000880">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_custom_RenovationMember"
      id="Fact000881">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_custom_AirConditionerMember"
      id="Fact000882">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_ComputerEquipmentMember"
      id="Fact000884">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_custom_SoftwareMember"
      id="Fact000886">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000888">&lt;p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zDVTBkhz5Ob" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.9&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_863_z4k9wJFUQg4l"&gt;Financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Initial
recognition and measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets are recognized when, and only when the entity becomes party to the contractual provisions of the instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value
through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction
costs of financial assets carried at FVPL are expensed in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
receivables are measured at the amount of consideration to which the Group expects to be entitled in exchange for transferring promised
goods or services to a customer, excluding amounts collected on behalf of third party, if the trade receivables do not contain a significant
financing component at initial recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Subsequent
measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Investments
in debt instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
measurement of debt instruments depends on the Group&#x2019;s business model for managing the asset and the contractual cash flow characteristics
of the asset. The three measurement categories for classification of debt instruments are amortized cost, fair value through other comprehensive
income (FVOCI) and FVPL. The Group only has debt instruments at amortized cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest
are measured at amortized cost. Financial assets are measured at amortized cost using the effective interest method, less impairment.
Gains and losses are recognized in profit or loss when the assets are derecognized or impaired, and through the amortisation process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Investments
in equity instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
initial recognition of an investment in equity instrument that is not held for trading, the Group may irrevocably elect to present subsequent
changes in fair value in other comprehensive income which will not be reclassified subsequently to profit or loss. Dividends from such
investments are to be recognized in profit or loss when the Group&#x2019;s right to receive payments is established. For investments in
equity instruments which the Group has not elected to present subsequent changes in fair value in other comprehensive income, changes
in fair value are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.9&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Financial instruments (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            assets (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Derecognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial asset is derecognized where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial
asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or
loss that had been recognized in other comprehensive income for debt instruments is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.55in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Initial
recognition and measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
liabilities are recognized when, and only when, the Group becomes a party to the contractual provisions of the financial instrument.
The Group determines the classification of its financial liabilities at initial recognition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
financial liabilities are recognized initially at fair value plus in the case of financial liabilities not at FVPL, directly attributable
transaction costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Subsequent
measurement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortized cost using the effective
interest method. Gains and losses are recognized in profit or loss when the liabilities are derecognized, and through the amortisation
process.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Borrowings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings
are presented as current liabilities unless the Group has an unconditional right to defer settlement for at least 12 months after the
balance sheet date, in which case they are presented as non-current liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings
are initially recognized at fair value (net of transaction costs) and subsequently carried at amortized cost. Any difference between
the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using
the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.9&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Financial instruments (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Derecognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. On derecognition,
the difference between the carrying amounts and the consideration paid is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000890">&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_zTvtswurBuz4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.10&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_862_ztFFXn91QRf9"&gt;Impairment of financial assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes an allowance for expected credit losses (&#x201c;ECLs&#x201d;) for all debt instruments not held at FVPL. ECLs are based
on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects
to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from
the sale of collateral held or other credit enhancements that are integral to the contractual terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ECLs
are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition,
ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For
those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is
recognized for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
trade receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit
risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix
that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic
environment which could affect debtors&#x2019; ability to pay.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group considers a financial asset in default when contractual payments are 30 days past due. However, in certain cases, the Group may
also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive
the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is
written off when there is no reasonable expectation of recovering the contractual cash flows.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="From2024-07-01to2025-06-30" id="Fact000892">&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_zEbBVId9vcLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.11&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_868_zrGwJwras9J7"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents include cash on hand, deposits with
financial institutions which are subject to an insignificant risk of change in value, and bank overdrafts. Bank overdrafts are presented
as current borrowings on the balance sheet. For cash subjected to restriction, assessment is made on the economic substance of the restriction
and whether they meet the definition of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <BMGL:DescriptionOfAccountingPolicyForInventoriesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000894">&lt;p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForInventoriesExplanatory_zqEuxNn1sUUk" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.12&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86A_zq3Oz7xXvOa7"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost and net realisable value, Cost is calculated using the weighted average basis and includes all costs
of purchase and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the
estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make
the sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
necessary, allowance is provided for damaged, obsolete and slow-moving item to adjust the carrying value of inventories to the lower
of cost and net realisable value.&lt;/span&gt;&lt;/p&gt;

</BMGL:DescriptionOfAccountingPolicyForInventoriesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000896">&lt;p id="xdx_84A_eifrs-full--DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory_z4i3ikD7CKWa" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.13&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_867_z0YCIUDfVGo"&gt;Offsetting of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset
and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000898">&lt;p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForProvisionsExplanatory_znYA0tqHSlMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.14&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86C_zS9WURuRBCS6"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions
are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow
of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated
reliably.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provisions
are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that
an outflow of economic resources will be required to settle the obligation, the provision is reversed. If the effect of the time value
of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to
the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Asset
Retirement Obligation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes a liability and capitalize an expense in property and equipment if the Group has a present legal or constructive obligation
to reinstate the leased premises to their original state upon expiry of the lease. The provision is made based on management&#x2019;s
best estimate of the expected costs to be incurred to reinstate the leased premises to their original state. The capitalized provision
for reinstatement costs in property and equipment is amortized over the period of the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000900">&lt;p id="xdx_84C_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_zR9ayGVXiuC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.15&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_862_zA0TdvBE7VEi"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, (or, where
applicable, when an annual impairment testing for an asset is required), the Group makes an estimate of the asset&#x2019;s recoverable
amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying values of all non-current assets are reviewed for impairment, either on a stand-alone basis or as part of a larger cash generating
unit, when there is an indication that the assets might be impaired. Additionally, goodwill and intangible assets which are not yet available
for use are tested for impairment annually.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairments
of goodwill are not reversed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
asset&#x2019;s recoverable amount is the higher of an asset&#x2019;s or cash-generating unit&#x2019;s fair value less costs of disposal
and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent
of those from other assets or group of assets. Where the carrying amount of an asset or cash-generating unit exceeds its recoverable
amount, the asset is considered impaired and is written down to its recoverable amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment
losses are recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
previously recognized impairment loss is reversed only if there has been a change in the estimates used to determine the asset&#x2019;s
recoverable amount since the last impairment loss was recognized. If that is the case, the carrying amount of the asset is increased
to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had
no impairment loss been recognized previously. Such reversal is recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000902">&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_zUuYUw0kOTQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.16&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_86B_z895DwYRVzTd"&gt;Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
                                            income tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid
to the taxation authority. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted
at the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income taxes are recognized in profit or loss except to the extent that the tax relates to items recognized outside profit or loss, either
in other comprehensive income or directly in equity. Management periodically evaluates positions taken in the tax returns with respect
to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: normal; width: 0.5in"&gt;&lt;b&gt;2.16&lt;/b&gt;&lt;/td&gt;
    &lt;td style="font-weight: normal"&gt;&lt;b&gt;Taxes (Continued)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.5in"&gt;(b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
                                            tax&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is provided using the liability method on temporary differences at the end of the reporting date between the tax bases of assets
and liabilities and their carrying amounts for financial reporting purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability
is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current income tax assets against
current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goods
                                            and Services Tax (&#x201c;GST&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues,
expenses and assets are recognized net of the amount of GST except:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;where
                                            the GST incurred on a purchase of assets or services is not recoverable from the taxation
                                            authority, in which case the GST is recognized as part of the cost of acquisition of the
                                            asset or as part of the expense item as applicable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;receivables
                                            and payables that are stated with the amount of GST included.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement
of financial position.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000904">&lt;p id="xdx_84F_eifrs-full--DescriptionOfAccountingPolicyForLeasesExplanatory_zvhp9UbmErB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.17&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
                                                                    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zXMQr25szXsj"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control
the use of an identified asset for a period of time in exchange for consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td&gt;As lessee&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets.
The Group recognizes lease liabilities representing the obligations to make lease payments and right-of-use assets representing the right
to use the underlying leased assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.17&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td&gt;As lessee (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Right-of-use
assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on
a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option,
depreciation is calculated using the estimated useful life of the asset. The right-of-use assets are also subject to impairment. The
accounting policy for impairment is disclosed in Note 2.15.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s right-of-use assets are presented in Note 9.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Lease
liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating the lease, if the lease term reflects the Group exercising the option to terminate. Variable lease payments that do not
depend on an index or a rate are recognized as expenses (unless they are incurred to produce inventories) in the period in which the
event or condition that triggers the payment occurs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g. changes to future payments
resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase
the underlying asset.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.17&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
                                            (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td&gt;As lessee (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Lease
liabilities&lt;/span&gt; (Continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s lease liabilities are included in borrowings (Note 15).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Short-term
leases and leases of low-value assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies the short-term lease recognition exemption to its short-term leases of office premises (i.e. those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognized
as expense on a straight-line basis over the lease term. The Group has no lease of low-value assets for the year.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000906">&lt;p id="xdx_84E_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zLbnIfLbRzwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.18&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_869_zErVOWCP1J1h"&gt;Currency translation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Functional
                                            and presentation currency &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment
in which the entity operates (&#x201c;functional currency&#x201d;). The consolidated financial statements are presented in Singapore Dollar,
which is the functional currency of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transactions
                                            and balances &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
in a currency other than the functional currency (&#x201c;foreign currency&#x201d;) are translated into the functional currency using the
exchange rates at the dates of the transactions. Currency exchange differences resulting from the settlement of such transactions and
from the translation of monetary assets and liabilities denominated in foreign currencies at the closing rates at the end of balance
sheet date are recognized in profit or loss. Monetary items include primarily financial assets (other than equity investments), contract
assets and financial liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
a foreign operation is disposed of or any loan forming part of the net investment of the foreign operation is repaid, a proportionate
share of the accumulated currency translation differences is reclassified to profit or loss, as part of the gain or loss on disposal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
exchange gains and losses that relate to borrowings are presented in the income statement within &#x201c;finance expense&#x201d;. All other
foreign exchange gains and losses impacting profit or loss are presented in the income statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.18&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Currency translation (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transactions
                                            and balances &lt;/i&gt;(Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-monetary
items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Translation
                                            of Group entities&#x2019; financial statements &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
results and financial position of all the Group entities (none of which has the currency of a hyperinflationary economy) that have a
functional currency different from the presentation currency are translated into the presentation currency as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;assets
                                            and liabilities are translated at the closing exchange rates at the reporting date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;income
                                            and expenses are translated at average exchange rates (unless the average is not a reasonable
                                            approximation of the cumulative effect of the rates prevailing on the transaction dates,
                                            in which case income and expenses are translated using the exchange rates at the dates of
                                            the transactions); and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-align: justify; text-indent: -21.3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;all
                                            resulting currency translation differences are recognized in other comprehensive income and
                                            accumulated in the currency translation reserve. These currency translation differences are
                                            reclassified to profit or loss on disposal or partial disposal with loss of control of the
                                            foreign operation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Goodwill
and fair value adjustments arising on the acquisition of foreign operations are treated as assets and liabilities of the foreign operations
and translated at the closing rates at the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Translations
of the consolidated balance sheets, consolidated statement of profit or loss and comprehensive income, consolidated statement of changes
in shareholders&#x2019; equity and consolidated statements of cash flows from S$ into US$ as of and for the year ended June 30, 2025 are
solely for the convenience of the reader and were calculated at the rate of S$1 = US$1.2719, as set forth in the statistical release
of the Federal Reserve System on June 30, 2025. No representation is made that the S$ amounts could have been, or could be, converted,
realized or settled into US$ at that rate on June 30, 2025, or at any other rate.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000908">&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_z1DrsIFo15i3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.19&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_860_zakbKSZ3qNXj"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Defined
                                            contribution plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify; text-indent: -32pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group makes contributions to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to
defined contribution pension schemes are recognized as an expense in the period in which the related service is performed.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.19&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Employee benefits (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
                                            employee benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term
employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is
recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result
of past service provided by the employee, and the obligation can be estimated reliably.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000910">&lt;p id="xdx_849_eifrs-full--DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory_z9f4subZNxTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.20&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zAaJgTtYdHae"&gt;Derivative
                                            financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;A
derivative financial instrument for which no hedge accounting is applied is initially recognized at its fair value on the date the contract
is entered into and is subsequently carried at its fair value. Changes in its fair value are recognized in profit or loss. The Group
does not apply hedge accounting for its derivative financial instruments.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000912">&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_zFFrc5tiaJS" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.21&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_866_zyfTi1CoYnAh"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings per share is computed by dividing net income attributable to the holders of ordinary shares by the weighted average number of
ordinary shares outstanding during the period presented. Diluted income per share is calculated by dividing net income attributable to
the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number
of ordinary shares and dilutive ordinary share equivalents outstanding during the period. However, ordinary share equivalents are not
included in the denominator of the diluted earnings per share calculation when inclusion of such shares would be anti-dilutive, such
as in a period in which a net loss is recorded.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000914">&lt;p id="xdx_843_eifrs-full--DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_z7O2XohbwfEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.22&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zKVVItQqxjU3"&gt;Share
                                            capital&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
from issuance of ordinary shares are recognized as share capital in equity. Incremental costs directly attributable to the issuance of
ordinary shares are deducted against share capital.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <BMGL:DescriptionOfAccountingPolicyForReservesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000916">&lt;p id="xdx_848_ecustom--DescriptionOfAccountingPolicyForReservesExplanatory_zzNfiz5l0SJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_865_zdWg2h5Q17nl"&gt;Merger
    reserve&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a business combination under common control, any difference between the consideration paid and the carrying amounts of assets and liabilities
received is presented as a change within equity and recorded under merger reserves.&lt;/span&gt;&lt;/p&gt;

</BMGL:DescriptionOfAccountingPolicyForReservesExplanatory>
    <BMGL:DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000918">&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory_zgQ4rvBzv7Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zM5sPpJ0twd4"&gt;Deferred
    Offering cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company defers specific incremental costs directly attributable to an equity securities offering. These costs will be charged against
the gross proceeds of the offering as a reduction of additional paid-in capital. If the Company does not complete the initial public
offering, the deferred costs of the aborted offering will be deferred and charged against the proceeds of a subsequent offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;2.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Material accounting policy information (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    offering cost (Continued)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
costs related to an aborted offering will be expensed in the period in which the Company elects to abort the offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the completion of the initial public offering, deferred offering costs, which mainly consist of direct incremental legal, auditing,
accounting, consulting, and other fees relating to the initial public offering, are capitalized on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

</BMGL:DescriptionOfAccountingPolicyForDeferredOfferingCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000920">&lt;p id="xdx_84B_eifrs-full--DescriptionOfAccountingPolicyForDividendsExplanatory_zt3Xm83uISgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.25&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 1pt; padding-left: 7.1pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zci6cjHtuHwc"&gt;Dividend
    to Company&#x2019;s shareholders&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
to the Company&#x2019;s shareholders are recognized when the dividends are approved for payment.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000922">&lt;p id="xdx_80E_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zXCSDbolq7Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
                                                                    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span id="xdx_821_zy876ojIElb1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Significant
                                            accounting judgements and estimates&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Group&#x2019;s financial statements requires management to make judgments, estimates and assumptions that affect the
reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting
period. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying
amount of the asset or liability affected in the future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Judgements
                                            made in applying accounting policies &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Management
is of the opinion that there are no significant judgements made in applying accounting estimates and policies that have a significant
risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Key
                                            sources of estimation uncertainty &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period are discussed
below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances
and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the
Group. Such changes are reflected in the assumptions when they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;3.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Significant accounting judgements and estimates (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Key
                                            sources of estimation uncertainty (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated
                                            useful lives of property and equipment (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group depreciates the property and equipment over their estimated useful lives after taking into account of their estimated residual
values. The estimated useful life reflects management&#x2019;s estimate of the period that the Group intends to derive future economic
benefits from the use of the Group&#x2019;s property and equipment. The residual value reflects management&#x2019;s estimated amount that
the Group would currently obtain from the disposal of the asset, after deducting the estimated costs of disposal, as if the asset were
already of the age and in the condition expected at the end of its useful life. Changes in the expected level of usage and technological
developments could affect the economics, useful lives and the residual values of these assets which could then consequentially impact
future depreciation charges. The carrying amounts of the Group&#x2019;s property and equipment as at June 30, 2025 and June 30, 2024 were
disclosed in Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inventory
                                            valuation method&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-down is made based on the current market conditions, historical experience and selling goods of similar nature. It could change
significantly as a result of changes in market conditions. A review is made periodically on inventories for excess inventories, obsolescence
and declines in net realisable value and an allowance is recorded against the inventory balances for any such declines. The realisable
value represents the best estimate of the recoverable amount and is based on the most reliable evidence available and inherently involves
estimates regarding the future expected realisable value. The carrying amount of the Company&#x2019;s inventories as at June 30, 2025
was S$&lt;span id="xdx_90B_eifrs-full--Inventories_iI_c20250630_zpsOuY8yYGE1" title="Inventories"&gt;376,291&lt;/span&gt; (US$&lt;span id="xdx_908_eifrs-full--Inventories_iI_uUSD_c20250630_zjvjJTZUX4Z8" title="Inventories"&gt;295,850&lt;/span&gt;) (June 30, 2024: S$&lt;span id="xdx_909_eifrs-full--Inventories_iI_c20240630_zq2u45m2aax7" title="Inventories"&gt;72,030&lt;/span&gt;). If the future expected realisable value was lower by 10% of its carrying amount,
the carrying amount of the Company&#x2019;s inventories would have been S$&lt;span id="xdx_902_eifrs-full--InventoriesTotal_iI_c20250630_zUHeDEWTeNHh" title="Inventories total"&gt;37,629&lt;/span&gt; (US$&lt;span id="xdx_90F_eifrs-full--InventoriesTotal_iI_uUSD_c20250630_zHUl9GmwG5lj" title="Inventories total"&gt;29,585&lt;/span&gt;) (June 30, 2024: S$&lt;span id="xdx_906_eifrs-full--InventoriesTotal_iI_c20240630_zZUiyrpWwaL4" title="Inventories total"&gt;7,203&lt;/span&gt;) lower.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allowance
                                            for expected credit losses of trade receivables&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group uses a provision matrix to calculate ECLs for trade receivables. The provision rates are based on days past due for groupings of
various customer segments that have similar loss patterns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
provision matrix is initially based on the Company&#x2019;s historical observed default rates. The Company will calibrate the matrix to
adjust historical credit loss experience with forward-looking information. At every reporting date, historical default rates are updated
and changes in the forward-looking estimates are analysed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate.
The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Company&#x2019;s historical credit
loss experience and forecast of economic conditions may also not be representative of customer&#x2019;s actual default in the future.
The information about the ECLs on the Company&#x2019;s trade receivables is disclosed in Note 23 (a). The carrying amount of the Company&#x2019;s
trade receivables as at the end of each reporting period were disclosed in Note 12.&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;3.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Significant accounting judgements and estimates (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Key
                                            sources of estimation uncertainty (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allowance
                                            for expected credit losses of other receivables &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group assessed the latest performance and financial position of the counterparties, adjusted for the outlook of the industry in which
the counterparties operate in, and concluded that there had been no significant increase in credit risk since initial recognition of
the financial assets. Accordingly, the Group measured the impairment loss allowance using 12-month ECL and determined that the ECL is
insignificant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Group&#x2019;s other receivables as at June 30, 2025 were S$&lt;span id="xdx_90C_ecustom--OthersReceivables_iI_c20250630_zNZeieUc2Gac"&gt;206,391&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(US$&lt;span id="xdx_903_ecustom--OthersReceivables_iI_uUSD_c20250630_zrKhZoRBu6u8"&gt;162,070&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
(June 30, 2024: S$&lt;span id="xdx_906_ecustom--OthersReceivables_iI_c20240630_zcicjvmP7p72"&gt;213,644&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(e)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Leases &#x2013; estimating the incremental borrowing rate&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate to measure
lease liabilities. The incremental borrowing rate is the rate of interest that the Group would have to pay to borrow over a similar term,
and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic
environment. The incremental borrowing rate therefore reflects what the Group &#x2018;would have to pay&#x2019;, which requires estimation
when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Group estimates
the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to make certain
entity-specific estimates.&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:Inventories
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000924"
      unitRef="SGD">376291</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000926"
      unitRef="USD">295850</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000928"
      unitRef="SGD">72030</ifrs-full:Inventories>
    <ifrs-full:InventoriesTotal
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000930"
      unitRef="SGD">37629</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000932"
      unitRef="USD">29585</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000934"
      unitRef="SGD">7203</ifrs-full:InventoriesTotal>
    <BMGL:OthersReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000935"
      unitRef="SGD">206391</BMGL:OthersReceivables>
    <BMGL:OthersReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000936"
      unitRef="USD">162070</BMGL:OthersReceivables>
    <BMGL:OthersReceivables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000937"
      unitRef="SGD">213644</BMGL:OthersReceivables>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000939">&lt;p id="xdx_80B_eifrs-full--DisclosureOfRevenueExplanatory_zzVe5du4kQEg" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zt9fFz8JZyg9"&gt;Revenue&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zg589ArOBNR8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zgY8SssJj8Ig"&gt;Summary
of revenue from transfer of goods and services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zJSMp0T9YV6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230701__20240630_zxDW9goPP9qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Type of service&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--Revenue_hifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zUrdzqUB9b12" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt"&gt;Rendering of services &#x2013; Medical services&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zYny4s4eHom6" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Rendering of services - Medical services"&gt;8,900,027&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_zwFhhuC4tmV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--Revenue_uUSD_c20240701__20250630_zqPXIcZVGZpl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;8,900,027&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Timing of transfer of service&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_hifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_z0kWK0HRvYI2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;At a point in time&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zCubJur4o6Si" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services"&gt;8,900,027&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_z9YYotkhmN3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Revenue_uUSD_c20240701__20250630_zYdCNdgWixj3" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services"&gt;8,900,027&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z0fN8uP1JDLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</ifrs-full:DisclosureOfRevenueExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices contextRef="From2024-07-01to2025-06-30" id="Fact000941">&lt;p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zg589ArOBNR8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zgY8SssJj8Ig"&gt;Summary
of revenue from transfer of goods and services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zJSMp0T9YV6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230701__20240630_zxDW9goPP9qi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Type of service&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--Revenue_hifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zUrdzqUB9b12" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt"&gt;Rendering of services &#x2013; Medical services&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--ProductsAndServicesAxis__custom--MedicalServicesMember_zYny4s4eHom6" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Rendering of services - Medical services"&gt;8,900,027&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_zwFhhuC4tmV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--Revenue_uUSD_c20240701__20250630_zqPXIcZVGZpl" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;8,900,027&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Timing of transfer of service&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_hifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_z0kWK0HRvYI2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;At a point in time&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--Revenue_uUSD_c20240701__20250630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zCubJur4o6Si" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services"&gt;8,900,027&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--Revenue_z9YYotkhmN3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Revenue_uUSD_c20240701__20250630_zYdCNdgWixj3" style="border-bottom: Black 1pt solid; text-align: right" title="Rendering of services - Medical services"&gt;8,900,027&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,319,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,050,923&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices>
    <ifrs-full:Revenue
      contextRef="From2024-07-012025-06-30_custom_MedicalServicesMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">8900027</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-012025-06-30_custom_MedicalServicesMember"
      decimals="0"
      id="Fact000943"
      unitRef="SGD">11319944</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2023-07-012024-06-30_custom_MedicalServicesMember"
      decimals="0"
      id="Fact000944"
      unitRef="SGD">10050923</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000951"
      unitRef="USD">8900027</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000948"
      unitRef="SGD">11319944</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000949"
      unitRef="SGD">10050923</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">8900027</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-012025-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"
      decimals="0"
      id="Fact000953"
      unitRef="SGD">11319944</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2023-07-012024-06-30_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"
      decimals="0"
      id="Fact000954"
      unitRef="SGD">10050923</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000961"
      unitRef="USD">8900027</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000958"
      unitRef="SGD">11319944</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000959"
      unitRef="SGD">10050923</ifrs-full:Revenue>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000963">&lt;p id="xdx_806_eifrs-full--DisclosureOfOtherOperatingIncomeExplanatory_zSDob4D2DEI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_zDNDgc47SXNa"&gt;Other
income&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_z0EGt6Y88i3d" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zmEFHk4BxpAd" style="display: none"&gt;Schedule
of Other income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zQcI36fMgvjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230701__20240630_zl8VqLXIeAnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--RevenueFromGovernmentGrants_maOGLzcHg_z6yPseML2Gs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Government grant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--RevenueFromGovernmentGrants_uUSD_c20240701__20250630_zsA5obhFXjpj" style="width: 14%; text-align: right" title="Government grant"&gt;59,003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;75,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;19,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--RevenueFromInterest_maOGLzcHg_zqQgjS01vjrl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--RevenueFromInterest_uUSD_c20240701__20250630_zx992W9DYSwh" style="text-align: right" title="Interest income"&gt;65,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ServiceIncome_maOGLzcHg_zvK55TG9uJh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Service income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ServiceIncome_uUSD_c20240701__20250630_zIoypFFBAt42" style="text-align: right" title="Service income"&gt;27,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--RentalIncome_maOGLzcHg_zxgglFPtjw4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rental
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--RentalIncome_uUSD_c20240701__20250630_zR3YwcLNx32j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Rental income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;123,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;157,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eifrs-full--OtherIncome_maOGLzcHg_ztN1apPL8Wk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--OtherIncome_uUSD_c20240701__20250630_z5Pd0wSjebmg" style="text-align: right" title="Other income"&gt;591,124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;751,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ReversalOfExpectedCreditLosses_maOGLzcHg_zS8tDxfRHIaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Reversal of ECL&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ReversalOfExpectedCreditLosses_uUSD_c20240701__20250630_ziAFvIafIb3d" style="border-bottom: Black 1pt solid; text-align: right" title="Reversal of ECL"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;55,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--OtherGainsLosses_iT_mtOGLzcHg_zbSfOr8b8zV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--OtherGainsLosses_iT_uUSD_c20240701__20250630_zEDsJGfzVwpe" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;866,580&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,102,203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;461,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zRlA7XZO8Ka9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;Other
income pertains to the reversal of long-outstanding payables which are no longer considered due. The reversal was made after confirming
that no obligation remains, as no claims or demands have been received from the creditors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact000965">&lt;p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutOtherIncomeExplanatory_z0EGt6Y88i3d" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zmEFHk4BxpAd" style="display: none"&gt;Schedule
of Other income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zQcI36fMgvjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230701__20240630_zl8VqLXIeAnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--RevenueFromGovernmentGrants_maOGLzcHg_z6yPseML2Gs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Government grant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--RevenueFromGovernmentGrants_uUSD_c20240701__20250630_zsA5obhFXjpj" style="width: 14%; text-align: right" title="Government grant"&gt;59,003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;75,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;19,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--RevenueFromInterest_maOGLzcHg_zqQgjS01vjrl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--RevenueFromInterest_uUSD_c20240701__20250630_zx992W9DYSwh" style="text-align: right" title="Interest income"&gt;65,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ServiceIncome_maOGLzcHg_zvK55TG9uJh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Service income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ServiceIncome_uUSD_c20240701__20250630_zIoypFFBAt42" style="text-align: right" title="Service income"&gt;27,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--RentalIncome_maOGLzcHg_zxgglFPtjw4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rental
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--RentalIncome_uUSD_c20240701__20250630_zR3YwcLNx32j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Rental income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;123,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;157,040&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eifrs-full--OtherIncome_maOGLzcHg_ztN1apPL8Wk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--OtherIncome_uUSD_c20240701__20250630_z5Pd0wSjebmg" style="text-align: right" title="Other income"&gt;591,124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;751,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ReversalOfExpectedCreditLosses_maOGLzcHg_zS8tDxfRHIaf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Reversal of ECL&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ReversalOfExpectedCreditLosses_uUSD_c20240701__20250630_ziAFvIafIb3d" style="border-bottom: Black 1pt solid; text-align: right" title="Reversal of ECL"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0992"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;55,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--OtherGainsLosses_iT_mtOGLzcHg_zbSfOr8b8zV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--OtherGainsLosses_iT_uUSD_c20240701__20250630_zEDsJGfzVwpe" style="border-bottom: Black 1pt solid; text-align: right" title="Other income"&gt;866,580&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,102,203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;461,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDetailedInformationAboutOtherIncomeExplanatory>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000970"
      unitRef="USD">59003</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000967"
      unitRef="SGD">75046</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000968"
      unitRef="SGD">19600</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromInterest
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000975"
      unitRef="USD">65466</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000972"
      unitRef="SGD">83267</ifrs-full:RevenueFromInterest>
    <BMGL:ServiceIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000980"
      unitRef="USD">27518</BMGL:ServiceIncome>
    <BMGL:ServiceIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000977"
      unitRef="SGD">35000</BMGL:ServiceIncome>
    <ifrs-full:RentalIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000985"
      unitRef="USD">123469</ifrs-full:RentalIncome>
    <ifrs-full:RentalIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000982"
      unitRef="SGD">157040</ifrs-full:RentalIncome>
    <ifrs-full:OtherIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000990"
      unitRef="USD">591124</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000987"
      unitRef="SGD">751850</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000988"
      unitRef="SGD">385688</ifrs-full:OtherIncome>
    <BMGL:ReversalOfExpectedCreditLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000993"
      unitRef="SGD">55741</BMGL:ReversalOfExpectedCreditLosses>
    <ifrs-full:OtherGainsLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001000"
      unitRef="USD">866580</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000997"
      unitRef="SGD">1102203</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000998"
      unitRef="SGD">461029</ifrs-full:OtherGainsLosses>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001002">&lt;p id="xdx_803_eifrs-full--DisclosureOfFinanceCostExplanatory_zxWbvWEIfUAe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zWoDLbfTk727"&gt;Finance
cost&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_897_ecustom--DisclosureOfDetailedInformationAboutFinanceCostExplanatory_zqI950I3xYy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zFJdkm8yEad1" style="display: none"&gt;Schedule
of Finance cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240701__20250630_zotMZH6LvfGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230701__20240630_zg6OGOwTaZC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense on:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--InterestExpenseOnBorrowings_maFCzCYG_zZQBUxzFcZ27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 46%; text-align: left"&gt;- Bank borrowings&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zvn8O8rQdoyi" style="width: 14%; text-align: right" title="Interest expense on bank borrowings"&gt;69,960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;88,982&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;160,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--InterestExpenseOnBorrowings_zZhIxQtlxiuj" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest expense on bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zLX1Qsmi04Y2" style="text-align: right" title="Interest expense on bank borrowings"&gt;69,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eifrs-full--InterestExpenseOnLeaseLiabilities_maFCzCYG_z2K4eUN2YWag" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;- Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zfQIkmOnEqP7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities"&gt;90,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;114,966&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,461&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--InterestExpenseOnLeaseLiabilities_zlGBw0jgAxJh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zk5ryB9OmTj7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities"&gt;90,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;114,966&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,461&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eifrs-full--FinanceCosts_iT_mtFCzCYG_zgNgOQGrKinf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Finance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--FinanceCosts_iT_uUSD_c20240701__20250630_zUmPJJUe9kOe" style="border-bottom: Black 1pt solid; text-align: right" title="Finance costs"&gt;160,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203,948&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;176,238&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zAgV9K51z6xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFinanceCostExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001004">&lt;p id="xdx_897_ecustom--DisclosureOfDetailedInformationAboutFinanceCostExplanatory_zqI950I3xYy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zFJdkm8yEad1" style="display: none"&gt;Schedule
of Finance cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240701__20250630_zotMZH6LvfGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230701__20240630_zg6OGOwTaZC1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense on:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--InterestExpenseOnBorrowings_maFCzCYG_zZQBUxzFcZ27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 46%; text-align: left"&gt;- Bank borrowings&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zvn8O8rQdoyi" style="width: 14%; text-align: right" title="Interest expense on bank borrowings"&gt;69,960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;88,982&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;160,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--InterestExpenseOnBorrowings_zZhIxQtlxiuj" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest expense on bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--InterestExpenseOnBorrowings_uUSD_c20240701__20250630_zLX1Qsmi04Y2" style="text-align: right" title="Interest expense on bank borrowings"&gt;69,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eifrs-full--InterestExpenseOnLeaseLiabilities_maFCzCYG_z2K4eUN2YWag" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;- Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zfQIkmOnEqP7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities"&gt;90,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;114,966&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,461&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--InterestExpenseOnLeaseLiabilities_zlGBw0jgAxJh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zk5ryB9OmTj7" style="border-bottom: Black 1pt solid; text-align: right" title="Interest expenses on lease liabilities"&gt;90,389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;114,966&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,461&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eifrs-full--FinanceCosts_iT_mtFCzCYG_zgNgOQGrKinf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Finance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--FinanceCosts_iT_uUSD_c20240701__20250630_zUmPJJUe9kOe" style="border-bottom: Black 1pt solid; text-align: right" title="Finance costs"&gt;160,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203,948&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;176,238&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDetailedInformationAboutFinanceCostExplanatory>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001009"
      unitRef="USD">69960</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001006"
      unitRef="SGD">88982</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001007"
      unitRef="SGD">160777</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001014"
      unitRef="USD">69960</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001011"
      unitRef="SGD">88982</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001012"
      unitRef="SGD">160777</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001019"
      unitRef="USD">90389</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001016"
      unitRef="SGD">114966</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001017"
      unitRef="SGD">15461</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001024"
      unitRef="USD">90389</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001021"
      unitRef="SGD">114966</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001022"
      unitRef="SGD">15461</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:FinanceCosts
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001029"
      unitRef="USD">160349</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001026"
      unitRef="SGD">203948</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001027"
      unitRef="SGD">176238</ifrs-full:FinanceCosts>
    <BMGL:DisclosureOfProfitLossBeforeTaxExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001031">&lt;p id="xdx_809_ecustom--DisclosureOfProfitLossBeforeTaxExplanatory_zYF8sn4ILxRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82D_zDDXbMHmOd9f"&gt;(Loss)/Profit before tax&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_z2CvdijwpRu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Profit
before tax has been arrived at after charging:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zV56QQ3MPSJ9" style="display: none"&gt;Schedule
of Profit before tax&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zfQRdLsNeQr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230701__20240630_zMrtXK5Z5jl5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--SalesAndMarketingExpense_zm4fxnBkkNl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Marketing and advertisement&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--SalesAndMarketingExpense_uUSD_c20240701__20250630_zXo0mueiFFY8" style="width: 14%; text-align: right" title="Marketing and advertisement"&gt;480,960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;611,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;698,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--ProfessionalFeesExpense_zP0bwYtAUvi3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Legal and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--ProfessionalFeesExpense_uUSD_c20240701__20250630_ztynUwXJj6Q2" style="text-align: right" title="Legal and professional fees"&gt;191,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;426,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--InsuranceExpense_zO1q2E0mtfTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--InsuranceExpense_uUSD_c20240701__20250630_zDSZI0xvCkbb" style="text-align: right" title="Insurance"&gt;269,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;342,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TransportationExpense_zR68IiE1L9Nc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Transportation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--TransportationExpense_uUSD_c20240701__20250630_zeqSo1EN0jRc" style="text-align: right" title="Transportation"&gt;34,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BadDebtsWrittenOff_zGWzKyGGE3Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bad debts written off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--BadDebtsWrittenOff_uUSD_c20240701__20250630_z03E7GGYrOV7" style="text-align: right" title="Bad debts written off"&gt;189,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ProvisionForExpectedCreditLosses_zEvrB05ZeEIj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Provision for expected credit losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ProvisionForExpectedCreditLosses_uUSD_c20240701__20250630_zOYlbTczwA79" style="text-align: right" title="Provision for expected credit losses"&gt;536,404&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--DepreciationPropertyPlantAndEquipment_zwKE2H3odbXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DepreciationOfPropertyAndEquipment_uUSD_c20240701__20250630_zG5S3Y8cTakf" style="text-align: right" title="Depreciation of property and equipment"&gt;84,174&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--AmortisationExpense_zW5o3xpAYzx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amortisation of right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--AmortisationExpense_uUSD_c20240701__20250630_zJ3QwWOoYRkc" style="text-align: right" title="Amortisation of right-of-use assets"&gt;843,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,073,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--RecruitmentExpenses_z2IYbQCtdvt1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Recruitment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RecruitmentExpenses_uUSD_c20240701__20250630_zyvbvwS5XRIc" style="text-align: right" title="Recruitment"&gt;1,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--SubscriptionCirculationRevenue_zF79tmeO4j6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Membership and subscription&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--SubscriptionCirculationRevenue_uUSD_c20240701__20250630_zuJkoceV38bi" style="text-align: right" title="Membership and subscription"&gt;16,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TelephoneExpense_zgw0ybXBITj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Telephone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TelephoneExpense_uUSD_c20240701__20250630_z3EWC2y2vs6j" style="text-align: right" title="Telephone"&gt;32,689&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EmployeeBenefitsExpenses_zPLHIBxTBCua" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employee benefit expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DirectorsSalariesAndBonuses_z2F7ar6XH5C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Director&#x2019;s salaries and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalariesAndBonuses_uUSD_c20240701__20250630_zJyZVBgcyzv5" style="text-align: right" title="Director's salaries and bonuses"&gt;261,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DirectorsCentralProvidentFund_zrcNNKeVszLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Director&#x2019;s CPF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsCentralProvidentFund_uUSD_c20240701__20250630_zLRb1v9xpyNk" style="text-align: right" title="Director's CPF"&gt;23,764&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--EmployeesSalariesAndBonus_zonympWtyKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Employees&#x2019; salaries and bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EmployeesSalariesAndBonus_uUSD_c20240701__20250630_z0jOwS3HTZP" style="text-align: right" title="Employees' salaries and bonus"&gt;3,773,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,799,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,218,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeesCentralProvidentFund_zY7HxnES0T58" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Employees&#x2019; CPF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EmployeesCentralProvidentFund_uUSD_c20240701__20250630_zWqqeuA7E587" style="text-align: right" title="Employees' CPF"&gt;346,363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OtherStaffExpenses_zLJfRmX5698b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Other staff expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--OtherStaffExpenses_uUSD_c20240701__20250630_zWuFaLYtWFXk" style="text-align: right" title="Other staff expenses"&gt;667,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;848,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A7_zs4kmrQapNAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</BMGL:DisclosureOfProfitLossBeforeTaxExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001033">&lt;p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory_z2CvdijwpRu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Profit
before tax has been arrived at after charging:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zV56QQ3MPSJ9" style="display: none"&gt;Schedule
of Profit before tax&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zfQRdLsNeQr7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230701__20240630_zMrtXK5Z5jl5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--SalesAndMarketingExpense_zm4fxnBkkNl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Marketing and advertisement&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--SalesAndMarketingExpense_uUSD_c20240701__20250630_zXo0mueiFFY8" style="width: 14%; text-align: right" title="Marketing and advertisement"&gt;480,960&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;611,733&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;698,336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--ProfessionalFeesExpense_zP0bwYtAUvi3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Legal and professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--ProfessionalFeesExpense_uUSD_c20240701__20250630_ztynUwXJj6Q2" style="text-align: right" title="Legal and professional fees"&gt;191,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;426,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--InsuranceExpense_zO1q2E0mtfTg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--InsuranceExpense_uUSD_c20240701__20250630_zDSZI0xvCkbb" style="text-align: right" title="Insurance"&gt;269,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;342,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TransportationExpense_zR68IiE1L9Nc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Transportation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--TransportationExpense_uUSD_c20240701__20250630_zeqSo1EN0jRc" style="text-align: right" title="Transportation"&gt;34,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BadDebtsWrittenOff_zGWzKyGGE3Ii" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bad debts written off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--BadDebtsWrittenOff_uUSD_c20240701__20250630_z03E7GGYrOV7" style="text-align: right" title="Bad debts written off"&gt;189,013&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ProvisionForExpectedCreditLosses_zEvrB05ZeEIj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Provision for expected credit losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ProvisionForExpectedCreditLosses_uUSD_c20240701__20250630_zOYlbTczwA79" style="text-align: right" title="Provision for expected credit losses"&gt;536,404&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--DepreciationPropertyPlantAndEquipment_zwKE2H3odbXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DepreciationOfPropertyAndEquipment_uUSD_c20240701__20250630_zG5S3Y8cTakf" style="text-align: right" title="Depreciation of property and equipment"&gt;84,174&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--AmortisationExpense_zW5o3xpAYzx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Amortisation of right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--AmortisationExpense_uUSD_c20240701__20250630_zJ3QwWOoYRkc" style="text-align: right" title="Amortisation of right-of-use assets"&gt;843,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,073,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--RecruitmentExpenses_z2IYbQCtdvt1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Recruitment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RecruitmentExpenses_uUSD_c20240701__20250630_zyvbvwS5XRIc" style="text-align: right" title="Recruitment"&gt;1,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--SubscriptionCirculationRevenue_zF79tmeO4j6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Membership and subscription&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--SubscriptionCirculationRevenue_uUSD_c20240701__20250630_zuJkoceV38bi" style="text-align: right" title="Membership and subscription"&gt;16,207&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--TelephoneExpense_zgw0ybXBITj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Telephone&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TelephoneExpense_uUSD_c20240701__20250630_z3EWC2y2vs6j" style="text-align: right" title="Telephone"&gt;32,689&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--EmployeeBenefitsExpenses_zPLHIBxTBCua" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employee benefit expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DirectorsSalariesAndBonuses_z2F7ar6XH5C9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Director&#x2019;s salaries and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalariesAndBonuses_uUSD_c20240701__20250630_zJyZVBgcyzv5" style="text-align: right" title="Director's salaries and bonuses"&gt;261,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DirectorsCentralProvidentFund_zrcNNKeVszLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Director&#x2019;s CPF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsCentralProvidentFund_uUSD_c20240701__20250630_zLRb1v9xpyNk" style="text-align: right" title="Director's CPF"&gt;23,764&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--EmployeesSalariesAndBonus_zonympWtyKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Employees&#x2019; salaries and bonus&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EmployeesSalariesAndBonus_uUSD_c20240701__20250630_z0jOwS3HTZP" style="text-align: right" title="Employees' salaries and bonus"&gt;3,773,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,799,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,218,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeesCentralProvidentFund_zY7HxnES0T58" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Employees&#x2019; CPF&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EmployeesCentralProvidentFund_uUSD_c20240701__20250630_zWqqeuA7E587" style="text-align: right" title="Employees' CPF"&gt;346,363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--OtherStaffExpenses_zLJfRmX5698b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Other staff expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--OtherStaffExpenses_uUSD_c20240701__20250630_zWuFaLYtWFXk" style="text-align: right" title="Other staff expenses"&gt;667,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;848,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,576&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</BMGL:DisclosureOfDetailedInformationAboutProfitLossBeforeTaxExplanatory>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001038"
      unitRef="USD">480960</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001035"
      unitRef="SGD">611733</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001036"
      unitRef="SGD">698336</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001043"
      unitRef="USD">191393</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001040"
      unitRef="SGD">243433</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001041"
      unitRef="SGD">426740</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:InsuranceExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001048"
      unitRef="USD">269199</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001045"
      unitRef="SGD">342394</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001046"
      unitRef="SGD">48112</ifrs-full:InsuranceExpense>
    <ifrs-full:TransportationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001053"
      unitRef="USD">34789</ifrs-full:TransportationExpense>
    <ifrs-full:TransportationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001050"
      unitRef="SGD">44248</ifrs-full:TransportationExpense>
    <ifrs-full:TransportationExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001051"
      unitRef="SGD">38367</ifrs-full:TransportationExpense>
    <BMGL:BadDebtsWrittenOff
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001058"
      unitRef="USD">189013</BMGL:BadDebtsWrittenOff>
    <BMGL:BadDebtsWrittenOff
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001055"
      unitRef="SGD">240405</BMGL:BadDebtsWrittenOff>
    <BMGL:ProvisionForExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001063"
      unitRef="USD">536404</BMGL:ProvisionForExpectedCreditLosses>
    <BMGL:ProvisionForExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001060"
      unitRef="SGD">682252</BMGL:ProvisionForExpectedCreditLosses>
    <BMGL:ProvisionForExpectedCreditLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001061"
      unitRef="SGD">50168</BMGL:ProvisionForExpectedCreditLosses>
    <BMGL:DepreciationOfPropertyAndEquipment
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001068"
      unitRef="USD">84174</BMGL:DepreciationOfPropertyAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001065"
      unitRef="SGD">107659</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001066"
      unitRef="SGD">30093</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:AmortisationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001073"
      unitRef="USD">843989</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001070"
      unitRef="SGD">1073469</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001071"
      unitRef="SGD">498635</ifrs-full:AmortisationExpense>
    <BMGL:RecruitmentExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001078"
      unitRef="USD">1815</BMGL:RecruitmentExpenses>
    <BMGL:RecruitmentExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001075"
      unitRef="SGD">2309</BMGL:RecruitmentExpenses>
    <BMGL:RecruitmentExpenses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001076"
      unitRef="SGD">131786</BMGL:RecruitmentExpenses>
    <ifrs-full:SubscriptionCirculationRevenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001083"
      unitRef="USD">16207</ifrs-full:SubscriptionCirculationRevenue>
    <ifrs-full:SubscriptionCirculationRevenue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001080"
      unitRef="SGD">20614</ifrs-full:SubscriptionCirculationRevenue>
    <ifrs-full:SubscriptionCirculationRevenue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001081"
      unitRef="SGD">38919</ifrs-full:SubscriptionCirculationRevenue>
    <BMGL:TelephoneExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001088"
      unitRef="USD">32689</BMGL:TelephoneExpense>
    <BMGL:TelephoneExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001085"
      unitRef="SGD">41806</BMGL:TelephoneExpense>
    <BMGL:TelephoneExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001086"
      unitRef="SGD">32746</BMGL:TelephoneExpense>
    <BMGL:DirectorsSalariesAndBonuses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001096"
      unitRef="USD">261813</BMGL:DirectorsSalariesAndBonuses>
    <BMGL:DirectorsSalariesAndBonuses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001093"
      unitRef="SGD">333000</BMGL:DirectorsSalariesAndBonuses>
    <BMGL:DirectorsSalariesAndBonuses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001094"
      unitRef="SGD">121200</BMGL:DirectorsSalariesAndBonuses>
    <BMGL:DirectorsCentralProvidentFund
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001101"
      unitRef="USD">23764</BMGL:DirectorsCentralProvidentFund>
    <BMGL:DirectorsCentralProvidentFund
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001098"
      unitRef="SGD">30226</BMGL:DirectorsCentralProvidentFund>
    <BMGL:DirectorsCentralProvidentFund
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001099"
      unitRef="SGD">137</BMGL:DirectorsCentralProvidentFund>
    <BMGL:EmployeesSalariesAndBonus
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001106"
      unitRef="USD">3773252</BMGL:EmployeesSalariesAndBonus>
    <BMGL:EmployeesSalariesAndBonus
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001103"
      unitRef="SGD">4799198</BMGL:EmployeesSalariesAndBonus>
    <BMGL:EmployeesSalariesAndBonus
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001104"
      unitRef="SGD">3218275</BMGL:EmployeesSalariesAndBonus>
    <BMGL:EmployeesCentralProvidentFund
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001111"
      unitRef="USD">346363</BMGL:EmployeesCentralProvidentFund>
    <BMGL:EmployeesCentralProvidentFund
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001108"
      unitRef="SGD">440539</BMGL:EmployeesCentralProvidentFund>
    <BMGL:EmployeesCentralProvidentFund
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001109"
      unitRef="SGD">177754</BMGL:EmployeesCentralProvidentFund>
    <BMGL:OtherStaffExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001116"
      unitRef="USD">667075</BMGL:OtherStaffExpenses>
    <BMGL:OtherStaffExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001113"
      unitRef="SGD">848452</BMGL:OtherStaffExpenses>
    <BMGL:OtherStaffExpenses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001114"
      unitRef="SGD">121576</BMGL:OtherStaffExpenses>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001118">&lt;p id="xdx_80E_eifrs-full--DisclosureOfIncomeTaxExplanatory_zmye4p91Mzl3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_820_zegVTmqWCEWc"&gt;Income
tax (benefit)/expense&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_zKRKvpvLPn99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
major components of income tax expense recognized in profit or loss for the periods ended June 30, 2025 and 2024 were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B4_zOkcU8aJDK4g" style="display: none"&gt;Schedule
of component of income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_z72t25CmNjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230701__20240630_zX7SCv2fJ87k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB_zP0ofMd8SLu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncome_maITECOzPgr_z05qB93wkJF1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;- Current year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CurrentTaxExpenseIncome_uUSD_c20240701__20250630_zO3fmtjagek9" style="width: 14%; text-align: right" title="- Current year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;383,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DeferredTaxExpenseIncome_maITECOzPgr_ztHkHoRmRErc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Deferred income tax&lt;/td&gt;&lt;td style="color: red"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DeferredTaxExpenseIncome_uUSD_c20240701__20250630_z9A8WG1h4nVb" style="text-align: right" title="- Deferred income tax"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: red"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,440&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzPgr_zQdnspfq28F6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    Underprovision in respect of prior years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zXgXqyvHf8mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="-Underprovision in respect of prior years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OverprovisionInRespectOfPriorYears_maITECOzPgr_zgZj4BoOjNTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- Overprovision in respect of prior years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zKFKwIK4YRt1" style="border-bottom: Black 1pt solid; text-align: right" title="- Overprovision in respect of prior years"&gt;(328,444&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,748&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzPgr_zcGFYykKQDHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income tax (benefit)/expense recognized in profit or loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zm5SOzgYM9vk" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense recognized in profit or loss"&gt;(328,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,393&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;331,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zqYqJuh9TNFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Relationship
between tax expense and accounting profit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_zc1V0F7XMD5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation between tax expense and the product of accounting (loss)/profit multiplied by the applicable corporate tax rate for the financial
periods ended June 30, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span id="xdx_8BE_zctMmdtSK9Sj" style="display: none"&gt;Schedule of reconciliation
between tax expense and corporate tax rate&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zyTwNGAOVeO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230701__20240630_ztlWz7Vx54xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_zd7CrxkW0Ep8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt"&gt;(Loss)/Profit before tax&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--ProfitLossBeforeTax_uUSD_c20240701__20250630_zwiWeCGx3CBc" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="(Loss)/Profit before tax"&gt;(9,832,138&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;(12,505,497&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;2,404,561&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_maITECOzdOp_zaUAzDhHu467" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax using the statutory tax rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eifrs-full--ApplicableTaxRate_pid_dp_c20240701__20250630_zJjAnKz6suE1" title="Statutory tax rate"&gt;17&lt;/span&gt;% (2024: &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_c20230701__20240630_zoshOBeXpck6" title="Statutory tax rate"&gt;17&lt;/span&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_uUSD_c20240701__20250630_zJXyOze5Zkke" style="text-align: right" title="Income tax using the statutory tax rate of 17% (2024: 17%)"&gt;(1,671,463&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,125,934&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effects of:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NondeductibleExpenses_maITECOzdOp_zt9IEb2eZ20i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NondeductibleExpenses_uUSD_c20240701__20250630_zRRkNWd47233" style="text-align: right" title="Non-deductible expenses"&gt;1,661,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,113,498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--TaxEffectOfTaxLosses_maITECOzdOp_zUJpTY9br8C2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Income not subject to tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--TaxEffectOfTaxLosses_uUSD_c20240701__20250630_z8toyypwFmve" style="text-align: right" title="Income not subject to tax"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxExemption_maITECOzdOp_z4Ao0HfzyZ85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Income tax exemption&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--IncomeTaxExemption_uUSD_c20240701__20250630_zndnrXr1Xlp2" style="text-align: right" title="Income tax exemption"&gt;(13,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,350&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--UtilisationOfCapitalAllowance_iN_di_msITECOzdOp_zPlXDmzsos7h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Utilisation of capital allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UtilisationOfCapitalAllowance_iN_di_uUSD_c20240701__20250630_zFbhGVB59ool" style="text-align: right" title="(Loss)/Profit before tax"&gt;(353&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(449&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,322&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--UtilisationOfDeferredTaxAssets_maITECOzdOp_zA18jw3pPKTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Utilisation of deferred tax assets not recognised in prior year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--UtilisationOfDeferredTaxAssets_uUSD_c20240701__20250630_z9s7XwgAYLPe" style="text-align: right" title="- Utilisation of deferred tax assets not recognised in prior year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,037&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_maITECOzdOp_zKr6icq0bUKc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Deferred tax asset not recognized during the financial year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_uUSD_c20240701__20250630_zj9zG7k3N1R9" style="text-align: right" title="Deferred tax asset not recognized during the financial year"&gt;23,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredIncomeTax_iN_di_msITECOzdOp_zSAuB8w5MtCh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Deferred income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DeferredIncomeTax_iN_di_uUSD_c20240701__20250630_ziuDHctyStcg" style="text-align: right" title="Deferred income tax"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,440&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzdOp_zysRGi0csu04" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-Underprovision
    in respect of prior years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zwZekJQntUE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underprovision in respect of prior years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--OverprovisionInRespectOfPriorYears_maITECOzdOp_zKEwAKwgm2T9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;-Overprovision in respect of prior years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zAS0PfjbLWgj" style="border-bottom: Black 1pt solid; text-align: right" title="Overprovision in respect of prior years"&gt;(328,444&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,748&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzdOp_zodhLq0HOyjg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income tax (benefit)/expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zhUZeXA4zcZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense"&gt;(328,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,393&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;331,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zTjUPeBSFAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001120">&lt;p id="xdx_899_ecustom--DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory_zKRKvpvLPn99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
major components of income tax expense recognized in profit or loss for the periods ended June 30, 2025 and 2024 were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B4_zOkcU8aJDK4g" style="display: none"&gt;Schedule
of component of income tax expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_z72t25CmNjaa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230701__20240630_zX7SCv2fJ87k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB_zP0ofMd8SLu" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentTaxExpenseIncome_maITECOzPgr_z05qB93wkJF1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;- Current year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CurrentTaxExpenseIncome_uUSD_c20240701__20250630_zO3fmtjagek9" style="width: 14%; text-align: right" title="- Current year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;383,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DeferredTaxExpenseIncome_maITECOzPgr_ztHkHoRmRErc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Deferred income tax&lt;/td&gt;&lt;td style="color: red"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DeferredTaxExpenseIncome_uUSD_c20240701__20250630_z9A8WG1h4nVb" style="text-align: right" title="- Deferred income tax"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: red"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: red; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,440&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzPgr_zQdnspfq28F6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    Underprovision in respect of prior years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zXgXqyvHf8mb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="-Underprovision in respect of prior years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OverprovisionInRespectOfPriorYears_maITECOzPgr_zgZj4BoOjNTa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- Overprovision in respect of prior years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zKFKwIK4YRt1" style="border-bottom: Black 1pt solid; text-align: right" title="- Overprovision in respect of prior years"&gt;(328,444&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,748&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzPgr_zcGFYykKQDHb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income tax (benefit)/expense recognized in profit or loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zm5SOzgYM9vk" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense recognized in profit or loss"&gt;(328,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,393&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;331,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</BMGL:DisclosureOfDetailedInformationAboutIncomeTaxExpenseExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001126"
      unitRef="SGD">383453</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001131"
      unitRef="SGD">-49440</ifrs-full:DeferredTaxExpenseIncome>
    <BMGL:UnderprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001138"
      unitRef="USD">279</BMGL:UnderprovisionInRespectOfPriorYears>
    <BMGL:UnderprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001135"
      unitRef="SGD">355</BMGL:UnderprovisionInRespectOfPriorYears>
    <BMGL:OverprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001143"
      unitRef="USD">-328444</BMGL:OverprovisionInRespectOfPriorYears>
    <BMGL:OverprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001140"
      unitRef="SGD">-417748</BMGL:OverprovisionInRespectOfPriorYears>
    <BMGL:OverprovisionInRespectOfPriorYears
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001141"
      unitRef="SGD">-2252</BMGL:OverprovisionInRespectOfPriorYears>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001148"
      unitRef="USD">-328165</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001145"
      unitRef="SGD">-417393</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001146"
      unitRef="SGD">331761</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001150">&lt;p id="xdx_89A_ecustom--DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory_zc1V0F7XMD5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation between tax expense and the product of accounting (loss)/profit multiplied by the applicable corporate tax rate for the financial
periods ended June 30, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span id="xdx_8BE_zctMmdtSK9Sj" style="display: none"&gt;Schedule of reconciliation
between tax expense and corporate tax rate&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zyTwNGAOVeO2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230701__20240630_ztlWz7Vx54xe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_zd7CrxkW0Ep8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt"&gt;(Loss)/Profit before tax&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--ProfitLossBeforeTax_uUSD_c20240701__20250630_zwiWeCGx3CBc" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="(Loss)/Profit before tax"&gt;(9,832,138&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;(12,505,497&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;2,404,561&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_maITECOzdOp_zaUAzDhHu467" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax using the statutory tax rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eifrs-full--ApplicableTaxRate_pid_dp_c20240701__20250630_zJjAnKz6suE1" title="Statutory tax rate"&gt;17&lt;/span&gt;% (2024: &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIHJlY29uY2lsaWF0aW9uIGJldHdlZW4gdGF4IGV4cGVuc2UgYW5kIGNvcnBvcmF0ZSB0YXggcmF0ZSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_c20230701__20240630_zoshOBeXpck6" title="Statutory tax rate"&gt;17&lt;/span&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_uUSD_c20240701__20250630_zJXyOze5Zkke" style="text-align: right" title="Income tax using the statutory tax rate of 17% (2024: 17%)"&gt;(1,671,463&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,125,934&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effects of:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--NondeductibleExpenses_maITECOzdOp_zt9IEb2eZ20i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NondeductibleExpenses_uUSD_c20240701__20250630_zRRkNWd47233" style="text-align: right" title="Non-deductible expenses"&gt;1,661,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,113,498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,416&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--TaxEffectOfTaxLosses_maITECOzdOp_zUJpTY9br8C2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Income not subject to tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--TaxEffectOfTaxLosses_uUSD_c20240701__20250630_z8toyypwFmve" style="text-align: right" title="Income not subject to tax"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxExemption_maITECOzdOp_z4Ao0HfzyZ85" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Income tax exemption&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--IncomeTaxExemption_uUSD_c20240701__20250630_zndnrXr1Xlp2" style="text-align: right" title="Income tax exemption"&gt;(13,700&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,350&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--UtilisationOfCapitalAllowance_iN_di_msITECOzdOp_zPlXDmzsos7h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Utilisation of capital allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--UtilisationOfCapitalAllowance_iN_di_uUSD_c20240701__20250630_zFbhGVB59ool" style="text-align: right" title="(Loss)/Profit before tax"&gt;(353&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(449&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,322&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--UtilisationOfDeferredTaxAssets_maITECOzdOp_zA18jw3pPKTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Utilisation of deferred tax assets not recognised in prior year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--UtilisationOfDeferredTaxAssets_uUSD_c20240701__20250630_z9s7XwgAYLPe" style="text-align: right" title="- Utilisation of deferred tax assets not recognised in prior year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,037&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_maITECOzdOp_zKr6icq0bUKc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Deferred tax asset not recognized during the financial year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DeferredTaxAssetsNotRecognizedOnTaxLosses_uUSD_c20240701__20250630_zj9zG7k3N1R9" style="text-align: right" title="Deferred tax asset not recognized during the financial year"&gt;23,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredIncomeTax_iN_di_msITECOzdOp_zSAuB8w5MtCh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Deferred income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DeferredIncomeTax_iN_di_uUSD_c20240701__20250630_ziuDHctyStcg" style="text-align: right" title="Deferred income tax"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,440&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--UnderprovisionInRespectOfPriorYears_maITECOzdOp_zysRGi0csu04" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-Underprovision
    in respect of prior years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--UnderprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zwZekJQntUE2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Underprovision in respect of prior years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--OverprovisionInRespectOfPriorYears_maITECOzdOp_zKEwAKwgm2T9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;-Overprovision in respect of prior years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OverprovisionInRespectOfPriorYears_uUSD_c20240701__20250630_zAS0PfjbLWgj" style="border-bottom: Black 1pt solid; text-align: right" title="Overprovision in respect of prior years"&gt;(328,444&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,748&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_mtITECOzdOp_zodhLq0HOyjg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income tax (benefit)/expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--IncomeTaxExpenseContinuingOperations_iT_uUSD_c20240701__20250630_zhUZeXA4zcZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Income tax (benefit)/expense"&gt;(328,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(417,393&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;331,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</BMGL:DisclosureOfEffectiveIncomeTaxRateReconciliationsExplanatory>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001155"
      unitRef="USD">-9832138</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001152"
      unitRef="SGD">-12505497</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001153"
      unitRef="SGD">2404561</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact001160"
      unitRef="Pure">0.17</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact001162"
      unitRef="Pure">0.17</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001164"
      unitRef="USD">-1671463</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001157"
      unitRef="SGD">-2125934</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001158"
      unitRef="SGD">408775</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <BMGL:NondeductibleExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001169"
      unitRef="USD">1661686</BMGL:NondeductibleExpenses>
    <BMGL:NondeductibleExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001166"
      unitRef="SGD">2113498</BMGL:NondeductibleExpenses>
    <BMGL:NondeductibleExpenses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001167"
      unitRef="SGD">16416</BMGL:NondeductibleExpenses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001172"
      unitRef="SGD">83039</ifrs-full:TaxEffectOfTaxLosses>
    <BMGL:IncomeTaxExemption
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001179"
      unitRef="USD">-13700</BMGL:IncomeTaxExemption>
    <BMGL:IncomeTaxExemption
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001176"
      unitRef="SGD">-17425</BMGL:IncomeTaxExemption>
    <BMGL:IncomeTaxExemption
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001177"
      unitRef="SGD">-75350</BMGL:IncomeTaxExemption>
    <BMGL:UtilisationOfCapitalAllowance
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001184"
      unitRef="USD">353</BMGL:UtilisationOfCapitalAllowance>
    <BMGL:UtilisationOfCapitalAllowance
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001181"
      unitRef="SGD">449</BMGL:UtilisationOfCapitalAllowance>
    <BMGL:UtilisationOfCapitalAllowance
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001182"
      unitRef="SGD">1322</BMGL:UtilisationOfCapitalAllowance>
    <BMGL:UtilisationOfDeferredTaxAssets
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001187"
      unitRef="SGD">-56037</BMGL:UtilisationOfDeferredTaxAssets>
    <BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001194"
      unitRef="USD">23830</BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses>
    <BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001191"
      unitRef="SGD">30310</BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses>
    <BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001192"
      unitRef="SGD">7932</BMGL:DeferredTaxAssetsNotRecognizedOnTaxLosses>
    <BMGL:DeferredIncomeTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001197"
      unitRef="SGD">49440</BMGL:DeferredIncomeTax>
    <BMGL:UnderprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001204"
      unitRef="USD">279</BMGL:UnderprovisionInRespectOfPriorYears>
    <BMGL:UnderprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001201"
      unitRef="SGD">355</BMGL:UnderprovisionInRespectOfPriorYears>
    <BMGL:OverprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001209"
      unitRef="USD">-328444</BMGL:OverprovisionInRespectOfPriorYears>
    <BMGL:OverprovisionInRespectOfPriorYears
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001206"
      unitRef="SGD">-417748</BMGL:OverprovisionInRespectOfPriorYears>
    <BMGL:OverprovisionInRespectOfPriorYears
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001207"
      unitRef="SGD">-2252</BMGL:OverprovisionInRespectOfPriorYears>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001214"
      unitRef="USD">-328165</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001211"
      unitRef="SGD">-417393</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001212"
      unitRef="SGD">331761</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001216">&lt;p id="xdx_800_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_ziJAZW2Jaev9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;9.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_821_zhD4feFeuw2k"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOfRightOfUseAssets_zcL0wtpCbpq7" style="margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_8B9_zyvUX4DjkF5b" style="display: none"&gt;Schedule of Right of use assets&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240701__20250630_zo6f1W5XaOWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230701__20240630_zDyKh9Q68n93" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zjygkYC3N1Ok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;At beginning of financial year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zj5MhPtewhta" style="width: 14%; text-align: right" title="At beginning of financial year"&gt;2,164,551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,753,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,753,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zshkwbPYjof4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlkes6T5WX77" style="text-align: right" title="Additions"&gt;2,575,627&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,275,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z58CQbzBjFf7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Additions"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zqreUGnhhKWb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zJ7F3mhHJ3Nl" style="text-align: right" title="Acquisition"&gt;3,793,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,825,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zxxlgJhDChf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Written off&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z8MmI9xatuU6" style="border-bottom: Black 1pt solid; text-align: right" title="Written off"&gt;(3,118,402&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,966,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zeomylu1puM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;At end of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z2XJujeLn8Qh" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;5,415,473&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,887,940&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,753,093&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_z7buZQ04Tbw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;At beginning of financial year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zepWJUzLP7Za" style="text-align: right" title="At beginning of financial year"&gt;2,146,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,729,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,230,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zwpUEpQBLFs2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zTsadXuGUNk9" style="text-align: right" title="Acquisition"&gt;2,902,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,691,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zfijastsiDWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zVIs6xVq42Gk" style="text-align: right" title="Depreciation"&gt;843,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,073,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zi1KIc4mhLS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Written off&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zYi5sbWCSxW8" style="border-bottom: Black 1pt solid; text-align: right" title="Written off"&gt;(2,974,369&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,783,101&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1264"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zKF5m2yJUibl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;At end of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zE4LvUsnRXf5" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;2,918,011&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,711,418&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,729,633&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--RightofuseAssets_iE_zmeDaEoioJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zxwq0muk8QL9" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;2,497,462&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,176,522&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,460&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--RightofuseAssets_iE_zRhvBajuORCf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;At end of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zjNFvH4G7Eog" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;2,497,462&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,176,522&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,460&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AB_zQ6GOtM1Symc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets contextRef="From2024-07-01to2025-06-30" id="Fact001218">&lt;p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOfRightOfUseAssets_zcL0wtpCbpq7" style="margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_8B9_zyvUX4DjkF5b" style="display: none"&gt;Schedule of Right of use assets&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240701__20250630_zo6f1W5XaOWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230701__20240630_zDyKh9Q68n93" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zjygkYC3N1Ok" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;At beginning of financial year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zj5MhPtewhta" style="width: 14%; text-align: right" title="At beginning of financial year"&gt;2,164,551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,753,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,753,093&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zshkwbPYjof4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlkes6T5WX77" style="text-align: right" title="Additions"&gt;2,575,627&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,275,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z58CQbzBjFf7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Additions"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zqreUGnhhKWb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zJ7F3mhHJ3Nl" style="text-align: right" title="Acquisition"&gt;3,793,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,825,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zxxlgJhDChf1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Written off&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z8MmI9xatuU6" style="border-bottom: Black 1pt solid; text-align: right" title="Written off"&gt;(3,118,402&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,966,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zeomylu1puM8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;At end of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_z2XJujeLn8Qh" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;5,415,473&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,887,940&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,753,093&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--RightofuseAssets_iS_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_z7buZQ04Tbw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;At beginning of financial year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--RightofuseAssets_iS_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zepWJUzLP7Za" style="text-align: right" title="At beginning of financial year"&gt;2,146,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,729,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,230,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zwpUEpQBLFs2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--AcquisitionsThroughBusinessCombinationsRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zTsadXuGUNk9" style="text-align: right" title="Acquisition"&gt;2,902,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,691,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--DepreciationRightofuseAssets_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zfijastsiDWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zVIs6xVq42Gk" style="text-align: right" title="Depreciation"&gt;843,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,073,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--WrittenOffRightofuseAssets_iN_di_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zi1KIc4mhLS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Written off&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WrittenOffRightofuseAssets_iN_di_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zYi5sbWCSxW8" style="border-bottom: Black 1pt solid; text-align: right" title="Written off"&gt;(2,974,369&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(3,783,101&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1264"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--RightofuseAssets_iE_uSGD_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zKF5m2yJUibl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;At end of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__custom--AccumulatedDepreciationMember_zE4LvUsnRXf5" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;2,918,011&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,711,418&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,729,633&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--RightofuseAssets_iE_zmeDaEoioJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zxwq0muk8QL9" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;2,497,462&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,176,522&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,460&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--RightofuseAssets_iE_zRhvBajuORCf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;At end of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--RightofuseAssets_iE_uUSD_c20240701__20250630_zjNFvH4G7Eog" style="border-bottom: Black 1pt solid; text-align: right" title="At end of financial year"&gt;2,497,462&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,176,522&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23,460&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</BMGL:DisclosureOfDetailedInformationAboutOfRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001223"
      unitRef="USD">2164551</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001220"
      unitRef="SGD">2753093</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001221"
      unitRef="SGD">2753093</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001228"
      unitRef="USD">2575627</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001225"
      unitRef="SGD">3275940</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001236"
      unitRef="USD">3793697</ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001233"
      unitRef="SGD">4825203</ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
    <BMGL:WrittenOffRightofuseAssets
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001241"
      unitRef="USD">3118402</BMGL:WrittenOffRightofuseAssets>
    <BMGL:WrittenOffRightofuseAssets
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001238"
      unitRef="SGD">3966296</BMGL:WrittenOffRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001246"
      unitRef="USD">5415473</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001243"
      unitRef="SGD">6887940</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001244"
      unitRef="SGD">2753093</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001251"
      unitRef="USD">2146106</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001248"
      unitRef="SGD">2729633</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2023-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001249"
      unitRef="SGD">2230998</ifrs-full:RightofuseAssets>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets
      contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001256"
      unitRef="USD">2902285</ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets
      contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001253"
      unitRef="SGD">3691417</ifrs-full:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001261"
      unitRef="USD">843989</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001258"
      unitRef="SGD">1073469</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="From2023-07-012024-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001259"
      unitRef="SGD">498635</ifrs-full:DepreciationRightofuseAssets>
    <BMGL:WrittenOffRightofuseAssets
      contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001266"
      unitRef="USD">2974369</BMGL:WrittenOffRightofuseAssets>
    <BMGL:WrittenOffRightofuseAssets
      contextRef="From2024-07-012025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001263"
      unitRef="SGD">3783101</BMGL:WrittenOffRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001271"
      unitRef="USD">2918011</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001268"
      unitRef="SGD">3711418</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30_custom_AccumulatedDepreciationMember"
      decimals="0"
      id="Fact001269"
      unitRef="SGD">2729633</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001276"
      unitRef="USD">2497462</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001273"
      unitRef="SGD">3176522</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001274"
      unitRef="SGD">23460</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001281"
      unitRef="USD">2497462</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001278"
      unitRef="SGD">3176522</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001279"
      unitRef="SGD">23460</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001283">&lt;p id="xdx_806_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zgtPu5hYnpsa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;10.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_82C_zEInHxyAxPcg"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_89B_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zuLG4kYM29k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zZwBvvjCIXla" style="display: none"&gt;Schedule
of Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B4_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--MachineryMember_zeOKGw84jUB6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Machinery&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BC_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--FixturesAndFittingsMember_zu3TCMeEiIui" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Furniture&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&amp;amp;
                                            Fittings&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--MedicalEquipmentMember_znlea5dKw731" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Medical&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RenovationMember_z5q4WpdegFRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Renovation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BE_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--AirConditionerMember_zpJcwKQZIC31" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Air&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;conditioner&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--ComputerAndOfficeEquipmentMember_zau2Ezgx4pfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Computer&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;amp; office&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BD_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--SoftwareMember_zUtHsdyzLZM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BE_zr61neq8C6rk" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zCZ5v7VZxk91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; width: 20%"&gt;At July 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;100,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;86,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;405,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;350,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,034,126&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zDaOUZgqvRbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1296"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1300"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,920&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,920&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zanp3BM2OHT2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;100,852&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;86,724&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;405,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358,168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,042,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zm91ZHPlscU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;Acquisition&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;367,243&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,500,493&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,285,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1318"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;378,669&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;86,978&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,618,519&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zw18jBJKfOPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1324"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zsRdT3QzTkZg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Written
    off&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1332"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(313,691&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(709,330&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(315,832&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1336"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(253,806&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,601,659&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlTKXLdOqJSe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iE_zquz533acuMe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;154,404&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;890,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,396,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,145&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;77,978&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,113,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zvLDGdQ3vFN1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;At July 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;977,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zmKIBQalHaZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,431&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,491&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1374"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,093&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zzLVbLoEvcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;100,664&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;81,533&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;382,200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;352,183&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,007,533&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zFfyPNabMaLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,244,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,192,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1390"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;317,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,116,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zCHxEv3eKnQ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1395"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,528&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1399"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zUoBhUuwjYa6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Written off&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(248,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(687,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(231,410&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1408"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(220,994&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,395,372&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iE_zmfezmVF0xVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;137,072&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;688,904&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,368,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;474,280&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;76,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,836,159&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net book values&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20230701__20240630_eifrs-full--PropertyPlantAndEquipment_iE_zTAn0Sf9Wfsf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;At June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1422"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;188&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,149&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1426"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;34,513&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_zvQBYqEaqWX" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,332&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;202,084&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1435"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,112&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;277,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;US$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_uUSD_zNRoMjmXqZC6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;158,884&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,104&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,694&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;874&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;218,183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p id="xdx_8AE_zJN5oUmqopW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001285">&lt;p id="xdx_89B_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zuLG4kYM29k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zZwBvvjCIXla" style="display: none"&gt;Schedule
of Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B4_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--MachineryMember_zeOKGw84jUB6" style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Machinery&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BC_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full--FixturesAndFittingsMember_zu3TCMeEiIui" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Furniture&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&amp;amp;
                                            Fittings&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--MedicalEquipmentMember_znlea5dKw731" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Medical&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B3_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--RenovationMember_z5q4WpdegFRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Renovation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BE_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--AirConditionerMember_zpJcwKQZIC31" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Air&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                                    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;conditioner&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B2_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--ComputerAndOfficeEquipmentMember_zau2Ezgx4pfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Computer&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;amp; office&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BD_ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis_custom--SoftwareMember_zUtHsdyzLZM2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BE_zr61neq8C6rk" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zCZ5v7VZxk91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; width: 20%"&gt;At July 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;100,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;86,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;405,349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;350,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,034,126&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zDaOUZgqvRbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1296"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1298"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1300"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,920&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,920&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iS_zanp3BM2OHT2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;100,852&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;86,724&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;405,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358,168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,042,046&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zm91ZHPlscU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;Acquisition&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;367,243&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,500,493&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,285,136&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1318"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;378,669&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;86,978&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,618,519&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zw18jBJKfOPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1324"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zsRdT3QzTkZg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Written
    off&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1332"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(313,691&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(709,330&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(315,832&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1336"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(253,806&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,601,659&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_zlTKXLdOqJSe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--GrossCarryingAmountMember_eifrs-full--PropertyPlantAndEquipment_iE_zquz533acuMe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;154,404&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;890,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,396,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,145&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;77,978&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,113,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43A_c20230701__20240630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zvLDGdQ3vFN1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;At July 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;977,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zmKIBQalHaZf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1368"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,888&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,431&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1372"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,491&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1374"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,093&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iS_zzLVbLoEvcr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;100,664&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;81,533&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;382,200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;352,183&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,007,533&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eifrs-full--AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zFfyPNabMaLd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Acquisition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,244,797&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,192,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1390"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;317,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,116,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--DepreciationPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zCHxEv3eKnQ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1395"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,528&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1399"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_hifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_zUoBhUuwjYa6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Written off&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(248,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(687,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(231,410&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1408"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(220,994&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,395,372&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_438_c20240701__20250630__ifrs-full--CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis__ifrs-full--AccumulatedDepreciationAndAmortisationMember_ecustom--PropertyPlantAndEquipmentAccumulatedDepreciation_iE_zmfezmVF0xVh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;47,226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;137,072&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;688,904&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,368,084&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;43,727&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;474,280&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;76,866&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,836,159&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net book values&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20230701__20240630_eifrs-full--PropertyPlantAndEquipment_iE_zTAn0Sf9Wfsf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;At June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1422"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;188&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,191&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,149&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1426"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,985&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;34,513&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_zvQBYqEaqWX" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,332&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;202,084&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1435"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,865&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,112&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;277,507&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;US$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_435_c20240701__20250630_eifrs-full--PropertyPlantAndEquipment_iE_uUSD_zNRoMjmXqZC6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;At June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;158,884&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,104&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1444"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,694&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;874&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;218,183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      decimals="0"
      id="Fact001287"
      unitRef="SGD">47226</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001288"
      unitRef="SGD">100852</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001289"
      unitRef="SGD">86724</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      decimals="0"
      id="Fact001290"
      unitRef="SGD">405349</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      decimals="0"
      id="Fact001291"
      unitRef="SGD">43727</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001292"
      unitRef="SGD">350248</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2023-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001294"
      unitRef="SGD">1034126</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001301"
      unitRef="SGD">7920</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001303"
      unitRef="SGD">7920</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      decimals="0"
      id="Fact001305"
      unitRef="SGD">47226</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001306"
      unitRef="SGD">100852</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001307"
      unitRef="SGD">86724</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      decimals="0"
      id="Fact001308"
      unitRef="SGD">405349</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      decimals="0"
      id="Fact001309"
      unitRef="SGD">43727</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001310"
      unitRef="SGD">358168</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001312"
      unitRef="SGD">1042046</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001315"
      unitRef="SGD">367243</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001316"
      unitRef="SGD">1500493</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      decimals="0"
      id="Fact001317"
      unitRef="SGD">1285136</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001319"
      unitRef="SGD">378669</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001320"
      unitRef="SGD">86978</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001321"
      unitRef="SGD">3618519</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001325"
      unitRef="SGD">13101</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      decimals="0"
      id="Fact001326"
      unitRef="SGD">21545</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001328"
      unitRef="SGD">20114</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001330"
      unitRef="SGD">54760</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001333"
      unitRef="SGD">-313691</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001334"
      unitRef="SGD">-709330</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      decimals="0"
      id="Fact001335"
      unitRef="SGD">-315832</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001337"
      unitRef="SGD">-253806</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001338"
      unitRef="SGD">-9000</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001339"
      unitRef="SGD">-1601659</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_MachineryMember"
      decimals="0"
      id="Fact001350"
      unitRef="SGD">47226</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001351"
      unitRef="SGD">154404</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001352"
      unitRef="SGD">890988</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_RenovationMember"
      decimals="0"
      id="Fact001353"
      unitRef="SGD">1396198</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_AirConditionerMember"
      decimals="0"
      id="Fact001354"
      unitRef="SGD">43727</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001355"
      unitRef="SGD">503145</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001356"
      unitRef="SGD">77978</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember"
      decimals="0"
      id="Fact001357"
      unitRef="SGD">3113666</ifrs-full:PropertyPlantAndEquipment>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      decimals="0"
      id="Fact001359"
      unitRef="SGD">47226</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001360"
      unitRef="SGD">100381</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001361"
      unitRef="SGD">75645</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001362"
      unitRef="SGD">363769</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      decimals="0"
      id="Fact001363"
      unitRef="SGD">43727</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001364"
      unitRef="SGD">346692</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2023-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001366"
      unitRef="SGD">977440</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001369"
      unitRef="SGD">283</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001370"
      unitRef="SGD">5888</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001371"
      unitRef="SGD">18431</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001373"
      unitRef="SGD">5491</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001375"
      unitRef="SGD">30093</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      decimals="0"
      id="Fact001377"
      unitRef="SGD">47226</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001378"
      unitRef="SGD">100664</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001379"
      unitRef="SGD">81533</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001380"
      unitRef="SGD">382200</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      decimals="0"
      id="Fact001381"
      unitRef="SGD">43727</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001382"
      unitRef="SGD">352183</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2024-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001384"
      unitRef="SGD">1007533</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001387"
      unitRef="SGD">277888</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001388"
      unitRef="SGD">1244797</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001389"
      unitRef="SGD">1192766</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001391"
      unitRef="SGD">317744</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001392"
      unitRef="SGD">83144</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001393"
      unitRef="SGD">3116339</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001396"
      unitRef="SGD">7020</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001397"
      unitRef="SGD">50042</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001398"
      unitRef="SGD">24528</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001400"
      unitRef="SGD">25347</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001401"
      unitRef="SGD">722</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001402"
      unitRef="SGD">107659</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001405"
      unitRef="SGD">-248500</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001406"
      unitRef="SGD">-687468</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001407"
      unitRef="SGD">-231410</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001409"
      unitRef="SGD">-220994</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001410"
      unitRef="SGD">-7000</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2024-07-012025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001411"
      unitRef="SGD">-1395372</BMGL:WrittenOffOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_MachineryMember"
      decimals="0"
      id="Fact001413"
      unitRef="SGD">47226</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001414"
      unitRef="SGD">137072</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001415"
      unitRef="SGD">688904</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_RenovationMember"
      decimals="0"
      id="Fact001416"
      unitRef="SGD">1368084</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_AirConditionerMember"
      decimals="0"
      id="Fact001417"
      unitRef="SGD">43727</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001418"
      unitRef="SGD">474280</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember_custom_SoftwareMember"
      decimals="0"
      id="Fact001419"
      unitRef="SGD">76866</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation
      contextRef="AsOf2025-06-30_ifrs-full_AccumulatedDepreciationAndAmortisationMember"
      decimals="0"
      id="Fact001420"
      unitRef="SGD">2836159</BMGL:PropertyPlantAndEquipmentAccumulatedDepreciation>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001423"
      unitRef="SGD">188</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001424"
      unitRef="SGD">5191</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_custom_RenovationMember"
      decimals="0"
      id="Fact001425"
      unitRef="SGD">23149</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001427"
      unitRef="SGD">5985</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001429"
      unitRef="SGD">34513</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001432"
      unitRef="SGD">17332</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001433"
      unitRef="SGD">202084</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_RenovationMember"
      decimals="0"
      id="Fact001434"
      unitRef="SGD">28114</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001436"
      unitRef="SGD">28865</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_SoftwareMember"
      decimals="0"
      id="Fact001437"
      unitRef="SGD">1112</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001438"
      unitRef="SGD">277507</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_ifrs-full_FixturesAndFittingsMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">13627</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_MedicalEquipmentMember"
      decimals="0"
      id="Fact001442"
      unitRef="USD">158884</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_RenovationMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">22104</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">22694</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30_custom_SoftwareMember"
      decimals="0"
      id="Fact001446"
      unitRef="USD">874</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001447"
      unitRef="USD">218183</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001449">&lt;p id="xdx_80A_eifrs-full--DisclosureOfInventoriesExplanatory_zktgVVJjpAJ9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;11.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_822_zS6cZbecu4sc"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_894_ecustom--DisclosureOfDetailedInformationAboutInventoriesExplanatory_z7nkwaMszD7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BC_zy27EmEnCk38" style="display: none"&gt;Schedule
of Inventories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630_zjXZUJMhFMC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zjoFjHzeNLT6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Statement of financial position:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--Inventories_iI_uSGD_zhGCMKEYdCgi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt"&gt;Medicine,drugs and medical devices&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--Inventories_iI_uUSD_c20250630_zUP6NJDGidO1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Medicine,drugs and medical devices"&gt;295,850&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;376,291&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;72,030&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Statement of comprehensive income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Inventories recognized as an expense in cost of sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uUSD_c20240701__20250630_zjPs8IGJFiue" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales"&gt;517,713&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20240701__20250630_z7srhafeFRTf" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales"&gt;658,479&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20230701__20240630_zquxUcgjmjg8" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales"&gt;637,037&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zCyvn2N2Km6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfInventoriesExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutInventoriesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001451">&lt;p id="xdx_894_ecustom--DisclosureOfDetailedInformationAboutInventoriesExplanatory_z7nkwaMszD7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BC_zy27EmEnCk38" style="display: none"&gt;Schedule
of Inventories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630_zjXZUJMhFMC5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zjoFjHzeNLT6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Statement of financial position:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--Inventories_iI_uSGD_zhGCMKEYdCgi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt"&gt;Medicine,drugs and medical devices&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--Inventories_iI_uUSD_c20250630_zUP6NJDGidO1" style="border-bottom: Black 1pt solid; width: 14%; text-align: right" title="Medicine,drugs and medical devices"&gt;295,850&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;376,291&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 14%; text-align: right"&gt;72,030&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Statement of comprehensive income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Inventories recognized as an expense in cost of sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uUSD_c20240701__20250630_zjPs8IGJFiue" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales"&gt;517,713&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20240701__20250630_z7srhafeFRTf" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales"&gt;658,479&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--CostOfInventoriesRecognisedAsExpenseDuringPeriod_uSGD_c20230701__20240630_zquxUcgjmjg8" style="border-bottom: Black 1pt solid; text-align: right" title="Inventories recognized as an expense in cost of sales"&gt;637,037&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDetailedInformationAboutInventoriesExplanatory>
    <ifrs-full:Inventories
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001456"
      unitRef="USD">295850</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001453"
      unitRef="SGD">376291</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001454"
      unitRef="SGD">72030</ifrs-full:Inventories>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001458"
      unitRef="USD">517713</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001460"
      unitRef="SGD">658479</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001462"
      unitRef="SGD">637037</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001464">&lt;p id="xdx_801_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zwS8tszNcRN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;12.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_827_zTbDVgTq3op1"&gt;Trade and other receivables&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_896_ecustom--DisclosureOfTradeAndOtherReceivableExplanatory_zProBPpufZgc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zVkSvGDeOPR7" style="display: none"&gt;Schedule
of trade and other receivables&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630_zLxTTTndWmGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_z02274trgh3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade receivables:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentTradeReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zS5i1iY7nyT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;- third parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CurrentTradeReceivables_iS_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zeAT30Q6n6m8" style="width: 14%; text-align: right" title="Trade receivables - third parties"&gt;2,580,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,281,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,133,573&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uSGD_z26AmgvKnYH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uUSD_c20250630_zsAyMoFdVC33" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Allowance for expected credit loss"&gt;(781,133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(993,524&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(460,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TradeReceivables_iI_uSGD_zPY9oXipJrh8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade Receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--TradeReceivables_iI_uUSD_c20250630_zdD1YLxBAWcg" style="text-align: right" title="Trade Receivables"&gt;1,799,180&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,288,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,673,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LongtermDeposits_iI_uSGD_z9Yjqdoe3dB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630_zInmKCnGFL1h" style="text-align: right" title="Deposits"&gt;5,362,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,820,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--Prepayments_iI_uSGD_zUR4bP5ubSvj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepayments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--Prepayments_iI_uUSD_c20250630_z4Vbs8my1Yma" style="text-align: right" title="Prepayments"&gt;326,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other receivables:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--OtherCurrentReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zLMVm3xS6ZJ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- third parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--OtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_z7Iu2zWVZEo6" style="border-bottom: Black 1pt solid; text-align: right" title="Other receivables - third parties"&gt;162,070&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;206,391&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;213,644&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TradeAndOtherCurrentReceivables_iI_uSGD_zYE5waP2kkl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630_z2plWLQfMay8" style="border-bottom: Black 1pt solid; text-align: right" title="Trade and other receivables"&gt;7,651,065&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,731,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,005,219&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zuYuNN2ctVzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Trade
receivables are unsecured, non-interest bearing and are generally on 60 days terms (June 30, 2024: 60 days).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;There
is no other class of financial assets that is past due and/or impaired except for trade receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Trade
and other receivables are denominated in Singapore Dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
deposits include payments made for custodian services amounting to S$&lt;span id="xdx_90D_eifrs-full--LongtermDeposits_iI_uSGD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CustodianServicesMember_zfOGA0XGYu72" title="Deposits"&gt;2,300,375&lt;/span&gt; (US$&lt;span id="xdx_90D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--CustodianServicesMember_zIyQs06tbUU" title="Deposits"&gt;1,683,776&lt;/span&gt;), which are classified as non-financial
assets and earmarked for use in upcoming mergers and acquisitions within the Singapore market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;12.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Trade and other receivables (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eifrs-full--DisclosureOfAllowanceForCreditLossesExplanatory_z6LgFI7dcwuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
movement in allowance for expected credit losses of trade receivables computed based on lifetime ECL was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zFOP7QBl50D6" style="display: none"&gt;Schedule
of movement in allowance for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20250630_zfCV8pkMULRf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230701__20240630_zg9SJ7kNNHCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AllowanceForExpectedCreditLoss_iS_uSGD_z77Y7vyaYfW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Beginning of financial year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iS_uUSD_c20240701__20250630_zs9ZH5cHIPNf" style="width: 14%; text-align: right"&gt;361,988&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;460,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;465,986&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AdditionAllowanceForExpectedCreditLosses_uSGD_zbPPBjasV45a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Allowance for expected credit losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AdditionAllowanceForExpectedCreditLosses_uUSD_c20240701__20250630_zYZyCn3xbuDh" style="text-align: right"&gt;536,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uSGD_zCTBSfgSGGGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Reversal of allowance for expected credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uUSD_c20240701__20250630_z2IQK6Qs4WWi" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Reversal of allowance for expected credit losses"&gt;(117,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(149,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(55,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AllowanceForExpectedCreditLoss_iE_uSGD_zSUBdrh9wBva" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;End of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForExpectedCreditLoss_iE_uUSD_c20240701__20250630_zXdSXVDETDOl" style="border-bottom: Black 1pt solid; text-align: right"&gt;781,133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;993,524&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;460,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zT5V0tyIHCul" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <BMGL:DisclosureOfTradeAndOtherReceivableExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001466">&lt;p id="xdx_896_ecustom--DisclosureOfTradeAndOtherReceivableExplanatory_zProBPpufZgc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zVkSvGDeOPR7" style="display: none"&gt;Schedule
of trade and other receivables&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630_zLxTTTndWmGi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_z02274trgh3h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade receivables:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentTradeReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zS5i1iY7nyT3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;- third parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CurrentTradeReceivables_iS_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zeAT30Q6n6m8" style="width: 14%; text-align: right" title="Trade receivables - third parties"&gt;2,580,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,281,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,133,573&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uSGD_z26AmgvKnYH3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Allowance for expected credit loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iNI_di_uUSD_c20250630_zsAyMoFdVC33" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Allowance for expected credit loss"&gt;(781,133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(993,524&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(460,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TradeReceivables_iI_uSGD_zPY9oXipJrh8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade Receivables&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--TradeReceivables_iI_uUSD_c20250630_zdD1YLxBAWcg" style="text-align: right" title="Trade Receivables"&gt;1,799,180&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,288,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,673,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LongtermDeposits_iI_uSGD_z9Yjqdoe3dB7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630_zInmKCnGFL1h" style="text-align: right" title="Deposits"&gt;5,362,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,820,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--Prepayments_iI_uSGD_zUR4bP5ubSvj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepayments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--Prepayments_iI_uUSD_c20250630_z4Vbs8my1Yma" style="text-align: right" title="Prepayments"&gt;326,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415,890&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other receivables:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--OtherCurrentReceivables_iI_uSGD_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_zLMVm3xS6ZJ6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- third parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--OtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--ThridPartiesMember_z7Iu2zWVZEo6" style="border-bottom: Black 1pt solid; text-align: right" title="Other receivables - third parties"&gt;162,070&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;206,391&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;213,644&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TradeAndOtherCurrentReceivables_iI_uSGD_zYE5waP2kkl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630_z2plWLQfMay8" style="border-bottom: Black 1pt solid; text-align: right" title="Trade and other receivables"&gt;7,651,065&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,731,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,005,219&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfTradeAndOtherReceivableExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AsOf2025-06-30_custom_ThridPartiesMember"
      decimals="0"
      id="Fact001471"
      unitRef="USD">2580313</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AsOf2025-06-30_custom_ThridPartiesMember"
      decimals="0"
      id="Fact001468"
      unitRef="SGD">3281902</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AsOf2024-06-30_custom_ThridPartiesMember"
      decimals="0"
      id="Fact001469"
      unitRef="SGD">2133573</ifrs-full:CurrentTradeReceivables>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001476"
      unitRef="USD">781133</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001473"
      unitRef="SGD">993524</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001474"
      unitRef="SGD">460413</BMGL:AllowanceForExpectedCreditLoss>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001481"
      unitRef="USD">1799180</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001478"
      unitRef="SGD">2288378</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001479"
      unitRef="SGD">1673160</ifrs-full:TradeReceivables>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001486"
      unitRef="USD">5362632</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001483"
      unitRef="SGD">6820731</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001484"
      unitRef="SGD">90252</ifrs-full:LongtermDeposits>
    <ifrs-full:Prepayments
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001491"
      unitRef="USD">326983</ifrs-full:Prepayments>
    <ifrs-full:Prepayments
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001488"
      unitRef="SGD">415890</ifrs-full:Prepayments>
    <ifrs-full:Prepayments
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001489"
      unitRef="SGD">28163</ifrs-full:Prepayments>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2025-06-30_custom_ThridPartiesMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">162070</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2025-06-30_custom_ThridPartiesMember"
      decimals="0"
      id="Fact001493"
      unitRef="SGD">206391</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2024-06-30_custom_ThridPartiesMember"
      decimals="0"
      id="Fact001494"
      unitRef="SGD">213644</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001501"
      unitRef="USD">7651065</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001498"
      unitRef="SGD">9731390</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001499"
      unitRef="SGD">2005219</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_custom_CustodianServicesMember"
      decimals="0"
      id="Fact001503"
      unitRef="SGD">2300375</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_custom_CustodianServicesMember"
      decimals="0"
      id="Fact001505"
      unitRef="USD">1683776</ifrs-full:LongtermDeposits>
    <ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001507">&lt;p id="xdx_89E_eifrs-full--DisclosureOfAllowanceForCreditLossesExplanatory_z6LgFI7dcwuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
movement in allowance for expected credit losses of trade receivables computed based on lifetime ECL was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zFOP7QBl50D6" style="display: none"&gt;Schedule
of movement in allowance for expected credit losses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20250630_zfCV8pkMULRf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230701__20240630_zg9SJ7kNNHCb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AllowanceForExpectedCreditLoss_iS_uSGD_z77Y7vyaYfW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Beginning of financial year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--AllowanceForExpectedCreditLoss_iS_uUSD_c20240701__20250630_zs9ZH5cHIPNf" style="width: 14%; text-align: right"&gt;361,988&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;460,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;465,986&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AdditionAllowanceForExpectedCreditLosses_uSGD_zbPPBjasV45a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Allowance for expected credit losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AdditionAllowanceForExpectedCreditLosses_uUSD_c20240701__20250630_zYZyCn3xbuDh" style="text-align: right"&gt;536,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uSGD_zCTBSfgSGGGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Reversal of allowance for expected credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ReversalOfAllowanceForExpectedCreditLosses_iN_di_uUSD_c20240701__20250630_z2IQK6Qs4WWi" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Reversal of allowance for expected credit losses"&gt;(117,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(149,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(55,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AllowanceForExpectedCreditLoss_iE_uSGD_zSUBdrh9wBva" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;End of financial year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForExpectedCreditLoss_iE_uUSD_c20240701__20250630_zXdSXVDETDOl" style="border-bottom: Black 1pt solid; text-align: right"&gt;781,133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;993,524&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;460,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001511"
      unitRef="USD">361988</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001509"
      unitRef="SGD">460413</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001510"
      unitRef="SGD">465986</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AdditionAllowanceForExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001515"
      unitRef="USD">536403</BMGL:AdditionAllowanceForExpectedCreditLosses>
    <BMGL:AdditionAllowanceForExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001513"
      unitRef="SGD">682252</BMGL:AdditionAllowanceForExpectedCreditLosses>
    <BMGL:AdditionAllowanceForExpectedCreditLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001514"
      unitRef="SGD">50168</BMGL:AdditionAllowanceForExpectedCreditLosses>
    <BMGL:ReversalOfAllowanceForExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001520"
      unitRef="USD">117258</BMGL:ReversalOfAllowanceForExpectedCreditLosses>
    <BMGL:ReversalOfAllowanceForExpectedCreditLosses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001517"
      unitRef="SGD">149141</BMGL:ReversalOfAllowanceForExpectedCreditLosses>
    <BMGL:ReversalOfAllowanceForExpectedCreditLosses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001518"
      unitRef="SGD">55741</BMGL:ReversalOfAllowanceForExpectedCreditLosses>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001524"
      unitRef="USD">781133</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001522"
      unitRef="SGD">993524</BMGL:AllowanceForExpectedCreditLoss>
    <BMGL:AllowanceForExpectedCreditLoss
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001523"
      unitRef="SGD">460413</BMGL:AllowanceForExpectedCreditLoss>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001526">&lt;p id="xdx_802_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_z90t0Y05TjLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;13.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_826_zzcIM0A7ZxYi"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_896_ecustom--DisclosureOfCashAndCashEquivalentExplanatory_zHWzwlOymI9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zyEKgIEHqG6a" style="display: none"&gt;Schedule
of cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630_zAPyEzVnff49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240630_zR2w2f76WZ77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CashOnHand_iI_zDzX0CsHdh7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Cash on hand&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CashOnHand_iI_uUSD_c20250630_zY27CGCTsgIj" style="width: 14%; text-align: right" title="Cash on hand"&gt;310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--BalancesWithBanks_iI_zJHDCQxJfTT7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cash at banks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--BalancesWithBanks_iI_uUSD_c20250630_zveTKI9tORR9" style="border-bottom: Black 1pt solid; text-align: right" title="Cash at banks"&gt;2,341,920&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,978,688&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,949,553&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CashAndCashEquivalents_i02I_zT8cFh5xiaK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630_zt2A4KpjDhbi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;2,342,230&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_znEVVkCNIcJ5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <BMGL:DisclosureOfCashAndCashEquivalentExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001528">&lt;p id="xdx_896_ecustom--DisclosureOfCashAndCashEquivalentExplanatory_zHWzwlOymI9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zyEKgIEHqG6a" style="display: none"&gt;Schedule
of cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630_zAPyEzVnff49" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240630_zR2w2f76WZ77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CashOnHand_iI_zDzX0CsHdh7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Cash on hand&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CashOnHand_iI_uUSD_c20250630_zY27CGCTsgIj" style="width: 14%; text-align: right" title="Cash on hand"&gt;310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--BalancesWithBanks_iI_zJHDCQxJfTT7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cash at banks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--BalancesWithBanks_iI_uUSD_c20250630_zveTKI9tORR9" style="border-bottom: Black 1pt solid; text-align: right" title="Cash at banks"&gt;2,341,920&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,978,688&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,949,553&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CashAndCashEquivalents_i02I_zT8cFh5xiaK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630_zt2A4KpjDhbi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash and cash equivalents"&gt;2,342,230&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</BMGL:DisclosureOfCashAndCashEquivalentExplanatory>
    <ifrs-full:CashOnHand
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001533"
      unitRef="USD">310</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001530"
      unitRef="SGD">395</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001531"
      unitRef="SGD">1500</ifrs-full:CashOnHand>
    <ifrs-full:BalancesWithBanks
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001538"
      unitRef="USD">2341920</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001535"
      unitRef="SGD">2978688</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001536"
      unitRef="SGD">1949553</ifrs-full:BalancesWithBanks>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001543"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001540"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001541"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001545">&lt;p id="xdx_800_eifrs-full--DisclosureOfRelatedPartyExplanatory_zWtzHhk5mmWc" style="font: bold 10pt Times New Roman, Times, Serif; display: none; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;14.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_82E_zwTlFbkOmlBh"&gt;Amount due from/to related parties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Amount
due from related parties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 27, 2023, Rainforest Capital VCC (the &#x201c;Purchaser&#x201d;) entered into a sale and purchase agreement with Dr. Kevin Yip (the
&#x201c;Seller&#x201d;) for the transfer of the entire share capital of Basel Medical Group Pte. Ltd. According to the sales and purchase
agreement, the Provisional Consideration shall be an aggregate amount equivalent to the sum of S$&lt;span id="xdx_90D_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zGqIez1SBZU6" title="Provisional consideration amount for transfer of share"&gt;24,000,000&lt;/span&gt; (US$&lt;span id="xdx_904_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_uUSD_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zbfu8XIKOoNd" title="Provisional consideration amount"&gt;18,191,465&lt;/span&gt;) and the Agreed
Amount. The Agreed Amount is computed based on the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net
amount due from a former director (Dr. Kevin Yip) to the Group less the net assets of the Group as at June 30, 2023. The Agreed Amount
will be a negative figure if the sum of the net amount due from Singmed Investment Pte. Ltd to the Group and the net amount due from
a director to the Group is more than the net assets of the Group as of June 30, 2023. The Agreed Amount was initially estimated to be
negative S$&lt;span id="xdx_907_eifrs-full--SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_c20230630__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z6blSUkAO8Lf" title="Estimated settlement liability"&gt;5,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 27pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x202f;
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 1, 2023, S$&lt;span id="xdx_90C_ecustom--CashPaidOnClosingInitialSettlement_c20230701__20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zIdQ0hvJdIq3" title="Cash paid on closing initial settlement"&gt;11,800,000&lt;/span&gt; (US$&lt;span id="xdx_909_ecustom--CashPaidOnClosingInitialSettlement_uUSD_c20230701__20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zGFg2Dj6NvT1" title="Cash paid on closing initial settlement"&gt;8,944,137&lt;/span&gt;) was paid from the Purchaser to the Seller. This was computed based on &lt;span id="xdx_904_ecustom--PercentageOfProvisionalConsiderationAmountForTransferOfShare_iI_dp_c20230701__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zOvv3D7iPKR5" title="Percentage of provisional consideration amount for transfer of share"&gt;70&lt;/span&gt;% of S$&lt;span id="xdx_902_eifrs-full--MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration_c20230627__20230627__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zBgdhcl1glgg" title="Provisional consideration amount for transfer of share"&gt;24,000,000&lt;/span&gt; and
Estimated Agreed Amount of negative S$&lt;span id="xdx_907_eifrs-full--SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions_c20230630__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z90apEOgBox3" title="Estimated settlement liability"&gt;5,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;14.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Amount due from/to related parties (continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the agreement on the purchase consideration between Rainforest Capital VCC as the buyer and Dr. Kevin Yip as the seller for the
purchase of the shares of Basel Medical Group Pte. Ltd. under the sale and purchase agreement dated June 27, 2023, the outstanding receivables
due from director, Dr. Kevin Yip, and related party, Singmed Investment Pte Ltd, have been assigned to and are borne by Rainforest Capital
VCC. On August 23, 2024, Rainforest Capital VCC entered into a deed of undertaking (the &#x201c;Repayment Deed&#x201d;) with the Group,
undertaking to fully transfer and pay to the Group, any and all outstanding receivables that is owed by Singmed Investment Pte Ltd and
Dr. Kevin Yip to the Group, being S$&lt;span id="xdx_907_eifrs-full--LoansAndAdvances_iI_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipAndSingmedInvestmentPteLtdMember_zPZ5t0DRBnv5" title="Loan amount"&gt;11,877,624&lt;/span&gt; (the &#x201c;Loan Amount&#x201d;), to the Group by September 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets out the amounts owed to the Group by Rainforest Capital VCC, which has assumed the obligations of Dr. Kevin Yip
and Singmed Investment Pte Ltd pursuant to the Repayment Deed as of the date indicated below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zPtPEuMmPGsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zC2JEy5rSo2l"&gt;Schedule
of amount due from related party&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230630_znLudtLnW56h" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zFT09TOy3V76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 72%; text-align: justify"&gt;Amount due from a director&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzuSgYcTlDH" style="width: 10%; text-align: right" title="Amount due from a director"&gt;976,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,320,457&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z6SSlYJZFT3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z81emXwnUhV5" style="border-bottom: Black 1pt solid; text-align: right" title="Amount due from related parties"&gt;7,806,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,557,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zAkXyPtHolqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630_zXCUsdqcUWKf" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;8,783,276&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,877,624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zXcBg8Jag026" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the financial year ended June 30, 2024, the Group incurred an aggregate sum of S$&lt;span id="xdx_904_eifrs-full--WagesAndSalaries_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zdrR2Ds9PCf" title="Professional medical practitioner salary"&gt;900,000&lt;/span&gt; (US$&lt;span id="xdx_902_eifrs-full--WagesAndSalaries_uUSD_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zN9jp70PYZpj" title="Professional medical practitioner salary"&gt;682,180&lt;/span&gt;) for professional medical practitioner
salaries owed to Dr. Kevin Yip for his services from July 1, 2023 to June 30, 2024. Such sum of US$&lt;span id="xdx_90C_eifrs-full--OtherPayables_iI_uUSD_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipMember_zDcVpgHjemdb" title="Salary payable"&gt;682,180&lt;/span&gt; will be set-off by the Group
against the amounts owed to the Group by Dr. Kevin Yip and Singmed Investment Pte Ltd. Thus, following such set-off, as of June 30, 2024,
total amounts due from Dr. Kevin Yip and Singmed Investment Pte Ltd is estimated to amount to US$&lt;span id="xdx_90D_eifrs-full--AmountsReceivableRelatedPartyTransactions_iI_uUSD_c20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DrKevinYipAndSingmedInvestmentPteLtdMember_zlybycqXgAne" title="Receivables from related parties"&gt;8,101,096&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, Rainforest Capital VCC has paid an aggregate sum of US$&lt;span id="xdx_90F_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z71kNQwuc7V6" title="Related party advance for IPO expenses paid"&gt;599,730&lt;/span&gt; for the period from July 1, 2023 to June 30, 2024 on behalf
of the Group for professional fees incurred in connection with the group&#x2019;s initial public offering. On February 27, 2024, July
22, 2024 and July 31, 2024, Rainforest Capital VCC also repaid a sum of US$&lt;span id="xdx_902_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240227__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zCu9XYqPzJo" title="Partial settlement of related party receivables"&gt;20,000&lt;/span&gt;, US$&lt;span id="xdx_901_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240722__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zFxwjeFUVA2a" title="Partial settlement of related party receivables"&gt;630,000&lt;/span&gt; and US$&lt;span id="xdx_901_eifrs-full--ReceivablesDueFromAssociates_iI_uUSD_c20240731__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zuyZMkF4bQB7" title="Partial settlement of related party receivables"&gt;4,048,000&lt;/span&gt; respectively to the Group
to partially settle the amounts due from a director and related parties. Finally, Rainforest Capital VCC has paid US$&lt;span id="xdx_907_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240815__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_z6O0HzkJH0Nf" title="Final settlement under repayment deed"&gt;750,000&lt;/span&gt; on August
15, 2024, US$&lt;span id="xdx_90E_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240816__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_za5uQHDQPiy9" title="Final settlement under repayment deed"&gt;750,000&lt;/span&gt; on August 16, 2024, US$&lt;span id="xdx_90F_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240920__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zzrmPel3Injb" title="Final settlement under repayment deed"&gt;651,000&lt;/span&gt; on September 20, 2024 and a final US$&lt;span id="xdx_907_ecustom--CashReceivedToFullySettleRelatedPartyReceivables_iI_uUSD_c20240923__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RainforestCapitalVCCMember_zgALa3JqZGe5" title="Final settlement under repayment deed"&gt;652,366&lt;/span&gt; on September 23, 2024 pursuant to the
Repayment Deed as final settlement of such amounts owed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
such repayment, the full amount due from a former director and Singmed Investment Pte Ltd, that has been assigned to Rainforest Capital
VCC, has been fully paid off.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Amount
due to related parties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Amount
due to related parties consist of amount due to shareholders and directors. The amounts are non-trade in nature, unsecured, interest-bearing,
repayable on demand and is to be settled in cash. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Amount
due to a related parties represents advances provided to cover various business expenses and other expenditures incurred by the Group
in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration
      contextRef="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001547"
      unitRef="SGD">24000000</ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration>
    <ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration
      contextRef="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">18191465</ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration>
    <ifrs-full:SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions
      contextRef="From2023-06-302023-06-30_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001551"
      unitRef="SGD">5000000</ifrs-full:SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions>
    <BMGL:CashPaidOnClosingInitialSettlement
      contextRef="From2023-07-012023-07-01_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001553"
      unitRef="SGD">11800000</BMGL:CashPaidOnClosingInitialSettlement>
    <BMGL:CashPaidOnClosingInitialSettlement
      contextRef="From2023-07-012023-07-01_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001555"
      unitRef="USD">8944137</BMGL:CashPaidOnClosingInitialSettlement>
    <BMGL:PercentageOfProvisionalConsiderationAmountForTransferOfShare
      contextRef="AsOf2023-07-01_custom_RainforestCapitalVCCMember"
      decimals="INF"
      id="Fact001557"
      unitRef="Pure">0.70</BMGL:PercentageOfProvisionalConsiderationAmountForTransferOfShare>
    <ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration
      contextRef="From2023-06-272023-06-27_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001559"
      unitRef="SGD">24000000</ifrs-full:MeasurementPeriodAdjustmentsRecognisedForParticularAssetsLiabilitiesNoncontrollingInterestsOrItemsOfConsideration>
    <ifrs-full:SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions
      contextRef="From2023-06-302023-06-30_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001561"
      unitRef="SGD">5000000</ifrs-full:SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions>
    <ifrs-full:LoansAndAdvances
      contextRef="AsOf2024-09-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember"
      decimals="0"
      id="Fact001563"
      unitRef="SGD">11877624</ifrs-full:LoansAndAdvances>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001565">&lt;p id="xdx_894_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zPtPEuMmPGsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zC2JEy5rSo2l"&gt;Schedule
of amount due from related party&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230630_znLudtLnW56h" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zFT09TOy3V76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 72%; text-align: justify"&gt;Amount due from a director&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzuSgYcTlDH" style="width: 10%; text-align: right" title="Amount due from a director"&gt;976,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,320,457&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_hifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z6SSlYJZFT3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--OthersRelatedPartiesMember_z81emXwnUhV5" style="border-bottom: Black 1pt solid; text-align: right" title="Amount due from related parties"&gt;7,806,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,557,167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zAkXyPtHolqk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_uUSD_c20230630_zXCUsdqcUWKf" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;8,783,276&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,877,624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2023-06-30_custom_DirectorsMember"
      decimals="0"
      id="Fact001569"
      unitRef="USD">976453</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2023-06-30_custom_DirectorsMember"
      decimals="0"
      id="Fact001567"
      unitRef="SGD">1320457</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2023-06-30_custom_OthersRelatedPartiesMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">7806823</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2023-06-30_custom_OthersRelatedPartiesMember"
      decimals="0"
      id="Fact001571"
      unitRef="SGD">10557167</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001577"
      unitRef="USD">8783276</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001575"
      unitRef="SGD">11877624</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:WagesAndSalaries
      contextRef="From2023-07-012024-06-30_custom_DrKevinYipMember"
      decimals="0"
      id="Fact001579"
      unitRef="SGD">900000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="From2023-07-012024-06-30_custom_DrKevinYipMember"
      decimals="0"
      id="Fact001581"
      unitRef="USD">682180</ifrs-full:WagesAndSalaries>
    <ifrs-full:OtherPayables
      contextRef="AsOf2024-06-30_custom_DrKevinYipMember"
      decimals="0"
      id="Fact001583"
      unitRef="USD">682180</ifrs-full:OtherPayables>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="AsOf2024-06-30_custom_DrKevinYipAndSingmedInvestmentPteLtdMember"
      decimals="0"
      id="Fact001585"
      unitRef="USD">8101096</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties
      contextRef="From2023-07-012024-06-30_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001587"
      unitRef="USD">599730</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <ifrs-full:ReceivablesDueFromAssociates
      contextRef="AsOf2024-02-27_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001589"
      unitRef="USD">20000</ifrs-full:ReceivablesDueFromAssociates>
    <ifrs-full:ReceivablesDueFromAssociates
      contextRef="AsOf2024-07-22_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001591"
      unitRef="USD">630000</ifrs-full:ReceivablesDueFromAssociates>
    <ifrs-full:ReceivablesDueFromAssociates
      contextRef="AsOf2024-07-31_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">4048000</ifrs-full:ReceivablesDueFromAssociates>
    <BMGL:CashReceivedToFullySettleRelatedPartyReceivables
      contextRef="AsOf2024-08-15_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001595"
      unitRef="USD">750000</BMGL:CashReceivedToFullySettleRelatedPartyReceivables>
    <BMGL:CashReceivedToFullySettleRelatedPartyReceivables
      contextRef="AsOf2024-08-16_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">750000</BMGL:CashReceivedToFullySettleRelatedPartyReceivables>
    <BMGL:CashReceivedToFullySettleRelatedPartyReceivables
      contextRef="AsOf2024-09-20_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001599"
      unitRef="USD">651000</BMGL:CashReceivedToFullySettleRelatedPartyReceivables>
    <BMGL:CashReceivedToFullySettleRelatedPartyReceivables
      contextRef="AsOf2024-09-23_custom_RainforestCapitalVCCMember"
      decimals="0"
      id="Fact001601"
      unitRef="USD">652366</BMGL:CashReceivedToFullySettleRelatedPartyReceivables>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001603">&lt;p id="xdx_80E_eifrs-full--DisclosureOfBorrowingsExplanatory_zZcTqjS6HeTd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;15.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_82E_zZ6TWi4fwlc3"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_89A_eifrs-full--DisclosureOfDetailedInformationAboutBorrowingsExplanatory_zmN8Qhr6RF51" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zdt7LE6MD55l" style="display: none"&gt;Schedule
of borrowings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zwlNex0l6wPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zZKEthUKq2Cf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CurrentPortionOfBorrowingsAbstract_iB_zQ729fu69Byb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_z9MC6pvOiik3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;- Bank overdraft&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_uUSD_c20250630_zHRARvdwfRui" style="width: 14%; text-align: right" title="- Bank overdraft"&gt;48,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;61,371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentLeaseLiabilities_iI_zU5gGaaZhtb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--CurrentLeaseLiabilities_iI_uUSD_c20250630_zpuJBUb8KF36" style="text-align: right" title="- Lease liabilities"&gt;1,619,426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,059,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BankBorrowings_iI_zFSQaeP0Gxvl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- Bank borrowings&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--BankBorrowings_iI_uUSD_c20250630_zvfOsocVggXl" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1620"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,677,856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--ShorttermBorrowings_iI_maCBACPzDNY_zA3J4qZPVtCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ShorttermBorrowings_iI_uUSD_c20250630_zhZW43QmPIC3" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Current"&gt;1,667,677&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,121,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,706,356&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_iB_zB4QdRluA1O1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_zfmOzutEoqvc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iI_uUSD_c20250630_ztiRF4DFLkPl" style="text-align: right" title="- Lease liabilities"&gt;1,020,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,298,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_zbiryHuikNkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- Bank borrowings&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_uUSD_c20250630_zSeXumxc9Os7" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1641"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--LongtermBorrowings_iI_maCBACPzDNY_z5BJ7i2ZDasg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--LongtermBorrowings_iI_uUSD_c20250630_zef1XgI4UvVa" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Non-Current"&gt;1,020,801&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,298,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_mtCBACPzDNY_zQITjCNLUDph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_uUSD_c20250630_zNR5XqMpmVPe" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings"&gt;2,688,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,419,476&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,289,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zmpOgHyCWPSk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
breakdown of borrowings are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_ziCBI0sPKCS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zWDdgdsTb0mh"&gt;Schedule
of breakdown borrowings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zNdeaiaRKbB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zfwvnxKW8Slf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zxoPc4KMg4pd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Term loan #1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zY1xyzDrTAa1" style="width: 14%; text-align: right" title="Term loan #1"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;206,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zeBcMdLSjO1h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zqLwc4NbzFN5" style="text-align: right" title="Term loan #2"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zkl0zIS7Oz7i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_z5YP4TD0ZUD4" style="text-align: right" title="Term loan #3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1668"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1665"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zxKTBFvAzdC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zvDBLiBftzX5" style="text-align: right" title="Term loan #4"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1673"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;195,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zIPzY2ktgdY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zetrWLakq162" style="text-align: right" title="Term loan #6"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1678"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1675"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zoOhaJDdCZj6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #7&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zCeq04oCt6Ie" style="text-align: right" title="Term loan #7"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1683"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zcDk25wLaR07" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #9&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zwdcDI3cuEua" style="text-align: right" title="Term loan #9"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1688"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;322,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_z7aQ7Mv5s3C7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zrUrbxCAElk5" style="text-align: right" title="Term loan #10"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1690"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,573,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zB8fnSzo1QW" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zwI8CWYChySb" style="text-align: right" title="Term loan #11"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1698"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1695"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;691,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z5m3JcKwdPS7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Term loan #12&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z371D7LxwDO2" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan #12"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1700"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1701"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zJQcXa01mFGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    loan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zu6KKmPCkRq5" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1708"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,261,290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p id="xdx_8A8_zcOobwGxFTUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;15.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Borrowings (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutBorrowings_z7Z3O9OHS2Jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of borrowings are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zqwfwL5RQPh5"&gt;Schedule
of details borrowings&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Term loan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Facility&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Effective&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Maturity date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%
                                            p.a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Term loan #1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zmwe5qGEnbYi" style="width: 20%; text-align: right" title="Term loan facility amount"&gt;S$600,000&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zXftvuI5Mfvc" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_z96JMNsqrX5i" title="Borrowing maturity date"&gt;October 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zo27zLqEwcfl" style="text-align: right" title="Term loan facility amount"&gt;S$1,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_z3zLZh8Q6KB7" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zCEof4omSSu5" title="Borrowing maturity date"&gt;October 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zZScS99VHdce" style="text-align: right" title="Term loan facility amount"&gt;S$600,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zEQDShG6OZE4" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zATvoJ4ZG6d" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zJP4gzAywMp5" style="text-align: right" title="Term loan facility amount"&gt;S$700,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_z4GhlSEknfH4" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zRa8gabc442g" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zSWuZ6MrwTv7" style="text-align: right" title="Term loan facility amount"&gt;S$1,400,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zcKiNqHB0Io6" title="Borrowings interest rate"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zOL0DfbOCMVj" title="Borrowing maturity date"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #7&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zjvSjDiIMNV" style="text-align: right" title="Term loan facility amount"&gt;S$1,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zyyRWErTzY9j" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zVCjHKippPUk" title="Borrowing maturity date"&gt;October 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #9&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_z8kNMs3jXSLd" style="text-align: right" title="Term loan facility amount"&gt;S$850,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zpW1oRi2kVWd" title="Borrowings interest rate"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zsJvLxwgL8rb" title="Borrowing maturity date"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zRLLPOyMADtc" style="text-align: right" title="Term loan facility amount"&gt;S$600,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zqoQHJtVtV5l" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_za5oe8qgkVF" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zIBpnDvgdMni" style="text-align: right" title="Term loan facility amount"&gt;S$1,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zvK0ob31ByUi" title="Borrowings interest rate"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zqiD5Y1yqA1h" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zjvXaaZgKAs1" style="text-align: right" title="Term loan facility amount"&gt;S$500,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_z9IZjshJeJtc" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zsx6e8CUqMi5" title="Borrowing maturity date"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_z3O9f7OqgR45" style="text-align: right" title="Term loan facility amount"&gt;S$529,890&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zXsBAnX0tHZ6" title="Borrowings interest rate"&gt;1.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zSZRyAqhlFXb" title="Borrowing maturity date"&gt;December 2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zDLFxKuDwkR7" style="text-align: right" title="Term loan facility amount"&gt;S$501,670&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zn8aOp0JAuJh" title="Borrowings interest rate"&gt;1.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_z8ws7KhQnl6k" title="Borrowing maturity date"&gt;December 2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_z27O3M099r9a" style="text-align: right" title="Term loan facility amount"&gt;S$400,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zCRg2dGta2K3" title="Borrowings interest rate"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zQ2J0zJXvgW8" title="Borrowing maturity date"&gt;January 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_z7nETdPtOQOd" style="text-align: right" title="Term loan facility amount"&gt;S$1,500,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zKHmVImFfpe3" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zZGx25X3Jklc" title="Borrowing maturity date"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #12&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zUpZt2bPFomb" style="text-align: right" title="Term loan facility amount"&gt;S$4,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zeo2FBScLV3" title="Borrowings interest rate"&gt;4.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z1FRr2XA00V1" title="Borrowing maturity date"&gt;One-month term, upon maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zsOZjll8XZX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
loan #1 to #12 was fully settled during the financial year, and as at June 30, 2025, there are no outstanding bank borrowings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;15.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Borrowings (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eifrs-full--DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_zbFJuUGQizij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of liabilities arising from financing activities is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zfiMpdyhrmdg"&gt;Schedule
of reconciliation of liabilities arising from financing activities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Beginning of&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Proceed from&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Non-cash changes&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;End of&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                              &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;financial
                                            year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash
    flows&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;
                                                                                                                                                                                                                              &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;bank&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                              &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;borrowings&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Addition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Accretion
                                            of&lt;/p&gt;
                                                                              &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;interests&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;financial&lt;/p&gt;
                                                                              &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;period&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 10%"&gt;- Current&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zt3WYqOApUYi" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings"&gt;22,407&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zULAica0qbTb" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows"&gt;(861,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z4Dg6eG11iNa" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zumGlwPxqnyi" style="width: 10%; text-align: right" title="Addition lease liabilities current"&gt;3,557,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z9m5DJkhsgUe" style="width: 10%; text-align: right" title="Accretion of interests current"&gt;90,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zh1GdGMnjdt9" style="width: 10%; text-align: right" title="Other non cash changes current"&gt;(1,188,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z5rjM5nVLmag" style="width: 10%; text-align: right" title="Lease liabilities current, ending"&gt;1,619,426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zCCXuDOVsfz8" style="text-align: right" title="Lease liabilities non-current, beginnings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1818"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeIUBS8onrIf" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z8GsKz6zc8pi" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zl07H7xrRPMc" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1824"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjmqj9cSZSb3" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1826"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zFhyROnbMh28" style="text-align: right" title="Other non cash changes non current"&gt;1,020,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zIWHiFuDIeF9" style="text-align: right" title="Lease liabilities non-current, ending"&gt;1,020,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--BankBorrowings_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zQ03przyNmv" style="text-align: right" title="Bank borrowings, beginnings"&gt;2,105,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zgjyNKdFBFcb" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current"&gt;(5,320,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUDWSvmuBqW7" style="text-align: right" title="Proceed from bank borrowings, current"&gt;3,144,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionBankBorrowingsCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zrOoTURCPyA6" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUYIJbWaaAYl" style="text-align: right" title="Accretion of interests bank borrowings current"&gt;69,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zue9Q6PgASn2" style="text-align: right" title="Other non cash changes bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--BankBorrowings_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zcs3uL1C2UCc" style="text-align: right" title="Bank borrowings, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z44DTK1GAyWf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings"&gt;1,244,936&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zIzI3cBpoz22" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent"&gt;(1,244,936&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zFFvWz4hnZ4h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AdditionBankBorrowingsNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zWdV86ZXOPIg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsYQmTbr5FZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUHbvi6QWvH1" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1856"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zMzTr4m7Mze4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zs1RvxrtUEc8" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings"&gt;3,372,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zZCSZn4dJfob" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings"&gt;(7,427,140&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z3nhdVOyuJ1a" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current"&gt;3,144,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zcTmyKWWRvvf" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"&gt;3,557,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zGdOLaZ5eRq2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current"&gt;160,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zFJbavN0oYCh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"&gt;(161,671&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zu66LVzQlkT2" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending"&gt;2,640,227&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;15.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Borrowings (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Beginning of&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Proceed
                                            from&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Non-cash changes&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;End
    of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;financial
                                            year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Cash flows&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;bank&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Addition&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Accretion
                                            of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;interests&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;financial
year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 10%"&gt;- Current&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--CurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zZkCagR1EcP6" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings"&gt;28,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbdVKp4xYHC8" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows"&gt;(1,096,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zS9GRUWFcb4" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeo4YnIcGu9g" style="width: 10%; text-align: right" title="Addition lease liabilities current"&gt;4,524,209&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z6YbZ6hH5uBh" style="width: 10%; text-align: right" title="Accretion of interests current"&gt;114,966&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zouRKEM8rSE" style="width: 10%; text-align: right" title="Other non cash changes current"&gt;(1,511,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--CurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zSqlGB2becgi" style="width: 10%; text-align: right" title="Lease liabilities current, ending"&gt;2,059,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJZH4bRh0yR9" style="text-align: right" title="Lease liabilities non-current, beginnings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zny0HBAasPxi" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1890"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zfqmOtgZKqBj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbUZvdy7iVyg" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z3NFbRxnAbLj" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_ziFc4frHhLQe" style="text-align: right" title="Other non cash changes non current"&gt;1,298,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJVjOxYKgQlf" style="text-align: right" title="Lease liabilities non-current, ending"&gt;1,298,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--BankBorrowings_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zd4RJQm3TgO9" style="text-align: right" title="Bank borrowings, beginnings"&gt;2,677,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuTsUG1V7vCd" style="text-align: right" title="Bank borrowings current cash flows"&gt;(6,766,838&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5OjWXPNfgOe" style="text-align: right" title="Proceed from bank borrowings, current"&gt;4,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AdditionBankBorrowingsCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zhyTlkOGjvIi" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1908"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z1Nibn0iDCo1" style="text-align: right" title="Accretion of interests bank borrowings current"&gt;88,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsgrdK3gkz03" style="text-align: right" title="Other non cash changes bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--BankBorrowings_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zTGx3TRaq7n6" style="text-align: right" title="Bank borrowings, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1914"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8wHAK9WGSy5" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zN6tU9fiYlHd" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current cash flows"&gt;(1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zV6SjydDYlTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1920"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zpAp65clDFN2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5uIHhwvKCQ2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEVJi6rswpba" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1926"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z0gDTthVuxd4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1928"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z7z9f1IDrXx1" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings"&gt;4,289,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zsY8H7j33HD1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayment of lease and bank liabilities cash flows"&gt;(9,446,580&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zMqxQZUOx8Yk" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current"&gt;4,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zD75IkMb2AWj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"&gt;4,524,209&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z99G6ECJKoNl" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current"&gt;203,948&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zEuO6YN4I9Ue" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"&gt;(213,262&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zBp1vkK8bi2c" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending"&gt;3,358,105&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--CurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zP372ZNlPoXd" style="text-align: right" title="Lease liabilities current, beginnings"&gt;566,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zERGdLLo45K1" style="text-align: right" title="Repayment of lease liabilities cash flows"&gt;(553,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_znqo69272iEe" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm5A180JBrke" style="text-align: right" title="Addition lease liabilities current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1950"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm31aQcXiosa" style="text-align: right" title="Accretion of interests current"&gt;15,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zRAessjprRXe" style="text-align: right" title="Other non cash changes current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--CurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjGwJ26L4kX5" style="text-align: right" title="Lease liabilities current, ending"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zBAk8eJkwj5b" style="text-align: right" title="Lease liabilities non-current, beginnings"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zc1p5vsFZ4Ik" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zdsbCwzQf6cj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOBAqgc2SVQi" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zUih1hJ51mS1" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1966"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOao7WUyTys8" style="text-align: right" title="Other non cash changes non current"&gt;(28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zMb6CDB6D4hf" style="text-align: right" title="Lease liabilities non-current, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1970"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--BankBorrowings_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEtuzHIWPoK" style="text-align: right" title="Bank borrowings, beginnings"&gt;3,223,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPeo5LD0MS4c" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current"&gt;(2,517,707&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zvbuW1upupy1" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AdditionBankBorrowingsCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPAvYTRS1XVa" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuf9MMclmfQi" style="text-align: right" title="Accretion of interests current"&gt;160,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zfBjlNMJHAxh" style="text-align: right" title="Other non cash changes current"&gt;1,811,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--BankBorrowings_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zJeXZUJvbral" style="text-align: right" title="Bank borrowings, ending"&gt;2,677,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zmqSRO5hu3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings"&gt;3,395,070&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zdzCUTrf0gYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zLUypYBpj3N5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1990"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8Tzxwk0Qalb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1992"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z45tYKiRywPe" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1994"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_ztaPrbh1zlF6" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes non current"&gt;(1,811,636&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zSgZjzQPcqV1" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z8KcFElCssf7" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings"&gt;7,212,759&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zOqXe0pjd2Ri" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings"&gt;(3,070,707&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zpsjjnUBMeG5" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings and lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zLto3361fobj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zuuNTzX4WiXf" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current"&gt;176,238&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zIJpZq6y9ihh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2010"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zF7NmYHGg4K5" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending"&gt;4,289,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zjUGRqdZzZqa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001605">&lt;p id="xdx_89A_eifrs-full--DisclosureOfDetailedInformationAboutBorrowingsExplanatory_zmN8Qhr6RF51" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zdt7LE6MD55l" style="display: none"&gt;Schedule
of borrowings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zwlNex0l6wPb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zZKEthUKq2Cf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CurrentPortionOfBorrowingsAbstract_iB_zQ729fu69Byb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_z9MC6pvOiik3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;- Bank overdraft&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--BankOverdraftsClassifiedAsCashEquivalents_iI_uUSD_c20250630_zHRARvdwfRui" style="width: 14%; text-align: right" title="- Bank overdraft"&gt;48,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;61,371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--CurrentLeaseLiabilities_iI_zU5gGaaZhtb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;- Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--CurrentLeaseLiabilities_iI_uUSD_c20250630_zpuJBUb8KF36" style="text-align: right" title="- Lease liabilities"&gt;1,619,426&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,059,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--BankBorrowings_iI_zFSQaeP0Gxvl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- Bank borrowings&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--BankBorrowings_iI_uUSD_c20250630_zvfOsocVggXl" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1620"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,677,856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--ShorttermBorrowings_iI_maCBACPzDNY_zA3J4qZPVtCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ShorttermBorrowings_iI_uUSD_c20250630_zhZW43QmPIC3" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Current"&gt;1,667,677&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,121,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,706,356&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract_iB_zB4QdRluA1O1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_zfmOzutEoqvc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;- Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iI_uUSD_c20250630_ztiRF4DFLkPl" style="text-align: right" title="- Lease liabilities"&gt;1,020,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,298,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_zbiryHuikNkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- Bank borrowings&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iI_uUSD_c20250630_zSeXumxc9Os7" style="border-bottom: Black 1pt solid; text-align: right" title="- Bank borrowings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1641"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--LongtermBorrowings_iI_maCBACPzDNY_z5BJ7i2ZDasg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--LongtermBorrowings_iI_uUSD_c20250630_zef1XgI4UvVa" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings Non-Current"&gt;1,020,801&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,298,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_mtCBACPzDNY_zQITjCNLUDph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_iTI_uUSD_c20250630_zNR5XqMpmVPe" style="border-bottom: Black 1pt solid; text-align: right" title="Borrowings"&gt;2,688,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,419,476&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,289,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001613"
      unitRef="USD">48251</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001610"
      unitRef="SGD">61371</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001618"
      unitRef="USD">1619426</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001615"
      unitRef="SGD">2059748</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001616"
      unitRef="SGD">28500</ifrs-full:CurrentLeaseLiabilities>
    <BMGL:BankBorrowings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001621"
      unitRef="SGD">2677856</BMGL:BankBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001628"
      unitRef="USD">1667677</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001625"
      unitRef="SGD">2121119</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001626"
      unitRef="SGD">2706356</ifrs-full:ShorttermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001636"
      unitRef="USD">1020801</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001633"
      unitRef="SGD">1298357</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001639"
      unitRef="SGD">1583434</ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived>
    <ifrs-full:LongtermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001646"
      unitRef="USD">1020801</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001643"
      unitRef="SGD">1298357</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001644"
      unitRef="SGD">1583434</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001651"
      unitRef="USD">2688478</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001648"
      unitRef="SGD">3419476</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001649"
      unitRef="SGD">4289790</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <BMGL:DisclosureOfDetailedInformationAboutBreakdownOfBorrowings contextRef="From2024-07-01to2025-06-30" id="Fact001653">&lt;p id="xdx_896_ecustom--DisclosureOfDetailedInformationAboutBreakdownOfBorrowings_ziCBI0sPKCS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zWDdgdsTb0mh"&gt;Schedule
of breakdown borrowings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630_zNdeaiaRKbB4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zfwvnxKW8Slf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zxoPc4KMg4pd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Term loan #1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zY1xyzDrTAa1" style="width: 14%; text-align: right" title="Term loan #1"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;206,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zeBcMdLSjO1h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zqLwc4NbzFN5" style="text-align: right" title="Term loan #2"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1663"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zkl0zIS7Oz7i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_z5YP4TD0ZUD4" style="text-align: right" title="Term loan #3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1668"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1665"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zxKTBFvAzdC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zvDBLiBftzX5" style="text-align: right" title="Term loan #4"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1673"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;195,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zIPzY2ktgdY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zetrWLakq162" style="text-align: right" title="Term loan #6"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1678"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1675"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;531,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zoOhaJDdCZj6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #7&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zCeq04oCt6Ie" style="text-align: right" title="Term loan #7"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1683"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zcDk25wLaR07" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #9&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zwdcDI3cuEua" style="text-align: right" title="Term loan #9"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1688"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1685"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;322,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_z7aQ7Mv5s3C7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zrUrbxCAElk5" style="text-align: right" title="Term loan #10"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1690"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,573,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zB8fnSzo1QW" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zwI8CWYChySb" style="text-align: right" title="Term loan #11"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1698"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1695"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;691,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z5m3JcKwdPS7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Term loan #12&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z371D7LxwDO2" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan #12"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1700"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1701"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LoansReceived_iI_hifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zJQcXa01mFGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    loan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--LoansReceived_iI_uUSD_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanMember_zu6KKmPCkRq5" style="border-bottom: Black 1pt solid; text-align: right" title="Term loan"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1708"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,261,290&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




</BMGL:DisclosureOfDetailedInformationAboutBreakdownOfBorrowings>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanOneMember"
      decimals="0"
      id="Fact001656"
      unitRef="SGD">206695</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanTwoMember"
      decimals="0"
      id="Fact001661"
      unitRef="SGD">280233</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanThreeMember"
      decimals="0"
      id="Fact001666"
      unitRef="SGD">178565</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanFourMember"
      decimals="0"
      id="Fact001671"
      unitRef="SGD">195299</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanSixMember"
      decimals="0"
      id="Fact001676"
      unitRef="SGD">531708</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanSevenMember"
      decimals="0"
      id="Fact001681"
      unitRef="SGD">280239</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanNineMember"
      decimals="0"
      id="Fact001686"
      unitRef="SGD">322818</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanTenMember"
      decimals="0"
      id="Fact001691"
      unitRef="SGD">1573744</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanElevenMember"
      decimals="0"
      id="Fact001696"
      unitRef="SGD">691989</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="AsOf2024-06-30_custom_TermLoanMember"
      decimals="0"
      id="Fact001706"
      unitRef="SGD">4261290</ifrs-full:LoansReceived>
    <BMGL:DisclosureOfDetailedInformationAboutBorrowings contextRef="From2024-07-01to2025-06-30" id="Fact001710">&lt;p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutBorrowings_z7Z3O9OHS2Jl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of borrowings are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zqwfwL5RQPh5"&gt;Schedule
of details borrowings&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Term loan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Facility&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Effective&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Maturity date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%
                                            p.a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Term loan #1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zmwe5qGEnbYi" style="width: 20%; text-align: right" title="Term loan facility amount"&gt;S$600,000&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_zXftvuI5Mfvc" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanOneMember_z96JMNsqrX5i" title="Borrowing maturity date"&gt;October 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zo27zLqEwcfl" style="text-align: right" title="Term loan facility amount"&gt;S$1,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_z3zLZh8Q6KB7" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwoMember_zCEof4omSSu5" title="Borrowing maturity date"&gt;October 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zZScS99VHdce" style="text-align: right" title="Term loan facility amount"&gt;S$600,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zEQDShG6OZE4" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanThreeMember_zATvoJ4ZG6d" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zJP4gzAywMp5" style="text-align: right" title="Term loan facility amount"&gt;S$700,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_z4GhlSEknfH4" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanFourMember_zRa8gabc442g" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zSWuZ6MrwTv7" style="text-align: right" title="Term loan facility amount"&gt;S$1,400,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zcKiNqHB0Io6" title="Borrowings interest rate"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSixMember_zOL0DfbOCMVj" title="Borrowing maturity date"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #7&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zjvSjDiIMNV" style="text-align: right" title="Term loan facility amount"&gt;S$1,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zyyRWErTzY9j" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanSevenMember_zVCjHKippPUk" title="Borrowing maturity date"&gt;October 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #9&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_z8kNMs3jXSLd" style="text-align: right" title="Term loan facility amount"&gt;S$850,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zpW1oRi2kVWd" title="Borrowings interest rate"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanNineMember_zsJvLxwgL8rb" title="Borrowing maturity date"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term loan #10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zRLLPOyMADtc" style="text-align: right" title="Term loan facility amount"&gt;S$600,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_zqoQHJtVtV5l" title="Borrowings interest rate"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenMember_za5oe8qgkVF" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zIBpnDvgdMni" style="text-align: right" title="Term loan facility amount"&gt;S$1,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zvK0ob31ByUi" title="Borrowings interest rate"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenOneMember_zqiD5Y1yqA1h" title="Borrowing maturity date"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zjvXaaZgKAs1" style="text-align: right" title="Term loan facility amount"&gt;S$500,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_z9IZjshJeJtc" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenTwoMember_zsx6e8CUqMi5" title="Borrowing maturity date"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_z3O9f7OqgR45" style="text-align: right" title="Term loan facility amount"&gt;S$529,890&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zXsBAnX0tHZ6" title="Borrowings interest rate"&gt;1.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenThreeMember_zSZRyAqhlFXb" title="Borrowing maturity date"&gt;December 2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zDLFxKuDwkR7" style="text-align: right" title="Term loan facility amount"&gt;S$501,670&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_zn8aOp0JAuJh" title="Borrowings interest rate"&gt;1.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTenFourMember_z8ws7KhQnl6k" title="Borrowing maturity date"&gt;December 2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #11&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_z27O3M099r9a" style="text-align: right" title="Term loan facility amount"&gt;S$400,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zCRg2dGta2K3" title="Borrowings interest rate"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenMember_zQ2J0zJXvgW8" title="Borrowing maturity date"&gt;January 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_z7nETdPtOQOd" style="text-align: right" title="Term loan facility amount"&gt;S$1,500,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zKHmVImFfpe3" title="Borrowings interest rate"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanElevenOneMember_zZGx25X3Jklc" title="Borrowing maturity date"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term loan #12&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eifrs-full--Borrowings_iI_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zUpZt2bPFomb" style="text-align: right" title="Term loan facility amount"&gt;S$4,000,000&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--BorrowingsInterestRate_iI_pid_dp_uPure_c20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_zeo2FBScLV3" title="Borrowings interest rate"&gt;4.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BorrowingsMaturity_c20240701__20250630__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--TermLoanTwelveMember_z1FRr2XA00V1" title="Borrowing maturity date"&gt;One-month term, upon maturity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDetailedInformationAboutBorrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanOneMember"
      decimals="0"
      id="Fact001712"
      unitRef="SGD">600000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanOneMember"
      decimals="INF"
      id="Fact001714"
      unitRef="Pure">0.0250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanOneMember"
      id="Fact001716">October 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTwoMember"
      decimals="0"
      id="Fact001718"
      unitRef="SGD">1000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTwoMember"
      decimals="INF"
      id="Fact001720"
      unitRef="Pure">0.0275</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTwoMember"
      id="Fact001722">October 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanThreeMember"
      decimals="0"
      id="Fact001724"
      unitRef="SGD">600000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanThreeMember"
      decimals="INF"
      id="Fact001726"
      unitRef="Pure">0.0275</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanThreeMember"
      id="Fact001728">November 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanFourMember"
      decimals="0"
      id="Fact001730"
      unitRef="SGD">700000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanFourMember"
      decimals="INF"
      id="Fact001732"
      unitRef="Pure">0.0250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanFourMember"
      id="Fact001734">November 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanSixMember"
      decimals="0"
      id="Fact001736"
      unitRef="SGD">1400000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanSixMember"
      decimals="INF"
      id="Fact001738"
      unitRef="Pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanSixMember"
      id="Fact001740">April 2026</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanSevenMember"
      decimals="0"
      id="Fact001742"
      unitRef="SGD">1000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanSevenMember"
      decimals="INF"
      id="Fact001744"
      unitRef="Pure">0.0275</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanSevenMember"
      id="Fact001746">October 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanNineMember"
      decimals="0"
      id="Fact001748"
      unitRef="SGD">850000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanNineMember"
      decimals="INF"
      id="Fact001750"
      unitRef="Pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanNineMember"
      id="Fact001752">April 2026</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTenMember"
      decimals="0"
      id="Fact001754"
      unitRef="SGD">600000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTenMember"
      decimals="INF"
      id="Fact001756"
      unitRef="Pure">0.0275</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTenMember"
      id="Fact001758">November 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTenOneMember"
      decimals="0"
      id="Fact001760"
      unitRef="SGD">1000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTenOneMember"
      decimals="INF"
      id="Fact001762"
      unitRef="Pure">0.0300</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTenOneMember"
      id="Fact001764">November 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTenTwoMember"
      decimals="0"
      id="Fact001766"
      unitRef="SGD">500000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTenTwoMember"
      decimals="INF"
      id="Fact001768"
      unitRef="Pure">0.0250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTenTwoMember"
      id="Fact001770">March 2026</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTenThreeMember"
      decimals="0"
      id="Fact001772"
      unitRef="SGD">529890</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTenThreeMember"
      decimals="INF"
      id="Fact001774"
      unitRef="Pure">0.0153</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTenThreeMember"
      id="Fact001776">December 2035</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTenFourMember"
      decimals="0"
      id="Fact001778"
      unitRef="SGD">501670</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTenFourMember"
      decimals="INF"
      id="Fact001780"
      unitRef="Pure">0.0153</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTenFourMember"
      id="Fact001782">December 2035</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanElevenMember"
      decimals="0"
      id="Fact001784"
      unitRef="SGD">400000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanElevenMember"
      decimals="INF"
      id="Fact001786"
      unitRef="Pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanElevenMember"
      id="Fact001788">January 2026</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanElevenOneMember"
      decimals="0"
      id="Fact001790"
      unitRef="SGD">1500000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanElevenOneMember"
      decimals="INF"
      id="Fact001792"
      unitRef="Pure">0.0250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanElevenOneMember"
      id="Fact001794">December 2025</ifrs-full:BorrowingsMaturity>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember"
      decimals="0"
      id="Fact001796"
      unitRef="SGD">4000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2025-06-30_custom_TermLoanTwelveMember"
      decimals="INF"
      id="Fact001798"
      unitRef="Pure">0.0430</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsMaturity
      contextRef="From2024-07-012025-06-30_custom_TermLoanTwelveMember"
      id="Fact001800">One-month term, upon maturity</ifrs-full:BorrowingsMaturity>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact001802">&lt;p id="xdx_89F_eifrs-full--DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_zbFJuUGQizij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of liabilities arising from financing activities is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zfiMpdyhrmdg"&gt;Schedule
of reconciliation of liabilities arising from financing activities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Beginning of&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Proceed from&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Non-cash changes&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;End of&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                              &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;financial
                                            year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash
    flows&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;
                                                                                                                                                                                                                              &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;bank&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                                                                                                                                              &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;borrowings&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Addition&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Accretion
                                            of&lt;/p&gt;
                                                                              &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;interests&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;financial&lt;/p&gt;
                                                                              &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;period&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;US$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 10%"&gt;- Current&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zt3WYqOApUYi" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings"&gt;22,407&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zULAica0qbTb" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows"&gt;(861,945&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z4Dg6eG11iNa" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zumGlwPxqnyi" style="width: 10%; text-align: right" title="Addition lease liabilities current"&gt;3,557,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z9m5DJkhsgUe" style="width: 10%; text-align: right" title="Accretion of interests current"&gt;90,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zh1GdGMnjdt9" style="width: 10%; text-align: right" title="Other non cash changes current"&gt;(1,188,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z5rjM5nVLmag" style="width: 10%; text-align: right" title="Lease liabilities current, ending"&gt;1,619,426&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncurrentLeaseLiabilities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zCCXuDOVsfz8" style="text-align: right" title="Lease liabilities non-current, beginnings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1818"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeIUBS8onrIf" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z8GsKz6zc8pi" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zl07H7xrRPMc" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1824"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjmqj9cSZSb3" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1826"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zFhyROnbMh28" style="text-align: right" title="Other non cash changes non current"&gt;1,020,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zIWHiFuDIeF9" style="text-align: right" title="Lease liabilities non-current, ending"&gt;1,020,801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--BankBorrowings_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zQ03przyNmv" style="text-align: right" title="Bank borrowings, beginnings"&gt;2,105,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zgjyNKdFBFcb" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current"&gt;(5,320,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProceedsFromCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUDWSvmuBqW7" style="text-align: right" title="Proceed from bank borrowings, current"&gt;3,144,901&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionBankBorrowingsCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zrOoTURCPyA6" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUYIJbWaaAYl" style="text-align: right" title="Accretion of interests bank borrowings current"&gt;69,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zue9Q6PgASn2" style="text-align: right" title="Other non cash changes bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--BankBorrowings_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zcs3uL1C2UCc" style="text-align: right" title="Bank borrowings, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z44DTK1GAyWf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings"&gt;1,244,936&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zIzI3cBpoz22" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent"&gt;(1,244,936&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zFFvWz4hnZ4h" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AdditionBankBorrowingsNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zWdV86ZXOPIg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsYQmTbr5FZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zUHbvi6QWvH1" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1856"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zMzTr4m7Mze4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zs1RvxrtUEc8" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings"&gt;3,372,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zZCSZn4dJfob" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings"&gt;(7,427,140&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z3nhdVOyuJ1a" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current"&gt;3,144,901&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zcTmyKWWRvvf" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"&gt;3,557,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zGdOLaZ5eRq2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current"&gt;160,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zFJbavN0oYCh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"&gt;(161,671&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_uUSD_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zu66LVzQlkT2" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending"&gt;2,640,227&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;15.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Borrowings (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Beginning of&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Proceed
                                            from&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Non-cash changes&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;End
    of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;financial
                                            year&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Cash flows&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;bank&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Addition&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Accretion
                                            of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;interests&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;financial
year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;S$&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 10%"&gt;- Current&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--CurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zZkCagR1EcP6" style="width: 10%; text-align: right" title="Lease liabilities current, beginnings"&gt;28,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbdVKp4xYHC8" style="width: 10%; text-align: right" title="Repayment of lease liabilities cash flows"&gt;(1,096,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zS9GRUWFcb4" style="width: 10%; text-align: right" title="Proceed from bank borrowings lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zeo4YnIcGu9g" style="width: 10%; text-align: right" title="Addition lease liabilities current"&gt;4,524,209&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z6YbZ6hH5uBh" style="width: 10%; text-align: right" title="Accretion of interests current"&gt;114,966&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zouRKEM8rSE" style="width: 10%; text-align: right" title="Other non cash changes current"&gt;(1,511,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--CurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zSqlGB2becgi" style="width: 10%; text-align: right" title="Lease liabilities current, ending"&gt;2,059,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncurrentLeaseLiabilities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJZH4bRh0yR9" style="text-align: right" title="Lease liabilities non-current, beginnings"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zny0HBAasPxi" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1890"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zfqmOtgZKqBj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings lease liabilities, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zbUZvdy7iVyg" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_z3NFbRxnAbLj" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_ziFc4frHhLQe" style="text-align: right" title="Other non cash changes non current"&gt;1,298,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncurrentLeaseLiabilities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zJVjOxYKgQlf" style="text-align: right" title="Lease liabilities non-current, ending"&gt;1,298,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--BankBorrowings_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zd4RJQm3TgO9" style="text-align: right" title="Bank borrowings, beginnings"&gt;2,677,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuTsUG1V7vCd" style="text-align: right" title="Bank borrowings current cash flows"&gt;(6,766,838&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ProceedsFromCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5OjWXPNfgOe" style="text-align: right" title="Proceed from bank borrowings, current"&gt;4,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AdditionBankBorrowingsCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zhyTlkOGjvIi" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1908"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z1Nibn0iDCo1" style="text-align: right" title="Accretion of interests bank borrowings current"&gt;88,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zsgrdK3gkz03" style="text-align: right" title="Other non cash changes bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1912"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--BankBorrowings_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zTGx3TRaq7n6" style="text-align: right" title="Bank borrowings, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1914"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8wHAK9WGSy5" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zN6tU9fiYlHd" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current cash flows"&gt;(1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zV6SjydDYlTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings, non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1920"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zpAp65clDFN2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z5uIHhwvKCQ2" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEVJi6rswpba" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1926"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z0gDTthVuxd4" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1928"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z7z9f1IDrXx1" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings"&gt;4,289,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zsY8H7j33HD1" style="border-bottom: Black 1pt solid; text-align: right" title="Repayment of lease and bank liabilities cash flows"&gt;(9,446,580&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zMqxQZUOx8Yk" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings lease liabilities, current and non current"&gt;4,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zD75IkMb2AWj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"&gt;4,524,209&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z99G6ECJKoNl" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current"&gt;203,948&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zEuO6YN4I9Ue" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"&gt;(213,262&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20240701__20250630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zBp1vkK8bi2c" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending"&gt;3,358,105&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--CurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zP372ZNlPoXd" style="text-align: right" title="Lease liabilities current, beginnings"&gt;566,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zERGdLLo45K1" style="text-align: right" title="Repayment of lease liabilities cash flows"&gt;(553,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_znqo69272iEe" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm5A180JBrke" style="text-align: right" title="Addition lease liabilities current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1950"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zm31aQcXiosa" style="text-align: right" title="Accretion of interests current"&gt;15,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zRAessjprRXe" style="text-align: right" title="Other non cash changes current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1954"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--CurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zjGwJ26L4kX5" style="text-align: right" title="Lease liabilities current, ending"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncurrentLeaseLiabilities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zBAk8eJkwj5b" style="text-align: right" title="Lease liabilities non-current, beginnings"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zc1p5vsFZ4Ik" style="font-weight: bold; text-align: right" title="Repayment of lease liabilities non current cash flows"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zdsbCwzQf6cj" style="font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseThroughNewLeasesLiabilitiesArisingNonCurrentFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOBAqgc2SVQi" style="font-weight: bold; text-align: right" title="Addition lease liabilities non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zUih1hJ51mS1" style="font-weight: bold; text-align: right" title="Accretion of interests Non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1966"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zOao7WUyTys8" style="text-align: right" title="Other non cash changes non current"&gt;(28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NoncurrentLeaseLiabilities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--LeaseLiabilitiesMember_zMb6CDB6D4hf" style="text-align: right" title="Lease liabilities non-current, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1970"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Bank borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;- Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--BankBorrowings_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zEtuzHIWPoK" style="text-align: right" title="Bank borrowings, beginnings"&gt;3,223,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPeo5LD0MS4c" style="text-align: right" title="Cash flows lease liabilities and bank borrowings current"&gt;(2,517,707&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--ProceedsFromCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zvbuW1upupy1" style="text-align: right" title="Proceed from bank borrowings and lease liabilities, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AdditionBankBorrowingsCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zPAvYTRS1XVa" style="font-weight: bold; text-align: right" title="Addition bank borrowings current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zuf9MMclmfQi" style="text-align: right" title="Accretion of interests current"&gt;160,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zfBjlNMJHAxh" style="text-align: right" title="Other non cash changes current"&gt;1,811,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--BankBorrowings_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zJeXZUJvbral" style="text-align: right" title="Bank borrowings, ending"&gt;2,677,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;- Non-current&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zmqSRO5hu3xf" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, beginnings"&gt;3,395,070&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zdzCUTrf0gYb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Cash flows lease liabilities and bank borrowings noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromNoncurrentBorrowings_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zLUypYBpj3N5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Proceed from bank borrowings and lease liabilities, noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1990"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionBankBorrowingsNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z8Tzxwk0Qalb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Addition bank borrowings non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1992"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_z45tYKiRywPe" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests noncurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1994"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_ztaPrbh1zlF6" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes non current"&gt;(1,811,636&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncurrentPortionOfNoncurrentSecuredBankLoansReceived_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--ShorttermBorrowingsMember_zSgZjzQPcqV1" style="border-bottom: Black 1pt solid; text-align: right" title="Bank borrowings non current, ending"&gt;1,583,434&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--LiabilitiesArisingFromFinancingActivities_iS_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_z8KcFElCssf7" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, beginnings"&gt;7,212,759&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zOqXe0pjd2Ri" style="border-bottom: Black 1pt solid; text-align: right" title="Cash flows lease liabilities and bank borrowings"&gt;(3,070,707&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProceedsFromBorrowingsClassifiedAsFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zpsjjnUBMeG5" style="border-bottom: Black 1pt solid; text-align: right" title="Proceed from bank borrowings and lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zLto3361fobj" style="border-bottom: Black 1pt solid; text-align: right" title="Addition bank lease liabilities current and non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zuuNTzX4WiXf" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of interests current and non current"&gt;176,238&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zIJpZq6y9ihh" style="border-bottom: Black 1pt solid; text-align: right" title="Other non cash changes current and non current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2010"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--LiabilitiesArisingFromFinancingActivities_iE_c20230701__20240630__ifrs-full--LiabilitiesArisingFromFinancingActivitiesAxis__ifrs-full--AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember_zF7NmYHGg4K5" style="border-bottom: Black 1pt solid; text-align: right" title="Reconciliation of liabilities financing activities current and non current, ending"&gt;4,289,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">22407</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">-861945</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">3557047</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">90389</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">-1188472</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">1619426</ifrs-full:CurrentLeaseLiabilities>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001828"
      unitRef="USD">1020801</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001830"
      unitRef="USD">1020801</ifrs-full:NoncurrentLeaseLiabilities>
    <BMGL:BankBorrowings
      contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001832"
      unitRef="USD">2105398</BMGL:BankBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001834"
      unitRef="USD">-5320259</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001836"
      unitRef="USD">3144901</ifrs-full:ProceedsFromCurrentBorrowings>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001840"
      unitRef="USD">69960</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001846"
      unitRef="USD">1244936</ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived>
    <BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001848"
      unitRef="USD">-1244936</BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001860"
      unitRef="USD">3372741</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001862"
      unitRef="USD">-7427140</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001864"
      unitRef="USD">3144901</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001866"
      unitRef="USD">3557047</BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001868"
      unitRef="USD">160349</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001870"
      unitRef="USD">-161671</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="AsOf2025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001872"
      unitRef="USD">2640227</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001874"
      unitRef="SGD">28500</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001876"
      unitRef="SGD">-1096308</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001880"
      unitRef="SGD">4524209</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001882"
      unitRef="SGD">114966</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001884"
      unitRef="SGD">-1511619</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001886"
      unitRef="SGD">2059748</ifrs-full:CurrentLeaseLiabilities>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001898"
      unitRef="SGD">1298357</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2025-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001900"
      unitRef="SGD">1298357</ifrs-full:NoncurrentLeaseLiabilities>
    <BMGL:BankBorrowings
      contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001902"
      unitRef="SGD">2677856</BMGL:BankBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001904"
      unitRef="SGD">-6766838</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001906"
      unitRef="SGD">4000000</ifrs-full:ProceedsFromCurrentBorrowings>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001910"
      unitRef="SGD">88982</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001916"
      unitRef="SGD">1583434</ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived>
    <BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings
      contextRef="From2024-07-012025-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001918"
      unitRef="SGD">-1583434</BMGL:CashFlowsFromUsedInIncreaseDecreaseInNonCurrentBorrowings>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001930"
      unitRef="SGD">4289790</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001932"
      unitRef="SGD">-9446580</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001934"
      unitRef="SGD">4000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001936"
      unitRef="SGD">4524209</BMGL:IncreaseThroughNewLeasesLiabilitiesAndBankBorrowingsArisingFromFinancingActivities>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001938"
      unitRef="SGD">203948</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities
      contextRef="From2024-07-012025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001940"
      unitRef="SGD">-213262</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="AsOf2025-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact001942"
      unitRef="SGD">3358105</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2023-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001944"
      unitRef="SGD">566039</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001946"
      unitRef="SGD">-553000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001952"
      unitRef="SGD">15461</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001956"
      unitRef="SGD">28500</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2023-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001958"
      unitRef="SGD">28500</ifrs-full:NoncurrentLeaseLiabilities>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_LeaseLiabilitiesMember"
      decimals="0"
      id="Fact001968"
      unitRef="SGD">-28500</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent>
    <BMGL:BankBorrowings
      contextRef="AsOf2023-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001972"
      unitRef="SGD">3223150</BMGL:BankBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001974"
      unitRef="SGD">-2517707</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001980"
      unitRef="SGD">160777</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrent>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001982"
      unitRef="SGD">1811636</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesCurrent>
    <BMGL:BankBorrowings
      contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001984"
      unitRef="SGD">2677856</BMGL:BankBorrowings>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2023-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001986"
      unitRef="SGD">3395070</ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived>
    <BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001996"
      unitRef="SGD">-1811636</BMGL:OtherLeaseLiabilitiesAndBankBorrowingsArisingFromFinancingActivitiesNonCurrent>
    <ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived
      contextRef="AsOf2024-06-30_ifrs-full_ShorttermBorrowingsMember"
      decimals="0"
      id="Fact001998"
      unitRef="SGD">1583434</ifrs-full:NoncurrentPortionOfNoncurrentSecuredBankLoansReceived>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="AsOf2023-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact002000"
      unitRef="SGD">7212759</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact002002"
      unitRef="SGD">-3070707</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent
      contextRef="From2023-07-012024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact002008"
      unitRef="SGD">176238</BMGL:IncreaseDecreaseInLeaseLiabilitiesInterestAndBankBorrowingsExpenseCurrentAndNonCurrent>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="AsOf2024-06-30_ifrs-full_AssetsHeldToHedgeLiabilitiesArisingFromFinancingActivitiesMember"
      decimals="0"
      id="Fact002012"
      unitRef="SGD">4289790</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002014">&lt;p id="xdx_80F_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zdpindPSPCMc" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;16.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_82E_zQ9gVc9pFpKc"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_89B_ecustom--DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_zKxJ7xXfueWl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z6Nk7R5z831k" style="display: none"&gt;Schedule
of trade and other payables&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250630_zLTYgA4E3Ym9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240630_zYyqsXkpafxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_maTAOPzVdB_zi02tmFckYoa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 58%; text-align: left"&gt;- third parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_uUSD_c20250630_zVy5PUMftfL8" style="width: 10%; text-align: right" title="Trade payable- third parties"&gt;1,649,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,097,415&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;829,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--Accruals_iI_maTAOPzVdB_zbLoTrZPRdcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--Accruals_iI_uUSD_c20250630_zVtkIXLjXUeb" style="text-align: right" title="Accruals"&gt;1,222,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,555,531&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,074,868&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--ValueAddedTaxPayables_iI_maTAOPzVdB_zhilMtwv2CYk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;GST payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ValueAddedTaxPayables_iI_uUSD_c20250630_zgh4jgwuoOui" style="text-align: right" title="GST payables"&gt;219,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;279,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;391,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--OtherPayables_iI_maTAOPzVdB_zNPe2CehumO4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- third parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--OtherPayables_iI_uUSD_c20250630_zLHXbmlFvPd5" style="border-bottom: Black 1pt solid; text-align: right" title="Other payables third parties"&gt;2,343,283&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,980,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;280,427&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherPayables_iTI_mtTAOPzVdB_zuyH3ZABFMDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--TradeAndOtherPayables_iTI_uUSD_c20250630_zodGfcyXNFAi" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;5,435,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,913,006&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,575,949&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zPkVeAP2qu8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
payables are non-interest bearing and are normally settled on &lt;span id="xdx_908_ecustom--TradePayablesMaturity_c20240701__20250630_zwvGO3jKESWh" title="Trade payable, maturity"&gt;30 to 90 days terms&lt;/span&gt; (June 30, 2024: &lt;span id="xdx_90C_ecustom--TradePayablesMaturity_c20230701__20240630_zwtSdzmqiGE7" title="Trade payable, maturity"&gt;30 to 90 days&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
payables are non-trade related, unsecured, non-interest bearing, repayable on demand and are to be settled in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
and other payables are denominated in Singapore Dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002016">&lt;p id="xdx_89B_ecustom--DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory_zKxJ7xXfueWl" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z6Nk7R5z831k" style="display: none"&gt;Schedule
of trade and other payables&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250630_zLTYgA4E3Ym9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240630_zYyqsXkpafxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_maTAOPzVdB_zi02tmFckYoa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 58%; text-align: left"&gt;- third parties&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--TradeAndOtherPayablesToTradeSuppliers_iI_uUSD_c20250630_zVy5PUMftfL8" style="width: 10%; text-align: right" title="Trade payable- third parties"&gt;1,649,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,097,415&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;829,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--Accruals_iI_maTAOPzVdB_zbLoTrZPRdcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--Accruals_iI_uUSD_c20250630_zVtkIXLjXUeb" style="text-align: right" title="Accruals"&gt;1,222,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,555,531&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,074,868&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--ValueAddedTaxPayables_iI_maTAOPzVdB_zhilMtwv2CYk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;GST payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ValueAddedTaxPayables_iI_uUSD_c20250630_zgh4jgwuoOui" style="text-align: right" title="GST payables"&gt;219,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;279,638&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;391,330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--OtherPayables_iI_maTAOPzVdB_zNPe2CehumO4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;- third parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--OtherPayables_iI_uUSD_c20250630_zLHXbmlFvPd5" style="border-bottom: Black 1pt solid; text-align: right" title="Other payables third parties"&gt;2,343,283&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,980,422&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;280,427&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherPayables_iTI_mtTAOPzVdB_zuyH3ZABFMDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--TradeAndOtherPayables_iTI_uUSD_c20250630_zodGfcyXNFAi" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;5,435,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,913,006&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,575,949&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002021"
      unitRef="USD">1649041</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002018"
      unitRef="SGD">2097415</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002019"
      unitRef="SGD">829324</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:Accruals
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002026"
      unitRef="USD">1222998</ifrs-full:Accruals>
    <ifrs-full:Accruals
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002023"
      unitRef="SGD">1555531</ifrs-full:Accruals>
    <ifrs-full:Accruals
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002024"
      unitRef="SGD">1074868</ifrs-full:Accruals>
    <ifrs-full:ValueAddedTaxPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002031"
      unitRef="USD">219858</ifrs-full:ValueAddedTaxPayables>
    <ifrs-full:ValueAddedTaxPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002028"
      unitRef="SGD">279638</ifrs-full:ValueAddedTaxPayables>
    <ifrs-full:ValueAddedTaxPayables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002029"
      unitRef="SGD">391330</ifrs-full:ValueAddedTaxPayables>
    <ifrs-full:OtherPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002036"
      unitRef="USD">2343283</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002033"
      unitRef="SGD">2980422</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002034"
      unitRef="SGD">280427</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002041"
      unitRef="USD">5435180</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002038"
      unitRef="SGD">6913006</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002039"
      unitRef="SGD">2575949</ifrs-full:TradeAndOtherPayables>
    <BMGL:TradePayablesMaturity contextRef="From2024-07-01to2025-06-30" id="Fact002043">30 to 90 days terms</BMGL:TradePayablesMaturity>
    <BMGL:TradePayablesMaturity contextRef="From2023-07-012024-06-30" id="Fact002045">30 to 90 days</BMGL:TradePayablesMaturity>
    <BMGL:DisclosureOfAmountDueToAFormerDirectorExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002047">&lt;p id="xdx_807_ecustom--DisclosureOfAmountDueToAFormerDirectorExplanatory_zhgZNHaNFPv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;17.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_820_zFQmBjqwhKjf"&gt;Amount due to a former director&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Amount
due to a former director is denominated in Singapore Dollar. Please refer to Note 14 for the terms of the sale and purchase agreement
between Rainforest Capital VCC and Dr. Kevin Yip, a former director. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


</BMGL:DisclosureOfAmountDueToAFormerDirectorExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002049">&lt;p id="xdx_802_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zW1VXfZQBfy9" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;18.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_82F_z8qKF0k7Ysd7"&gt;Share capital&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company was established under the laws of BVI on August 10, 2023 with authorized share of &lt;span id="xdx_907_eifrs-full--NumberOfSharesAuthorised_iI_c20230810_zpUDIhfvuD7e" title="Ordinary shares, authorized"&gt;16,250,000&lt;/span&gt; ordinary shares amounting to S$&lt;span id="xdx_902_ecustom--ValueOfSharesAuthorised_iI_c20230810_zTfIUUysnkxb" title="Ordinary shares, amount"&gt;24,455,178&lt;/span&gt;
(US$&lt;span id="xdx_908_ecustom--ValueOfSharesAuthorised_iI_uUSD_c20230810_zGJS85MeZv5h" title="Ordinary shares, amount"&gt;18,362,500&lt;/span&gt;) at a subscription price of US$&lt;span id="xdx_90E_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20230810_zbGJnWe72Qdh" title="Share subscription price"&gt;1.13&lt;/span&gt; per share at the time of incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 96pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company is authorized to issue one class of ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
holders of ordinary shares are entitled to receive dividends as and when declared by the Group. All ordinary shares carry one vote per
share without restrictions. The ordinary shares have no par value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;In
February 2025, following the Company&#x2019;s initial public offering on Nasdaq, &lt;span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_c20250228__ifrs-full--ComponentsOfEquityAxis__custom--InitialPublicOfferingMember_zoovN8LMXNTf" title="Share issue on capital market"&gt;2,205,000&lt;/span&gt; ordinary shares at a subscription price of
US$&lt;span id="xdx_90B_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20250228__ifrs-full--ComponentsOfEquityAxis__custom--InitialPublicOfferingMember_zB7kD3RbJtx3" title="Share subscription price"&gt;4.00&lt;/span&gt; per share were issued. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;In
March 2025, following the exercise of the overallotment option by the underwriter, &lt;span id="xdx_903_eifrs-full--NumberOfSharesIssued_iI_c20250331__ifrs-full--ComponentsOfEquityAxis__custom--OverAllotmentOptionsMember_zNvzOvn22j29" title="Share issue on capital market"&gt;330,750&lt;/span&gt; ordinary shares at a subscription price of
US$&lt;span id="xdx_908_eifrs-full--ParValuePerShare_iI_uUSDPShares_c20250331__ifrs-full--ComponentsOfEquityAxis__custom--OverAllotmentOptionsMember_zTRP35jlTVw7" title="Share subscription price"&gt;4.00&lt;/span&gt; per share were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2025, &lt;span id="xdx_90A_eifrs-full--NumberOfSharesIssued_iI_c20250630_zzXGYbeBvZl8" title="Number of share issued"&gt;18,785,750&lt;/span&gt; ordinary shares of the Company were issued in total.&lt;/span&gt;&lt;/p&gt;
</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="AsOf2023-08-10"
      decimals="INF"
      id="Fact002051"
      unitRef="Shares">16250000</ifrs-full:NumberOfSharesAuthorised>
    <BMGL:ValueOfSharesAuthorised
      contextRef="AsOf2023-08-10"
      decimals="0"
      id="Fact002053"
      unitRef="SGD">24455178</BMGL:ValueOfSharesAuthorised>
    <BMGL:ValueOfSharesAuthorised
      contextRef="AsOf2023-08-10"
      decimals="0"
      id="Fact002055"
      unitRef="USD">18362500</BMGL:ValueOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2023-08-10"
      decimals="INF"
      id="Fact002057"
      unitRef="USDPShares">1.13</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-02-28_custom_InitialPublicOfferingMember"
      decimals="INF"
      id="Fact002059"
      unitRef="Shares">2205000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2025-02-28_custom_InitialPublicOfferingMember"
      decimals="INF"
      id="Fact002061"
      unitRef="USDPShares">4.00</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-03-31_custom_OverAllotmentOptionsMember"
      decimals="INF"
      id="Fact002063"
      unitRef="Shares">330750</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2025-03-31_custom_OverAllotmentOptionsMember"
      decimals="INF"
      id="Fact002065"
      unitRef="USDPShares">4.00</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact002067"
      unitRef="Shares">18785750</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002069">&lt;p id="xdx_80D_eifrs-full--DisclosureOfLeasesExplanatory_zNrnzAX0gSI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;19.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_825_zNNwkJ1JBg1k"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 28.35pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Company
as a lessee&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company has lease contracts for clinics. The Company&#x2019;s obligations under these leases are secured by the lessor&#x2019;s title to
the leased assets. The Company is restricted from assigning and subleasing the leased assets. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company also has certain leases of machinery with lease terms of &lt;span id="xdx_905_ecustom--LeaseTermOfContract_dtM_c20240701__20250630__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--MachineryMember_zkZGmHGA9lRa" title="Lease term"&gt;12&lt;/span&gt; months or less and leases of office equipment with low value. The
Company applies the &#x2018;short-term lease&#x2019; and &#x2018;lease of low-value assets&#x2019; recognition exemptions for these leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(a)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Carrying amounts of right-of-use assets under leasing arrangements&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
carrying amounts of right-of-use assets under leasing arrangements are disclosed in Note 9.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(b)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Lease liabilities&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of lease liabilities (included under borrowings) and the movements during the year are disclosed in Note 15 and the maturity
analysis of lease liabilities is disclosed in Note 22 under liquidity risk. The Company adopt &lt;span id="xdx_904_eifrs-full--WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_iI_dp_uPure_c20250630_zAEK63GqtCC9" title="Weighted average borrowing rate"&gt;5&lt;/span&gt;% as weighted average borrowings rate
to determine the present value of the lease payments. The weighted average remaining life of the lease was 1 year.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;19.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Leases (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_892_ecustom--DisclosureOfLeaseRelatedExpensesTableTextBlock_zEdUSPhrJEv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zzvUbXrLCC2g"&gt;Schedule
of amounts recognized in profit or loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(c)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Amounts recognized in profit or loss&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20250630_zMIG3aDMmcqd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230701__20240630_zoA8EUzu3Dxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--DepreciationRightofuseAssets_zr0aogHlwPNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: justify"&gt;Depreciation of right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630_zjHtOc7VspNl" style="width: 10%; text-align: right" title="Depreciation of right-of-use assets"&gt;843,989&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,073,469&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;498,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--InterestExpenseOnLeaseLiabilities_zajyIKN3s6Vh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zQRGWEPLldXg" style="text-align: right" title="Interest expense on lease liabilities"&gt;90,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease expense not capitalized in lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_zuzdLirjcTX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;- Expense relating to short-term leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_uUSD_c20240701__20250630_zTg9aLWWruhc" style="border-bottom: Black 1pt solid; text-align: right" title="Expense relating to short-term leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_zuOZvYvg1lE8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total amount recognized in profit or loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_uUSD_c20240701__20250630_zeeVw7pGL8G9" style="border-bottom: Black 1pt solid; text-align: right" title="Total amount recognized in profit or loss"&gt;934,378&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,188,435&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;517,276&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zjXndZ1SG6S5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(d)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Total cash outflow&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had total cash outflows for leases of S$&lt;span id="xdx_900_eifrs-full--CashOutflowForLeases_c20240701__20250630_zPA3DTp2Cvu2" title="Cash outflow for leases"&gt;1,096,308&lt;/span&gt; (US$&lt;span id="xdx_90F_eifrs-full--CashOutflowForLeases_uUSD_c20240701__20250630_zOclcdB87uci" title="Cash outflow for leases"&gt;861,945&lt;/span&gt;) (June 30, 2024: S$&lt;span id="xdx_90B_eifrs-full--CashOutflowForLeases_c20230701__20240630_zggItRhNyzTk" title="Cash outflow for leases"&gt;566,039&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(e)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Extension options&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: 7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has several lease contracts that include extension options. These options are negotiated by management to provide flexibility
in managing the leased-asset portfolio and align with the Company&#x2019;s business needs. Management exercises significant judgement
in determining whether these extension options are reasonably certain to be exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


</ifrs-full:DisclosureOfLeasesExplanatory>
    <BMGL:LeaseTermOfContract
      contextRef="From2024-07-012025-06-30_ifrs-full_MachineryMember"
      id="Fact002071">P12M</BMGL:LeaseTermOfContract>
    <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact002073"
      unitRef="Pure">0.05</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
    <BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact002075">&lt;p id="xdx_892_ecustom--DisclosureOfLeaseRelatedExpensesTableTextBlock_zEdUSPhrJEv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zzvUbXrLCC2g"&gt;Schedule
of amounts recognized in profit or loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;(c)&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;Amounts recognized in profit or loss&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20250630_zMIG3aDMmcqd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230701__20240630_zoA8EUzu3Dxe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--DepreciationRightofuseAssets_zr0aogHlwPNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: justify"&gt;Depreciation of right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--DepreciationRightofuseAssets_uUSD_c20240701__20250630_zjHtOc7VspNl" style="width: 10%; text-align: right" title="Depreciation of right-of-use assets"&gt;843,989&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,073,469&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;498,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--InterestExpenseOnLeaseLiabilities_zajyIKN3s6Vh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--InterestExpenseOnLeaseLiabilities_uUSD_c20240701__20250630_zQRGWEPLldXg" style="text-align: right" title="Interest expense on lease liabilities"&gt;90,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease expense not capitalized in lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_zuzdLirjcTX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;- Expense relating to short-term leases&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_uUSD_c20240701__20250630_zTg9aLWWruhc" style="border-bottom: Black 1pt solid; text-align: right" title="Expense relating to short-term leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_zuOZvYvg1lE8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total amount recognized in profit or loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16_uUSD_c20240701__20250630_zeeVw7pGL8G9" style="border-bottom: Black 1pt solid; text-align: right" title="Total amount recognized in profit or loss"&gt;934,378&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,188,435&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;517,276&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:DisclosureOfLeaseRelatedExpensesTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002080"
      unitRef="USD">843989</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002077"
      unitRef="SGD">1073469</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002078"
      unitRef="SGD">498635</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002085"
      unitRef="USD">90389</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002082"
      unitRef="SGD">114966</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002083"
      unitRef="SGD">15461</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002088"
      unitRef="SGD">3180</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002095"
      unitRef="USD">934378</ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16>
    <ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002092"
      unitRef="SGD">1188435</ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16>
    <ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002093"
      unitRef="SGD">517276</ifrs-full:AmountRecognisedInProfitOrLossForReportingPeriodToReflectChangesInLeasePaymentsThatAriseFromRentConcessionsOccurringAsDirectConsequenceOfCovid19PandemicToWhichLesseeAppliedPracticalExpedientInParagraph46AOfIFRS16>
    <ifrs-full:CashOutflowForLeases
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002097"
      unitRef="SGD">1096308</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002099"
      unitRef="USD">861945</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002101"
      unitRef="SGD">566039</ifrs-full:CashOutflowForLeases>
    <BMGL:DisclosureOfSignificantRelatedPartyExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002103">&lt;p id="xdx_805_ecustom--DisclosureOfSignificantRelatedPartyExplanatory_zVXmrBJcPg7e" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;20.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span id="xdx_822_zcjNc75MDGRb"&gt;Significant related party transactions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfTransactionsWithRelatedPartyExplanatory_zGuasCrT7mLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;In
addition to the related party information disclosed elsewhere in the consolidated financial statements, the following transactions with
related parties took place at terms agreed between the parties during the financial period:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span id="xdx_8BC_zb9wgXRCFjXl" style="display: none"&gt;Schedule of transactions with
related parties&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zgyvd0rOAcl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zZmR0Df9i1y6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--InterestIncomeOnLoansAndReceivable_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_z57jlsdK27Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"&gt;Interest income on loan to related party&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--InterestIncomeOnLoansAndReceivable_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zghxAXZ9dL0h" title="Interest income on loan to related party"&gt;1,507&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ManagementFee_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zCp1F2zFTJmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
    fee&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ManagementFee_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zojJerwhMhXa" title="Management fee"&gt;3,852,504&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2113"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zfpY8fj25SHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt"&gt;Payment made on behalf to related parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zBpXczlu1ZRe" title="Payment made on behalf to related parties"&gt;3,715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,725&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zVZr7J9zHg6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Compensation
of key management personnel&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_z4XNVvVbHTid" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span id="xdx_8B7_zC8yZ2n2EV39" style="display: none"&gt;Schedule of
compensation of key management personnel&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zctqUncmGv89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20240630_z2iqErxQlKz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--WagesAndSalaries_maKMPCzbwJ_zGlLrYwfMeUe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: left"&gt;Salaries and bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;544,854&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;693,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;121,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--CentralProvidentFund_maKMPCzbwJ_zq33XkIqskpb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;CPF&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;46,540&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;59,194&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;137&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--KeyManagementPersonnelCompensation_iT_mtKMPCzbwJ_zecM9P1e6kK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;591,394&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;752,194&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;121,337&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zXzeaS786D76" style="display: none; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</BMGL:DisclosureOfSignificantRelatedPartyExplanatory>
    <BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002105">&lt;p id="xdx_896_ecustom--ScheduleOfTransactionsWithRelatedPartyExplanatory_zGuasCrT7mLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;In
addition to the related party information disclosed elsewhere in the consolidated financial statements, the following transactions with
related parties took place at terms agreed between the parties during the financial period:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span id="xdx_8BC_zb9wgXRCFjXl" style="display: none"&gt;Schedule of transactions with
related parties&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zgyvd0rOAcl1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230701__20240630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zZmR0Df9i1y6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--InterestIncomeOnLoansAndReceivable_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_z57jlsdK27Qk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"&gt;Interest income on loan to related party&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--InterestIncomeOnLoansAndReceivable_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zghxAXZ9dL0h" title="Interest income on loan to related party"&gt;1,507&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ManagementFee_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zCp1F2zFTJmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
    fee&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--ManagementFee_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zojJerwhMhXa" title="Management fee"&gt;3,852,504&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,900,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2113"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_hifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zfpY8fj25SHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.8pt; padding-left: 8.8pt"&gt;Payment made on behalf to related parties&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--CashRepaymentsOfAdvancesAndLoansFromRelatedParties_uUSD_c20240701__20250630__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--RelatedPartiesMember_zBpXczlu1ZRe" title="Payment made on behalf to related parties"&gt;3,715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,725&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:ScheduleOfTransactionsWithRelatedPartyExplanatory>
    <BMGL:InterestIncomeOnLoansAndReceivable
      contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002110"
      unitRef="USD">1507</BMGL:InterestIncomeOnLoansAndReceivable>
    <BMGL:InterestIncomeOnLoansAndReceivable
      contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002107"
      unitRef="SGD">1917</BMGL:InterestIncomeOnLoansAndReceivable>
    <BMGL:ManagementFee
      contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002115"
      unitRef="USD">3852504</BMGL:ManagementFee>
    <BMGL:ManagementFee
      contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002112"
      unitRef="SGD">4900000</BMGL:ManagementFee>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties
      contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002120"
      unitRef="USD">3715</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties
      contextRef="From2024-07-012025-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002117"
      unitRef="SGD">4725</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties
      contextRef="From2023-07-012024-06-30_ifrs-full_RelatedPartiesMember"
      decimals="0"
      id="Fact002118"
      unitRef="SGD">1311390</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <BMGL:ScheduleOfCompensationOfKeyManagementPersonnelExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002122">&lt;p id="xdx_899_ecustom--ScheduleOfCompensationOfKeyManagementPersonnelExplanatory_z4XNVvVbHTid" style="font: 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span id="xdx_8B7_zC8yZ2n2EV39" style="display: none"&gt;Schedule of
compensation of key management personnel&lt;/span&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20250630_zctqUncmGv89" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20240630_z2iqErxQlKz7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--WagesAndSalaries_maKMPCzbwJ_zGlLrYwfMeUe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: left"&gt;Salaries and bonuses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;544,854&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;693,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;121,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--CentralProvidentFund_maKMPCzbwJ_zq33XkIqskpb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;CPF&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;46,540&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;59,194&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;137&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--KeyManagementPersonnelCompensation_iT_mtKMPCzbwJ_zecM9P1e6kK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;591,394&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="margin: 0"&gt;752,194&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;121,337&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:ScheduleOfCompensationOfKeyManagementPersonnelExplanatory>
    <ifrs-full:WagesAndSalaries
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002124"
      unitRef="SGD">693000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002125"
      unitRef="SGD">121200</ifrs-full:WagesAndSalaries>
    <BMGL:CentralProvidentFund
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002127"
      unitRef="SGD">59194</BMGL:CentralProvidentFund>
    <BMGL:CentralProvidentFund
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002128"
      unitRef="SGD">137</BMGL:CentralProvidentFund>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact002130"
      unitRef="SGD">752194</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact002131"
      unitRef="SGD">121337</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfGoodwillExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002133">&lt;p id="xdx_809_eifrs-full--DisclosureOfGoodwillExplanatory_zJn8lmsAotUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; width: 0.5in"&gt;21.&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt; &lt;span id="xdx_82F_zo5HLuKJIash"&gt;Impairment loss on goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition of Bethesda Medical Pte Ltd and its subsidiary, Oasis Medical Clinic Pte Ltd (&#x201c;Bethesda Group Acquisition&#x201d;)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 1pt 0 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;On April 30, 2025, the Company completed its acquisition on all of the ordinary shares in the issued and paid-up share capital of Bethesda
Medical Pte Ltd, a company incorporated in Singapore. Pursuant to the Sale and Purchase Agreement, the aggregate consideration is S$&lt;span id="xdx_90E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_c20250430_zAb6XuybgHpl" title="Consideration transferred"&gt;10,308,000&lt;/span&gt;
(US$&lt;span id="xdx_907_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_uUSD_c20250430_zR4ylFwOhXAf" title="Consideration transferred"&gt;8,000,000&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following the completion of the acquisition, Bethesda Medical Pte Ltd became a wholly owned indirect subsidiary of Basel Medical Group
Ltd.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eifrs-full--DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_zvMglfu9Iu7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
fair value of identifiable assets and liabilities of Bethesda Group as at the acquisition date were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;span id="xdx_8BA_z7nji0UumfN2"&gt;Schedule
of fair value of identifiable assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250430_zIGEZzMVyiPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_znTdXUgmookc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Purchase Consideration&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;10,308,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Assets and liabilities recognised as a result of the acquisition:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_iI_zFFMwjARNYb8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;502,180&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_z427Po6Vqe38" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,133,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DeferredTaxAssetsRecognisedAsOfAcquisitionDate_iI_zBDHMaHsycg8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--InvestmentRecognisedAsOfAcquisitionDate_iI_zFOsNFqmAT69" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment in associate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--InventoryRecognisedAsOfAcquisitionDate_iI_zyfjupa7QVKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Inventories&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--FairValueOfAcquiredReceivables_iI_zBwWrZZfQNlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;669,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_iI_zUM2ni11yyYf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;168,895&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LeaseLiabilitiesRecognisedAsOfAcquisitionDate_iI_zVzLSQOUwhCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(431,744&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--BorrowingsRecognisedAsOfAcquisitionDate_iNI_di_zzsyeNLArTV9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(453,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_iNI_di_zjngBgwWr8Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,544,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AmountDueRecognisedAsOfAcquisitionDate_iI_zbEBiQ0upnh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amount due to director&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(193,945&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_zhyQkKtUZaQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net identifiable liabilities acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(837,691&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_zbPR2aYXYPj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Add: Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,145,691&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Purchase consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zW29lKC3N9k4" title="Purchase consideration"&gt;10,308,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_ziYlOJwKHpF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;As
the new subsidiary&#x2019;s operation has yet to be turned around, an impairment loss on the goodwill from this investment has been fully
recognised in year ended June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
purchase consideration of S$&lt;span id="xdx_909_eifrs-full--CashTransferred_iI_c20250430_zNXplRcECIug" title="Consideration transferred cash"&gt;10,308,000&lt;/span&gt; was settled by cash hence, there is a S$&lt;span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zUHBbXapDN5d" title="Purchase consideration"&gt;10,308,000&lt;/span&gt; of net cash outflow impact on the acquisition.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
goodwill is attributable to Basel Medical Group&#x2019;s expansion strategy in Singapore and the broader Southeast Asian healthcare market.
By broadening its service offerings and integrating advanced medical solutions, Basel Medical Group is positioning itself as a key player
in the region&#x2019;s evolving healthcare ecosystem.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
acquired business contributed revenue of S$&lt;span id="xdx_90B_eifrs-full--RevenueOfAcquiree_c20250501__20250630_zAJB3wOWwUu" title="Revenue"&gt;895,362&lt;/span&gt; and net loss of S$&lt;span id="xdx_903_eifrs-full--ProfitLossOfAcquiree_c20250501__20250630_zgDA3nQrh578" title="Net loss"&gt;448,857&lt;/span&gt; to the Group for the period from 1 May 2025 to 30 June 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfGoodwillExplanatory>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002135"
      unitRef="SGD">10308000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002137"
      unitRef="USD">8000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002139">&lt;p id="xdx_89D_eifrs-full--DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_zvMglfu9Iu7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
fair value of identifiable assets and liabilities of Bethesda Group as at the acquisition date were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;span id="xdx_8BA_z7nji0UumfN2"&gt;Schedule
of fair value of identifiable assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250430_zIGEZzMVyiPi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_znTdXUgmookc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-bottom: 1pt"&gt;Purchase Consideration&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;10,308,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Assets and liabilities recognised as a result of the acquisition:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_iI_zFFMwjARNYb8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;502,180&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_z427Po6Vqe38" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,133,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--DeferredTaxAssetsRecognisedAsOfAcquisitionDate_iI_zBDHMaHsycg8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--InvestmentRecognisedAsOfAcquisitionDate_iI_zFOsNFqmAT69" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Investment in associate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--InventoryRecognisedAsOfAcquisitionDate_iI_zyfjupa7QVKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Inventories&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--FairValueOfAcquiredReceivables_iI_zBwWrZZfQNlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;669,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_iI_zUM2ni11yyYf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;168,895&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LeaseLiabilitiesRecognisedAsOfAcquisitionDate_iI_zVzLSQOUwhCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(431,744&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--BorrowingsRecognisedAsOfAcquisitionDate_iNI_di_zzsyeNLArTV9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Borrowings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(453,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_iNI_di_zjngBgwWr8Ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,544,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AmountDueRecognisedAsOfAcquisitionDate_iI_zbEBiQ0upnh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Amount due to director&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(193,945&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_iNI_di_zhyQkKtUZaQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net identifiable liabilities acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(837,691&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--GoodwillRecognisedAsOfAcquisitionDate_iI_zbPR2aYXYPj7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Add: Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,145,691&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Purchase consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--ProfitLossOfCombinedEntity_c20250430__20250430_zW29lKC3N9k4" title="Purchase consideration"&gt;10,308,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002141"
      unitRef="SGD">10308000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002143"
      unitRef="SGD">502180</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002145"
      unitRef="SGD">1133786</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002147"
      unitRef="SGD">34700</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <BMGL:InvestmentRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002149"
      unitRef="SGD">49</BMGL:InvestmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002151"
      unitRef="SGD">276077</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <ifrs-full:FairValueOfAcquiredReceivables
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002153"
      unitRef="SGD">669746</ifrs-full:FairValueOfAcquiredReceivables>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002155"
      unitRef="SGD">168895</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <BMGL:LeaseLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002157"
      unitRef="SGD">-431744</BMGL:LeaseLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002159"
      unitRef="SGD">453250</ifrs-full:BorrowingsRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002161"
      unitRef="SGD">2544185</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <BMGL:AmountDueRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002163"
      unitRef="SGD">-193945</BMGL:AmountDueRecognisedAsOfAcquisitionDate>
    <ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002165"
      unitRef="SGD">837691</ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002167"
      unitRef="SGD">11145691</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:ProfitLossOfCombinedEntity
      contextRef="From2025-04-302025-04-30"
      decimals="0"
      id="Fact002169"
      unitRef="SGD">10308000</ifrs-full:ProfitLossOfCombinedEntity>
    <ifrs-full:CashTransferred
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact002171"
      unitRef="SGD">10308000</ifrs-full:CashTransferred>
    <ifrs-full:ProfitLossOfCombinedEntity
      contextRef="From2025-04-302025-04-30"
      decimals="0"
      id="Fact002173"
      unitRef="SGD">10308000</ifrs-full:ProfitLossOfCombinedEntity>
    <ifrs-full:RevenueOfAcquiree
      contextRef="From2025-05-012025-06-30"
      decimals="0"
      id="Fact002175"
      unitRef="SGD">895362</ifrs-full:RevenueOfAcquiree>
    <ifrs-full:ProfitLossOfAcquiree
      contextRef="From2025-05-012025-06-30"
      decimals="0"
      id="Fact002177"
      unitRef="SGD">448857</ifrs-full:ProfitLossOfAcquiree>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002179">&lt;p id="xdx_809_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_zpQPBL6iYbS6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;22.&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&lt;span id="xdx_82C_zbIWqI0kpMOa"&gt;Fair value of assets and liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Assets
and liabilities not measured at fair value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and cash equivalents, other receivables, amount due from/(to) related parties, other payables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of these balances approximate their fair values due to the short-term nature of these balances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Trade
receivables and trade payables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of these receivables and payables approximate their fair values as they are subject to normal trade credit terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Borrowings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of borrowings approximate their fair values as they are subject to interest rates close to market rate of interests
for similar arrangements with financial institutions.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002181">&lt;p id="xdx_802_eifrs-full--DisclosureOfFinancialRiskManagementExplanatory_zutlzvfpcVk6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;23.&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt; &lt;span id="xdx_824_zoH2nrhmmYM1"&gt;Financial risk management&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s activities expose it to a variety of financial risks from its operations. The key financial risks include credit risk,
market risk (including foreign currency risk, interest rate risk) and liquidity risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors review and agree policies and procedures for the management of these risks, which are executed by the management team. It is,
and has been throughout the current and previous financial year, the Group&#x2019;s policy that no trading in derivatives for speculative
purposes shall be undertaken.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following sections provide details regarding the Group&#x2019;s exposure to the abovementioned financial risks and the objectives, policies
and processes for the management of these risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
has been no change to the Group&#x2019;s exposure to these financial risks or the manner in which it manages and measures the risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit
risk refers to the risk that the counterparty will default on its contractual obligations resulting in a loss to the Group. The Group&#x2019;s
exposure to credit risk arises primarily from trade and other receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has adopted a policy of only dealing with creditworthy counterparties. The Group performs ongoing credit evaluation of its counterparties&#x2019;
financial condition and generally do not require a collateral.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit
risk on an ongoing basis throughout each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has determined the default event on a financial asset to be when internal and/or external information indicates that the financial
asset is unlikely to be received, which could include default of contractual payments due for more than 60 days, default of interest
due for more than 30 days or there is significant difficulty of the counterparty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
minimise credit risk, the Group has developed and maintained the Group&#x2019;s credit risk gradings to categorise exposures according
to their degree of risk of default. The credit rating information is supplied by publicly available financial information and the Group&#x2019;s
own trading records to rate its major customers and other debtors. The Group considers available reasonable and supportive forward-looking
information which includes the following indicators:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Actual
                                            or expected significant adverse changes in business, financial or economic conditions that
                                            are expected to cause a significant change to the debtor&#x2019;s ability to meet its obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Actual
                                            or expected significant changes in the operating results of the debtor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
                                            increases in credit risk on other financial instruments of the same debtor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
                                            changes in the expected performance and behaviour of the debtor, including changes in the
                                            payment status of debtors in the Group and changes in the operating results of the debtor.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 70.9pt; text-align: justify; text-indent: -21.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regardless
of the analysis above, a significant increase in credit risk is presumed if a debtor is more than 30 days past due in making contractual
payment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group determined that its financial assets are credit-impaired when:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
                                            is significant difficulty of the debtor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
                                            breach of contract, such as a default or past due event&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
                                            is becoming probable that the debtor will enter bankruptcy or other financial reorganisation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
                                            is a disappearance of an active market for that financial asset because of financial difficulty&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group categorises a receivable for potential write-off when a debtor fails to make contractual payments more than 120 days past due.
Financial assets are written off when there is evidence indicating that the debtor is in severe financial difficulty and the debtor has
no realistic prospect of recovery.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_zog6lTZLQyq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s current credit risk grading framework comprises the following categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span id="xdx_8B2_zYzUwT9fUvRi" style="display: none"&gt;Schedule of group&#x2019;s current
credit risk grading framework&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 10%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Definition
    of category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
                                            for recognising&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;expected
    credit loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(ECL)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;I&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zVczdX1ZFn16" title="Definition of category"&gt;Counterparty
    has a low risk of default and does not have any past-due amounts.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zNyyOW8P7z1j" title="Basis for recognizing ECL"&gt;12-month
    ECL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;II&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zRLruJZXQntb" title="Definition of category"&gt;Amount
    is &amp;gt;30 days past due or there has been a significant increase in credit risk since initial recognition.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zkukHFujJcZ" title="Basis for recognizing ECL"&gt;Lifetime
    ECL - not credit-impaired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;III&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z9U7FpNFObC9" title="Definition of category"&gt;Amount
    is &amp;gt;60 days past due or there is evidence indicating the asset is credit-impaired (in default).&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z4YRgcfhBHXh" title="Basis for recognizing ECL"&gt;Lifetime
    ECL - credit impaired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IV&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zt9RtvWDB877" title="Definition of category"&gt;There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zYzuI04ZA2wj" title="Basis for recognizing ECL"&gt;Amount
    is written off&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_zqYNOEEcEJq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_zKm570U498u4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below details the credit quality of the Group&#x2019;s financial assets, as well as maximum exposure to credit risk by credit risk
rating categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span id="xdx_8B8_zrG1GeTypH5h" style="display: none"&gt;Schedule of financial assets,
minimum exposure to credit risk&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;12-month
                                            or&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;lifetime&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ECL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;allowance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.85pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt"&gt;Note 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt"&gt;Lifetime ECL (simplified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_ziTubbL19H18" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;2,580,313&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zlUyH4k8RT1a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;(781,133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_z7fiYqAVot4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;1,799,180&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z3LbbXTeA2P4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;5,362,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUWmScCAw49k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zME7G9b0uaXh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;5,362,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;(781,133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;12-month
                                            or&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;lifetime
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ECL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;allowance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.65pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt"&gt;Note 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt"&gt;Lifetime ECL (simplified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zI5oyuT6Qu42" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;3,281,902&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zsLG2ZF2P4Sd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;(993,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zr47nPmnEtz8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;2,288,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.65pt"&gt;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zqKJeUcVd6Gd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;6,820,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWCpyLh8alNh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2223"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zIbc0ZOVrFui" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;6,820,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ExpectedCreditLosses_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zKUfOFKE1Taf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses"&gt;(993,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;Note 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Lifetime ECL (simplified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zq5uK3F5IJVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;2,133,573&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zwDyLLeajhh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;(460,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zPcX0KAr0NH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;1,673,160&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z7EHk61iRdth" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;90,252&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zJzifXoOaLn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zBxg9HJHStW4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;90,252&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;Amount due from&#160;&#160;related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUPrVPwObpD" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWrqjJ0jJc96" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zhC9d4R2trJ8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zGTw3eF0G8f3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses"&gt;(460,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zp9uUKXq0Ri8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Trade
receivables&lt;/span&gt;&lt;/b&gt; (Note 1)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all
trade receivables. The Group determines the ECL by using a provision matrix, estimated based on historical credit loss experience based
on the past due status of the debtors, adjusted as appropriate to reflect current conditions and estimates of future economic conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfExpectedCreditRiskExplanatory_z7GFIIDMZome" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span id="xdx_8B8_z0PTqeAx9RTg" style="display: none"&gt;Schedule of credit risk&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zSWj97CBRD38" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_z8VWMWkzkBS5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zxdsx6dfxx67" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zrhImKX3LN81" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zbYszB9rMicc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250630_zDHftNBWLb35" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Days past due&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Not past&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;due&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;1 &#x2013; 60&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;61 &#x2013; 120&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 120 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 365 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zOQLD6ESaT5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"&gt;ECL rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2256"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--TradeReceivables_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zB4qKU2FXWRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Estimated total gross carrying amount at&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;703,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;843,949&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;133,126&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;644,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;255,034&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,580,315&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ExpectedCreditLosses_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zyrjjlngKzb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(130,816&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(97,778&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(34,150&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(263,355&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(255,034&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(781,133&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630_z7aXZHiS2tO" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;1,799,182&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zhq2ibgnSIne" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zoN70IEmx7P4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_z4hJs9mERKW3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zKpbcz8XHpYi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zi6k2QOgYn5c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250630_zDcRTUyZPDdi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Days past due&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Not past&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;due&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;1 &#x2013; 60&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;61 &#x2013; 120&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 120 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 365 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFtwuIwycojf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"&gt;ECL rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2279"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TradeReceivables_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zb1J5GV3pMq2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Estimated total gross carrying amount at&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;895,308&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,073,420&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;169,323&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;819,473&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;324,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,281,902&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ExpectedCreditLosses_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFqaNuN7FvK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(166,385&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(124,365&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(43,436&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(334,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(324,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(993,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--CreditRiskTradeReceivables_iI_c20250630_zJ6JINQ8o1d1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;2,288,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;ECL rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zcJwzkYlvbrf" title="ECL rate"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zQsdCAPyt6Hh" title="ECL rate"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zUJ39UpmVr8a" title="ECL rate"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zy7ZnMYaXuI6" title="ECL rate"&gt;10.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zUhfYuAVsWdf" title="ECL rate"&gt;89.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Estimated total gross carrying amount at&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zge5wyrSroV9" title="Estimated total gross carrying amount at"&gt;814,544&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zPtCBonBXbLg" title="Estimated total gross carrying amount at"&gt;321,783&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zE32rCuLq1L2" title="Estimated total gross carrying amount at"&gt;227,123&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zCkKjpLhdN08" title="Estimated total gross carrying amount at"&gt;323,323&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zd8w0DKwHK1h" title="Estimated total gross carrying amount at"&gt;446,800&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zMh3HipymTd3" title="Estimated total gross carrying amount at"&gt;2,133,573&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zpBBQn7jbiyj" title="ECL"&gt;(15,880&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zt9l4iR1bBlk" title="ECL"&gt;(6,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zRTtaH1tSFkk" title="ECL"&gt;(5,939&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zJxe2eSSgzUd" title="ECL"&gt;(34,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_znOSSRDaQy3" title="ECL"&gt;(398,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zPSKFY2iDg8h" title="ECL"&gt;(460,413&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20240630_zwIIwwVh3NK9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;1,673,160&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;div style="clear: both"&gt;&lt;/div&gt;

&lt;p id="xdx_8A4_zdoHYasj5Hte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Information
regarding movement of loss of allowance of trade receivables is disclosed in Note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Excessive
risk concentration&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentrations
arise when a number of counterparties are engaged in similar business activities, or activities in the same geographical region, or have
economic features that would cause their ability to meet contractual obligations to be similarly affected by changes in economic, political
or other conditions. Concentrations indicate the relative sensitivity of the Group&#x2019;s performance to developments affecting a particular
industry.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Exposure
to credit risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group have no significant concentration of credit risk other than those balances with related company comprising &lt;span id="xdx_907_ecustom--PercentageOfTradeReceivables_dp_c20240701__20250630_zFBePr3Vba25" title="Percentage of trade receivables"&gt;1&lt;/span&gt;% (June 30, 2024: &lt;span id="xdx_908_ecustom--PercentageOfTradeReceivables_dp_c20230701__20240630__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zDomN74dqWdb" title="Percentage of trade receivables"&gt;2&lt;/span&gt;%
and &lt;span id="xdx_904_ecustom--PercentageOfTradeReceivables_dp_c20230701__20240630__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zffazXWcOzwd" title="Percentage of trade receivables"&gt;1&lt;/span&gt;%) of trade receivables. The Group has credit policies and procedures in place to minimise and mitigate its credit risk exposure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Other
receivables, amount due from related parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group assessed the latest performance and financial position of the counterparties, adjusted for the future outlook of the industry in
which the counterparties operate in, and concluded that there has been no significant increase in the credit risk since the initial recognition
of the financial assets. Accordingly, the Group measured the impairment loss allowance using 12-month ECL and determined that the ECL
is insignificant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;b)&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Market risk&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Market
risk is the risk that changes in market prices, such as interest rates and foreign exchange rates will affect the Group&#x2019;s income.
The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing
the return on risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Foreign
currency risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 68pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s foreign exchange risk results mainly from cash flows from transactions denominated in foreign currencies. At present, the
Group does not have any formal policy for hedging against currency risk. The Group ensures that the net exposure is kept to an acceptable
level by buying or selling foreign currencies at spot rates, where necessary, to address short term imbalances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has transactional currency exposures arising from sales or purchases that are denominated in a currency other than the functional
currency of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group determined that sensitivity to the exchange rate changes does not impose significant impact on the results and operations of the
Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;b)&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Market risk (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Interest
rate risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
rate risk is the risk that the fair value or future cash flows of the Group&#x2019;s financial instruments will fluctuate because of changes
in market interest rates. The Group&#x2019;s exposure to interest rate risk arises primarily from fixed deposits. These transactions and
balances were not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group does not expect any significant effect on the Group&#x2019;s profit or loss arising from the effects of reasonably possible changes
to interest rates on interest bearing financial instruments at the end of the financial year due to those interest-bearing assets and
liabilities are insignificant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;c)&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Liquidity risk&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity
risk refers to the risk that the Group will encounter difficulties in meeting its short-term obligations due to shortage of funds. The
Group&#x2019;s exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. It is
managed by matching the payment and receipt cycles. The Group&#x2019;s objective is to maintain a balance between continuity of funding
and flexibility through the use of standby credit facilities. The Group finances its working capital requirements through funds generated
from operations of the Group. Management is satisfied that funds are available to finance the operation of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Analysis
of financial instruments by remaining contractual maturities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eifrs-full--MaturityAnalysisForNonderivativeFinancialLiabilities_zHuwj19Xz6Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarises the maturity profile of the Group&#x2019;s financial assets and liabilities at the reporting date based on contractual
undiscounted repayment obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span id="xdx_8B8_zTqCxxh6D5Qg" style="display: none"&gt;Schedule of remaining contractual
undiscounted repayment obligations&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zDDiv7Uyiqie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zfr36bvkRSbc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zLkTVD1YOtD2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zvbVnaM9Of34" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;to five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_zvJDoZzrgjHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;7,323,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;7,323,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;7,323,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2344"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_uUSD_zmW9cWmnPnXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zs51y2g0Ooci" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_ziLkbRfhBvgb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,666,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,666,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,666,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2359"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Financial
                                            risk management&lt;/span&gt; (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;c)&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Liquidity risk (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Analysis
of financial instruments by remaining contractual maturities&lt;/span&gt; (Continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znO760aU70nh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zurfTvoC7Yye" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zb5RlKmYKbZb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhWJyUO6pjGd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;to five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025 (Continued)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_uUSD_zsHKTzy7TL71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2364"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_zrIw9nuG007f" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify"&gt;Amount due to related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AmountDueToFormerDirector_iI_zcxyvuJAgCp9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify"&gt;Amount due to a former director&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--Borrowings_iI_uUSD_zqkAZygjtpY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,688,478&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,688,478&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,667,677&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,020,802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_z2zpiHjOhMxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total undiscounted financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,903,800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,903,800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,882,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,020,802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_uUSD_zvvGDwrZUDEl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total net undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,762,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,762,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,783,113&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,020,802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zhdhZnAY4t68" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zW4tLDXGLexd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zNgEeiziSPd8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhhxnr1PC8wj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years to&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_zMSKFELmFdhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2394"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zgJePvqtm8xi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2399"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_zJXtpSinTMGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2404"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zspTpalBKRai" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,368&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,368&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,368&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2409"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--Borrowings_iI_zkkKL6iOu2D8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,419,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,419,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,121,119&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,298,358&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_zjnCSjWNQJw3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,052,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,052,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,754,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,298,358&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_z5LgE80ohDmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total net undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,241,739&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,241,739&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,540,096&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,298,358&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Analysis
of financial instruments by remaining contractual maturities&lt;/span&gt; (Continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znN8DpCkgdq6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zY9OSMmQ8S63" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zlWNv2tbOdO" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zqIuGgJuqj83" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;to five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_z9OLBq9OEQF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2429"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zNPISg6gTXh4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2434"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_z3wIzxMYjFO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2439"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_ztvSrpCVRiw9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2444"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zodiNqYuKph3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2449"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z8RYXNGOL424" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2454"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AmountDueToFormerDirector_iI_zWRDy7mbp5w5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to a former director&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--Borrowings_iI_zDMi5kh8vIKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,289,790&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,289,790&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,706,356&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z8tOCrqCxNie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,897,258&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,897,258&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,313,824&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_zEskyGVecE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total net undiscounted financial assets/(liabilities)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,374,447&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,374,447&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,957,881&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,583,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z6PafSkHHsDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact002183">&lt;p id="xdx_89E_ecustom--DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock_zog6lTZLQyq" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s current credit risk grading framework comprises the following categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span id="xdx_8B2_zYzUwT9fUvRi" style="display: none"&gt;Schedule of group&#x2019;s current
credit risk grading framework&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 10%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Definition
    of category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis
                                            for recognising&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;expected
    credit loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(ECL)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;I&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zVczdX1ZFn16" title="Definition of category"&gt;Counterparty
    has a low risk of default and does not have any past-due amounts.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryOneMember_zNyyOW8P7z1j" title="Basis for recognizing ECL"&gt;12-month
    ECL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;II&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zRLruJZXQntb" title="Definition of category"&gt;Amount
    is &amp;gt;30 days past due or there has been a significant increase in credit risk since initial recognition.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryTwoMember_zkukHFujJcZ" title="Basis for recognizing ECL"&gt;Lifetime
    ECL - not credit-impaired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;III&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z9U7FpNFObC9" title="Definition of category"&gt;Amount
    is &amp;gt;60 days past due or there is evidence indicating the asset is credit-impaired (in default).&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryThreeMember_z4YRgcfhBHXh" title="Basis for recognizing ECL"&gt;Lifetime
    ECL - credit impaired&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IV&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--DescriptionOfCreditRisk_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zt9RtvWDB877" title="Definition of category"&gt;There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--BasisForRecognizingExpectedCreditLoss_c20240701__20250630__custom--CategoryAxis__custom--CategoryFourMember_zYzuI04ZA2wj" title="Basis for recognizing ECL"&gt;Amount
    is written off&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</BMGL:DisclosureInCurrentRiskGradingFrameworkExplanatoryTextBlock>
    <BMGL:DescriptionOfCreditRisk
      contextRef="From2024-07-012025-06-30_custom_CategoryOneMember"
      id="Fact002185">Counterparty
    has a low risk of default and does not have any past-due amounts.</BMGL:DescriptionOfCreditRisk>
    <BMGL:BasisForRecognizingExpectedCreditLoss
      contextRef="From2024-07-012025-06-30_custom_CategoryOneMember"
      id="Fact002187">12-month
    ECL</BMGL:BasisForRecognizingExpectedCreditLoss>
    <BMGL:DescriptionOfCreditRisk
      contextRef="From2024-07-012025-06-30_custom_CategoryTwoMember"
      id="Fact002189">Amount
    is &gt;30 days past due or there has been a significant increase in credit risk since initial recognition.</BMGL:DescriptionOfCreditRisk>
    <BMGL:BasisForRecognizingExpectedCreditLoss
      contextRef="From2024-07-012025-06-30_custom_CategoryTwoMember"
      id="Fact002191">Lifetime
    ECL - not credit-impaired</BMGL:BasisForRecognizingExpectedCreditLoss>
    <BMGL:DescriptionOfCreditRisk
      contextRef="From2024-07-012025-06-30_custom_CategoryThreeMember"
      id="Fact002193">Amount
    is &gt;60 days past due or there is evidence indicating the asset is credit-impaired (in default).</BMGL:DescriptionOfCreditRisk>
    <BMGL:BasisForRecognizingExpectedCreditLoss
      contextRef="From2024-07-012025-06-30_custom_CategoryThreeMember"
      id="Fact002195">Lifetime
    ECL - credit impaired</BMGL:BasisForRecognizingExpectedCreditLoss>
    <BMGL:DescriptionOfCreditRisk
      contextRef="From2024-07-012025-06-30_custom_CategoryFourMember"
      id="Fact002197">There
    is evidence indicating that the debtor is in severe financial difficulty and the debtor has no realistic prospect of recovery.</BMGL:DescriptionOfCreditRisk>
    <BMGL:BasisForRecognizingExpectedCreditLoss
      contextRef="From2024-07-012025-06-30_custom_CategoryFourMember"
      id="Fact002199">Amount
    is written off</BMGL:BasisForRecognizingExpectedCreditLoss>
    <BMGL:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002201">&lt;p id="xdx_89F_ecustom--ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory_zKm570U498u4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below details the credit quality of the Group&#x2019;s financial assets, as well as maximum exposure to credit risk by credit risk
rating categories:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span id="xdx_8B8_zrG1GeTypH5h" style="display: none"&gt;Schedule of financial assets,
minimum exposure to credit risk&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;12-month
                                            or&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;lifetime&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ECL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;allowance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.85pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt"&gt;Note 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt"&gt;Lifetime ECL (simplified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_ziTubbL19H18" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;2,580,313&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zlUyH4k8RT1a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;(781,133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_z7fiYqAVot4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;1,799,180&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z3LbbXTeA2P4" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;5,362,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUWmScCAw49k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--LongtermDeposits_iI_uUSD_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zME7G9b0uaXh" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;5,362,632&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;(781,133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;12-month
                                            or&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;lifetime
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                      &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ECL&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;allowance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 1.65pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center; padding-left: 5.4pt"&gt;Note 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: left; padding-left: 5.4pt"&gt;Lifetime ECL (simplified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zI5oyuT6Qu42" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;3,281,902&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zsLG2ZF2P4Sd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;(993,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CreditRiskTradeReceivables_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zr47nPmnEtz8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Trade receivables"&gt;2,288,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.65pt"&gt;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zqKJeUcVd6Gd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;6,820,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWCpyLh8alNh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2223"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--LongtermDeposits_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zIbc0ZOVrFui" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Deposits"&gt;6,820,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ExpectedCreditLosses_iI_c20250630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zKUfOFKE1Taf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses"&gt;(993,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;Note 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;Lifetime ECL (simplified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zq5uK3F5IJVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;2,133,573&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zwDyLLeajhh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;(460,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--CreditRiskTradeReceivables_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--LifeTimeExpectedCreditLossMember_zPcX0KAr0NH6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;1,673,160&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1.85pt"&gt;Deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_z7EHk61iRdth" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;90,252&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zJzifXoOaLn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--LongtermDeposits_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zBxg9HJHStW4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deposits"&gt;90,252&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;Amount due from&#160;&#160;related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;I&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;12-month ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--GrossCarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zUPrVPwObpD" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zWrqjJ0jJc96" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--CarryingAmountMember__custom--CategoryAxis__custom--CategoryOneMember__ifrs-full--TypesOfRisksAxis__custom--TwelveExpectedCreditLossMember_zhC9d4R2trJ8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Amount due from related parties"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--BusinessCombinationsAxis__ifrs-full--AllowanceForCreditLossesMember_zGTw3eF0G8f3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected credit losses"&gt;(460,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:ScheduleOfFinancialAssetsRepresentsTheMaximumCreditExposureExplanatory>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002203"
      unitRef="USD">2580313</BMGL:CreditRiskTradeReceivables>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002205"
      unitRef="USD">-781133</BMGL:CreditRiskTradeReceivables>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002207"
      unitRef="USD">1799180</BMGL:CreditRiskTradeReceivables>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002209"
      unitRef="USD">5362632</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002213"
      unitRef="USD">5362632</ifrs-full:LongtermDeposits>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002215"
      unitRef="SGD">3281902</BMGL:CreditRiskTradeReceivables>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002217"
      unitRef="SGD">-993524</BMGL:CreditRiskTradeReceivables>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002219"
      unitRef="SGD">2288378</BMGL:CreditRiskTradeReceivables>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002221"
      unitRef="SGD">6820731</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002225"
      unitRef="SGD">6820731</ifrs-full:LongtermDeposits>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_AllowanceForCreditLossesMember"
      decimals="0"
      id="Fact002227"
      unitRef="SGD">-993524</BMGL:ExpectedCreditLosses>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002229"
      unitRef="SGD">2133573</BMGL:CreditRiskTradeReceivables>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002231"
      unitRef="SGD">-460413</BMGL:CreditRiskTradeReceivables>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_LifeTimeExpectedCreditLossMember"
      decimals="0"
      id="Fact002233"
      unitRef="SGD">1673160</BMGL:CreditRiskTradeReceivables>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002235"
      unitRef="SGD">90252</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002239"
      unitRef="SGD">90252</ifrs-full:LongtermDeposits>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_GrossCarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002241"
      unitRef="SGD">10557240</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember_custom_CategoryOneMember_custom_TwelveExpectedCreditLossMember"
      decimals="0"
      id="Fact002245"
      unitRef="SGD">10557240</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_AllowanceForCreditLossesMember"
      decimals="0"
      id="Fact002247"
      unitRef="SGD">-460413</BMGL:ExpectedCreditLosses>
    <BMGL:ScheduleOfExpectedCreditRiskExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002249">&lt;p id="xdx_89B_ecustom--ScheduleOfExpectedCreditRiskExplanatory_z7GFIIDMZome" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span id="xdx_8B8_z0PTqeAx9RTg" style="display: none"&gt;Schedule of credit risk&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zSWj97CBRD38" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_z8VWMWkzkBS5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zxdsx6dfxx67" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zrhImKX3LN81" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zbYszB9rMicc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250630_zDHftNBWLb35" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Days past due&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Not past&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;due&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;1 &#x2013; 60&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;61 &#x2013; 120&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 120 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 365 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zOQLD6ESaT5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"&gt;ECL rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2256"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--TradeReceivables_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zB4qKU2FXWRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Estimated total gross carrying amount at&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;703,914&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;843,949&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;133,126&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;644,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;255,034&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,580,315&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ExpectedCreditLosses_iI_pid_uUSD_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zyrjjlngKzb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(130,816&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(97,778&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(34,150&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(263,355&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(255,034&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;(781,133&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--CreditRiskTradeReceivables_iI_uUSD_c20250630_z7aXZHiS2tO" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;1,799,182&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250630__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zhq2ibgnSIne" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zoN70IEmx7P4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250630__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_z4hJs9mERKW3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zKpbcz8XHpYi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250630__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zi6k2QOgYn5c" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250630_zDcRTUyZPDdi" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Trade receivables&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Days past due&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Not past&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;due&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;1 &#x2013; 60&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;61 &#x2013; 120&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;days&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 120 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&amp;gt; 365 days&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFtwuIwycojf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"&gt;ECL rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2279"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TradeReceivables_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zb1J5GV3pMq2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Estimated total gross carrying amount at&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;895,308&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,073,420&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;169,323&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;819,473&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;324,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,281,902&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ExpectedCreditLosses_iI_pid_hifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zFqaNuN7FvK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(166,385&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(124,365&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(43,436&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(334,960&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;(324,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(993,524&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--CreditRiskTradeReceivables_iI_c20250630_zJ6JINQ8o1d1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;2,288,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;ECL rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zcJwzkYlvbrf" title="ECL rate"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zQsdCAPyt6Hh" title="ECL rate"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zUJ39UpmVr8a" title="ECL rate"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zy7ZnMYaXuI6" title="ECL rate"&gt;10.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ExpectedCreditLossRate_iI_pid_dp_uPure_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zUhfYuAVsWdf" title="ECL rate"&gt;89.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Estimated total gross carrying amount at&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zge5wyrSroV9" title="Estimated total gross carrying amount at"&gt;814,544&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zPtCBonBXbLg" title="Estimated total gross carrying amount at"&gt;321,783&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zE32rCuLq1L2" title="Estimated total gross carrying amount at"&gt;227,123&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zCkKjpLhdN08" title="Estimated total gross carrying amount at"&gt;323,323&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_zd8w0DKwHK1h" title="Estimated total gross carrying amount at"&gt;446,800&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--TradeReceivables_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zMh3HipymTd3" title="Estimated total gross carrying amount at"&gt;2,133,573&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;ECL&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--NotPastDueMember_zpBBQn7jbiyj" title="ECL"&gt;(15,880&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneMonthAndNotLaterThanTwoMonthsMember_zt9l4iR1bBlk" title="ECL"&gt;(6,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__custom--LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_zRTtaH1tSFkk" title="ECL"&gt;(5,939&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanFourMonthsMember_zJxe2eSSgzUd" title="ECL"&gt;(34,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember__ifrs-full--PastDueStatusAxis__ifrs-full--LaterThanOneYearMember_znOSSRDaQy3" title="ECL"&gt;(398,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ExpectedCreditLosses_iI_c20240630__ifrs-full--TypesOfRisksAxis__ifrs-full--CreditRiskMember_zPSKFY2iDg8h" title="ECL"&gt;(460,413&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--CreditRiskTradeReceivables_iI_c20240630_zwIIwwVh3NK9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade receivables"&gt;1,673,160&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;div style="clear: both"&gt;&lt;/div&gt;

</BMGL:ScheduleOfExpectedCreditRiskExplanatory>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002251"
      unitRef="Pure">0.19</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002252"
      unitRef="Pure">0.12</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002253"
      unitRef="Pure">0.26</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002254"
      unitRef="Pure">0.41</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002255"
      unitRef="Pure">1</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002258"
      unitRef="USD">703914</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002259"
      unitRef="USD">843949</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002260"
      unitRef="USD">133126</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002261"
      unitRef="USD">644290</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002262"
      unitRef="USD">255034</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002263"
      unitRef="USD">2580315</ifrs-full:TradeReceivables>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002265"
      unitRef="USD">-130816</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002266"
      unitRef="USD">-97778</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002267"
      unitRef="USD">-34150</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002268"
      unitRef="USD">-263355</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002269"
      unitRef="USD">-255034</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002270"
      unitRef="USD">-781133</BMGL:ExpectedCreditLosses>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002272"
      unitRef="USD">1799182</BMGL:CreditRiskTradeReceivables>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002274"
      unitRef="Pure">0.19</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002275"
      unitRef="Pure">0.12</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002276"
      unitRef="Pure">0.26</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002277"
      unitRef="Pure">0.41</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002278"
      unitRef="Pure">1</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002281"
      unitRef="SGD">895308</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002282"
      unitRef="SGD">1073420</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002283"
      unitRef="SGD">169323</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002284"
      unitRef="SGD">819473</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002285"
      unitRef="SGD">324378</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002286"
      unitRef="SGD">3281902</ifrs-full:TradeReceivables>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_custom_NotPastDueMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002288"
      unitRef="SGD">-166385</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002289"
      unitRef="SGD">-124365</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002290"
      unitRef="SGD">-43436</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanFourMonthsMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002291"
      unitRef="SGD">-334960</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002292"
      unitRef="SGD">-324378</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2025-06-30_ifrs-full_CreditRiskMember"
      decimals="INF"
      id="Fact002293"
      unitRef="SGD">-993524</BMGL:ExpectedCreditLosses>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact002295"
      unitRef="SGD">2288378</BMGL:CreditRiskTradeReceivables>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember"
      decimals="INF"
      id="Fact002297"
      unitRef="Pure">0.0195</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember"
      decimals="INF"
      id="Fact002299"
      unitRef="Pure">0.0202</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember"
      decimals="INF"
      id="Fact002301"
      unitRef="Pure">0.0261</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember"
      decimals="INF"
      id="Fact002303"
      unitRef="Pure">0.1054</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:ExpectedCreditLossRate
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember"
      decimals="INF"
      id="Fact002305"
      unitRef="Pure">0.8908</ifrs-full:ExpectedCreditLossRate>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember"
      decimals="0"
      id="Fact002307"
      unitRef="SGD">814544</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember"
      decimals="0"
      id="Fact002309"
      unitRef="SGD">321783</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember"
      decimals="0"
      id="Fact002311"
      unitRef="SGD">227123</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember"
      decimals="0"
      id="Fact002313"
      unitRef="SGD">323323</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002315"
      unitRef="SGD">446800</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember"
      decimals="0"
      id="Fact002317"
      unitRef="SGD">2133573</ifrs-full:TradeReceivables>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_NotPastDueMember"
      decimals="0"
      id="Fact002319"
      unitRef="SGD">-15880</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember"
      decimals="0"
      id="Fact002321"
      unitRef="SGD">-6494</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_custom_LaterThanTwoMonthsAndNotLaterThanFourMonthsMember"
      decimals="0"
      id="Fact002323"
      unitRef="SGD">-5939</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanFourMonthsMember"
      decimals="0"
      id="Fact002325"
      unitRef="SGD">-34093</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002327"
      unitRef="SGD">-398007</BMGL:ExpectedCreditLosses>
    <BMGL:ExpectedCreditLosses
      contextRef="AsOf2024-06-30_ifrs-full_CreditRiskMember"
      decimals="0"
      id="Fact002329"
      unitRef="SGD">-460413</BMGL:ExpectedCreditLosses>
    <BMGL:CreditRiskTradeReceivables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002331"
      unitRef="SGD">1673160</BMGL:CreditRiskTradeReceivables>
    <BMGL:PercentageOfTradeReceivables
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact002333"
      unitRef="Pure">0.01</BMGL:PercentageOfTradeReceivables>
    <BMGL:PercentageOfTradeReceivables
      contextRef="From2023-07-012024-06-30_ifrs-full_TopOfRangeMember"
      decimals="INF"
      id="Fact002335"
      unitRef="Pure">0.02</BMGL:PercentageOfTradeReceivables>
    <BMGL:PercentageOfTradeReceivables
      contextRef="From2023-07-012024-06-30_ifrs-full_BottomOfRangeMember"
      decimals="INF"
      id="Fact002337"
      unitRef="Pure">0.01</BMGL:PercentageOfTradeReceivables>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities contextRef="From2024-07-01to2025-06-30" id="Fact002339">&lt;p id="xdx_893_eifrs-full--MaturityAnalysisForNonderivativeFinancialLiabilities_zHuwj19Xz6Ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarises the maturity profile of the Group&#x2019;s financial assets and liabilities at the reporting date based on contractual
undiscounted repayment obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span id="xdx_8B8_zTqCxxh6D5Qg" style="display: none"&gt;Schedule of remaining contractual
undiscounted repayment obligations&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zDDiv7Uyiqie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zfr36bvkRSbc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zLkTVD1YOtD2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zvbVnaM9Of34" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;to five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_zvJDoZzrgjHk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;7,323,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;7,323,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;7,323,882&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2344"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_uUSD_zmW9cWmnPnXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zs51y2g0Ooci" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_ziLkbRfhBvgb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,666,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,666,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,666,112&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2359"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Financial
                                            risk management&lt;/span&gt; (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify; text-indent: -7.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;c)&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Liquidity risk (Continued)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Analysis
of financial instruments by remaining contractual maturities&lt;/span&gt; (Continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znO760aU70nh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zurfTvoC7Yye" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zb5RlKmYKbZb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhWJyUO6pjGd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;to five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025 (Continued)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--TradeAndOtherPayables_iI_uUSD_zsHKTzy7TL71" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2364"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_zrIw9nuG007f" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify"&gt;Amount due to related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AmountDueToFormerDirector_iI_zcxyvuJAgCp9" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: justify"&gt;Amount due to a former director&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--Borrowings_iI_uUSD_zqkAZygjtpY6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,688,478&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,688,478&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,667,677&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,020,802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_z2zpiHjOhMxk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total undiscounted financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,903,800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,903,800&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,882,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,020,802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_uUSD_zvvGDwrZUDEl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total net undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,762,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,762,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,783,113&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,020,802&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_zhdhZnAY4t68" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zW4tLDXGLexd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zNgEeiziSPd8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zhhxnr1PC8wj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years to&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_zMSKFELmFdhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2394"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zgJePvqtm8xi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2399"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_zJXtpSinTMGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2404"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zspTpalBKRai" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,368&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,368&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,368&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2409"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--Borrowings_iI_zkkKL6iOu2D8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,419,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,419,476&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,121,119&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,298,358&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_zjnCSjWNQJw3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,052,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,052,844&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,754,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,298,358&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_z5LgE80ohDmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total net undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,241,739&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,241,739&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,540,096&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,298,358&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financial
                                            risk management (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
                                            risk (Continued)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Analysis
of financial instruments by remaining contractual maturities&lt;/span&gt; (Continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--CarryingAmountMember_znN8DpCkgdq6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Carrying&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;amount&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240630__ifrs-full--MaturityAxis__custom--ContractualCashFlowsMember_zY9OSMmQ8S63" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Contractual&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240630__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zlWNv2tbOdO" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;One year&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;or less&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240630__ifrs-full--MaturityAxis__ifrs-full--LaterThanOneYearMember_zqIuGgJuqj83" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;Two years&lt;/p&gt;
                                                                  &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"&gt;to five years&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_iI_z9OLBq9OEQF5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2429"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_iI_zNPISg6gTXh4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2434"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_z3wIzxMYjFO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2439"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TotalUndiscountedFinancialAssets_iI_ztvSrpCVRiw9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2444"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: justify"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_zodiNqYuKph3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2449"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z8RYXNGOL424" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2454"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AmountDueToFormerDirector_iI_zWRDy7mbp5w5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to a former director&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--Borrowings_iI_zDMi5kh8vIKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,289,790&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,289,790&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,706,356&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z8tOCrqCxNie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Total undiscounted financial liabilities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,897,258&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,897,258&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,313,824&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,583,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--TotalNetUndiscountedFinancialAssetsliabilities_iI_zEskyGVecE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total net undiscounted financial assets/(liabilities)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,374,447&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,374,447&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,957,881&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,583,434&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002341"
      unitRef="USD">7323882</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002342"
      unitRef="USD">7323882</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002343"
      unitRef="USD">7323882</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002346"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002347"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002348"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002356"
      unitRef="USD">9666112</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002357"
      unitRef="USD">9666112</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002358"
      unitRef="USD">9666112</BMGL:TotalUndiscountedFinancialAssets>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002361"
      unitRef="USD">5215322</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002362"
      unitRef="USD">5215322</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002363"
      unitRef="USD">5215322</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002376"
      unitRef="USD">2688478</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002377"
      unitRef="USD">2688478</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002378"
      unitRef="USD">1667677</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002379"
      unitRef="USD">1020802</ifrs-full:Borrowings>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002381"
      unitRef="USD">7903800</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002382"
      unitRef="USD">7903800</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002383"
      unitRef="USD">6882999</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002384"
      unitRef="USD">1020802</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002386"
      unitRef="USD">1762312</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002387"
      unitRef="USD">1762312</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002388"
      unitRef="USD">2783113</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002389"
      unitRef="USD">-1020802</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002391"
      unitRef="SGD">9315500</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002392"
      unitRef="SGD">9315500</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002393"
      unitRef="SGD">9315500</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002396"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002397"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002398"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002401"
      unitRef="SGD">12294583</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002402"
      unitRef="SGD">12294583</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002403"
      unitRef="SGD">12294583</BMGL:TotalUndiscountedFinancialAssets>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002406"
      unitRef="SGD">6633368</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002407"
      unitRef="SGD">6633368</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002408"
      unitRef="SGD">6633368</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002411"
      unitRef="SGD">3419476</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002412"
      unitRef="SGD">3419476</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002413"
      unitRef="SGD">2121119</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002414"
      unitRef="SGD">1298358</ifrs-full:Borrowings>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002416"
      unitRef="SGD">10052844</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002417"
      unitRef="SGD">10052844</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002418"
      unitRef="SGD">8754487</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002419"
      unitRef="SGD">1298358</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002421"
      unitRef="SGD">2241739</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002422"
      unitRef="SGD">2241739</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002423"
      unitRef="SGD">3540096</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2025-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002424"
      unitRef="SGD">-1298358</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002426"
      unitRef="SGD">1763412</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002427"
      unitRef="SGD">1763412</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002428"
      unitRef="SGD">1763412</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002431"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002432"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002433"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002436"
      unitRef="SGD">10557240</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002437"
      unitRef="SGD">10557240</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002438"
      unitRef="SGD">10557240</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002441"
      unitRef="SGD">14271705</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002442"
      unitRef="SGD">14271705</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002443"
      unitRef="SGD">14271705</BMGL:TotalUndiscountedFinancialAssets>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002446"
      unitRef="SGD">2184619</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002447"
      unitRef="SGD">2184619</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002448"
      unitRef="SGD">2184619</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002451"
      unitRef="SGD">1311390</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002452"
      unitRef="SGD">1311390</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002453"
      unitRef="SGD">1311390</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002456"
      unitRef="SGD">111459</BMGL:AmountDueToFormerDirector>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002457"
      unitRef="SGD">111459</BMGL:AmountDueToFormerDirector>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002458"
      unitRef="SGD">111459</BMGL:AmountDueToFormerDirector>
    <ifrs-full:Borrowings
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002461"
      unitRef="SGD">4289790</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002462"
      unitRef="SGD">4289790</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002463"
      unitRef="SGD">2706356</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002464"
      unitRef="SGD">1583434</ifrs-full:Borrowings>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002466"
      unitRef="SGD">7897258</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002467"
      unitRef="SGD">7897258</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002468"
      unitRef="SGD">6313824</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002469"
      unitRef="SGD">1583434</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2024-06-30_ifrs-full_CarryingAmountMember"
      decimals="0"
      id="Fact002471"
      unitRef="SGD">6374447</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2024-06-30_custom_ContractualCashFlowsMember"
      decimals="0"
      id="Fact002472"
      unitRef="SGD">6374447</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2024-06-30_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      id="Fact002473"
      unitRef="SGD">7957881</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <BMGL:TotalNetUndiscountedFinancialAssetsliabilities
      contextRef="AsOf2024-06-30_ifrs-full_LaterThanOneYearMember"
      decimals="0"
      id="Fact002474"
      unitRef="SGD">-1583434</BMGL:TotalNetUndiscountedFinancialAssetsliabilities>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002476">&lt;p id="xdx_803_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zFzaAV8cAUle" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;24.&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_82A_zIFdHuv9GwKb"&gt;Financial instruments by category&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the reporting date, the aggregate carrying amounts of financial assets, at FVPL, financial assets measured at amortized cost and financial
liabilities at amortized cost were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_zmCC3cVS4V3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zZnnlwFhzcd8" style="display: none"&gt;Schedule
of financial assets measured at amortized cost and financial
liabilities at amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zVEFq3dl8azk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zmZEV0hdg5X9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financial assets measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--TradeAndOtherCurrentReceivables_iI_z0LKC611wQmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zC2ElVRk1an3" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Trade and other receivables"&gt;7,324,082&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iI_zxW5T2z5Aw84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zTqqPBT1zTHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and cash equivalents"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zwvylzcMY9hh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2490"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--TotalUndiscountedFinancialAssets_iI_zGe8bkeB0v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total financial assets measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zZgeX7zugoW8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial assets measured at amortized cost"&gt;9,666,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financial liabilities measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TradeAndOtherPayables_iI_zt9Vfjrdue9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--TradeAndOtherPayables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zATLIUf99y0j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and other payables"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,369&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z2yV5YWknT0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zpqOqmykWp4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2506"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2503"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AmountDueToFormerDirector_iI_zgR4cCpHnL2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to a former director&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmountDueToFormerDirector_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zNcRi8uGR6ai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to a former director"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2511"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2508"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--Borrowings_iI_zy6Wr8d5EP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--Borrowings_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zYAiDlnSzWja" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Borrowings"&gt;48,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;61,371&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,261,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z2g9QyNok5Ie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total financial liabilities measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zLxzGpFYvJzg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial liabilities measured at amortized cost"&gt;5,263,573&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,694,739&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,868,758&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zkAu9wq9lKU4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <BMGL:ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002478">&lt;p id="xdx_89E_ecustom--ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory_zmCC3cVS4V3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zZnnlwFhzcd8" style="display: none"&gt;Schedule
of financial assets measured at amortized cost and financial
liabilities at amortized cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zVEFq3dl8azk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zmZEV0hdg5X9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;S$&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financial assets measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--TradeAndOtherCurrentReceivables_iI_z0LKC611wQmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"&gt;Trade and other receivables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--TradeAndOtherCurrentReceivables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zC2ElVRk1an3" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Trade and other receivables"&gt;7,324,082&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;9,315,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;1,763,412&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iI_zxW5T2z5Aw84" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--CashAndCashEquivalents_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zTqqPBT1zTHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cash and cash equivalents"&gt;2,342,230&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,979,083&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,951,053&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherReceivablesDueFromRelatedParties_iI_zwvylzcMY9hh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Amount due from related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2490"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,557,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--TotalUndiscountedFinancialAssets_iI_zGe8bkeB0v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total financial assets measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--TotalUndiscountedFinancialAssets_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zZgeX7zugoW8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial assets measured at amortized cost"&gt;9,666,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,294,583&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,271,705&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Financial liabilities measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--TradeAndOtherPayables_iI_zt9Vfjrdue9l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Trade and other payables&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--TradeAndOtherPayables_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zATLIUf99y0j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Trade and other payables"&gt;5,215,322&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,633,369&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,184,619&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_z2yV5YWknT0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zpqOqmykWp4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2506"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2503"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,311,390&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AmountDueToFormerDirector_iI_zgR4cCpHnL2i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Amount due to a former director&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmountDueToFormerDirector_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zNcRi8uGR6ai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amount due to a former director"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2511"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2508"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,459&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--Borrowings_iI_zy6Wr8d5EP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Borrowings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--Borrowings_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zYAiDlnSzWja" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Borrowings"&gt;48,251&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;61,371&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,261,290&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_z2g9QyNok5Ie" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;Total financial liabilities measured at amortized cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DerivativeFinancialLiabilitiesUndiscountedCashFlows_iI_uUSD_c20250630__ifrs-full--CategoriesOfFinancialAssetsAxis__ifrs-full--FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_zLxzGpFYvJzg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total financial liabilities measured at amortized cost"&gt;5,263,573&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,694,739&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,868,758&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</BMGL:ScheduleOfFinancialAssetsMeasuredAtAmortizedCostAndFinancialLiabilitiesAtAmortizedCostExplanatory>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002483"
      unitRef="USD">7324082</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002480"
      unitRef="SGD">9315500</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002481"
      unitRef="SGD">1763412</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002488"
      unitRef="USD">2342230</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002485"
      unitRef="SGD">2979083</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002486"
      unitRef="SGD">1951053</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002491"
      unitRef="SGD">10557240</ifrs-full:TradeAndOtherReceivablesDueFromRelatedParties>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002496"
      unitRef="USD">9666312</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002493"
      unitRef="SGD">12294583</BMGL:TotalUndiscountedFinancialAssets>
    <BMGL:TotalUndiscountedFinancialAssets
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002494"
      unitRef="SGD">14271705</BMGL:TotalUndiscountedFinancialAssets>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002501"
      unitRef="USD">5215322</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002498"
      unitRef="SGD">6633369</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002499"
      unitRef="SGD">2184619</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002504"
      unitRef="SGD">1311390</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <BMGL:AmountDueToFormerDirector
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002509"
      unitRef="SGD">111459</BMGL:AmountDueToFormerDirector>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002516"
      unitRef="USD">48251</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002513"
      unitRef="SGD">61371</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002514"
      unitRef="SGD">4261290</ifrs-full:Borrowings>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002521"
      unitRef="USD">5263573</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2025-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002518"
      unitRef="SGD">6694739</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="AsOf2024-06-30_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"
      decimals="0"
      id="Fact002519"
      unitRef="SGD">7868758</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <BMGL:CapitalManagementExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002523">&lt;p id="xdx_807_ecustom--CapitalManagementExplanatory_zKWYOklXuIm4" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; display: none; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;25.&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt; &lt;span id="xdx_829_zDrs2MakOlxk"&gt;Capital management&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
primary objective of the Group&#x2019;s capital management is to safeguard the entity&#x2019;s ability to continue as a going concern.
The related parties have undertaken not to recall the amounts due to them until such time the Company is in the position to repay these
amounts without impairing its liquidity position and to provide continuing financial support and adequate funds to enable the Company
to meet its liabilities as and when they fall due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
changes were made in the objectives, policies or processes during the financial year ended June 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group is not subjected to either internal or external imposed capital requirement. The Group&#x2019;s overall strategy remains unchanged
from 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basel
                                            Medical Group Ltd. and its Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
year ended June 30, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


</BMGL:CapitalManagementExplanatory>
    <ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory contextRef="From2024-07-01to2025-06-30" id="Fact002525">&lt;p id="xdx_80E_eifrs-full--DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_zrE0f8up98E8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;26.&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_824_zQoD25TCaUnc"&gt;Events occurring after the reporting period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no significant events that occurred after the financial year ended June 30, 2025, which require adjustment to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;However,
the following non-adjusting events occurred subsequent to the reporting period:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            July 2025, the Company has appointed NLA DFK Assurance PAC as its new auditor, in place of
                                            Onestop Assurance PAC.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            July 2025, the Company has put on hold the plan for the acquisition of Bitcoin in exchange
                                            for the issue of ordinary shares in the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            July 2025, Basel Medical Group Pte Ltd has made &lt;span id="xdx_905_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zHz1BQ46TLka" title="Investments percentage"&gt;&lt;span id="xdx_905_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zyzkgV3yp9zh" title="Investments percentage"&gt;&lt;span id="xdx_909_ecustom--InvestmentsPercentage_pid_dp_uPure_c20250701__20250731__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zzgm5LhtVKJa" title="Investments percentage"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% investments in SSOC Novena Pte. Ltd.,
                                            SSOC Orchard Pte. Ltd. and SSOC Farrer Park Pte. Ltd. In September 2025, &lt;span id="xdx_90E_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zrPqT0yIUyXa" title="Investments sale percentage"&gt;&lt;span id="xdx_90F_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1lqMQe4h8zd" title="Investments sale percentage"&gt;&lt;span id="xdx_905_ecustom--InvestmentsSalePercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zYRCPWbpxRdg" title="Investments sale percentage"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% of these investments
                                            in each of the 3 companies has been sold to external party, such that the company holds &lt;span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCNovenaPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zifyCwlFvWJe" title="Investments hold percentage"&gt;&lt;span id="xdx_90D_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCOrchardPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zti3fExn0fBl" title="Investments hold percentage"&gt;&lt;span id="xdx_908_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--SSOCFarrerParkPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zcLO6L8LAk1j" title="Investments hold percentage"&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;%
                                            of the share capital in each of the 3 companies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            July 2025, the Company&#x2019;s subsidiary, Pharma Avenue Pte Ltd, increased its share capital
                                            to &lt;span id="xdx_90D_eifrs-full--NumberOfSharesIssued_iI_c20250731__ifrs-full--CounterpartiesAxis__custom--PharmaAvenuePteLtdMember__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_zdYrgspkxlX2" title="Number of shares issued"&gt;100,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            August 2025, Mr Tan Boon Chye (Darren) was appointed as the Chief Commercial Officer of the
                                            Company. In the same month, Mr Vincent Teo resigned as Chief Partnership Officer from the
                                            Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            September 2025, Eyetrust Medical Pte Ltd was incorporated with Basel Medical Group Pte Ltd
                                            holding &lt;span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20250901__20250930__ifrs-full--CounterpartiesAxis__custom--EyetrustMedicalPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_znrYhAnyo6z8" title="Investments hold percentage"&gt;65&lt;/span&gt;% of the ordinary shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            September 2025, the Company&#x2019;s subsidiary, Bethesda Medical Pte Ltd, has fully disposed
                                            its investment in associate company, Cereza Bethesda Medical Pte Ltd.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            October 2025, Chartered Imaging Pte Ltd was incorporated with Basel Medical Group Pte Ltd
                                            holding &lt;span id="xdx_90B_ecustom--InvestmentsHoldPercentage_pid_dp_uPure_c20251001__20251031__ifrs-full--CounterpartiesAxis__custom--CharteredImagingPteLtdMember__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_ziYrHvnXvOD4" title="Investments hold percentage"&gt;100&lt;/span&gt;% of the ordinary shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            October 2025, Basel Medical Group Pte Ltd has obtained a S$&lt;span id="xdx_901_eifrs-full--NetDebt_iI_c20251031__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventsAfterReportingPeriodMember_z1Hr2BKEC9t2" title="Loan"&gt;3,000,000&lt;/span&gt; term loan facility for
                                            a 3 year tenor.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
                                                                            &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;j)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;The major shareholder, Rainforest Capital VCC has agreed to provide financial support for at least 12 months from the date of the auditor&#x2019;s
report.&lt;/td&gt;&lt;/tr&gt;
                                                                            &lt;/table&gt;

</ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory>
    <BMGL:InvestmentsPercentage
      contextRef="From2025-07-012025-07-31_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002527"
      unitRef="Pure">0.60</BMGL:InvestmentsPercentage>
    <BMGL:InvestmentsPercentage
      contextRef="From2025-07-012025-07-31_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002529"
      unitRef="Pure">0.60</BMGL:InvestmentsPercentage>
    <BMGL:InvestmentsPercentage
      contextRef="From2025-07-012025-07-31_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002531"
      unitRef="Pure">0.60</BMGL:InvestmentsPercentage>
    <BMGL:InvestmentsSalePercentage
      contextRef="From2025-09-012025-09-30_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002533"
      unitRef="Pure">0.07</BMGL:InvestmentsSalePercentage>
    <BMGL:InvestmentsSalePercentage
      contextRef="From2025-09-012025-09-30_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002535"
      unitRef="Pure">0.07</BMGL:InvestmentsSalePercentage>
    <BMGL:InvestmentsSalePercentage
      contextRef="From2025-09-012025-09-30_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002537"
      unitRef="Pure">0.07</BMGL:InvestmentsSalePercentage>
    <BMGL:InvestmentsHoldPercentage
      contextRef="From2025-09-012025-09-30_custom_SSOCNovenaPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002539"
      unitRef="Pure">0.53</BMGL:InvestmentsHoldPercentage>
    <BMGL:InvestmentsHoldPercentage
      contextRef="From2025-09-012025-09-30_custom_SSOCOrchardPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002541"
      unitRef="Pure">0.53</BMGL:InvestmentsHoldPercentage>
    <BMGL:InvestmentsHoldPercentage
      contextRef="From2025-09-012025-09-30_custom_SSOCFarrerParkPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002543"
      unitRef="Pure">0.53</BMGL:InvestmentsHoldPercentage>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2025-07-31_custom_PharmaAvenuePteLtdMember_ifrs-full_TopOfRangeMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002545"
      unitRef="Shares">100000</ifrs-full:NumberOfSharesIssued>
    <BMGL:InvestmentsHoldPercentage
      contextRef="From2025-09-012025-09-30_custom_EyetrustMedicalPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002547"
      unitRef="Pure">0.65</BMGL:InvestmentsHoldPercentage>
    <BMGL:InvestmentsHoldPercentage
      contextRef="From2025-10-012025-10-31_custom_CharteredImagingPteLtdMember_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="INF"
      id="Fact002549"
      unitRef="Pure">1</BMGL:InvestmentsHoldPercentage>
    <ifrs-full:NetDebt
      contextRef="AsOf2025-10-31_custom_NonadjustingEventsAfterReportingPeriodMember"
      decimals="0"
      id="Fact002551"
      unitRef="SGD">3000000</ifrs-full:NetDebt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
